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uPAR Urokinase plasminogen Activator Receptor 
VEGF Vascular endothelial growth factor 
VHL Von Hippel Lindau 
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Constitutive upregulation of glycolysis is likely to be a cellular adaption to hypoxic 
conditions, being recently recognized as a hallmark of cancer. Interestingly, it has 
been shown that cancer stem cells (CSC), as well as normal stem cells, use 
preferentially glycolysis over oxidative phosphorylation as their main source of 
energy, exhibiting increased adaptation to oxidative stress, with enhanced antioxidant 
protective systems and low reactive oxygen species (ROS) content. These properties 
provide cells with increased invasive and metastatic properties, as well as increased 
ability to escape to oxidative stress-induced anoikis. In breast cancer, these CSC, 
which are known to persist in the human body after therapy due to their unique 
metabolic properties, are responsible for promoting relapses and metastasis.  
P-cadherin, a calcium dependent cell-cell adhesion molecule encoded by the CDH3 
gene, is a protein whose expression is highly associated with undifferentiated cells of 
adult epithelial tissues, including the normal mammary gland, as well as with poorly 
differentiated carcinomas. In breast cancer, P-cadherin is aberrantly expressed in 
high-grade tumours with basal-like phenotype, being a well-established indicator of 
poor patient prognosis. Moreover, P-cadherin expression promotes breast cancer cell 
invasion, partially through the secretion of matrix metalloproteinases (MMPs), such as 
MMP1 and MMP2, and induces cell-extracellular matrix (ECM) attachment and 
alterations in the actin cytoskeleton. Importantly, P-cadherin is also known to promote 
stem-like properties in breast cancer cells, such as tumourigenic capacity and 
anoikis-resistance, allowing cells to survive in anchorage-independent conditions. The 
expression of this protein confers radiation-resistance to breast cancer cells and, 
upon apoptotic stimuli, decreased P-cadherin expression increases breast cancer cell 
death in a caspase-dependent mechanism. 
 
In this work, we demonstrate, for the first time, that aberrant P-cadherin expression is 
associated with the hypoxic/glycolytic and acid resistant phenotype in invasive breast 
carcinomas, represented by a panel of markers including HIF-1α (hypoxia-inducible 
factor 1α), GLUT1 (glucose transporter 1), CAIX (carbonic anhydrase IX), MCT1 
(monocarboxylate transporter 1) and CD147. We also show that P-cadherin 
expression is modulated by hypoxia in a time dependent manner, that HIF-1α 
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stabilization increases membrane P-cadherin expression and that P-cadherin-
enriched cancer cell population shows increased GLUT1 and CAIX expression. 
These populations also comprise high mammosphere forming efficiency, suggesting 
that P-cadherin overexpressing breast cancer cells are more likely to exhibit 
increased glycolysis and to survive to metabolic-driven pH alterations.  
We were still able to demonstrate that P-cadherin expression is responsible for 
oxidative phosphorylation (OXPHOS) suppression in BLBC (basal-like breast cancer) 
cells, due to the observation that downregulation of its expression induces a 
metabolic shift towards OXPHOS, with concomitant increase of ATP production. 
Furthermore, we observed that oxidative stress is modulated by P-cadherin 
expression in breast cancer cells, since its overexpression was associated with low 
ROS levels, probably due to the induced upregulation of superoxide dismutases 1 
and 2 (SOD1 and 2) antioxidant systems. 
 
Taken together, these results led us to postulate that HIF-1α might be stabilizing 
membrane P-cadherin expression in breast CSC, or even selecting P-cadherin-
enriched breast CSC populations in the hypoxic niche. In turn, P-cadherin expression 
is inducing a metabolic reprogramming and antioxidant response of these cells, which 
might be responsible for tumour aggressiveness, as well as for their ability to survive 
and resist, compared to the neighbour low P-cadherin expressing cells. In this case, 
P-cadherin is mediating the survival of aggressive cells thought to be resistant to 
chemo and radiotherapy, being responsible for tumour relapses and metastasis in 
breast cancer patients. 
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O aumento constitutivo do metabolismo glicolítico é, provavelmente, um mecanismo 
de adaptação celular a condições de hipóxia, sendo actualmente reconhecido como 
um dos “Hallmarks of Cancer”. Curiosamente, tem sido demonstrado que as células 
estaminais do cancro, bem como células estaminais normais, utilizam 
preferencialmente a glicólise como principal fonte de energia, apresentando assim 
uma maior adaptação ao stress oxidativo, com sistemas de protecção antioxidante 
aumentados e baixos níveis de espécies reactivas de oxigénio. Estas propriedades 
aumentam a capacidade invasiva e metastática das células tumorais, uma vez que 
conferem uma maior aptidão para estas escaparem à morte induzida por stress 
oxidativo (anoikis). Assim, devido às suas propriedades metabólicas, foi demonstrado 
que as células estaminais de cancro da mama permanecem no corpo humano após 
terapias oncológicas, sendo responsáveis por recidivas e formação de metástases 
em doentes com este tipo de cancro. 
A caderina-P é uma molécula de adesão célula-célula dependente de cálcio, 
codificada pelo gene CDH3, cuja expressão se encontra associada a células 
indiferenciadas de tecidos epiteliais adultos, como a glândula mamária, bem como a 
carcinomas pouco diferenciados. Em cancro da mama, a caderina-P encontra-se 
sobre-expressa em tumores de alto grau histológico e com fenótipo basal, sendo um 
indicador de mau prognóstico. Sabe-se também que a expressão de caderina-P 
promove a invasão de células de cancro da mama, parcialmente através da secreção 
de metaloproteinases de matriz (MMPs), como MMP1 e MMP2,  promovendo ainda a 
ligação célula-matriz extracelular e induzindo alterações no citoesqueleto de actina. A 
caderina-P é conhecida pela promoção de propriedades estaminais em células de 
cancro da mama, tais como a capacidade tumorigénica e resistência à anoikis, 
permitindo que estas células sobrevivam em condições independentes da adesão à 
matriz. A expressão desta proteína confere também resistência à radiação e, 
mediante estímulos apoptóticos, a diminuição da sua expressão induz a morte de 
células de cancro da mama, através de um mecanismo dependente de caspases. 
Neste trabalho, demonstrámos pela primeira vez, que a expressão aberrante de 
caderina-P se encontra associada ao fenótipo hipóxico, glicolítico e de resistência à 
acidose em carcinomas invasivos da mama, através da avaliação da expressão de 
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um painel de marcadores como HIF-1α, GLUT1, CAIX, MCT1 e CD147. Observámos 
que a expressão de caderina-P é modulada por hipóxia, de uma forma dependente 
do tempo, que a estabilização de HIF-1α induz aumento de expressão de caderina-P 
na membrana celular, e ainda que as populações de células com expressão 
aumentada de caderina-P se encontram igualmente enriquecidas na expressão de 
GLUT1 e CAIX. Estas populações mostram também uma capacidade aumentada de 
formação de mamosferas, sugerindo que as células de cancro da mama com 
expressão aberrante de caderina-P apresentam uma capacidade glicolítica 
aumentada e uma maior capacidade de sobreviver a variações de pH induzidas por 
alterações metabólicas. 
 
Neste trabalho, mostrámos ainda que a caderina-P é responsável pela supressão da 
fosforilação oxidativa em células de cancro da mama, bem como pela adaptação ao 
stress oxidativo, uma vez que células com expressão aberrante desta proteína 
apresentam níveis reduzidos de espécies reactivas de oxigénio, provavelmente 
associados à indução de sistemas antioxidantes, como SOD1 e SOD2. 
 
Em suma, estes resultados sugerem que o factor de transcrição HIF-1α estabiliza a 
expressão de caderina-P na membrana das células de cancro da mama, ou que 
selecciona populações de células com aumento de expressão desta molécula de 
adesão em nichos hipóxicos. Por sua vez, a caderina-P induz uma reprogramação 
metabólica e uma adaptação ao stress oxidativo nestas células, podendo ser 
responsável pelo aumento da agressividade tumoral, bem como pelo aumento da 
capacidade de sobrevivência das células enriquecidas na expressão de caderina-P. 
Em conclusão, acreditamos que a caderina-P medeie a sobrevivência de células 
agressivas de cancro da mama, com resistência a quimio e radioterapia, 
responsáveis pelo aparecimento de recidivas e metástases em doentes com cancro 
da mama. 
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In Chapter I, a general introduction presents the current knowledge about cancer 
metabolism, as well as about metabolism and stemness/differentiation. It summarizes 
several aspects of cancer metabolism, namely the effect of tumour microenvironment 
in this context and the metabolic switch observed in stem cells and CSCs, with a 
particular focus in breast carcinogenesis and breast CSCs. Moreover, it also 
discloses what is currently known and described regarding the role of P-cadherin 
expression in cell differentiation and in breast cancer.  
The rationale and aims of this Thesis are presented in Chapter II, which are in line 
with the background described in the introduction.  
Chapter III describes the material and methods and Chapter IV encloses original data 
of this Thesis, published in BMC Cancer, as well as unpublished and ongoing work, 
which are in preparation to be published in an international peer reviewed journal.  
A general discussion integrating all the results is presented in Chapter V, followed by 
Conclusions and Future Perspectives in Chapter VI. 
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1. METABOLISM AND CANCER 
 
The link between cancer and metabolism is not new. Early observations in the 
beginning of the cancer research area identified metabolic alterations as a common 
feature of tumours. However, these were proven to be inadequate to explain the 
tumourigenic process and the field of oncogene research pushed metabolism to the 
margins of cancer research. Recently, there is a renewed interest on tumour 
metabolism, since several signalling pathways affected by oncogenic alterations and 
tumour microenvironment were found to have a significant effect in metabolism, 
making “cancer metabolism” a subject highly important in cancer biology. 
 
1.1 THE WARBURG EFFECT 
 
In the presence of oxygen, most differentiated cells rely primarily on mitochondrial 
oxidative phosphorylation (OXPHOS) to generate energy for cellular processes, 
metabolizing glucose to carbon dioxide by oxidation of glycolytic pyruvate in the 
mitochondrial tricarboxylic acid (TCA) cycle (Figure 1). The final electron acceptor in 
glucose oxidation is oxygen, being an essential element in this process. This reaction 
produces NADH (reduced nicotinamide adenine dinucleotide), which fuels OXPHOS 
to maximize ATP (adenosine triphosphate) production, with minimal production of 
lactate. However, in anaerobic conditions, differentiated cells redirect pyruvate away 
from the mitochondria and produce large amounts of lactate, with the production of 
lower levels of energy. Most cancer cells and proliferating tissues also produce great 
quantities of lactate, regardless of the availability of oxygen, being their metabolism 
often referred as “aerobic glycolysis”. This effect was originally described by Otto 
Warburg, which hypothesized that cancer cells present mitochondrial defects leading 
to impaired aerobic respiration, and subsequently rely on glycolytic metabolism for 
ATP production [3]. However, normal mitochondrial function was observed in cancer 
cells and in normal proliferating cells, suggesting the existence of an alternative 
explanation for aerobic glycolysis in cancer cells [4, 5].  
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Figure 1. Representation of the differences between oxidative phosphorylation, anaerobic 
glycolysis and aerobic glycolysis in differentiated, cancer and proliferating cells. In the presence 
of oxygen, differentiated tissues metabolize glucose to pyruvate via glycolysis and then completely 
oxidize most of that pyruvate in the mitochondria to CO2 during oxidative phosphorylation. When 
oxygen is in limiting levels, cells can redirect the pyruvate generated by glycolysis away from 
mitochondrial oxidative phosphorylation by generating lactate (anaerobic glycolysis). Production of 
lactate during anaerobic glycolysis allows glycolysis to continue (by cycling NADH back to NAD+), but 
results in minimal ATP production when compared with oxidative phosphorylation. Normal proliferative 
tissues and cancer cells tend to convert most glucose to lactate, regardless the presence of oxygen 
(aerobic glycolysis/Warburg effect). Adapted from Vander Heiden et al. [6] 
 
Nevertheless, aerobic glycolysis is a less efficient mechanism for ATP generation 
comparing to oxidative phosphorylation. In proliferating cells, approximately 10% of 
the glucose is diverted into other biosynthetic pathways upstream of pyruvate 
production. The metabolism of glucose to lactate generates only 2 ATPs per molecule 
of glucose, whereas OXPHOS generates up to 36 ATPs after complete oxidation of 
one glucose molecule [6]. Furthermore, enhanced glycolysis imposes the production 
of lactate, which is further discarded by the cell. 
These observations led to the following question: why a less efficient energetic 
metabolism is selected in proliferating and in cancer cells? The dynamic regulation of 
cell’s metabolism should be taken into account in order to understand this paradox. 
Cell metabolism is an integration of cellular needs with external signals, such as 
morphogens, substrates, and oxygen, among others. Cancer cells are relatively 
independent from these external signals in order to maintain their uncontrolled 
growth, being this characteristic one of the hallmarks of cancer [7, 8]. Thus, these 
Fig. 2.
Schematic representation of the differences between oxidative phosphorylation, anaerobic
glycolysis, and aerobic glycolysis (Warburg effect). In the presence of oxygen,
nonproliferating (differentiated) tissues first metabolize glucose to pyruvate via glycolysis and
the  co pletely oxidize most of that pyruvate in the mitochondria to CO2 during the process
of oxidative phosp rylation. Because oxyg n is required as the final electron acceptor to
completely xidize the glucose, oxygen is es ential f r his process. When oxygen is limiting,
cells can redirect the pyruvate generated by glycolysis away from mitochondrial oxidative
phosphorylation by generating lactate (anaerobic glycolysis). This generation of lactate during
anaerobic glycolysis allows glycolysis to continue (by cycling NADH back to NAD+), but
results in minimal ATP production when compared with oxidative phosphorylation. Warburg
observed that cancer cells tend to convert most glucose to lactate regardless of whether oxygen
is present (aerobic glycolysis). This property is shared by normal proliferative tissues.
Mitochondria remain functional and some oxidative phosphorylation continues in both cancer
cells and normal proliferating cells. Nevertheless, aerobic glycolysis is less efficient than
oxidative phosphorylation for generating ATP. In proliferating cells, ~10% of the glucose is
diverted into biosynthetic pathways upstream of pyruvate production.
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cells use flexibly their metabolic processes with the adoption of distinct metabolic 
programs. Terminally differentiated cells adopt a catabolic metabolism for maximal 
energetic efficiency, providing them appropriate energetic charge to sustain their 
functions, as is the case of high energy-requiring phenotypes, such as cardimyocytes 
and neurons [9]. However, when a cell is committed to rapid and active proliferation, 
ATP and NADH are not the only required products, and glycolysis and TCA do not 
function only for compensating cellular energetic demands. In such cases, these 
pathways and their intermediate products are deviated to other molecular pathways, 
such as pentose phosphate pathway (PPP), hexosamine synthesis and serine/glycine 
synthesis pathways, in order to provide precursors for the synthesis of lipids, proteins, 
DNA and RNA (Figure 2) [6, 9, 10]. 
Thus, proliferating cells usually adopt anabolic metabolism so that energy production 
and the synthesis of molecular precursors necessary for cell growth and subsequent 
division are assured. Moreover, ATP production by glycolysis is much faster than by 
OXPHOS and, if enough glucose is available, sufficient amounts of energy will be 
produced. Furthermore, ATP levels are sensed by the cells, allowing them to adapt 
their metabolic processes. When increased levels of cellular ATP are present, there is 
a decrease in glycolytic rates by inactivation of AMPK (5' adenosine monophosphate-
activated protein kinase). ATP can also act as a direct allosteric inhibitor of glycolytic 
enzymes. Still, the metabolic shift towards glycolysis has also been proposed as a 
mechanism to protect cells from increased ROS produced in the mitochondria [11, 
12]. 
Metabolism is a dynamically regulated system, where the activity of several enzymes 
allows the cell to fit the requirements for proliferation energetic needs of each 
differentiated tissue. In normal proliferating tissues, such as in the developing 
embryos, signals from growth factors allow cells to utilize nutrients to match their 
need [13, 14]. In cancer, oncogenic pathways drive cell-autonomous nutrient uptake 
and program proliferative metabolism, whereas tumour suppressor pathways prevent 
nutrient utilization for anabolic processes. Thus, oncogenic alterations provide cells 
the ability to acquire nutrients and coordinately regulate metabolic pathways to 
support proliferation and survival [6]. 
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Figure 2. Metabolic pathways underlying active proliferation. The significance of some of the 
metabolites and intermediates resulting from the main pathways branching from glycolysis. Red dotted 
arrows represent anaplerotic reactions of the Krebs cycle. Abbreviations: 3PG, 3-phosphoglycerate; 
6PG, 6-phosphogluconate; 6PGL, 6-phosphogluconolactone; α-KG, α-ketoglutarate; AcCoA, acetyl-co-
enzyme A; Ala, alanine; Cit, citrate; FBP, fructose-1,6-biphosphate; F6P, fructose-6-phosphate; Fum, 
fumarate; GLA6P, glucosamine-6-phosphate; G6P, glucose-6-phosphate; Glu, glutamate; Gln, 
glutamine; GAD3P, glyceraldehyde-3-phosphate; Gly, glycine; IsoCit, isocitrate; Lac, lactate; Mal, 
malate; MTHF, methylenetetrahydrofolate; Oac, oxaloacetate; Pyr, pyruvate; R5P, ribose-5-phosphate; 
Ser, serine; Suc, succinate; SucCoA, succinyl-co-enzyme A; THF, tetrahydrofolate; UDP-GlcNAc, 
uridine diphosphate-N-acetylglucosamine. Adapted from Pereira et al. [9] 
 
fibroblasts deficient for glucose-6-phosphate ehydrogena e (the first
enzyme in the PPP and responsible for catalyzing one of the steps yielding
NADPH) proliferate less and show evidence of early senescence when
compared with control cells, a phenotype related to an increment in
oxidative stress (Ho et al., 2000).
Thehexosaminebiosyntheti pathway is alsonecessary for cell growth
and survival (Wellen et al., 2010). This pathway recruits fructose-6-
phosphate from glycolysis and yieldsN-acetylglucosamine in a glutamine
and acetil-CoA dependent fashion (Fig. 3). N-acetylglucosamine is the
substrate for protein glycosylation and was shown to be necessary to
Figure3 Metabolic pathways underlying active proliferation. The significance of someof themetabolites and intermediates resulting from themain path-
ways branching from glycolysis is described. Red dotted arrows represent anaplerotic reactions of the Krebs cycle. Abbreviations: 3PG,
3-phosphoglycerate; 6PG, 6-phosphogluconate; 6PGL, 6-phosphogluconolactone; a-KG, a-ketoglutarate; AcCoA, acetyl-co-enzyme A; Ala, alanine;
Cit, citrate; FBP, fructose-1,6-biphosphate; F6P, fructose-6-phosphate; Fum, fumarate; GLA6P, glucosamine-6-phosphate; G6P, glucose-6-phosphate;
Glu, glutamate; Gln, glutamine; GAD3P, glyceraldehyde-3-phosphate; Gly, glycine; IsoCit, isocitrate; Lac, lactate; Mal, malate; MTHF, methylenetetrahy-
drofolate; Oaa, oxaloacetate; Pyr, pyruvate; R5P, ribose-5-phosphate; Ser, serine; Suc, succinate; SucCoA, succinyl-co-enzyme A; THF, tetrahydrofolate;
UDP-GlcNAc, uridine diphosphate-N-acetylglucosamine.
Metabolism in gametogenesis and cancer 9
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Interestingly, glycolysis upregulation is the basis of the clinical tumour imaging FdG 
PET (18fluorodeoxyglucose Positron-Emission Tomography), which uses the glucose 
analogue tracer FdG to mimic glucose [15, 16]. This imaging technique, based on the 
enhanced glycolysis of tumours, allows the identification of primary and metastatic 
tumours in oncology patients (Figure 3).  
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1.2 CELL-ENVIRONMENT MODEL FOR CARCINOGENESIS: THE IMPLICATIONS OF HYPOXIA 
AND GLYCOLYSIS UPREGULATION  #
Aerobic glycolysis is a near-universal observation in tumours, being a crucial 
component of the malignant phenotype [17] and a new hallmark of cancer [8]. 
Upregulation of glycolytic metabolic pathways in tumours is the result of an adaptation 
of cancer cells to consistent environmental pressures in pre-malignant lesions, when 
diffusion thought to be responsible for the development of invasive and metastatic 
tumour cells. Cellular traits selected by these conditions include constitutive 
upregulation of glycolysis and resistance to acid-induced apoptosis [1, 18]. In an 
attempt to explain carcinogenesis, Gatenby and Gillies proposed a model of cell-
environment interactions, where hypoxic environment and acquisition of a glycolytic 
phenotype and acidosis resistance are implicated in cancer development and 
progression [1, 18]. Since blood vessels are confined to the stromal compartment, 
Figure 3. Positron-emission tomography 
imaging with 18fluorodeoxyglucose of a 
patient with lymphoma. Nodes indicated by 
arrows show high uptake of FdG, 
demonstrating that tumour cells in these nodes 
have high levels of FdG uptake. The bladder 
(yellow arrow) also has high activity, because 
of excretion of the radionuclide). Adapted from 
Gillies and Gatenby [1]. 
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the extracellular space, which might result in cellular
toxicity24–26 (FIG. 4a,b). Intuitively, it would seem that the
Darwinian forces prevailing during the somatic evolu-
tion of invasive cancers would select against a metabolic
phenotype that is more than an order of magnitude less
efficient than its competitors and that is environmen-
tally poisonous. In other words, the accepted tenet of
‘survival of the fittest’ would seem to generally favour
populations with more efficient and sophisticated sub-
strate metabolism. So, why do tumour populations con-
sistently evolve to the inefficient and potentially toxic
glycolytic phenotype?
We propose that the remarkable prevalence of
upregulated glycolysis in clinical cancers is neither ran-
dom nor accidental. Rather, it represents an evolved
solution to common environmental growth constraints
during carcinogenesis, and its persistence in primary
and metastatic malignancy indicates that it continues to
confer a proliferative advantage even to fully trans-
formed cells. So, we suggest that increased glycolysis is
an essential component of the malignant phenotype
and, therefore, a hallmark of invasive cancers. Herein we
explore its causes and consequences.
The microenvironment in pre-malignant lesions
Although pre-malignant lesions are often characterized
as highly vascularized, this is true only in a macroscopic
sense. That is, although a pre-malignant lesion such as a
polyp or carcinoma in situ might have a vascular stroma,
the hyperplastic epithelia are physically separated from
their blood supply by a basement membrane. This is
illustrated in FIG. 5, as the hyperplastic epithelium of a
carcinoma in situ is clearly delimited from the stroma by
a thin basement membrane. Blood vessels are confined
to the stromal compartment and, therefore, early car-
cinogenesis and development of the malignant pheno-
type actually occur in an avascular environment. As a
result, substrates, such as oxygen and glucose, must dif-
fuse from the vessels across the basement membrane and
through layers of tumour cells, where they are metabo-
lized. This process of diffusion and consumption was
modelled by Krogh as early as 1919 through
reaction–diffusion equations that showed that oxygen
concentrations decreased with distance from a capillary
such that oxygenated cells were limited to a distance of
less than 150 µm from a blood vessel27. In the 1950s,
empirical studies by Thomlinson and Gray showed that
viable tumour cells were not observed at distances
greater than 160 µm from blood vessels, consistent with
Krogh’s calculations28. Subsequent experimental studies
in WINDOW CHAMBERS in animal models have demonstrated
that near-zero partial pressures of oxygen (pO2) are
observed at distances of only 100 µm from a vessel29,30.
Therefore, pre-malignant lesions, provided their
basement membranes remain intact, will inevitably
develop hypoxic regions near the oxygen diffusion limit,
as persistent proliferation leads to a thickening of the
epithelial layer, pushing cells ever more distant from
their blood supply, which remains on the other side of
the basement membrane. At this penumbral layer,
microenvironmental selection forces will favour
WINDOW CHAMBER
A metal chamber with a glass
window that is placed on the
dorsal skin of an animal. This
allows in vivo tumour growth to
be continuously observed
microscopically.
Figure 2 | Positron-emission tomography imaging with
18fluorodeoxyglucose of a patient with lymphoma. The
mediastinal nodes (purple arrow) and supraclavicular nodes
(green arrows) show high uptake of 18fluorodeoxyglucose
(FdG), showing that tumours in these nodes have high levels
of FdG uptake. The bladder (yellow arrow) also has high
activity, because of excretion of the radionuclide.
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Figure 3 | Pasteur and Warburg effects in non-invasive
and metastatic breast cancer cell lines. In both cell lines,
glucose consumption is reduced in the presence of oxygen
— the Pasteur effect (P). However, the more aggressive cell
line, MDA-MB-231, has much higher glucose consumption 
in the presence of oxygen than the MCF-7 cells with a 
non-invasive phenotype — the Warburg effect (W). This is
consistent with positron-emission tomography scans with
18fluorodeoxyglucose, which show that higher glucose
uptake correlates with more aggressive phenotypes and
poorer clinical outcomes. 
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early carcinogenesis occurs in an avascular environment. In pre-malignant lesions, 
increased proliferation leads to a thickening of the epithelial layer and cells become 
distant from their blood supply, developing in a hypoxic environment. Hypoxia then 
favours selection of the best adapted cells to harsh conditions of low oxygen and 
nutrients availability by the acquisition of a glycolytic phenotype. As a consequence of 
increased acidosis, tumours become acidotic, leading to the selection of cells with 
increased motility and invasion abilities. After the breakdown of the basement 
membrane, cells have access to blood and lymphatic vessels, which constitute the 
main routes for the spreading of cancer cells, promoting metastatic disease (Figure 
4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Model for cell–environment interactions in carcinogenesis. The stages of tumour growth 
and their associated physiological states, showing that progression from one stage to the next is 
governed by state processes. Normal epithelial cells (grey) become hyperproliferative (pink) following 
induction. As they reach the oxygen diffusion limit, they become hypoxic (blue), which can either lead 
to cell death (apoptotic cells shown with blebbing) or adaptation of a glycolytic phenotype (green), 
which allows cells to survive. As a consequence of glycolysis, lesions become acidotic, which selects 
for motile cells (yellow) that eventually breach the basement membrane. As cancer progression 
proceeds, the mutations in cells increase (nuclei shown as light orange for one mutation and darker 
oranges for more mutations). Adapted form Gatenby and Gillies [1]. 
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achieved through multiple mechanisms, including
oncogene activation or stabilization of transcription
factors such a  HIF1_.
Angiogenesis
We suggest that the glycolytic phenotype evolves in a
microenvironment that is avascular; that is, the evolv-
ing tumour cells remain physically separated from
their blood supply by a basement membrane, as
occurs in in situ tumours. This invokes the diffusion
of substrates from the vascularized stroma to the pro-
liferating tumour epithelium. Therefore, even though
late-stage carcinoma in situ can be characterized as
‘angiogenic’, the tumour does not become vascular-
ized until the basement membrane is breached by an
invasive cell. In fact, there is emerging evidence that
the ‘glycolytic switch’ occurs before the ‘angiogenic
switch’; lactic acid has been observed in regions of
invasive gliomas76,77 that lack vessel permeability, as
shown by the absence of contrast enhancement with
MRI78. We do not wish to indicate that angiogenesis
does not have a role in this process. In fact, it is likely
that angiogenic factors, such as VEGF, are produced
by the tumour and that this will promote increased
vascularity within the stroma (FIG. 6). However, these
new vessels remain physically separated from the
tumour cells by the basement membrane (see figure 2
Multiple cellular pathways might lead to the gly-
colytic phenotype, so that altered glucose metabolism
might even result in cells with normal HIF levels. For
example, upregulation of glycolytic enzymes can be
coordinated in response to oxidation–reduction
changes by the Sp1 transcription-factor complex68.
GLUT1 can be upregulated directly by MYC13,69 or indi-
rectly by KRAS70. Interestingly, in this latter study,
KRAS activation was only associated with a subset of
GLUT1-positive colon cancers, indicating that it is one
of several mechanisms to activate glycolysis in this sys-
tem. RAS activation of GLUT1 transcription seems to
be mediated through HIF1_ transactivation71.
Hexokinase II can be transcriptionally activated by
mutant p53 (REF. 72) or through demethylation of its
promoter73. It is also intriguing to note that transfection
of fibroblasts with H+-ATPase or Na+–H+ exchange
raises the intracellular pH, makes them tumorigenic
and leads to marked increases in glycolysis74,75. These
alternative systems for upregulating glycolysis are con-
sistent with our basic proposal that the mechanism of
induction is not as important as the induction itself.
That is, the glycolytic phenotype is not a secondary
phenomenon that results from induction of some
other pathway during carcinogenesis. Rather, it is
directly selected because it provides a growth advantage
and acquisition of the glycolytic phenotype might be
Tumour
stage
Physiological
state
Model
Process
Basement
membrane
Normal
epithelium
Invasive
carcinoma
Metastatic
disease
Intermittant
hypoxia
Initiation HIF1_
stabilization
Glycolytic
phenotype
Acidosis Motility Degradation of
basement 
membrane and 
vascularization
Interstitial
neoplasia
Carcinoma
in situ
O2 diffusion limit
Glucose diffusion limit
Blood vessel
Stroma
Proliferation Selection Selection
VEGF
Induction Metabolism
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Taken together, these authors propose that environmental constraints represent 
crucial evolutionary steps in the development of invasive cancer. With the acquisition 
of a phenotype with a powerful proliferative advantage through persistent aerobic 
glycolysis, cells modulate the local microenvironment with increased acidosis, which 
can be harmless to itself, but fatal to other non-adapted populations. This acidification 
facilitates tumour invasion, both through destruction of adjacent normal populations, 
as well as through acid-induced degradation of the ECM and promotion of 
angiogenesis [1].  
 
1.3 HYPOXIA IN BREAST CANCER 
 
Several molecular mechanisms lead to constitutive upregulation of aerobic glycolysis. 
The key regulator of the glycolytic response is the transcription factor HIF-1α, first 
discovered by Semenza and Wang [19]. HIF-1α combines with HIF-1β to form a 
heterodimeric transcription factor that regulates the expression of several cellular 
processes. HIF-1α and HIF-1β are constitutively expressed in cells. However, HIF-1α 
expression is destabilized in the presence of O2 by proline hydroxylation, being 
targeted for proteassomal degradation by the Von Hippel Lindau (VHL) ubiquitin 
ligase [20-22]. When it accumulate in cells, as in the case of low oxygen tensions, the 
HIF-1 complex binds hypoxia responsive elements (HREs; canonically CCATG) in the 
promoter region of target genes. The transcriptional activity of HIF-1α is known to 
mediate the cellular response to hypoxic stress by inducing genes involved in 
survival, glycolysis, angiogenesis, pH regulation, as well as haematopoiesis [23]. 
Hypoxic microenvironment is a feature of many solid tumours and occurs when a 
rapidly dividing tumour mass exceeds the existent vascular supply [24, 25]. Areas of 
necrosis can be observed in highly proliferative solid tumours and hypoxia has also 
been associated with treatment resistance, local invasion, poor clinical outcome and 
mortality [23, 26-28]. In addition, the undifferentiated phenotype of solid tumours, 
including breast cancer, strongly correlates with tumour hypoxia [29]. 
Interestingly, it has been widely demonstrated the effect of hypoxia, via HIF-1α, in the 
induction of EMT (epithelial to mesenchymal transition), invasion and migration. EMT 
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is characterized by the acquisition of migratory ability by the cells, including the loss 
of E-cadherin expression [30]. Several reports have been demonstrating the 
association of hypoxia with loss of E-cadherin expression in several types of cancer, 
including breast cancer [31]. One of the responsible mechanisms seems to involve 
HIF-1α induction of LOX (Lysyl Oxidase), which is highly expressed in breast cancer 
cells with high metastatic potential [32, 33]. LOX is able to modify ECM components 
[34] and is also known to activate the expression of Snail. So, HIF-1α induces LOX 
activation, which in turn leads to Snail activation and consequently to the repression 
of E-cadherin expression. The other described mechanism for hypoxia-induced E-
cadherin repression involves the Notch signalling and the activity of HES1 and HEY2, 
leading to Slug and Snail increased expression and E-cadherin downregulation [31]. 
Within the wide range of genes induced by HIF, some are involved in the acquisition 
of invasion, migratory and proteolytic activities, namely vimentin, fibronectin, 
cytokeratins (CK14, 18 and 19), matrix metalloproteinase 2 (MMP2), cathepsin D and 
urokinase plasminogen activator receptor (uPAR) [25]. Migratory ability is also 
potentiated by hypoxia/HIF-1α through the induction of autocrine motility factor (AMF), 
receptor tyrosine kinase c-Met, TGF-α (transforming growth factor-α), as well as of 
cytokine receptor (CXCR4) [25, 35-37]. Still, hypoxia/HIF-1α is also implicated in the 
selection, expansion and maintenance of cancer cell populations with stem-like 
properties [38, 39]. 
Hypoxia has been recognized as being determinant for clinical outcomes in several 
human tumours, including breast cancer [40-42]. Several authors have associated 
hypoxia-related gene signatures with poor prognosis in breast cancer. Winter et al. 
demonstrated that hypoxia metagene of head and neck cancer (HNSCC) present a 
poor prognosis relevance in independent breast cancer data sets [41]. Moreover, Chi 
et al. showed that human tumours, including breast carcinomas, could be stratified 
according to their hypoxia response, demonstrating that breast tumours with a strong 
gene expression signature of response to hypoxia, present a significantly worse 
prognosis, correlated with breast cancer progression and metastasis [40]. These 
authors also demonstrated that the prognostic information of the hypoxia signature 
was independent of other previously reported signatures and more predictive of 
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outcomes than other clinical parameters used in the clinical practice [40]. 
HIF-1α expression is observed in 25-40% of invasive breast carcinomas and is 
associated to poor prognosis, short patient’s survival, high proliferation and poor 
tumour differentiation [43-45]. Moreover, the expression of this transcription factor is a 
predictive marker of chemotherapy failure. Generalli et al. demonstrated a significant 
inverse correlation of HIF-1α expression before treatment and patient’s disease 
response [43]. Moreover, Schwab et al. also demonstrated that HIF-1α enhances 
primary tumour growth and lung metastasis using a model of HIF-1α wild-type and 
HIF-1α-null mammary tumour epithelial cells (MTECs) [46]. 
 Interestingly, hypoxia has been also shown to decrease ER expression in breast 
cancer cell lines [47], either at the transcriptional [48] or post-transcriptional levels, 
through proteasome dependent degradation [49-51]. Still, loss of ER expression is 
observed in breast tumours in hypoxic/necrotic areas of the tissue [49, 51], 
associating hypoxia with dedifferentiation by loss of oestrogen receptor (ER) 
expression. 
Moreover, BRCA1-related mutation carriers, which typically develop tumours with a 
basal-like phenotype [52], were described as presenting high levels of HIF-1α 
expression, comparing with sporadic breast tumours [53]. Furthermore, Yan et al. 
proposed that the aggressive nature of BRCA1 and basal-like tumours may be 
explained by an enhanced hypoxic response through the altered expression of 
proteins involved in the O2-dependent mechanism of HIF-1α degradation [54]. 
Furthermore, overexpression of HIF-1α also associates with the reduction of reactive 
oxygen species [55], increased radioresistance [56, 57] and protection of cells from 
drug induced apoptosis and senescence cancer therapy [58, 59]. 
 
1. 4 METABOLIC SWITCH AND MOLECULAR ADAPTATION TO GLYCOLYSIS 
 
Constitutive upregulation of glycolysis is likely to be an adaption to hypoxia, since this 
condition selects cells that rely on anaerobic metabolism [1]. However, some cancer 
cells that do not persist in hypoxic environment seem to exhibit preferentially 
glycolysis over oxidative phosphorylation. Examples of these highly glycolytic cells 
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that reside in high oxygen levels are leukemic cells, that can be found in the 
bloodstream [13, 60], and lung cancer cells, that are exposed to oxygen during 
tumourigenesis [61, 62]. Although HIF-1α strongly links aerobic glycolysis to 
carcinogenesis [63], it is not entirely true that glycolytic phenotype in tumours is 
invariably due to hypoxia. Besides hypoxia, a wide range of other physiological and 
pathological factors can activate HIF system, such as growth promoters like insulin 
growth factor and epidermal growth factor amplification systems, together with Ras 
and Myc oncogenes [64]. Moreover, alterations in tumour suppressor genes, such as 
p53 and VHL, can also be responsible for the activation of this system [22, 23]. For 
example, mutation in the VHL, in which the wild-type function targets HIF-1α for 
degradation, are associated with constitutively high HIF-1α expression and therefore 
with high glucose consumption rates, as in the case of renal cell carcinomas [65]. 
Moreover, the observation of glycolysis upregulation in primary tumours and in 
metastasis also leads to the suggestion that, besides being a solution to 
microenvironmental growth constrains, increased glycolysis in solid tumours seems to 
be a hallmark of cancer [8, 17]. Thus, these evidences suggest that hypoxia may not 
be a major contributor in the switch to aerobic glycolysis by cancer cells.  
As a requirement for the increased glucose uptake, GLUTs must be upregulated in 
this process. GLUT1 is the most well studied member of the GLUT family of glucose 
transporters, which mediates transport of glucose into the cells. It is expressed in 
several types of tumours such as brain, non-small cell lung and hepatocellular 
carcinomas [66-68]. This protein is also present in breast cancer [69], being 
associated with poor prognosis [70, 71]. Moreover, GLUT1 is an important stress 
response mediator of cancer cell survival when glucose is limited, and its role in 
tumour growth in in vitro and in vivo mammary mouse models was already described 
[72], promoting the consideration of this molecule as an attractive therapeutic target. 
The importance and prevalence of aerobic glycolysis in breast cancer is highlighted 
by the importance of glucose metabolism in breast cancer cells. In fact, several 
reports have demonstrated the increased glucose uptake and modulation of the 
expression of specific GLUTs in breast cancer cells [70, 73]. Specifically, GLUT1 
expression was found to be upregulated in breast cancer cells, being associated with 
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higher proliferation and high histological grade [70]. Consistently, it was shown that 
glucose deprivation, as well as treatment with 2-deoxy-D-glucose (2-DG), induces 
breast cancer cell apoptosis, reinforcing their dependence on glucose metabolism 
[74]. In accordance with the reliable identification of primary and metastatic tumours 
using FdG PET, glycolytic rates are also associated with aggressiveness, either in 
vitro or in vivo as well as in breast cancer patients. Interestingly, higher 18FDG was 
observed in more aggressive molecular subtypes of breast carcinomas, namely in 
HER2 (receptor tyrosine-protein kinase erbB-2) overexpressing and triple negative 
tumours [75]. 
However, this increased glycolysis, the so-called “metabolic switch”, results in the 
acidification of the intracellular space. In normal cells, prolonged exposure to acidosis 
might result in necrosis or apoptosis by a p53- and caspase 3-dependent mechanism 
[76-78]. In tumours, cells harbour alterations, such as p53 mutations, that allow them 
to escape acidosis-induced cell death and thus continue to proliferate. So, constitutive 
upregulation of glycolysis requires an additional adaptation to the negative effects of 
acidosis through resistance to apoptosis or upregulation of membrane transporters, 
responsible for cellular homeostasis (Figure 5) [79]. 
The intracellular pH homeostasis is maintained by upregulation of several H+ 
transporters, leading to the acidification of the extracellular medium [1]. Cancer cells 
have the ability to acidify the extracellular medium by different mechanisms, such as 
the extrusion of lactic acid and also by proton-pump activity [80]. This acidification 
leads to the activation of metalloproteases and/or cathepsins [80, 81], which will be 
responsible for the degradation of the ECM and basement membrane, facilitating 
tumour invasion and metastasis [82]. Montcourrier et al. demonstrated that 
metastatic, highly invasive and hormone receptor (HR) negative breast cancer cell 
lines have a higher ability to acidify their extracellular medium comparing to non-
invasive and non-metastatic cell lines, hormonal receptor expressing cells [80]. 
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Figure 5. Molecular and metabolic adaptation of breast cancer cells upon HIF-1α mediated 
signalling. Signalling cascade results in nuclear translocation of HIF-1α and consequent activation of 
genes, such as GLUT1, MCT1 and MCT4, as well as CAIX. Then, cancer cells reprogram their 
metabolism towards the glycolytic pathway, resulting in an increased production of lactate and in high 
intracellular acidification. Overexpression of CAIX results in the production of HCO3-, which is actively 
transported to the inside of cancer cells, compensating the intracellular acidification and maintaining 
cell survival. Activation of CAIX also results in acidification of the extracellular medium by the 
production of protons, promoting cancer cell invasion. Adapted from McDonald et al. [79] 
 
CAIX, a major downstream target of HIF-1α, plays an important role in the pH 
regulation and adaptation to acidosis through the reversible hydration of CO2 [83, 84]. 
The resultant HCO3- is transported inside the cell, in order to decrease the acidity 
created by increased metabolic activity; moreover, the protons derived from CAIX 
activity will promote ECM degradation, potentiating growth and invasion of surviving 
cells [85, 86]. In vivo studies, using orthotopic mouse models, have demonstrated that 
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CAIX depletion in breast cancer cells impairs primary tumour growth and also 
metastasis formation in nude mice [87]. CAIX is present in tumours with the ability to 
respond to hypoxia, including breast carcinomas, and is associated with poor patients 
prognosis, short disease free survival, basal-like phenotype; it is also described to be 
an independent poor prognosis factor [71, 88-91]. Moreover, this protein is known to 
induce tumour growth and cell migration, as well as cell invasion [92]. Inhibition of 
CAIX activity, using monoclonal antibodies or small molecule inhibitors, prevents 
cellular acidification and consequently decreases cell survival and invasion ability of 
cancer cells [79]. 
Other important cellular pH regulators are MCTs (monocarboxylate transporters), 
which are responsible for the extrusion of the excessive lactic acid resulting from 
increased glycolysis [93].  MCTs are found to be upregulated in several types of 
tumours, such as high-grade glial neoplasms, colorectal and cervical cancer [94-98]. 
In breast cancer, MCT1 is upregulated in poor prognosis basal-like breast carcinomas 
[99], being also associated with high histological grade tumours, negativity for 
hormone receptor and expression of CK5, CK14 and Vimentin [71]. Moreover, MCT1 
and MCT4 expression are significantly associated with CD147 expression in breast 
carcinomas [99]. CD147, or EMMPRIN (extracellular matrix metalloproteinase 
inducer), is a cell surface glycoprotein which expression is required for MCT1 and 
MCT4 proper expression, location and activity [100, 101]. However, CD147 is also 
known to induce MMP production in cancer cells as well as in their neighbouring 
fibroblasts [102]. Sun et al. demonstrated that CD147 transfection in MDA-MB-435 
induced an increase of expression of MMP, particularly of MMP2 [103]. In addition, it 
was also demonstrated, in in vivo experiments, that EMMPRIN induced expression in 
breast cancer cells resulted in the enhanced tumour growth in nude mice, associated 
with increased MMP expression [104]. Thus, it seems that CD147 or EMMPRIN-
mediated MMP induction is a mechanism that is present in pathological conditions, 
such as breast cancer. In addition, Pinheiro et al. demonstrated that, in breast cancer, 
CD147 expression is associated with basal-like phenotype, high histological grade, 
hormone receptor negative status, basal cytokeratins 14/5 and also with Vimentin 
expression [99].  
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Moreover, the expression and activity of lactate dehidrogenase (LDH), an enzyme 
responsible for the interconversion between pyruvate and lactate, has also been 
shown to be essential in breast cancer metabolism. Specifically, LDH-A is 
upregulated in breast tumours [105-107] and downregulation of its expression and 
activity was associated with stimulation of mitochondrial respiration, decreased 
membrane potential, decreased ability of cells to proliferate under hypoxic conditions, 
as well as tumourigenicity in mice models [4]. Moreover, LDH-A expression silencing 
in metastatic breast cancer cells is associated to decreased invasion, migration and 
glycolysis, enhancing oxygen consumption, ROS and ATP content. These alterations 
were accompanied by decreased primary tumour growth and metastatic ability of 
these highly aggressive murine 4T1 breast cancer cells [106]. Acidosis, by lactate 
accumulation due to metabolic changes, associates with increased aggressiveness in 
breast cancer. In 2011,using metabolic measurements of LDH-A and lactate levels, 
Serganova et al. observed that aggressive 4T1 xenografts exhibit higher LDH-A 
expression and produced higher levels of lactate when compared to 67NR tumours, 
which show less aggressive and metastatic potential [107]. Moreover, the inhibition of 
this molecule inhibited the formation of metastasis and was accompanied by in vivo 
changes in tumour cell metabolism [106]. 
Interestingly, the acquisition of hypoxia, glycolysis and acid resistance phenotype was 
proposed to play important causal roles in breast carcinogenesis (Figure 6). Chen et 
al. provided evidences for a model of somatic evolution adaptation to 
microenvironmental conditions. These authors claim that hypoxia, glycolytic and acid-
resistant phenotypes, represented by the expression of HIF-1α, GLUT1 and CAIX 
expression in tissue samples of normal mammary gland, ductal hyperplasia (DH), 
atypical ductal hyperplasia (ADH), in situ and invasive ductal breast carcinomas [89], 
symbolize a powerful adaptive advantage and an aggressive phenotype to breast 
tumours. Taken together, it is undeniable that this phenotype is highly associated to 
malignant features of breast cancer. 
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Figure 6. A model for somatic evolution during breast carcinogenesis. Ductal hyperplasia leads to 
a thickening of the epithelium, resulting in profound hypoxia. Hypoxia leads to upregulated glycolysis, 
which results in acidosis in the microenvironment. The role of HIF-1α changes from response to 
proliferation to tumour progression during breast carcinogenesis. Adapted form Chen et al. [89]. 
 
Interestingly, BLBC present a more emphasized response to hypoxia than tumours 
with luminal characteristics. It has been shown that this group of tumours present a 
differential expression of proteins whose genes are induced by hypoxia and are 
responsible for the development of a hypoxic and glycolytic/acid resistant phenotype 
[71, 91, 99], that confers selective advantage to tumours, allowing them to grow and 
escape cell death in adverse conditions.  Several reports have been emerging in the 
literature, attributing a role to hypoxia-induced effects in BLBC aggressiveness. In 
2011, Voss et al. showed that resistance to anti-angiogenic factors was linked to 
hypoxia-induced migration, mediated by an autocrine action of released signal 
substances in BLBC cells [108]. Moreover, several hypoxia-induced molecules have 
been reported as playing a role in aggressive behaviour of these breast tumours 
[109]. 
 
1.5 METABOLIC ALTERATIONS IN BREAST CANCER #
As stated before, metabolic reprogramming is currently considered as one of the 
major hallmarks of cancer [8]. In fact, several studies have been highlighting the 
importance of metabolism in breast cancer initiation and progression, trying to provide 
putative diagnostic and prognostic biomarkers, as well as new therapeutics targets 
demonstrated that constitutive expression of CAIX protein
in the breast cancer cell lines tested under normoxic
conditions was indicative of a hypoxic-independent mech-
anism of CAIX expression (Fig. 2). This is consistent with
previous findings showing that CAIX is induced in high-
density cultures via the phosphatidylinositol-3-kinase
(PI3K) pathway [29] and by the mitogen-activated protein
kinase (MAPK) pathway during both normoxia and
hypoxia [30]. Taken together, these observations suggest
that CAIX expression is not only regulated by hypoxia but
also driven by specific signaling pathways.
In clinical tissue specimens, we observed GLUT1 and
CAIX expressed only in DCIS and IDC. GLUT1 and CAIX
were frequently expressed in high grade DCIS. CAIX
expression was significantly associated with poor histolog-
ical grade of IDC. Therefore, our results suggest that the
glycolytic, acid-resistant phenotype has a powerful adaptive
advantage, which promotes unconstrained proliferation, and
may be a crucial selection force in the transition from DCIS
to an invasive cancer. GLUT1 and CAIX proteins play a
role in a later stage of breast carcinogenesis.
During the course of carcinogenesis, the pre-invasive
stages occur in an avascular environment because the
hyperplastic cells within the ductal lumens are separated from
the blood vessels by a basement membrane. In DH and ADH,
cell proliferation develops hypoxia near the oxygen diffusion
limit, in which HIF-1α expression is responsive to
proliferation-induced hypoxia. In turn, HIF-1α may be
adaptive for DH to maintain a high proliferative rate. When
the proliferation persists, hypoxia-mediated GLUT1 expres-
sion, a glycolytic phenotype, allows increasing anaerobic
glycolysis, in response to high levels of cellular proliferation
and confers a proliferative advantage [31]. However, prolif-
eration is again constrained by microenvironmental acidosis
due to anaerobic respiration of glucose. The new environ-
mental selection force selects for phenotypes that are
resistant to acid-induced toxicity. In addition, upregulated
glycolysis persists even under normoxic conditions (Warburg
effect) in cancer cells [32], which gives rise to increased acid
production. Acidosis induces apoptosis through p53-
dependent caspase activation [33]. The transformed cells
resist the acidic environment through the upregulation of H+
transporters (e.g., CAIX), by acquiring p53 mutations or
overexpression of the apoptosis-inhibitor protein Bcl-2, all of
which substantially reduce acid-mediated cell death [34].
Extracellular acidity can degrade extracellular matrix and
basement membranes, favoring tumor invasion [35]. Fur-
thermore, acidosis itself can be mutagenic and clastogenic
[36] and thus accelerates the progress of carcinogenesis.
CAIX works to regulate pH and helps counteract the acidic
condition [9]. CAIX expression, an acid-resistant phenotype,
allows cells to adapt to acidosis and then contributes to
tumor progression and invasive growth.
In the present study, we determined hypoxia-induced
HIF-1α, GLUT1, and CAIX expression in breast cancer
Table 3 Association between CAIX expression and other hypoxia
response proteins in invasive ductal carcinoma
CAIX p value
Negative Positive
HIF-1α
Negative 10 3 N.S
Positive 31 15
GLUT1
Negative 30 3 <0.001
Positive 11 15
Fig. 4 A model for somatic evoluti n during breast carcinogenesis.
Initially, ductal hyperplasia leads to a thickening of the epithelium,
resulting in profound hypoxia. Hypoxia leads to upregulated glycolysis,
which results in acidosis in the microenvironment. The role of HIF-1α
changes from response to proliferation to tumor rogression during breast
carcinogenesis. GLUT1 and CAIX expression (glycolytic and acid-
resistant phenotype) has a powerful adaptive advantage and may be a
crucial selection force in the final stages of breast carcinogenesis
Virchows Arch (2010) 457:53–61 59
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[89, 110-113]. 
Interestingly, Lu et al. proposed the “Two-step theory of breast cancer progression”, 
where metabolite alterations seems to play a role either in initial transformation of 
normal murine mammary gland cells as well as in the acquisition of metastatic ability 
of breast cancer cells[110]. Using high throughput metabolomics analysis in 4T1 
syngeneic mouse model of breast cancer progression, these authors identified the 
deregulation of hundreds of metabolites involved in metabolic pathways and provided 
valuable knowledge implicating metabolites belonging to TCA, glycolysis nucleotides 
synthesis and antioxidant processes, in breast cancer initial transformation and 
progression [110]. Moreover, it was recently shown that breast cancer progression is 
accompanied by a decrease in cellular OXPHOS capacity, independently of 
mitochondrial copy number or electron transport chain (ETC) protein expression 
[112]. Using a model of breast cancer progression of immortalized mammary 
epithelial cell line (MCF10A), Shaw et al. demonstrated a decrease of cellular oxygen 
consumption rate with increase aggressiveness of human breast cancer cells [112]. 
Still, comprehensive metabolic profiles identified metabolite deregulation in invasive 
breast carcinomas compared with normal breast tissue, also implicating changes in 
metabolic pathways in breast cancer progression [113, 114]. In 2012, Budczies et al. 
analysed the metabolic changes in the central pathways between invasive carcinoma 
and normal breast tissues and identified key metabolic markers that separate cancer 
from normal tissues with high sensitivity and specificity [113]. 
Moreover, oestrogen stimulation induces several metabolic alterations that contribute 
to the metabolic cancer phenotype and allows breast cancer cell proliferation. 
Estradiol, the most active form of oestrogen, enhances glucose and glutamine 
consumption, as well increased lactate production [115, 116]. Additionally, estradiol 
increases PPP by upregulation of glucose-6-phosphate dehydrogenase, favouring 
biosynthetic processes for building blocks necessary for cell proliferation [116, 117]. 
Upregulation of glycolysis leads to microenvironmental acidosis requiring evolution to 
phenotypes resistant to acid-induced cell toxicity. Thus, cell population with increased 
glycolysis and acid resistance has a powerful growth advantage, promoting tumour 
progression. Thus, distinguishing unique metabolic adaptations of cancer has 
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obviously been seen as a valuable therapeutic target. Consequently, intensive 
research has been carried to pursuit an effective strategy to target those metabolic 
reactions. 
 
2. METABOLISM AND STEMNESS 
 
It has been widely accepted that metabolic pathways play a critical role in somatic 
reprogramming [118]. Moreover, distinct metabolic properties and mitochondrial 
functionalities have been attributed to different types of stem cells and to their more 
differentiated counterparts. Moreover, the microenvironment where stem cells are 
known to exist seems to be also important for the maintenance of their pluripotent 
state, as well as for their metabolic program [2]. 
 
2.1 STEM CELL MICROENVIRONMENT AND METABOLISM #
2.1.1 STEM CELL NICHE MICROENVIRONMENT 
 
Characterization of stem cell neighbours, expression patterns of signalling molecules 
and local environmental factors, such as extracellular matrices and oxygen pressure, 
suggests that stem cells reside in individual compartments, called stem cell niches, 
with specific microenvironmental conditions. However, the identification of these 
niches and the understanding of how they are regulated, is still a challenge. The stem 
cell niche is defined by the microenvironment surrounding stem cells, that not also 
maintains their stemness as well as it prevents them from differentiating [119].  
Early mammalian development occurs in a relatively oxygen-poor environment, 
because before the establishment of the circulatory system, delivery of oxygen to the 
embryo is subject to the limits of diffusion (approximately 150 mm) [1, 120]. Thus, 
embryogenesis is heavily influenced by oxygen gradients. Evidences for this concept 
were found measuring oxygen tensions in endometrial and trophoblastic tissues 
during early pregnancy [121, 122]. In adult tissues, several stem cell niches have 
been reported as presenting low oxygen tensions, and due to the abnormal 
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vasculature, different hypoxia tensions are experienced, and can be as low as 1% of 
oxygen, which is relatively low comparing to other tissues (Figure 7). These oxygen 
tensions observed in animal tissues, specifically in stem cell niches, make the 
scientific community to link hypoxia signalling with stem cell behaviour [2, 123]. 
 
Figure 7. Low Oxygen Tension Measurements in Various Stem Cell Compartments. 
Representation of current available data for the hematopoietic (HSC), mesenchymal (MSC), and neural 
stem cells (NSC) in their designated niches: the bone marrow, adipose tissue, and the subventricular 
zone, respectively. Red cells represent HSCs, MSCs, and NSCs. Various oxygen tension 
measurements from the tissues and blood supply where hematopoietic and mesenchymal stem cells 
reside have been reported in the literature. Adapted from Mohyeldin et al. [2]. 
 
Low oxygen tensions in stem cell niches offers a selective advantage that is well 
suited to their particular biological roles [124]. Hypoxia has been shown to activate 
molecular pathways in multiple stem cell systems that appear to regulate Oct4 and 
Notch signalling, important regulators of stemness [125]. Moreover, proliferation and 
stem cell quiescence may also be regulated by oxygen tension of their niche. It is 
reported that oxygen tensions, as low as 1%, appear to decrease proliferation and 
maintain embryonic stem cell (ESC) pluripotency, while higher oxygen tensions (3% 
to 5%) seems to maintain pluripotency, with no effect on proliferation [126]. 
Interestingly, hypoxia also plays a role in the maintenance of self-renewal, 
undifferentiated state and pluripotency of ESC, HSC (hematopoietic stem cells), NSC 
oxygen tensions in ambient air that are typically considered
‘‘normoxic’’ by conventional standards of cell-culture practice.
However, oxygen concentrations between 2%–9% have re-
cently been appreciated by some scientists to constitute
physiologic normoxia (Simon and Keith, 2008). Nonetheless,
it is challenging to assay the precise oxygen pressures that
a given cell might experien e in vivo, and so physiologic
normoxia for one cell may be higher or lower in different environ-
ments or tissues or even under different pathologic conditions.
For example, adult tissues that exhibit unique vascular supply
(i.e., t e kidney medulla/papilla [Brezis et al., 1984]) or low
vascular density (such as the rat retina [Yu and Cringle, 2005]
and some areas of the brain [Erecinska and Silver, 2001]) can
extend this gradient further and experience oxygen tensions
as low as 1% (7.2 mm Hg), a relatively hypoxic environment
when compared to other tissues. From a molecular perspective,
physiologic normoxia is considered to be hypoxic because a
conserved molecular response is deployed under oxygen
tensions in the range of 2%–9%. This molecular response is
discussed in more detail in other reviews and includes hypoxia-
inducible transcriptions factors (HIFs), oxygen sensitive ion chan-
nels, the environmental sensing mammalian target of rapamycin
(mTOR), and the endoplasmic reticulum (ER) stress response (Liu
and Simon, 2004; Semenza, 1999; Wouters et al., 2005).
It has been hypothesized that the presence of low oxygen
tensions in stem cell niches offers a selective advantage that
is well suited to their particular biological roles (Cipolleschi
et al., 1993). That is, essentially all cells that undergo aerobic
metabolism are subject to some degree of oxidative stress
through the generation of reactive oxygen species that can
damage DNA. This risk is supported by direct evidence that
mouse embryonic fibroblasts accumulate more mutations and
senesce faster when cultured under 20% O2 than cells cultured
under 3% O2 (Busuttil et al., 2003). By residing in anatomical
compartments that experience r latively lo oxygen tensions
(in the range of 1%–9%), stem cells may escape this damage
and corre ponding growth p essure (Fig re 1). In addition,
hypoxia has been shown to activate molecular pathways in
multipl tem cell systems that appear to regulate Oct4 and
Notch signaling, two important regulators of stemness (Simon
and Keith, 2008). Finally, oxygen tensions as low as 1% appear
to decrease proliferation and maintain ESC pluripotency, while
higher oxygen tensions (3%–5%) appear to maintain pluripo-
tency with no effect on proliferation (Ezashi et al., 2005). These
results suggest that proliferation and perhaps even stem cell
quiescence may be regulated by gradients of oxygen tension
supplied by their local niche.
Embryogenesis, Embryonic Stem Cells, and Oxygen
Gradients
Embryogenesis is heavily influenced by oxygen gradients. Direct
evidence for this finding was made available when oxygen
tensions were measured in endometrial and trophoblastic
tissues during early pregnancy (Mitchell and Yochim, 1968;
Rodesch et al., 1992). Oxygen has a diffusion distance of
approximately 150 mm (Folkman et al., 2000; Gatenby and
Figure 1. Low Oxygen Tension Measurements in Various Stem Cell Compartments
Schematic models are depicted based on current available data for the hematopoietic, mesenchymal, and neural stem cells in their designated niches: the bone
marrow, adipose tissue, and the subventricular zone (SVZ), respectively. Red cells represent HSCs, MSCs, and NSCs. Various oxygen tension measurements
from the tissues and blood supply where hematopoietic andmesenchymal stem cells reside have been reported in the literature. Citations include data fromdirect
measurements, mathematical models, or reviews written about the subject. Concentrations from both rodent and human data were used when it was available.
Although direct measurements from the SVZ have never been performed, measurements of oxygen tension as low as 0.55% O2 in various areas of the brain
suggest that gradients of oxygen may exist in the SVZ. Depiction of the SVZ niche and vascular supply are based on rodent data and are being used conceptually
in this figure as characterization of the human SVZ and its relationship with local vasculature are a subject of ongoing research.
Cell Stem Cell 7, August 6, 2010 ª2010 Elsevier Inc. 151
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(neural stem cells), iPSC (induced-pluripotent stem cells), as well as CSC [124, 127-
131]. For example, hypoxia seems to be important in the generation of iPSC, since 
HIF-2α and HIF-3α increases endogenous expression of transcription factors used to 
generate iPSC from differentiated somatic cells [2]. 
 
2.1.2 STEM CELL METABOLISM 
 
Different types of cells involved in spermatogenesis, oogenesis and embryogenesis, 
present specific mitochondrial characteristics, exhibiting peculiar metabolic 
phenotypes (Figure 8) [9]. 
Consistently, it is described that, during the early stages of embryonic development, 
there is a metabolic shift from oxidative phosphorylation (OXPHOS) to glycolysis, and 
oxidative metabolism is only fully reinstituted after implantation [132]. 
Mitochondrial and metabolic remodelling may underlie acquisition and maintenance of 
pluripotency. Pluripotent ESCs can differentiate into any cell type in the adult 
organism. They present specific mitochondrial morphology, with arranged in small 
perinuclear clusters, with immature morphology [133-135]. Differentiation involves 
alterations in mitochondrial networks, suggesting higher OXPHOS activity [133, 136]. 
Several reports have demonstrated that differentiation of ESCs in vitro induces 
changes in mitochondrial dynamics, namely in the increasing number and 
morphology of mitochondria [14, 133, 135-137]. Concomitantly, there is an increase 
of the O2 consumption rates and ATP production as well a decrease in lactate 
production, suggesting that a switch in energy metabolism from glycolysis to oxidative 
phosphorylation is required for proper cell differentiation [138]. The increase in the 
number of mitochondria and OXPHOS in differentiated cells also leads to an increase 
in ROS production [133, 139], which has been proved to be important for the 
differentiation of hESCs into cardiomyocytes [140]. Several authors have reported 
similar characteristics in adult stem cell differentiation [141-143]. iPSC are somatic 
cells that have been reprogrammed to pluripotency, usually by the use of 
pluripotency-associated molecules such as Oct3/4, Sox2, Klf4 and c-Myc, with distinct 
methodologies [144]. Interestingly, iPSCs exhibit similar profile of mitochondrial 
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activity and metabolic behaviour as ESCs. These similarities comprise characteristics 
such as decreased mitochondrial mass, mtDNA copy number and expression of 
mitochondrial biogenesis genes as well as increased upregulation of glycolytic 
enzymes, and consequently a glycolytic metabolic programme [145-147].  
 
Figure 8. Mitochondrial characteristics and energy metabolism of different types of 
reproductive cells and embryos. Different mitochondrial morphologies and consequent metabolic 
pathways thought to be prevalent in the different stages of gametogenesis and early development. 
Adapted from Pereira et al. [9]. 
 
2.2 BREAST STEM CELLS #
In the last decade, it has been firmly established that, like most tissues, if not all, the 
mammary gland has also a hierarchical organization, similar to the hematopoietic 
system [148]. At the top of this cell-hierarchy, there is a small population of cells with 
self-renewal capability, breast stem cells, responsible for generating and maintaining 
the tissue architecture and permitting tissue remodelling and repairing. 
Independent of the developmental stage, mammary epithelium taken from any area of 
mitochondrial membrane potential, the TE cells are highly polarized and
very metabolically active producing more ATP and consuming more
oxygen (Barnett et al., 1996; Houghton, 2006; Van Blerkom et al.,
2006), suggesting that, as is the case with spermatogonia, cells with
high development potential remain more glycolytic.
Energ MetabolisminPluripotent
Stem Cells
Mitochondrial function in ESCs
Pluripotent ESCs that can differentiate into any cell type in the adult or-
ganism are isolated from theblastocyst ICM, grow in colonies, and canbe
propagated indefinitely in culture. Moreover they recapitulate metabol-
ically some of the blastocyst characteristics noted above. Although there
are line-specific differences, it has been shown that, similarly to ICMcells,
undifferentiated human ESC (hESC) have few ovoid mitochondria
arranged in small perinuclear clusters, with immature morphology evi-
denced by the presence of few cristae and low electron lucid matrix
(Fig. 2) (Oh et al., 2005; St John et al., 2005; Cho et al., 2006).
In general, differentiation involves a shift from small individual oval
mitochondria to dynamic tubular networks, with an increase in the
number of mitochondrial cristae, suggesting higher OXPHOS activity
(Cho et al., 2006; St John et al., 2010). It has also been shown that
hypoxia may facilitate cell growth and pluripotency (Ezashi et al., 2005;
Kondoh et al., 2007). The rationale for using low O2 tension in ESC
culture is related to the conditions found in the female reproductive
tract, thus mimicking the physiological environment for ICM cells.
However, this is not a straightforward issue, because, although O2
may vary throughout the tract, it also seems sufficient to maintain
active OXPHOS (see Ramalho-Santos et al. (2009) for review).
Several studies have differentiated ESCs in vitro and observed changes
in mitochondrial dynamics during differentiation (St John et al., 2005;
Facucho-Oliveira et al., 2007). When ESCs differentiate the number of
mitochondria increase and changes in morphology can also be observed
Figure 2 Mitochondrial characteristics and energy metabolism found in the different types of reproductive cells and embryos. Different mitochondrial
morphologies andmetabolic pathways thought to be prevalent in the different stages of gametogenesis and early development discussed in this review. The
information summarized in the figur was obtained fromAmaral et al. (2013), Bajpai et al. (1998), DeMartino et al. (1979), Meinhardt et al. (1999), Prince
(2002), Ramalho-Santos andAmaral (2013), Ramalho-Santos et al. (2009), St. John (2012), Swain and Smith (2011), Varum et al. (2011) and Vorup-Jensen
et al. (1999).
6 Pereira et al.
 at Universidade do Porto on September 8, 2014
http://humupd.oxfordjournals.org/
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the mammary gland is able to fully reconstitute a ductal tree when grafted to cleared 
fat pads, indicating that stem cells and their niches are distributed at regular intervals 
throughout the ductal system along development (Figure 9). 
 
 
 
 
 
 
 
 
 
 
Figure 9. Stem cell distribution at different stages of mammary gland development. Schematic 
representation of distinct stages of mammary gland development with respective distribution of stem 
cells, not drawn to scale. Mammary epithelium taken from any area of the mammary gland is able to 
fully reconstitute a ductal tree when grafted to cleared fat pads indicating that stem cells and their 
niches are distributed at regular intervals throughout the mammary gland. Adapted from Brisken and 
Duss [149]. 
 
Stem cells in the mammary gland are scarce and, although they have been purified 
and isolated using different techniques, they have not yet been fully characterized. A 
number of different cell surface markers have been described to define stem and 
progenitor mammary cells from both human and mice origin. In 2001, using 
Fluorescence Activated Cell Sorting (FACS), Stingl et al. fractionated the human 
mammary epithelial gland using the markers EpCAM and CD49f and the isolated 
subpopulations were characterized for lineage restricted in vitro colony forming ability 
[150]. Since then, several groups have used different markers to isolate and 
characterize in vitro colony forming ability, as well as in vivo mammary repopulating 
capacity [150-154], identifying subsets of cells that were also enriched in mammary 
stem cells but expressing the different sets of markers[154-157]. 
Hormone signalling, such as ER signalling is important to stem cell function and 
mammary epithelium development [149] and human breast stem cells are likely to be 
ER negative and to require the presence of ER positive cells, the so-called sensored 
Control of Stem Cells and the Stem Cell Niche
by Hormones and Cell–Cell Interactions
Our laboratory is interested in understanding how the
female reproductive hormones control mammary gland
development and influence breast tumorigenesis. Combin-
ing the use of hormone receptor deficient mice with tissue
recombination techniques, we and others have revealed that
the hormones act sequentially on the mammary gland
through their respective receptors in the epithelium (Fig. 2).
Estrogens and progestins, drive ductal elongation and
side branching respectively; both processes involve exten-
sive cell proliferation. We propose that the two hormones
signaling through their respective receptors expressed on a
subset of luminal epithelial cells induce the expression of
local factors that trigger the assembly and the activation of
the stem cell niche. In this way the activity of stem cells
and their niches respond to a systemic stimulus, which in
turn reflects systemic requirements.
During estrogen-driven ductal outgrowth, stem cells at
the tip of the growing ducts, called cap cells, are in direct
contact with the stroma because the basal lamina is
disrupted in this zone. Thus, stromal cells can be recruited
to fulfill the niche cell function (Fig. 3). During progester-
one-induced lat ral branching, th basal lamina may
become thinner but remains intact, and yoepithelial cells
are recruited to form the niche (Fig. 4). Thus the
composition of the niche varies related to the requirements
of the specific developmental stage. Both models will be
discussed below in the context of recent work from our lab.
Estrogen and the Stem Cell Niche
Role of Estrogen Signaling in the Mammary Gland
The role of estrogens in mammary gland development is
illustrated by the finding that pubertal ductal outgrowth
comes to a halt when the ovaries are removed. Outgrowth is
restored when 17-β-estradiol is administered locally by
means of slow release pellets grafted to the mammary gland
[20]. Consistent with estrogens driving ductal outgrowth, in
mammary glands of mice deficient for the estrogen receptor
α (ERα), the prime mediator of estrogen function, a normal
rudimentary d ctal system is for ed but subsequent
development is blocked. When ERα deficient epithelium
is grafted to cleared fat pads of wild type (wt) mice it does
not develop indicating that ERα signaling in the mammary
epithelium is essential for ductal outgrowth.
estrogen progesterone prolactin
rudimentary               ductal elongation/bifurcation              sidebranching alveologenesis
ductal system lactogenic differentiation
Fig. 2 Schematic representation of mammary gland development
(black) and hormonal control (red) of different morphogenetic steps.
Tissue recombination experiments with hormone receptor deficient mouse
strains revealed that the female reproductive hormones estrogens,
progesterone, and prolactin act sequentially during mammary gland
development through their respective receptors in the mammary epithelium
Placode Formation           Mammary Bud         Ductal elongation               Sidebranching
Mammary 
Stem Cell
Fig. 1 Stem cell distribution at
different stages of mammary
gland development. Schematic
representation of distinct stages
of mammary gland development
with respective distribution of
stem cells, not drawn to scale.
Mammary epithelium taken
from any area of the mammary
gland is able to fully reconstitute
a ductal tree when grafted to
cleared fat pads indicating that
stem cells and their niches are
distributed at regular intervals
throughout the mammary gland
Stem Cell Rev (2007) 3:147–156 149
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cells [153, 157-159]. Moreover, it has also been shown that putative mammary stem 
cells in the mouse typically show the expression of EGFR (epidermal growth factor 
receptor) and high molecular weight cytokeratins, weak or almost absent expression 
of CK18 and lack the expression of ER and HER2 [158, 160]. Thus, it is hypothesized 
that mammary stem cells reside within the basal compartment of the mammary gland. 
However, no definitive phenotype is described for the stem cell at the top of the 
hierarchy or the progenitor cells. 
 
2.3 CANCER STEM CELLS (CSC) #
2.3.1 CANCER STEM CELL DEFINITION AND CHARACTERIZATION 
 
Normal adult stem cells have self-renewal and differentiation capacity into several 
lineages; tumour cells have high proliferative capacity, phenotypic plasticity and 
aberrant differentiation [161]. These similarities between stem cells and tumour cells 
have given rise to the hypothesis that breast tumours arise from undifferentiated stem 
or progenitor cells. Moreover, stem cells and CSC share innumerable properties and 
characteristics, such as self-renewal and the reliance on similar signalling pathways 
(for example, Wnt or Notch pathways) and markers such as CD133 [161]. 
The CSC hypothesis or hierarchical model, postulates that a small subpopulation of 
cancer cells is tumourigenic and has the ability to self-renew and generate the 
heterogeneity of cells that comprise the tumour [161, 162]. These cells, named 
cancer stem cells (CSC) or tumour-initiating cells (TIC), share similar properties with 
normal tissue stem cells, including self-renewal and differentiation capacity. 
One major breakthrough in cancer biology has been the isolation and characterization 
of CSC [163]. CSCs have now been isolated from several human tumours, including 
leukaemia [164], breast [165], brain [166], melanoma [167] and colon [168], and the 
presence of these tumour cell subsets correlate strongly with tumour recurrence and 
treatment failure. 
Most authors use cell surface proteins, in order to define a subpopulation of cells that 
represents the breast CSC population. In 2003, Michael Clarke’s group isolated a 
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subset of breast cancer cells with the phenotype ESA+/CD44+/CD24-/low, which were 
able to self-renew and were highly tumourigenic at a low cell inoculum [165]. Since 
then, several other phenotypes and markers have been described to be able to 
identify and isolate breast CSCs. However, the complexity of CSC markers continues 
to pose challenges for identifying and isolating the putative tumour stem cell 
populations by the cell-sorting approach [169].  
Immunohistochemically, basal-like breast tumours share a profile similar to the 
stem/progenitor cells of the normal female breast, including c-kit, α6-integrin, CK5, 
CK14 and prion protein. It is believed that the stem cell at the top of the hierarchy is 
triple negative (ER-/PgR-/HER2-), EGFR+, p63+ and p21-, similarly to myoepithelial 
cells of the mammary gland. One of the most accepted phenotype to identify breast 
CSC in poor prognosis basal-like breast tumour is the CD44+/CD24- phenotype.  
Basal-like breast tumours are mainly composed of cells expressing the CSC marker 
CD44 [157, 170, 171] and an association between the CD44+/CD24- phenotype and 
BLBC subtype has been reported [172-174], indicating possible stem cell features for 
this molecular subtype of cancer. However, the CSC phenotype CD44+CD24-/low is not 
universal and other phenotypes have been proposed to better describe CSCs present 
in basal-like mammary tumours. Other cell markers associated with stem cell 
properties were identified in BLBC, such as the enzyme aldehyde dehydrogenase-1 
(ALDH1), which was correlated with poor prognosis cancers [155, 173]. Also, in 
human ER-negative breast cancers, the phenotype CD44+CD49fhighCD133/2high 
defines a population of tumour initiating cells with self-renewal capacity [175]. 
Moreover, human BRCA1 gene inactivation, which is often associated with this 
phenotype of breast cancer, causes a defect in progenitor cell lineage commitment, 
with an increase in the immature CK14+/CK19+ cells [176], as well as an increase in 
ALDH1 activity with loss of mature luminal differentiation markers [177]. In mice 
breast tumours harbouring BRCA1 deletion, additionally to the CD44+CD24-/low 
subpopulation, the population defined as CD133+ (Prominin+) correlated with stem 
cell activity, producing increased spheroids, being more resistant to DNA damaging 
drugs, and having increased tumourigenic ability [178]. 
In addition to the ability to initiate tumours, CSCs are thought to be capable of 
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initiating metastasis, not only due to their increased ability to invade through Matrigel 
matrix [179], as well as by their link to EMT [156]. Furthermore, the prevalence of 
CD44+CD24- cells in breast cancer patients indicates a link between high numbers of 
stem-like cancer cells and metastasis [180]. Recurrence of breast cancer may reflect 
the inherent ability of CSCs to survive as circulating tumour cells and to form 
micrometastasis, remaining quiescent in distant sites for a long period. The metastatic 
behaviour of cancer cells is also associated to the acquisition of a mesenchymal 
phenotype, which enables certain stem-like characteristics [156, 181]. 
From a clinical point of view, CSCs are a major concern due to their resistance to 
oncologic therapy regimens. Classical antineoplastic treatments, such as 
chemotherapy or radiation, can efficiently eradicate the majority of proliferating and 
genetically unstable malignant cells within neoplastic lesions. However, these 
treatments are inefficient in the eradication of the subpopulation of CSCs because 
these hold innate resistance mechanisms against radiation- and chemotherapy- 
induced cell death, allowing them to survive and cause tumour recurrence. The 
mechanisms of intrinsic therapy resistance in normal and malignant mammary stem 
cells involve enhanced DNA repair mechanisms and anti-apoptotic, which confer 
resistance of stem cells to DNA-damaging agents [182-185], as well as increased 
stem-cell maintenance signalling pathways, such as Wnt/β-ctn and Notch signalling 
[186, 187]. Still, CSCs express high levels of multidrug resistance transporter proteins 
[188]. 
 
2.3.2 CANCER STEM CELL NICHES AND MICROENVIRONMENT INFLUENCE 
 
Oxigen influences not only embryonic, but also adult stem cell and CSC biology [127]. 
CSC niches represent a subject of deep research due to the strong correlation with 
tumour recurrence and treatment failure in several types of cancer. Two different CSC 
niches with different localizations have been described (Figure 10). The first one, the 
perivascular niche, near the blood vessels, such as the one suggested for brain 
tumour initiating cells [189]. The existence of these niches is reinforced by the 
identification of integrin α6 [190] and nitric oxide (NO) [191] as regulators of glioma 
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stem cells (GSC). In fact, it was proposed that hypoxia inducible factors might be 
activated by NO in the perivascular niche of several known cell lines in vitro, despite 
the levels of oxygen in this region [192]. The second CSC niche is thought to be a 
hypoxic niche, away from vasculature [130]. The hypoxic environment observed in 
these niches seems to activate signalling pathways, through the activity of hypoxia 
inducible factors, which are responsible for known characteristics of CSC, such as 
development of an EMT phenotype, maintenance of stemness and self-renewal, as 
well as a metabolic shift. Thus, microenvironmental conditions of these niches have 
been proved to be fundamental for maintenance of stem and CSCs. Essentially, this 
condition has also become acceptable for the increased activity of several types of 
CSCs, such as human acute myeloid leukaemia (AML) and gliomas [130, 193]. In 
gliomas, HIF-2α, but not HIF-1α, has been shown to reduce activity of CSC in 
patients xenografts [130]. In contrast, HIF-1α was shown to be important in CSC 
activity in rodent transplant model of lymphoma and AML patient xenografts, through 
Notch signalling pathway [193]. 
 
 
 
 
 
 
In breast cancer, emerging data has established the link between hypoxia and CSC 
activity. Schwab et al. have demonstrated that HIF-1α promotes mammosphere 
Figure 10. Cancer stem cell niches. CSCs were 
initially described to reside in a perivascular niche 
around tumour vasculature. Recent evidence 
suggests that NO produced by endothelial cells 
maintains the CSC phenotype. Inhibition of this 
signalling pathway results in loss of neurosphere 
forming capacity and attenuation of tumourigenic 
forming capacity in vivo. A secondary niche more 
distal from the vasculature exhibits lower oxygen 
tension and has also been shown to regulate the 
cancer stem cell phenotype. Adjacent to the rim of 
necrotic cells, this hypoxic niche contains cancer stem 
cells whose activity is modulated by multiple HIF-
regulated genes, such as HIF-2α and HIF-1α, and 
other signalling molecules (Oct4, VEGF, Notch, and c-
myc). Adated from Mohyeldin et al. [2].  
et al., 1994), breast (Al-Hajj et al., 2003), rain (Galli et al., 2004;
Lee et al., 2006; Singh et al., 2004), melanoma (Schatton et al.,
2008), colon (O’Brien et al., 2007), and pancreatic cancer
(Hermann et al., 2007), and the presence of these tumor subsets
correlate strongly with tumor recurrence and treatment failure.
Elucidation of the CSC niche and regulators of their biology
has been a subject of intense research. Initial reports on CSCs
argued for an intimate relationship with tumor vasculature, sug-
gesting a perivascular niche like that seen in NSCs (Figure 2)
(Calabrese et al., 2007). This observation has gained wider
acceptance, especially with the recent identification of integrin
a6 (Lathia et al., 2010) and nitric oxide (NO) (Charles et al.,
2010) as potent regulators of glioma CSCs. Holland and
colleagues have demonstrated that endothelial nitric oxide
synthase (eNOS) is highly expressed in tumor vasculature, and
the elaboration of NO by vascular endothelial cells can regulate
adjacent Nestin- and Notch-expressing glioma cells as evi-
denced by an increase in neurosphere-forming capacity in vitro
and enhancement of tumorigenic capacity in vivo (Charles
et al., 2010). Interestingly, eNOS-deficient mice demonstrated
improved survival in a PDGF-induced glioma model (Charles
et al., 2010).
Despite a well-established perivascular niche, CSCs have
recently been proposed to exist in a secondary niche within
cancers that, ironically, is further away from vasculature and,
as a consequence, is more hypoxic (Li et al., 2009). Hypoxic
microenvironments within tumors have long been appreciated
to be a product of aberrant vasculature and due to a rapidly
dividing tumor mass that outstrips its vascular supply (Figure 2)
(Carmeliet and Jain, 2000; Pouyssegur et al., 2006). Zones of
necrosis can readily be seen in rapidly dividing cancers, and
hypoxia has been associated with treatment resistance, local
invasion, and poor clinical outcome (Gordan and Simon, 2007;
Keith and Simon, 2007; Schindl et al., 2002; Zhong et al.,
1999). In addition, the undifferentiated phenotype of solid tumors
seen often in neuroblastoma, breast, and cervical cancers
strongly correlates with tumor hypoxia (Axelson et al., 2005).
Since HIFs, and in particular HIF-2a, have been shown to regu-
late signaling pathways that regulate stem cell self-renewal and
multipotency, it was hypothesized that tumor hypoxia may serve
as another stimulus to regulate CSCs and ultimately influence
tumor progression by the direct activation of this transcription
factor (Keith and Simon, 2007). Direct evidence for this model
was recently provided by Jeremy Rich’s group, who demon-
strated that CD133+ CSCs from gliomas preferentially expressed
HIF-2a and multiple HIF-regulated genes when compared to
non-stem tumor cells and normal neural progenitors (Heddleston
et al., 2009; Li et al., 2009). HIF-2a is a critical and unique
transcriptional regulator in brain tumor stem cells that, when
silenced, leads to the inhibition of self-renewal, proliferation,
and survival in vivo with dramatic attenuation of tumor initiation
potential of glioma CSCs (Li et al., 2009).
The discovery of HIF-2a regulation of Oct4, as well as several
downstream targets that maintain stem cell self renewal, has led
to a considerable amount of interest in the role of this transcrip-
tion factor in stem cells (Covello et al., 2006). Recently, conver-
gence of several observations supports a more prominent
oncogenic role of HIF-2a in several genetically diverse cancers
that may exploit this signaling cascade (Franovic et al., 2009;
Li et al., 2009). Franovic et al. demonstrated that inhibition
of HIF-2a in highly aggressive glioblastoma, colorectal, and
non-small lung carcinomas, cancers that have been shown to
harbor CSC populations, prevented in vivo growth and tumori-
genesis regardless of their mutational status and tissue of origin
(Franovic et al., 2009). NO has been shown to activate HIF in
several known cell lines in vitro (Berchner-Pfannschmidt et al.,
2007); thus, it will be interesting to see if HIF is indeed activated
by NO in the perivascular niche, despite adequate levels of
oxygen in this region. HIF-2a has already been shown to induce
eNOS (Coulet et al., 2003), which makes the hypothesis that an
autocrine loop that regulates the CSC phenotype in hypoxic
niches both plausible and testable.
Notch signaling has emerged as a critical regulator of stem
cells (Gustafsson et al., 2005). This relationship has led investiga-
tors to examine its role in CSCs and, more specifically, in epithe-
lial-to-mesenchymal transition (EMT) within tumors (Sahlgren
et al., 2008). For example, blockade of Notch signaling with
gamma-secretase inhibitors depletes cancer stem-like cells in
gliomas and inhibits growth of xenografts (Fan et al., 2010).
In addition, it has been proposed that the initial steps in local
Figure 2. Cancer Stem Cell Niche
Nestin- and Notch-expressing glioma-initiating
cells (ca cer stem cells) were initially described
to reside in a perivascular niche around tumor
vasculature. Recent evidence suggests that NO
produced by endothelial cells maintains the
cancer stem cell phenotype. Inhibition of this
signaling pathway results in loss of neurosphere
forming capacity and attenuation of tumorigenic
forming capacity in vivo. A secondary niche more
distal from the vasculature exhibits lower oxygen
tension and has also been shown to regulate the
cancer stem cell phenotype. Adjacent to the rim
of necrotic cells, this hypoxic niche contains
cancer stem cells whose activity is modulated by
multiple HIF-regulated genes, such as HIF-2a
and HIF-1a, and other signaling molecules (Oct4,
VEGF, Notch, and c-myc). Recent evidence
suggests that cancer stem cells differentially
respond to hypoxia with distinct HIF induction
patterns. Targeted inhibition of HIF-2a inhibits
self-renewal, proliferation, and survival in vitro
and attenuates tumor initiation potential.
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formation and enhances CSC frequency in vivo, in part by the regulation of the 
expression of markers associated with the basal lineage and Notch pathway [46]. 
Furthermore, it was shown that repetitive hypoxia/reoxygenation cycles are able to 
select and expand a highly tumourigenic, with EMT phenotype, stem-like breast 
cancer cell subpopulation [39]. Still, Gammon et al. demonstrated that hypoxia selects 
a breast cancer cells population with EMT features and increased mammosphere 
ability, a typical characteristic of CSCs [38]. Interestingly, differential expression of 
HIF-1α was observed in human primary invasive breast carcinomas with CD44+CD24-
/low phenotype [194]. 
Importantly, breast CSC expansion by tumour hypoxia seems to play a causal role in 
the limited efficacy of anti-angiogenic therapies. Blocking angiogenesis through 
inhibition of the vascular endothelial growth factor (VEGF) pathway reduces tumour 
growth. Clinically, VEGF-neutralizing antibody Avastin (bevacizumab) and VEGF 
receptor tyrosine kinase inhibitors (sorafenib and sunitinib) have been used as anti-
cancer treatments in several tumour types, including breast cancer [195]. However, 
only a moderate increase in progression-free survival and little benefit in overall 
survival have been observed [196]. This inefficacy was partially attributed to the 
generation of intratumoural hypoxia, which leads to an increase of breast CSC 
population, through Wnt pathway via Akt/β-ctn signalling [197]. 
Moreover, hypoxia-induced CAIX is also involved in the expansion and maintenance 
of CSC. In 2012, Lock et al. described CAIX as a critical mediator of the expansion of 
breast CSCs in hypoxic niches by supporting the mesenchymal and ‘stemness’ 
phenotypes of these cells, pointing to CAIX as an important therapeutic target for 
selectively depleting breast CSCs and improvement of chemotherapeutic response 
[198]. Glucose restriction is also involved in CSC expansion. This is the case of 
glioblastomas, for example, where nutrient limitation contributes to tumour 
progression by the enrichment of brain CSC. Flavahan et al. demonstrated that non-
brain CSC are able to adapt and survive to glucose deprivation environments by the 
acquisition on brain CSC features. Importantly, these authors demonstrated that 
growth and tumourigenic potential of these aggressive tumours is highly influenced by 
GLUT3 mediated glucose uptake by brain CSC [199]. Thus, suppressing the hypoxic 
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response and/or targeting pathways of nutrient uptake and metabolism, may be 
beneficial for cancer patients due to their involvement in breast CSC subpopulation 
activity and expansion, that are thought to be responsible for patient relapse and 
metastasis. 
 
2.3.3 BREAST CANCER STEM CELL METABOLISM 
 
Interestingly, stem and CSCs also share unique metabolic properties, in common with 
actively proliferating cells. The increased glycolytic profile, low OXPHOS and low 
mitochondrial activity, characteristics observed in pluripotent stem cells, are shared 
with CSC.  Recently, Vega-Naredo et al. showed that embryonal carcinoma stem 
cells present a glycolytic phenotype, decreased mitochondrial activity and biogenesis 
and increased resistance to DCA (dichloroacetate), comparing to their differentiated 
counterparts [200]. Specifically in breast cancer, cells with stem-like properties 
present a glycolytic metabolism comparing to their differentiated counterparts. Feng 
et al. have recently demonstrated that breast CSC, defined by CD49fhigh/Epcamlow 
phenotype, use preferentially glycolysis instead of OXPHOS as their metabolic 
programme, when compared with non-breast CSC [201]. Expression and activation of 
mitochondrial pyruvate dehydrogenase (PDH), which makes the link between 
glycolytic pathway and OXPHOS, favouring OXPHOS, was also found to be 
decreased in breast CSC when compared to non-breast CSC, explaining the unique 
metabolic programme of these cells [201]. Other authors have also demonstrated the 
glycolytic behaviour of breast CSC. Using proteomic and targeted metabolomics 
analysis, Ciavardelli et al. demonstrated that breast CSC shift from mitochondrial 
oxidative phosphorylation (OXPHOS) towards glycolytic metabolism and present 
increased expression of key enzymes of anaerobic metabolism, such as PKM2 
(Pyruvate dehydrogenase kinase M2), LDH, and G6PD (glucose-6-phosphate 
dehydrogenase), as well as increased antioxidant defence system [202]. Still, 
Gammon et al. also demonstrated that a breast CSC population with EMT 
characteristics, presented high levels of HIF-1α, decreased mitochondrial mass and 
membrane potential, consumed less oxygen and presented lower levels of ROS [38]. 
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Moreover, several studies have been reporting that glycolytic inhibitors and OXPHOS 
enhancers, selectively targets breast cancer cells [203], as well as breast CSC, 
highlighting the dependence of these cells on glycolytic metabolism [201, 202]. 
 
2.3.4 OXIDATIVE STRESS IN STEM AND CANCER STEM CELLS 
 
ROS are a highly reactive group of oxygen-containing molecules, including free 
radicals and peroxides, such as superoxide anion (O2•− ) and hydrogen peroxide (H2 
O2), generated as common by-products of oxidative metabolism, or in response to the 
activation of several oxidative enzyme complexes [204-207]. At physiologic 
concentrations, ROS functions as signalling molecules, being involved in redox-
dependent regulation of multiple signal transduction pathways, meeting different 
biological processes such cell adhesion, migration, proliferation, differentiation, and 
survival [204-207]. An imbalance between the production of ROS and cellular 
antioxidant mechanisms, that detoxify these reactive molecules, leads to an 
excessive accumulation of ROS, exerting damaging effects through oxidative stress 
in cells. The maintenance of highly regulated mechanisms to control ROS levels and 
functional specificity is therefore essential for normal cellular homeostasis and proper 
response to environmental stimuli. 
Cells that undergo aerobic metabolism are subject to some degree of oxidative stress 
through the generation of ROS that can damage DNA. For instance, mouse 
embryonic fibroblasts accumulate more mutations and senesce faster when cultured 
under 20% O2 than when cultured under 3% O2 [208]. By residing in low oxygen 
tensions compartments, stem and CSC not only maintain slow cycling proliferation, 
quiescent and undifferentiated state, but they can also escape the oxidative stress 
damage associated with oxygenated tissues [124, 127, 208, 209]. As described 
above, hypoxia induces a metabolic switch that shunts glucose metabolites to 
glycolysis to maintain ATP production and prevent increase of ROS levels to a toxic 
level [55]. Thus, HIF-1α is likely to be a candidate to regulate this mechanism, not 
only due to its function as a glycolytic metabolism inducer, as well as due to its role in 
mediating cell-cycle arrest [210]. Several types of cells, including HSC and early 
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progenitors, contain low levels of ROS comparing to their more mature progeny [211, 
212]. This difference seems to be critical for maintaining stem cell function. In the 
mammary gland, the two specific types of cells, the luminal and the 
basal/myoepithelial cell layer, were found to present different levels of ROS, which 
was attributed to differences in their mitochondrial content [213, 214]. Interestingly, 
normal human basal mammary epithelial cells present low levels of ROS, which are 
thought to be maintained by glutathione-dependent mechanisms, while the matching 
purified luminal progenitor cells contained higher levels of ROS, multiple-independent 
antioxidants and oxidative nucleotide damaging control proteins, consuming oxygen 
at higher levels [214]. Moreover, luminal progenitor cells are known to be more 
resistant to glutathione depletion than basal cells and also to be more resistant to 
oxidative stress caused by H2O2 and ionizing radiation [214]. Moreover, it was also 
demonstrated that mammary epithelial cells coordinate their responses to detachment 
through the increase of antioxidant systems, such as SOD2 (superoxide dismutase 
2), decreasing ROS production from mitochondrial oxidation, and allowing them to 
escape ECM-detachment cell death [215]. Similarly, normal mammary epithelial stem 
cells, as well as subsets of CSCs in some human and murine breast tumours, contain 
lower ROS levels than their corresponding mature progeny cells and non-
tumourigenic cells (NTCs), respectively [213]. Since ROS are critical mediators of 
ionizing radiation-induced cell death [216], the idea that CSC are able to survive to 
radiation induced cell death due to their low content of ROS is extremely attractive. 
Similar to normal tissue stem cells, subsets of CSCs in breast tumours contain lower 
ROS levels and enhanced ROS defences compared to their non-tumourigenic 
progeny, which may contribute to tumour radioresistance. Dihen et al. demonstrated 
that breast CSC develop less DNA damage and are preferentially spared after 
irradiation compared to NTCs [213]. Moreover, other reports have corroborated this 
concept through the demonstration that breast CSCs are a radioresistant 
subpopulation of breast cancer cells, which are expanded in number after short 
courses of fractionated irradiation [217]. 
Thus, metabolic properties of stem and CSC, as well the environment of the place 
were they reside, are implicated in the resistance to therapy by the opportunity to 
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escape to oxidative stress. Taken together, since CSC might be responsible for 
recurrence, metastasis and therapeutic resistance, combination of CSC target 
therapies, with current available therapeutic regimens, is a goal for the improvement 
of cancer treatment (Ablett et al., 2012). 
 
3. P-CADHERIN IN STEMNESS AND IN CANCER 
 
P-cadherin (or placental cadherin) is a cell-cell adhesion molecule, whose expression 
is highly associated with undifferentiated cells in normal adult epithelial tissues, as 
well as with poorly differentiated carcinomas. Its expression has been already 
reported in human ESC and it is presumed to be a marker of stem or progenitor cells 
of some epithelial tissues. In normal breast, P-cadherin has an essential role during 
ductal mammary branching, being expressed by the monolayer of epithelial cap cells 
at the end buds. In mature mammary tissue, its expression is restricted to the 
myoepithelium. In breast cancer, P-cadherin is frequently overexpressed in high-
grade tumours, being a well-established indicator of poor patient prognosis. 
Moreover, P-cadherin is an important inducer of breast cancer cell migration and 
invasion. Due to P-cadherin’s role in cancer cell invasion and metastasis formation, a 
humanized monoclonal antibody, which antagonizes P-cadherin-associated signalling 
pathways, was already produced and used in clinical trials. 
 
3.1 PROTEIN STRUCTURE AND FUNCTION #
P-cadherin was the third classical cadherin to be identified and characterized in the 
mouse visceral endoderm cell line PSA5-E [218, 219]. Its expression was originally 
observed in mouse placenta throughout pregnancy [218, 220] and, although the 
name might suggest, P-cadherin is not expressed in human placenta [220]. 
The gene encoding P-cadherin (CDH3), sharing 66% of homology with the far more 
well characterized CDH1 (the gene that encodes E-cadherin), maps to chromosome 
16q22.1, a region that contains a cluster of several cadherin genes, just 32 kilobases 
upstream of the gene encoding human E-cadherin [221, 222]. It is composed by 16 
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exons and exhibits a high degree of conservation in intron positions, as well as a 
large intron after exon 2 [223]. Additionally, this gene harbours a 5′!located CpG 
island on its promoter region (Figure 11) [224, 225]. 
Mutations in the CDH3 gene have been reported to be responsible for congenital 
hypotrichosis associated with juvenile macular dystrophy, which is a rare autosomal-
recessive disorder characterized by abnormal growth of scalp hair, followed by 
progressive macular retinal degeneration that leads to early blindness [226]. 
The mature P-cadherin glycoprotein has a molecular weight of 118 kDa, and its 
structure is similar to that of classical cadherins [218]. It comprises three distinct 
domains (extracellular, transmembrane and cytoplasmic) and it mainly, but not 
exclusively, promotes homotypic interactions (between P-cadherins molecules) [218, 
227]. The amino- terminal domain is essential for the creation of lateral dimmers that 
act together in a zipper-like structure between neighbouring cells (Figure 11) [228, 
229]. 
The function and strength of P-cadherin mediated adhesion depends on its dynamic 
association with a group of cytoplasmic molecules, called catenins. These molecules 
serve to link the cadherin cytoplasmic tail to the actin cytoskeleton and facilitate 
clustering into the junctional structure, forming cadherin-catenin complexes (Figure 
11) [229, 231]. This tail comprises two main domains: the catenin binding domain 
(CBD), which is known to be essential for cadherin function, and the juxtamembrane 
domain (JMD), which has been suggested to play a critical role in allowing cells to 
relocate [227]. The α, β, γ and p120 catenins are the documented interaction partners 
[232]. β-ctn (and also γ-ctn) is a signalling molecule that is involved in tissue 
patterning, and it is regulated by the CBD, tyrosine phosphorylation and 
transcriptional factors [233]. 
p120-ctn interacts directly with the JMD and is also regulated by tyrosine kinases, 
modulating cadherin intracellular trafficking, stability, adhesive capacity and cell 
motility [234-236]. The α-ctn links the cadherin-catenin junctional complex to the actin 
cytoskeleton [233]. 
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In 1989, Shimoyama and co-workers [220] showed that NIH3T3 cells transfected with 
human P-cadherin cDNA expressed the functional cadherin molecule, which was able 
to mediate cell-cell adhesion.  The adherens-type junctions play an important role in 
cell sorting during embryogenesis and in the maintenance of specific organ and adult 
tissue architecture [237, 238]. These are also essential in intracellular signalling 
mechanisms [233, 239], which regulate cell polarity, differentiation, growth and 
migration [240]. 
 
Figure 11. Schematic representation of the structural components of the P-cadherin adhesive 
junction. Lateral clustering of P-cadherin molecules is required to form stable cell-to-cell contacts in 
BT20 breast cancer cells [immunofluorescence: P-cadherin (green), F-actin (red), DAPI (blue)]. In the 
intercellular space, P-cadherin extracellular domains interact with P-cadherin extracellular domains of 
adjacent cells to mediate cell adhesion. The intra-cellular catenins bind to the cytoplasmic tail of P-
cadherin. p120-ctn binds the cadherin tail at the juxtamembrane domain (JMD), whereas β-ctn binds to 
the distal catenin binding domain (CBD). α-ctn associates with β-ctn and is directly linked to the actin 
cytoskeleton. The lower panel shows the genomic structure of CDH3/P-cadherin gene, which is 
constituted by 16 exons: the extracellular part of P-cadherin is encoded by 10 exons (exons 4-13), 
whereas the transmembrane and intracellular domains are determined only by the information included 
in the last 3 exons (exons 14-16). Adapted From Albergaria et al. [230]. 
 
3.2 CDH3 REGULATION #
Regulation of cadherin-mediated adhesion seems to be a very dynamic, elegant and 
complex net of mechanisms and players, which underlie the dynamics of the 
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downstream signalling (Suyama et al., 2002).
P-cadherin is also often reported to correlate with increased 
tumour cell motility and invasiveness when overexpressed (Cheung 
et al., 2010, Paredes et al., 2004, Ribeiro et al., 2010, Taniuchi et 
al., 2005). Although the role of P-cadherin encoding gene (CDH3) 
in cancer is far less well characterized than the one attributed to 
CDH1, the opposite effects in mammary cancer are weird, since 
these molecules share more than 67% of homology (Hulpiau and 
van Roy, 2009). The CDH3JHQHKDUERXUVH[RQV)LJDQG
maps to chromosome 16q22.1, a region that contains a cluster of 
several cadherin genes, just 32 kilobases upstream of the gene 
encoding human E-cadherin (Bussemakers et al., 1994). The 
mature P-cadherin glycoprotein structure is similar to that of clas-
sical cadherins, comprising three distinct domains (extracellular, 
transmembrane and intracellular), in order to promote homotypic 
interactions. At the cell membrane, these create lateral dimers that 
act together in a zipper-like structure between neighbouring cells 
(Shapiro et al., 1995))LJ
The function and strength of P-cadherin-mediated adhesion 
depends on its dynamic association with catenins, which link the 
cadherin cytoplasmic tail to the actin cytoskeleton and facilitate 
clustering into the junctional structure, forming cadherin/catenin 
complexes. This tail comprises two main domains: the juxtamem-
brane domain (JMD), which has been suggested to play a critical 
role in cadherins stability at the cell membrane, and the catenin-
binding domain (CBD), which is known to be essential for cadherin 
function. The p120-catenin (p120ctn), ` -catenin (`ctn) and _-catenin 
(_ctn) are the major documented interaction partners that bind to 
cadherin intracellular domains and allow the binding to the actin 
cytoskeleton of the cell *UHHQ et al., 2010))LJ
P-cadherin upregulation was frequently observed in various 
malignant tumours, including breast, gastric, endometrial, colo-
rectal and pancreatic carcinomas, and is correlated with poor 
survival of breast cancer patients (Hardy et al., 2002, Imai et al., 
2008, Paredes et al., 2005, Stefansson et al., 2004, Taniuchi et 
al., 2005) ,QFRQWUDVWVLJQLÀFDQWO\ ORZ OHYHOVRI WKH3FDGKHULQ
gene expression were detected in a diverse panel of normal tis-
sues (Imai et al., 2008). Thus, disruption of P-cadherin signalling 
represents an intriguing opportunity for the development of novel 
targeted therapeutic agents in cancer.
P-cadherin role in epithelial cell differentiation
Classical cadherins play important roles in maintaining the 
structural integrity of epithelial tissues and are mainly involved 
in cell differentiation during embryogenesis. There are several 
indications in the literature that point to the relationship between 
cell adhesion molecules and stem cell features, not only as 
biomarkers that help to isolate and characterise stem cells, but 
also as important mediators of stem cell activity, via modulation 
of signalling pathways (Raymond et al., 2009). Regarding the 
classical cadherins, an important amount of data comes from the 
LGHQWLÀFDWLRQRI3FDGKHULQDVDPDUNHURIXQGLIIHUHQWLDWHGVWHP
or progenitor cells (Kendrick et al., 2008, Raymond et al., 2009). 
In a very recent study, it has been shown that CDH3 is one of 
the genes that encode a surface protein that identify the pluripotent 
population of human embryonic stem cells (Kolle et al., 2009). This 
expression is concomitant with the one of E-cadherin, which was 
Fig. 1. Schematic representation of the structural components of the P-cadherin adhesive junction. Lateral clustering of P-cadherin molecules 
is required to form stable cell-to-cell contacts in BT-20 breast cancer cells [immunofluorescence: P-cadherin (green), F-actin (red), DAPI (blue)]. In the 
intercellular space, P-cadherin extracellular domains interact with P-cadherin extracellular domains of adjacent cells to mediate cell adhesion. The intra-
cellular catenins bind to the cytoplasmic tail of P-c dherin. p120-cat nin binds the cadhe in tail at the juxtamembrane domain (JMD), whereas ` -catenin 
binds to the distal catenin binding domain (CBD). _-catenin associates with `-catenin and is directly linked to the actin cytoskeleton. The lower panel 
shows the genomic structure of CDH3/P-cadherin gene, which is constituted by 16 exons: the extracellular part of P-cadherin is encoded by 10 exons 
(exons 4-13), whereas the transmembrane and intra llular domains are determined only by the information i cluded in the last 3 ex ns (exons 14-16).
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adhesive interaction between cells. Although the described evidences that the 
expression of inappropriate cadherins can result from growth factors and hormones 
stimulation in the tumour microenvironment, or from changes in the promoter regions 
of cadherins and transcriptional, and post-translational regulation, specific data 
concerning CDH3 gene regulation is still very limited. 
The pivotal molecular mechanism involved in CDH3/P-cadherin deregulation is mainly 
occurring at the promoter region of the gene and not by structural alterations of its 
coding sequences. The main described regulators of CDH3 are ERα [241] and 
BRCA1/c-Myc/Sp1 [242], which act as repressors of P-cadherin expression, and β-ctn 
[243], C/EBPβ [244] and p63 [245], that are able to activate its expression (Figure 
12). 
 
Figure 12. Transcriptional regulators of CDH3/P-cadherin gene promoter. β-ctn, p63 and C/EBPβ 
are transcriptional activators of the CDH3 promoter. In contrast, BRCA-1/c-Myc/Sp1 complex acts as 
transcriptional repressor of the CDH3 promoter. Moreover, oestrogen receptor (ER) can indirectly 
repress P-cadherin expression by controlling epigenetic changes in CDH3 gene promoter. Adapted 
from Albergaria et al. [230]. 
 
In 2004, we described that the lack of ERα signalling is responsible for the P-cadherin 
de novo expression, categorizing CDH3 as a putative oestrogen-repressed gene. It 
was also showed that the anti-oestrogen ICI 182,780 is able to increase CDH3 
promoter activity, mRNA and protein levels in a time and dose dependent manner 
[241]. Furthermore, this anti-ER drug induces a chromatin structural remodelling, 
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capacity through the matrigel matrix (Ribeiro et al., 2010). This 
same migratory phenotype was observed in bladder, pancreatic 
and cholangiocarcinoma cancer cell lines (Baek et al., 2010, Man-
deville et al., 2008, Taniuchi et al., 2005, Van Marck et al., 2011). 
Curiously, we have noticed that P-cadherin is able to induce 
invasion only in cell systems which already express an endogenous 
and functional cadherin, like E-cadherin in breast cancer cells, 
or N-cadherin in HEK293T cells and PDAC pancreatic cancer 
cells (Paredes et al., 2004, Ribeiro et al., 2010, Taniuchi et al., 
2005). Bas d o  this hypothesis, w  have recently proved that 
P-cadherin is able to interact with E-cadherin in breast tumours 
and cancer cells, promoting cancer cell invasion by disrupting the 
interaction between E-cadherin and both p120ctn and ` ctn. In the 
absence of E-cadherin expression, in the same cancer model, P-
cadherin is able to suppress invasion by its strong interaction with 
catenins, surrogating the role of E-cadherin in cell-cell adhesion 
(unpublished data).
P-cadherin role in EMT and cadherin switch
Among the cadherin families, E-cadherin and N-cadherin are 
the most highly characterized subgroup of adhesion proteins. 
E- adheri  is ubiquitously expressed throughout most epithelial 
tissues and serves as a negative regulator to functionally block 
the `ctn signalling pathway and suppress tumour cell growth and 
invasion (Onder et al., 2008). However, numerous preclinical and 
clinical studies have shown that the loss of E-cadherin occurs 
concurrently with the upregulation of N-cadherin or other cadherin 
family members implicated in invasive growth, like P-cadherin or 
cadherin-11. This process, known as cadherin switching, has been 
reported to promote epithelial-to-mesenchymal transition (EMT) and 
leads to tumour cell invasion and metastasis (Thiery et al., 2009). 
Indeed, the switch from E- to N-cadherin is the one better known 
and reported by several studies. N-cadherin overexpression, via 
cadherin switching, was observed in various invasive cancer cell 
lines and tumours, namely from the esophagus, prostate, cervix, 
DQGRYDU\7KLVVSHFLÀFFDGKHULQVZLWFKOHDGVWRWKHLQKLELWLRQRI
cell-cell contacts and elicits active signals that support tumour-
cell migration, invasion, and metastatic dissemination (Thiery et 
al., 2009). 
The cadherin switch from E- to P-cadherin is a common event 
during embryo dev lopment; however, few reports describe it during 
tumour progression. Indeed, some invasive and aggressive epi-
thelial tumours, namely the loc l advanced IBC, and some highly 
metastatic breast cancer cells, as the 4T1 cell model, maintain 
E-cadherin expression at the cell membrane and show aberrant 
concomitant expression of P-cadherin (Ben Hamida et al., 2008, 
Lou et al., 2008). Nevertheless, there are some reports showing 
a switch from these two epithelial cadherins during tumour pro-
gression, namely in ovarian, endometrial and bladder carcinoma 
(Bryan et al., 2008, Patel et al., 2003, Stefansson et al., 2004). In 
DOOWKHVHVWXGLHV3FDGKHULQLQFUHDVHGH[SUHVVLRQVLJQLÀFDQWO\FRU-
related with decre sed E-cadherin expression and, conseque tl , 
represented a key step in disease progression. However, it has 
been already shown that, in holangiocarcinoma cell , the E- to
P-cadherin switch does not induce EMT signalling, since does not 
affect the expression of mesenchymal markers, such as Snail 1 
DQGYLPHQWLQDQGÀEURQHFWLQ(Baek et al., 2010).
Recognized regulators of CDH3/P-cadherin transcription
Signalling pathways or other cellular mechanisms that are in-
volved in the regulation of cadherin-mediated adhesion are thought 
to underlie the dynamics of the adhesive interactions between cells. 
Fig. 3. Schematic representation of the described transcriptional regulators of CDH3 /P-cadherin promoter gene. It has been shown that 
`-catenin, p63 and C/EBP` are transcriptional activators of CDH3 promoter, inducing its expression at the mRNA and protein level. In contrast, 
estrogen receptor (ER), as well as the BRCA1/c-Myc/Sp1 complex, act as transcriptional repressors of CDH3 promoter gene.
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eventually allowing the binding of nearby transcriptions factors [246]. 
The expression profiling of BRCA1-deficient hereditary tumours has identified a 
pattern of gene expression similar to basal-like breast tumours [52]. Thus, as a gene 
associated with the basal-like phenotype in breast cancer, the mRNA and protein 
levels of CDH3/P-cadherin gene were shown to be also transcriptionally repressed by 
functional BRCA1 protein in breast cancer cell lines. This repression is achieved after 
the formation of BRCA1 and c-Myc repressor complex (BRCA1-c-Myc complex) on 
the promoters of specific basal genes, including CDH3 gene, and represent a 
potential mechanism to explain the observed overexpression of key basal markers in 
BRCA1-deficient tumours [242]. In fact, in breast carcinomas, it has been shown that 
P-cadherin expression is strongly associated with the presence of BRCA1 mutations 
[247], which means that this repression does not occur in breast cancer cells with a 
BRCA1 mutation and the CDH3 gene is expressed. 
Conversely, in vitro and in vivo studies also have shown that β-catenin activates 
CDH3 promoter, leading to overexpression of P-cadherin in basal mammary epithelial 
cells. In fact, it was shown that activation of β-catenin signalling correlates with 
upregulation of CDH3 promoter and P-cadherin expression, as well as 
downregulation of endogenous β-catenin levels inhibited CDH3 promoter activity 
[243]. 
Another putative transcription factor of P-cadherin is CCAAT/enhancer-binding 
protein β (C/EBPβ), which was demonstrated as able to upregulate CDH3 promoter in 
breast cancer cells. Moreover, the expression of P-cadherin and C/EBPβ are highly 
associated in human breast carcinomas and both linked with a worse prognosis of 
breast cancer patients [246]. 
From the p53 family related factor,p63 is a key regulator of adhesion and survival in 
basal cells of the mammary gland, showing that several cell adhesion-associated 
genes were downregulated due to p63 expression, which also led to detachment 
between mammary epithelial cells [248]. This involvement of p63 in cell adhesion 
mechanisms was linked with CDH3 gene in developmental models, where P-cadherin 
has been described as a direct p63 transcriptional target, interplaying a crucial role in 
human limb bud and hair follicle development [245]. Moreover, unpublished work form 
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our group demonstrates that different p63 isoforms have different abilities to modulate 
the activity of CDH3 promoter in breast cancer cells, being the truncated TAp63γ 
isoform the one which greater represses CDH3 activity. Additionally, we also 
observed a decreased of the P-cadherin induced functional proprieties, such as 
invasion and mammosphere formation efficiency (MFE), when cells were transfected 
with TAp63γ, being this effect dependent on p53 wild type or mutated status. 
Moreover, epigenetic alterations are also responsible for regulation of CDH3 
expression. P-cadherin negative epithelial/luminal normal breast cells are consistently 
methylated in a specific region of the CDH3 gene promoter, whereas in breast 
cancer, it was established the existence of a significant correlation between P- 
cadherin overexpression and hypomethylation of this same specific promoter region 
[249]. Regulatory role of DNA methylation in the expression of P-cadherin is also 
present in other cancer models. Analysis of CDH3 promoter revealed that it was 
hypomethylated in colorectal and gastric cancer, leading to increased P-cadherin 
expression; however, in pancreatic and melanoma cancer models, CDH3 was shown 
to be silenced by aberrant hypermethylation [250-252]. 
In 2005, we analysed P-cadherin promoter methylation in normal breast tissue, from 
which only epithelial cells were microdissected, and methylation of CDH3 gene 
promoter was found in the normal epithelial/luminal cell layer from all the specimens 
analysed, which was associated with negative P-cadherin expression in these cells. 
Moreover, P-cadherin overexpression results from CDH3 promoter hypomethylation. 
Using a large series of invasive breast carcinomas, we found that 71% of P-cadherin-
negative breast cancer cases were methylated for the CDH3 gene, whereas 65% of 
P-cadherin-positive cases were unmethylated [249]. 
However, promoter methylation is not the only epigenetic event that may regulate the 
CDH3 gene promoter. Genomic structure of the gene, like the enrichment in CpG site, 
as well as the attributed DNA hypersensitive sites can also play a role in the 
regulation of CDH3 expression. We have observed an upregulation of CDH3 
promoter activity and P-cadherin expression in cells treated with the histone 
deacetylases (HDAC) inhibitor Trichostatin A (TSA), showing that chromatin-
activating modifications play an important role in the modulation of this gene [246]. 
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3.3 ROLE IN STEMNESS AND EPITHELIAL CELL DIFFERENTIATION 
 
Classical cadherins play important roles in maintaining the structural integrity of 
epithelial tissues and are mainly involved in cell differentiation during embryogenesis 
[230]. There are clear indications in the literature establishing the link between cell 
adhesion molecules and stem cell features, not only as biomarkers that help to isolate 
and characterise stem cells, but also as important mediators of stem cell activity, via 
modulation of signalling pathways [253]. 
P-cadherin was already identified as a marker of undifferentiated stem or progenitor 
cells [253, 254]. In a recent study, CDH3 is one of the genes that encode a surface 
protein that identifies the pluripotent population of human ESC [255]. However, the 
most dramatic expression of P-cadherin is observed in the placenta, both in the 
embryonic and maternal regions, hence the classical denomination of placental-
cadherin. Early reports specified low P-cadherin expression in human placenta, but 
high amounts in mice placenta [220]. 
In adult tissues, the expression of P-cadherin is mainly found in the basal layer of 
several epithelial structures, such as skin, uterine cervix, prostate, and lung, 
contributing to the maintenance of the epithelial phenotype. The expression of 
cadherin molecules was extensively studied in mouse epidermis, in adulthood and 
during fetal development, where it has been found that E-cadherin is expressed both 
in the basal and intermediate layers of epidermis, whereas P-cadherin is only 
expressed in the basal and proliferative layer [256]. Furthermore, loss of E-cadherin 
plays an important role in bud formation and in the acquisition of an invasive 
behaviour, whereas P-cadherin becomes predominant expressed later in 
development, namely in the growing hair follicle and in the early progenitor cells from 
hair germs and small hair placodes [257, 258]. Like hair follicles, sweat glands and 
mammary glands develop also from the same discrete accumulation of stem cells 
resting in the primitive epidermis, the outermost cell layer of an embryo, and there is 
strong evidence that dynamic changes in the composition of adherens junctions are 
important for the development of skin appendages [257]. 
The final evidence showing the importance of P-cadherin for the architecture and 
development of epithelial tissues was demonstrated by human genetic syndromes 
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that are induced due to P-cadherin loss. CDH3 gene mutations have been shown to 
cause P-cadherin functional inactivation, leading to developmental defects associated 
with two inherited diseases in humans: 1) hypotrichosis with juvenile macular 
dystrophy (HJMD) and 2) ectodermal dysplasia, ectrodactyly, and macular dystrophy 
(EEM syndrome). No defects were described for these conditions, concerning the 
human mammary development [230]. 
P-cadherin is transiently expressed in various tissues during development [259, 260] 
and its permanent expression is limited to adult epithelial tissues, at cell-cell 
boundaries [261]. It has been associated with undifferentiation and proliferation of 
tissues, as well as with the connection or segregation of cell layers, as found for other 
cadherins [218, 257, 261, 262]. 
 
3.3.1 P-CADHERIN IN MAMMARY GLAND DIFFERENTIATION 
 
During normal breast development, P-cadherin has an essential role in the ductal 
mammary branching, being expressed by the monolayer of epithelial cap cells at the 
terminal end buds (TEBs) [263]. Moreover, this molecule is important for the 
undifferentiated state of the normal mammary gland [264], where its expression is 
restricted to the myoepithelium, although it has been postulated that it may also be 
present in early luminal progenitor cells [228, 230, 265]. 
P-cadherin is extremely important to the establishment of the correct architecture of 
the tissue, as demonstrated by functional-blocking antibody experiments in vitro and 
in vivo. Daniel and collaborators exposed the end buds and mature mammary glands 
of 5 week-old virgin mice to slow-release plastic implants liberating a monoclonal 
antibody for P-cadherin. No effect in the luminal layer was found, but disruption of the 
basally located cap cell layer was clearly observed [263]. Also, more recently, 
Chanson et al., described that P-cadherin contributes specifically to the organization 
of the myoepithelial cell layer of the breast, since when an antibody that blocks P-
cadherin function was used in an in vitro self-organizing assay of the human 
mammary bilayer, the migration of mammary epithelial cells (MEC), occurring during 
normal sorting of both layers, was compromised [266]. These experiments indicate 
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that selective expression of P-cadherin in the basal layer is necessary for the 
maintenance of mammary tissue integrity. 
In fact, deletion of P-cadherin affects normal mammopoiesis, since the CDH3-null 
female mice exhibit precocious mammary gland differentiation in the virgin state, and 
breast hyperplasia and dysplasia with age [264]. These observations in knockout 
animals indicate P-cadherin cell-cell interactions and signalling as regulatory 
determinants of the negative growth of the luminal epithelium, being important for the 
maintenance of an undifferentiated state of the normal mammary gland. 
The expression of P-cadherin is activated in human mammary luminal cells during 
late pregnancy and lactation [267]. In these alveolar lactating cells, the pattern of P-
cadherin expression is not restricted to the cell-cell borders, but shows a cytoplasmic 
staining, typical of a secreted protein. Indeed, in human milk, a soluble fragment of P-
cadherin (sP-cad) with 80KDa was found to be present, corresponding to the 
extracellular domain of the molecule [267]. Mannello and collaborators showed that 
the highest concentration of sP-cad is detected in milk collected during the first 
trimester of lactation [268]. However, the biological and physiological role of this 
fragment in the normal function of the breast is still unclear. Some authors suggest a 
role for sP-cad in alveolar differentiation during lactation, or in the immune response 
of the mother or the baby, or as a signalling protein between epithelial and 
myoepithelial cells. This fragment was also found in different body fluids serum, like 
semen, nipple aspirate fluid (NAF) and breast cyst and amniotic fluid [267, 268]. 
 
3.4 P-CADHERIN IN BREAST CANCER #
Because of their importance in normal development, disorders involving dysfunction 
of classical cadherins/catenins are related to various disease states, including cancer 
[232, 269, 270]. Particularly in breast cancer, P-cadherin has been recognized as a 
poor prognosis marker, due to its pro-invasive role in breast cancer cells, being 
considered as a putative therapeutic target in this disease. 
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3.4.1 POOR PROGNOSIS MARKER 
 
P-cadherin expression has been found in several solid tumours, including breast, 
prostate, colon, pancreatic and bladder cancer [271], being considered as a tumour-
associated antigen. In breast cancer, P-cadherin is aberrantly expressed in 25% of 
ductal carcinomas in situ (DCIS), as well as in 20% to 40% of invasive breast 
carcinomas [228, 272-274]. 
Importantly, several studies have reported P-cadherin as a marker of poor prognosis 
in breast cancer, since P-cadherin expressing tumours were significantly associated 
with short-term overall and disease-free survival, as well as with distant and loco-
regional relapse-free interval [249, 275-277]. Accordingly, P-cadherin expression has 
also been positively associated with poorly differentiated and high histological grade 
tumours, as well as with well established markers of poor prognosis, like Ki-67, 
EGFR, CK4 and CK14 and negatively associated with age at diagnosis, hormonal 
receptors (ER and PgR), and Bcl-2 expression [38, 249, 271, 276, 277].  Besides the 
strong association between P-cadherin and poor prognosis, there is no significant 
association between P-cadherin expression and the histological subtypes of breast 
cancer. The majority of positive P-cadherin tumours are invasive ductal carcinomas 
NOS, or carcinomas with metaplastic or medullary features [249, 277, 278]. However, 
metaplastic and medullary breast carcinomas are consistently immunoreactive for P-
cadherin supporting the hypothesis of a myoepithelial/basal transcriptomic 
programme for these lesions [279, 280]. P-cadherin is also overexpressed in an 
aggressive form of locally advanced breast cancer with high metastatic potential and 
high death rate, the inflammatory breast carcinomas (IBC) [281]. Moreover, Mannello 
et al. demonstrated a significant increase of soluble P-cadherin (sP-cad) in NAF in 
woman with breast cancer when compared with healthy subjects or with women with 
pre-cancer conditions, suggesting its possible release via proteolytic processing in 
cancer cells [268]. However, the levels of the soluble P-cadherin fragment were not 
correlated with the presence of P-cadherin positive breast cancer [282]. 
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3.4.2 BIOMARKER OF BASAL-LIKE BREAST CARCINOMAS 
 
P-cadherin aberrant expression is found predominantly in poor prognosis basal-like 
and HER2-overexpressing breast carcinomas [228, 247, 273, 274, 277, 283]. 
BLBC are characterized by a triple negative (TN) phenotype, lacking the expression 
of hormone receptors (ER and PgR) and HER2. BLBC express genes characteristic 
of basal epithelial cells such as high-molecular weight basal cytokeratins (CK5/6, 
CK14, CK17), vimentin, caveolins 1/2 and EGFR [247]. Histologically, BLBC are 
poorly differentiated carcinomas, present high nuclear and histological grade and 
frequently show medullary and metaplastic features [284-288]. A distinct pattern of 
metastasis to brain and lungs, known to be associated with poor prognosis, and less 
significant involvement of axillary lymph nodes, has also been described in BLBC 
[170, 288, 289]. Until now, the most suitable immunohistochemical criterion to identify 
BLBC is the triple negative phenotype along with positivity for CK5 and/or EGFR 
[290]. However, we have previously demonstrated that P-cadherin expression shows 
higher sensitivity to distinguish the basal phenotype of breast carcinomas, being a 
reliable additional marker to be used in the daily practice of breast pathology 
laboratories for the identification of BLBC [283]. 
 
3.4.3 PROMOTER OF ONCOGENIC EFFECTS 
 
Although the effect of P-cadherin expression in cancer is unquestionable, its role in 
the carcinogenesis process remains object of debate, since it can behave differently 
depending on the tumour cell model and context. In melanoma, P-cadherin seems to 
have a tumour suppressive function [291]. However, in breast cancer and in other 
tumour models, such as bladder and pancreatic cancer, P-cadherin is described to 
exhibit tumour-promoting effects [230, 292-294]. 
We have found that overexpression of P-cadherin promotes breast cancer cell 
motility, migration and invasion abilities when cultured in matrigel matrix [295]. 
Although the mechanisms by which P-cadherin promotes oncogenic-associated 
effects, we described that it induces the secretion of matrix metalloproteinases, such 
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as MMP1 and MMP2, leading to the cleavage of the extracellular domain of P-
cadherin (sP-cad), which is responsible for the induction of invasion of non-invasive 
breast cancer cells [295]. 
Furthermore, we have recently demonstrated that P-cadherin functional role is 
dependent of E-cadherin expression in breast cancer cells [296]. We showed that E- 
and P-cadherin co-expressing breast cancer cells significantly enhanced in vivo 
tumour growth and that the expression of both cadherins is significantly correlated 
with high-grade breast carcinomas, biologically aggressive, and with poor patient 
survival, being a strong prognostic factor in this disease. Moreover, we showed that 
P-cadherin, in this context, was able to promote these effects by the interaction with 
E-cadherin, and disrupting its interaction with both p120-ctn and β-ctn, perturbing 
normal adhesion complex. In the absence of E-cadherin expression, in the same 
cancer model, P-cadherin is able to suppress invasion by its strong interaction with 
catenins, surrogating the role of E-cadherin in cell-cell adhesion [296]. Accordingly, in 
2008, we have already shown that primary invasive breast carcinomas co-expressing 
E- and P-cadherin present a worse patient survival than carcinomas that express only 
one of the cadherins or that do not express any of these adhesion molecules [297]. 
These tumours have a decrease in membrane staining of p120-ctn and an increase in 
the cytoplasmic localization for this catenin. In pancreatic and ovarian cancer, it was 
shown that p120-ctn, once in the cytoplasm can activate Rho-GTPases (Ras 
homologue gene), Rac1 (Ras-related C3 botulinum toxin substrate 1) and Cdc42 (cell 
division cycle 42 Rho-family GTPase), altering the actin cytoskeleton polymerization 
and promoting cell motility [292, 298]. 
Importantly, P-cadherin aberrant expression is also found in other malignancies such 
as gastric, endometrial, colorectal and pancreatic carcinomas [271, 292, 299, 300]. 
Targeting P-cadherin in cancer may be a good therapeutical approach, since normal 
associated counterparts express very low levels of this molecule [271]. In fact, a novel 
and highly selective human monoclonal antibody against P-cadherin (PF-03732010) 
demonstrated anti-tumour and anti-metastatic activity in a panel of P-cadherin 
overexpressing tumour models, without significant secondary effects in mice [301, 
302]. 
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3.4.4 BREAST CSC MARKER 
 
Several studies supports the hypothesis that cancers are propagated by a small 
population of cells that are present in the malignant tissue, with the ability to form a 
hierarchy similar to the one present in normal tissues [303]. These CSCs are able to 
proliferate, originating more stem-like cells, to exhibit resistance to current therapies 
and to remain quiescent during long periods of time. However, it is still not clear 
whether the CSC originates from the normal stem cells of the tissue that deregulate 
their self-renewal ability, or from normal mature cells or progenitor cells that acquired 
stem cell characteristics [303]. 
Although it is extremely important to define a universal phenotype for the breast 
CSCs, the existence of a single phenotype would be difficult mainly due to the high 
heterogeneity of this malignancy. 
As described above, the aggressiveness and lack of target therapy exhibited by 
BLBC [304], draw much attention to the need of define a CSC phenotype for this 
poor-prognosis group of breast cancer. Recently, it has been demonstrated that the 
luminal progenitor of normal breast hierarchy is the cell of origin for this malignancy, 
since the induction of a BRCA1 mutation in this cell was able to induce the formation 
of a tumour with basal phenotype [152, 305]. Since CDH3 gene is repressed by 
BRCA1, it is likely that P-cadherin could be a good CSC marker of BLBC. 
We have recently proposed P-cadherin as a breast CSC marker and a valuable target 
to be used in order to define the CSC phenotype of BLBC and the cell of origin of this 
disease [306]. We demonstrated that P-cadherin expression is able to promote stem 
like properties, such as mammosphere forming and 3D growth ability, being 
associated with the expression of CSC markers such as, CD44, CD49f and ALDH1. 
Additionally, cell lines with basal-like phenotype presented higher ALDEFLUORbright 
positivity comparing to luminal breast cancer cell lines [306]. We were able to 
establish the link between P-cadherin expression and the luminal progenitor and 
tumourigenic phenotype CD44+CD24+CD49f+ [152, 307]. 
Recently, we have also demonstrated that P-cadherin is responsible for the adhesion 
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of breast cancer cells to ECM, since its inhibition led to a significant decreased 
adhesion of cancer cells to the basement membrane substrate laminin, as well as to a 
major reduction in the expression of the laminin receptor α6β4 integrin [308]. 
Remarkably, the expression of this heterodimer was required for the invasive capacity 
and increased MFE induced by P-cadherin expression, which might explain the stem 
cell and invasive properties induced by P-cadherin in breast cancer cells, pointing to a 
new molecular mechanism that may be targeted to counteract the effects induced by 
this adhesion molecule [308]. 
Resistant to therapy regiments allows breast CSCs the ability to survive and persist in 
the tumour, being responsible for recurrence of the disease. Furthermore, it is 
accepted that breast CSC might be responsible for tumour relapses and further 
metastasis [217, 309]. Importantly, P-cadherin confers resistance to radiation in 
breast cancer cells. We have recently demonstrated that, when irradiated, P-
cadherin-enriched cell population has increased ability to survive in anchorage-
independent conditions [306]. Furthermore, we demonstrated that upon an apoptotic 
stimuli, decreased P-cadherin expression increases breast cancer cell death in a 
caspase-dependent mechanism [296].  
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Poor prognosis presented by patients with BLBC has been associated, among other 
factors, with the glycolytic metabolism that these tumours present. Molecular 
adjustment to hypoxia and specific metabolic programs are responsible for the 
maintenance and expansion of breast cancer cells with stem-like properties, which 
are known to account for chemo and radioresistance of BLBC as well as to patient’s 
relapses and distant metastasis. Despite the implications of the basal marker P-
cadherin in patient’s poor prognosis and the in vitro knowledge about the 
aggressiveness and stem-like properties of breast cancer cells with aberrant P-
cadherin expression, nothing is known about the role of this protein in the adaptation 
of BLBC cells to adverse microenvironment conditions and to metabolic alterations 
occurring during tumour progression.  
 
Main Aim 
The main objective of this work was to evaluate the role of the basal epithelial marker 
P-cadherin in breast cancer cell metabolism. 
 
Specific Aims 
Using a series of primary invasive breast carcinomas and human breast cancer cell 
lines, the studies were performed in order to address the following specific aims: 
 
I) To study the association between P-cadherin overexpression and the adapted 
molecular phenotype of breast cancer cells to hypoxia and to 
microenvironmental metabolic stress. 
 
II) To evaluate if P-cadherin expression is affected by hypoxia and how its 
expression is connected to the molecular machinery involved in glycolytic and 
acid resistance phenotype of breast cancer cells. 
 
III) To unravel the effect of P-cadherin expression in breast cancer cell’s 
metabolism. 
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This chapter describes the materials and the methods used for all the data presented 
in the Results section. 
 
Materials 
 
Breast tumour samples 
Primary invasive breast carcinomas used in this study were included in TMAs (Tissue 
Microarays) blocks, where representative areas of each breast tumour sample were 
carefully selected on the H&E-stained sections and marked on individual paraffin 
blocks. Two tissue cores (2 mm in diameter) were obtained from each specimen and 
precisely deposited into a recipient paraffin block using a TMA workstation (TMA 
builder 20010.02, Histopatholoy Ltd, Hungary).  
A series of 473 formalin-fixed, paraffin-embedded invasive breast carcinomas was 
retrieved from the histopathology files of three Departments of Pathology: from 
University Hospital of the Federal University of Santa Catarina (Florianópolis, Brazil), 
from Hospital Divino Espírito Santo (Ponta Delgada, Portugal) and from a private 
Laboratory of Pathology (Araçatuba, Brazil). Data from clinical and pathological 
features of the tumours is summarized in Table 1. Immunohistochemical 
characterisation of this series was previously studied and described [283]. An 
independent series of 466 invasive breast carcinomas from the Department of 
Pathology, Hospital Xeral Cíes, Vigo, Spain, diagnosed between 1978 and 1992, was 
also used in part of this work. Detailed information about clinical and molecular 
characteristics is described by Vieira et al. [306]. The studies using this material were 
conducted under the national regulative law for the handling of biological specimens 
from tumour banks, being the samples exclusively available for research purposes in 
retrospective studies. 
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Table 1. Clinical, pathological and immunohistochemical characteristics of the 473 primary invasive 
breast carcinomas. Characterization of the breast cancer series concerning age of the patients at the 
diagnosis, tumour size, lymph-node metastasis, histological grade, molecular subtype, ER, PgR, HER2 
and Ki67 status, as well as expression of P-cadherin, HIF-1α, GLUT1, CAIX, MCT1, MCT4 and 
CD147.  
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Cell culture 
Human breast cancer cell lines were obtained as follows: BT20 and MDA-MB-468 
were acquired from American Type Culture Collection (Manassas, VA, USA), 
SUM149 was kindly provided by Dr. Stephen Ethier (University of Michigan, USA) 
and MCF-7/Az was kindly given by Prof. Marc Mareel, Ghent University, Belgium. 
MCF-7/Az cell line was retrovirally stable transduced to encode P-cadherin (MCF-
7/Az.Pcad cell line), as described earlier [241]. MCF-7/Az.Mock cell line, encoding 
only EGFP, was used as a control. Cells were routinely maintained at 37°C and 5% 
CO2 in the following media (Invitrogen Ltd, UK): DMEM for BT20 and for MDA-MB-
468 and 50% DMEM/50% Ham-F12 for SUM149 and MCF-7/Az. In BT20 and MCF-
7/Az, the media contained 10% heat-inactivated fetal bovine serum, FBS, (Greiner 
bio-one, Belgium) and in SUM149 cell line, media was supplemented with 5% FBS, 5 
µg/ml of insulin and 1 µg/ml of hydrocortisone (Sigma-Aldrich, USA). All media were 
supplemented with 100 IU/ml penicillin and 100 mg/ml streptomycin (Invitrogen Ltd, 
UK).  
 
Primary Antibodies 
The following primary anti-human antibodies were used for western blot (WB), 
immunohistochemistry (IHC) and flow cytometry (FC) against: P-cadherin [clone 56, 
BD Transduction Biosciences, USA; diluted 1:500 (WB) and 1:50 (IHC)] and APC-
conjugated P-cadherin, R&D, USA; diluted 1:10 (FC)], HIF-1α [clone 54, BD 
Transduction Biosciences, USA; diluted 1:500 (WB) and 1:50 (IHC)], CAIX [ab15086, 
AbCam, Cambridge, UK; diluted 1:1000 (WB), 1:2000 (IHC) and 1:10 (FC)], GLUT1 
[ab15309, AbCam, UK; diluted 1:400 (WB), 1:500 (IHC) and 1:10 (FC)], MCT1 
[AB3538P, Chemicon International, USA; diluted 1:200 (IHC)], MCT4 [AB3316P, 
Chemicon International, USA; diluted 1:100 (IHC)], CD147 [18-7344, Zymed 
Laboratories Inc., USA; diluted 1:750 (IHC)], CD44 [clone 156-3C11; Cell Signalling 
Technology, USA; diluted 1:100 (IHC)], CD49f [HPA001814; Sigma-Aldrich, USA, 
diluted 1:10 (IHC)], SOD1 [Cell Signalling Technology, USA; diluted 1:2000 (WB)], 
SOD2 [HPA001814, Sigma-Aldrich; diluted 1:2500 (WB)], p-PDH Ser293 [ab177461, 
AbCam, UK; diluted 1:2000 (WB)], PDH E1 [clone 9H9AF5, MitoSciences, USA; 
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diluted 1:1000 (WB)], PDK2 [HPA008287, Sigma-Aldrich, USA; diluted 1:1000 (WB)], 
GAPDH [0411, Santa Cruz Biotechnologies, USA; diluted 1:10000 (WB)] and β-actin 
[clone I-19, Santa Cruz Biotechnologies, USA; diluted 1:1000 (WB)].   
 
METHODS 
 
Immunohistochemistry 
The immunohistochemical assays were performed with specific antibodies for P-
cadherin, HIF-1α, GLUT1, CAIX, MCT1, MCT4, CD147, CD44 and CD49f. Details 
about experimental procedures, primary antibodies, antigen retrieval detection 
systems and scoring are described elsewhere [71, 99, 283, 306]. Specifically, HIF-1α 
immunohistochemistry was performed using CSA, Catalyzed Signal Amplification 
System (DAKOCytomation, USA), according to manufacturer’s instructions. 
Reactions were independently evaluated by two pathologists. All the proteins showed 
membrane staining, consistent with their cellular function, except for HIF-1α, which 
presented a nuclear pattern of expression and was considered positive whenever any 
strong and dark nuclear staining was observed. For the different antibodies studied, 
some samples could not be evaluated for the 473 cases of the series due to TMA’s 
cores missing or to insufficient representation of the tumour in the TMA core. 
Statistical analysis was performed by SPSS statistics 17.0 software (SPSS Inc., 
USA). χ2 test and contingency tables were used to determine associations between 
groups and the results were considered statistically significant when the p-value was 
lower than 0.05.  
 
cDNA Microarrays  
cDNA Microarray procedure and analyses are described in previous works from our 
group [310, 311]. The complete array data from MCF-7/Az and BT20 models can be 
viewed in Gene Expression Omnibus database (GEO accession No GSE54319) and 
in the ArrayExpress microarray database (accession No E-MEXP-3329), respectively. 
Differences in gene expression (p<0.01 and fold-change>2) between the two 
conditions in both models were functionally annotated using DAVID [Database for 
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Annotation, Visualization and Integrated Discovery [312]]. Using DAVID's default 
parameters, several significantly enriched biological pathways/gene ontology terms 
were obtained which are further described in the Results section. 
 
Hypoxia 
Breast cancer cells were plated in flasks in order to be at approximately 40% of 
confluence and to avoid overconfluence at the end of the 5th day of the experiment. 
After the adhesion of the cells overnight, the flasks were placed in the incubator at 1% 
of oxygen and 5%CO2, at 37°C. In the end of each time point, cells were immediately 
placed on ice, washed twice in PBS (phosphate-buffered saline) and lysed with 
catenin lysis buffer (See “Protein extraction and western blot analysis” in this section) 
in the shortest time possible in order to avoid oxygen-induced HIF-1α degradation. 
 
CoCl2 treatment 
Breast cancer cells were plated in T25 flasks or in coverslips, for FACS or western 
blot and for immunofluorescence, respectively. After 24hours, cells were treated with 
200µM CoCl2 (Cobalt(II) chloride hexahydrate, Sigma-Aldrich, USA) for 4 hours.  
 
Protein extraction and western blot analysis 
Protein lysates were prepared from cells, using catenin lysis buffer [1% (v/v) Triton X-
100 and 1% (v/v) NP-40 (Sigma-Aldrich, USA) in PBS] supplemented with 1:7 
proteases inhibitors cocktail (Roche Diagnostics GmbH, Germany) for 10 min, at 4°C. 
Cell lysates were mixed with a vortex and centrifuged at 14000 rpm at 4°C, during 10 
min. Supernatants were collected and protein concentration was determined using 
the Bradford assay (BioRad Protein Assay kit, USA). Proteins were dissolved in 
sample buffer [Laemmli with 5% (v/v) 2-β-mercaptoethanol and 5% (v/v) bromophenol 
blue] and boiled for 5 min at 95°C or at 65°C (for GLUT1 staining). Samples were 
separated by SDS–PAGE and proteins were transferred into nitrocellulose 
membranes [Amersham Hybond enhanced chemiluminescence (ECL)]. For 
immunostaining, membranes were blocked with 5% (w/v) non-fat dry milk in PBS 
containing 0.5% (v/v) Tween20 and incubated during 1 hour with anti-P-cadherin, 
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anti-GAPDH and anti-β-actin, two hours with anti-CAIX and anti-GLUT1 and overnight 
for anti-HIF-1α, SOD1, SOD2, SOD2-k68, p-PDH, PDH and anti-PDK. After washes 
with PBS-Tween20, membranes were incubated with HRP-conjugated anti-mouse, 
goat or rabbit secondary antibodies (Santa Cruz Biotechnologies, USA) diluted 
1:2000 for one hour. Proteins were then detected using ECL reagent (Amersham, 
USA) as a substrate. Quantity One software (BioRad, USA) was used for 
quantification of the differences in protein expression comparing with GAPDH 
expression. 
 
Flow Cytometry and Cell Sorting 
For flow cytometry analysis, cells were harvested with versene/0.48mM EDTA 
(Invitrogen, UK), washed with PBS supplemented with 0.5% FBS and re-suspended 
in the stain buffer (2mM EDTA and 0.5% bovine albumin in PBS). Single cell 
suspension was labelled with APC-conjugated P-cadherin, GLUT1 and CAIX 
antibodies. Cells transfected with the control siRNA and with CDH3 siRNA were 
doubled stained either with P-cadherin and GLUT1 or CAIX antibodies. A live-dead 
stain (Invitrogen, UK) and the primary and secondary antibodies were incubated at 
4°C, in the dark, for 15 minutes. Secondary Alexafluor-488-conjugated goat anti-
rabbit IgG (Invitrogen, UK) was used in a 1:100 dilution. The labelled cells were then 
washed in the stain buffer and analysed on a FACS Canto-II (BD Biosciences, USA).  
For the sorting experiments, the subpopulations of SUM149 and BT20 breast cancer 
cells were selected according to P-cadherin expression (highest and lowest 20% 
expressing cells). Cells were sorted using BD Influx or FACS ARIA-II (BD 
Biosciences) and collected into 10% Hanks buffered solution (Invitrogen, UK). The 
purity of sorted populations was 80-95%. In addition, a further sample was also 
collected of cells passed through the laser under pressure, but not sorted, to act as a 
control for the effect of the pressure on the cells.  
 
Immunofluorescence and confocal microscopic analysis 
Cells were cultured on glass coverslips and 24 hours later they were treated either 
with 200µM of CoCl2 or with the respective vehicle (Ethanol) during 4 hours. After 
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that, cells were fixed with 4% paraformaldehyde (20 minutes), treated with NH4Cl 
(50mM) for 10 minutes, washed with PBS, and permeabilized with 0.1% Triton X-100 
in PBS for 5 minutes, at room temperature. Unspecific reactions were blocked by 
incubation of cells with blocking solution (5% BSA in PBS-tween 0,5%) during 30 
minutes. Cells were then stained with the primary antibodies, followed by incubation 
in the dark with Alexa488 or Alexa-594-conjugated secondary IgGs (Dako 
Cytomation, Carpinteria, CA) in a 1:500 dilution. Primary and secondary antibodies 
were diluted in blocking solution. Each sample was mounted with Vectashield (Vector 
Laboratories, Inc, Burlingame, CA) containing 4,6-diamidine-2- 
phenylindolendihydrochrolide (DAPI) and visualized with Leica SP5 confocal 
microscope (Leica Microsystems GmbH, Germany). Volume of cells of both 
conditions was acquired by Z-stack measurements. 
 
siRNA transfection  
Gene silencing was performed with validated small interfering RNAs (siRNA), specific 
for CDH3 (50nM, Hs_CDH3_6), HIF-1α (50nM, Hs_HIF1A_5), GLUT1 (100nM 
Hs_SLC2A1_2) and CAIX (50nM, Hs_CA9_2). All siRNAs were from Qiagen (USA). 
Transfections were carried out using Lipofectamine 2000 (Invitrogen, UK), according 
to manufacturer’s recommended procedures. After incubation for 5 minutes, the 
siRNA and Lipofectamine 2000 solutions were mixed, incubated for additional 20 
minutes and added to cell culture medium. A scrambled siRNA sequence, with no 
homology to any gene, was used as a negative control (Qiagen, USA). Gene 
inhibition was evaluated after 48 hours of cell transfection for CDH3, HIF-1α and 
GLUT1 and after 72 hours for CAIX.  
  
RNA extraction and qRT-PCR  
RNA extraction was performed using RNeasy Mini Kit (Qiagen, USA) and cDNA was 
synthesized using the Omniscript Reverse Transcription kit (Qiagen, USA), following 
the manufacturer’s instructions. Quantitative-Real-Time-PCR (qRT-PCR) reaction 
was performed with TaqMan Gene Expression Assays (Applied Biosystems, USA), 
using gene-specific IDT probes (Integrated DNA Technologies, Inc., USA): CDH3 
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(Hs.PT.51.5028751), GLUT1 (Hs.PT.47.19044492.g), CAIX (Hs.PT.47.1458063.g), 
and GAPDH (Hs.PT.39a.22214836).  Analysis was performed with the ABI PRISM 
7700 Sequence Detection System Instrument and software (Applied Biosystems, 
USA), following the manufacturer's recommendations. The internal standard human 
GAPDH was used to normalize cDNA quantity. Data was analysed by the 
comparative 2(-ΔΔCT) method [313]. For all data comparisons, the Student's t-Test 
was used (two tailed, unequal variance). All reactions were done in triplicate and the 
results presented as mean of the values from three or more independent 
experiments. 
 
Mammosphere forming efficiency (MFE) assay  
After the 72h of the siRNA transfection, cells were enzymatically harvested and 
manually disaggregated with a 25-gauge needle to form a single-cell suspension and 
resuspended in cold PBS. Cells were plated at 500/cm2 in non-adherent culture 
conditions, in flasks coated with 1.2% poly(2-hydroxyethylmethacrylate)/95%ethanol 
(Sigma-Aldrich, USA) and allowed to grow for 5 days, in DMEM/F12 containing B27 
supplement (Invitrogen Ltd, UK) , and 500 ng/ml hydrochortisone Sigma-Aldrich, 
USA), 40 ng/ml insulin (Sigma-Aldrich, USA), 20 ng/ml EGF )Sigma-Aldrich, USA) in 
a humidified incubator at 37°C and 5% (v/v) CO2. Mammosphere forming efficiency 
was calculated as the number of mammospheres (≥50 µm) formed divided by the 
number of cells plated, being expressed as a percentage.  
 
OCR and ECAR measurements  
Oxidative phosphorylation and glycolysis was accessed using a Seahorse XF96 
Extracellular Flux Analyzer (Seahorse Bioscience, USA). The oxygen-sensitive 
fluorophore measures OCR (oxygen consumption rate) during OXPHOS and the pH-
sensitive fluorophore measures the extracellular acidification rate (ECAR), which is 
proportional to the rate of lactate production by glycolysis. 
Twenty-four hours after the transfection, 40000 cells were seeded in a XF96 cell 
culture microplates and allowed to adhere overnight at 37°C and 5%CO2, reaching 
80-90% confluence in the next day. The XF sensor cartridge was calibrated overnight 
Materials and Methods 
97"
with XF Calibrant Solution (Seahorse Bioscience, USA) in a 0% CO2 incubator. In the 
following day, cells were equilibrated in unbuffered XF Base Medium (Seahorse 
Bioscience, USA), for 1 hour at 0% CO2 prior to analysis. This XF Base medium was 
supplemented with glucose (3,15 g/dL of glucose for SUM149 and with 4,5g/dL and 
MDA-MB-468), 2mM L-glutamine (Invitrogen Ltd, UK) and 1mM pyruvate (Invitrogen 
Ltd, UK). Bioenergetics measurements were performed by the injection of oligomycin 
to a final concentration between 3µg/mL. Maximal FCCP (carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone) effect was observed with two injections to final 
concentrations between 1µM and 3µM. Experiments were performed independently 
for at least three times, each one with eight technical replicates. Oligomycin A and 
FCCP (carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone) were obtained from 
Sigma-Aldrich, USA.  
After the XF assay, the number of cells in each well was measured with Vibrant dye 
(Life Technologies, USA). The dye was incubated at 1µM during 15 minutes and the 
number of cells was determined by object counting in IncuCyte incubator and using 
IncuCyte Analyser V1 software.  
 
ATP analysis 
ATP measurements were performed using CellTiter-Glo Luminescent Cell Viability 
Assay kit (Promega, USA), according to manufacturer’s instructions. 5X104 of control 
and CDH3 siRNA transfected cells were resuspended in 80µL and plated in a clear 
bottom 96 well plate. Cells were then treated with PBS (control), oligomycin A 
(10µg/mL) and FCCP (30µM), alone or in combination with 100µM sodium 
iodoacetate (Sigma-Aldrich, USA). Following 1 hour of incubation with the reagents at 
37°C and 5% CO2, 100µL of Cell Titer Glo reaction mix were added to each well for a 
final volume of 200µL. Plates were then analysed for luminescence in Labsystems 
Luminoskan Ascent Microplate luminometer (Thermo Scientific, USA). Measurements 
were performed 1 hour after the cells were plated, as well as after 24 hours of 
incubation in normoxia or hypoxia. Experiments were performed independently for at 
least three times, each one with five technical replicates. 
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ROS assay 
After incubation for 4 to 6 hours with transfection reagents, cells were washed twice 
with PBS and the medium was changed to DMEM/F12 with no phenol-red (Invitrogen 
Ltd, UK), without serum nor antibiotics, until the endpoint of transfection (~48 hours).  
Cells were then washed and DCHF-DA (Sigma-Aldrich, USA) was added to a final 
concentration of 10µM for 30 minutes at 37°C. After washing twice, 200µL of PBS 
was added to each well and fluorescence was read on λex=485nm and λem=535nm.  
 
Superoxide dismutase activity  
Superoxide dismutase activity in breast cancer cell extracts was determined by native 
PAGE staining according to Flohé and Otting [314]. After electrophoresis of the cells 
extracts under native conditions, the gel was incubated in the dark for 30 minutes in a 
solution containing 2.5 mM NBT (nitroblue tetrazolium) followed by a 20 minutes 
incubation in developing solution, composed of 36 mM phosphate buffer, pH 7.8, 28 
mM TEMED, and 2.8×10−5M riboflavin. The gel was rinsed in dH2O and kept under 
shaking and light (60 W) until bands became visible. The reaction was stopped in a 
7.5% acetic acid solution. 
 
Apoptosis assay 
Twenty-four hours after the transfection, 12 000 cells were seeded in a 96 well plate. 
When cells were adherent, a caspase 3/7 substrate (NucViewTM 488, Essen 
Bioscience, USA) was added to a final concentration of 5µM and the plate was placed 
in the IncuCyte incubator (Essen Bioscience, USA) in order to be monitored at each 3 
hours. Phase contrast and fluorescence data were obtained at each time point. Data 
analysis of AUC (Area Under Curve) of apoptosis measurements was performed 
using IncuCyte Analyzer V1 software. Experiments were performed independently for 
at least three times, each one with ten technical replicates. 
 
Mitotracker CMXRos 
Mitotracker CMXRos (Invitrogen Ltd, UK) was used to evaluate mitochondrial 
membrane potential by FACS analysis. Control and CDH3 siRNA transfected cells 
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were incubated with 250nM of Mitotracker CMXRos during 30 minutes. After wash 
twice with PBS, cells were harvested with versene/0.48mM EDTA (Invitrogen, UK), 
washed with PBS supplemented with 0.5% FBS and re-suspended in the stain buffer, 
as described above (See “Flow Cytometry and Cell Sorting” in this section). Single 
cell suspension was labelled with APC-conjugated P-cadherin (1:10) during 15 
minutes, washed in the stain buffer and analysed on a FACS Canto-II (BD 
Biosciences, USA).  
 
Statistical analysis 
Results are representative of three or more independent experiments. Quantifications 
are expressed as mean ± SEM of the biological replicates considered. Statistical 
analyses were performed using Office Excel 2010 (Microsoft Corporation, Reading, 
UK). All statistical tests were two-sided and considered as significant when P value 
was less than 0.05.  
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I. ASSOCIATION BETWEEN P-CADHERIN OVEREXPRESSION AND THE ADAPTED 
MOLECULAR PHENOTYPE OF BREAST CANCER CELLS TO HYPOXIA AND TO 
MICROENVIRONMENTAL METABOLIC STRESS 
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The main purpose of this part of the work was to search for evidences that would 
support the association between P-cadherin aberrant expression and hypoxic 
conditions, as well as metabolic alterations observed in breast cancer. For that, we 
examined online available gene expression databases and used bioinformatics 
predictive tools. Additionally, we also analysed the mRNA profile of two distinct breast 
cancer cell models after P-cadherin modulation, in order to find if this could affect the 
expression of genes implicated in tumour microenvironmental-induced cellular 
response. Finally, we also evaluated the expression of P-cadherin and hypoxic, 
glycolytic and acidosis markers in a series of primary invasive breast carcinomas.  
 
Ia) Bioinformatics evidences of P-cadherin modulation by microenvironmental 
conditions in breast cancer  
 
The analysis of an online available gene expression profile (GEP) (E-GEOD-9649) 
[315] in Gene Expression Atlas [316] revealed that CDH3 gene is indeed altered in 
human mammary epithelial cells (HMEC) when exposed to different 
microenvironmental conditions observed in solid tumours. Comparing to normoxia 
conditions, CDH3 was found to be upregulated when HMEC were cultured for 24 
hours in hypoxia (2% of oxygen) at neutral pH (Figure 13A). Moreover, CDH3 levels 
were also upregulated in lactic acidosis (25mM of lactic acid at pH 6.7) and 
downregulated in lactosis conditions (25mM of sodium lactate, neutral pH) (Figure 
13B). 
Interestingly, using bioinformatics prediction tools [317, 318], we were also able to 
recognize a putative binding site for HIF-1 transcription factor, positioned in a CpG 
island within the CDH3/P-cadherin promoter [319].  
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Figure 13. CDH3 expression alterations in different microenvironmental conditions observed in 
solid tumours. Gene expression analysis of Array Express E-GEO-9649 shows that CDH3 is enriched 
in HMEC cultured during 24 hours in hypoxia comparing to normoxia culture conditions. Lactic acidosis 
also increases CDH3 levels in HMEC, while lactosis induces a decrease of CDH3 expression. 
 
 
Ib) P-cadherin is associated with the expression of genes related to the 
response to oxygen levels and metabolic processes in breast cancer cells  
 
The analysis of cDNA microarrays data, obtained from previous experiments 
performed in our research group, suggested that the expression of P-cadherin is able 
to induce alterations in the expression of genes implicated in cellular response to 
oxygen, nutrients, as well as in metabolic changes of breast cancer cells. 
The mRNA profile after P-cadherin modulation was evaluated in two different models: 
the MCF-7/Az luminal breast cancer cell model, where P-cadherin was constitutively 
overexpressed, and the BT20 BLBC cell model, where P-cadherin expression was 
silenced using a specific CDH3 siRNA. Gene ontology terms, specific genes and fold 
enrichment are summarized in Table 2. 
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Table 2.  Gene ontology terms, genes and fold change of the differentially expressed genes of 
MCF-7/Az and BT20 models with P-cadherin overexpression and silencing, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In MCF-7/Az model, the mRNA profile identified 867 genes whose expression was 
deregulated in MCF-7/Az.P-cadherin cells comparing to the control MCF-7/Az.mock 
cells (p<0.01; fold-change>2). Interestingly, we found that genes involved in 
glutathione metabolism, which can be responsible for regulation of antioxidant 
balance and detoxifying processes, were deregulated in breast cancer cells with 
overexpression of P-cadherin in comparison to the control cells (fold change=33.7; 
p=0.0308); in addition, genes associated with cyclic nucleotide metabolic processes 
(fold change=3.3; p=9.49X10-9) and with the transport of carboxylic acids (fold 
change=2.1; p=0.0456) were also found to be deregulated by P-cadherin 
overexpression (Table 2). Moreover, although not statistically significant, we also 
observed alterations of about 17.5-fold change in gene expression linked to the 
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response to nutrient levels and a 2-fold change in the response to oxygen levels 
(Table 2). 
Concerning the BT20 breast cancer cell model, as previously described [310], the 
profile identified 237 genes, whose expression was deregulated (p<0.01; fold-
change>2) in cells with CDH3 siRNA comparing to the control cells. Again, we could 
observe that the GEP involving several metabolic processes was distinct in cells with 
P-cadherin knockdown comparing the one presented by the control cells. 
Interestingly, we observed that P-cadherin downregulation interferes with the glycerol 
(fold change=10.4; p=0.0327) and glucose metabolic processes (fold change=3.1; 
p=0.0421), (Table 2). In addition, we also found that genes involved in lipid 
metabolism (fold change=3.6; p=0.0508), apoptotic mitochondrial changes (fold 
change=7.7; p=0.0564), as well as with fructose 6-phosphate metabolism, were also 
being deregulated by P-cadherin expression in breast cancer cells, although the 
difference was not statistically significant (Table 2). 
Although these results need further validation, they strongly suggests that, in 
normoxia conditions, P-cadherin overexpression in breast cancer cells is interfering 
with the expression of genes involved in the response to oxygen levels, as well as 
with metabolic alterations observed in breast cancer.  
 
Ic) P-cadherin overexpression is significantly associated with the expression of 
hypoxic, glycolytic and acidosis biomarkers in primary invasive breast 
carcinomas 
 
In a large series of invasive breast carcinomas (n=473), previously classified for 
molecular subtypes [283], immunohistochemistry staining was performed for P-
cadherin, HIF-1α, GLUT1, CAIX, MCT1, MCT4, and CD147 (Figure 14). Membrane 
P-cadherin expression was found in 145/468 (31%) of the cases. Nuclear HIF-1α was 
considered positive in 104/315 (33%) carcinomas. Concerning the membrane 
expression of GLUT1, CAIX, MCT1, MCT4 and CD147, we observed 140/327 
(42.8%), 66/316 (20.8%), 106/407 (26%), 69/419 (16.5%) and 24/217 (11%) positive 
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cases, respectively. Membrane GLUT1 and CAIX expression was frequently detected 
in peri-necrotic tumour areas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Breast cancer immunoreactivity for P-cadherin, hypoxia, glycolytic and acid resistant 
biomarkers. Immunohistochemical staining for P-cadherin (A), HIF-1α (B), GLUT1 (C), CAIX (D), 
MCT1 (E), MCT4 (F) and CD147 (G) expression in primary invasive breast carcinomas. Images A, C, 
D, F and G are in 200x magnification; B and E are in 100X magnification. 
 
 
The association between the expression of each one of these markers with the 
classical breast cancer prognostic factors (Table 3), as well as with the molecular 
subtypes and biomarkers ER, PgR, HER2 and Ki67, was evaluated (Table 4). As 
previously reported, P-cadherin expression was significantly associated with high-
grade carcinomas (p<0.0001), HER2-overexpressing and basal-like molecular 
subtypes (p<0.0001), ER and PgR negativity (p<0.0001), high expression of HER2 
(p<0.0001), as well as with high Ki67 (p=0.0141). Accordingly, HIF-1α expression 
was also associated with grade III (p<0.0001) and high proliferative (p=0.0197) 
tumours. Concerning the expression of GLUT1, CAIX, MCT1 and CD147, all have 
been significantly associated with high-grade (p<0.001), basal-like (p<0.001), ER and 
PgR negative tumours (p<0.05); absence of lymph node metastasis was more 
frequently observed in MCT1 expressing tumours (p=0.0223) and CAIX expression 
was associated with an increased tumour size (p=0.0005). Additionally, the 
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expression of GLUT1, MCT1 and CD147 was associated with high proliferation 
indexes measured by Ki67 expression (p=0.0339, p=0.0297, p=0.0179, respectively).  
 
 
Table 3. Association of P-cadherin, HIF-1α , GLUT1, CAIX, MCT1, MCT4 and CD147 expression 
with the classic prognostic factors in breast cancer. 
 
 
 
Table 4. Association of P-cadherin, HIF-1α , GLUT1, CAIX, MCT1, MCT4 and CD147 with 
molecular subtypes and biomarkers ER, PgR, HER2 and Ki67 in breast cancer.  
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P-cadherin HIF-1α  GLUT1 CAIX MCT1 MCT4 CD147 
Positive Negative p Positive Negative p Positive Negative p Positive Negative p Positive Negative p Positive Negative p Positive Negative p 
Histological 
Grade 
I 
21 
(14.5%) 
133 
(41.9%) 
<0.0001 
30 
(28.8%) 
91 
(44.2%) 
<0.0001 
35 
(25.7%) 
84 
(45.4%) 
<0.0001 
13 
(20.3%) 
100 
(40.7%) 
<0.0001 
29 
(28.4%) 
99 
(33.1%) 
0.0011 
28 
(40.6%) 
109  
(31.7%) 
0.2663 
0 
(0%) 
44  
(22.8%) 
<0.0001 II 
57 
(39.3%) 
140 
(44.2%) 
39 
(37.5%) 
88 
(42.7%) 
53 
(39%) 
76 
(41.1%) 
23 
(35.9%) 
101 
(41%) 
35 
(34.3%) 
142 
(47.5%) 
24 
(34.8%) 
153  
(44.5%) 
6 
(25%) 
96  
(49.7%) 
III 
67 
(46.2%) 
44 
(13.9%) 
35 
(33.7%) 
27 
(13.1%) 
48 
(35.3%) 
25 
(13.5%) 
28 
(43.8%) 
45 
(18.3%) 
38 
(37.3%) 
58 
(19.4%) 
17 
(24.6%) 
82  
(23.8%) 
18 
(75%) 
53  
(27.5%) 
Lymph-node 
metastasis 
Positive 
63 
(47.7%) 
134 
(50.2%) 
0.6438 
44 
(50.6%) 
90 
(51.1%) 
0.9317 
65 
(53.7%) 
72 
(45%) 
0.1477 
32 
(57.1%) 
102 
(46.8%) 
0.1668 
36 
(39.6%) 
138 
(53.5%) 
0.0223 
31 
(57.4%) 
147 
(48.7%) 
0.2372 
9 
(37.5%) 
90 
(52.9%) 
0.1566 
Negative 
69 
(52.3%) 
133 
(49.8%) 
43 
(49.4%) 
86 
(48.9%) 
56 
(46.3%) 
88 
(55%) 
24 
(42.9%) 
116 
(53.2%) 
55 
(60.4%) 
120 
(46.5%) 
23 
(42.6%) 
155 
(51.3%) 
15 
(62.5%) 
80 
(47.1%) 
Tumour Size 
Mean±SE 
(n) 
33.1±2.5 
(81) 
30.8±1.7 
(145) 
0.4375 
34.8±3.2 
(60) 
36.1±2.9 
(67) 
0.764 
30±2.7 
(54) 
29.3±2.1 
(67) 
0.8581 
42.2±6.4 
(21) 
27.2±1.4 
(98) 
0.0005 
35.5±3.6 
(38) 
31.2±1.7 
(165) 
0.2617 
24.1±2.7 
(15) 
32.5±1.6 
(186) 
0.1454 
29.4±3.5 
(22) 
32.1±1.6 
(180) 
0.5906 
!
 
 
P-cadherin HIF-1α  GLUT1 CAIX MCT1 MCT4 CD147 
Positive Negative p Positive Negative p Positive Negative p Positive Negative p Positive Negative p Positive Negative p Positive Negative p 
M
ol
ec
ul
ar
 S
ub
ty
pe
s 
Luminal A 35 (35.4%) 
223 
(69.5%) 
<0.0001 
49 
(48.6%) 
122 
(59.5%) 
0.076 
73 
(53.3%) 
121 
(62.9%) 
0.0001 
26 
(40%) 
162 
(66.7%) 
<0.0001 
48 
(46.2%) 
171 
(58.5%) 
<0.0001 
44 
(65.6%) 
186 
(54.4%) 
0.032 
4 
(18.2%) 
110 
(58.8%) 
<0.0001 
Luminal B 3 (3.0%) 
11 
(3.4%) 
6 
(5.9%) 
6 
(2.9%) 
3 
(2.2%) 
4 
(2.2%) 
0 
(0%) 
7 
(2.9%) 
3 
 (2.9%) 
10 
 (3.4%) 
3  
(4.5%) 
10  
(2.9%) 
0 
(0%) 
7 
(3.7%) 
HER2 OE 38 (38.4%) 
18 
(5.6%) 
16 
(15.8%) 
27 
(13.2%) 
12  
(8.8%) 
20 
(11%) 
10 
(15.4%) 
20 
(8.2%) 
8 
(7.7%) 
44 
(15.1%) 
3 
(4.5%) 
52 
(15.2%) 
4 
(18.2%) 
28 
(15%) 
Basal 23 (23.2%) 
27 
(8.4%) 
23 
(22.8%) 
27 
(13.2%) 
41  
(29.9%) 
17  
(9.4%) 
24 
(36.9%) 
33 
(13.6%) 
38 
(36.5%) 
37 
(12.7%) 
15 
(22.4%) 
59 
(17.3%) 
12 
(54.5%) 
29 
(15.5%) 
Unclassified 0 (0%) 
42 
(13.1%) 
7 
(6.9%) 
23 
(11.2%) 
8  
(5.8%) 
19 
(10.5%) 
5 
(7.7%) 
21 
(8.6%) 
7  
(6.7%) 
30 
(10.3%) 
2 
 (3%) 
35 
(10.2%) 
2 
(9.1%) 
13 
(7%) 
ER 
Positive 37 (25.9 %) 
233 
(72.1%) 
<0.0001 
 
56 
(30.6%) 
46 
(35.4%) 
0.3736 
76 
(54.7%) 
123 
(65.8%) 
0.0421 
25 
(37.9%) 
168 
(67.5%) 
<0.0001 
50 
(47.6%) 
182 
(60.5%) 
0.022 
48 
 (70.6%) 
194 
(55.4%) 
0.0205 
5 
(20.8%) 
118 
(61.5%) 
0.0002 
Negative 106 (74.1%) 
90 
(27.9%) 
127 
(69.4%) 
84 
(64.6%) 
63 
(45.3%) 
64 
(34.2%) 
41 
(62.1%) 
81 
(32.5%) 
55 
(52.4%) 
119 
(39.5%) 
20 
 (29.4%) 
156 
(44.6%) 
19  
(79.2%) 
74 
 (38.5%) 
PgR 
Positive 24 (16.8%) 
150 
(46.9%) 
<0.0001 
34 
(33.7%) 
82 
(39%) 
0.3579 
41 
(29.3%) 
87 
(46.5%) 
0.016 
19 
(28.8%) 
106 
(42.4%) 
0.0443 
30  
(28.3%) 
121 
(40.6%) 
0.0245 
30 
 (43.5%) 
129 
 (36.5%) 
0.2402 
2 
(8.3%) 
78  
(40.6%) 
0.002 
Negative 119 (83.2%) 
170 
(53.1%) 
67 
(66.3%) 
128 
(61%) 
99  
(70.7%) 
100 
(53.5%) 
47 
(71.2%) 
144 
(57.6%) 
76  
(71.7%) 
177 
(59.4%) 
39 
 (56.5%) 
224 
(63.5%) 
22 
 (91.7%) 
114 
(59.4%) 
HER2 
Positive 41 (28.7%) 
28 
(8.9%) 
<0.0001 
22 
(21.6%) 
32 
(15.7%) 
0.2032 
15 
(10.9%) 
23 
(12.5%) 
0.6705 
10 
(15.4%) 
26 
(10.6%) 
0.2857 
10 
 (9.7%) 
54 
(18.4%) 
0.0397 
6 
(9%) 
61 
(17.8%) 
0.0738 
4 
(17.4%) 
35 
 (18.4%) 
0.904 
Negative 102 (71.3%) 
287 
(91.1%) 
80 
(78.4%) 
172 
(84.3%) 
122 
(89.1%) 
161 
(87.5%) 
55 
(84.6%) 
219 
(89.4%) 
93 
 (90.3%) 
240 
(81.6%) 
61 
 (91%) 
282 
(82.2%) 
19  
(82.6%) 
155 
(81.6%) 
Ki67 
High 43 (48.9%) 
51 
(33.5%) 
0.0141 
29 
(43.3%) 
18 
(24.7%) 
0.0197 
33 
(57.9%) 
26 
(38.8%) 
0.0339 
12 
(54.5%) 
47 
(53%) 
0.5214 
22 
(51.2%) 
59 
(33.3%) 
0.0297 
7  
(8.9%) 9 (6.5%) 
0.5258 
14  
(58.3%) 
65  
(33.7%) 
0.0179 
Low 45 (51.1%) 
101 
(66.5%) 
38 
(56.7%) 
55 
(75.3%) 
24 
(42.1%) 
41 
(61.2%) 
10 
(45.5%) 
53 
(47%) 
21 
(48.8%) 
118 
(66.7%) 
72 
(91.1%) 
129 
(93.5%) 
10  
(41.7%) 
128 
(66.3%) 
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There was still an expected significant association between the expression of 
hypoxic, glycolytic and acid resistant phenotype markers (Table 5).  
 
Table 5. Association between the hypoxia, glycolytic and acid resistant phenotype markers 
within the series of invasive breast carcinomas.  
 
Interestingly, P-cadherin overexpression was also significantly associated with the 
expression of HIF-1α (p<0.0001), GLUT1 (p<0.0001), CAIX (p<0.0001), MCT1 
(p=0.0337) and CD147 (p<0.0001) (Table 6); in contrast, no association was found 
with MCT4 expression (p=0.553).  
 
Table 6. Association between aberrant P-cadherin overexpression and the expression of 
proteins involved in hypoxic/glycolytic metabolism and acidic microenvironmental regulation, 
namely HIF-1α , GLUT1, CAIX, MCT1, MCT4 and CD147, in a series of invasive breast 
carcinomas. 
 
 
Supplementary Table 5. P-cadherin overexpression is associated with the expression of markers of hypoxia, 
glycolytic and acid-resistant phenotype in breast cancer*. 
 
*Contingency table and the chi-square test were applied to determine the statistical association between the aberrant P-
cadherin expression and the HIF-1α, GLUT1, CAIX, MCT1, MCT4 and CD147 expression, in a series of invasive breast 
carcinomas. p values less than 0.05 were considered statistically significant. 
 
 
HIF-1α  GLUT1 CAIX MCT1 MCT4 CD147 
Positive Negative p Positive Negative p Positive Negative p Positive Negative p Positive Negative p Positive Negative p 
P-cadherin 
Positive 48 (46.2%) 
51 
(24.4%) 
<0.0001 
60 
(43.5%) 
35 
(18.8%) 
<0.0001 
38 
(57.6%) 
56 
(22.7%) 
<0.0001 
43 
(41%) 
89 
(29.7%) 
0.0337 
24 
(34.8%) 
109 
(31.1%) 
0.5527 
18 
(75%) 
64 
(33.3%) 
<0.0001 
Negative 56 (53.8%) 
158 
(75.6%) 
78 
(56.5%) 
151 
(81.2%) 
28 
(42.4%) 
191 
(77.3%) 
62 
(59%) 
211 
(70.3%) 
45 
(65.2%) 
241 
(68.9%) 
6 
(25%) 
128 
(66.7%) 
Supplementary Table 4. Association between the hypoxia, glycolytic and acid-resistant phenotype markers within 
the series of invasive breast carcinomas*. 
 
HIF-1α  GLUT1 CAIX MCT1 MCT4 
Positive Negative p  Positive Negative p  Positive Negative p  Positive Negative p  Positive Negative p  
GLUT1 
Positive 38 
(69.1%) 
56 
(34.6%) 
<0.0001 
    
Negative 17 
(30.9%) 
106 
(65.4%) 
CAIX 
Positive 24 
(44.4%) 
26 
(16.1%) 
<0.0001 
52 
(38.5%) 
14 
(7,9%) 
<0.0001  
  
Negative 30 
(55.6%) 
135 
(83.9%) 
83 
(61,5%) 
163 
(92,1%) 
MCT1 
Positive 27 
(27%) 
58 
(28.7%) 
0.7554 
52 
(39.7%) 
26 
(16.4%) 
<0.0001 
26 
(40.6%) 
52 
(23.5%) 
0.0069 
 
 
 
 
 
 
 
Negative 73 
(73%) 
144 
(71.3%) 
79 
(60.3%) 
133 
(83.6%) 
38 
(59.4%) 
169 
(76.5%) 
MCT4 
Positive 26 
(26.3%) 
30 
(14.4%) 
0.012 
38 
(28.6%) 
26 
(15%) 
0.0039 
18 
(27.7%) 
45 
(19.4%) 
0.1486 
29 
(27.9%) 
38 
(12.8%) 
0.0004 
 
Negative 73 
(73.7%) 
178 
(85.6%) 
95 
(71.4%) 
147 
(85%) 
47 
(72.3%) 
187 
(80.6%) 
75 
(72.1%) 
258 
(87.2%) 
CD147 
Positive 7 
(11.1%) 
4 
(5.6%) 
0.249 
12 
(23.5%) 
2 
(3.6%) 
0.0025 
8 
(38.1%) 
7 
(8.3%) 
0.0005 
19 
(45.2%) 
5 
(2.9%) 
<0.0001 
5 
(31.3%) 
19 
(9.6%) 
0.0083 
Negative 56 
(88.9%) 
67 
(94.4%) 
39 
(76.5%) 
53 
(96.4%) 
13 
(61.9%) 
77 
(91.7%) 
23 
(54.8%) 
167 
(97.1%) 
11 
(68.7%) 
179 
(90.4%) 
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With this data, we could demonstrate that breast carcinomas with positive expression 
to HIF-1α, GLUT1, CAIX, MCT1 and CD147 are significant associated to tumours 
showing a high percentage of cancer cells stained for the basal epithelial marker P-
cadherin (Figure 15). 
 
 
Figure 15. Aberrant P-cadherin expression in HIF-1α , GLUT1, CAIX, MCT1, MCT4 and CD147 
expressing breast carcinomas. P-cadherin overexpression is significantly associated with the 
expression of HIF-1α (p<0.0001), GLUT1 (p<0.0001), CAIX (p<0.0001), MCT1 (p=0.0337) and CD147 
(p<0.0001). No association was found with MCT4 expression (p=0,553). *p<0.05; **p<0.0001 
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II. P-CADHERIN MODULATION BY HYPOXIA AND ITS INVOLVEMENT IN GLYCOLYTIC 
AND ACID RESISTANCE PHENOTYPE IN BREAST CANCER !
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The evidences found concerning the association between P-cadherin expression and 
the development of a hypoxic/glycolytic and acid resistant phenotype in breast cancer 
cells, led us to further understand this putative link. We then decided to study the in 
vitro effect of hypoxia and HIF-1α in the expression of P-cadherin in breast cancer 
cells. We further evaluated the link between P-cadherin and the molecular machinery 
responsible for glycolytic and acid resistant phenotype, which is also known as 
playing a role in breast CSC survival and expansion. Due to the implications of P-
cadherin expression in stem-like properties of breast cancer, we also evaluated the 
function of HIF-1α, GLUT1 and CAIX in the ability to survive to anchorage-
independent conditions, as well as their association with P-cadherin related CSC 
markers in breast carcinomas. 
 
IIa) P-cadherin expression is modulated by hypoxia in breast cancer cells  
 
In order to evaluate the effect of hypoxia in P-cadherin expression of breast cancer 
cells, we cultured BT20 and SUM149 cells at atmosphere oxygen levels (Normoxia, 
21% of oxygen) and at low oxygen levels (Hypoxia, 1% of oxygen). Using western 
blot, we were able to observe that hypoxia has a time dependent effect in P-cadherin 
expression of breast cancer cells (Figure 16). Short-time incubations in low oxygen 
tension, until approximately 24 hours, showed an increase of P-cadherin expression 
levels (Figure 16); however, after 48 hours in hypoxia, breast cancer cells start to 
exhibit a decrease in P-cadherin expression comparing with cells cultured in 
normoxia, being these results more pronounced after 5 days in these conditions. As a 
control of the experiment, we could observe an increase of hypoxia-inducible CAIX 
expression in hypoxic conditions compared with normoxia (Figure 16). 
 
Results 
116!
                        
Figure 16. P-cadherin expression is modulated by hypoxia in a time dependent manner. Western 
blot shows an increase of P-cadherin expression in BT20 and SUM149 breast cancer cells when 
exposed to 1% of oxygen during 24hours. After 48hours of culture in hypoxia, P-cadherin expression is 
decreased in comparison to its expression in normal culture conditions. This effect is maintained until 
the 5th day in culture. CAIX expression increases in hypoxia comparing to normoxia conditions. (N: 
Normoxia, H: Hypoxia, d: days). 
 
 
IIb) HIF-1α stimulation by CoCl2 increases membrane P-cadherin expression in 
breast cancer cells  
 
HIF-1α is the oxygen sensing subunit of HIF-1 heterodimer, involved in sensing and 
adaptation of cancer cells to low oxygen tensions. Due to the direct association found 
between P-cadherin and HIF-1α expression in invasive breast carcinomas, as well as 
to the effect of hypoxia in the modulation of P-cadherin expression in breast cancer 
cells, we decided to evaluate if HIF-1α was being responsible for the modulation of 
the expression of P-cadherin in breast cancer cells. 
Treatment of SUM149 breast cancer cells with CoCl2, a chemical stabilizer of HIF-1α, 
resulted, as expected, in an increased HIF-1α expression (Figure17). However, we 
could not observe any alterations in CDH3 expression, either at mRNA or protein 
levels (Figure17), in comparison with the cells treated only with the vehicle. 
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Figure 17. HIF-1α accumulation has no effect in CDH3 expression either at the mRNA or at total 
protein level in SUM149 breast cancer cells.  CoCl2 leads to an increase of HIF-1α expression when 
compared with the cells treated with the vehicle (ethanol), whereas the levels of CDH3 mRNA and total 
protein expression do not present any alterations (EtOH: ethanol).  
 
 
Nevertheless, by FACS analysis, we could observe a statistically significant increase 
of membrane P-cadherin expression upon HIF-1α stabilization (p=0.0246; Figure 
18A and B). We confirmed this result by confocal microscopy (Figure 18C), where 
we could notice that CoCl2 treatment resulted in nuclear accumulation of HIF-1α, as 
well as in an increased expression of P-cadherin at the cell membrane, when 
compared with cells treated only with the vehicle (ethanol). Although not statistically 
significant (p=0.0716), we also observed a decrease in the cellular height after CoCl2 
treatment (Figure 18D), indicating a re-organization of the cytoskeleton after HIF-1α 
stabilization, which can be associated with the induction of P-cadherin expression. 
        
Results 
118!
  
Figure 18. HIF-1α stimulation with CoCl2 induces the expression of P-cadherin in the membrane 
of SUM149 breast cancer cells. HIF-1α stabilization and accumulation by CoCl2 treatment was 
confirmed by western blot (A). Using FACS analysis, we observe a statistically significant increase 
(p=0.0246) in the expression of membrane P-cadherin in CoCl2 treated cells when compared with the 
control cells treated with the vehicle (EtOH) (B). Immunofluorescence of CoCl2-treated cells shows 
nuclear HIF-1α expression (red) and an increase of membrane P-cadherin expression (green) 
compared with vehicle treated cells (C). Z-stack measurements reveal a decrease in the height of 
CoCl2-treated cells comparing with the control cells (p=0,0716) (D). 
 
 
IIc) P-cadherin expression interferes with GLUT1 and CAIX mRNA levels in 
breast cancer cells 
 
To further explore if there was a crosstalk between P-cadherin expression and the 
machinery involved in the glycolytic and acid resistance phenotype in breast cancer 
cells, we decided to silence CDH3 transcripts by siRNA-mediated knockdown in 
TN/basal-like P-cadherin overexpressing breast cancer cell models (BT20 and 
SUM149). By real-time PCR, we could observe that CDH3 silencing leads to a 
statistically significant downregulation of GLUT1 and CAIX mRNA in BT20 breast 
Results 
119!
cancer cells (p<0.05) (Figure 19A). Although not statistically significant, we could 
also find a tendency to a decrease in GLUT1 and CAIX mRNA levels in SUM149 
breast cancer cells (Figure 19D). No significant alterations were found in the mRNA 
expression of HIF-1α, MCT1 and CD147 upon the silencing of CDH3 in both cell lines 
(Figure 19A and D). Interestingly, when GLUT1 (Figure 19B and E) and CAIX 
(Figure 19C and F) were silenced in both cell lines, there were no significant 
alterations in CDH3 mRNA levels. 
 
 
 
Figure 19. P-cadherin expression affects GLUT1 and CAIX mRNA levels in breast cancer cells. 
mRNA expression measured by qRT-PCR of CDH3, HIF-1α, GLUT1, CAIX, MCT1 and CD147 when 
inducing siRNA-mediated knockdown of CDH3 , GLUT1   and CAIX  in BT20 and 
SUM149 breast cancer cell lines. Upon CDH3 silencing in BT20 cells (A), there is significant decrease 
of the mRNA expression of GLUT1 and CAIX in BT20 (A) and a tendency, although not statistically 
significant, of decrease in SUM149 cells (D). No differences are observed in the mRNA expression of 
HIF-1α, MCT1 and CD147 in both cell lines. On the other hand, there are no alterations in CDH3 
mRNA expression in BT20 (B and C) and in SUM149 (E and F) breast cancer cell lines, when we 
silence GLUT1 (B and E) and CAIX (C and F). *p<0.05; **p<0.0001. 
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IId) P-cadherin is co-expressed with GLUT1 and CAIX in basal-like breast 
cancer cell lines 
 
The above results led us to go further on the relationship between P-cadherin and 
GLUT1 and CAIX, since we observed that the expression of these both molecules 
was being responsive to P-cadherin in breast cancer cells. Thus, we decided to study 
if there was an enrichment of P-cadherin expression in GLUT1 and/or CAIX positive 
populations. Interestingly, we found that P-cadherin is co-expressed with GLUT1 and 
CAIX in triple negative BLBC cell lines (Figure 20). 
We observed that SUM149 cells presenting the highest expression of P-cadherin 
(20% high P-cad) were the ones also presenting the highest expression of GLUT1 
and CAIX, while the ones showing the lowest expression of P-cadherin (20% low P-
cad) demonstrated the lowest levels of GLUT1 and CAIX (Figure 20A). This result 
was confirmed when we sorted and separated the 20% high and low P-cadherin cell 
populations and analysed the expression of GLUT1 and CAIX by western blot (Figure 
20B). Furthermore, when we selected the population of cells by their GLUT1 
expression, the 20% high/low GLUT1 cells also presented the highest and lowest 
levels of P-cadherin expression, respectively (Figure 20C). Still, the cells selected by 
CAIX expression also presented the same tendency concerning P-cadherin 
expression (Figure 20D). Similar results were obtained in BT20 breast cancer cells.  
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Figure 20. P-cadherin is co-expressed with GLUT1 and CAIX in triple negative and basal-like 
SUM149 breast cancer cell lines. By flow cytometry analysis, we observe that the 20% of cells with 
the highest and lowest P-cadherin expression presents highest and lowest, respectively, expression of 
GLUT1 and CAIX (A). When cells were sorted by P-cadherin expression, lysed and analysed in SDS-
PAGE, the same result was observed concerning the high and low expression of GLUT1 and CAIX (B). 
On the other hand, 20% of cells with the highest and lowest levels of GLUT1 and CAIX (C and D, 
respectively) expression also present highest and lowest P-cadherin expression. 
 
 
IIe) Hypoxic, glycolytic and acidosis biomarkers expression affects MFE in 
basal-like breast cancer cells and is associated with P-cadherin-related CSC 
markers in breast carcinomas 
 
Since it has been already described that HIF-1α, GLUT1 and CAIX are required for 
CSC survival and tumour aggressiveness, and that we have recently shown that P-
cadherin is also involved in the maintenance of stem-like properties of breast CSCs, 
we decided to evaluate the effect of the inhibition of all these molecules, alone or in 
combination, on the mammosphere forming efficiency (MFE%) of basal-like SUM149 
model (Figure 21).  
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As expected, silencing the expression of CDH3, as well as of HIF-1α, GLUT1 and 
CAIX, showed a significant decrease of the ability to form mammospheres when 
compared with the cells transfected with the control siRNA (p=0.0153, p=0.0156, 
p=0.000284 and p=0.000902, respectively). Moreover, when we simultaneously 
silenced CDH3 and HIF-1α, we also observed a decrease of MFE of the target cells 
(p=0.0367), although not cumulative. If, in addition to CDH3 and HIF-1α, we silence 
GLUT1 and CAIX (siRNA CDH3+HIF-1α+GLUT1+CAIX), there is still a non-
cumulative decrease effect in MFE (%) (p=0.0152). 
Based on the above presented results, we also evaluated the association of HIF-1α, 
GLUT1 and CAIX with the CSC markers, CD44 and CD49f (Table 7), already 
described to be enriched in P-cadherin overexpressing tumours, using a previously 
Figure 21. MFE (%) decreases when 
inducing siRNA-mediated silencing of 
CDH3, HIF-1α, GLUT1 and CAIX in SUM149 
breast cancer cells. A statistically significant 
decrease in MFE (%) is observed when we 
silence CDH3 (p=0.0153), HIF-1α (p=0.0156), 
GLUT1 (p=0.000284) and CAIX (p=0.000902). 
The simultaneous silencing of CDH3 and HIF-
1α also revealed a significant decrease of MFE 
(%) of the target cells (p=0.0367), although not 
cumulative. Still, the silencing of the expression 
of all transcripts tested, also leaded to a non-
cumulative inhibition of the MFE compared to 
the control cells (p=0.0152). Protein levels of P-
cadherin, HIF-1α, GLUT1 and CAIX were 
confirmed by western blot after specific siRNA 
silencing. *p<0.05 
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characterized and independent series of 466 primary invasive breast carcinomas 
[174, 306]. Accordingly, we were able to validate the associations above described of 
P-cadherin expression with HIF-1α and GLUT1 (p=0.009 and p<0.001, respectively); 
however, no association was found between P-cadherin and CAIX expression 
(p=0.819) (Table 7). 
As previously reported, P-cadherin expressing tumours were significantly enriched in 
the expression of CD44 (p=0.003) and CD49f (p=0.001). Interestingly, we were able 
to find that GLUT1 was significantly associated with the expression of CD44 and 
CD49f  (p=0.002 and p=0.001, respectively). Moreover, CAIX expression was found 
to be associated with CD44 expression (p=0.017); no association was found between 
CAIX and CD49f expression (p=0.877). Still, no significant associations were found 
between HIF-1α and CD44 and CD49f (p=0.168 and p=0.062, respectively) (Table 7). 
 
 
Table 7. Association between P-cadherin-related CSC markers and hypoxia, glycolytic and 
acidosis markers in primary invasive breast cancer.  
 
 
 ! !
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III. P-CADHERIN’S EFFECT IN BREAST CANCER CELL’S METABOLISM 
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The results presented before suggests that P-cadherin overexpressing breast cancer 
cells are most likely to exhibit increased glycolysis and to survive to metabolic driven 
pH alterations. In fact, it has been already shown that breast CSC present decreased 
OXPHOS, increased glycolytic metabolism and contain lower levels of ROS, 
providing them a protection against oxidative stress. Taken into account that P-
cadherin is a survival factor in breast cancer cells, that it confers resistance to x-ray 
induced cell death, and also that it mediates stem cell properties in BLBC cells, we 
decided to further investigate the effect of P-cadherin in breast cancer cell 
metabolism, as well as in mitochondrial functional characteristics, such as ATP 
production, ROS levels and their scavenging systems and mitochondrial membrane 
potential. 
 
IIIa) P-cadherin expression regulates metabolic activity and ATP content of 
basal-like breast cancer cells 
 
In order to functionally evaluate the role of P-cadherin expression in cellular 
bioenergetics, we used Seahorse technology and analysed the oxidative 
phosphorylation, measured by oxygen consumption rate (OCR), as well as glycolysis, 
measured by ECAR.  
Initially, we evaluated the metabolic behaviour of SUM149 and MDA-MB-468 BLBC 
cells. Basal OCR and ECAR was measured over time followed by mitochondrial 
function assays, where the effect of well characterized inhibitors of electron transport 
chain, such as oligomycin A and FCCP, was evaluated. Figure 22 shows the 
metabolic profile of SUM149 and MDA-MB-468 cells.  
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Figure 22. Bioenergetic profile of triple negative BLBC cells. Real time analysis of OCR and ECAR 
of SUM149 and MDA-MB-468 breast cancer cells at basal levels and OCR rates upon the injection of 
3µg/mL of oligomycin and 0,1 and 0,3µM of FCCP. 
 
 
SUM149 breast cancer cells presented a basal OCR rate of about 5-fold change 
lower than MDA-MB-468 cells, while ECAR was only slightly lower. Furthermore, the 
injection of 3ug/mL of oligomycin A showed a drastic effect in the OCR of MDA-MB-
468, suggesting that these cells have a much higher ATP linked respiration than 
SUM149 (Figure 22). This profile also revealed that the maximum OCR (upon proton 
ionophore FCCP injection) is higher in MDA-MB-468 cells than in SUM149. This data 
indicates that SUM149 are more glycolytic than MDA-MB-468 cells meaning that 
these cells preferentially use glycolysis instead of mitochondrial oxidative 
phosphorylation to meet their energy demands, being a good model to evaluate the 
putative glycolytic promoter role of P-cadherin in breast cancer cells. 
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We have previously demonstrated that P-cadherin acts as a survival factor in BT20 
breast cancer cells [296]. In this work, we were able to confirm the survival role of P-
cadherin in SUM149 breast cancer cells. Apoptosis was increased upon CDH3 
siRNA-mediated downregulation in SUM149 cells (Figure 23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. P-cadherin is a survival factor in BLBC cells. SUM149 breast cancer cells with CDH3 
silencing present a higher number of apoptotic cells comparing with the control cells (A). Quantification 
of the AUC (area under curve) of apoptotic graphs shows a statistically significant increase of cell 
death in CDH3 silenced cells (B). Representative image of apoptotic cells (green) in control and CDH3 
siRNA transfected SUM149 breast cancer cells (C). *p<0,05 **p<0,001 
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We then analysed the basal OCR and ECAR rates in highly glycolytic SUM149 with 
CDH3 downregulation. Interestingly, we observed that P-cadherin silencing (Figure 
24A) induces an increase of the basal OCR/ECAR ratio comparing to control cells 
(siRNA Ctr) (Figure 24B), indicating a metabolic shift towards oxidative 
phosphorylation. 
 
 
Since OXPHOS levels were increasing upon P-cadherin knockdown, we then decided 
to evaluate the ATP content in SUM149 breast cancer cells. Accordingly, we 
observed a statistically significant increase (p=0.0174) of approximately 35% in the 
ATP content of CDH3 silenced breast cancer cells compared with the control (Figure 
25A).  
ATP levels increased after 24 hours of seeding the cells, when compared to 
measurements at 1 hour after seeding, as expected by cell proliferation and 
increased metabolic activity. Moreover, hypoxia cultured cells decreased their ATP 
content comparing to the cells exposed to atmospheric oxygen levels for the same 24 
hours, which was also expected by the metabolic shift towards glycolysis observed in 
hypoxia.  Interestingly, the increase of ATP content in CDH3 silenced breast cancer 
Figure!24.!P,cadherin!inhibition!increases!
OXPHOS! in! SUM149! breast! cancer! cells.!
Western! blot! showing! P0cadherin!
knockdown! in! siRNA0mediated! CDH3%
silenced! SUM149! comparing! to! the!
control! cells! (A).! P0cadherin! knockdown!
induces! an! increase! in! OCR/ECAR! ratio!
comparing!to!the!control!cells!(B).!
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cells was observed 1 hour after seeding, as well as 24 hours later, in normoxia and in 
hypoxia conditions (Figure 25B).  
 
Figure 25. P-cadherin expression modulates ATP content in SUM149 breast cancer cells.  ATP 
content is increased in SUM149 cells with CDH3 downregulation in comparison to control cells 
(p=0.0174) (A). After 24hours in culture, SUM149 cells presented higher levels of ATP in relation to the 
ATP levels after one hour of seeding the cells; ATP levels are lower when SUM149 cells were culture 
during 24 hours in hypoxia comparing to normoxia (B). *p<0.05.  
 
 
Using glycolysis-targeting compounds, we were able to measure the ATP derived 
from glycolysis, as a measure of percentage of glycolysis. Surprisingly, there were no 
differences between SUM149 cells with CDH3 downregulation in comparison with the 
control cells. Moreover, ATP derived from glycolysis was similar in SUM149 cultured 
in normoxic and in hypoxic environments. 
These results imply that P-cadherin expression could be interfering with the metabolic 
behaviour of breast cancer cells at the oxidative phosphorylation, rather than at the 
glycolysis level. In an attempt to understand if the effect of P-cadherin could be 
through the interference with OXPHOS regulators, we then focused on the expression 
of phosphorylated PDH (pyruvate dehydrogenase) and PDK2 (pyruvate 
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dehydrogenase kinase 2), which activity can modulate oxidative metabolism. 
However, we were not able to see any differences concerning p-PDH and PDK2 
expression (Figure 26).  
 
 
 
 
 
 
 
IIIb) P-cadherin expression induces alterations in ROS levels of breast cancer 
cells through the modification of detoxifying enzymes 
 
Since ROS are able to induce cell death, either by apoptosis or anoikis, and 
mitochondrial respiration is the major source of ROS, we decided to evaluate the 
production of ROS upon P-cadherin modulation in breast cancer cells (Figure 27). 
We were able to observe that CDH3 silencing leads to a statistically significant 
increase (p<0.05) of ROS levels in MDA-MB-468 cells when compared to control cells 
(Figure 27A). Although not statistically significant, we could also find a tendency to 
an increase in ROS in BT20 and SUM149 cells, when a downregulation of P-cadherin 
expression was induced (Figure 27B and C, respectively). Furthermore, ROS levels 
decreased in MCF-7/Az.P-cadherin cells, where P-cadherin is overexpressed, 
comparing to MCF-7/Az.mock cells (p<0.05) (Figure 27D). 
 
 
 
 
Figure!26.!P,cadherin!expression!does!not!interfere!
with! the! expression! of! OXPHOS! modulators.!
Western! blot! shows! no! differences! in! the!
expression! of! PDK2! as! well! as! in! phosphorylated!
and!total!levels!of!PDH.!
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Figure 27. P-cadherin expression regulates ROS production in breast cancer cells. Compared 
with the control cells (siCtr), inhibition of P-cadherin expression leads to a statistically significant 
increase (p=0.0123) of ROS production in MDA-MB-468 (A) as well as in SUM149 (B) and BT20 (C), 
although not statistically significant (p=0.140 and p=0.0716, respectively). MCF-7/Az cells with 
overexpression of P-cadherin shows lower levels of ROS comparing to mock cells (D, p=0,0434). 
Western blot confirmed the inhibition and overexpression of P-cadherin in all the models presented. 
*p<0.05.  
 
 
Aiming to address if the variations in ROS levels could be associated with alterations 
in scavenging systems, we evaluated the expression and activity of detoxifying 
enzymes, such as Cu/Zn-SOD (SOD1) and Mn-SOD (SOD2) (Figure 28). 
CDH3 silencing in SUM149 breast cancer cells led to a statistically significant 
decrease (p=0.000299) of SOD1 expression (Figure 28A), as well as to a significant 
decrease (p=0.0228) in SOD2 activity (Figure 28D), which was consistent with the 
increased ROS levels in these cells when compared to control cells. Furthermore, 
MCF-7/Az cells with overexpression of P-cadherin, where ROS levels were found to 
be downregulated, showed an increased expression of SOD1 (p=0.0399) and, 
although not statistically significant, we could also observe a tendency for an increase 
in SOD2 activity in cells with overexpression of P-cadherin (p=0.202). We did not 
observe any significant alterations in SOD 1 activity as well as SOD2 expression in 
breast cancer cells with CDH3 altered expression (Figure 28B and C, respectively). 
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Figure 28. P-cadherin expression modulates antioxidant systems in breast cancer cells. 
Inhibition of P-cadherin expression in SUM149 cells leads to a statistically significant decrease in 
SOD1 expression, while P-cadherin overexpressing MCF-7/Az cells presented higher levels of SOD1 
expression, comparing to the respective control cells. No alterations in SOD1 activity were observed 
upon CDH3 deregulation (B). On the other hand, SOD2 expression did not show any significant 
alterations in breast cancer cells when P-cadherin expression was modulated (C); however, SOD2 
activity decreased significantly when inducing CDH3 downregulation and, although not statistically 
significant, MCF-7/Az cells with overexpression of P-cadherin shows higher SOD2 activity comparing 
to mock cells (D).  
 
 
IIIc) Effect of P-cadherin in mitochondrial function 
 
Given the alterations in the production of ROS, as well as the metabolic shift and ATP 
production induced by P-cadherin expression in breast cancer cells, we decided to 
evaluate its effect in the mitochondrial membrane potential (Figure 29). We were not 
able to find any significant alteration in the fluorescence intensity of Mitotracker 
CMXRos when we silenced P-cadherin expression in SUM149 breast cancer cells 
(Figure 29A). Still, low P-cadherin expressing or P-cadherin-enriched cell populations 
did not present significant differences in mitochondrial membrane potential (Figure 
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29B). However, further studies are still needed to comprehend the overall role of P-
cadherin in mitochondrial functional characteristics. 
 
              A                                                                B 
                              
 
Figure 29. P-cadherin expression has no effect in mitochondrial membrane potential. Mitotracker 
CMXRos fluorescence is not altered in SUM149 breast cancer cells when inducing CDH3 
downregulation (A). Cell population with the higher and lower P-cadherin expression did not present 
alterations in mitochondrial membrane potential measured by Mitotracker CMXRos fluorescence in 
FACS analysis (B).  
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The results presented in this work provide novel insights about the role of P-cadherin 
expression in microenvironment adaptation by breast cancer cells as well as the 
possible implications of its expression in breast cancer progression and development 
of metastasis.  
 
 
P-CADHERIN OVEREXPRESSION IS SIGNIFICANTLY ASSOCIATED WITH THE EXPRESSION OF 
HYPOXIC, GLYCOLYTIC AND ACIDOSIS MARKERS IN PRIMARY INVASIVE BREAST CARCINOMAS. 
 
In the last years, there is an increased recognition that microenvironmental stress that 
solid tumours are exposed to, such as hypoxia, lactic acidosis and glucose 
deprivation, play an important role in breast carcinogenesis [18, 320]. Interestingly, 
the immunohistochemical expression of HIF-1α, GLUT1 and CAIX in a histological 
model of breast cancer progression, including normal mammary gland, ductal 
hyperplasia (DH), atypical ductal hyperplasia (ADH), in situ and invasive ductal breast 
carcinomas, Chen et al. proposed that this phenotype is a powerful adaptive 
advantage associated to an aggressive phenotype in breast carcinomas [89]. 
 
In this work, we demonstrate, for the first time, that aberrant P-cadherin expression, a 
well described poor prognostic factor in breast cancer and an inducer of aggressive 
behaviour of breast cancer cells in vitro, is associated with the hypoxic/glycolytic and 
acid resistant phenotype in breast carcinomas, evaluated by a panel of markers 
including HIF-1α, CAIX, GLUT1, MCT1 and CD147.  
 
Although it is well established the association between both HIF-1α and P-cadherin 
with several features of aggressive breast tumour behaviour, our results 
demonstrated for the first time a significant association between P-cadherin and HIF-
1α expression in breast cancer. It is widely known that, similarly to P-cadherin, HIF-1α 
expression in breast cancer is also associated to worse prognosis, short patient’s 
survival, high proliferation and poor tumour differentiation [43, 47].  
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Unexpectedly, there was no statistically significant association between HIF-1α and 
ER in this breast cancer series. However, we could find an enrichment of HIF-1α 
positivity in ER negative breast tumours. We also found that HIF-1α expression is 
predominant in highly proliferative and high-grade tumours, but no correlation was 
found with age of the patients’ diagnosis, size of the tumour, lymph node invasion, 
molecular subtype, nor molecular biomarkers of breast cancer such as ER, PgR and 
HER2. These results are in accordance with Tan et al., since they found that HIF-1α 
expression was not associated with age, size, ER and HER2 [91]. Moreover, we also 
found an association of HIF-1α expression with its downstream targets, such as CAIX 
and GLUT1, which is in accordance with previous reports [89, 321].  
Although there are several reports in the literature about immunohistochemical HIF-
1α expression in breast cancer, there is a high degree of contradictory observations 
among these studies concerning associations with hormone receptors, HER2, lymph 
nodes and histological grade [54, 322]. These differences may be due to the use of 
different classification criteria for HIF-1α, or to the analyses of specific tumours areas, 
or even to the use of tissue microarrays (TMA), especially for a marker that presents 
so much intratumoural heterogeneity as HIF-1α [323]. 
  
Several studies have been reporting that BLBC present a stronger response to 
hypoxia than tumours with luminal characteristics. This group of tumours, where P-
cadherin is frequently overexpressed, is particularly relevant in the clinical setting, 
since they are associated with aggressive tumour behaviour and shorter overall 
survival when compared with other molecular subtypes of breast tumours. 
Phenotypically, these tumours are characterized by the lack of the expression of 
hormone receptors (ER and PgR) and HER2; and histologically, they are poorly 
differentiated carcinomas, with high nuclear and histological grade and frequently 
show medullary and metaplastic features [284-288]. A distinct pattern of metastasis to 
brain and lungs, known to be associated with poor prognosis, and less significant 
involvement of axillary lymph nodes, has also been described in BLBC [170, 288, 
289]. Interestingly, these tumours also present a differential expression of proteins 
induced by hypoxia and the development of a glycolytic/acid resistant phenotype [71, 
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91, 99], which confers a selective advantage to cancer cells to grow and escape cell 
death under these adverse conditions. Accordingly, our results also showed an 
association between P-cadherin expression and HIF-1α downstream targets, such as 
GLUT1, CAIX, MCT1 and CD147. These proteins are important stress response 
mediators of cancer cell survival in stressful microenvironments, being associated 
with poor patient prognosis in breast cancer [71, 91, 99].  
 
In fact, it is expected that triple negative and BLBC show a high metabolic activity 
[324-327]. Interestingly, Kim et al.  evaluated the metabolic phenotype among the 
different molecular subtypes of triple negative breast carcinomas, based on the 
immunohistochemical expression profiles of GLUT1 and CAIX, representing a 
Warburg, Reverse Warburg, mix and null phenotype, taken into account their 
expression in tumour and stromal cells. In consistence with our results, they observed 
that triple-negative breast cancer (TNBC) presented a highly glycolytic activity in 
tumour cells and, consequently, a Warburg molecular phenotype. However, they did 
not found any significant association between the metabolic phenotype and the 
molecular subtypes of TNBC [328]. 
It has also been reported by several other authors that the expression of GLUT1, 
CAIX, MCT1 and CD147 is associated with aggressive clinico-pathological 
characteristics in primary invasive breast carcinomas such as high proliferation rates, 
high histological grade and poor patient’s survival and are also known to be 
differentially expressed in basal-like breast carcinomas, in addition to their association 
with molecular characteristics of BLBC, such as absence of hormone receptors and 
expression of key basal markers such as CK5, EGFR, CK14 and Vimentin [71, 91, 
99, 326, 329]. 
 
Moreover, we did not find association between MCT4 and P-cadherin expression in 
breast carcinomas when evaluating its expression in tumour cells. In the literature, 
there are contrasting results concerning MCT4 expression in breast cancer. For 
example, Pinheiro et al. did not find any significant association between MCT4 and 
clinicopathological data [99]. However, prognostic value was attributed to MCT4 when 
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expressed in the stromal compartment of the tumour [328]. Kim et al. found that 
stromal MCT4 absence was associated with short overall survival of breast cancer 
patients [328]. In contrast, stromal MCT4 expression was previously described as a 
predictive factor of decreased overall survival in TNBC [330]. These conflicting results 
can be explained by the use of different methodologies, namely in the classification 
method, as well as in the antibodies used to access the expression of MCT4. 
As stated above, in order to avoid acidosis-induced cell death caused by increased 
glycolytic rates, membrane transporters, such as CAIX and MCTs, are upregulated in 
order to maintain pH homeostasis inside the cells. Consequently, this cellular 
behaviour induces extracellular acidification, which is known to facilitate in vitro 
cancer cell invasion and in vivo metastization, through the acidic degradation of the 
extracellular matrix [82]. CD147/EMMPRIN, a molecular chaperone of MCT1 and 
MCT4, is known to induce MMP production [102], to promote tumour growth, inhibit 
cell apoptosis and enhance cell migration under hypoxic conditions [331]. Using in 
vivo models, it was also demonstrated that EMMPRIN-induced expression in breast 
cancer cells resulted in enhanced tumour growth in nude mice, associated to MMP2 
expression [104]. Interestingly, the high significant association found between P-
cadherin and CD147 is in accordance not only with the above-described reports, but 
also with our previous data, showing that P-cadherin induces an invasive behaviour in 
breast cancer cells by a mechanism involving the activation of MMP1 and MMP2 
[295].  
In addition to its differential expression in BLBC, P-cadherin is also enriched in HER2 
overexpressing breast tumours [228, 230, 332].  Interestingly, breast tumours with 
simultaneous expression of HIF-1α and HER2 present worse survival, indicating that 
HER2-mediated tumour aggressiveness in breast cancer can be partially due to HIF-
1α activation [333]. 
 
Taken together, the association between markers of hypoxic, glycolytic and acid-
resistance phenotype and P-cadherin expression in primary invasive breast 
carcinomas, is consistent with the relevant data concerning their expression in breast 
carcinomas.  
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P-CADHERIN EXPRESSION IS MODULATED BY HYPOXIA AND IS CONNECTED TO THE 
MACHINERY INVOLVED IN GLYCOLYTIC AND ACID RESISTANCE PHENOTYPE IN BREAST 
CANCER CELLS 
 
Based on the concept that P-cadherin, hypoxia and metabolic alterations are 
associated with poor prognosis in breast cancer, as well as on the associations found 
between P-cadherin and biomarkers of this phenotype in breast carcinomas, we 
decided to study if P-cadherin expression has a role in the adaptation of breast 
cancer cells to hypoxia and to evaluate its involvement in the regulation of the 
machinery responsible for the acquisition of this adapted glycolytic and acid resistant 
phenotype. 
 
Hypoxia has been recognized as being determinant for clinical outcomes in human 
cancers. In fact, several studies have been validating gene signatures associated with 
hypoxia as a prognostic factor in several types of cancer, including breast cancer. For 
instance, Winter et al. obtained a hypoxia metagene of head and neck cancer 
(HNSCC), which was further found to have a poor prognosis relevance in 
independent data sets, including in breast cancer [41]. Moreover, Chi et al. showed 
that human tumours, including breast carcinomas, could be stratified according to the 
presence and amplitude of a hypoxia response, using a hypoxia-response signature 
derived from mammary epithelial cells [40]. These authors showed that breast 
tumours with a strong gene expression signature of hypoxia response presented a 
significantly worse prognosis, correlated with breast cancer progression and 
metastasis. They still demonstrated that the prognostic information of the hypoxia 
signature was independent of other previously reported signatures and more 
predictive of outcome than other clinical parameters used in the clinical practice [40]. 
 
In this work, we demonstrate for the first time an association between the expression 
of P-cadherin and HIF-1α in breast carcinomas, which was validated using in vitro 
breast cancer models. We showed that P-cadherin expression is modulated in a time-
dependent way by hypoxia, since short-time incubations of BLBC cells in low oxygen 
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levels increased P-cadherin expression, whereas 24 hours of incubation of cells in 
these conditions, lead to a significant decrease of the expression levels of this 
protein. In our opinion, this transient increase of P-cadherin expression might be 
important to the initial induction of the aggressive response of breast cancer cells to 
hypoxia and be also partially responsible for the development of adaptation of breast 
cancer cells to the hypoxic environment. This opinion is also supported by the 
enrichment of CDH3 transcripts in hypoxic conditions, found in the analysis of the 
online available GEP from Chen et al. study [315]. Moreover, it is know that in solid 
tumours, hypoxia is highly heterogeneous concerning its spatial distribution and 
intensity. Concerning kinetics, hypoxia is also highly diverse, since it is able to 
regulate several different cellular pathways with unique activation kinetics and 
sensitivity to oxygen concentration. However, most of the studies underlying the 
prognosis relevance of hypoxia signature in breast tumours do not take into account 
the time dependency of hypoxia-regulated gene expression. Interestingly, Seigneuric 
et al. studied the impact of the time-dependent response to hypoxia in the prognostic 
value of breast cancer patients [334]. By the analysis of gene signatures derived from 
either early or late hypoxic exposure of several primary cell lines, including a HMEC 
cell line, these authors observed that early hypoxia signatures show a significant 
prognostic power comparing to late hypoxia signatures, being the best prognostic 
factor in breast cancer after lymph node status, tumour size and Elston grade [334]. 
 
Thus, the recognition of P-cadherin as a poor prognosis marker in breast cancer, 
being significantly associated with short-term overall and disease free survival [228, 
230, 277, 306], in addition to the data showing that early hypoxia-responses have 
increased prognosis value in breast cancer patients, are in accordance with our 
results showing that P-cadherin expression increases at early hypoxia exposure of 
breast cancer cells.  
 
Besides the kinetics of hypoxia-induced signalling, it is also important to take into 
account that biological systems are extremely heterogeneous regarding oxygen 
concentrations: normoxia conditions of cell cultures in vitro is, by definition, the 
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oxygen tension of ambient air. However, oxygen concentrations between 2% and 9% 
have recently been reported by some authors to constitute physiologic normoxia 
[125]. Thus, it is important to set among experiments the most accurate oxygen 
pressure as possible, in order to more precisely reproduce the real tension 
experienced by a given cell in vivo. Although our in vitro results demonstrates that 
hypoxia modulates P-cadherin expression in a time dependent manner, implicating 
the kinetics of P-cadherin regulation by hypoxia, it would be also important to analyse 
P-cadherin modulation in different oxygen tensions that would reproduce hypoxia 
conditions observed in human breast carcinomas. 
 
Further, and validating the association in breast carcinomas, as well as the enhanced 
P-cadherin expression in early hypoxia exposure times, we also find that HIF-1α 
stabilization promotes membrane P-cadherin expression in breast cancer cells upon 
CoCl2 treatment. However, no alterations were detected in CDH3 mRNA levels, which 
led us to hypothesize that increased P-cadherin membrane expression after HIF-1α 
accumulation occurs at a post-transcriptional level and not as a direct effect. 
 
Thus, based in our findings and on previous data reported by others, the crosstalk 
between HIF-1α and P-cadherin might be explained by several hypotheses. One 
explanation can be related with the proteasome-dependent ER degradation induced 
by hypoxia through HIF-1α [49], observed in hypoxic/necrotic areas of breast 
carcinomas that show ER loss [49, 51]. Interestingly, ER negativity was already 
coupled to P-cadherin overexpression in breast carcinomas [249, 273]. In fact, in 
2004, we have found that the antiestrogen ICI 182,780 (Faslodex) induces aberrant 
P-cadherin overexpression in breast cancer cells [241] by a mechanism involving 
chromatin remodelling of the gene promoter [246], identifying ER as a transcription 
CDH3 repressor. Thus, hypoxia can be inducing HIF-1α, which promotes ER 
degradation and consequently P-cadherin increased expression. Other explanation 
can also be related to the existent link between hypoxia and BRCA1, which is also a 
CDH3 transcriptional repressor [242]. It is known that hypoxia induces BRCA1 
downregulation [335] and that BRCA1-mutated breast carcinomas, which are 
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enriched in HIF-1α expression [54], present aberrant expression of P-cadherin [247]. 
In addition, CAIX is also associated with somatic loss of BRCA1 protein and pathway 
activity in triple negative breast cancer [336]. Actually, Neumeister et al. 
demonstrated that CAIX expression was inversely related with nuclear BRCA1 
expression in breast cancer patients and also that high CAIX protein expression 
occurs in patients who show the BRCA1 mutant signature and low levels of BRCA1 
protein [336].  
Finally, since it is also accepted that hypoxia, via HIF-1α, induces EMT with 
consequent E-cadherin loss of expression in different tumours models [337], including 
breast cancer [31], we can also hypothesize that P-cadherin increased expression, 
either in hypoxia and in CoCl2 treated breast cancer cells, might be a consequence of 
hypoxia/ HIF-1α-induced E-cadherin downregulation. In fact, loss of E-cadherin has 
also been associated with increased aggressive behaviour in several human tumours, 
as well as with tissue dysfunction and cell death in early mouse embryos and in 
lactating mammary gland [338, 339]. Accordingly, our unpublished work shows that 
siRNA-mediated downregulation of E-cadherin leads to increased P-cadherin 
expression in breast cancer cell lines and it has also been shown that epidermal 
basal layer of skin respond to E-cadherin loss with an increase in P-cadherin 
membrane expression [340].  
Interestingly, the HIF-1α-dependent gene product CAIX has also been associated 
with E-cadherin loss. In 2006, it was shown that VHL inactivation and HIF activation in 
precancerous lesions in kidneys from patients with VHL disease correlates with 
downregulation of E-cadherin [341], since portions of the distal tubules that expresses 
CAIX shows a substantial decrease in E-cadherin expression.  
 
Concomitantly with P-cadherin increased levels, we also observed a decrease in the 
cellular height of breast cancer cells after CoCl2 treatment, indicating a putative re-
organization of the cytoskeleton, with the acquisition of a phenotype associated to 
breast cancer cell aggressiveness, such as increased ability of migration and motility 
[342]. This observation is consistent with our previous data, showing that P-cadherin 
expression is able to induce invasion, migration and motility of breast cancer cells 
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[295] and that its modulation also interferes with GTPase-mediated signal 
transduction and actin cytoskeleton organization [310]. 
 
After describing the significant associations in primary tumours, as well as the link 
between P-cadherin and HIF-1α transcription factor, either in breast carcinomas and 
in vitro, we found, using BLBC cell lines, that P-cadherin silencing is still able to 
induce the downregulation of GLUT1 and CAIX mRNA, although GLUT1 and CAIX 
knockdown showed little or no effect in CDH3 mRNA expression. Because the 
expression variations were not so prominent as expected for a direct molecular target, 
we believe that P-cadherin is putatively involved in a signalling pathway that interferes 
with the metabolic reprograming of cancer cells. In accordance, we observed that the 
cell populations expressing more/less P-cadherin at the cell surface were the same 
presenting higher/lower levels of GLUT1 and CAIX and vice-versa. These results 
suggest that P-cadherin overexpressing breast cancer cells are most likely to exhibit 
increased glycolysis and to survive to metabolic-driven pH alterations, justifying the 
enhanced invasion and metastatic properties. Still, these concepts, as well as the 
above-discussed results, are reinforced by GEP analysis of breast cancer cells with 
CDH3 deregulation, which revealed alterations in genes that regulate oxygen and 
nutrient levels. Accordingly, alterations in cyclic nucleotide metabolic processes, as 
well as in carboxylic acid transport processes, which are intimately associated with 
the adjustment of cells to nutrient and oxygen deprivation, were also found to be 
deregulated by P-cadherin expression in these GEP studies. Moreover, these results 
also strengthen the hypothesis that P-cadherin might have a role in the development 
of an advantageous phenotype of breast cancer cells, in order for them to survive and 
grow in adverse microenvironmental conditions.  
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P-CADHERIN, HIF-1α, GLUT1 AND CAIX AS CANCER CELL MARKERS IN BASAL-LIKE 
BREAST CANCER CELLS 
 
Hypoxia and hypoxia inducible factors are implicated in tumourigenesis of several 
cancer models, including breast cancer. In 2006, Li et al. demonstrated that HIF-1α 
knockdown reduces tumourigenicity of breast cancer cells by reducing tumour growth 
in orthotopic and subcutaneous xenograft models and sensitizes cells to 
chemotherapy [343]. This effect is known to be attributed to the role of hypoxia in the 
expansion of a population of cancer cells with stem-like properties, the CSC [130]. 
Specifically in breast cancer, several reports have demonstrated that HIF-1α directly 
regulates breast CSC activity in vitro and in vivo [39, 46]. Using metastatic breast 
cancer cell lines, Louie et al. demonstrated that repetitive cycles of hypoxia and 
reoxygenation selects and expands a breast cancer cell population with high ability to 
form colonies in vitro, tumours in immune-deficient mice and with stem-like and EMT 
properties [39]. Recently, Schwab et al. also showed the pivot role of HIF-1α in the 
maintenance, expansion, as well as increased activity of breast CSCs, with 
implications in tumour growth and lung metastasis [46]. Moreover, it is accepted that 
the limited efficacy of anti-angiogenic therapies, which surprisingly demonstrated to 
increase invasive and metastatic properties of breast cancer cells, can be attributed 
to breast CSC expansion by tumour hypoxia. Using human breast cancer xenografts, 
Conley et al. demonstrated that anti-angiogenic factors, such as sunitinib and 
bevacizumab, are able to increase intratumoural hypoxia, which in turn leads to an 
increase of the breast CSC population, through the activation of Wnt pathway via 
Akt/β-ctn signalling [197]. Accordingly, Oliveira-Costa et al. also showed that HIF-1α 
was differently expressed in CD44+/CD24-/low breast CSCs [194]. In addition to these 
reports, is has also been shown that CAIX also plays a role in the regulation of 
stemness and expansion of breast CSCs in hypoxic niches, since its expression and 
activity is required for the expansion of 4T1 CD44+/CD24-/low cells in hypoxia [344]. 
Lock et al. showed that small-molecule mediated inhibition of CAIX expression or 
activity in breast cancer cell lines resulted in the inhibition of breast CSC expansion in 
hypoxia through the mTORC1 pathway [198]. In vivo, these authors also 
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demonstrated that the treatment of mice bearing orthotopic breast tumours with CAIX-
specific small-molecule inhibitors results in a significant depletion of CSCs within 
these tumours. Accordingly, CAIX was shown to modulate the expression of EMT 
markers, as well as drivers of stemness such as Notch1 and Jagged1 in breast CSC 
[198]. Thus, CAIX is suggested to be a promising target for depleting CSCs from 
breast tumours, leading to improved chemotherapeutic response, since CAIX 
inhibitors, in combination with paclitaxel, decreased tumour growth and the formation 
of lung metastasis [198].  
 
Recently, we have also demonstrated that P-cadherin expression is able to mediate 
stem cell properties in BLBC cells in vitro, which can be responsible for the 
aggressive behaviour of BLBC [306]. With P-cadherin gene expression manipulation, 
either by silencing with siRNA or by overexpression, as well as separation of P-
cadherinhigh and P-cadherinlow cell populations, we showed that this molecule induces 
stem cell activity and self-renewal of mammospheres, as well as clonogenic activity in 
3D cultures of BLBC cells. We still demonstrated that P-cadherin-enriched cell 
populations have increased tumourigenic ability in athymic nude mice [306]. 
 
Taken together, all the described data indicate that all these molecules, which are 
representative of an adaptation to hypoxia with the acquisition of a glycolytic 
metabolism, are associated with stem-like properties in breast cancer cells. 
Accordingly, this work demonstrates that the inhibition of CDH3, HIF-1α, GLUT1 and 
CAIX in BLBC cells significantly reduces their MFE, an important measure of breast 
CSC activity. We still show that the silencing of CDH3 and HIF-1α, or even the 
simultaneous inhibition of CDH3, HIF-1α, GLUT1 and CAIX, have a non-cumulative 
effect in the inhibition of MFE comparing to the single silencing of each one of these 
molecules. In a way, this result confirms our observation that the cell subpopulation 
expressing increased levels of P-cadherin at the cell surface was also the same 
presenting higher levels of GLUT1 and CAIX, demonstrating that we are targeting the 
same breast cancer cell population, which presents an increased stem cell activity. 
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Our results also demonstrated an association between glycolytic and acid-resistant 
markers with P-cadherin-related breast CSC markers, such as CD44 and CD49f. 
These molecules are putative mammary gland stem cell [152, 345, 346], as well as 
CSC markers of the basal phenotype [175, 178, 347], and are enriched in breast 
cancer cell lines with basal-like phenotype [179, 306, 348, 349], where P-cadherin is 
also known to be enriched. Besides the in vitro association found between P-cadherin 
expression and the breast CSC markers CD44 and CD49f, our group also reported 
the association of CD44 and CD49f with P-cadherin expression in human primary 
breast carcinomas [306]. Still, P-cad+/CD44+ tumours present worse patient’s survival, 
comparing with P-cad+/CD44- or with tumours with absence of P-cadherin expression 
[306]. 
Using immunohistochemistry in an independent series of primary invasive breast 
carcinomas, we were able to validate not only the above-described associations 
between P-cadherin with HIF-1α and GLUT1, as well as the association between P-
cadherin, CD44 and CD49f expression, as previously reported [306].  Importantly, we 
found that GLUT1 expression was significantly associated with the expression of 
CD44 and CD49f, and CAIX expression was found to be significantly associated with 
CD44 expression. These results are in accordance with the concept that breast CSCs 
present an enhanced glycolytic phenotype [201]. Interestingly, CD44 was described 
as playing a role in the regulation of metabolism of glycolytic cancer cells [350]. 
Tamada et al. demonstrated that CD44 ablation reduces glucose uptake through the 
suppression of GLUT1 expression in p53 knockout cells in vitro [350]. 
 
Moreover, CAIX expression was already associated with the expression of CSC 
markers. Currie et al. studied the expression of CSC markers and its relationships 
with hypoxia and angiogenesis markers in breast carcinomas [329]. These authors 
found that CAIX expression was associated with the CSC marker CD133, but not with 
CD44+/CD24-/low or with ALDH1 expression. Microvessel density, measured by CD31 
immunoreactivity, was only associated with ALDH1 positive breast carcinomas[329].  
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HIF-1α is also a known regulator of CD44 expression in breast cancer cells. 
Krishnamachary et al. have demonstrated that hypoxia, via HIF-1α, induces the 
expression of the two CD44 variant isoforms, CD44v6 and CD44v8, in triple negative 
breast cancer cells in vitro [351]. They also showed an increased expression of CD44 
in hypoxia regions of tumours in vivo, suggesting that increased expression of CD44 
may be an additional mechanism by which hypoxia mediates a more aggressive 
phenotype and also reinforcing the presence of CSCs in hypoxic environments [351]. 
Moreover, other authors have also described a significant association between the 
expression of CD44 and HIF-1α, evaluated by immunohistochemistry in invasive 
breast tumours [352]. In contrast with these results, we were not able to find an 
association between HIF-1α and the P-cadherin associated CSC markers, CD44 and 
CD49f. Anyway, our previous results demonstrating that P-cadherin expression is 
able to modulate the expression of CD49f and CD44 in BLBC cells, as well as the 
above described studies, supporting the association between P-cadherin expression 
and the glycolytic and acid-resistance phenotype, corroborates the associations found 
between GLU1 and CAIX with breast CSC markers. 
 
  
Discussion 
152$
P-CADHERIN IS RESPONSIBLE FOR OXPHOS SUPRESSION IN BREAST CANCER CELLS 
 
In this work we demonstrated, for the first time, that P-cadherin silencing was able to 
modulate cellular bioenergetics of SUM149 breast cancer cells, by allowing an 
increased OCR/ECAR rate, as well as cellular ATP content. These results suggest 
that P-cadherin is responsible for suppression of OXPHOS in these highly glycolytic 
IBC cells and that its expression influences the way by which cancer cells obtain their 
energy.  
 
Several reports in the literature have been attempting to compare the metabolic 
profile of normal mammary tissue with breast tumours, implicating metabolic 
alterations in breast cancer progression [110-112, 353]. Most of these studies show 
an increased glycolytic activity and a decreased OXPHOS with cancer progression. 
Budczies et al. performed a metabolic map of breast cancer showing alterations in 
energy metabolism, catabolism of amino acids and nucleotide metabolism [113]. 
Furthermore, Richardson et al. also found key alterations in metabolic processes 
including PPP, TCA cycle, as well as synthesis of glutamate, glutathione and fatty 
acid upon breast cancer transformation, as well as alterations in de novo synthesis of 
glycine and proline in metastatic breast cancer cells [111]. Furthermore, a “two-step 
theory of breast cancer progression” was proposed by Lu et al., also implicating 
metabolic deregulation in both breast tumourigenesis and progression [110]. Using a 
series of isogenic tumourigenic cell lines mimicking breast cancer progression, these 
authors demonstrated, by the quantitative analysis of metabolites involved in 
metabolic pathways, that fatty acid and nucleotide biosynthesis, glutathione 
antioxidant pathway, as well as glycolysis, TCA and PPP accompanies transformation 
and acquisition of metastatic potential of breast cancer cells [110]. Still, using the 
model of breast cancer progression of the immortalized mammary epithelial cell line 
MCF-10A, Shaw and co-workers demonstrated a decline of oxygen consumption rate 
in a series of cell lines mimicking breast cancer progression, thus proposing that it is 
accompanied by a decrease in cellular OXPHOS capacity [112]. Taken together, the 
above-presented studies implicate the deregulation of several metabolic processes in 
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breast cancer tumourigenesis and progression, which we also found to be altered in 
the analysis of GEP of breast cancer cells with modulation of P-cadherin expression. 
These results can be associated to the P-cadherin role in stemness maintenance, in 
the normal and cancer context. Kolle et al. have identified CDH3 as one of the genes 
encoding a surface protein able to identify the pluripotent population of human ESC 
[255] and it expression was already reported in early progenitor cells from hair germs 
and small hair epidermal [257, 258], as well as in mammary stem cells [254]. In 
normal mammary gland, P-cadherin expression is confined to the myoepithelium, 
where adult stem cells are thought to exist. The same localization is also found in the 
development of the gland, where P-cadherin is observed in the precursor cell [230, 
253-255]. Functionally, this adhesion molecule seems to be responsible for the 
maintenance of the undifferentiated state of the mammary gland, since the CDH3-null 
female mice exhibit precocious mammary gland differentiation in the virgin state, and 
breast hyperplasia and dysplasia with age [264]. Normal stem cells from several 
different tissues in the human body have distinct metabolic properties when 
compared to their more differentiated progeny [147, 354].  These undifferentiated 
cells use glycolysis as their main pathway to obtain ATP for their energetic demands, 
suggesting that increased glycolysis is a conserved stem cell property. It is believed 
that the hypoxic environment where stem cells reside, in stem cell niches, prevents 
differentiation being responsible for the maintenance of self-renewal and pluripotency 
of stem cells [2, 126]. ESC and iPSC exhibit similar bioenergetic metabolic profiles, 
redox status and mitochondrial function [355]. In fact, several reports have 
demonstrated that these cells exhibit enhanced glycolysis, as well as under-
developed mitochondrial network and low mitochondrial activity compared with their 
more differentiated counterparts [147, 356-360]. Furthermore, Simsek et al. 
demonstrated that HSC present a unique metabolic profile, using glycolysis instead of 
oxidative phosphorylation, with low mitochondrial membrane potential and NADH 
levels, which provide these cells survival advantage during severe hypoxic or anoxic 
insults, which would eliminate more differentiated cells that rely on oxidative 
metabolism. Importantly, the transcriptional regulation of HIF-1a by Meis1 highlights 
the involvement of stem cell-associated transcription factors in the regulation of HSC 
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metabolism and indicates that the glycolytic phenotype of HSCs is not merely a 
product of their hypoxic environment [354]. In fact, hypoxic environments and 
mitochondrial inhibition have been associated with reduced stem cell differentiation 
and improved generation of iPSC [126, 128, 147]. Somatic cells undergo a metabolic 
shift in order to acquire ES cell-like features. Moreover, functionally active 
mitochondria are necessary for successful differentiation of ES cells, which requires 
an opposite switch in energy metabolism from anaerobic glycolysis to aerobic 
OXPHOS [133, 137]. Panapoulos et al. evaluated the bioenergetic alterations of 
somatic cell reprogramming, by the analysis of metabolomic and cellular bioenergetic 
of human iPSC relative to ESC and to their somatic cells of origin [118]. These 
authors found that somatic cells present a higher overall oxidative/glycolytic (by 
OCR/ECAR rates) compared to pluripotent stem cells, indicating that energy 
production of more differentiated cells is more dependent on oxidative 
phosphorylation than their pluripotent induced counterparts [118].  
Due to the similarities of induced pluripotency and cancer, it is recognized that 
changes in cell metabolism that are important in the regulation of somatic cell 
reprogramming are also important in cancer [361]. Similar metabolism of normal stem 
cells is also observed in cancer cells with stem-like properties. The majority of the 
studies underlying the metabolic profile of CSCs are performed in gliomas [362-365].  
GSC found in primary samples were found to have a pro-glycolytic phenotype [362-
364]. In contrast, in other reports using glioma cell lines, GSCs and progenitor cells 
were found to be less glycolytic, consume less glucose, produce less lactate and 
present higher ATP levels than their differentiated progeny [365]. In this last study, 
GSCs and progenitor cells were found to use additional metabolic pathways, since 
inhibition of either glycolysis or oxidative phosphorylation had minimal effect on 
energy production [365].  
Interestingly, breast CSCs are also described as presenting a glycolytic phenotype. 
Feng and co-workers demonstrated that CSC, from human and mice mammary 
tumours, use preferentially glycolysis instead of OXPHOS as their metabolic 
programme, when compared with non-breast CSC, where decreased expression and 
activity of mitochondrial PDH is being responsible for this metabolic behaviour [201]. 
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These authors found that breast CSC present a higher ratio of lactate production to 
oxygen consumption, higher glucose consumption as well as fewer and less active 
mitochondria, than non-breast CSC [201]. The glycolytic dependence of breast CSC 
was further confirmed by the treatment of cells with metabolism-targeting drugs, 
where they concluded that oxidative phosphorylation promotion in breast CSC could 
represent a potential therapeutic strategy for targeting these aggressive breast cancer 
cells [201, 202]. The metabolic behaviour of breast CSC was recently confirmed by 
Ciavardelli et al., using proteomic and targeted metabolomics analysis [202].  These 
authors demonstrated breast CSC shift from mitochondrial oxidative phosphorylation 
towards glycolytic metabolism and present increased expression of key enzymes of 
anaerobic metabolism, such as PKM2, LDH, and glucose-6- phosphate 
dehydrogenase, as well as increased antioxidant defence system [202]. Moreover, 
they observed that breast CSC treatment with 2-DG, an inhibitor of glycolysis, inhibits 
their proliferation when used alone and shows a synergic effect when used in 
combination with doxorubicin [202]. 
 
In conclusion, we suggest that inhibition of glycolysis may be a potentially effective 
strategy to target breast CSCs. Our results are concordant with the role of P-cadherin 
in the maintenance of stem-like properties in glycolytic breast CSC, as well as with 
the increased glycolytic and decreased oxidative phosphorylation associated with 
breast cancer progression. Since we demonstrate that P-cadherin inhibition in highly 
glycolytic breast cancer cells induces a metabolic shift towards oxidative metabolism, 
we hypothesize that this metabolic effect might be responsible for the decreased 
ability breast cancer cells to survive in anchorage independent condition upon CDH3 
silencing.  
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P-CADHERIN SUPRESSES OXIDATIVE STRESS IN BREAST CANCER CELLS 
 
High rates of aerobic glycolysis are usually associated with increased proliferation 
and this phenotype is observed in rapidly proliferating cells, described as the 
“Warburg effect”. However, stem and CSCs, which are relative quiescent, are 
described as having a glycolytic metabolic phenotype. For instance, HSC are more 
glycolytic, even though they are more quiescent than their differentiated counterparts 
[366]. Moreover, when comparing proliferating with quiescent fibroblasts, Lemons et 
al. observed that quiescent fibroblasts showed high glycolytic rates comparing to the 
proliferating ones [367]. Besides conferring fragility to Warburg hypothesis, these 
observations indicate that stem and CSCs undergo a metabolic glycolytic 
reprogramming independently of their cell cycle state. However, this phenotype is 
thought to be advantageous due to the diversion of metabolic intermediates into 
biosynthetic pathways, in order to meet the energetic demands for proliferation. 
Importantly, another advantage of this phenotype is the consequent ability to escape 
oxidative stress induced cell death. Oxidative stress occurs when production of 
reactive oxygen species (ROS) exceeds the capacity of the cellular defence systems, 
consisting of redox enzymes and other antioxidant molecules.  
 
In this work, we observed a significant increase of ROS levels upon P-cadherin 
downregulation, as well as a decrease of ROS content upon P-cadherin 
overexpression in breast cancer cells. 
 
At physiologic concentrations, ROS exerts essential signalling functions, being 
involved in the redox-dependent regulation of multiple signal transduction pathways, 
essential to biological processes, such cell adhesion, migration, proliferation, 
differentiation, and survival [204-207]. However, at high levels, ROS can induce 
damaging effects through oxidative stress. This is caused by an imbalance between 
the production of ROS and the ability of cellular antioxidant mechanisms to readily 
detoxify the reactive intermediates, making the maintenance of highly regulated 
mechanisms to control ROS levels and functional specificity, an essential process for 
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normal cellular homeostasis and cancer development. A glycolytic metabolism 
produces less ROS when compared with mitochondrial oxidative phosphorylation 
[11]. Thus, in accordance with their pro-glycolytic behaviour, several types of stem 
cells [211, 212] contain lower levels of ROS and manifest enhanced mechanisms for 
protection against ROS-mediated damage, comparing to their more mature progeny. 
Similarly, also cancer cells with stem-like properties have been described to present 
these same characteristics. In breast biology, normal mammary epithelial stem cells, 
as well as CSCs in human and murine breast tumours, contain lower ROS levels and 
increased scavenging systems [213, 217]. Particularly, Dihen et al. demonstrated that 
normal mammary stem cells, defined as a population enriched for mammary 
repopulating units, with the phenotype CD44med/CD49fhighLin-, displayed low to 
intermediate levels of ROS, when compared to progenitor enriched populations [213]. 
Moreover, transplantation of these mammary stem cell populations according to their 
ROS levels, confirmed that mammary repopulation, a stem-like property, was 
associated with intracellular ROS, since these mammary stem cells sorted by their 
lower to intermediate ROS concentrations gave rise to epithelial outgrowth when 
transplanted in cleared mammary fat pad. Similarly, these authors also showed that, 
breast CSCs with CD44+/CD24-/low/Lin- phenotype presented higher levels of 
antioxidant defence associated genes, as well as lower levels of ROS [213]. 
 
Breast CSC are thought to persist in the tumour as a distinct population after therapy, 
causing relapses and metastasis, giving rise to new tumours. Along with other tumour 
microenvironmental factors, ROS are known to play a role in CSC formation, partially 
by the development of EMT. In fact, CSC exhibits increased expression of oxidative 
stress response genes, implicated in the survival of these cells to anticancer therapy 
[368, 369]. Emerging data have proven that high doses of ROS induce cell death in 
acute exposure, but the adaptation of cancer cells to this oxidative stress enables 
cells to survive and persist in the tumours. Interestingly, breast CSC are thought to be 
the most resistant pool of cells within the tumour bulk to therapeutical intervention, 
including radiation and oxidative stress inducing drugs [370]. ROS coming from 
mitochondria are responsible for anoikis-induced cell death in endothelial cells, as 
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well as in CSC, and the anoikis-resistance observed in CSC are thought to be due to 
lower ROS levels and enhanced scavenging systems observed in these cells [371]. 
Thus, the glycolytic behaviour of CSC as well, as their reduced OXPHOS, enabling 
low production of ROS, constitutes a survival advantage to breast CSC in their 
hypoxic niches, as well as in the exposure to hypoxic/anoxic episodes in the tumour 
microenvironment. Moreover, cell death induced by radiotherapy and 
chemotherapeutic drugs used in breast cancer, such as cisplatin, Adriamycin and 5-
Fluorouracil, are thought to be mediated by the lethal effect of ROS [216, 372-376]. 
Thus, chemo and radioresistance exhibited by CSCs (Phillips de mama, Dallas 
chemoresistance colorectal cancer research 2009) have been attributed to their low 
levels of ROS and enhanced ROS defences. Survival of CSCs after ionizing radiation 
has been largely documented in brain tumours [377], as well as in breast CSC [213, 
217]. Mice bearing MMTV-Wnt-1 tumours treated with short fractioned ionizing 
radiation showed a two-fold increase in the percentage of breast CSC comparing with 
non-breast CSC after irradiation, confirming the radioresistance of CSC in breast 
tumours. Accordingly, using breast cancer cell lines, Phillips and colleagues also 
reported that breast CSC represent a radioresistant subpopulation of breast cancer 
cells that are expanded after short courses of fractionated irradiation [217]. In this 
study, the authors observed a higher survival and lower ROS content in breast cancer 
cells growing in non-adherent conditions (representative of breast CSC), compared to 
cells growing in monolayer, after short courses of fractionated irradiation [217].  
 
Recently, an interesting major role has been attributed to ROS in both outside-in and 
inside-out signalling of integrins, cadherins and small GTPases, raising the possibility 
that ROS constitute master regulators of the crosstalk between fundamental cell 
adhesion receptors [378]. Interestingly, our previous and ongoing work has been 
disclosing important knowledge about P-cadherin, a poor prognosis factor in breast 
cancer, as a pro-invasion molecule when co-expressed with E-cadherin, promoting 
cell-ECM attachment and alterations in the actin cytoskeleton, by increasing the 
expression of the laminin receptor α4β6 integrin, inducing p120-ctn cytoplasmic 
delocalization, and the activation of Src, FAK, AKT, Rac1 and MMP1/2[295, 296, 
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308].  Taken together, these findings reinforce the observed role of P-cadherin 
expression in ROS signalling. 
Many studies have been trying to understand the mechanism for adaptation to ROS-
induced toxicity leading to acquired chemotherapeutic resistance in breast cancer 
cells. Interestingly, Mahalingaiah et al. demonstrated that persistent exposure to 
oxidative stress increases tumourigenic and metastatic potential of breast cancer 
cells. These authors observed that, while acute exposure to H2O2-induced ROS 
inhibits the growth of MCF-7 breast cancer cells, chronic exposure leads to increased 
cell growth and survival, with increased number of soft agar colonies, upregulation of 
pro-metastatic genes VEGF, WNT1 and CD44, as well as to downregulation of E-
cadherin [379]. Interestingly, E-cadherin loss and EMT have been widely associated 
with enhanced radioresistance in breast cancer cells. Using clonogenic survival 
experiments in breast cancer cell lines, Theys et al. have demonstrated that low 
expression of E-cadherin confers resistance to radiation in breast cancer cells and 
reintroduction of E-cadherin sensitize cells after irradiation [380]. Moreover, Mori et al. 
also showed a decreased E-cadherin expression and enhanced expression of MMPs 
in mouse mammary gland epithelial cells, when exposed to oxidative stress for two to 
four days, with consequent enhanced invasive potential [381]. Interestingly, it is also 
reported that oestrogen-induced ROS is associated with E-cadherin downregulation 
[382]. However, besides its tumour/invasion suppressor function, the “dark side” of E-
cadherin has already been described [383], and the regulation of energy metabolism 
is an important part of this aggressive behaviour [384]. Loss of E-cadherin and 
overexpression of E-cadherin regulators, such as ZEB1, in highly aggressive breast 
cancer cells, was shown to reduce tumour growth and metastasis formation, and 
gene profiling analysis demonstrated that loss of hypoxia response of IBC cells was 
the responsible mechanism for these observations [384]. In this study, Chu et al. 
demonstrated that E-cadherin silencing reduced tumour growth and this effect was 
rescued by HIF-1α expression; in addition, they demonstrated that E-cadherin 
expression downregulates the expression of HIF-1α, as well as some of its targets 
genes, such as CAIX. Accordingly, they also observed a reduction of lactate 
production and ECAR of IBC cells when E-cadherin expression was silenced, 
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showing that E-cadherin promotes glycolytic behaviour of IBC cells [384]. 
Tamada et al. have demonstrated that CD44 modulates metabolism of cancer cells, 
promoting glycolysis by the interaction with PKM2 in cancer cells that are either 
deficient in p53 or exposed to hypoxia, suggesting that CD44 is a potential 
therapeutic target for glycolytic cancer cells that manifest drug resistance [350]. Using 
siRNA-mediated knockdown, these authors showed that CD44 downregulation 
induces a metabolic shift towards mitochondrial respiration, with increased metabolic 
flux to TCA and concomitantly decreased entry into glycolysis and the PPP. These 
effects were also accompanied by a decrease in ATP cellular content as well as an 
increased the intracellular ROS levels. Furthermore, they also showed that treatment 
of cancer cells with mitochondrial respiration enhancer, DCA, have the same effect as 
CD44 decreased expression in the metabolic shift observed in glycolytic cancer cells. 
Interestingly, they also found that CD44 ablation enhanced the chemotherapy-
induced cell death, probably by the increase in ROS levels [350]. 
 
The unique metabolic programme of aggressive breast CSC, like their glycolytic 
behaviour, reduced ROS levels and increased antioxidant defences, which enables 
these cells to survive to radiation and chemotherapy-induced cell death, is an 
extremely attractive therapeutical strategy for the development of breast CSC target 
drugs. Thus, oxidative stress modulation has been suggested as an effective strategy 
to target CSC and to increase radio and chemotherapy efficiency. For example, 2-
DG, a glucose analogue, known to decrease glycolytic metabolism, has been used in 
cancer diagnosis and treatment. In vitro studies have shown that this compound 
inhibits cancer cell growth in several cancer models [385, 386]. Interestingly, breast 
CSC were found to be more sensitive to 2-DG treatment than their non-CSC 
counterparts [201], alone or in combination with chemotherapic drugs such as 
doxorubicin [202]. However, the clinical success of this compound was compromised 
due to its increased autophagy and toxicity to the brain and heart. Another example is 
3-BromoPyruvate (3-BrP), which although is not in any clinical trial, it has been 
considered as a potential cancer therapeutic agent due to its effects on different 
cancer types, including breast cancer [387-390]. Finally, DCA, a pyruvate analogue 
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that inhibits pyruvate dehydrogenase kinase (PDK), diverting pyruvate to 
mitochondrial Krebs cycle [162, 391, 392], has been also target of several studies that 
stressed out the possible role of DCA as a potential anti-cancer drug for several types 
of cancer, including breast cancer [203, 393, 394], due to its anti-proliferative and pro-
apoptotic potential. Interestingly, DCA seems to play an important role in cell death 
induction, specifically in CSC. In vitro and in vivo studies have been shown that DCA 
treatment inhibits proliferation of glioblastoma stem-like cells [395]. In breast cancer, 
DCA was also found to decrease breast CSC clonogenicity in 3D spheroid culture 
systems in a dose dependent manner [201]. This effect seems to be related with the 
decreased expression and activity of PDH found in breast CSC when compared with 
non-breast CSC [201]. DCA was already on the base of one phase II clinical trial 
[395] and another trial with DCA in currently on going (‘ClinicalTrials.gov’).  
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P-CADHERIN MODULATES ANTI-OXIDANT PROPERTIES IN BREAST CANCER CELL 
 
ROS are mainly produced in the mitochondria and the accumulation of these 
molecules is controlled by the potent anti-oxidant machinery of the cell. Antioxidants 
seem to have dichotomous activities in tumourigenesis. By one side, they suppress 
tumourigenesis by preventing oxidative damage to DNA [396]. By the other side, they 
promote tumourigenesis by allowing survival of cancer cells. In fact, increased 
antioxidant activity has been reported as playing an important role in breast cancer 
progression. Lu et al. reported a reduced anti-oxidant activity in tumourigenic and 
metastatic cells lines, suggesting that aggressive behaviour of breast cancer cells is 
associated with decreased ROS levels and increased anti-oxidant defence systems 
[110]. Furthermore, a recent study has revealed that enhanced PPP flux and 
increased antioxidant capacity correlates with metastasis of breast cancer cells to the 
brain [397]. 
 
The first line of defence of ROS-induce DNA-damage is the activity of mitochondrial 
isoenzymes SODs, which main function is to dismutase superoxide anion into H2O2 
and O2. MnSOD (SOD2) reduces oxidative stress caused by respiratory chain leak 
and is responsible for the detoxification of ROS in the mitochondrial matrix [398]. 
Either decreased or increased expression of SOD2 has been reported, comparing to 
their normal counterparts, depending on the type and grade of tumour [399-403]. In 
breast cancer, SOD2 expression is dependent of ER status and associated with 
invasive and metastatic properties of breast cancer cells. ER positive cell lines exhibit 
low SOD2 expression, in contrast with MCF-10A and HMEC, while high levels of 
expression are present in oestrogen independent and metastatic breast cancer cells 
[404, 405]. In human breast tumours, SOD2 is decreased in in situ breast carcinomas 
and in benign hyperplasias [406], while in invasive tumours, its expression is found to 
be increased, specially in advanced, high grade and poorly differentiated tumours 
[406-408]. Moreover, it was also reported that micro and macro-metastasis presented 
higher levels of SOD2 when compared to their matched primary breast tumour [409]. 
Still, high SOD2 is associated with hormone receptor negativity, p53 mutations, 
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decreased disease free survival, as well as with high histological grade in breast 
cancer samples [409]. However, other reports have been describing the decreased 
SOD2 expression in invasive breast carcinomas. The expression and activity of this 
antioxidant protein is regulated by deacetylase sirtuin-3 (SIRT3)  [410], which is found 
to be lost or decreased in 87% of breast cancers [411]. Since SIRT3 is able to 
modulate the activity of SOD2 [410], being responsible for the increase of ROS levels 
in cancer cells [412], SIRT3 downregulation is essential for the metabolic 
reprograming toward glycolysis, through the stabilization of HIF-1α [410].  Based on 
this increased ROS levels due to SOD2 downregulation, cancer cells were found to 
upregulate SOD1 in order to retain low levels of superoxide and avoid irreversible 
damage and allow cell survival, known as the “SOD2 to SOD1 switch”. 
Overexpression of SOD1 is able to promote growth and survival of different types of 
cancer, including breast cancer. In fact, increased SOD1 expression is a frequent 
event in breast cancer. Papa et al. demonstrated that loss of SOD2 correlates with 
the overexpression of SOD1, either in breast cancer cells lines as well as in human 
breast carcinomas, suggesting that SOD1 increase in breast cancer cells with SOD2 
downregulation is a mechanism for breast cancer cell survival [413]. Moreover, 
mammary tumour models present high levels of SOD1 protein, while normal 
mammary gland does not exhibit the expression of this protein [413]. Accordingly, it is 
reported that LCS-1, a molecule that target SOD1 activity, leads to mitochondrial 
damage and inhibits breast cancer cell growth in vitro,supporting the hypothesis that 
SOD1 is essential for adaptation of breast cancer cells to oxidative stress [413].  
 
In this work, we demonstrated that P-cadherin expression is associated with low ROS 
content, probably by the induction of ROS scavenging systems, such as SOD1 
expression and SOD2 activity (superoxide dismutase 1 and 2). Conversely, we also 
observed that inhibition of P-cadherin expression increases ROS levels with 
concomitant decreased SOD antioxidant systems. These results are in agreement 
with our GEP analysis of breast cancer cells with P-cadherin deregulation, which 
revealed alterations in gene expression associated with antioxidant mechanisms, 
such as glutathione metabolism. Moreover, these results are also in agreement with 
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our previously reported findings, also observed in this work, showing the increased 
caspase-dependent cell death in P-cadherinlow breast cancer cells populations, as 
well as with the increased anoikis observed in P-cadherinlow versus P-cadherinhigh 
cells. Accordingly, our GEP analysis also suggests that P-cadherin expression is 
involved in mitochondrial apoptotic defects, which are crucial for oncogenesis and 
resistance to therapy and can be associated with metabolic reprogramming of breast 
cancer cells. 
 
Interestingly, cellular adaptation to oxidative stress is recognized to be a mechanism 
of intrinsic and acquired resistance to several anticancer drugs, since antioxidant 
capacity is one of the classical stress response mechanisms that modulate apoptosis. 
For instance, lapatinib, a drug targeting epidermal growth factor receptors 1 and/or 2 
(EGFR/HER2), has been used in treatment of IBC, triple negative breast carcinomas 
which typically present overexpression or activation EGFR/HER2. However, a 
significant number of patients have demonstrated acquired resistance to lapatinib, 
despite the decrease in EGFR/HER2 phosphorylation and downstream signalling 
activation [414-416]. Aird et al. analysed the role of oxidative stress adaptation in 
lapatinib-analogue (GW583340) sensitive and resistant IBC cell lines and 
demonstrated that, cells with acquired resistance to this compound, presented high 
levels of SOD1 and SOD2, as well as glutathione content, with no alterations in ROS 
levels, when comparing to sensitive cells [417]. They also observed that modulation 
of SOD activity in GW583340-resistant cells was able to induce apoptosis in the 
presence of ROS generators, implicating SOD and antioxidant mechanism 
deregulation in cell survival, responsible for resistance to lapatinib in the aggressive 
form locally advance breast cancer [417]. Accordingly, Williams et al. also 
demonstrated an increased expression of SOD2, as well as an increase of pro-
survival factors such as XIAP and Bcl-2, in SUM149 cells with resistance to lapatinib 
[418]. These authors observed that reverted resistance to lapatinib in IBC cells, by 
drug removal, resulting in a re-sensitization to multiple drugs, was accompanied by a 
decrease of SOD2 expression, increased ROS levels, increase p-AMP, indicators of 
an enhanced oxidative stress, as well a decreased in the pro-survival machinery 
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[418]. 
 
Moreover, the vast majority of studies focuses on bulk population of cells and do not 
take into account the heterogeneity of the tumours. Given that this heterogeneity is 
also reflected in a distinct metabolic behaviour of cancer cells, it is important to 
combine target therapies targeting different aspects of metabolism in order to obtain 
more dramatic effects in the clinical outcome. The failure of metabolic target drugs 
can be explained by the action of these compounds in CSC, which comprises only a 
small population of cells within the tumours. For this reason, it is extremely important 
to focus the effect of the drugs specifically in breast CSC.  
 
Cancer cells develop resistance to anoikis, defined as the induction of apoptosis due 
to the detachment from the ECM, allowing tumour progression and metastasis [419, 
420]. Matrix detachment of normal mammary epithelial cells markedly stimulates the 
generation of ROS, leading to induction of anoikis [421, 422]. However, in order to 
counteract the deleterious effect of ROS, these cells develop mechanism to prevent 
accumulation of ROS. Oxidative metabolism and stress response are know to play a 
major role in the survival of normal mammary epithelial cells as well as breast CSCs. 
It is described that normal mammary epithelial cells attenuates glucose oxidative 
metabolism [215] and also enhances antioxidant ability to detoxify ROS, lowering 
oxidative stress and prolonging survival in suspension [409]. Schafer et al. 
demonstrated that detachment of mammary epithelial cells from ECM causes an ATP 
deficiency due to loss of glucose transport, which could be rescued by 
overexpression of HER2 by restoring glucose uptake through stabilization of EGFR 
and PI3K activation [422]. Moreover, Kamarajugadda et al. demonstrated that, in 
response to matrix detachment, mammary epithelial cells inhibit oxidative metabolism 
of glucose and increase SOD2 expression, conferring them anoikis-resistance, and 
also that depletion of SOD2 expression sensitizes these cells to anoikis by the 
increased ROS content [409]. Cancer cells already exhibit a metabolic program with 
reduced glucose oxidation, which allows the maintenance of low ROS levels and 
escape to anoikis. ECM-detached breast CSC exhibit a specific pro-glycolytic 
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behaviour and an enhanced ROS scavenging systems [110, 201], which allows them 
to decrease oxidative stress, being able to escape anoikis, survive in circulation and 
enhance metastasis formation. Thus, inhibition of ROS detoxification coupled with 
stimulation of glucose oxidative metabolism may be an efficient strategy to enhance 
anoikis, and since this type of cell death is a barrier to breast cancer metastasis, it is 
probably a good therapeutical approach to impair breast cancer metastasis. 
Importantly, P-cadherin expression promotes stem-like properties to BCC, such as 
tumourigenic capacity and anoikis-resistance, allowing cells to survive in anchorage-
independent conditions [306]. In addition, P-cadherin also conferred radiation-
resistance to breast cancer cells and, upon apoptotic stimuli, decreased P-cadherin 
expression increases breast cancer cell death in a caspase-dependent mechanism 
[296, 306]. 
 
Taken together, we hypothesize that the role of P-cadherin in oxidative stress can be 
responsible for anoikis-resistance observed in breast CSC. Still, the obtained data 
suggests that P-cadherin might be a player in the radiotherapy resistance through the 
metabolic regulation of breast CSCs, due to its role in the adaptation to oxidative 
stress.  $
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Conclusions 
 
The data presented and discussed in this thesis allowed us to conclude that: 
 
1. Aberrant P!cadherin expression is associated with the hypoxic/glycolytic and acid!
resistant phenotype in invasive breast carcinomas. Using immunohistochemistry, we 
were able to prove that breast carcinomas with HIF-1α, GLUT1, CAIX, MCT1 and 
CD147 expression show a high percentage of P-cadherin positivity. 
 
2. The expression of P-cadherin is associated with HIF-1α in breast cancer.  Primary 
invasive breast tumours with P-cadherin aberrant expression also exhibit an 
enrichment of HIF-1α expression. Moreover, hypoxia/HIF-1α accumulation in breast 
cancer cells in vitro is able to induce an increased membrane P-cadherin expression 
in basal-like breast cancer cells. 
 
3. P-cadherin regulates and is co-expressed with effectors of the metabolic 
reprograming, such as GLUT1 and CAIX, in basal-like breast cancer cell populations 
with increased ability to survive in anchorage-independent conditions. 
 
4. Glycolytic and acid resistance phenotypes are associated with the expression of P-
cadherin-related breast CSC markers in human breast carcinomas. This suggests 
that the stem-like properties of P-cadherin-enriched breast cancer cells can be 
associated with the P-cadherin role in breast cancer cell metabolism.  
 
5. P-cadherin expression is responsible for the maintenance of the glycolytic 
behaviour of aggressive IBC. Decreased expression of P-cadherin induces a 
metabolic shift towards oxidative phosphorylation, with an increase in energy 
production in inflammatory/basal-like breast cancer cells. 
 
6. Oxidative stress is modulated by P-cadherin expression in breast cancer cells. 
ROS content as well as antioxidant systems, SOD1 and SOD2, are modulated by P-
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cadherin expression in breast cancer cells, which might be responsible for cell 
survival of P-cadherin-enriched breast CSC populations.  
 
Considering the initial aims of this PhD project, we believe that we have successfully 
addressed most of the questions we have proposed to answer. In conclusion, the 
results presented in this study highlighted P-cadherin as a relevant molecule for 
breast cancer metabolism.   
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Future perspectives 
 
It is now clear that aggressive behaviour induced by P-cadherin in breast cancer cells 
might be mediated by its implications in cellular metabolism. However, the data 
resulting from this work raises many interesting questions and challenges that remain 
to be elucidated. In order to better understand the mechanism and the resulting 
implications of P-cadherin’s regulation of metabolism, we aim to develop the 
knowledge on metabolomics and mitochondrial functionality in breast cancer cells. 
Moreover, the results from this work also led us to believe that P-cadherin expression 
might be mediating anoikis-resistance by the modulation of cellular metabolism and 
oxidative stress, being responsible for the survival of breast CSC and consequently 
for the development of breast cancer metastasis. Thus, additional questions should 
be addressed in future studies: 
 
1. To understand how P-cadherin expression specifically influences the metabolic flux 
of basal-like BC cells. 
 
2. To better comprehend the expression and activity of the glycolytic and OXPHOS 
machinery specifically involved in P-cadherin signalling. 
 
3. To evaluate the effect of P-cadherin expression in the metabolic profile of breast 
CSC, in anchorage-independent conditions. 
 
4. To evaluate the mitochondrial biogenesis, complexity and function mediated by P-
cadherin expression in breast CSC. 
 
5. To understand the oxidative stress suppressor role of P-cadherin in anoikis-
resistance of breast CSC with enriched P-cadherin expression. 
 
6. To evaluate the effect of targeting anoikis-resistant P-cadherin-enriched breast 
CSCs by in vitro metabolic reprograming, using metabolic targeting drugs, such as 
DCA. 
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7. To examine the putative synergistic effect of P-cadherin silencing and metabolic 
targeting drugs, such as DCA, in the effective elimination of P-cadherin-enriched 
breast CSC in vitro. 
 
8. To evaluate the potential synergistic effect metabolic reprograming by targeting 
glycolytic breast CSCs with DCA, as well as with P-cadherin silencing, in breast 
cancer metastasis, using in vivo models. 
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13 Abstract
14 Background: Cancer stem cells are hypoxia-resistant and present a preponderant glycolytic metabolism. These
15 characteristics are also found in basal-like breast carcinomas (BLBC), which show increased expression of cancer
16 stem cell markers.
17 Recently, we demonstrated that P-cadherin, a biomarker of BLBC and a poor prognostic factor in this disease, mediates
18 stem-like properties and resistance to radiation therapy. Thus, the aim of the present study was to evaluate if P-cadherin
19 expression was associated to breast cancer cell populations with an adapted phenotype to hypoxia.
20 Methods: Immunohistochemistry was performed to address the expression of P-cadherin, hypoxic, glycolytic and
21 acid-resistance biomarkers in primary human breast carcinomas. In vitro studies were performed using basal-like breast
22 cancer cell lines. qRT-PCR, FACS analysis, western blotting and confocal microscopy were used to assess the expression
23 of P-cadherin after HIF-1α stabilization, achieved by CoCl2 treatment. siRNA-mediated knockdown was used to silence
24 the expression of several targets and qRT-PCR was employed to evaluate the effects of P-cadherin on HIF-1α signaling.
25 P-cadherin high and low breast cancer cell populations were sorted by FACS and levels of GLUT1 and CAIX were
26 assessed by FACS and western blotting. Mammosphere forming efficiency was used to determine the stem cell activity
27 after specific siRNA-mediated knockdown, further confirmed by western blotting.
28 Results: We demonstrated that P-cadherin overexpression was significantly associated with the expression of HIF-1α,
29 GLUT1, CAIX, MCT1 and CD147 in human breast carcinomas. In vitro, we showed that HIF-1α stabilization was
30 accompanied by increased membrane expression of P-cadherin and that P-cadherin silencing led to a decrease of the
31 mRNA levels of GLUT1 and CAIX. We also found that the cell fractions harboring high levels of P-cadherin were the same
32 exhibiting more GLUT1 and CAIX expression. Finally, we showed that P-cadherin silencing significantly decreases the
33 mammosphere forming efficiency in the same range as the silencing of HIF-1α, CAIX or GLUT1, validating that all these
34 markers are being expressed by the same breast cancer stem cell population.
35 Conclusions: Our results establish a link between aberrant P-cadherin expression and hypoxic, glycolytic and
36 acid-resistant breast cancer cells, suggesting a possible role for this marker in cancer cell metabolism.
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38 Background
39 The tumor microenvironment is markedly defective on
40 oxygen and nutrients, which seems to have a huge influence
41 on the selection and survival of cancer stem cell
42 populations. In fact, it is widely accepted that developing
43 embryos, as well as regions of tissues with cells harboring
44 stem cell properties (stem cell niches), usually present low
45 oxygen tensions, suggesting hypoxia as a crucial event to
46 maintain the undifferentiated state of stem/progenitor
47 cells [1,2]. Additionally, it is already widely accepted that
48 undifferentiated cells, such as human embryonic stem
49 cells (hESC) and induced-pluripotent stem cells (iPSC),
50 present a glycolytic phenotype, decreased oxidative
51 phosphorylation and ROS (reactive oxygen species)
52 production, as well as altered lipid metabolism, when
53 compared to their normal differentiated counterparts [3].
54 Cancer cells with stem-like properties, also known as
55 cancer stem cells (CSC) or tumor-initiating cells (TICs),
56 are also thought to reside in hypoxic niches within the
57 tumor [2], exhibiting a metabolic program that allows
58 their survival in this aggressive microenvironment [3].
59 This metabolic reprogramming is now recognized as a
60 hallmark of cancer [4] and several players involved in
61 cell metabolism are currently being considered as targets
62 for cancer therapy [5].
63 HIF-1α, either induced by hypoxia or by alterations in
64 oncogenes and/or tumor suppressor genes, induces the
65 expression of gene products responsible for mediating
66 changes in energy metabolism, pH regulation, angiogenesis,
67 survival, invasion and motility [6]. In breast cancer, HIF-1α
68 expression is associated with high-grade tumors, loss of
69 estrogen receptor (ER), increased proliferation levels,
70 decreased disease-free and overall patient survival and also
71 with chemo- and radiotherapy resistance [7]. Moreover,
72 cancer cells usually require increased glucose consumption,
73 achieved by enhanced expression of glucose transporters
74 (such as GLUT1). The increased glycolysis leads to
75 intracellular acidosis that is controlled by upregulation of
76 other membrane transporters, such as carbonic anhydrase
77 IX (CAIX), monocarboxylate transporters (MCT1 and
78 MCT4) and CD147/EMMPRIN (an extracellular matrix
79 metalloproteinase inducer, required for proper location
80 and function of MCT1 and MCT4).
81 Interestingly, the adaptation of cancer cells to limited
82 oxygen availability, altered glucose metabolism and extra-
83 cellular acidosis, are linked to a poor patient prognosis in
84 breast cancer [8-10]. Chen et al. demonstrated that
85 hypoxia, glycolytic and acid-resistant phenotypes are a
86 powerful tumor cellular advantage and are associated
87 to an aggressive behavior of breast carcinomas [11].
88 Moreover, several studies have been reporting that basal-
89 like breast carcinomas (BLBC) show a stronger response to
90 hypoxia [8,10], as well as a higher glycolytic metabolism,
91 than tumors with luminal characteristics [12-16]. In fact,
92triple-negative and HER2-overexpressing breast carcinomas
93present the higher tissue glucose metabolism, measured by
9418 F-FDG PET scan, in comparison with the other
95breast cancer molecular subtypes [17], reinforcing the
96association between glycolytic metabolism and breast
97cancer poor prognosis.
98P-cadherin, a calcium dependent cell-cell adhesion
99molecule encoded by the CDH3 gene, is a protein whose
100expression is highly associated with undifferentiated cells
101in normal adult epithelial tissues, as well as with poorly
102differentiated carcinomas [18]. Its expression has been
103already reported in hESCs and is presumed to be a
104marker of stem or progenitor cells in epithelial tissues
105[19,20]. During normal breast development, P-cadherin
106has a crucial role in the ductal mammary branching,
107being expressed by the monolayer of epithelial cap cells
108at the terminal end buds (TEBs) [21]. Moreover, this
109molecule is important for the undifferentiated state of
110the normal mammary gland [19], with its expression
111being restricted to the myoepithelium, although it has
112been postulated that it may be also present in early
113luminal progenitor cells [18,22,23]. In breast cancer,
114P-cadherin is aberrantly expressed in high-grade in situ
115[24] and invasive tumors [25], being a well-established
116indicator of poor patient prognosis [18,22,26]. The
117expression of P-cadherin is significantly associated with
118basal-like molecular subtype [25], which is mainly charac-
119terized by a triple-negative phenotype [ER, progesterone
120receptor (PgR) and HER2 negativity] and by the expression
121of basal/myoepithelial markers [27].
122Moreover, P-cadherin expression promotes oncogenic-
123associated effects in breast cancer [18,22]. Using in vitro
124and in vivo models, we demonstrated that it induces
125tumorigenesis, as well as cancer cell invasion partially
126through the secretion of matrix metalloproteinases (MMPs),
127such as MMP1 and MMP2 [28]. We have also disclosed
128that P-cadherin functional role is dependent on E-cadherin
129cellular context, since it interferes with the endogen-
130ous cadherin/catenin complex, inducing p120-catenin
131cytoplasmic delocalization and the consequent associated
132alterations in the actin cytoskeleton [29].
133Recently, our group demonstrated that P-cadherin
134expression is associated with breast cancer stem cell
135markers, namely CD44, CD49f and ALDH1 [30]. We
136revealed that highly tumorigenic P-cadherin-enriched
137breast cancer cell populations harbor increased survival,
138resistance to radiation and stem cell properties [30].
139Additionally, since it is accepted that breast cancer stem
140cells are pro-glycolytic [31] and more resistant to radio-
141therapy regimens [32], we hypothesized that the expression
142of P-cadherin could be associated to cell populations with
143an adapted phenotype to hypoxia and altered metabolism.
144Interestingly, by the analysis of an online available gene
145expression profile (E-GEOD-9649) [9], we could observe
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146 that CDH3 gene is indeed upregulated in hypoxia
147 compared to normoxic conditions, as well as in response
148 to lactic acidosis.
149 In this work, we demonstrate that there is a significant
150 association between aberrant P-cadherin expression and
151 hypoxic, glycolytic and acid-resistant breast cancer
152 cells, suggesting a role for this epithelial basal marker
153 in cancer cell metabolism.
154 Methods
155 Breast tumor samples
156 Formalin-fixed, paraffin-embedded tissues of 473 invasive
157 breast carcinomas in Tissue Microarrays (TMAs) were re-
158 trieved from the histopathology files of three Departments
159 of Pathology: University Hospital of the Federal University
160 of Santa Catarina (UFSC, Florianópolis, Brazil), Hospital
161 Divino Espírito Santo (Ponta Delgada, Portugal) and from a
162 private Laboratory of Pathology (Veronese Patologia e
163 Citologia Araçatuba, Brazil). The tumors have been
164 characterized for clinical and pathological features (data are
165 summarized in Table S1 in Additional file 1). Molecular
166 characterization of this series was previously studied and
167 described [27]. This study was approved by the UFSC Eth-
168 ics Committee for Human Research (CEPSH), by the Ethics
169 Committee for Health from the Hospital do Divino Espírito
170 Santo de Ponta Delgada E.P.E., as well as by the research
171 review boards from the Veronese Patologia e Citologia
172 Araçatuba Pathology Laboratory. Patients have signed a
173 written informed consent, which implies that the spare
174 biological material, which has not been used for diagnosis,
175 can be used for research. This is in accordance with the
176 national regulative law for the handling of biological
177 specimens from tumor banks, being the samples exclusively
178 available for research purposes in retrospective studies, as
179 well as under the international Helsinki declaration.
180 Cell culture
181 Human breast cancer cell lines were obtained as follows:
182 BT20 was acquired from American Type Culture Collection
183 (Manassas, VA, USA) and SUM149 was kindly provided by
184 Dr. Stephen Ethier (University of Michigan, USA). Cells
185 were routinely maintained at 37°C, 5% CO2, in the following
186 media (Invitrogen Ltd, UK): DMEM for BT20 and 50%
187 DMEM/50% Ham-F12 for SUM149. In BT20, the media
188 contained 10% heat-inactivated fetal bovine serum, FBS,
189 (Greiner bio-one, Belgium) and in SUM149 cell line, media
190 was supplemented with 5% FBS, 5 μg/ml of insulin and
191 1 μg/ml of hydrocortisone (Sigma-Aldrich, USA). All
192 media were supplemented with 100 IU/ml penicillin
193 and 100 mg/ml streptomycin (Invitrogen Ltd, UK).
194 Primary antibodies
195 The following primary anti-human antibodies were used
196 for western blot (WB), immunohistochemistry (IHC)
197and flow cytometry (FC) against: P-cadherin [clone 56,
198BD Transduction Biosciences, USA; diluted 1:500 (WB)
199and 1:50 (IHC)], and APC-conjugated P-cadherin, R&D,
200USA; diluted 1:10 (FC)], HIF-1α [clone 54, BD Transduction
201Biosciences, USA; diluted 1:500 (WB) and 1:50 (IHC)],
202CAIX [ab15086, AbCam, Cambridge, UK; diluted 1:1000
203(WB), 1:2000 (IHC) and 1:10 (FC)], Glut1 [ab15309,
204AbCam, Cambridge, UK; diluted 1:400 (WB), 1:500 (IHC)
205and 1:10 (FC)], MCT1 [AB3538P, Chemicon International,
206USA; diluted 1:200 (IHC)], MCT4 [AB3316P, Chemicon
207International, USA; diluted 1:100 (IHC)], CD147 [18-7344,
208Zymed Laboratories Inc., USA; diluted 1:750 (IHC)],
209GAPDH [0411, Santa Cruz Biotechnologies, USA; diluted
2101:10000 (WB)] and β-actin [clone I-19, Santa Cruz
211Biotechnologies, USA; diluted 1:1000 (WB)].
212Immunohistochemistry
213The immunohistochemical assays were performed with spe-
214cific antibodies for P-cadherin, HIF-1α, GLUT1, CAIX,
215MCT1, MCT4 and CD147. Details about experimental
216procedures, primary antibodies, antigen retrieval detection
217systems and scoring are described elsewhere [12,13,27].
218Specifically, HIF-1α immunohistochemistry was per-
219formed using CSA, Catalyzed Signal Amplification System
220(DAKOCytomation, USA), according to manufacturer’s
221instructions. Reactions were independently evaluated by
222two pathologists (FS and RG). All the proteins showed
223membrane staining, consistent with their cellular function,
224except for HIF-1α, which presented a nuclear pattern of ex-
225pression and was considered positive whenever any strong
226and dark nuclear staining was observed. For the different
227antibodies studied, some samples could not be evaluated for
228the 473 cases of the series due to TMA’s cores missing or to
229insufficient representation of the tumor in the TMA core.
230siRNA transfection
231Gene silencing was performed with validated siRNA,
232specific for CDH3 (50nM, Hs_CDH3_6), HIF-1α (50nM,
233Hs_HIF1A_5), GLUT1 (100nM Hs_SLC2A1_2) and
234CAIX (50nM, Hs_CA9_2). All siRNAs were from Qiagen
235(USA). Transfections were carried out using Lipofecta-
236mine 2000 (Invitrogen, UK), according to manufacturer’s
237recommended procedures. After incubation for 5 minutes,
238the siRNA and Lipofectamine 2000 solutions were mixed,
239incubated for additional 20 minutes and added to cell
240culture medium. A scrambled siRNA sequence, with no
241homology to any gene, was used as a negative control
242(Qiagen, USA). Gene inhibition was evaluated after
24348 hours of cell transfection for CDH3, HIF-1α and GLUT1
244and after 72 hours for CAIX.
245CoCl2 treatment
246Breast cancer cells were plated in T25 flasks for qRT-PCR
247and FACS, or in coverslips for immunofluorescence. After
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248 24 hours, cells were treated with 200uM CoCl2 (Cobalt(II)
249 chloride hexahydrate, Sigma-Aldrich, USA) diluted in
250 ethanol for 4 hours.
251 RNA extraction and qRT-PCR
252 RNA extraction was performed using RNeasy Mini Kit
253 (Qiagen, USA) and cDNA was synthesized using the
254 Omniscript Reverse Transcription kit (Qiagen, USA),
255 following the manufacturer’s instructions. Quantitative-
256 Real-Time-PCR (qRT-PCR) reaction was performed with
257 TaqMan Gene Expression Assays (Applied Biosystems,
258 USA), using gene-specific IDT probes (Integrated
259 DNA Technologies, Inc., USA): CDH3 (Hs.PT.51.5028751),
260 GLUT1 (Hs.PT.47.19044492.g), CAIX (Hs.PT.47.14063.g),
261 and GAPDH (Hs.PT.39a.22214836). Analysis was performed
262 with the ABI PRISM 7700 Sequence Detection System
263 Instrument and software (Applied Biosystems, USA),
264 following the manufacturer's recommendations. The
265 internal standard human GAPDH was used to normalize
266 cDNA quantity. Data was analyzed by the comparative 2
267 (-ΔΔCT) method [33]. For all data comparisons, the
268 Student's t-Test was used (two tailed, unequal variance).
269 All reactions were done in triplicate and the results
270 presented as mean of the values from three or more
271 independent experiments.
272 Immunofluorescence and confocal microscopic analysis
273 Cells were cultured on glass coverslips and 24 hours
274 later they were treated either with 200uM of CoCl2 or
275 with the respective vehicle (Ethanol) during 4 hours.
276 After that, cells were fixed with 4% paraformaldehyde
277 (20 minutes), treated with NH4Cl (50 mM) for 10 minutes,
278 washed with PBS, and permeabilized with 0.1% Triton
279 X-100 in PBS for 5 minutes, at room temperature.
280 Unspecific reactions were blocked with 30 minutes incuba-
281 tion of cells with blocking solution (5% BSA in PBS-tween
282 0,5%). Cells were then stained with the primary antibodies,
283 followed by incubation in the dark of Alexa488 or
284 Alexa-594-conjugated secondary IgG (Dako Cytomation,
285 Carpinteria, CA) in a 1:500 dilution. Primary and secondary
286 antibodies were diluted in blocking solution. Each sample
287 was mounted with Vectashield (Vector Laboratories,
288 Inc, Burlingame, CA) containing DAPI and visualized
289 with Leica SP5 confocal microscope (Leica Microsystems
290 GmbH, Germany). Volume of cells of both conditions was
291 acquired by Z-stack measurements.
292 FACS analysis and sorting
293 For FACS analysis, cells were harvested with versene/
294 0.48 mM EDTA (Invitrogen, UK), washed with PBS
295 supplemented with 0.5% FBS and re-suspended in the stain
296 buffer (2 mM EDTA and 0.5% bovine albumin in PBS).
297 Single cell suspension was labeled with APC-conjugated
298 P-cadherin, GLUT1 and CAIX antibodies. Cells transfected
299with the control siRNA and with CDH3 siRNA were dou-
300bled stained either with P-cadherin and GLUT1 or CAIX
301antibodies. A live-dead stain (Invitrogen, UK) and the
302primary and secondary antibodies were incubated at
3034°C, in the dark, for 15 minutes. Secondary Alexafluor-
304488-conjugated goat anti-rabbit IgG (Invitrogen, UK) was
305used in a 1:100 dilution. The labeled cells were then
306washed in the stain buffer and analyzed on a FACS
307Canto-II (BD Biosciences, USA).
308For the sorting experiments, the subpopulations of
309SUM149 and BT20 breast cancer cells were selected
310according to P-cadherin expression (highest and lowest
31120% expressing cells). Cells were sorted using BD Influx
312or FACS ARIA-II (BD Biosciences) and collected into 10%
313Hanks buffered solution (Invitrogen, UK). The purity of
314sorted populations was 80-95%. In addition, a further
315sample was also collected of cells passed through the laser
316under pressure, but not sorted, to act as a control for the
317effect of the pressure on the cells.
318Protein extraction and western blot analysis
319Protein lysates were prepared from sorted cells, using
320catenin lysis buffer [1% (v/v) Triton X-100 and 1% (v/v)
321NP-40 (Sigma-Aldrich, USA) in deionized phosphate-
322buffered saline (PBS)] supplemented with 1:7 proteases
323inhibitors cocktail (Roche Diagnostics GmbH, Germany)
324for 10 min, at 4°C. Cell lysates were mixed with a vortex
325and centrifuged at 14000 rpm at 4°C, during 10 min.
326Supernatants were collected and protein concentration
327was determined using the Bradford assay (BioRad Protein
328Assay kit, USA). Proteins were dissolved in sample buffer
329[Laemmli with 5% (v/v) 2-b-mercaptoethanol and 5% (v/v)
330bromophenol blue] and boiled for 5 min at 95°C or
331at 65° (for GLUT1 staining). Samples were separated
332by SDS–PAGE and proteins were transferred into
333nitrocellulose membranes [Amersham Hybond enhanced
334chemiluminescence (ECL)]. For immunostaining, mem-
335branes were blocked with 5% (w/v) non-fat dry milk in PBS
336containing 0.5% (v/v) Tween20 and incubated during 1 hour
337with anti-P-cadherin and anti-GAPDH, two hours
338with anti- CAIX and anti- GLUT1 and overnight with
339anti-HIF-1α. After washes with PBS-Tween20, membranes
340were incubated with HRP-conjugated anti-mouse, goat or
341rabbit secondary antibodies (Santa Cruz Biotechnologies,
342USA) diluted 1:2000 for one hour. Proteins were then
343detected using ECL reagent (Amersham, USA) as a
344substrate. Quantity One software (BioRad, USA) was
345used for quantification of the differences in protein
346expression comparing with GAPDH expression.
347Mammosphere forming efficiency (MFE) assay
348After the 72 h of the siRNA transfection, cells were
349enzymatically harvested and manually disaggregated
350with a 25-gauge needle to form a single-cell suspension
Sousa et al. BMC Cancer 2014, 14:734 Page 4 of 13
http://www.biomedcentral.com/1471-2407/14/734
351 and resuspended in cold PBS. Cells were plated at 500/cm2
352 in nonadherent culture conditions, in flasks coated
353 with 1.2% poly(2-hydroxyethylmethacrylate)/95%ethanol
354 (Sigma-Aldrich, USA) and allowed to grow for 5 days, in
355 DMEM/F12 containing B27 supplement, and 500 ng/ml
356 hydrochortisone, 40 ng/ml insulin, 20 ng/ml EGF in a
357 humidified incubator at 37°C and 5% (v/v) CO2.
358 Mammosphere forming efficiency was calculated as the
359 number of mammospheres (≥50 μm) formed divided by
360 the cell number plated, being expressed as a percentage.
361 Statistical analysis
362 For immunohistochemistry results on breast cancer
363 samples, statistical analysis was performed by SPSS
364 statistics 17.0 software (SPSS Inc., USA). χ2 test and
365 contingency tables were used to determine associations
366 between groups and the results were considered
367 statistically significant when the p-value was lower
368 than 0.05. Concerning the functional in vitro assays, all
369 were performed independently and in triplicate. Data were
370 analyzed using the unpaired Student t test and considered
371 statistically significant when the P value was less than
372 0.05. Statistical analyses were performed using Office
373 Excel 2010 (Microsoft Corporation, Reading, UK). All
374 statistical tests were two-sided.
375 Results
376 P-cadherin overexpression is significantly associated with
377 the expression of hypoxic, glycolytic and acidosis markers
378 in primary invasive breast carcinomas
379 In a large series of invasive breast carcinomas, previously
380 classified for molecular subtypes [27], immunohistochemis-
381 try staining was performed for P-cadherin, HIF-1α, GLUT1,
382 CAIX, MCT1, MCT4, and CD147 (FigureF1 1). Membrane
383 P-cadherin expression was found in 145/468 (31%) of the
384 cases. Nuclear HIF-1α was considered positive in 104/315
385(33%) carcinomas. Concerning the membrane expression
386of GLUT1, CAIX, MCT1, MCT4 and CD147, we observed
387140/327 (42.8%), 66/316 (20.8%), 106/407 (26%), 69/419
388(16.5%) and 24/217 (11%) positive cases, respectively.
389Membrane GLUT1 and CAIX expression was frequently
390detected in peri-necrotic tumor areas (Figure 1).
391The association between the expression of each one of
392these markers with the classical breast cancer prognostic
393factors (Table S2 in Additional file 1) as well as with the
394molecular subtypes and biomarkers ER, PgR, HER2 and
395Ki67 (Table S3 in Additional file 1) was evaluated.
396As previously reported, P-cadherin expression was
397significantly associated with high-grade carcinomas
398(p < 0.0001), HER2-overexpressing and basal-like molecular
399subtypes (p < 0.0001), ER and PgR negativity (p < 0.0001),
400high expression of HER2 (p < 0.0001), as well as with high
401Ki67 (p = 0.0141). Accordingly, HIF-1α expression was also
402associated with grade III (p < 0.0001) and high proliferative
403(p = 0.0197) tumors. Concerning the expression of GLUT1,
404CAIX, MCT1 and CD147, all have been significantly
405associated with high-grade (p < 0.001), basal-like (p < 0.001),
406ER and PgR negative (p < 0.05) tumors; absence of lymph
407node metastasis was more frequently observed in MCT1
408expressing tumors (p = 0.0223) and CAIX expression
409was associated with an increased tumor size (p = 0.0005).
410Additionally, the expression of GLUT1, MCT1 and CD147
411was associated with high proliferation indexes measured
412by Ki67 expression (p = 0.0339, p = 0.0297, p = 0.0179,
413respectively). There was still an expected significant
414association between the expression of hypoxic, glycolytic
415and acid-resistant phenotype markers (Table S4 in
416Additional file 1).
417Interestingly, P-cadherin overexpression was also
418significantly associated with the expression of HIF-1α
419(p < 0.0001), GLUT1 (p < 0.0001), CAIX (p < 0.0001),
420MCT1 (p = 0.0337) and CD147 (p < 0.0001) (Table S5
Figure 1 Immunoexpression of P-cadherin, HIF-1α, GLUT1, CAIX, MCT1, MCT4 and CD147 in breast cancer samples. Immunohistochemical
staining for P-cadherin (A), HIF-1α (B), GLUT1 (C), CAIX (D), MCT1 (E), MCT4 (F) and CD147 (G) expression in primary invasive breast carcinomas.
Images A, C, D, F and G are in 200x magnification; B and E are in 100X magnification. N: necrosis.
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421 in Additional file 1); in contrast, no association was
422 found with MCT4 expression (p = 0.553). With this
423 data, we could demonstrate that breast carcinomas with
424 positive expression to HIF-1α, GLUT1, CAIX, MCT1 and
425 CD147 are significant associated to tumors showing a high
426 percentage of cancer cells stained for the basal epithelial
427 marker P-cadherin (FigureF2 2).
428 HIF-1α stabilization by CoCl2 increases membrane
429 P-cadherin expression in breast cancer cells
430 Due to the direct association found between P-cadherin
431 and HIF-1α expression in invasive breast carcinomas, as
432 well as to the described association between both
433 markers and the maintenance of stem-like properties,
434 we decided to evaluate if HIF-1α stabilization could be
435 affecting the expression of P-cadherin in breast cancer
436 cells. Furthermore, by the use of a bioinformatics prediction
437 tool [34,35], we were able to recognize a putative binding
438 site for HIF-1 transcription factor, positioned within a CpG
439 island of CDH3/P-cadherin promoter [36]. Thus, we treated
440 SUM149 breast cancer cells with CoCl2 in order to increase
441 the expression of HIF-1α (FigureF3 3A). Although there were
442 no alterations in CDH3mRNA levels (p = 0.562, Figure 3B),
443 we could observe, by FACS analysis, a statistically signifi-
444 cant increase of membrane P-cadherin expression upon
445 HIF-1α stabilization (p = 0.0246; Figure 3C). We confirmed
446 this result by confocal microscopy (Figure 3D), where
447 we noticed that CoCl2 treatment resulted in nuclear
448 accumulation of HIF-1α, as well as in an increased
449 expression of P-cadherin at the cell membrane, when
450 compared with cells treated only with the vehicle
451 (ethanol). Although not statistically significant (p = 0.0716),
452 we also observed a decrease in the cellular height after
453 CoCl2 treatment (Figure 3E), indicating a re-organization of
454 the cytoskeleton after HIF-1α stabilization, which can be
455 associated with the induction of P-cadherin expression.
456P-cadherin expression interferes with GLUT1 and CAIX
457mRNA levels in breast cancer cells
458The direct associations found in primary invasive breast
459carcinomas established, for the first time, a connection
460between P-cadherin expression and metabolic alterations
461of tumor cells. Therefore, in order to find out if these
462associations were reflecting a crosstalk between P-cadherin
463expression and the metabolic shift experienced by breast
464cancer cells, we decided to silence CDH3 transcripts by
465siRNA-mediated knockdown in basal-like P-cadherin over-
466expressing breast cancer cell models (BT20 and SUM149).
467By real-time PCR, we could observe that CDH3 silencing
468led to a statistically significant downregulation of GLUT1
469and CAIX mRNA in BT20 breast cancer cells (p < 0.05)
470(Figure F44A). Although not statistically significant, we could
471also find a tendency to a decrease in GLUT1 and CAIX
472mRNA levels in SUM149 breast cancer cells (Figure 4D).
473No significant alterations were found in the mRNA expres-
474sion of HIF-1α, MCT1 and CD147 upon CDH3 silencing in
475both cell lines (Figure 4A and D). Interestingly, when
476GLUT1 (Figure 4B and E) and CAIX (Figure 4C and F)
477were silenced, there were no significant alterations in
478CDH3 mRNA levels.
479P-cadherin is co-expressed with GLUT1 and CAIX in
480basal-like breast cancer cell lines
481The above results led us to go further on the relationship
482between P-cadherin and GLUT1 and CAIX, since we
483observed that the expression of these both molecules
484was being somewhat responsive to P-cadherin in
485breast cancer cells. Thus, we decided to study if there was
486an enrichment of P-cadherin expression in GLUT1 and/or
487CAIX positive populations. Interestingly, we observed
488that cells presenting the highest expression of P-cadherin
489(20% high P-cad) were the ones also presenting the
490highest expression of GLUT1 and CAIX, while the ones
Figure 2 Aberrant P-cadherin expression in HIF-1α, GLUT1, CAIX, MCT1, MCT4 and CD147 expressing breast carcinomas. P-cadherin
overexpression was significantly associated with the expression of HIF-1α, GLUT1, CAIX, MCT1 and CD147. No association was found with MCT4
expression. *p < 0.05; **p < 0.0001.
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491 showing the lowest expression of P-cadherin (20% low
492 P-cad) demonstrated the lowest levels of GLUT1 and
493 CAIX (FigureF5 5A). This result was confirmed when we
494 sorted and separated the 20% high and low P-cadherin cell
495 populations and analyzed the expression of GLUT1 and
496 CAIX by western blot (Figure 5B). Furthermore, when
497 we selected the population of cells by their GLUT1
498 expression, the 20% high/low GLUT1 cells also presented
499 the highest and lowest levels of P-cadherin expres-
500 sion, respectively (Figure 5C). Still, the cells selected
501 by CAIX expression also presented the same tendency
502 concerning P-cadherin expression (Figure 5D). Similar
503 results were obtained in BT20 breast cancer cells
504 (Figure S1 in Additional file 2).
505 The inhibition of CDH3, HIF-1α, GLUT1 and CAIX affects
506 MFE in basal-like breast cancer cells
507 Our previous results show that HIF-1α stabilization was
508 accompanied by an increase of membrane P-cadherin
509 expression, which was co-expressed with GLUT1 and
510 CAIX in breast cancer cells. Since it has been already
511 described that HIF-1α, GLUT1 and CAIX are required
512 for CSC survival and tumor aggressiveness, and that we
513have recently shown that P-cadherin is also involved in
514the maintenance of stem-like properties of basal-like
515breast CSCs, we decided to evaluate the effect of the
516inhibition of all these molecules, alone or in combination,
517on the mammosphere forming efficiency (MFE%) of the
518SUM149 breast cancer cell model (Figure F66). As expected,
519silencing the expression of CDH3, as well as of HIF-1α,
520GLUT1 and CAIX, showed a significant decrease of the
521ability to form mammospheres when compared with
522the cells transfected with the control siRNA (p = 0.0153,
523p = 0.0156, p = 0.000284 and p = 0.000902, respectively).
524Moreover, when we simultaneously silenced CDH3 and
525HIF-1α, we also observed a decrease of MFE of the target
526cells (p = 0.0367), although not cumulative. If, in addition
527to CDH3 and HIF-1α, we silence the downstream targets
528GLUT1 and CAIX (siRNA CDH3 +HIF-1α +GLUT1 +
529CAIX), there is still a non-cumulative decrease effect in
530MFE (%) (p = 0.0152).
531Discussion
532Much attention has been paid to the tissue microenviron-
533ment, highlighting the importance of hypoxia as a mediator
534of cell survival, pluripotency, stemness and proliferation of
Figure 3 HIF-1α stabilization induces the expression of P-cadherin in the membrane of SUM149 breast cancer cells. HIF-1α stabilization
and accumulation by CoCl2 treatment was confirmed by western blot (A). qRT-PCR showed no significant alterations (p = 0.562) in CDH3 mRNA
levels upon CoCl2 treatment (B). Using FACS analysis, a statistically significant increase (p = 0.0246) was observed in the expression of membrane
P-cadherin in CoCl2 treated cells, when compared with the control cells treated with the vehicle (EtOH) (C). Immunofluorescence of CoCl2 treated
cells showed nuclear HIF-1α expression (red) and an increase of membrane P-cadherin expression (green), compared with vehicle treated cells
(D). Z-stack measurements revealed a decrease in the height of CoCl2-treated cells comparing with the control cells (E). *p < 0.05.
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535 normal stem cells [2,3] Alterations in metabolism have also
536 been proven to be important for the maintenance of stem
537 cell properties [3]. hESC and iPSC tends be more glycolytic
538 and less oxidative comparing to their somatic counterparts
539 [37-39]. Interestingly, the behavior of some tumor cells
540 resembles in many aspects the behavior of hESC, as well as
541 adult stem cells [3].
542 P-cadherin has been recently described as a mediator of
543 stem-like properties in basal-like breast cancer cell lines.
544 The main goal of this work was to understand if there was
545 an association between P-cadherin overexpression and
546 the phenotype of adaptation of breast cancer cells to
547 microenvironment stresses, such as hypoxia, lactic acidosis
548 and glycolytic metabolism, also characteristics of the
549 undifferentiated state of stem, progenitor and breast CSC.
550 Interestingly, we showed that P-cadherin is associated to
551 the hypoxic phenotype and metabolic reprogramming of
552 breast cancer cells.
553 We demonstrated an association between the expression
554 of P-cadherin and HIF-1α in breast carcinomas. Similarly
555 to P-cadherin, HIF-1α expression is associated to worse
556 prognosis in breast cancer, short patient’s survival, high
557proliferation and poor tumor differentiation [7,40].
558Interestingly, we found that HIF-1α stabilization promotes
559membrane P-cadherin expression in breast cancer cells,
560although no alterations were detected in CDH3 mRNA
561levels after CoCl2 treatment. With these results, we
562can hypothesize that increased P-cadherin membrane
563expression observed after HIF-1α accumulation occurs
564at a post-transcriptional level, and not as a direct
565effect. Thus, based on our findings and on previous
566data reported by others, the crosstalk between these
567molecules might be explained by several hypotheses.
568Since hypoxia, through HIF-1α [41], is able to induce
569ER degradation and that ER is a transcription CDH3
570repressor [26,42], it is possible that hypoxia can be
571inducing HIF-1α, promoting ER degradation and
572allowing CDH3 transcription. Other possible explanation
573is related to the link between hypoxia and BRCA1,
574another CDH3 transcriptional repressor [43]. It is known
575that hypoxia induces BRCA1 downregulation [44] and
576that BRCA1-mutated breast carcinomas, which are
577enriched in HIF-1α expression [45], present aberrant
578expression of P-cadherin [46].
Figure 4 P-cadherin expression affects GLUT1 and CAIX mRNA levels in breast cancer cells. mRNA expression measured by qRT-PCR of
CDH3, HIF-1α, GLUT1, CAIX, MCT1 and CD147 when inducing siRNA-mediated knockdown of CDH3 , GLUT1 and CAIX in BT20 and
SUM149 breast cancer cell lines. Upon CDH3 silencing, there was a significant decrease of the mRNA expression of GLUT1 and CAIX in BT20
(A) and a tendency, although not statistically significant, to a decrease in SUM149 cells (D). No differences were observed in the mRNA expression of
HIF-1α, MCT1 and CD147 in both cell lines. On the other hand, there were no alterations in CDH3 mRNA expression in BT20 (B and C) and in SUM149
(E and F) breast cancer cell lines, when GLUT1 (B and E) and CAIX (C and F) were silenced. *p < 0.05; **p < 0.0001.
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579 Concomitantly with the increase of membrane P-cadherin
580 expression, we still observed a decrease in the cellular
581 height after CoCl2 stabilization, indicating a putative
582 re-organization of the cytoskeleton and cell morphology,
583 with the acquisition of a phenotype associated to breast can-
584 cer cell aggressiveness [47]. This observation is consistent
585 with our previous data, showing that P-cadherin expression
586 is able to induce invasion, migration and motility in breast
587 cancer cells [28] and that its modulation also inter-
588 feres with GTPase-mediated signal transduction and actin
589 cytoskeleton organization [29].
590 Our results also showed an association between
591 P-cadherin and GLUT1, CAIX, MCT1 and CD147. These
592 molecules are important response mediators of cancer cell
593 survival in stressful microenvironments and are upregulated
594 in poor prognosis BLBC [12,13], where P-cadherin is
595 aberrantly expressed. Upregulation of membrane trans-
596 porters, such as CAIX and MCTs, is responsible for the
597 extracellular acidification, assisting in vitro cancer cell
598 invasion and in vivo metastization through the acidic
599 degradation of the ECM [48]. CD147/EMMPRIN is
600 known to induce MMP production [49], such as MMP2
601 [50], to promote tumor growth, inhibit cell apoptosis and
602 enhance cell migration under hypoxic conditions [51].
603 Interestingly, the highly significant association found
604 between P-cadherin and CD147 is in accordance with the
605 above-described reports and also with our previous data,
606 showing that P-cadherin induces an invasive behavior in
607breast cancer cells through the activation of MMP1 and
608MMP2 [28].
609Using basal-like breast cancer cell lines, we found that
610P-cadherin silencing is able to induce the downregulation
611of GLUT1 and CAIX mRNA, whereas GLUT1 and CAIX
612knockdown showed little or no effect in CDH3 mRNA
613expression. Thus, although the expression variations found
614were not so prominent as expected for direct molecular
615targets, we believe that P-cadherin is putatively involved
616in a signaling pathway that interferes with the metabolic
617reprograming of cancer cells. Moreover, we also demon-
618strated that the cell subpopulation expressing more/less
619P-cadherin at the cell surface was the same presenting
620higher/lower levels of GLUT1 and CAIX and vice-versa.
621These results suggests that P-cadherin overexpressing
622breast cancer cells are most likely to exhibit increased
623glycolysis and to survive to metabolic-driven pH alterations,
624justifying the enhanced aggressive behavior and metastatic
625properties.
626In breast cancer, hypoxia and HIF-1α have a pivot role
627in promoting tumor growth and metastasis through the
628maintenance, expansion as well as increased activity of
629breast CSCs [52-54]. Oliveira-Costa et al. showed that
630HIF-1α was differently expressed in CD44+/CD24-/low
631breast cancer cells [55]. Moreover, CAIX also plays a role
632in the regulation of stemness and expansion of breast CSCs
633in hypoxic niches [56]. Recently, our group demonstrated
634that P-cadherin expression is able to mediate stem cell
Figure 5 P-cadherin is co-expressed with GLUT1 and CAIX in basal-like breast cancer cell lines. By flow cytometry analysis, we observed
that the 20% of cells with the highest and lowest P-cadherin expression presented highest and lowest, respectively, expression of GLUT1 and
CAIX (A). When cells were sorted by P-cadherin expression, lysed and analyzed in SDS-PAGE, the same result was observed concerning the high and
low expression of GLUT1 and CAIX (B). On the other hand, 20% of cells with the highest and lowest levels of GLUT1 and CAIX (C and D, respectively)
expression also presented highest and lowest P-cadherin expression.
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635 properties in basal-like breast cancer cells [30]. Still,
636 we showed that BLBC, which are enriched in P-cadherin
637 expression, present a high percentage of cells with CSC
638 phenotype [57]. Accordingly, we demonstrated that the
639 inhibition of CDH3, HIF-1α, GLUT1 and CAIX in
640 basal-like breast cancer cells significantly reduces their
641 MFE, an important measure of breast cancer stem cell
642 activity. We still show that the silencing of CDH3 and
643 HIF-1α, or even the simultaneous inhibition of CDH3,
644 HIF-1α, GLUT1 and CAIX, have a non-cumulative effect
645 in the inhibition in MFE comparing to the single silencing
646 of any of these molecules. This result is in accordance with
647 our observation that the cell subpopulation expressing
648increased levels of P-cadherin also presents higher levels of
649GLUT1 and CAIX, demonstrating that we are targeting the
650same breast cancer stem cell population.
651Taking together, we believe that the hypoxic environment
652in breast tumors might be selecting a pool of cancer cells
653with stem-like properties, showing increased P-cadherin
654expression as well as a distinct metabolic state. These
655characteristics will be accounted for therapeutic resistance,
656since breast CSCs are resistant to radiotherapy and are
657thought to be responsible for breast cancer metastasis
658[32,58]. Interestingly, previous data from our group also
659demonstrated that P-cadherin inhibition sensitizes breast
660cancer cells to radiation-induced cell death [30].
Figure 6 MFE (%) decreases upon siRNA-mediated silencing of CDH3, HIF-1α, GLUT1 and CAIX in SUM149 cells. siRNA-mediated silencing
of CDH3, HIF-1α, GLUT1 and CAIX was confirmed by western blot analysis (A). A statistically significant decrease in MFE (%) was observed when
we silenced CDH3, HIF-1α, GLUT1 and CAIX. The simultaneous silencing of CDH3 and HIF-1α also revealed a significant decrease of MFE (%) of the
target cells, although not cumulative. Still, the silencing of the expression of all transcripts tested led to a non-cumulative inhibition of the MFE
compared to the control cells (B). *p < 0.05.
Sousa et al. BMC Cancer 2014, 14:734 Page 10 of 13
http://www.biomedcentral.com/1471-2407/14/734
661 Conclusions
662 In conclusion, we demonstrated that aberrant P-cadherin
663 expression is associated with the hypoxic/glycolytic and
664 acid-resistant phenotype in invasive breast carcinomas,
665 represented by a panel of markers including HIF-1α,
666 GLUT1, CAIX, MCT1 and CD147. We also showed that
667 membrane P-cadherin expression can be increased by
668 HIF-1α stabilization, as well as can modulate GLUT1 and
669 CAIX expression. Moreover, we still demonstrated that
670 P-cadherin is differentially expressed in basal-like breast
671 cancer cells that also present higher levels of GLUT1 and
672 CAIX. Thus, we believe that HIF-1α might be stabilizing
673 membrane P-cadherin expression in breast CSC or even
674 selecting P-cadherin-high expressing breast CSCs in the
675 hypoxic stem cell niche. In its turn, P-cadherin expression
676 is probably shifting the metabolic program of these cells,
677 which might be responsible for tumor aggressiveness, as
678 well as for their ability to survive, compared to the
679 low P-cadherin expressing cells. In this case, P-cadherin is
680 mediating the survival of aggressive cells thought to be
681 resistant to standard cancer therapies, being responsible for
682 tumor relapses and metastasis in breast cancer patients.
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 P-cadherin role in normal breast development and cancer
ANDRÉ ALBERGARIA1, ANA-SOFIA RIBEIRO1, ANDRÉ-FILIPE VIEIRA1, BÁRBARA SOUSA1,
ANA-RITA NOBRE1, RAQUEL SERUCA1,2, FERNANDO SCHMITT1,2 and JOANA PAREDES*,1,2
1IPATIMUP – Institute of Molecular Pathology and Immunology of the University of Porto and 
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ABSTRACT  P-cadherin is a cell-cell adhesion molecule, whose expression is highly associated with 
undifferentiated cells in normal adult epithelial tissues, as well as with poorly differentiated carcino-
mas. Its expression has been already reported in human embryonic stem cells and it is presumed to 
be a marker of stem or progenitor cells of some epithelial tissues. In normal breast, P-cadherin has 
an essential role during ductal mammary branching, being expressed by the monolayer of epithelial 
cap cells at the end buds. In mature mammary tissue, its expression is restricted to the myoepithe-
lium; it has been postulated that it may also be present in early luminal progenitor cells. In breast 
cancer, P-cadherin is frequently overexpressed in high-grade tumours, being a well-established 
indicator of poor patient prognosis. It has been reported as an important inducer of cancer cell 
migration and invasion, with underlying molecular mechanisms involving the signalling mediated 
by its juxtamembrane domain, the secretion of matrix metalloproteases to the extracellular media, 
and the cleavage of a P-cadherin soluble form with pro-invasive activity. Intracellularly, this protein 
interferes with the endogenous cadherin/catenin complex, inducing p120-catenin delocalization 
to the cytoplasm, and the consequent activation of Rac1/Cdc42 and associated alterations in the 
actin cytoskeleton. Considering P-cadherin’s role in cancer cell invasion and metastasis formation, 
a humanized monoclonal antibody was recently produced to antagonize P-cadherin-associated sig-
nalling pathways, which is currently under Phase I clinical trials. In this review, the most important 
findings about the role of P-cadherin in normal breast development and cancer will be illustrated 
and discussed, with emphasis on the most recent data.
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Introduction
Classical cadherins constitute a family of molecules that mediate 
calcium-dependent cell-cell adhesion, localized to the adherens-
type junctions. The intracellular domains of cadherins bind directly 
to cytoplasmic catenins, which link them with the actin cytoskel-
eton, providing the molecular basis for stable cell interactions. 
The cadherin/catenin complex, as well as the signalling pathways 
controlled by this structure, represent a major regulatory mechanism 
WKDWJXLGHFHOOIDWHGHFLVLRQVWKURXJKLWVLQÁXHQFHRQFHOOJURZWK
differentiation, motility, and survival (Cavallaro and Dejana, 2011).
Classical cadherins include CDH1/E-cadherin (epithelial), 
CDH2/N-cadherin (neuronal), CDH3/P-cadherin (placental) and 
CDH4/R-cadherin (retinal), designated by their tissue distribution. 
E-cadherin is the predominant cadherin family member expressed in 
all epithelial tissues, being extremely important to the maintenance 
of the cell shape and polarity; in fact, it is well known that CDH1 
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`; CK, cytokeratin; CSC, cancer stem cell; CTC, circulating tumour cell; E-cad, 
E-cadherin; EC, epithelial cell; EEM, ectodermal dysplasia, ectrodactyly, and 
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ZMKMX\WZ#-5<MXQ\PMTQIT\WUM[MVKPaUIT \ZIV[Q\QWV#./.:ÅJZWJTI[\OZW_\P
factor receptor; HDAC, histone deacetylase; HJMD, hypotrichosis with juvenile 
UIK]TIZLa[\ZWXPa#1*+QVÆIUUI\WZaJZMI[\KIVKMZ#25,R]`\IUMUJZIVMLW-
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XKI\MVQV#;0.5[XTQ\PIVLNWW\UITNWZUI\QWV#[8KIL[WT]JTM8KILPMZQV#
TEB, terminal end buds; TSA, trichostatin A.
acts as a tumour suppressor gene, negatively regulating the inva-
sion and metastasis of tumour cells in several malignancies (Yilmaz 
and Christofori, 2010). In contrast, N-cadherin is up-regulated 
in several cancers and contributes to an invasive phenotype by 
LQWHUDFWLQJZLWKÀEUREODVWJURZWKIDFWRUUHFHSWRU)*)5DQGLWV
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downstream signalling (Suyama et al., 2002).
P-cadherin is also often reported to correlate with increased 
tumour cell motility and invasiveness when overexpressed (Cheung 
et al., 2010, Paredes et al., 2004, Ribeiro et al., 2010, Taniuchi et 
al., 2005). Although the role of P-cadherin encoding gene (CDH3) 
in cancer is far less well characterized than the one attributed to 
CDH1, the opposite effects in mammary cancer are weird, since 
these molecules share more than 67% of homology (Hulpiau and 
van Roy, 2009). The CDH3JHQHKDUERXUVH[RQV)LJDQG
maps to chromosome 16q22.1, a region that contains a cluster of 
several cadherin genes, just 32 kilobases upstream of the gene 
encoding human E-cadherin (Bussemakers et al., 1994). The 
mature P-cadherin glycoprotein structure is similar to that of clas-
sical cadherins, comprising three distinct domains (extracellular, 
transmembrane and intracellular), in order to promote homotypic 
interactions. At the cell membrane, these create lateral dimers that 
act together in a zipper-like structure between neighbouring cells 
(Shapiro et al., 1995))LJ
The function and strength of P-cadherin-mediated adhesion 
depends on its dynamic association with catenins, which link the 
cadherin cytoplasmic tail to the actin cytoskeleton and facilitate 
clustering into the junctional structure, forming cadherin/catenin 
complexes. This tail comprises two main domains: the juxtamem-
brane domain (JMD), which has been suggested to play a critical 
role in cadherins stability at the cell membrane, and the catenin-
binding domain (CBD), which is known to be essential for cadherin 
function. The p120-catenin (p120ctn), ` -catenin (`ctn) and _-catenin 
(_ctn) are the major documented interaction partners that bind to 
cadherin intracellular domains and allow the binding to the actin 
cytoskeleton of the cell *UHHQ et al., 2010))LJ
P-cadherin upregulation was frequently observed in various 
malignant tumours, including breast, gastric, endometrial, colo-
rectal and pancreatic carcinomas, and is correlated with poor 
survival of breast cancer patients (Hardy et al., 2002, Imai et al., 
2008, Paredes et al., 2005, Stefansson et al., 2004, Taniuchi et 
al., 2005) ,QFRQWUDVWVLJQLÀFDQWO\ ORZ OHYHOVRI WKH3FDGKHULQ
gene expression were detected in a diverse panel of normal tis-
sues (Imai et al., 2008). Thus, disruption of P-cadherin signalling 
represents an intriguing opportunity for the development of novel 
targeted therapeutic agents in cancer.
P-cadherin role in epithelial cell differentiation
Classical cadherins play important roles in maintaining the 
structural integrity of epithelial tissues and are mainly involved 
in cell differentiation during embryogenesis. There are several 
indications in the literature that point to the relationship between 
cell adhesion molecules and stem cell features, not only as 
biomarkers that help to isolate and characterise stem cells, but 
also as important mediators of stem cell activity, via modulation 
of signalling pathways (Raymond et al., 2009). Regarding the 
classical cadherins, an important amount of data comes from the 
LGHQWLÀFDWLRQRI3FDGKHULQDVDPDUNHURIXQGLIIHUHQWLDWHGVWHP
or progenitor cells (Kendrick et al., 2008, Raymond et al., 2009). 
In a very recent study, it has been shown that CDH3 is one of 
the genes that encode a surface protein that identify the pluripotent 
population of human embryonic stem cells (Kolle et al., 2009). This 
expression is concomitant with the one of E-cadherin, which was 
Fig. 1. Schematic representation of the structural components of the P-cadherin adhesive junction. Lateral clustering of P-cadherin molecules 
is required to form stable cell-to-cell contacts in BT-20 breast cancer cells [immunofluorescence: P-cadherin (green), F-actin (red), DAPI (blue)]. In the 
intercellular space, P-cadherin extracellular domains interact with P-cadherin extracellular domains of adjacent cells to mediate cell adhesion. The intra-
cellular catenins bind to the cytoplasmic tail of P-cadherin. p120-catenin binds the cadherin tail at the juxtamembrane domain (JMD), whereas ` -catenin 
binds to the distal catenin binding domain (CBD). _-catenin associates with `-catenin and is directly linked to the actin cytoskeleton. The lower panel 
shows the genomic structure of CDH3/P-cadherin gene, which is constituted by 16 exons: the extracellular part of P-cadherin is encoded by 10 exons 
(exons 4-13), whereas the transmembrane and intracellular domains are determined only by the information included in the last 3 exons (exons 14-16).
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shown to be present even at the one cell stage of embryogenesis 
+\DÀO et al., 1980))LJ$,QIDFWPRXVHHPEU\RLPSODQWDWLRQLQWR
the uterine epithelium involves both E- and P-cadherin. The most 
dramatic expression of P-cadherin was observed in the placenta, 
both in the embryonic and maternal regions, hence the classical 
denomination of placental-cadherin. The expression of P-cadherin 
in the uterus began with the appearance of the decidua, into which 
the extraembryonic cells expressing P-cadherin of implanted em-
bryos invade to establish the embryo-maternal connection (Aplin 
et al., 2009, Nose and Takeichi, 1986)(DUO\UHSRUWVVSHFLÀHGORZ
expression in human placenta (Shimoyama et al., 1989), although 
P-cadherin is detectable where trophoblasts adjoin (cytotrophoblast-
cytotrophoblast and cytotrophoblast–syncytiotrophoblast) in the 
ÀUVW WULPHVWHUYLOOXVZLWKVRPH LPPXQRUHDFWLYLW\VWLOOGHWHFWDEOH
at term (Aplin et al., 2009))LJ$
In contrast, E-cadherin was found expressed only in the em-
bryonic region of placenta with a sharp boundary to the maternal 
region. These observations may suggest complementary roles of 
the two cadherins, such that P-cadherin is required for association 
of embryonic and maternal tissues during the late implantation 
stage, while E-cadherin is essential in preventing the embryonic 
tissues from mixing with the maternal tissues (Aplin et al., 2009, 
Nose and Takeichi, 1986))LJ$
It was also shown that E- and P-cadherins are both expressed 
in the ectoplacental cone, ectoderm, some endodermal tissues and 
nephric tubules, whereas both P- and N-cadherins are expressed 
in each cell of the lateral plate mesoderm, corneal endothelium, 
and pigmented retina (Nose and Takeichi, 1986))LJ$
Fig. 2. Schematic representation of P-cadherin expression during embryogenesis and mammary gland development. (A) Undifferentiated 
embryonic stem cells included in the morula, as well as in the inner mass of the blastocyst express E- and P-cadherin. During the blastocyst embryo 
implantation in the endometrial lining of the uterus, the trophectoderm differentiates into the cytotrophoblast and syncytiotrophoblast, which are key 
steps in placental development. There is an E-cadherin downregulation in the syncytiotrophoblast, which mainly expresses P-cadherin, while cells 
actively invade the uterine wall. Early in embryonic development, there is the formation of the neural tube, where a strip of specialized cells, forming 
the notochord, induces the cells of the ectoderm directly above it to become the primitive nervous system. Meanwhile, the ectoderm and endoderm 
continue to curve around and fuse beneath the embryo to create the body cavity, completing the transformation of the embryo from a flattened disk 
to a three–dimensional body. It is known that the ectoderm is E- and P-cadherin positive, which will give rise to the skin and its appendages. After cad-
herin switch, the neural tube becomes N-cadherin positive, as well as the somites. It was described that the notochord is N- and P-cadherin positive. 
(B) The ducts of the developing mammary gland are established, with their inner luminal epithelial cell layers (ECs) and outer myoepithelial cell layers 
(MECs), while the terminal end buds (TEB) move through the mammary fat pad. It is thought that cap cells at the tip of the TEB, which are P-cadherin 
positive, generate transit cells of the myoepithelial lineage on the outer side of the TEB (E- and P-cadehrin positive); at the same time, these cells also 
generate transit cells that form the central TEB mass, known as body cells, which will constitute the luminal epithelial lineage (E-cadherin positive). The 
ductal lumen is formed as body cells enter in apoptose and outer cells differentiate into luminal epithelial cells. Extracellular-matrix enzymes degrade 
the stroma in front of the TEB to enable it to move through the fat pad; however, it is unclear how the structures actually move through the gland. 
During lactation, secretory cells in the breast alveoli become P-cadherin positive at the cytoplasm, and secrete a soluble form of this protein (sP-cad) 
that is found in the milk.
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In adult tissues, the expression of P-cadherin is mainly found in 
the basal layer of several epithelial structures, such as skin, uterine 
cervix, prostate, and lung, contributing to the maintenance of the 
epithelial phenotype. The expression of cadherin molecules was 
extensively studied in mouse epidermis, in adulthood and during 
fetal development, where has been found that E-cadherin is ex-
pressed both in the basal and intermediate layers of epidermis, 
whereas P-cadherin is only expressed in the basal and prolifera-
tive layer (Pizarro et al., 1995))XUWKHUPRUHORVVRI(FDGKHULQ
plays an important role in bud formation and in the acquisition of 
an invasive behaviour, whereas P-cadherin becomes predominant 
expressed later in development, namely in the growing hair follicle 
and in the early progenitor cells from hair germs and small hair 
placodes )XMLWD et al., 1992, Rhee et al., 2006). Like hair follicles, 
sweat glands and mammary glands develop also from the same 
discrete accumulation of stem cells resting in the primitive epi-
dermis, the outermost cell layer of an embryo, and there is strong 
evidence that dynamic changes in the composition of adherens 
junctions are important for the development of skin appendages 
)XMLWD et al., 1992).
7KHÀQDOHYLGHQFHVKRZLQJWKHLPSRUWDQFHRI3FDGKHULQIRU
the architecture and development of epithelial tissues was dem-
onstrated by human genetic syndromes that are induced due to 
P-cadherin loss. CDH3 gene mutations have been shown to cause 
P-cadherin functional inactivation, leading to developmental defects 
associated with two inherited diseases in humans: 1) hypotrichosis 
with juvenile macular dystrophy (HJMD) and 2) ectodermal dys-
plasia, ectrodactyly, and macular dystrophy (EEM syndrome). The 
common features of both diseases are sparse hair and macular 
dystrophy of the retina, while only EEM syndrome shows the ad-
GLWLRQDOÀQGLQJRIVSOLWKDQGIRRWPDOIRUPDWLRQ6+)0(Kjaer et 
al., 2005, Sprecher et al., 2001). No defects were described for 
these conditions, concerning the human mammary development, 
or other epithelial bud structures. However, it is known that during 
bud patterning, a special arrangement occurs, where cells change 
their interaction with their neighbours and break their attachments 
to the extracellular matrix (ECM). Cells achieve this by activating 
VSHFLÀFWUDQVFULSWLRQDOSURJUDPV(Shimomura et al., 2008). 
P-cadherin role in normal breast development
Two members of the cadherin family are found to be expressed 
in the normal adult mature non-lactating mammary gland, usually 
at sites of cell-to-cell contact: E-cadherin is present in both luminal 
epithelial (ECs) and myoepithelial cells (MECs), whereas P-cadherin 
LVFRQÀQHGWRWKHP\RHSLWKHOLXP(Paredes et al., 2002). This type 
of cell localization is already found during mammary gland develop-
ment, since P-cadherin expression is only found in the precursor 
cells of the myoepithelial compartment, the cap cells of the ductal 
end buds, whereas luminal cells and body cells do not show any 
expression of P-cadherin and are typically E-cadherin positive 
(Daniel et al., 1995))LJ%
Besides the restricted expression of P-cadherin in the normal 
breast, this protein is extremely important to the establishment 
of the correct architecture of the tissue, as demonstrated by 
functional-blocking antibody experiments in vitro and in vivo. Daniel 
and collaborators exposed the end buds and mature mammary 
glands of 5 week-old virgin mice to slow-release plastic implants 
liberating a monoclonal antibody for P-cadherin. No effect in the 
luminal layer was found, but disruption of the basally located cap 
cell layer was clearly observed (Daniel et al., 1995). Also, more 
recently, Chanson et al., described that P-cadherin contributes 
VSHFLÀFDOO\ WR WKHRUJDQL]DWLRQRI WKHP\RHSLWKHOLDOFHOO OD\HURI
the breast, since when an antibody that blocks P-cadherin func-
tion was used in an in vitro self-organizing assay of the human 
mammary bilayer, the migration of MECs, occurring during normal 
sorting of both layers, was compromised (Chanson et al., 2011). 
These experiments indicate that selective expression of P-cadherin 
in the basal layer is necessary for the maintenance of mammary 
tissue integrity.
In fact, deletion of P-cadherin affects normal mammopoiesis, 
since the CDH3-null female mice exhibit precocious mammary 
gland differentiation in the virgin state, and breast hyperplasia 
and dysplasia with age (Radice et al., 1997). These observations 
in knockout animals indicate P-cadherin cell-cell interactions and 
signalling as regulatory determinants of the negative growth of 
the luminal epithelium, being important for the maintenance of an 
undifferentiated state of the normal mammary gland. 
Interestingly, the expression of this adhesion molecule is acti-
vated in human mammary luminal cells during late pregnancy and 
lactation (Soler et al., 2002). However, in these alveolar lactating 
cells, P-cadherin expression pattern is not restricted to the cell-cell 
borders, but shows a cytoplasmic staining, typical of a secreted 
protein. Indeed, in human milk, a soluble fragment of P-cadherin 
(sP-cad) with 80KDa was found to be present, corresponding to 
the extracellular domain of the molecule (Soler et al., 2002))LJ
2B). Recently, Mannello and collaborators showed that the high-
est concentration of sP-cad is detected in milk collected during 
WKHÀUVWWULPHVWHURIODFWDWLRQ(Mannello et al., 2008). Still, it is not 
clear which is the biological and physiological role attributed to 
this fragment in the normal function of the breast. Some authors 
suggest a role for sP-cad in alveolar differentiation during lacta-
tion, or in the immune response of the mother or the baby, or as a 
VLJQDOOLQJSURWHLQEHWZHHQHSLWKHOLDODQGP\RHSLWKHOLDOFHOOV)XUWKHU
studies are in progress to determine the sites of proteolysis of the 
V3FDGVHFUHWHGSURWHLQLQGLIIHUHQWERG\ÁXLGVZKHUHLWKDVEHHQ
previously described (such as milk, serum, semen, nipple aspirate 
ÁXLG1$)EUHDVWF\VWÁXLGDQGDPQLRWLFÁXLG(Mannello et al., 
2008, Soler et al., 2002).
Prognostic relevance of P-cadherin in breast cancer
As mentioned above, P-cadherin is expressed in normal breast 
MECs and in MECs associated with non-invasive breast prolif-
HUDWLRQVVKRZLQJQRVLJQLÀFDQWFURVVUHDFWLYLW\ZLWKOXPLQDO(&V
VWURPDOP\RÀEUREODVWVDQGEORRGYHVVHOV5HLV)LOKR et al., 2003). 
However, P-cadherin was described as being overexpressed in 
20% to 40% of invasive breast carcinomas, as well as in 25% of 
ductal carcinomas in situ (DCIS) (Paredes et al., 2007a, Paredes 
et al., 2007b, Paredes et al., 2002). Most important, several studies 
have reported P-cadherin as a marker of poor prognosis in breast 
FDQFHUVLQFH3FDGKHULQSRVLWLYHFDUFLQRPDVZHUHVLJQLÀFDQWO\
DVVRFLDWHGZLWKVKRUWWHUPRYHUDOODQGGLVHDVHVSHFLÀFVXUYLYDO
as well as with distant and loco-regional relapse-free interval 
*DPDOOR et al., 2001, Paredes et al., 2005, Peralta Soler et al., 
1999, Turashvili et al., 2011). 
P-cadherin expression has also been positively associated with 
high histological grade tumours, as well as with well-established 
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markers of poor prognosis, like Ki-67, epidermal growth factor 
UHFHSWRU(*)5F\WRNHUDWLQ&.YLPHQWLQSDQG+(5
expression and negatively associated with age at diagnosis, hor-
monal receptors (ER and PgR), and Bcl-2 expression. Interestingly, 
QRQHRIWKHVHUHSRUWVVKRZHGDVLJQLÀFDQWDVVRFLDWLRQZLWKWXPRXU
size and lymph node metastasis *DPDOOR et al., 2001, Paredes et 
al., 2005, Peralta Soler et al., 1999, Turashvili et al., 2011).
Besides the strong association between P-cadherin expression, 
poor patient prognosis and tumour aggressiveness, transgenic 
mice overexpressing CDH3/P-cadherin in the luminal epithelial 
layer of the mammary gland, under the control of the MMTV 
promoter, showed normal morphogenesis, architecture, lactation 
and involution, and no mammary tumours formed spontaneously 
(Radice et al., 2003). Nevertheless, Mannello et al., demonstrated 
DVLJQLÀFDQWLQFUHDVHGVKHGGLQJRIV3FDGLQ1$)VIURPZRPHQ
with breast cancer when compared with healthy subjects or with 
women with pre-cancer conditions, suggesting its possible release 
via proteolytic processing in cancer cells (Mannello et al., 2008). 
P-cadherin: marker of histological and molecular sub-
types in breast cancer
Besides the strong association between P-cadherin expres-
VLRQ DQGSRRU SDWLHQW SURJQRVLV QR VLJQLÀFDQW FRUUHODWLRQZDV
HYHUREVHUYHGEHWZHHQWKLVSURWHLQDQGDVSHFLÀFEUHDVWFDQFHU
histological type. The majority of positive P-cadherin tumours are 
invasive ductal carcinomas NOS, or carcinomas with metaplastic 
or medullary features (Paredes et al.  5HLV)LOKR et al., 
2003, Turashvili et al., 2011). The observation that metaplastic 
and medullary breast carcinomas are consistently immunoreac-
tive for P-cadherin supports a myoepithelial/basal transcriptomic 
programme for these lesions (Han et al., 1999, Jacquemier et al., 
2005). Han and coworkers reported P-cadherin expression in almost 
all studied cases of medullary, carcinosarcomas, and sarcomatoid 
metaplastic breast carcinomas (Han et al., 1999); in addition, all the 
metaplastic cases that we have studied were positive for at least 
one basal/myoepithelial marker, including P-cadherin 5HLV)LOKR et 
al., 2003). We also showed that P-cadherin expression, in canine 
PDOLJQDQWWXPRXUVZDVVLJQLÀFDQWO\UHODWHGWRVSLQGOHFHOOFDUFL-
noma, carcinosarcoma and osteosarcoma. In these lesions, both 
carcinomatous and sarcomatous components of carcinosarcoma 
expressed P-cadherin *DPD et al.*DPD et al., 2008). 
&RQFHUQLQJ PROHFXODU SURÀOLQJ FODVVLÀFDWLRQ DW OHDVW ÀYH
VXEW\SHVRI LQYDVLYHEUHDVWFDUFLQRPDZHUH LGHQWLÀHG/XPLQDO
A and B, Normal-like, HER2-overexpressing and Basal-like), ex-
hibiting distinct clinical prognostic behaviour (Perou et al., 2000). 
P-cadherin is one of the most important biomarkers to identify 
basal-like and HER2-overexpressing breast cancers (Arnes et 
al., 2005, Paredes et al., 2007b, Turashvili et al., 2011). Basal-like 
breast cancer expresses genes characteristic of basal epithelial 
cells, which include, besides P-cadherin, high-molecular weight 
basal cytokeratins (CK5/6, CK14, CK17), vimentin, _B-crystalline, 
FDYHROLQVDQG(*)5(Arnes et al., 2005). Until now, the most 
accepted criterion to identify basal-like breast carcinomas, by im-
munohistochemistry, is the triple negative phenotype along with 
&.DQGRU(*)5SRVLWLYLW\(Nielsen et al., 2004). However, we 
demonstrated that P-cadherin expression shows higher sensitivity 
to distinguish the basal phenotype of breast carcinomas, being a 
UHOLDEOHRSWLRQFRPSDUHGWRWKH´JROGVWDQGDUGµSDLU&.(*)5
(Sousa et al., 2010). Although this still need validation by gene 
H[SUHVVLRQSURÀOHVWKHVHUHVXOWVFDQLQWURGXFHWKHLGHDRIXVLQJ
P-cadherin as an additional option in the daily workup of breast 
pathology laboratories to identify basal-like breast cancers.
3FDGKHULQLVDOVRSURPLQHQWO\H[SUHVVHGLQLQÁDPPDWRU\EUHDVW
cancer (IBC), which is a distinct and aggressive form of locally-
advanced breast cancer, with high metastatic potential and high 
death rate. These tumours are characterized by frequent basal and 
HER2 phenotypes but, surprisingly, luminal IBC also express the 
basal marker P-cadherin (Ben Hamida et al., 2008)7KLVSURÀOH
VXJJHVWVDVSHFLÀFLW\WKDWQHHGVWREHIXUWKHULQYHVWLJDWHG
,QWHUHVWLQJO\WKHH[SUHVVLRQSURÀOLQJRIBRCA1GHÀFLHQWKHUHGL-
WDU\WXPRXUVKDVLGHQWLÀHGDSDWWHUQRIJHQHH[SUHVVLRQVLPLODU
to basal-like breast tumours (Palacios et al., 2003). Very recently, 
*RUVNL et al. showed that BRCA1 and c-Myc form a repressor 
FRPSOH[RQWKHSURPRWHUVRIVSHFLÀFEDVDOJHQHVLQFOXGLQJCDH3 
gene, and represent a potential mechanism to explain the observed 
overexpression of key basal markers in BRCA1-GHÀFLHQWWXPRXUV
*RUVNL et al., 2010). Actually, it has been shown that P-cadherin 
expression in breast carcinomas is strongly associated with the 
presence of BRCA1 mutations (Arnes et al., 2005).
P-cadherin role in adhesion, invasion and motility
Carcinomas progress by promotion of local invasion and distant 
metastasis. The acquisition of this invasive behaviour is one of 
WKHÀUVWVWHSVLQWKHPHWDVWDWLFSURFHVV7KRVHFDQFHUFHOOVRIWHQ
develop alterations in their shape, as well as in their attachment 
to other cells and to ECM. Therefore, cell-cell and cell-matrix in-
teractions play the most important role during tumour progression, 
since disruption of cell-cell adhesion during carcinogenesis is the 
basis for motility, invasion and metastasis of tumour cells (Yilmaz 
and Christofori, 2010).
P-cadherin has been detected as altered in various human 
tumours, but its effective role in the carcinogenesis process re-
mains discussible, since it behaves differently depending on the 
VWXGLHGWXPRXUFHOOPRGHODQGFRQWH[W)RULQVWDQFHLQDFRORUHFWDO
cancer cell line (HT-29), P-cadherin has been suggested to act as 
a pro-adhesive and anti-invasive/anti-migration molecule, exactly 
as E-cadherin (Van Marck et al., 2011). Also, in melanomas, P-
cadherin behaves as an invasion suppressor gene. Indeed, in highly 
invasive melanoma cell lines (that lack E-cadherin expression), 
P-cadherin overexpression was able to promote the formation of 
cell-cell contacts and counteract invasion (Van Marck et al., 2005). 
7KHDQWLLQYDVLYHHIIHFWRI3FDGKHULQZDVDOVRUHFHQWO\FRQÀUPHG
in in vivo experiments, showing that its expression is refractory to 
LQYDVLYHVLJQDOVLQGXFHGE\P\RÀEUREODVWV1HYHUWKHOHVVLWZDV
found a secreted truncated variant of P-cadherin in malignant mela-
nomas, which negatively regulates cell-cell adhesion and induces a 
more motile phenotype, thus playing an important role in migration 
and metastasis of melanoma cells (Bauer and Bosserhoff, 2006). 
On the other hand, in several other models, including breast 
cancer, P-cadherin behaves as an oncogene, and is often reported 
to correlate with increased tumour cell motility and invasiveness 
when aberrantly expressed (Cheung et al., 2010, Mandeville et 
al., 2008, Paredes et al., 2007a, Paredes et al., 2004, Taniuchi 
et al., 2005, Van Marck et al., 2011). Using in vitro breast cancer 
cell models, we found that overexpression of P-cadherin promotes 
single cell motility, directional cell migration, as well as invasion 
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capacity through the matrigel matrix (Ribeiro et al., 2010). This 
same migratory phenotype was observed in bladder, pancreatic 
and cholangiocarcinoma cancer cell lines (Baek et al., 2010, Man-
deville et al., 2008, Taniuchi et al., 2005, Van Marck et al., 2011). 
Curiously, we have noticed that P-cadherin is able to induce 
invasion only in cell systems which already express an endogenous 
and functional cadherin, like E-cadherin in breast cancer cells, 
or N-cadherin in HEK293T cells and PDAC pancreatic cancer 
cells (Paredes et al., 2004, Ribeiro et al., 2010, Taniuchi et al., 
2005). Based on this hypothesis, we have recently proved that 
P-cadherin is able to interact with E-cadherin in breast tumours 
and cancer cells, promoting cancer cell invasion by disrupting the 
interaction between E-cadherin and both p120ctn and ` ctn. In the 
absence of E-cadherin expression, in the same cancer model, P-
cadherin is able to suppress invasion by its strong interaction with 
catenins, surrogating the role of E-cadherin in cell-cell adhesion 
(unpublished data).
P-cadherin role in EMT and cadherin switch
Among the cadherin families, E-cadherin and N-cadherin are 
the most highly characterized subgroup of adhesion proteins. 
E-cadherin is ubiquitously expressed throughout most epithelial 
tissues and serves as a negative regulator to functionally block 
the `ctn signalling pathway and suppress tumour cell growth and 
invasion (Onder et al., 2008). However, numerous preclinical and 
clinical studies have shown that the loss of E-cadherin occurs 
concurrently with the upregulation of N-cadherin or other cadherin 
family members implicated in invasive growth, like P-cadherin or 
cadherin-11. This process, known as cadherin switching, has been 
reported to promote epithelial-to-mesenchymal transition (EMT) and 
leads to tumour cell invasion and metastasis (Thiery et al., 2009). 
Indeed, the switch from E- to N-cadherin is the one better known 
and reported by several studies. N-cadherin overexpression, via 
cadherin switching, was observed in various invasive cancer cell 
lines and tumours, namely from the esophagus, prostate, cervix, 
DQGRYDU\7KLVVSHFLÀFFDGKHULQVZLWFKOHDGVWRWKHLQKLELWLRQRI
cell-cell contacts and elicits active signals that support tumour-
cell migration, invasion, and metastatic dissemination (Thiery et 
al., 2009). 
The cadherin switch from E- to P-cadherin is a common event 
during embryo development; however, few reports describe it during 
tumour progression. Indeed, some invasive and aggressive epi-
thelial tumours, namely the local advanced IBC, and some highly 
metastatic breast cancer cells, as the 4T1 cell model, maintain 
E-cadherin expression at the cell membrane and show aberrant 
concomitant expression of P-cadherin (Ben Hamida et al., 2008, 
Lou et al., 2008). Nevertheless, there are some reports showing 
a switch from these two epithelial cadherins during tumour pro-
gression, namely in ovarian, endometrial and bladder carcinoma 
(Bryan et al., 2008, Patel et al., 2003, Stefansson et al., 2004). In 
DOOWKHVHVWXGLHV3FDGKHULQLQFUHDVHGH[SUHVVLRQVLJQLÀFDQWO\FRU-
related with decreased E-cadherin expression and, consequently, 
represented a key step in disease progression. However, it has 
been already shown that, in cholangiocarcinoma cells, the E- to 
P-cadherin switch does not induce EMT signalling, since does not 
affect the expression of mesenchymal markers, such as Snail 1 
DQGYLPHQWLQDQGÀEURQHFWLQ(Baek et al., 2010).
Recognized regulators of CDH3/P-cadherin transcription
Signalling pathways or other cellular mechanisms that are in-
volved in the regulation of cadherin-mediated adhesion are thought 
to underlie the dynamics of the adhesive interactions between cells. 
Fig. 3. Schematic representation of the described transcriptional regulators of CDH3 /P-cadherin promoter gene. It has been shown that 
`-catenin, p63 and C/EBP` are transcriptional activators of CDH3 promoter, inducing its expression at the mRNA and protein level. In contrast, 
estrogen receptor (ER), as well as the BRCA1/c-Myc/Sp1 complex, act as transcriptional repressors of CDH3 promoter gene.
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Although the evidence that the expression of cadherins can result 
from growth factors and from changes in the promoter regions of 
cadherins, data concerning CDH3 promoter regulation is still very 
limited. 
One of the most prominent demonstrations regarding the 
importance of a classical transcription factor in the regulation of 
cell adhesion programmes in epithelial cells was demonstrated 
by Carroll and collaborators. This study implicated p63, a p53-
family related transcription factor, as a key regulator of adhesion 
and survival in basal cells of the mammary gland. Importantly, the 
authors showed that p63 expression caused downregulation of cell 
adhesion-associated genes and detachment between mammary 
epithelial cells (Carroll et al., 2006). This involvement of p63 in cell 
DGKHVLRQPHFKDQLVPVZDVÀQDOO\OLQNHGZLWKCDH3 gene, when 
Shimomura and colleagues demonstrated that P-cadherin is a 
direct p63 transcriptional target and that this interplay has a crucial 
role in human limb bud and hair follicle development (Shimomura 
et al., 2008))LJ
)XUWKHUPRUHLWKDVEHHQVKRZQWKDW` ctn is also associated with 
CDH3 promoter activation and P-cadherin expression in basal mam-
mary epithelial cells. Down-regulation of endogenous `ctn levels 
inhibited CDH3 promoter activity, while activation of ` ctn signalling 
was correlated with up-regulation of P-cadherin expression in in 
vivo mammary gland mice models, eventually contributing to the 
establishment of the basal phenotype )DUDOGR et al., 2007))LJ
Recently, we still found that the CCAAT/enhancer-binding protein 
` (C/EBP`) transcription factor was able to activate CDH3 promoter 
in breast cancer cells. We showed that this novel activator of CDH3 
promoter activity exerts its activation preferably through its trun-
cated LIP isoform, being the abundance of Sp1 sites within CDH3 
promoter a feature which potentiate the C/EBP`-LIP activation role 
on CDH3 gene (Albergaria et al., 2010))LJ
Regulation of CDH3 gene has been also explored in terms of 
its transcriptional repression. In 2004, our group explored the link 
between ER-signalling and the regulation of P-cadherin expression 
in breast cancer cell lines, since we have already observed that 
breast tumours positive for P-cadherin expression were essentially 
(5QHJDWLYH:HYHULÀHGWKDW3FDGKHULQH[SUHVVLRQZDVLQGXFHG
by the pure anti-oestrogen ICI 182,780 and counteracted by 17`-
oestradiol. In fact, breast cancer cells treated with ICI 182,780 
VKRZHGDVLJQLÀFDQW LQFUHDVHRI3FDGKHULQP51$DQGSURWHLQ
levels in a time and dose dependent manner, establishing that the 
lack of ER-signalling is responsible for the increase of P-cadherin, 
therefore, categorizing CDH3 as an ER-repressed gene (Paredes 
et al., 2004))LJ9HU\UHFHQWO\LQRUGHUWRGHHSO\H[SORUHWKLV
antiestrogen-mediated mechanism, we described a cellular ad-
aptation process where ICI 182,780 is able to induce a chromatin 
structural remodelling, which lead to activation of CDH3 gene and 
overexpression of P-cadherin protein (Albergaria et al., 2010). Such 
genomic de-repression effect may contribute to an augmented 
invasive phenotype of ER-positive breast cancer cells. 
As a gene associated with the basal-like phenotype in breast 
cancer, CDH3/P-cadherin gene was recently described to be 
transcriptionally repressed by functional BRCA1 protein in breast 
cancer cell lines, at both mRNA and protein level. This same study 
also showed that, together with BRCA1, c-Myc form a repressor 
complex on the CDH3SURPRWHU )LJVXJJHVWLQJDSRWHQWLDO
mechanism to explain the observed overexpression of key basal 
PDUNHUVLQ%5&$GHÀFLHQWWXPRXUV*RUVNL et al., 2010). 
Epigenetic regulation of P-cadherin expression
Epigenetic regulation of CDH3/P-cadherin has been highly 
reported in the last few years, with greater emphasis in cancer 
PRGHOV 7KH HSLJHQHWLF GHUHJXODWLRQ RI 3FDGKHULQ ZDV ÀUVWO\
demonstrated by Sato et al., which LGHQWLÀHGCDH3 gene promoter 
to be aberrantly methylated in 20% of pancreatic cancers, but not 
in normal pancreatic epithelia (Sato et al., 2003). Similarly, CDH3 
gene was also shown to be silenced by methylation in melanoma 
cells (Tsutsumida et al., 2004). 
However, in 2005, we analysed P-cadherin promoter methyla-
tion in normal breast tissue, from which only epithelial cells were 
microdissected, and methylation of CDH3 gene promoter was 
found in the normal epithelial/luminal cell layer from all the speci-
mens analysed, which was associated with negative P-cadherin 
H[SUHVVLRQLQWKHVHFHOOV%XWLQFRQWUDVWWRZKDWKDVEHHQYHULÀHG
in E-cadherin control of expression by hypermethylation of its pro-
PRWHULQFDQFHURXUJURXSIRXQGDVLJQLÀFDQWFRUUHODWLRQEHWZHHQ
P-cadherin overexpression and CDH3 promoter hypomethylation. 
Using a large series of invasive breast carcinomas, we found that 
71% of P-cadherin-negative breast cancer cases were methylated 
for the CDH3 gene, whereas 65% of P-cadherin-positive cases 
were unmethylated (Paredes et al., 2005). 
Indeed, the genomic structure of the proximal CDH3 gene 
SURPRWHUVXFKDVWKHHQULFKPHQWLQ&S*LVODQGVDVZHOODVWKH
attributed DNA hypersensitive sites, suggests that it is likely to 
be regulated by epigenetic events, others than only methylation. 
In fact, we observed an up-regulation of CDH3 promoter activity 
and P-cadherin protein expression in cells treated with the histone 
deacetylases (HDAC) inhibitor Trichostatin A (TSA), showing that 
FKURPDWLQDFWLYDWLQJPRGLÀFDWLRQVDUHDOVRLPSRUWDQWLQWKHPRGX-
lation of this gene (Albergaria et al., 2010). Thus, if we previously 
described that overexpression of P-cadherin could result from a 
loss of promoter methylation, we have now evidences to assume 
that chromatin remodelling also play an important modulator role 
in CDH3 gene activity.
Reinforcing our results, CDH3 promoter was also found hypo-
methylated in colonic aberrant crypt foci, in colorectal cancer, and, 
occasionally, in the normal epithelium adjacent to cancer (Milicic et 
al., 2008). This hypomethylation pattern was associated with the 
LQGXFWLRQRI3FDGKHULQH[SUHVVLRQLQWKHQHRSODVWLFFRORQ)LQDOO\
demethylation of the CDH3 gene was recently detected in a large 
SHUFHQWDJHRI SULPDU\ JDVWULF FDUFLQRPDVDQGZDV VLJQLÀFDQWO\
associated with increasing TNM stage, suggesting that it is also a 
frequent event in gastric carcinomas (Kim et al., 2010). 
P-cadherin-downstream signalling pathways
Increasing evidences indicate that cadherins role in carcino-
genesis and tumour progression do not solely lie on their adhesive 
function, but also depend on their interaction with other molecules 
(such as cytoskeletal components, integrins, and growth-factor 
receptors, among others) and signalling pathways (Onder et al., 
2008). Therefore, the stabilization of the cadherin/catenin complex 
represents a major regulatory mechanism for oncogenic signalling 
pathways, that guide cell fate decisions through the modulation of 
VSHFLÀFJHQHVDWWKHWUDQVFULSWLRQDOOHYHODQGDVDFRQVHTXHQFH
regulation of several crucial cellular processes, as proliferation, 
survival, polarization, differentiation, shape and migration, which 
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in turn affect embryogenesis, tissue formation and pathogenic 
events, such as cancer. 
Although E-cadherin-induced signalling pathways have been 
extensively studied in cancer, little is known about the role of P-
cadherin (Paredes et al., 2004, Taniuchi et al., 2005, Van Marck et 
al., 2005). It is some kind expected that P-cadherin share common 
signalling pathways with other cadherins, due to its function as a 
cell-cell adhesion molecule; however, it is not known whether the 
pathways are triggered in the same way. 
Sarrió and collaborators analysed microarray gene expression 
of a breast cancer cell line (MDA-MB-231), negative for cadher-
ins, after expression of E- and P-cadherin. The data revealed 
that these molecules can activate signalling pathways leading to 
VLJQLÀFDQWFKDQJHVLQJHQHH[SUHVVLRQ$OWKRXJKWKHH[SUHVVLRQ
patterns induced by E- and P-cadherin showed more similarities 
WKDQGLIIHUHQFHVJHQHVZHUHGLIIHUHQWLDOO\PRGLÀHGE\WKHH[-
pression of either cadherin type. According to data bases, these 
genes belonged to a wide range of biological functions, including 
VLJQDOWUDQVGXFWLRQDQGJURZWKIDFWRUV9(*)&)*)5FHOOF\FOH
(CCNA2), cell adhesion and ECM (CDH4, COL12A1), or cytokines 
DQGLQÁDPPDWLRQ,/DPRQJRWKHUV(Sarrio et al., 2009). This 
indicates that, in addition to their role in cell adhesion, E-cadherin 
DQG3FDGKHULQKDYHDVLJQLÀFDQW LPSDFWRQ WKHRYHUDOOJHQHWLF
program of breast cancer cells. 
One of the molecules that have been several times referred has 
KDYLQJDVSHFLÀFUROHLQVLJQDOOLQJUHODWHGWR3FDGKHULQLVSFWQ
)LJ:HGHPRQVWUDWHGWKDWWKHSURLQYDVLYHDFWLYLW\RI3FDGKHULQ
requires the JMD of its cytoplasmic tail. Transfection of HEK293T 
cells with several mutants of P-cadherin showed that only the ones 
with altered JMD were not able to induce cell invasion in in vitro cell 
models (Paredes et al., 2004). Moreover, we observed that breast 
carcinomas co-expressing E- and P-cadherin were associated with 
p120ctn cytoplasmic localisation and poor patient survival (Paredes 
et al., 2008). Since then, several other reports have been exploring 
that pathway. Indeed, Taniuchi et al., showed that the induced cell 
migration by P-cadherin expression was due to activation of the Rho 
Fig. 4. Schematic representation of the signalling pathways regulated by P-cadherin expression. P-cadherin signals are transduced by many 
intracellular signalling pathways, which ultimately result in alterations of the cancer cells survival, as well as cell migration and invasion capacity. For 
simplicity, only some of the known interactions are depicted. It should be noted that the effect of P-cadherin on the overall gene expression program 
of cancer cells is highly dependent on the cellular type and the biological context.
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*73DVHV5DFDQG&GFWKURXJKDFFXPXODWLRQRISFWQLQWKH
cytoplasm in pancreatic cancer cell model (Taniuchi et al., 2005) 
)LJ9HU\UHFHQWO\3FDGKHULQKDVEHHQDOVRVKRZQWRFRRSHU-
ate with insulin-like growth factor-1 receptor to promote metastatic 
signalling of gonadotropin-releasing hormone in ovarian cancer via 
p120ctn (Cheung et al., 2010). These same authors had previously 
shown that this p120ctn signalling mediated by P-cadherin expres-
VLRQDOVROHDGWRLQFUHDVHGDFWLYLW\OHYHOVRI5DFDQG&GF)LJ
4). Still another study has shown that p120ctn and P-cadherin, but 
not E-cadherin, regulate cell motility and invasion of DU145 prostate 
cancer cells (Kumper and Ridley, 2010). 
Although binding of proteins to the JMD of P-cadherin has just 
been documented for p120ctn (Reynolds et al., 1996), other mol-
ecules, like Hakai and presenilin-1 (PS-1), have been reported to 
bind to the JMD of classical cadherins. This binding is established 
through a sequence adjacent to, or overlapping, the p120ctn-binding 
domain, thereby competing with p120ctn (Baki et al.)XMLWD 
et al., 2002)$OWKRXJKWKHVLJQLÀFDQFHRIWKHVHLQWHUDFWLRQVLVQRW
well known, we cannot exclude the possibility that disruption of the 
p120ctn–binding sequence may introduce conformational changes 
and/or uncouples the interaction of these or other proteins, which 
could explain our observations. Striking examples of this were 
shown for E-cadherin, where functional differences have been 
noted between larger and minimal deletions of the JMD, with even 
the minimal changes disrupting binding of multiple molecules (Baki 
et al., 2001).
Recently, it has been shown that the P-cadherin regulatory role in 
cell migration is also related with the expression of the non-muscle 
myosin II-B isoform, which is an ATP-dependent molecular motor 
SURWHLQWKDWFDQLQWHUDFWZLWKDQGFRQWUDFWÀODPHQWRXVDFWLQ)DFWLQ
(Jacobs et al., 2010))LJ7KHVHUHVXOWVLPSOLFDWHWKDWWKHUHLV
a coordinated cross-talk between adhesion molecules and cellular 
migration-related proteins.
More recently, the role of P-cadherin was investigated in oral 
squamous cancer cell model, where the authors used a cell line 
WKDWZDVGHÀFLHQWIRUFODVVLFDOFDGKHULQV$IWHU3FDGKHULQRYHU-
expression, cells gained an epithelial-like morphology, with Snail 
translocation to the cytoplasm. Analysing the signalling mechanism 
behind it, they found glycogen-synthase-kinase-3`*6.`) bound 
WR6QDLODVZHOODVDQLQFUHDVHLQDFWLYDWHG*6.` that phospho-
rylated Snail leading to its cytoplasmic translocation (Bauer et al., 
2009). These same authors also showed that Slit-2, a secreted 
ECM glycoprotein that acts as a molecular guidance cue in cellular 
migration, facilitates the interaction of P-cadherin with Robo-3, its 
receptor, and inhibits cell migration in oral squamous cell carcinoma 
cell line models (Bauer et al., 2011))LJ
In terms of breast cancer cell invasion, we found that the pres-
ence of P-cadherin, in an E-cadherin positive cellular background, 
is able to provoke the secretion of pro-invasive factors, such as 
MMP-1 and MMP-2, leading to P-cadherin ectodomain cleavage 
(sP-cad) which induces a pro-invasive activity by itself (Ribeiro 
et al., 2010)7KLVVWXG\FODULÀHGWKHPHFKDQLVPDVVRFLDWHGWR3
cadherin-induced cancer cell invasion. 
Different signalling pathways should be triggered in different cell 
models, in order to identify new interaction partners of P-cadherin, as 
well as to study whether the interaction of known partner molecules 
GLIIHUEHWZHHQFDGKHULQV)LQDOO\ LW LV LPSRUWDQW WRKLJKOLJKW WKDW
the effect of cadherins on the overall gene expression program of 
cancer cells is highly dependent on the cellular type and the biologi-
FDOFRQWH[W7KXV3FDGKHULQUHJXODWLRQRIVSHFLÀFWUDQVFULSWLRQDO
factors may depend on the activation of other signalling pathways, 
or on the presence of additional molecular alterations.
P-cadherin as a breast cancer stem cell marker
An increasing body of evidence supports the notion that cancers 
are propagated by a small population of cells present in the malignant 
tissue, that possess the ability to form a hierarchy similar to the 
one present in normal tissues (Visvader, 2011). These cancer stem 
cells (CSCs) are able to proliferate, originating more stem-like cells, 
to exhibit resistance to current therapies and to remain quiescent 
during long periods of time. However, it is still not clear whether 
the CSC originates from the normal stem cells of the tissue that 
deregulate their self-renewal ability, or from normal mature cells or 
progenitor cells that acquired stem cell characteristics (Visvader, 
2011) ,PSRUWDQWO\DWWHPSWVKDYHEHHQPDGH LQRUGHU WRÀQGD
universal phenotype for the breast cancer stem cell; but due to 
the high heterogeneity of this malignancy, it is not expected that a 
single CSC phenotype would apply to all breast cancers. 
7KH LGHQWLÀFDWLRQRIDFDQFHUVWHPFHOOPDUNHU IRUEDVDOOLNH
subtype of breast cancer is of particular importance, due to its 
high mortality rate, fast relapses and lack of target therapy (Rakha 
et al., 2009). Recently, it has been demonstrated that the luminal 
progenitor of normal breast hierarchy is the cell of origin for this 
malignancy, since the induction of a BRCA1 mutation in this cell 
was able to induce the formation of a tumour with basal phenotype 
(Lim et al., 2009, Molyneux et al., 2010). Since CDH3 gene is 
repressed by BRCA1, it is likely that P-cadherin could be a good 
FDQFHUVWHPFHOOPDUNHURIWKLVVSHFLÀFW\SHRIWXPRXUV,QIDFW
using a series of breast cancer cell lines, we found that P-cadherin 
enriched populations (by genetic manipulation or by sorting) were 
HQULFKHGIRUPDPPRVSKHUHIRUPLQJHIÀFLHQF\0)(DVZHOODV
for the expression of CD24, CD44 and CD49f, already described 
as CSC markers. When compared with luminal cell lines, basal-like 
FHOOOLQHVDOVRVKRZHGDJUHDWHU$/'()/825bright subpopulation 
and the P-cadherin positive subfraction of these cell lines was 
HQULFKHGLQVWHPFHOODFWLYLW\0)(DQG'JURZWKXQSXEOLVKHG
data). This observation linked P-cadherin expression with the 
luminal progenitor phenotype, which is CD44+CD24+CD49f+ (Lim 
et al., 2009). Importantly, it has been described that the phenotype 
CD44+CD24+ is tumorigenic (Meyer et al., 2009). Hence, the strat-
egy of directing therapies to the luminal progenitor phenotype, by 
VSHFLÀFDOO\WDUJHWLQJ3FDGKHULQFRXOGSRWHQWLDOO\KHOSWRHUDGLFDWH
the CSCs. Interestingly, P-cadherin also conferred resistance to 
X-ray induced DNA damage, supporting a role for this molecule in 
the maintenance of yet another CSC property (unpublished data). 
P-cadherin - potential therapeutic target in cancer
As clearly stated in this review, P-cadherin–mediated adhesion 
and the associated signalling pathways play diverse roles in the 
regulation of cancer cell survival, invasiveness and metastatic 
potential. Interestingly, in 2008, Imai and collaborators have sug-
gested CDH3/P-cadherin as a possible target for immunotherapy 
RISDQFUHDWLFJDVWULFDQGFRORUHFWDOFDQFHUVVLQFHLWZDVLGHQWLÀHG
as a novel tumour-associated antigen, meaning that was strongly 
expressed in tumour cells, but not in normal cells (Imai et al., 2008). 
Indeed, we have found that P-cadherin silencing, in breast cancer 
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FHOOVLQRFXODWHGLQQXGHPLFHZDVDEOHWRVLJQLÀFDQWO\LQKLELW in 
vivo tumour growth (unpublished data).
Recently, a novel and highly selective human monoclonal an-
WLERG\DJDLQVW3FDGKHULQ3)ZDVSURGXFHGGHPRQ-
strating anti-tumour and anti-metastatic activity in a diverse panel 
of P-cadherin–overexpressing tumour models, without introducing 
any adverse secondary effects in mice (Zhang et al., 2010). This 
antibody failed to bind to the most closely target-related family 
members, including E-cadherin, N-cadherin, and VE-cadherin. 
3)DOVRUHGXFHGO\PSKQRGHPHWDVWDVHVDQGORZHUHG
the levels of circulating tumour cells (CTC) in whole blood of P-
cadherin+ tumour bearing mice. The anti-metastatic property of 
WKHDQWLERG\ZDVUHPDUNDEOHVLQFHLWVLJQLÀFDQWO\LQKLELWHGWXPRXU
FHOOLQÀOWUDWLRQLQWRWKHOXQJV3)VWLOOVXSSUHVVHG`ctn, 
cyclin D1, Vimentin, Bcl-2, and survivin expression, decreased 
the Ki67 levels, and increased caspase-3 expression (Zhang et 
al., 2010))LJ
Taken together, these recent data highlight the critical role of 
P-cadherin signalling in regulating tumorigenesis and metastasis, 
especially because its inhibition leads to anti-tumour and anti-
metastatic effects in target-associated tumour models without any 
adverse indication. These observations provide the rationale and 
JXLGDQFHIRUWKHFOLQLFDOGHYHORSPHQWRI3)LQZKLFK
tumours with high P-cadherin expression will be essential criteria 
IRUSDWLHQWVHOHFWLRQ)XWXUHZRUNLVZDUUDQWHGWRVHHNDUHSURGXF-
LEOHPHWKRGWRTXDQWLI\3FDGKHULQLQKXPDQWXPRXUVDQGWRÀQGD
reasonable cut-off of expression related with therapeutic response, 
in an attempt to reach the full potential for clinical development 
RIWKHDQWLERG\3)LVFXUUHQWO\XQGHU3KDVH,FOLQLFDO
trial development.
Conclusions
Although this review is mainly focused on P-cadherin role as 
a poor prognostic factor, as well as a therapeutic target in breast 
cancer, its upregulation is also found in several other malignan-
cies, affecting organs such as pancreas, stomach, bladder and 
prostate, where it is also associated with an aggressive phenotype 
and poor prognosis. Thus, antagonizing P-cadherin represents a 
novel approach for anticancer therapy, by targeting tumours with 
high P-cadherin expression. Interestingly, P-cadherin silencing 
LQGXFHV VLJQLÀFDQW JURZWK LQKLELWLRQ LQ VHYHUDO WXPRXU PRGHOV
tested; however, this anti-proliferative activity was never observed 
in vitro (Zhang et al., 2010). This discrepancy suggests that fully 
functioning P-cadherin signalling may require the cell-cell and cell-
stroma crosstalk in intact tumour architecture during tumorigenesis 
and metastasis, a process that may not be recapitulated under in 
vitro conditions and that should be further studied in the future.
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Cell–cell adhesion is an elementary process in normal
epithelial cellular architecture. Several studies have shown
the role mediated by cadherins in this process, besides
their role in the maintenance of cell polarity, differentia-
tion and cell growth. However, during tumour progression,
these molecules are frequently altered. In breast cancer,
tumours that overexpress P-cadherin usually present a
high histological grade, show decreased cell polarity and
are associated with worse patient survival. However, little
is known about how this protein dictates the very
aggressive behaviour of these tumours. To achieve this
goal, we set up two breast cancer cell models, where
P-cadherin expression was differently modulated and
analysed in terms of cell invasion, motility and migration.
We show that P-cadherin overexpression, in breast cancer
cells with wild-type E-cadherin, promotes cell invasion,
motility and migration. Moreover, we found that the
overexpression of P-cadherin induces the secretion of
matrix metalloproteases, specifically MMP-1 and MMP-
2, which then lead to P-cadherin ectodomain cleavage.
Further, we showed that soluble P-cadherin fragment is
able to induce in vitro invasion of breast cancer cells.
Overall, our results contribute to elucidate the mechanism
underlying the invasive behaviour of P-cadherin expres-
sing breast tumours.
Oncogene advance online publication, 9 November 2009;
doi:10.1038/onc.2009.338
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Introduction
Cell migration and invasion are critical properties that
characterize malignant neoplastic cells. Recently, a
number of molecular mechanisms have been identified
in transformed cells that become migratory and invasive
during carcinogenesis. These includes alterations in cell–
cell and cell–matrix adhesion, activation of small
GTPases or modulation of receptor tyrosine kinase-
mediated signal transduction pathways (Cavallaro and
Christofori, 2004).
Cell–cell adhesion is crucial for the maintenance of
normal epithelial cellular architecture and is frequently
altered in tumour progression, inducing a multistep
process termed epithelial-to-mesenchymal transition
(EMT) (Thiery, 2002). During EMT, tumour cells
progressively downregulate their cell–cell adhesion
epithelial-specific proteins, such as E-cadherin, and
express de novo mesenchymal adhesion molecules, such
as N-cadherin. This cadherin switch leads to the
inhibition of cell–cell contacts and elicits active signals,
which support tumour cell migration, invasion and
metastatic dissemination (Frixen et al., 1991; Chen et al.,
1997). However, regardless the major progress in
understanding the in vitro molecular processes under-
lying EMT and tumour progression, a number of
questions remain unsolved. For instance, the majority
of breast cancer subtypes are diagnosed as invasive and
malignant under pathological criteria, but rarely loose
complete E-cadherin expression and infrequently gain
de novo N-cadherin expression (Sarrio et al., 2008).
Our group has been focused in studying the role
of another classical cadherin in breast cancer, namely
P-cadherin. As mentioned before, in breast cancer, many
of the highly aggressive tumours do not actually show a
cadherin switch. In contrast, these tumours overexpress
P-cadherin, maintaining the normal E-cadherin expres-
sion (Paredes et al., 2005, 2008). In clinical terms, these
P-cadherin-overexpressing tumours present high histolo-
gical grade, with decreased cell polarity, aggressive
behaviour and worse patient survival (Peralta Soler
et al., 1999; Gamallo et al., 2001; Paredes et al., 2002,
2005). On the basis of these observations, we aimed to
understand how P-cadherin, in an E-cadherin wild-type
background, could influence the behaviour of these
tumours. Thus, we have studied earlier the expression of
classical cadherins in a small collection of breast cancer
cell lines (Paredes et al., 2007), and we associated this
expression with the invasiveness potential of these cells.
Received 13 February 2009; revised 9 September 2009; accepted 16
September 2009
Correspondence: Dr J Paredes, IPATIMUP, Institute of Molecular
Pathology and Immunology, University of Porto, Rua Dr Roberto
Frias s/n, Porto 4200-465, Portugal.
E-mail: jparedes@ipatimup.pt
Oncogene (2009), 1–11
& 2009 Macmillan Publishers Limited All rights reserved 0950-9232/09 $32.00
www.nature.com/onc
Indeed, it is possible to see that there is a significant
association between P-cadherin overexpression and the
invasion capacity of breast cancer cells that maintain the
expression of wild-type E-cadherin.
In this study, we show for the first time that
P-cadherin overexpression, in wild-type E-cadherin
breast cancer cells, is able to induce increased cell
invasion, motility and migration. Additionally, we
found that the presence of P-cadherin is able to provoke
the secretion of pro-invasive factors, such as matrix
metalloproteases (MMPs), MMP-1 and MMP-2, which
then lead to P-cadherin ectodomain cleavage. Interest-
ingly, we observed that this formed soluble P-cadherin
fragment (sP-cad) is responsible for the in vitro invasion
of wild-type E- and P-cadherin expressing cells, which
clarifies the mechanism associated to cell invasion
and may explain the poor prognosis of patients
harbouring breast tumours expressing these two mole-
cules (Paredes et al., 2008).
Results
P-cadherin overexpression in wild-type E-cadherin breast
cancer cell lines is associated with an increase in cell
invasion
In a recent study, we analysed the mRNA expression
levels of the major classical cadherins (E-, P- and N-
cadherins) among a small collection of different breast
cancer cell lines, using RT–PCR (Paredes et al., 2007).
Comparing these results with the knowledge acquired
about these cell lines in earlier publications (Figure 1a),
especially concerning their invasiveness potential, EMT
phenotype and gene expression profile (Charafe-Jauffret
et al., 2006; Lombaerts et al., 2006; Neve et al., 2006;
Blick et al., 2008), we can clearly see that E-cadherin
mRNA is only expressed by cell lines that maintain an
epithelial phenotype, whereas N-cadherin is expressed
by cells that show a mesenchymal phenotype. Besides
the phenotype, the expression of these cadherins is also
highly correlated with cell invasiveness capacity, where
E-cadherin-positive cell lines show low invasive poten-
tial, whereas N-cadherin expressing cells are widely
described as highly invasive. When breast cancer cell
lines are classified in accordance with their gene
expression profile, E-cadherin is also predominantly
expressed by both Luminal and Basal A cell lines,
whereas N-cadherin transcripts are restricted to Basal B
cell lines.
Although these associations are already well known
for E- and N-cadherin, similar findings were never
found, concerning P-cadherin expression and these cell
properties. Looking carefully to these associations
(Figure 1a), P-cadherin mRNA transcripts are predo-
minantly detected in E-cadherin-positive cells, being
mostly associated with an epithelial phenotype. Cur-
iously, this cadherin is strongly expressed by cell lines
classified as Basal A, being also associated with an
increased cell invasive capacity, compared with other
epithelial cell lines harbouring a Luminal gene expres-
sion profile. Using Matrigel invasion assay, we con-
firmed the invasion potential of two Luminal cell lines,
namely MCF-7/AZ and T47D, and two Basal A cell
lines, MDA-MB-468 and BT-20. Figure 1b shows that
cell lines with higher levels of P-cadherin expression
revealed an increased ability to invade through Matrigel.
More importantly, these results are in agreement with
what has been described in invasive primary breast
tumours, showing the clinical relevance of P-cadherin
expression in the diagnosis and prognosis of patients
with aggressive mammary carcinomas (Peralta Soler
et al., 1999; Paredes et al., 2005).
To determine whether or not P-cadherin expression is
in part responsible by the moderate/high invasive
capacity of Basal A cells lines, we set up two
E-cadherin-positive cancer cell models: (1) the stable
induction of P-cadherin overexpression in non-invasive
MCF-7/AZ cells, by retroviral infection; and (2) the
transient silencing of P-cadherin in invasive BT-20 cells,
using specific small interference RNA (siRNA). As can
be noticed in Figure 2a, these two cell models were
established and the role of P-cadherin in cell invasion
was, therefore, analysed. P-cadherin-overexpressing
MCF-7/AZ cells showed a significant increase in cell
invasion capacity, which was repressed when cells were
treated with a P-cadherin inhibitory-function antibody,
pointing to a P-cadherin-dependent cell invasion me-
chanism (Figure 2b). Identically, BT-20 invasive poten-
tial was significantly inhibited when P-cadherin was
silenced by siRNA (Figure 2c).
As a conclusion, we can state that P-cadherin-over-
expressing breast cancer cells, although maintaining its
epithelial phenotype, have selective advantage to invade
when compared with cell lines that mostly express
E-cadherin.
P-cadherin overexpression promotes cell motility
and cell migration of breast cancer cells
To further explore the function of P-cadherin in breast
cancer, its effect on cell motility and cell migration was
also tested.
We evaluated breast cancer single cell motility by
time-lapse microscopy, during 6 h of culture (see movies
in Supplementary data). Figure 3 represents snapshot
images from time-lapse movies, where differences were
seen between the motility of MCF-7/AZ.Mock and
MCF-7/AZ.Pcad cells. Figure 3 also shows the results
obtained with BT-20 cells transfected with a control
siRNA or with an siRNA that specifically abolish P-
cadherin expression. The trajectory of the cell’s nuclei
from both cell lines is showed in Figure 3a. MCF-7/
AZ.Mock cells barely showed significant movement,
whereas MCF-7/AZ.Pcad cells exhibited increased cell
motility. Besides this significant increase in the total
number of cells with motile capability, MCF-7/AZ.Pcad
cells also showed a fourfold increase in cell speed
(Figure 3b). P-cadherin silencing in BT-20 cells, turns
these cells significantly less motile, and the cell speed was
decreased for half of the one showed by BT-20 control
cells (Figures 3c and d).
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Besides analysing cell motility, we evaluated cell
migration capacity, using a wound-healing migration
assay. As observed in Figures 4a and b, P-cadherin-
positive cells migrated significantly faster into the
wound compared with control cells; importantly,
this result was not due to an increase in cell proliferation
rate of P-cadherin-overexpressing cells (Figure 4c).
To confirm that induced migration was dependent of
P-cadherin expression in these cells, the same experiment
was performed in the presence of a functionally
blocking antibody against P-cadherin activity (the
NCC-CAD-299 clone). As shown in Figure 4b,
the presence of this antibody significantly inhibited
the migration capacity of P-cadherin-overexpressing
cells into the wound area, whereas a non-specific
IgG did not. An obvious observation of P-cadherin-
induced cell migration was the evident pattern of
collective cell migration, as P-cadherin-overexpressing
cells do not lose their E-cadherin cell–cell contacts,
and cells migrate faster and cohesive. Time-lapse
microscopy movies clearly show this result (see Supple-
mentary data).
In both assays, besides the increase in cell motility and
migration, it was also possible to observe clear
differences between cell’s phenotype (see Supplementary
data), where P-cadherin-overexpressing cells presented
an increased number of membrane protrusions, struc-
tures that are usually associated to moving cells.
Figure 1 Association between P-cadherin expression and cell invasiveness in wild-type E-cadherin breast cancer cell lines. (a) Table
comparing the pattern of expression of classical cadherins (namely E-, P- and N-cadherin) in different breast cancer cell lines with their
invasiveness potential, EMT (epithelial-to-mesenchymal transition) phenotype and gene expression profile. (b) Matrigel invasion assay
was used to analyse the invasion potential of two Luminal cell lines, MCF-7/AZ and T47D and two Basal A cell lines, MDA-MB-468
and BT-20. The basal cell lines showed significant increase in cell invasion, when compared with the Luminal cell lines (*Po0.005
compared with MCF-7/AZ non-invasive cells).
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P-cadherin overexpression induces the formation of cell
membrane protrusive structures
An effective cell migration requires the integration
of localized and transient signalling events, leading
to changes in cellular architecture, namely in the
re-organization of the actin cytoskeleton. Given that
P-cadherin affects cell migration, motility and invasion,
we analysed the effect of P-cadherin overexpression on
the actin cytoskeleton organization, by F-actin fluores-
cence immunostaining. Differences between control and
MCF-7/AZ.Pcad cells were evident as P-cadherin-over-
expressing cells showed an increase in membrane
ruffling and in actin cellular extensions, as well as in
their cytoplasmic area (Figure 5). Indeed, P-cadherin-
overexpressing cells, including MCF-7/AZ.Pcad and
BT-20, show an upper cell localized nuclei and appear
as rounded and flat cells with actin-rich sheet-like
membrane protrusive structures that, according with
the literature, are essentially observed during crawling
cell motility and spreading (Yamazaki et al., 2005;
Chhabra and Higgs, 2007).
Using double F-actin and p120ctn staining,
MCF-7/AZ.Mock versus MCF-7/AZ.Pcad cells showed
distinct aggregation ability, where MCF-7/AZ.Mock
cells, in contrast to P-cadherin-overexpressing cells,
showed well-formed and tight aggregates (Figure 5).
Indeed, microscopic fluorescence imaging of P-cadherin
expressing cells showed that P-cadherin destabilizes
cell–cell adhesion, promoting cytoskeleton changes,
leading to a different cell phenotype. The cells resemble
the aggressive morphology observed in primary basal-
like P-cadherin-positive breast carcinomas, as these cells
normally acquire a large cytoplasm and several mem-
brane protrusions, and cell–cell adhesion is not usually
mediated by a compact zipper-like structure (Yamazaki
et al., 2005; Chhabra and Higgs, 2007).
These results clearly show an association between
P-cadherin expression and actin cytoskeleton reorgani-
zation, suggesting that P-cadherin has a role in the
mechanism that regulates the cellular architecture
changes that are needed to promote cell migration and
invasion.
P-cadherin overexpression induces active MMPs that are
responsible for its extracellular cleavage and shedding
One of the families of proteases, which are well known
to be involved in cell invasion induction, namely in the
extracellular matrix (ECM) degradation process, is the
family of MMPs. On the basis of this, MMP activity
levels were assessed in the conditioned medium from
P-cadherin-overexpressing breast cancer cells, using
b-casein and gelatin zymography. The results obtained
showed that P-cadherin expression induces significantly
the levels of active MMP-1 (42 kDa) and active MMP-2
(66 kDa) in the conditioned medium compared with
control cells (Figure 6a). These observations were
further confirmed by western blot, using antibodies
specifically to analyse the expression of inactive and
active forms of MMP2 and MMP1 (Figure 6b).
Accordingly, also high levels of active MMP-1 and
MMP-2 were found in the conditioned medium from
BT-20 cells, although transient P-cadherin silencing was
not enough to abrogate the expression levels of these
active MMP forms (data not shown).
Given that MMPs were already described to shed the
extracellular domains of membrane glycoproteins,
including E-cadherin, giving rise to a soluble fragment
with pro-invasive activity (Lochter et al., 1997;
Herren et al., 1998; Noe et al., 2001), we looked forward
for the presence of soluble fragments of cadherins in
the conditioned medium from the studied cell lines.
Surprisingly, no significant differences were observed
Figure 2 P-cadherin is involved in breast cancer cell invasion.
(a) P-cadherin and a-tubulin protein expression in two different
breast cancer cell models: induction of P-cadherin overexpression
in MCF-7/AZ cells, by retroviral infection, and silencing of
P-cadherin overexpression in BT-20 cells, using specific small
interference RNA (siRNA). (b) Matrigel invasion assay of control
MCF-7/AZ.Mock cells, and MCF-7/AZ.Pcad cells in the absence
or presence of a function-blocking anti-P-cadherin antibody (NCC-
CAD-299, P¼ 0.0029 and 0.0022, respectively). (c) Matrigel
invasion assay of BT-20 siRNA control cells compared with
BT-20 with P-cadherin knockdown expression (P¼ 0.0019).
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concerning the presence of soluble E-cadherin (sE-cad);
however, sP-cad was increased 8.7-fold in the condi-
tioned medium from MCF-7/AZ.Pcad cells (Figure 6c).
BT-20 cells also showed high levels of sP-cad, which
were significantly decreased when these cells were
transfected with P-cadherin siRNA (Figure 7a). These
results showed, as expected, a direct association between
full-length P-cadherin overexpression at the cell mem-
brane and the presence of sP-cad in the conditioned
media.
Finally, our goal was to assess if MMPs might have a
role in P-cadherin shedding, as was described earlier for
Figure 3 Promotion of cell motility by P-cadherin overexpression in breast cancer cells. Snapshot images from time-lapse movies of
MCF-7/AZ.Mock and MCF-7/AZ.Pcad cells (a) and BT-20 siRNActr and BT-20 siRNAPcad (c). Cells were monitored during 6 h,
and trajectories for each cell were determined manually based on the centre of the nuclei along time. Black lines represent the
trajectories performed by cells. Cell speed, considering the ratio from the distance made by cells versus the time of movement, was
quantified for MCF-7/AZ.Mock and MCF-7/AZ.Pcad cells (b) and for BT-20 siRNActr and BT-20 siRNAPcad (d), where 300 cells
were analysed per cell line (Po0.001). In both cell models, is possible to conclude that P-cadherin expression promotes an increase in
cell motility and cell speed.
Figure 4 Induction of cell migration by P-cadherin overexpression in breast cancer cells. (a) Cell migration was estimated by means of
wound-healing migration assay, and monitored by time-lapse microscopy. The distances migrated by breast cancer cells were measured
at several time points: 0, 1, 2, 3, 4, 5 and 6 h. The experiment shown is relative to a representative experiment that was repeated three
times. (b) Migration of MCF-7/AZ.Mock and MCF-7/AZ.Pcad cell lines, in the presence or absence of a function-blocking
anti-P-cadherin antibody (NCC-CAD-299) was evaluated by wound-healing migration assay (*Po0.05, corresponding to P-values
from MCF-7/AZ.Pcadþ IgG compared with MCF-7/AZ.Mockþ IgG cells; **Po0.05, ***Po0.01, corresponding to P-values from
MCF-7/AZ.Pcadþ IgG compared with MCF-7/AZ.PcadþNCC-CAD-299 antibody treatment). P-cadherin expression is directly
implicated in the migratory capabilities of this cell line. (c) BrdU proliferation assay was performed in MCF-7/AZ.Mock and MCF-7/
AZ.Pcad cells, to exclude that differences observed in cell migration were due to altered cell proliferation. No differences were observed
in the percentage of cell proliferation in both cell lines.
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E-cadherin. Thus, MCF-7/AZ.Pcad cells were treated
with a MMP inhibitor (with higher affinity to inhibit
MMP-1 and MMP-2), the conditioned medium was
recovered and the presence of sP-cad was evaluated by
western blot. Remarkably, the treatment with the MMP
inhibitor reduced the levels of sP-cad, showing that
MMPs have an important role in P-cadherin cleavage
and shedding (Figure 6d). To understand if P-cadherin
shedding had also a role in the production of MMPs,
inducing a mechanism of positive feedback, the parental
cell line MCF-7/AZ was treated with human recombi-
nant P-cadherin (hrP-cad). This peptide should mimic
the effect of sP-cad, as it only harbours the extracellular
part of this complete adhesion molecule. Interestingly,
we found that hrP-cad induced the secretion of active
MMP-1 and MMP-2, as happens in MCF-7/AZ.Pcad
cells (Figure 6e). We also showed that hrP-cad is also
cleaved by MMPs, originating an 80 kDa fragment,
identical to sP-cad; the levels of this fragment were
decreased when cells were treated with hrP-cad in
combination with MMP inhibitor, confirming the
importance of these MMPs to full-length P-cadherin
cleavage (Figure 6f).
These results show that P-cadherin overexpression,
sP-cad cleavage, as well as active MMPs secretion, are
highly correlated. Briefly, P-cadherin expression leads to
the secretion of active MMPs, enzymes that then cleave
the extracellular domain of P-cadherin, giving rise to
sP-cad. This soluble fragment is able to induce and
maintain the secretion of active MMPs.
sP-cad has pro-invasive activity in breast cancer cells
As a crucial step for invasion and metastasis is the
destruction of biological barriers (basement membrane
and ECM) by activated proteolytic enzymes, we aimed
to assess whether the medium from P-cadherin-over-
expressing breast cancer cells, rich in MMPs and sP-cad,
was enough to facilitate cell invasion of non-invasive
cells. Thus, we performed the same invasion assay using
the parental MCF-7/AZ cell line, treated with the
conditioned medium obtained from MCF-7/AZ.Mock
and MCF-7/AZ.Pcad cells (Figures 7a and b). Interest-
ingly, only the conditioned medium from P-cadherin-
overexpressing cells itself was able to significantly induce
invasion. This effect was not observed in the presence of
the conditioned medium secreted by cells without
P-cadherin overexpression (MCF-7/AZ.Mock). To con-
firm these results, these same cells were treated with the
conditioned medium from BT-20 cells, which also
contain high levels of sP-cad and MMPs, and ‘de novo’
invasive cell behaviour was observed. These results show
that P-cadherin-overexpressing cells secrete factors to
the medium that are crucial for cell invasion induction
(Figures 7a and b).
In the past, in vitro studies showed that sE-cad has a
pro-invasive role in tumour cell lines, although its
mechanism of action is still not well understood (Noe
et al., 2001). However, the potential activity of sP-cad in
cell invasion induction has never been described in
in vitro studies. To understand whether sP-cad would
have a role in breast cancer cell invasion, we depleted the
Figure 5 P-cadherin overexpression induces the formation of cell membrane protrusions and large cytoplasm. Breast cancer cells were
seeded on a glass surface, fixed and stained for P-cadherin (I, IV, VII). FITC-phalloidin staining was also performed (II, V, VII), to
visualize actin filaments (1000! amplification), where it was possible to confirm alterations in the actin cytoskeleton re-organization in
P-cadherin-overexpressing cells. Confocal microscopy imaging of aggregates from MCF-7/AZ.Mock (III), MCF-7/AZ.Pcad (VI) and
BT-20 cells (IX), stained for F-actin (green) and p120ctn (red) (400! amplification) was performed. Cell phenotype and structure of
cell clusters were different, attributing a role for P-cadherin in the induction of loose aggregates. The white line in each picture
represents 20mm scale.
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sP-cad fragment from the conditioned medium of MCF-7/
AZ.Pcad cells by repeated immunoprecipitations,
using a specific P-cadherin antibody (Figures 7a and b).
Moreover, we treated the cells with hrP-cad, which was
added to the conditioned medium collected from
MCF-7/AZ.Mock cells. Afterwards, we performed
Matrigel invasion assay using the parental non-invasive
MCF-7/AZ cells, treated with these mediums: or with
the hrP-cad-rich medium or with the depleted (without
sP-cad) conditioned medium of P-cadherin-overexpres-
sing cells. Although hrP-cad-rich medium promoted cell
invasion capacity to a non-invasive cell line, this effect
was completely abolished when sP-cad was depleted
from the medium (Figures 7a and b). Moreover, when
MCF-7/AZ cells were treated with the conditioned
medium from BT-20 cells, where P-cadherin was
silenced by siRNA, its invasion was significantly
reduced comparing with BT-20 control cells. Together,
these results clearly show a critical role for sP-cad in
breast cancer cell invasion.
Finally, to understand whether the invasion effect
induced by sP-cad was due to homotypic interactions
with endogenous P-cadherin on the surface of the cells,
we decided to measure the invasion rates of BT-20 target
cells, with P-cadherin siRNA knockdown, exposed to
conditioned medium rich in sP-cad or rich in hrP-cad
(Figure 7c). Interestingly, we found that in both
situations, it is possible to restore the invasion capacity
of these cells. These results show that the invasive effect
mediated by sP-cad is not due to a homotypic
interaction with endogenous P-cadherin at the cell
membrane.
Discussion
Previous studies have shown that P-cadherin expression
in breast carcinomas is able to identify a subgroup of
lesions with a more aggressive behaviour and poor
Figure 6 P-cadherin overexpression induces increased levels of MMP-1 and MMP-2 activity, which have a role in P-cadherin
shedding. (a) b-casein zymography, which allows identification of activity of MMP-1 and MMP-2, was performed using the
conditioned medium from mock and MCF-7/AZ.Pcad cells, cultured in collagen type-I. (b) Western blot to detect the secretion of
active-MMP-1 and active-MMP-2 into the conditioned medium was evaluated and compared between mock and P-cadherin-
overexpressing cells. (c) Detection for the presence of sE-cadherin and sP-cadherin fragments in the medium was achieved by
performing western Blot for these proteins, using the conditioned medium obtained from each cell line. (d) Effect of MMPs in
the shedding of P-cadherin was evaluated by analysing the presence of the sP-cad fragment in the conditioned medium from
MCF-7/AZ.Pcad cells treated with different concentrations of the MMP inhibitor III. (e) Zymography detecting increased MMP-2
activity levels in parental MCF-7/AZ cells treated with a human recombinant fragment of P-cadherin (hrP-cad). Western blot for
active-MMP-1 and active-MMP-2 present in the conditioned medium from control cells treated with hrP-cad. (f) Protein expression
analysis for the conditioned medium from control cells treated with hrP-cad and MMPi, to confirm that hrP-cad can be shed to an
80 kDa form and that this process is MMP dependent.
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patient survival (Peralta Soler et al., 1999; Gamallo
et al., 2001; Paredes et al., 2002, 2004, 2005, 2007, 2008).
Similar associations between P-cadherin expression and
poor prognosis are described in other cancer models,
namely endometrial, cervical, gastric and pancreatic
carcinomas (Stefansson et al., 2004; Longatto Filho
et al., 2005; Taniuchi et al., 2005).
Our group has previously shown in vitro that, using
HEK 293 T cells as a model system, P-cadherin has a
pro-invasive activity, through its juxtamembrane do-
main (Paredes et al., 2004). In contrast, in highly
invasive melanoma cell lines, P-cadherin overexpression
is able to promote the formation of cell–cell contacts
and counteract invasion (Van Marck et al., 2005),
showing that it may function either as an invasion
promoter or as an invasion suppressor depending on
tissue specificity. On the basis of clinical evidences and
on its contradictory biological role in distinct tumour
tissues, we aimed at understanding how P-cadherin
influences tumour aggressiveness. Furthermore, we
aimed to clarify, besides cell invasion, its role in
migration, motility and activation of MMPs, using
breast cancer-derived cell lines.
Using in vitro cell models, we found for the first time
that overexpression of exogenous P-cadherin is able to
promote single cell motility, inducing an increase in the
number of moving cells and speed when compared with
cells with low levels of this protein. Furthermore,
P-cadherin-overexpressing cells not only showed in-
creased single cell motility, but also increased directional
cell migration, as well as, invasion capacity through the
Matrigel. This behaviour was shown to be directly
dependent on P-cadherin, as when overexpressing cells
were treated with a P-cadherin blocking antibody or
transfected with a siRNA to inhibit P-cadherin tran-
scripts, there was an inhibition of both effects (migra-
tion and invasion). Interestingly, Simpson et al. (2008)
also identified CDH3 (the P-cadherin codifying gene) as
one of the genes involved in the regulation of breast cell
migration using an siRNA approach. Further, in other
studies, using different cancer cell models, P-cadherin
was shown to have a role in promoting cell migration.
Namely, Taniuchi et al. (2005) showed that a pancreatic
cancer cell line, transfected with wild-type P-cadherin,
migrated faster than the cells without this molecule.
Epithelial cell migration requires the coordination of
three basic cellular processes: actin cytoskeleton reorga-
nization, matrix adhesion and matrix re-modelling
(Lauffenburger and Horwitz, 1996; Fenteany et al.,
2000). In this present study, we also show, by time-lapse
microscopy and actin phalloidin staining, that P-cadherin
is able to induce phenotypic changes involving alterations
in cell polarity and leading edge morphology, formation
of membrane protrusions, as well as, increase of their
cytoplasmic area, which usually is characteristic from
cells with a motile behaviour.
Further, we aimed to determine the molecular
mechanisms underlying P-cadherin overexpression and
its cellular-associated effects in breast cancer cells. It has
been described that the degradation of the ECM, with
recruitment of proteolytic enzymes, occurs in a variety
of cellular events requiring tissue reorganization, such as
embryonic development, wound healing and cancer
progression (Vu and Werb, 2000). Among these
enzymes, MMPs are able to degrade almost all the
ECM components, and have largely been involved in
both tumour invasion in vitro and in early and late
stages of tumour progression in vivo. When we evaluated
the cell invasion capacity of non-invasive parental cells
exposed to conditioned media from P-cadherin-over-
Figure 7 sP-cad has pro-invasive activity. (a) Western blot for
several conditioned medium, showing different levels of sP-cad.
Conditioned medium from MCF-7/AZ.Pcad cells (with sP-cad)
was subjected to serial immunoprecipitations for the sP-cad
fragment, using a specific monoclonal P-cadherin antibody,
originating the conditioned medium with sP-cad depletion. (b) To
clarify the specific role of s-Pcad in breast cancer cell invasion,
matrigel invasion assay was performed in non-invasive parental
MCF-7/AZ cells incubated with the conditioned medium from
the different cell lines that present different levels of sP-cad
(shown in a). Control cells were treated conditioned medium from
MCF-7/AZ.Mock cells (with and without hrP-cad), conditioned
medium from MCF-7/AZ.Pcad cells (with and without sP-cad
depletion) and with conditioned medium from BT-20 cells (with
and without P-cadherin knockdown). Student’s t-test was per-
formed and the statistically different values are indicated (*Po0.05
and **Po0.01 compared to control conditioned medium). (c) To
understand whether the invasion effect induced by sP-cad was due
to homotypic interactions with endogenous P-cadherin on the
surface of the cells, we calculated the invasion rates of BT-20 with
P-cadherin knockdown, exposed to conditioned medium from BT-
20 control cells (rich in sP-cad) or rich in hrP-cad. We observed a
rescue in the invasion capacity of these cells.
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expressing cells, we conclude that indeed P-cadherin
induces the secretion of factors that facilitate cell
invasion of non-invasive MCF-7/AZ cells that we
identified as being active forms of MMP-1 and
MMP-2. More importantly, we showed that these enzymes
are responsible by the shedding of a soluble extracellular
fragment of P-cadherin harbouring pro-invasive activ-
ity, as its depletion from the conditioned medium of
P-cadherin-overexpressing cells re-establish the non-
invasive phenotype of E-cadherin breast cancer cells.
Our results are in accordance with several recent
studies, concerning the role of MMP-2, MMP-1 and
sP-cad in breast cancer. In vivo, MMP-2 is described as a
key enzyme for the degradation of the ECM and
facilitating tumour invasion and metastasis, being its
active form present in half of all human breast
carcinomas (Stetler-Stevenson et al., 1993; Remacle
et al., 1998). Not only MMP-2 has pro-invasive
activities, but also MMP-1 overexpression has been
shown in a variety of advanced carcinomas, being
associated with poor prognosis (Murray et al., 1998a, b;
Ito et al., 1999; Fujimoto et al., 2008; Okuyama et al.,
2008). High levels of MMP-1 expression have been
detected in human breast cancer cells with elevated
metastatic capacity towards the bone, providing evi-
dence for its role in cancer cell invasion and metastasis
(Kang et al., 2003; Okuyama et al., 2008). However, the
molecular mechanism by which P-cadherin expression
induces the secretion of these both enzymes to the
medium remains unsolved.
The mechanism of ectodomain cleavage of adhesion
proteins, mediated by MMPs, has been already well
described (Lochter et al., 1997; Herren et al., 1998; Noe
et al., 2001). MMP-3 and MMP-7 have a role in the
shedding of the extracellular domain of E-cadherin,
generating a soluble 80 kDa fragment (Noe et al., 2001).
Interestingly, the sE-cad fragment, when released,
inhibits E-cadherin functions in a paracrine way,
inducing cell invasion into collagen type I and inhibiting
E-cadherin-dependent cell–cell aggregation (Noe et al.,
2001). Very recently, Mannello et al. (2008) showed a
significant increased shedding of soluble fragments of P-
cadherin in nipple aspirate fluids from women with
breast cancer, when compared with healthy subjects or
with women with pre-cancer conditions. This suggests
its possible release through proteolytic processing in
cancer cells. Until nowadays, there are only few studies
showing the presence of sP-cad in biological human
fluids (such as milk (Soler et al., 2002) and sperm (De
Paul et al., 2005)), but no specific cellular effect has been
attributed to this fragment. Our results show, for the
first time, that sP-cad is produced by proteolytic
enzymes (MMP-1 and MMP-2) and is responsible for
the invasive capacity of breast cancer cells. Moreover,
this invasive effect induced by sP-cad is independent
from the endogenous expression of P-cadherin at the cell
membrane. Further research is needed to elucidate
which signalling pathways are activated by this pro-
invasive factor.
In conclusion, the results herein described contribute
to clarify the role of P-cadherin expression in breast
cancer, as they unravel the molecular mechanism and
the associated cellular effects mediated by this protein.
In breast cancer cells, P-cadherin expression gives an
advantage to cells to migrate and move, as well as the
possibility to secrete pro-invasive factors, such as MMPs
and sP-cad.
Materials and methods
Cell culture and transfection
Human cancer cell lines were obtained as described: MCF-7/
AZ (kindly given by Prof. Marc Mareel, Ghent University,
Belgium), T47D, MDA-MB-468 and BT-20 from American
Type Culture Collection (Manassas, VA, USA). Cell lines were
routinely maintained at 37 1C, 5% CO2, in the following media
(Invitrogen Ltd, Paisley, UK): 50% DMEM/50% HamF12
(MCF-7/AZ), DMEM (BT-20, T47D, MDA-MB-468). All the
media contained 10% heat-inactivated fetal bovine serum
(Greiner bio-one, Wemmel, Belgium), 100 IU/ml penicillin and
100 mg/ml streptomycin. MCF-7/AZ cell line was retrovirally
stable transduced to encode P-cadherin (MCF-7/AZ.Pcad cell
line), as described earlier (Paredes et al., 2004). MCF-7/
AZ.Mock cell line, encoding only EGFP, was used as a
control. BT-20 transient transfection with siRNA specific for
P-cadherin (50 nM, Hs_CDH3_6, GW Validated siRNA,
Qiagen, Cambridge, MA, USA) was carried out using
Lipofectamine 2000 (Invitrogen), according to the manufac-
turer’s procedures. A negative control, with no homology to
any gene, was also used (Qiagen).
For the conditioned medium assays, cells were grown until
confluence in collagen-type I-coated flasks (0.2mg/ml—Sigma,
Steinheim, Germany) and incubated in serum-free medium for
48 h. The conditioned medium was filtered and the proteins
secreted were quantified in the recovered supernatant.
Antibodies and chemicals
Primary antibodies. P-cadherin (Western blot: clone 56, BD
Biosciences, Lexington, KY, USA; immunofluorescence: Cell
Signalling tecnhology, Boston, MA, USA; P-Cadherin-block-
ing-function antibody: clone NCC-CAD-299, Zymed Labora-
tories, San Francisco, CA, USA), E-cadherin (clone HECD-1,
Takara Bio Inc., Shiga, Japan), p120ctn (clone 98, BD
Biosciences), b-actin (I-19, Santa Cruz Biotechnologies, CA,
USA), MMP-1 and MMP-2 (Ab-6 and Ab-7 respectively,
Neomarkers, Fremont, CA, USA).
Chemicals. MMP inhibitor III (treatement with 10 nM or
100 nM, for 48 h, Calbiochem, EMD Chemicals, Darmstadt,
Germany); Recombinant human P-cadherin/Fc chimaera
(20 mg/ml; hrPcad, R&D Systems, Inc., Minneapolis, MN,
USA). For detailed description see Supplementary data.
Cancer cell motility and wound-healing assay
For the motility assay, cells were monitored with an inverted
time-lapse controller (Leica FW 4000, DMIRE 2, Pecon,
Leica, Bensheim, Germany) and distance moved by the cells
was determined, as well as cell speed (mm/h).
For the wound-healing migration assay, wounds were made
across the cell monolayer and distances between the wound
edges were determined. Cells were also treated with NCC-
CAD-299 (100mg/ml) or control mouse immunoglobulin G
(IgG; 100mg/ml, Upstate, Millipore, Billerica, MA, USA).
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BrdU proliferation assay was performed to exclude that
difference in cell migration was due to cell proliferation. For
detailed description see Supplementary data.
Immunofluorescence and confocal microscopic analysis
Cells were plated on glass coverslips (Becton Dickinson
Labware, Franklin Lakes, NJ, USA), fixed with 4% for-
maldehyde. For protocol details see Supplementary data.
Gelatin and b-casein zymography
The conditioned medium was analysed for proteinases activity
using gelatin and b-casein zymography (gels loaded with 12
and 100 mg of protein, respectively) as described earlier
(Oliveira et al., 2003). Quantification of band density was
done using the Quantity One software (version 4.0, Bio-Rad,
Hercules, CA, USA), unless specified.
Immunodepletion and western blot
For sP-cad immunodepletion, 300ml of conditioned medium
collected from MCF-7/AZ.Pcad cells was incubated with
NCC-CAD-299 and immunoprecipitated twice. Western Blot
was performed as described earlier (Paredes et al., 2007).
The experiments selected to show are representative ones. For
more detailed description on immunoprecipitation and western
Blot see Supplementary data.
Matrigel invasion assay
Matrigel invasion assay was performed according to manu-
facter’s instrutions (BD Biosciences). For more detailed
description see Supplementary data.
Statistical analysis
Data are expressed as mean values of at least three
independent experiments±s.d. Student’s t-tests were used to
determine statistically significant differences (Po0.05).
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ICI 182,780 induces P-cadherin overexpression in
breast cancer cells through chromatin remodelling
at the promoter level: a role for C/EBPb in CDH3
gene activation
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CDH3/P-cadherin is a classical cadherin. Overexpression of which has been associated with proliferative
lesions of high histological grade, decreased cell polarity and poor survival of patients with breast cancer.
In vitro studies showed that it can be up-regulated by ICI 182,780, suggesting that the lack of ERa signalling
is responsible for the aberrant P-cadherin overexpression and for its role in inducing breast cancer cell inva-
sion and migration. However, the mechanism by which ER-signalling inhibition leads to P-cadherin
expression is still unknown. The aim of this study was to explore the molecular mechanism linking the
ERa-signalling and P-cadherin-regulated expression in breast cancer cell lines. This study showed that ICI
182,780 is able to increase CDH3 promoter activity, inducing high levels of the active chromatin mark H3
lysine 4 dimethylation. We also observed, for the first time, that the transcription factor C/EBPb is able to
up-regulate CDH3 promoter activity in breast cancer cells. Moreover, we showed that the expression of P-
cadherin and C/EBPb are highly associated in human breast carcinomas and linked with a worse prognosis
of breast cancer patients. This study demonstrates the existence of an epigenetic regulation by which ICI
182,780 up-regulates P-cadherin expression in MCF-7/AZ breast cancer cells through chromatin remodelling
at CDH3 promoter, bringing forward the growing evidence that ERa signalling-abrogation by anti-oestrogens
is able to induce the expression of ERa-repressed genes which, in the appropriate cell biology context, may
contribute to a breast cancer cell invasion phenotype.
CDH3 GenBank accession no. NT_010498.
INTRODUCTION
Classical cadherins, such as E-, N-, and P-cadherin, are
the major structural components of the adherens junctions
in many tissues (1). This superfamilly of transmembrane
glycoproteins is responsible for calcium-dependent cell–cell
adhesion, mediating specific homophilic protein interactions
through their extracellular domain and being intracellularly
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linked to the actin cytoskeleton (2). Previous studies showed
the involvement of classical cadherins in many biological
processes, such as cell recognition, cell signalling, morpho-
genesis and tumour development (1).
Among these, P-cadherin has extensively been studied by our
and other groups, where it has currently been recognized as an
important biomarker in breast cancer. In human breast carci-
nomas, which represent a heterogeneous group of tumours,
diverse in behaviour, outcome and response to therapy,
P-cadherin was found to be aberrantly expressed in 30–50% of
invasive ductal carcinomas of the breast, being strongly associ-
ated with proliferative lesions of high histological grade,
decreased cell polarity and poor survival of patients over short-
term follow-up (3–7). In addition, the expression of P-cadherin,
together with other well-described basal markers, such as cyto-
keratin (CK)5, constitutes one of the most useful adjunctive
markers to distinguish basal-like carcinomas of the breast (8).
At the in vitro level, our group demonstrated that P-cadherin
plays an important role in cell invasion induction through its
juxtamembrane domain (5), and that its overexpression
induces motility and migration in wild-type E-cadherin breast
cancer cell lines, through the secretion of pro-invasive
factors, such as matrix metalloproteinase (MMP)-1 and
MMP-2. These recent findings revealed the mechanism under-
lying this in vitro invasion behaviour induced by overexpres-
sion of P-cadherin and most likely associated with the poor
prognosis of breast tumours (9,10).
However, although P-cadherin-associated functions in
breast cancer have been extensively studied, the mechanisms
controlling P-cadherin overexpression are still unclear.
It is known that the expression of an inappropriate cadherin
can result from growth factors and hormones stimulation in the
tumour environment, as well as from changes in the promoter
regions of cadherin-encoding genes (11). In non-cancer
models, CDH3 promoter was shown to be genetically regu-
lated through direct binding of transcription factors, such as
p63 (12) and b-catenin (13).
In 2005, we have reported a significant association between
P-cadherin overexpression and the hypomethylation of a specific
region of CDH3 promoter, suggesting an important regulatory
role for CpG DNA methylation in the regulation of P-cadherin
expression in breast cancer. Interestingly, the study of normal
P-cadherin-negative epithelial/luminal cells revealed consistent
hypermethylation at this same promoter region (3). The epige-
netic regulation of CDH3/P-cadherin gene was recently demon-
strated in other cancer models, like pancreatic and colorectal
carcinomas, as well as in melanomas (14–17).
Indeed, one of our current aims is to find upstream regula-
tors and identify the epigenetic mechanisms that are involved
in P-cadherin overexpression in breast cancer cells. In this
study, we explored the link between ER-signalling and
P-cadherin-regulated expression in breast cancer cell lines,
since P-cadherin-positive tumours are essentially ER negative.
In fact, our group found that abnormal P-cadherin expression
results from a lack of ER-a signalling (5), since treatment of
breast cancer cells with the pure anti-oestrogen ICI 182,780
(ICI, Fulvestrant) induced a 2–3-fold increase of P-cadherin
protein and CDH3 mRNA levels in a time- and dose-
dependent manner, being this effect counteracted by
17b-oestradiol (E2) (18). Taken together, these previous
findings suggested that the lack of ER-a signalling was
responsible for the increase of P-cadherin, categorizing
CDH3 as an oestrogen-repressed gene. However, until now,
it remained to be determined whether the induction of the
CDH3 gene was due to an epigenetic effect of the anti-
oestrogens at CDH3 promoter level and/or if it would
require the prior induction of other genes/proteins.
Herein, we describe the epigenetic remodelling induced by
the anti-oestrogen ICI, which leads to higher levels of the
active chromatin mark H3 lysine 4 dimethylation
(H3K4me2) at CDH3 promoter sites. We demonstrated in
this study that when ER-positive breast cancer cells are
treated with ICI, specific transcription sites of the CDH3 pro-
moter become exposed to putative transcription regulators
that, if located nearby, can induce the inappropriate expression
of P-cadherin protein. Moreover, we observed, for the first
time, that expression of the transcription factor C/EBPb is
able to directly activate P-cadherin promoter and its transcrip-
tion in breast cancer cells. We further supported our in vitro
results, showing that the expression of P-cadherin and
C/EBPb are highly associated in human breast carcinomas
and linked with a worse prognosis of breast cancer patients.
RESULTS
ERa signalling pathway inhibition induces the
transcription and up-regulation of the pro-invasive
CDH3/P-cadherin in breast cancer cells
P-cadherin expression is tightly regulated by ERa-signalling
pathway in breast cancer cells (5). In MCF-7/AZ cells,
P-cadherin protein and mRNA expression levels were
up-regulated after the treatment with anti-oestrogen ICI and
down-regulated by oestradiol (Fig. 1A and B). However, until
now, the molecular mechanism leading to increased levels of
P-cadherin by ICI was never determined. In this study, we
tested whether the ICI-induced P-cadherin overexpression was
due to a molecular effect at the CDH3 promoter level, as a
consequence of ERa-signalling pathway deregulation.
To address if ERa-signalling pathway was able to regulate P-
cadherin expression levels through CDH3 promoter activation/
repression, a luciferase reporter gene assay was performed in
ERa-positive MCF-7/AZ breast cancer cells. The full-length
CDH3 gene promoter was cloned at pGL3-basic vector, as
well as PS2/TFF1 promoter, which is a well-known direct
oestrogen-responsive gene, here used as a positive control.
Cells were transiently transfected with the pGL3-basic empty
vector, CDH3 or PS2/TFF1 promoter vector, and treated with
E2 or with the anti-oestrogen ICI. As a negative control, cells
were treated with ethanol (drug vehicle). As expected, PS2/
TFF1 promoter was strongly activated by E2 and inhibited by
the pure anti-oestrogen in the hormonal-dependent MCF-7/
AZ breast cancer cells (Fig. 1C). Concerning P-cadherin, we
found that ICI significantly increased CDH3 promoter activity,
whereas E2 repressed it (Fig. 1C). These effects mediated by
ICI and E2 were detected at mRNA and protein level. Although
these differences were not as evident as the ones observed for
the positive control PS2/TFF1 gene, the results were statisti-
cally significant. pGL3–control (pLUC) containing a modified
coding region for firefly luciferase, optimized for monitoring
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transcriptional activity in transfected eukaryotic cells, was used
as positive luciferase assay control. As expected, pLUC–
control activity was high and similar in all the treatment con-
ditions. pGL3-basic empty vector did not show any activity
with or without treatments.
Similarly, breast cancer cells were transiently transfected
with ERa-siRNA, in order to test if the up-regulation of P-
cadherin expression could be indeed attributed to specific
ERa degradation, or if the ICI-mediated P-cadherin induction
could be due to a secondary effect not related to the ERa-
signalling pathway. As can be seen in Figure 2A and B, the
siRNA for ERa also induced an increased P-cadherin
expression at the mRNA and protein level. Overall, we
showed that the inhibition of ERa-signalling pathway, by ICI
or by ERa-siRNA, induces the transcription and up-regulation
of the pro-invasive CDH3/P-cadherin in breast cancer cells.
The anti-oestrogen ICI 182,780 up-regulated P-cadherin
expression is associated with high levels of the active
chromatin mark H3K4me2 at CDH3 promoter
regulatory regions
On the basis of the above-mentioned results, we also aimed to
understand the molecular mechanism by which ICI is able to
increase the transcription of P-cadherin gene.
Epigenetic mechanisms were already described as induced
by ICI (19), which most probably can affect CDH3 transcrip-
tion. In previous works, we showed that CDH3 promoter is
able to be regulated by methylation (3), but ICI did not
caused any significant change in the methylation pattern of
CDH3 promoter (data not shown). However, it was previously
described that pure anti-oestrogen ICI can induce gene
transcription through releasing HDACs and ERa from Sp1
sites in ERa-repressed genes (19). Varshochi et al. (19)
demonstrated that, in the presence of ICI, ERa and HDACs
are dissociated from Sp1, resulting in an increased histone
acetylation and de-repression of the p21Waf1 promoter and
expression induction. However, for CDH3gene, which promo-
ter is enriched in Sp1 and ERa binding sites, ICI-induced
histone acetylation changes were never studied.
In order to access whetherCDH3 promoter is prone to be regu-
lated by acetylation mechanisms, cells transfected with the full-
length CDH3 gene promoter were treated with increased doses
of Trichostatin A (TSA), a known histone deacetylase (HDAC)
inhibitor. The CDH3 promoter transfected into MCF-7/AZ
breast cancer cells showed a significant dose-dependent acti-
vation after treatment with 0.05 mM TSA and with 0.1 mM TSA
for 12 h, compared with the activation from the cells treated
only with the vehicle [dimethyl sulfoxide (DMSO) (Fig. 3A)].
The increase in CDH3 promoter activation is also reflected at P-
cadherin protein levels (Fig. 3B), indicating thatCDH3 promoter
is sensitive to chromatin alterations and that these alterations
affect P-cadherin expression. No alterations in ERa expression
levels were observed after TSA treatment.
In order to address which type of chromatin modifications
could be induced by ICI in CDH3 promoter potentially
Figure 1. Regulation of P-cadherin expression by the anti-oestrogen ICI 182,780 in MCF-7/AZ breast cancer cells. MCF-7/AZ cells were treated with the indi-
cated concentrations of ICI or 17b-estradiol (E2) for 24 h. (A) ERa protein levels of MCF-7/AZ cells treated with E2 or ICI were both decreased, whereas the
P-cadherin protein expression was 3.8-fold increased after ICI treatment, relative to the ethanol control treatment. In contrast, P-cadherin expression was reduced
in !55% when cells were treated with E2. Immunostaining for anti-b-actin was done to control for equal loading. (B) mRNA levels of cells treated with E2 or
ICI showed no alteration concerning ERa expression, but a marked increased in P-cadherin levels is showed after treatment with ICI. A slight reduction of
!25% in P-cadherin expression is observed after treatment with E2. GAPDH housekeeping gene amplification was used as a control. (C) Luciferase reporter
assay quantification was done using relative light units—RLU (relative to renilla). ICI significantly induced CDH3 gene promoter activity when cells were
treated with the pure anti-oestrogen (∗P , 0.001), while E2 slightly induced down-regulation of the promoter activity. Oestrogen-responsive PS2/TFF1 gene
promoter vector showed the efficiency and activity of both treatments, namely been activated in the presence of E2 and highly repressed by the presence of
ICI. As a negative control, the pGL3-empty vector showed no activity with any of the treatments.
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leading to increased mRNA and protein overexpression, chro-
matin immunoprecipitation (ChIP) assays were performed
using specific antibodies to identify conventional histone-
activating (H3K4me2, H3K9ac and H3ac) or repressive
marks (H3K27me3 and H4K20me3) within the CDH3 gene
promoter region. We studied two different DNA promoter
regions (a distal Region 1 and a proximal Region 2) that
were selected according to CpG islands enrichment and to
the attributed DNA hypersensitive (DHS) sites within the
CDH3 gene promoter sequence. On the basis of the already
described effect of ICI in ERa-repressed genes, predicted
ERa and Sp1-binding sites were also considered to select
these studied promoter regions (Fig. 4A). No significant altera-
tions in the levels of activating or repressive histones marks
were detected at CDH3 Promoter Region 1 after treatment
with ICI (Fig. 4B). However, anti-oestrogen ICI-treatment
induced a strong enrichment in H3K4me2 levels, a mark for
transcription activation at the proximal CDH3 promoter
Region 2, while neither active H3K9ac and H3ac or repressive
H3K27me3 and H4K20me3 marks showed alterations
(Fig. 4C).
Altogether, it is suggested that the proximal CDH3
Promoter Region 2, which is closer to the transcriptional
start site (TSS) and ATG, is prone to epigenetic regulation
under ICI-treatment, in order to become transcriptionally
active.
The C/EBPb transcription factor activates CDH3
promoter in breast cancer cells
H3K4me2 is an epigenetic mark which is frequently enriched
at regions surrounding known TSSs (20,21). Therefore, we
decided to analyse which transcription factors were better rep-
resented within a sequence region flanking 250 bp up- and
downstream the CDH3 Promoter Region 2, overlapping with
the first nucleotides of the TSS. Combining data from three
transcription factors bioinformatic tools (Genomatix,
TFSearch and TESS), the transcription factor CCAAT/
enhancer-binding protein (C/EBPb) was predominantly
present at this studied region, being this frequency validated
by at least two of the three predictive software resources.
Accordingly, five putative C/EBPb-binding sites were found
around and comprising the CDH3 Promoter Region 2
(Fig. 5A), turning this transcription factor as a putative candi-
date for playing a novel regulatory role on CDH3 promoter
activation in breast cancer cells.
C/EBPb is a well-known transcription factor and a key reg-
ulator of epithelial cell growth, proliferation and differen-
tiation of the mammary gland (22,23). C/EBPb is expressed
in several distinct protein isoforms [liver-enriched transcrip-
tional activating protein (LAP1, LAP2) and liver-enriched
transcriptional inhibitory protein (LIP)] that harbour particular
regulatory functions (24–26). On the basis of this knowledge,
Figure 2. Regulation of P-cadherin expression by the siRNA for ERa in MCF-7/AZ breast cancer cells. (A) Real-time PCR showed that cells transfected with
siRNA for ERa show a significant increase in P-cadherin expression at the mRNA level. P-cadherin high expressing breast cancer cells BT-20 were used as
detection sensitivity control for P-cadherin probe, when P-cadherin is inhibited with a specific siRNA (∗P , 0.005). (B) At the protein level, the up-regulation
of P-cadherin was observed when cells were transfected with an ERa siRNA concentration of 100 nM. The knock-down of ERa expression was observed at both
ERa siRNA concentrations of 50 and 100 nM.
Figure 3. Regulation of CDH3 promoter and P-cadherin expression by epigenetic activating mechanisms. (A) MCF-7/AZ cells transiently transfected with
CDH3 promoter vector were treated with sequential concentrations of TSA during 12 h. An increase of promoter activation was observed when cells were
treated with gradual of TSA concentrations (∗P, 0.0001). (B) The western blot also showed a gradual increased of P-cadherin protein levels without alteration
of ERa protein levels.
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we decided to test the relevance of these different C/EBPb iso-
forms in CDH3 promoter activation, as well as their relevance
in CDH3 expression at mRNA level.
By luciferase gene reporter assay, using the cloned CDH3
promoter, different C/EBPb cDNAs vectors, codifying for a
particular C/EBPb isoform (LAP1, LAP2, or LIP) were inde-
pendently co-transfected in a cDNA amount titration basis
(5, 10 and 20 ng of cDNA) into MCF-7/AZ cells. Luciferase
readouts revealed that CDH3 promoter was gradually activated
by the three isoforms, although the promoter activation induced
by the C/EBPb-LIP isoforms was significantly greater com-
pared with the activation induced by LAP1 and LAP2. CDH3
promoter activation observed with the lowest co-transfected
amount of C/EBPb-LIP (5 ng) was higher when compared
with the highest amount of LAP1 and LAP2 isoforms (20 ng)
co-transfected into MCF-7/AZ cells. Most importantly, promo-
ter activation was raised when titration was done using higher
amounts of C/EBPb-LIP isoform (Fig. 5B). This result shows
that among the three C/EBPb isoforms with known regulatory
functions in breast cancer, in vitro, the LIP isoform is the
most important in CDH3 promoter activation.
In order to test this hypothesis, MCF-7/AZ cells were
co-transfected with CDH3 promoter and with C/EBPb-LIP
vector isoform and treated with ICI/control ethanol (EtOH)
and luciferase activity was measured. This same experiment
was repeated in order to evaluate CDH3 mRNA expression
levels by real-time PCR. The luciferase reporter assay
showed that further than the demonstrated activation of
CDH3 promoter by C/EBPb-LIP isoform, the treatment with
ICI provoked a significant synergistic effect towards the acti-
vation of CDH3 promoter (Fig. 5C). The same trend was also
observed at the mRNA levels, although not statistically signifi-
cant (Fig. 5D). In order to see if the induction of P-cadherin
expression by ICI would coincide with C/EBPb nuclear
accumulation, immunofluorescence for this transcription
factor was performed. Interestingly, we could observe that
C/EBPb is highly expressed at the nuclei of MCF-7/AZ
breast cancer cells, independently if these are treated with
ICI or EtOH (Fig. 5E).
All these results allowed us to conclude that ICI is able to
actively remodel the chromatin at CDH3 promoter, which
permit to expose the C/EBPb-binding sites. Since C/EBPb
is available in the nuclei of these cells, it will promote
P-cadherin transcription and consequent expression.
C/EBPb is associated with P-cadherin expression and with
features of poor prognosis in human breast carcinomas
Similar to what we have previously described for P-cadherin
expression, high levels of C/EBPb have also been associated
with tumour progression and as an indicative of an unfavour-
able prognosis in breast cancer. Most importantly, for the
shorter isoform LIP, correlations with ER-negative and
poorly differentiated phenotype were previously demonstrated
(27,28). Taking into account these results and our in vitro data,
we decided to perform an immunohistochemical characteriz-
ation of C/EBPb expression in a series of 249 invasive
primary breast carcinomas previously characterized for
P-cadherin expression profile.
From the total 249 cases, only the ones with clear nuclear
expression of C/EBPb were selected for immunohistochemis-
try classification. Strong immunoexpression of C/EBPb is
observed in the nuclei of luminal epithelial cells from adjacent
normal ducts, as showed in Figure 6A. In parallel with what is
found for P-cadherin expression in normal epithelial gland
(Fig. 6A), C/EBPb is also expressed in the vast majority of
Figure 4. Chromatin immunoprecipitation (ChIP) analysis of histone modifications at CDH3 promoter after treatment with the pure anti-oestrogen ICI. (A) Rep-
resentation of the CDH3 promoter structure showing epigenetic regulatory regions (CpG islands and DHS—DNAase hypersensitive sites) and putative ERa/Sp1
sites, predicted by bioinformatic tools (Genomatix, TESS and TFSearch). Transcription start site (TSS) and the analysed distal CDH3 Promoter Region 1 and
proximal CDH3 Promoter Region 2 are also illustrated. (B) and (C) ICI-mediated induction of histone activating (H3K4me2, H3K9ac and H3ac) and repressive
(H3K27me3 and H4K20me3) marks in CDH3 Promoter Region 1 and 2, respectively. In promoter Region 1, weak pronounced chromatin alterations were
detected after treatment with ICI. In contrast, significant levels of enrichment for H3K4me2 were observed in promoter Region 2, induced by the anti-oestrogen
treatment (C).
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the myoepithelial/basal cells. In positive tumour samples,
C/EBPb expression was restricted to the nuclei of malignant
cells, while P-cadherin presented its typical membranous
staining (Fig. 6B). C/EBPb was positive (.10% of positive
cells) in the nuclei of 43% (86 of 198) of the invasive carci-
nomas, whereas P-cadherin was present in 33% (64 of 194).
Importantly, C/EBPb was significantly associated with
P-cadherin expression (P ¼ 0.004), with nearly 60% of
co-expression of these two proteins (Table 1). When we
compared the expression of C/EBPb with the molecular
subtype, we found that while 60% of C/EBPb-negative
cases were comprised in the luminal A subtype, basal-like
subtype carcinomas expressed C/EBPb in !74% of the
cases (Table 1). On the basis of these results, we showed
that the expression of C/EBPb strongly associates with aggres-
sive behaviour features as high proliferation rates, poor
differentiation and basal-like phenotype. Furthermore, the
expression of C/EBPb was associated with high histological
Figure 5. Activation of CDH3 promoter and P-cadherin mRNA levels by the transcription factor C/EBPb in MCF-7/AZ cells. (A) Proximal CDH3 promoter
region showing five C/EBPb-binding sites with their predicted sequences based on transcription factors bioinformatic tools. The DNA sequence inside the black
area represents the concordant sequence that was validated by at least two of the three bioinformatic tools used (high score), whereas the grey sequence area
results from the prediction of a single web tool out of the three used (low score). There is one putative C/EBPb-binding site at the CDH3 TSS region and another
two inside the studied promoter region 2. Two high-scored C/EBPb-binding sites are also localized immediately before the limits of the established proximal
CDH3 promoter region. (B) CDH3 luciferase reporter assay where MCF-7/AZ cell were transfected with different amounts (5, 10 and 20 ng) of C/EBPb cDNA
isoforms (LAP1, LAP2 and LIP). Comparative with the pLENTI empty vector, the C/EBPb–LIP isoform significantly activates the CDH3 promoter in a dose-
dependent manner (∗P , 0.001). (C) CDH3 promoter activation by the C/EBPb–LIP isoform in response to ICI treatment in MCF-7/AZ cells, where the anti-
oestrogen induced a synergistic effect with C/EBPb–LIP towards the activation of CDH3 promoter (∗P , 0,001). (D) Real-time PCR analysis of P-cadherin
mRNA expression levels after ICI treatment. P-cadherin mRNA was up-regulated not only by the transfection of C/EBPb–LIP isoform, but also by an ICI-
mediated synergistic effect. (E) MCF-7/AZ cells show nuclear expression of C/EBPb (Alexa 488—green), treated with ethanol or ICI. The DAPI staining
(blue) confirms the nuclei localization of C/EBPb (see the merge image). All the figures show a ×630 magnification. The white line in each picture represents
a 20 mm scale.
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grade (P ¼ 0.002), but no association was found with tumour
size or regional lymph node involvement. We also found a
strong association of C/EBPb with breast cancer markers of
aggressive phenotype, namely CK14 (P ¼ 0.015), vimentin
(P ¼ 0.001), high proliferative index-MIB-1 (P , 0.0001)
and EGFR (P ¼ 0.002), where 90% of the cases that expressed
EGFR were also positive for C/EBPb. Figure 6B shows an
example of a high-grade invasive carcinoma, which was con-
comitantly positive for P-cadherin, C/EBPb, vimentin, EGFR
and MIB-1 expression.
In summary, we demonstrated, for the first time, an associ-
ation of the expression of this transcription factor with the
expression of P-cadherin, a pro-invasive and migration
inducer protein, which also constitutes an important marker
of poor prognosis and aggressive basal-like phenotype in
breast carcinomas.
DISCUSSION
Over the last years, we and others have been describing the
association of P-cadherin expression with malignant behaviour,
poor prognosis and short survival in breast cancer (3,6,7,29,30).
Recent findings have contributed to the elucidation of P-cadherin
function in breast tumour cell biology (10), but the expression
regulation of this protein in breast cancer has poorly been
explored. Previously, we reported a significant association
betweenP-cadherinoverexpressionandCDH3hypomethylation,
suggesting an important regulatory role of epigenetic events in
the regulation of P-cadherin expression in breast cancer (3).
Moreover, we demonstrated that the abrogation of ERa-
signalling pathway, caused by the pure anti-oestrogen ICI, was
responsible for the increase of P-cadherin protein and mRNA
expression, pointing CDH3 as an oestrogen-repressed gene (5).
However, the mechanisms by which epigenetic events and ERa-
signalling inhibition leads to P-cadherin expression and to
aggressive tumour behaviour are still unknown.
In the present study, we identified, for the first time, the
existence of an epigenetic regulation by which ICI
up-regulates P-cadherin expression in MCF-7/AZ breast
cancer cells through chromatin remodelling at CDH3 promo-
ter. After treatment of this ERa-positive breast cancer cell
line with the oestrogen antagonist ICI, an important
histone-activating mark (H3K4me2) was enriched at the prox-
imal region of the CDH3/P-cadherin promoter.
Previous studies showed that chromatin structural remodel-
ling and nuclear entropy can be induced by the treatment of
breast cells with anti-oestrogens such as ICI (31). In fact,
and although it was initially believed that anti-oestrogens
function merely by competing with endogenous oestrogens
for receptor binding, recent studies also demonstrated that
ICI and tamoxifen can induce distinct conformational
changes in ER, implying that the ligand-bound ER can
recruit specific co-regulators to modulate different gene pro-
moters, thereby regulating gene expression (32,33).
Figure 6. (A) Immunohistochemistry representation of the expression pattern of C/EBPb and P-cadherin in normal breast tissue. P-cadherin expression is
restricted to myoepithelial cell layer, whereas nuclear expression of C/EBPb is seen in myoepithelial cells of a normal breast duct and in scattered normal
luminal cells (magnification ×400). (B) An immunohistochemical panel of a grade III invasive breast carcinoma (Haematoxylin–eosin staining), showing posi-
tive membrane expression for P-cadherin and EGFR, membranar/cytoplasmic expression for vimentin and nuclear expression for C/EBPb and MIB-1 (magni-
fication ×200).
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A study in 2005 showed that ICI can induce transcription of
the ERa-repressed gene p21Waf1, through the dissociation of
HDACs and ERa from Sp1 sites and therefore, resulting in
increased histone acetylation and de-repression of the
p21Waf1 promoter (19). In fact, the authors not only found
that the proximal Sp1 sites are crucial in mediating the promo-
ter’s response to ICI, but also that HDAC inhibition by TSA
leads to p21Waf1 promoter activity (19). Further than the fact
that most of the proximal promoter regions are generally
important to gene transcription regulation, the studied CDH3
proximal Region 2, which showed an ICI-induced enrichment
for the active histone mark H3K4me2, additionally displays a
CpG island and a DNaseI hypersensitive site (DHS) region,
overlapping with the TSS. As described by the ENCODE
Project Consortium, the aggregate signal of histone modifi-
cations is mainly attributable to active TSS region, in particu-
lar those near CpG islands and DHS, both genomic regions
thought to be enriched for regulatory information (34). Impor-
tantly, after a prediction analysis of the proximal CDH3 pro-
moter, comprising a region from the TSS to the ATG, we
observed that this promoter area was remarkably enriched in
Sp1 sites, having also a significant number of ERa coupled
with those (Fig. 4A). Hence, if a repression complex, mediated
by ERa and HDACs at Sp1 sites, is able to be released by the
treatment with ICI and therefore enhancing the gene transcrip-
tion, the characteristics of the proximal CDH3 promoter,
together with the H3K4me2 enrichment in Region 2, strongly
suggest that this chromatin de-repression mechanism plays an
important role in the ICI-induced promoter transcriptional
activation. Reinforcing this, we also observed an up-regulation
of CDH3 promoter activity and P-cadherin protein expression
in cells treated with TSA, showing that chromatin-activating
modifications are indeed important to the modulation of this
gene.
The most prominent activating mark found within the
CDH3 promoter Region 2 was H3K4me2, which is the
histone modification better correlated with DHS regions and
chromatin accessibility (20,21,34), as well as with active
gene transcription (35).
Herein, we further investigated which transcription factors
were strongly represented within CDH3 promoter Region 2,
TSS and DHS region. We have found that putative C/EBPb-
binding sites were predominantly present within this region.
Furthermore, we tested the ability of C/EBPb to transactivate
P-cadherin protein andmRNA expression, as well asCDH3 pro-
moter, demonstrating, for the first time, that, among the three
different C/EBPb isoforms, C/EBPb-LIP was the most relevant
in a P-cadherin expression activation setting. C/EBPb proteins
are transcription factors which regulate cellular proliferation,
differentiation and apoptosis in mammary gland (24).
However, like P-cadherin, C/EBPb is not mutated in breast
tumours, but its overexpression has widely been described in a
subset of aggressive breast cancer (25). Interestingly, transgenic
and overexpression studies showed that C/EBPb–LIP induces
proliferation in mammary epithelial cells and that a C/EBPb–
LIP-initiated growth cascademay play a role in the development
of breast cancer (24,26). At a clinicopathological level, LIP
isoform correlateswith an ER-negative breast cancer phenotype,
high proliferative index and histological grade, aneuploidy and
poor differentiation. These findings are not only suggestive of
the involvement of C/EBPb–LIP in tumour progression and
indicative of an unfavourable patient prognosis (27), but also
show that its expression should be evaluated as a prognostic
marker for breast cancer patients (28). Remarkably, breast carci-
nomas expressing C/EBPb–LIP displays the unfavourable clin-
icopathological features described for the aggressive breast
tumours overexpressing P-cadherin. Additionally, we also
observed an association of C/EBPb with aggressive markers,
namely EGFR, CK14 and vimentin expression, as well with
basal-like molecular phenotype. Thus, based in our results, it
is tempting to consider that, under conditions of ICI-mediated
increased chromatin accessibility, C/EBPb, and most likely
the LIP isoform, can play a role in the activation of CDH3 pro-
moter towards a typical P-cadherin-related aggressive tumour
phenotype.
Our results are also of clinical relevance since there is
growing evidence that selective ER modulators, such as
Table 1. Association of C/EBPb expression with clinicopathological features
and immunohistochemical markers in invasive breast carcinomas
Variables No. C/EBPb negative
(%)
C/EBPb positive
(%)
P-value
Tumour size 187
,15 mm 16 11 (68.7) 5 (31.3) 0.288
≥15 mm 171 94 (55.0) 77 (45.0)
LNI 180
Present 91 55 (60.4) 36 (39.6) 0.138
Absent 89 44 (49.4) 45 (50.6)
Tumour grade 198
GI 42 31 (73.8) 11 (26.2) 0.002
GII 90 54 (60.0) 36 (40.0)
GIII 66 27 (40.9) 39 (59.1)
NPI 169
NPI, 3.4 38 26 (68.4) 12 (31.6) 0.067
3.4 ≤ NPI ≤ 5.4 85 39 (45.9) 46 (54.1)
NPI. 5.4 46 25 (54.3) 21 (45.6)
EGFR 197
Positive 10 1 (10.0) 9 (90.0) 0.002
Negative 187 111 (59.4) 76 (40.6)
P-Cadherin 194
Positive 64 27 (42.2) 37 (57.8) 0.004
Negative 130 83 (63.8) 47 (36.2)
CK5 198
Positive 41 22 (53.7) 19 (46.3) 0.673
Negative 157 90 (57.3) 67 (42.7)
CK14 193
Positive 10 2 (20.0) 8 (80.0) 0.015
Negative 183 107 (58.5) 76 (41.5)
Vimentin 178
Positive 25 7 (28.0) 18 (72.0) 0.001
Negative 153 95 (62.0) 58 (38.0)
MIB-1 197
,10 94 70 (74.5) 24 (25.5) ,0.0001
10–20 20 9 (45.0) 11 (55.0)
.20 83 33 (39.8) 50 (60.2)
Subtype 178
Luminal 122 74 (60.7) 48 (39.3) 0.001
HER-2 22 14 (63.7) 8 (36.3)
Basal 34 9 (26.5) 25 (73.5)
Data presented as n (%) unless stated otherwise.
C/EBPb, CCAAT/enhancer-binding protein beta; LNI, lymph node
involvement; NPI, Nottingham prognostic index; EGFR, epidermal growth
receptor; P-cadherin, placental cadherin; CK, cytokeratin; MIB-1, mindbomb
homolog 1; HER-2, human epidermal growth factor receptor 2.
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tamoxifen or ICI (Fulvestrant), are able to induce expression
of genes which, in the appropriate cell context, may contribute
to adverse cell phenotype, in part by inducing breast cancer
cell invasion (36). Although anti-oestrogens have been the
mainstay of therapy in patients with ERa-positive breast
cancer and have provided significant improvements in survi-
val, their benefits are limited by tumour recurrence in a signifi-
cant proportion of initially drug-responsive breast cancer
patients due to acquired anti-oestrogen resistance (36). There-
fore, it is tempting to assume that one of the important mech-
anisms by which this endocrine resistance occur should be the
inappropriate activation of ER-repressed genes at late stages of
long-course endocrine therapeutic regimens.
To date, mechanistic studies have revealed important roles
for growth factor signalling pathways, such as those regulated
EGFR and HER2, as contributors to endocrine resistance (37–
39). Similarly, in ER-positive breast cancer cells, tamoxifen
has been reported to increase the expression of poor prognosis
markers in breast cancer patients [14-3-3s (40)], as well as of
signalling elements frequently linked to tumour migration and
invasion (MAPK, FAK and Src) (41,42).
The present study highlights that, in ERa-positive breast
cancer cells, the anti-oestrogen ICI is able to induce the
expression of CDH3 gene, leading to P-cadherin overexpres-
sion, which is described as a pro-invasive protein in breast
cancer. These data, together with other studies, contribute to
clarify the ability of selective ER modulators and steroidal
anti-oestrogens, like fulvestrant, to induce expression of
genes normally repressed by oestrogen/ER signalling, and
thus, playing an important role in the capacity of breast
cancer cells to evade their growth inhibitory effects (37,43).
It is important to know which signalling pathways are acti-
vated in anti-oestrogen resistant breast cancer, in order to
find new and effective therapeutic targets to use in this
setting. In the future, it would be interesting to study if P-
cadherin can be a good biomarker in this group of breast
tumour recurrences that occur upon endocrine therapy.
MATERIALS AND METHODS
Antibodies and chemicals
The following primary anti-human antibodies were used for
western blot (WB), immunohistochemistry (IHC) and immu-
nofluorescence (IF) against: P-cadherin [mouse monoclonal,
clone 56; BD Transduction Biosciences, Lexington, KY,
USA; dilutions: 1:250 (WB) and 1:50 (IHC)], C/EBPb
[mouse monoclonal, clone H7, Santa Cruz Biotechnologies,
CA, USA; dilutions: 1:500 (WB) and 1:100 (IHC, IF)],
b-actin [goat monoclonal, I-19; Santa Cruz Biotechnologies;
dilutions: 1:1000 (WB)], ERa [mouse monoclonal,
NCL-L-ER-6F11; Novocastra, Newcastle; dilutions: 1:50
(WB) and 1:200 (IHC)]. Anti-mouse and anti-goat horseradish
peroxidase-conjugated secondary antibodies were also used
for WB [HRP-conjungated, Santa Cruz Biotechnologies;
dilutions: 1:2000]. For chromatin immnunoprecipitation
(ChIP) assays, the following antibodies were used:
anti-acetyl-H3K9 antibody (07–352; Upstate Biotechnology,
Lake Placid, NY, USA), anti-acetyl-H3 antibody (17–615;
Upstate), anti-dimethyl-H3K4 antibody (07–030; Upstate),
anti-trimethyl-H3K27 antibody (07–449; Upstate), anti-
trimethyl-H4K20 antibody (ab9053; Abcam plc, Cambridge,
UK) and rabbit anti-mouse-IgG antiserum (M7023; Sigma-
Aldrich, Bornem, Germany).
ICI 182,780 Imperial Chemical Industries (ICI),
17b-oestradiol (E2) and Trichostatin A (TSA) were all pur-
chased from Sigma. ICI and E2 were dissolved in 100%
ethanol (EtOH) while TSA was dissolved in DMSO.
Cell culture, transfection and treatment conditions
The human breast cancer cell line MCF7/AZ was kindly given
by Prof. Marc Mareel (Laboratory of Experimental Cancerol-
ogy, Ghent University, Belgium), whereas BT-20 breast
cancer cell line was purchased from American Type Culture
Collection—ATCC (Manassas, VA, USA). Cell lines were
cultured in growth media consisting of Dulbecco’s modified
Eagle’s medium [DMEM (Invitrogen Ltd, Paisley, UK)], sup-
plemented with 10% heat inactivated fetal bovine serum (Invi-
trogen), 100 IU/mL penicillin and 100 mg/ml of streptomycin
(Invitrogen), at 378C. MCF/AZ cells were grown at 10% CO2
and BT-20 cells at 5% CO2 controlled atmosphere.
For transient transfections, reagents were used as described
subsequently. For gene reporter assays, MCF-7/AZ cells were
grown in 96-well plates to 60–70% confluence and transfec-
tion was achieved using the liposome-mediated FuGENE 6
transfection reagent (Roche Diagnostic GmbH, Mannheim,
Germany), prepared according to the manufacturer’s instruc-
tions. These transient transfections used a charge ratio
(FuGENE/DNA) of 3:1 where equal amounts (20 ng) of
CDH3 promoter vector, as well as from the expression
vector, were added together with 5 ng of pCMV-Renilla nor-
malization vector. For RNA or protein expression assays,
MCF-7/AZ cells were grown in 6-well plates to 70–80% con-
fluence. Transient transfections of 1 mg of C/EBPb expression
vector were done using Lipofectamine 2000 (Invitrogen),
using a ratio (Lipofectamine/DNA) of 3:1 prepared according
to the manufacture’s instruction.
Whenever not specified, cells treatments with ICI were
carried out for 24 h at a final concentration of 0.1 mM
(1027 M), while treatments with E2 were performed at a
final concentration of 0.01 mM (1028 M) for 24 h. In treatments
with TSA, cell measurements were done after 12 h of incu-
bation at the final concentration of 0.05 mM or 0.1 mM.
Promoter vectors and cDNA constructs
The human pLENTI-C/EBPb expression vectors
(C/EBPb-LAP1, C/EBPb-LAP2 and C/EBPb-LIP) were
kindly provided by Dr. Peter Gott (Institute of Anthropology
and Human Genetics, Tu¨bingen, Germany). To generate the
full-length CDH3-luciferase vector, a 2.1 kb 5′ untranslated
region of human CDH3 gene (GenBank accession no.
NT_010498) was generated by PCR, using a Pfu DNA Poly-
merase (MBI Fermentas, Burlington, Canada), the sense
primer (5′-TGCTAGGCCTGAGAGAGCAAG-3′) and anti-
sense primer (5′-CCTTCCGGGACTCCCTTG-3′). The PCR
product was subcloned into a TOPO Cloning TA vector (Invi-
trogen) and then transferred to a pGL3-luciferase reporter
plasmid (Promega, Corporation, Madison, WI, USA), after
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digestion of both recipient vector and PCR fragment with KpnI
and NcoI restriction enzymes (MBI Fermentas). Ligation was
performed using T4 ligase enzyme (New England Biolabs,
Ipswich, MA, USA), and a pGL3/CDH3-luciferase reporter
full-length vector (positions from 21834 to +1 ATG site),
framed with ATG/firefly luciferase cDNA from the
pGL3-luciferase reporter plasmid, was generated. Direct
sequencing (ABI, Perkin-Elmer, Foster City, CA, USA) was
performed to confirm the cloning frame and integrity of the
promoter.
CDH3-luciferase reporter gene assay
MCF-7/AZ cells were co-transfected with the human full-
length pGL3-CDH3/luc promoter vector and with
pCMV-Renilla luciferase construct (Promega), for normaliza-
tion of transfection efficiency. For promoter analysis, 24 h
after transfection, cells were washed twice in PBS-cold and
then harvested and lysed for firefly/Renilla luciferase assays
using the Luclite Reporter Gene Assay System (Perkin
Elmer, Beaconsfield, UK), according to the manufacturer’s
instructions. Luciferase bioluminescence from Renilla was
measured using native coelenteranzine substrate reagent
(Lux Biotechnology, Edinburgh, UK). Individual transfection
experiments were repeated at least three times and in quadru-
plicate per transfection condition. Empty pGL3-basic vector
(E1751) and pGL3-Control (pLUC) vector (E1741), both
from Promega, were included as controls in all CDH3-reporter
assays. Luminescence was then read using the Wallac/Perkin
Elmer-1450-028 Trilux Microbeta (Perkin Elmer) plate
reader, and the results are shown as mean of relative light
units (RLU).
Protein extraction and WB analysis
Protein lysates were prepared from cultured cells, using
catenin lysis buffer [1% (v/v) Triton X-100 and 1% (v/v)
NP-40 (Sigma) in deionized phosphate-buffered saline
(PBS)] supplemented with 1:7 proteases inhibitors cocktail
(Roche Diagnostics GmbH, Germany). Cells were washed
twice with PBS and were allowed to lyse in 500 ml of
catenin lysis buffer for 10 min, at 48C. Cell lysates were
mixed with a vortex for three times and centrifuged at
20 000g at 48C, during 10 min. Supernatants were collected
and protein concentration was determined using the Bradford
assay (BioRad Protein Assay kit). Proteins were dissolved in
sample buffer [Laemmli with 5% (v/v) 2-b-mercaptoethanol
and 5% (v/v) bromophenol blue] and boiled for 5 min at
958C. Samples were separated by SDS–PAGE, and proteins
were transferred into nitrocellulose membranes [Amersham
Hybond enhanced chemiluminescence (ECL)] at 130 V for
1 h. For immunostaining, membranes were blocked with 5%
(w/v) non-fat dry milk in PBS containing 0.5% (v/v)
Tween-20. These were subsequently incubated with primary
antibodies, during !1–2 h, followed by four 5 min washes
in PBS/Tween-20 (PBS-T). Then the membranes are incu-
bated with horseradish peroxidase-conjugated secondary anti-
bodies, during 45 min. Proteins were detected using ECL
reagent (Amersham), as a substrate, and blots were exposed
to an autoradiographic film. Quantification of WBs was per-
formed using Quantity One software (BioRad), and the ones
selected to show are representative experiments.
Immunofluorescence
Briefly, MCF-7/AZ cells were cultured on glass coverslips,
and fixed with cold methanol for 10 min on ice. After fixation,
cells were permeabilized with 1% Triton X-100 in PBS for
5 min, at room temperature. Non-specific binding was
blocked by cell treatment with PBS containing 3% BSA, for
30 min, at room temperature. Cells were then stained with
the primary antibody for C/EBPb (Santa Cruz), during 1 h,
at 1:100 dilution. After PBS washes, cells were incubated,
for 1 h, with the rabbit polyclonal secondary antibody, conju-
gated with Alexa 488 (Invitrogen), at 1:500 dilution. After a
wash with PBS, each sample was mounted with Vectashield
(Vector Laboratories, Inc., Burlingame, CA, USA) containing
4,6-diamidine-2-phenylindolendihydrochrolide (DAPI). The
C/EBPb and DAPI dual cell staining was observed with a
Zeiss microscope (Imager Z1) with apotome, and images
were acquired using the Axiovision software.
ChIP assay
Exponentially growing MCF-7/AZ cells were treated with ICI
for 24 h and fixed with 1% formaldehyde (378C, 10 min). The
reaction was stopped with addition of glycine to a final con-
centration of 0.125 M. Whole-cell fixed lysed extracts were
prepared for use in ChIP assays as described previously
(44). Briefly, fragmented chromatin to an average size of
300–1000 bp was incubated (48C, 1 h) with 30 ml of
blocked protein-A-agarose beads (Sigma) on a rotating
wheel. Pre-cleared chromatin (150 mg) was immunoprecipi-
tated (48C, overnight) with 10 ml anti-acetyl-H3K9 antibody,
10 ml anti-acetyl-H3 antibody, 5 ml anti-dimethyl-H3K4
antibody, 5 ml anti-trimethyl-H3K27 antibody, 5 ml anti-
trimethyl-H4K20 antibody and 2 ml of a rabbit anti-
mouse-IgG antiserum as a negative control. After elution of
immune complexes, DNA was resuspended in 100 ml of TE
(10 mM Tris, 1 mM EDTA at pH 8.0) solution. Quantification
of precipitated DNA was performed using real-time qPCR
amplification carried out on a Chromo4 DNA engine
(Biorad), using SYBR green jumpstart PCR master mix
(Sigma) and 0.3 mM of the following primers: distal promoter
region 1, forward: 5′-CAGGTTAGCCCTGGAAGGTCAA-3′;
reverse: 5′-TGAGATGGAGTCTCACTGTCGTCC-3′; proxi-
mal promoter region 2, forward 5′-CTGTGAAATGGAAG
AAGCGGTC-3′, reverse 5′-GCTGGTCTTGAACTTCTGGA
CTC-3′. The amount of DNA precipitated by each antibody
was normalized against 1 in 10 of the starting input material.
Gene silencing with small interfering RNAs (siRNAs)
MCF-7/AZ and BT-20 cells in 2 ml of culture medium were
transfected with siRNA for ERa (50 nM and 100 nM
Hs_ESR1, GW Validated siRNA, Qiagen, Cambridge, MA,
USA) or for P-Cadherin (50 nM, Hs_CDH3_6, GW Validated
siRNA, Qiagen). Transfection was carried out at starvation
conditions for 6 h after which appropriated culture, medium
was added to the cells. After 48 h, the cells were harvested
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for RNA isolation or protein extraction for real-time PCR or
WB analysis.
RNA isolation and real-time PCR
RNA was isolated using a Qiagen RNAeasy extraction kit
(Qiagen), according to the protocol provided by the manufac-
turers and concentration was determined in a ND-1000 spec-
trometer (Nanodrop). One microgram of RNA per sample
was used to synthesize cDNA, using reverse-transcriptase
RT (Invitrogen). CDH3 TaqMan probe (HS00354998_m1,
Applied Biosystems, Foster City, CA, USA) was used to
specifically recognize CDH3 fragments, which were amplified
through 40 cycles (Applied Biosystems 7000). Relative CDH3
gene expression was determined by its normalization with
GAPDH expression, using a Human GAPDH endogenous
control (NM_002046.3, Applied Biosystems).
Patient selection
A series of 249 cases of primary operable invasive breast car-
cinomas were retrieved from the files of the Department of
Pathology, Hospital of Divino Espı´rito Santo, Azores, Portugal
and from the Federal University of Santa Catarina,
Floriano´polis-SC, Brazil. These samples were obtained from
patients with age ranging from 30 to 89 years old. All the
formalin-fixed paraffin-embedded histological sections were
reviewed by three pathologists (V.C., F.S. and F.M.) and the
diagnoses were confirmed as follows: 208 invasive ductal car-
cinomas, 7 invasive lobular carcinomas, 3 mixed, 3 tubular,
8 medullary and 20 invasive breast carcinomas of other
special histological types. These tumours have been fully
characterized for the clinical and pathological features,
namely tumour size, lymph nodes invasion, tumour grade,
Nottingham Prognostic Index (NPI) and for the following
breast cancer markers: ERa, PR, HER-2, EGFR, P-cadherin,
CK5, CK14, vimentin and MIB-1, as well as classified for
breast cancer subtype (4,7,8,45,46).
This study was conducted under the national regulative law
for the usage of human biological specimens, where the
samples are delinked from their donor’s identification and
are exclusively available for retrospective research purposes.
Immunohistochemistry analysis
IHC was performed in 3 mm formalin-fixed paraffin-
embedded sections. The IHC technique was performed using
an Envision Detection System (DAKO Cytomation Envision
System HRP, DAKO Corporation, Carpinteria, CA, USA) or
the classical streptavidin–avidin–biotin complex (SABC)
method according with the manufacturer’s instructions.
Expression of C/EBPb was analysed using a mouse mono-
clonal antibody. Sections were deparaffinised with xylene and
rehydrated in a series of decreasing concentrations of ethanol sol-
utions. Heat-induced epitope retrieval was carried out in 10 mM
citrate buffer (sodium citrate) (pH 6) (LabVision Corporation,
Fremont, CA, USA), in a 988C water bath, for 30 min. After
cooling retrieval solutions, for at least 30 min at room tempera-
ture, the slides were treated for 10 min with 3% H2O2 in metha-
nol, in order to block endogenous peroxidase. Slides were
incubated overnight at 48C with monoclonal antibody for C/
EBPb and then labelled with the Envision Detection System
from DAKO. Colour reaction product was developed with
3,3′-diaminobenzidine, tetrahydrochloride (DAB plus, DAKO
Glostrup, Denmark) as a substrate, and nuclear contrast was
achieved with haematoxylin/ammoniacal water counterstaining.
Formalin-fixed paraffin-embedded sections from normal breast
gland, skin or normal gastric mucosa were used as positive con-
trols. Also, negative controls were performed by replacing the
primary antibody with PBS/non-immune mouse serum.
Immunostained slides were reviewed by two pathologists
(F.M. and F.S.) and cases with .10% of nuclei-stained posi-
tive cells for C/EBPb were considered positive.
Statistical analysis
C/EBPb immunoexpression associations were analysed using
StatView, version 5.0 software (SAS Institute, Inc.). Continu-
ous variables were presented as mean+ standard deviation
(SD), and categorical variables were presented as number
(%). The clinicopathological features and immunohistochem-
ical markers of the tumours were compared across groups of
expression of C/EBPb using ANOVA and the chi-square
test, respectively, for continuous and categorical variables.
For luciferase reporter gene analysis, independent quadru-
plicate measurements per each analysed variable were per-
formed and RLU were compared between variables using
Student’s t-test. This same statistical method was also used
to assess the variations in RNA expression.
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Summary. Introduction: The most suitable immuno-
histochemical criterion to identify basal-like breast
carcinomas (BLBC), a molecular subgroup of breast
cancer associated with poor prognosis, is the triple
negative phenotype along with CK5 and/or EGFR
immunoreactivity. However, several putative basal
markers have been suggested as alternatives to identify
BLBC with more accuracy. Experimental Design: The
expression of CK5, EGFR, P-cadherin, CK14, Vimentin
and p63 were evaluated in 462 invasive breast
carcinomas to determine their sensitivity and specificity
for BLBC identification. Results: P-cadherin and CK5
showed higher sensitivity values, while EGFR, Vimentin
and CK14 were the most specific markers. The
combination of CK5 with P-cadherin, Vimentin or CK14
proved to be a reliable option for distinguishing the basal
phenotype, compared to the “gold standard” pair
CK5/EGFR. Furthermore, P-cadherin was still able to
recognize a large number of putative BLBC among the
“unclassified” group (ER-/PR-/HER2-/CK5-/EGFR-).
Conclusions: P-cadherin, Vimentin and CK14 can
recognize BLBC already identified in triple negative/
CK5 and/or EGFR+ tumors, and due to P-cadherin
sensitivity for BLBC identification this marker can
reliably recruit a large number of breast carcinomas with
basal phenotype among immunohistochemistry triple
negative/ CK5 and/or EGFR - pool of tumors. Although
they need GEP validation, our results can introduce the
idea of these markers as additional options in the daily
workup of breast pathology laboratories to identify
BLBC.
Key words: Basal-like breast cancer, P-cadherin, CK14,
Vimentin
Introduction
In the European Union, breast cancer is the most
incident form of cancer in women, with an estimated
429.900 cases diagnosed per year (28.9% of all incident
cases in women) (Ferlay et al., 2007; Milanezi et al.,
2008). Breast cancer is frequently designated as a
heterogeneous disease with divergent biological
behaviors. cDNA microarray studies have provided an
improvement in cellular and molecular understanding of
breast cancer, identifying distinct subtypes of breast
carcinomas with different molecular signatures and
clinical outcomes (Perou et al., 2000; Sorlie et al., 2001,
2003; Rakha et al., 2006a,b). The basal-like subtype has
definitely drawn the attention of the scientific
community. These tumors are characterized by a triple
negative (TN) phenotype, lacking the expression of
hormone receptors (HR) [estrogen and progesterone
receptors (ER and PR, respectively)] and HER2. Basal-
like breast carcinomas (BLBC) are associated with
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aggressive tumor behavior and shorter overall survival
when compared to the luminal and HER2-
overexpressing subtypes and there is an enthusiastic
search for molecular markers expressed in BLBC that
could be used as targets to therapy (Nielsen et al., 2004).
Histologically, they are poorly differentiated carcinomas,
present high nuclear and histological grade and
frequently show medullary and metaplastic features
(Tsuda et al., 2000; Fulford et al., 2006; Livasy et al.,
2006; Rakha et al., 2006a,b). A distinct pattern of
metastasis to brain and lungs, known to be associated
with poor prognosis, and less significant involvement of
axillary lymph nodes, has also been described in BLBC
(Tsuda et al., 2000; Banerjee et al., 2006; Fulford et al.,
2007). Nowadays, gene expression profiles (GEP) or
cDNA microarrays studies are currently considered the
“gold standard” methods for the identification of breast
carcinomas with basal phenotype, since these
technologies were the first to identify BLBC as a distinct
subgroup with a specific molecular signature (Perou et
al., 2000) and clinical identity (Sorlie et al., 2001, 2003;
van't Veer et al., 2002). However, GEP are expensive,
not easily applicable as a routine laboratory diagnostic
tool in large scale clinical-pathological analysis and have
limited value in retrospective studies using formalin-
fixed paraffin-embedded (FFPE) tissues (Cheang et al.,
2008; Reis-Filho and Tutt, 2008). Thus, the idea of
developing an immunohistochemical (IHC)-based assay
for the identification of BLBC is appealing. The
variation in the transcriptional and translational
programs of cells that accounts for the different
molecular identities of breast carcinomas also reinforces
the interest in creating an IHC-based assay for BLBC
definition. The characteristic protein expression of
tumors would be a useful surrogate of GEP, and the IHC
profile would help to standardize investigations and
uniformly identify a group of tumors with a basal-like
transcriptional program (Reis-Filho and Tutt, 2008). 
However, the most appropriate panel of antibodies to
be used, in order to identify breast carcinomas with basal
phenotype, has not reached a consensus yet. In 2008,
Tang et al. (2008) compared the different IHC
classifications that have been used to define basal-like
and non basal-like breast carcinomas; interestingly, they
showed that in high grade breast carcinomas, which is a
common feature of basal phenotype, the rates of BLBC
ranged between 19% and 76%, indicating the need for a
more consensual strategy between laboratories.
The TN phenotype criterion is used by some authors
who assume that Triple Negative tumors and BLBC are
synonymous (Kreike et al., 2007; Spitale et al., 2008). In
fact, this criterion is quite convenient, since it includes
standard biomarkers already used in the clinical
management of breast cancer. However, relying on
negative results to perform a diagnostic interpretation
may be risky due to technical failures leading to a
decrease in specificity. Other authors use high molecular
weight cytokeratins alone (CK5/6, CK14 or CK17) to
identify BLBC, claiming that BLBC and triple negative
tumors are different identities (van de Rijn et al., 2002;
Abd El-Rehim et al., 2004; Fulford et al., 2007; Rakha et
al., 2007b). In addition, since basal-like breast
carcinomas express proteins that are characteristic from
the basal/myoepihelial outer layer of the mammary
gland, such as EGFR, p63, P-cadherin, calponin, CD10,
S100 and α-smooth-muscle actin (α-SMA) (Jones et al.,
2001; Reis-Filho et al., 2003; Nielsen et al., 2004;
Livasy et al., 2006), some definitions of BLBC associate
the lack of expression of ER, PR and HER2 with the
immunoreactivity for some of these basal markers that
were already correlated with basal phenotype and poor
prognosis (Nielsen et al., 2004; Matos et al., 2005;
Laakso et al., 2006). Our group has previously
demonstrated that using a panel of antibodies for ER,
PR, HER2, CK5/6 and/or EGFR and/or P-cadherin
and/or p63 it is possible to distinguish invasive (Matos et
al., 2005) and in situ (Paredes et al., 2007b) BLBC.
However, Nielsen et al. (2004) found that expression of
CK5/6 and EGFR together with negativity for ER and
HER2 would be the immunoprofile that identifies the
same basal-like carcinomas found by cDNA
microarrays, with a sensitivity of 76% and a specificity
of 100%. This criterion is, therefore, considered the
“gold standard” immunoprofile to classify BLBC.
In this study, we aim to refine the immunohisto-
chemical criterion to identify BLBC by analyzing the
sensitivity and the specificity of the main basal markers
that have been described, namely CK5, EGFR, P-
cadherin, CK14, Vimentin and p63 and suggest possible
additional markers for BLBC identification, especially in
CK5 and EGFR negative breast carcinomas.
Materials and methods
Breast tumour samples
Formalin-fixed, paraffin-embedded tissues of 462
invasive breast carcinomas were consecutively retrieved
from the histopathology files of three Departments of
Pathology: University Hospital of the Federal University
of Santa Catarina (Florianópolis, Brazil), Hospital
Divino Espírito Santo (HDES), (Ponta Delgada, São
Miguel, Portugal), and a private Laboratory of Pathology
in Araçatuba, Brazil. All cases were reviewed by three
pathologists (FM, FS and LV) on haematoxylin and
eosin-stained (H&E) sections.
TMA construction
Representative areas of the invasive breast
carcinomas were carefully selected on the H&E-stained
sections and marked on individual paraffin blocks. Two
tissue cores (2 mm in diameter) were obtained from each
specimen and precisely deposited into a recipient
paraffin block using a TMA workstation (TMA builder
20010.02, Histopatholoy Ltd, Hungary). Forty seven
TMA blocks were constructed, each one containing 24
tissue cores, arranged in a 4x6 sector. In each TMA
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block, normal breast and testicular tissue were included
as controls. After construction, 2 µm tissue sections
were cut and adhered to glass slides (PolysineTM,
Menzel-Glasser, Germany) for the immunohistochemical
studies and a H&E-stained section from each TMA
block was reviewed in order to confirm the presence of
morphological representative areas of the original
lesions. 
Immunohistochemistry
All the immunohistochemical assays were
performed with specific monoclonal antibodies. Details
about primary antibodies, antigen retrieval and IHC
detection systems are described in Table1. Except for
EGFR, in which epitope retrieval was performed by
proteolytic enzyme digestion for 20 minutes (pepsin A, 4
g/l; Sigma-Aldrich, USA) at 37°C, all epitope retrieval
was heat-induced at 98ºC in a water-bath during 30
minutes, using a commercially available citrate buffer
solution (Vector Laboratories, USA), 1:100, pH=6.0, or
an ethylenediaminetetraacetic (EDTA) solution
(Novocastra, UK), 1:10, pH=9.0, as antigen unmasking
solutions. After the respective antigen retrieval and
washes in a phosphate buffer solution (PBS),
endogenous peroxidase activity was blocked with a 3%
hydrogen peroxide solution (Panreac, Spain) in methanol
(Sigma-Aldrich, USA) for 10 minutes. The slides were
incubated in a blocking serum (LabVision, USA) for 15
min and then incubated with the respective primary
monoclonal antibodies. Immunoassays were performed
using the streptavidin-biotin-peroxidase technique
(SABC), (LabVision Corporation, Fremont, CA, USA)
or the HRP labeled polymer (DakoCytomation, USA)
detection system, according to manufacturer ’s
instructions. All reactions were revealed with diamino-
benzidine (DAB) chromogen (DakoCytomation).
Tissues were then counterstained with Mayer ’s
haematoxylin, dehydrated and coverslipped using a
permanent mounting solution (Mounting Medium,
Richard Allan Scientific, USA). Positive and negative
controls were included in every set of reactions for each
antibody used. Normal breast ducts and lobules present
in many of the selected areas were also used as internal
controls, as well as the non-neoplastic breast tissue cores
included in each array. The evaluation of
immunohistochemistry results was performed by three
pathologists as follows: ER, PR and p63 were
considered positive whenever more than 10% of the
neoplastic cells showed nuclear staining; similarly, the
same cutoff was used for CK5, CK14 and Vimentin
cytoplasmic staining, as well as for P-cadherin
membrane staining. Membrane expression for HER2 and
EGFR was evaluated according to the DakoCytomation
HercepTest® scoring system (Reis-Filho et al., 2005).
Breast carcinomas were considered HER2-
overexpressing whenever the immunohistochemical
reaction was classified as 3+ or when gene amplification
was confirmed by Chromogenic In Situ hybridization
(CISH) in the 2+ cases, as described in other works
(Ricardo et al., 2007). For EGFR, the cases were
considered positive whenever the immunostaining was
2+ or 3+.
Hormone receptor (ER and PR) positive tumors
were considered luminal A and B whether or not they
overexpressed HER2, respectively (Sotiriou et al., 2003;
Matos et al., 2005; Paredes et al., 2007b; Spitale et al.,
2008; Tamimi et al., 2008). Cases lacking ER/PR with
overexpression of HER2 were classified as HER2
overexpressing tumors. ER-/PR-/HER2- cases with
immunoreactivity for EGFR and/or CK5 were
considered BLBC according to the gold standard
Nielsen’s criterion and cases without expression of the
five biomarkers were considered unclassified. When the
immunoreactivity for the additional basal markers,
namely P-cadherin, CK14 and Vimentin are used, the
positive cases for at least one of these markers were
considered as BLBC (P-cad and/or CK14 and/or Vim).
Since for some markers the immunohistochemical result
was not interpretable, the statistical analyses were
performed using only 387 breast tumors cases which
were classified for all the biomarkers tested.
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Table 1. Conditions of the immunohistochemical reactions performed in this study.
Primary antibodies Antigen retrieval buffer Detection method
Antigen Clone Origin Incubation time (min) Dilution
ER SP1 Neomarkers, USA 30 1:150 Citrate SABC*
PR SP2 Neomarkers, USA 30 1:300 Citrate HRP-Polymer **
HER2 SP3 Neomarkers, USA 30 1:80 Citrate SABC*
CK5 XM26 Neomarkers, USA 60 1:50 Tris-EDTA SABC*
EGFR 31G7 Zymed 60 1:100 Pepsin HRP-Polymer **
P-cadherin 56 BD Transduction 60 1:50 Tris-EDTA HRP-Polymer **
CK14 LL002 Novocastra, UK 60 1:400 Tris-EDTA HRP-Polymer **
Vimentin V9 Dako, USA 30 1:150 Citrate SABC*
p63 4A4 Neomarkers, USA 60 1:150 Citrate SABC*
* SABC: streptavidin-avidin-biotin-complex; **: HRP-Polymer (horseradish peroxidase - polymer).
Statistical analysis
Statistical analysis was performed by SPSS statistics
17.0 (SPSS Inc., Chicago, IL, USA) software program.
χ2 contingency test was used to determine associations
between groups and the results were considered
statistically significant if the p value was lower than
0.05. In order to determine which were the most
sensitive and specific biomarkers to identify BLBC, the
sensitivity and the specificity of the antibodies used were
calculated. Sensitivity measurement was defined by the
quotient between the true positive (TrueP) cases and the
sum of the true positive and the false negative (FalseN)
cases [sensitivity = TrueP/(TrueP+FalseN)]. Specificity
was measured in a similar way, by the quotient between
the true negative (TrueN) cases with the sum of the true
negatives and the false positives (FalseP) [specificity =
TrueN/(TrueN+FalseP)]. PPV (Positive Predictive
Value) and NPV (Negative Predictive Value) were
calculated as follows: PPV = TrueP/(TrueP+FalseP) and
PNV = TrueN/(TrueN+FalseN). As described before,
ER/PR/HER2 negative tumors that express CK5/6
and/or EGFR were considered BLBC. Consequently,
TrueP and TrueN cases were the BLBC tumors that were
positive or negative, respectively, to the marker or pair
of markers in analysis. Inversely, FalseP and FalseN
were non BLBC positive or negative to the basal
markers in study. 
Follow-up information was available for 282 of the
387 cases and a maximum cutoff of 77 months was
considered. Survival curves were estimated by the
Kaplan-Meier method using log-rank test to assess
significant differences for overall survival.
Results
In this series of 387 breast carcinomas, 223/387
(57.6%) and 144/387 (37.2%) cases were ER and PR
positive, respectively, and 65/387(16.8%) overexpressed
HER2. Using the ER/PR/HER2- (TN) criterion, this
series comprises 109 (28.2%) triple negative and 278
(71.8%) non-Triple Negative tumors. Considering the
molecular subtypes of breast cancer, 213 (55%) cases
were luminal A, 13 (3.4%) luminal B and 52 (13.4%)
HER2-overexpressing tumors. According to Nielsen’s
criterion, 37 (9.6%) cases presented a basal-like
phenotype and 72 (18.6%) were considered
“unclassified” by this criterion. We analyzed the
associations between CK5, EGFR, P-cadherin, CK14,
p63 and Vimentin and the BLBC versus non BLBC
(Table 2). As expected, the markers were significantly
associated with the basal phenotype (p‹0.0001), with the
exception for p63 (p=0.5403). Fig. 1 shows the
immunohistochemical staining for CK5, EGFR, P-
cadherin, Vimentin and CK14 in BLBC.
Afterwards, the sensitivity, specificity, PPV and
NPV of each biomarker for the identification of BLBC
were calculated (Table 3), except for p63 which was not
even related with basal phenotype. CK5 was the most
sensitive biomarker (91.9%), followed by P-cadherin
(67.6%). CK14 and EGFR were the most specific
markers, presenting 98.6% and 97.1% of specificity,
respectively, and vimentin was also shown to be very
specific (86.9%). 
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Fig. 1. Expression of CK5 (a), EGFR (b), P-
cadherin (c), CK14 (d) and Vimentin (e) in basal-
like breast carcinomas, defined by ER/PR/HER2
negativity and CK5 and /or EGFR positivity. 
x 200
In order to find the best combination of basal
markers with the ability to identify BLBC, we evaluated
the most sensitive and the most specific markers in pairs
(CK5, P-cadherin with CK14, EGFR or Vimentin). Since
P-cadherin presented good sensitivity and specificity
values, we also evaluated its association with CK5
(Table 4). The statistical associations considered cases
that were positive for both markers (+/+), positive for at
least one marker (+/- or -/+) or negative for both (-/-).
Table 5 shows the percentages of sensitivity, specificity,
PPV and NPV for the several pairs of markers. In these
analyses, we considered as true positive the cases that
were +/+ and positive for at least one of the markers in
the subgroup of BLBC previously distinguished by
Nielsen’s criterion, and as false positive the cases that
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Fig. 2. Distribution of P-cadherin, vimentin and CK14 expression in triple
negative tumors that were negative for CK5 and EGFR.
Table 2. Association between the expression of CK5, EGFR, P-
cadherin, CK14, p63 and vimentin with basal-like and non basal-like
breast carcinomas.
n Basal n (%) Non basal n(%) P
387 37(9.6%) 350(90.4%)
CK5 <0.0001
+ 89 34(91.9%) 55(15.7%)
- 298 3(8.1%) 295(84.3%)
EGFR <0.0001
+ 21 11(29.7%) 10(2.9%)
- 366 26(70.3%) 340(97.1%)
P-cadherin <0.0001
+ 123 25(67.6%) 98(28%)
- 264 12(32.4%) 252(72%)
CK14 <0.0001
+ 17 12(32.4%) 5(1.4%)
- 370 25(67.6%) 345(98.6%)
p63 0.5403
+ 14 2(5.4%) 12(3.4%)
- 373 35(94.6%) 338(96.6%)
Vimentin <0.0001
+ 63 17(45.9%) 46(13.1%)
- 324 20(54.1%) 304(86.9%)
Table 3. Sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) of the IHC method for the basal-
markers studied to discriminate a basal-like carcinoma. 
Sensitivity (%) Specificity (%) PPV (%) PNV (%)
CK5 91.9 84.3 38.2 99.0
EGFR 29.7 97.1 52.4 92.9
P-cadherin 67.6 72.0 20.3 95.5
CK14 32.4 98.6 70.6 93.2
Vimentin 45.9 86.9 27.0 93.8
Table 4. Association between the expression of pairs of basal markers
with basal-like and non basal-like breast carcinomas.
n Basal n (%) Non basal n(%) p
CK5/EGFR <0.0001
+/+ 11 8(21.6%) 3(0.8%)
At least one + 88 29(78.4%) 59(16.9%)
-/- 288 0(0%) 288(82.3%)
CK5/CK14 <0.0001
+/+ 11 11(29.7%) 0(0%)
At least one + 83 23(62.2%) 60(17.1%)
-/- 293 3(8.1%) 290(82.9%)
CK5/Vim <0.0001
+/+ 24 16(43.2%) 8(2.3%)
At least one + 104 19(51.4%) 85(24.3%)
-/- 259 2(5.4%) 257(73.4%)
P-cadherin/EGFR <0.0001
+/+ 13 8(21.6%) 5(1.4%)
At least one + 118 20(54.1%) 98(28%)
-/- 256 9(24.3%) 247(70.6%)
P-cadherin/CK14 <0.0001
+/+ 12 9(24.3%) 3(0.9%)
At least one + 116 19(51.4%) 97(27.7%)
-/- 259 9(24.3%) 250(71.4%)
P-cadherin/Vim <0.0001
+/+ 41 11(29.7%) 30(8.6%)
At least one + 104 20(54.1%) 84(24%)
-/- 242 6(16.2%) 236(67.4%)
P-cadherin/CK5 <0.0001
+/+ 38 23(62.2%) 15(4.3%)
At least one + 136 13(35.1%) 123(35.1%)
-/- 213 1(2.7%) 212(60.6%)
Table 5. Sensitivity, specificity, PPV and NPV of the IHC method for the
pairs of basal-markers antibodies studied to discriminate a basal-like
carcinoma.
Sensitivity (%) Specificity (%) PPV (%) PNV (%)
CK5/EGFR 100 82.3 11.4 100
CK5/CK14 91.9 82.9 10.5 99
CK5/Vim 94.6 73.4 12.0 99.2
P-cadherin/EGFR 75.7 70.6 10.2 96.5
P-cadherin/CK14 75.7 71.4 10.1 96.5
P-cadherin/Vim 83.8 67.4 11.6 97.5
P-cadherin/CK5 97.3 60.6 14.5 99.5
were positive for the two markers and the ones
expressing at least one marker in non basal-like tumors.
True negative and false negative were the -/- cases in
non basal-like and in BLBC, respectively. All the
associations were statistically significant (p‹0.0001). The
pair CK5/EGFR presented, as expected, the highest
values of sensitivity and specificity, 100% and 82.3%,
respectively. However, concerning sensitivity, the pairs
CK5/CK14, P-cadherin/CK5 and CK5/Vimentin showed
similar values to the “gold standard” CK5/EGFR pair,
with 91.9%, 97.3% and 94.6% of sensitivity,
respectively. The specificity of CK5/CK14 combination
(82.9%) was approximately equal to the one presented
by CK5/EGFR (82.3%). 
In the BLBC group, when analyzing the number of
cases that were +/+ and positive for at least one of the
markers of the pair, against the -/- cases (Table 6), it is
possible to observe that only one basal-like breast
carcinoma was negative for both markers in P-
cadherin/CK5 pair. The CK5/Vimentin pair missed the
expression in 2 cases, while CK5/CK14 did not stain
three BLBC. All the other pairs were positive in BLBC
for the two markers, or for at least one of them, in at
least 75.7% of breast carcinomas with basal phenotype.
More importantly, given the sensitivity of P-cadherin
and the specificity of CK14 and Vimentin, we also
analyzed their expression among the TN/CK5 and EGFR
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Fig. 3. Kaplan-Meier survival curves for overall survival (OS) of triple
negative breast carcinoma patient’s cohort, with a 77 months cut-off.
BLBC defined by TN/CK5 and/or EGFR+ [BLBC (CK5 and/or EGFR+)],
BLBC defined as ER/PR/HER2-, CK5/EGFR- and immunoreactivity for
P-cadherin and/or CK14 and/or Vimentin [BLBC (P-cad and/or CK14
and/or Vim)] and tumors that were negative for all the basal markers in
study were analyzed, p=0.267 (not statistically significant).
Table 6. Analyzes of the distribution of expression of the pairs of
markers in BLBC.
Basal n (%)
CK5/EGFR +/+ and at least one + 37(100%)
-/- 0(0%)
CK5/CK14 +/+ and at least one + 34(91.9%)
-/- 3(9.1%)
CK5/Vim +/+ and at least one + 35(94.6%)
-/- 2(5.4%)
P-cadherin/EGFR +/+ and at least one + 28(75.7%)
-/- 9(24.3%)
P-cadherin/CK14 +/+ and at least one + 28(75.7%)
-/- 9(24.3%)
P-cadherin/Vim +/+ and at least one + 31(83.8%)
-/- 6(16.2%)
P-cadherin/CK5 +/+ and at least one + 36(97.3%)
-/- 1(2.7%)
Table 7. Expression of P-cadherin, vimentin and CK14 in the 72 TN
tumors also negative for CK5 and EGFR.
TN/CK5 and EGFR- n=72
P-cadherin + 29(40.3%)
- 43(59.7%)
Vimentin + 18(25%)
- 54(75%)
CK14 + 5(6.9%)
- 67(93.1%)
Table 8. Distribution of histological grade among triple negative breast carcinomas of the studied series.
Histological grade
Triple negative tumors (n=103*) I II III
BLBC (CK5 and/or EGFR+) (n=34) 3 (9%) 12 (35%) 19 (56%)
BLBC (P-cadherin and/or CK14 and/or Vimentin+) (n=32) 2 (6%) 15 (47%) 15 (47%)
Unclassified (TN,CK5, EGFR, P-cad, CK14 and Vim-) (n=37) 17 (46%) 15 (40%) 5 (14%)
BLBC (CK5 and/or EGFR+) are the TN tumors that were positive for CK5 and/or EGFR and BLBC (P-cadherin and/or CK14 and/or Vimentin+) are the
TN/CK5 and EGFR- tumors immunoreactive for one of the additional markers in study: P-cadherin, CK14 and vimentin. *: Histological grade of some
cases could not be assessed because the patients were submitted to preoperative chemotherapy.
negative tumors (“unclassified” by Nielsen’s criterion).
In 38/72 (52.8%) cases, none of the biomarkers were
expressed; however, in the other 34/72 cases (47.2%),
there was the expression of, at least, one of the
biomarkers. P-cadherin was present in 29 (40.3%),
Vimentin in 18 (25%) and CK14 in 5 (6.9%) of these
tumors (Table 7). In a more detailed analysis, 15 cases
were positive only for P-cadherin, while only one and
three cases were positive for CK14 and for Vimentin
alone, respectively (Fig. 2). 
Interestingly, if we consider as BLBC these TN/CK5
and EGFR- “unclassified” cases that presented
immunoreactivity for P-cadherin, CK14 and/or Vimentin
[BLBC (Pcad and/or CK14 and/or Vimentin+)], this
series presents 71/387 (18%) of BLBC. BLBC defined
by TN/CK5 and/or EGFR+ and BLBC defined as
ER/PR/HER2-, CK5/EGFR- and immunoreactivity for
P-cadherin and/or CK14 and/or Vimentin were analyzed
separately. These two differently defined BLBC
presented a similar percentage of high histological grade
tumors [56% and 47% in BLBC (CK5 and/or EGFR+)
and in BLBC (Pcad and/or CK14 and/or Vimentin+),
respectively], (Table 8). The overall survival was similar
for the two groups as we can see in Figure 3.
Discussion
The need for a more precise diagnosis of breast
cancer that converges with the clinical outcome and the
choice of the most appropriate therapy has motivated
studies in different areas of breast cancer research. The
cDNA microarray technology is a “gold standard”
method for the recognition of the basal phenotype, but
from a practical point of view, we need to translate these
results to an accessible method. It is undeniable that the
BLBC immunohistochemistry definition requires cDNA
microarray validation, since these tumors were first
identified by this technique (Perou et al., 2000; Livasy et
al., 2006). However, from the pathologists and
oncologists point of view, the lack of molecular targets
for therapy in this subgroup of patients indicates the
urgent need for an easier and less expensive way to
identify BLBC patients. Based on this, there is an
attempt to establish an immunohistochemical surrogate
panel, easily applied on FFPE samples, which identifies
a pool of breast cancer patients who may require more
aggressive systemic therapy and that would be the most
appropriate subjects for clinical trials, specifically
targeting this molecular subgroup of breast cancer.
However, there is still no consensual definition about the
ideal IHC panel of biomarkers to distinguish the basal
phenotype. In fact, many different panels have been
used, in which CK5, EGFR, P-cadherin, CK14 and
Vimentin are included. Due to this diversity of criteria, a
wide range of percentages of BLBC are described in the
several studied series (van de Rijn et al., 2002; Foulkes
et al., 2004; Jones et al., 2004; Abd El-Rehim et al.,
2005; Arnes et al., 2005; Collett et al., 2005; Kusinska et
al., 2005; Laakso et al., 2005; Potemski et al., 2005;
Banerjee et al., 2006; Fulford et al., 2006, 2007; Kim et
al., 2006; Rakha et al., 2006a,b, 2007a,b,c; Rodriguez-
Pinilla et al., 2006, 2007; Siziopikou and Cobleigh,
2007). Nielsen et al. (2004) demonstrated that CK5 and
EGFR could reliably discriminate BLBC that were
identified by GEP, considering these two basal markers
the “gold standard” immunohistochemical panel of
antibodies to the BLBC identification, together with ER
and HER2 lack of expression. Recently, Cheang et al.
(2008) compared two BLBC immuno-panels and
concluded that the ER-/PR-/HER2- and expression of
CK5 and/or EGFR provides the more accurate definition
of BLBC and can better predict breast cancer patient’s
survival. 
However, we cannot assure which are the best
antibodies to be included in a daily practice panel for the
recognition of the basal phenotype in breast carcinomas:
should we look for the most sensitive or the most
specific ones? None of these markers are actually
pathognomonic of a basal phenotype, since they are
variably expressed in the other subgroups of breast
carcinomas, which support the search for “ideal”
biomarkers to be used in the anatomic pathology workup
and with clinical relevance.
We demonstrate herein that P-cadherin, Vimentin or
CK14 may possibly be useful biomarkers to include in
IHC panels for distinguishing BLBC. P-cadherin reveals
consistent values of sensitivity and specificity, while
Vimentin and CK14 presented high specificity values.
The three markers were able to reliably recognize the
basal phenotype, especially when associated to CK5. 
The presence of P-cadherin, an adhesion molecule
expressed in myoepithelial cells of the normal mammary
gland, was already described in invasive and in in situ
breast carcinomas with worst prognosis, namely in those
with high histological grade and basal phenotype
(Peralta Soler et al., 1999; Gamallo et al., 2001; Kovacs
and Walker, 2003; Paredes et al., 2005, 2007b). The role
of P-cadherin in breast carcinogenesis has been one of
the main fields of our research group’s interest and we
have observed that this molecule presents an inverse
correlation with HR (Peralta Soler et al., 1999; Gamallo
et al., 2001; Kovacs and Walker, 2003; Paredes et al.,
2005) and a direct correlation with EGFR (Kovacs and
Walker, 2003), HER2 and high proliferation rates,
strengthening the value of P-cadherin as a poor
prognostic indicator in breast cancer (Palacios et al.,
1995; Peralta Soler et al., 1999; Gamallo et al., 2001;
Paredes et al., 2005). The expression of P-cadherin in
neoplastic cells has already been related to a histogenetic
origin in cap cells or to the acquisition of a stem cell-like
phenotype, suggesting that P-cadherin-expressing
tumors could be associated to a stem cell origin (Peralta
Soler et al., 1999, Gamallo et al., 2001, Paredes et al.,
2007). Recently, it has been suggested that basal-like
breast carcinomas may be genuine stem/early progenitor
cell tumors of the mammary gland, relating their origin
to a more undifferentiated type of precursor cells
(Honeth et al., 2008). Also, Rakha et al. (2009)
969
P-cadherin, Vimentin and CK14 in basal-like-breast carcinomas
demonstrated more evidence of the features of dual-
lineage differentiation/stem cell phenotype of BLBC by
showing a higher frequency of CK19 expression in this
type of tumor.
CK14 does not show a differential presence in breast
carcinomas with basal phenotype identified by cDNA
microarray technology, but this cytokeratin is frequently
associated with poor prognosis (Jones et al., 2004) and
with the morphological features observed in BLBC
(Tsuda et al., 2000). For this reason, CK14 has been
included in the immunopanel used to identify BLBC by
several other authors (Laakso et al., 2005, 2006; Rakha
et al., 2006a,b; Reis-Filho et al., 2006).
Vimentin is an intermediate filament protein whose
expression in normal mammary gland is also restricted
to myoepithelial/ basal layer. Its expression has been
associated with high histological grade, lack of ER, p53
mutations, high proliferation rates (Raymond and Leong,
1989; Domagala et al., 1990a,b; Koutselini et al., 1995;
Santini et al., 1996; Thomas et al., 1999) and expression
of CK5/6 and EGFR (Korsching et al., 2005; Reis-Filho,
2005). Vimentin-expressing carcinomas have been
observed in association with sporadic and familial
BLBC and with a specific pattern of metastasis similar
to BLBC (Rodriguez-Pinilla et al., 2007). Like P-
cadherin, Vimentin was also described to be
differentially expressed by BLBC identified by GEP,
being proposed to integrate the panel of antibodies for
the identification of BLBC (Livasy et al., 2006).
Our results show that P-cadherin, CK14 and
Vimentin, together with CK5, can identify almost all
BLBC that were classified as such using the most widely
accepted IHC panel to classify BLBC: ER/PR/HER2-
and CK5 and/or EGFR+.
Triple negative phenotype by IHC is one of the
characteristic features of BLBC and several authors
claim that basal tumors are almost all TN tumors (Diaz
et al., 2007; Kreike et al., 2007). Kreike et al. (2007), in
a series of 97 TN cases, observed that 90% of these
tumors have a basal phenotype by cDNA microarray
analysis. However, the lack of expression of ER, PR and
HER2 as the sole criterion to identify these tumors is
risky (Rakha et al., 2008) because there are technique
limitations when dealing with FFPE tissue samples,
which reinforces the need for a more suitable panel.
There is a significant overlapping of features shared
by triple negative and BLBC in what concerns, for
example, the prevalence of these types of cancer in
younger patients, in African-American women (Morris
et al., 2007), their presentation as interval cancers, a
similar pattern of recurrence (Dent et al., 2007;
Tischkowitz et al., 2007), the more aggressive behavior
comparing with other types of breast cancer (Reis-Filho
and Tutt, 2008) and the biological and clinical similarity
between sporadic TN and BLBC with breast carcinomas
arising from BRCA1 mutation carriers (Reis-Filho and
Tutt, 2008). However, several studies claim that this
overlap is not complete (Bertucci et al., 2008, Rakha and
Ellis, 2009). It is known that TN carcinomas with basal
phenotype have a significant shorter disease-free
survival than TN without expression of basal markers
(Rakha et al., 2007a; Tischkowitz et al., 2007) and that
germline BRCA1 mutation carriers are more probably
found in TN tumors expressing CK5/6 and /or EGFR
than in TN with no expression of these basal markers
(Turner et al., 2007; Rakha et al., 2009). It has also been
observed in GEP that triple negative group is composed
by other subgroups of tumors with different outcomes,
namely the normal breast-like tumors (Perou et al., 2000;
Sorlie et al., 2001, 2003; Sotiriou et al., 2003; Fan et al.,
2006; Hu et al., 2006; Hennessy et al., 2009) and a
recently described subgroup of claudin-low tumors
(Herschkowitz et al., 2007; Hennessy et al., 2009). The
existence of TN tumors that do not react
immunohistochemically with any of the basal markers
routinely used has been described, and variably
designated as non basal triple negative, unclassified,
undetermined, null phenotype (Liu et al., 2008) or
TN3BKE- (Triple Negative 3 Basal Keratins and 
EGFR-) (Rakha et al., 2009). It seems extremely
important to distinguish BLBC from the whole triple
negative group, reducing the TN heterogeneity, since
their biological behavior appears to be different. The
lightening of this heterogeneity would enable patients to
benefit from their differential recognition (Rakha et al.,
2007a, 2008, 2009; Liu et al., 2008; Reis-Filho and Tutt,
2008; Tan et al., 2008; Rakha and Ellis, 2009). This
distinction is also important because TN tumors defined
by IHC tend to be clinically considered as BLBC and
selected for clinical trials (Bertucci et al., 2008),
probably misleading the effect of the drugs in the clinical
trials. 
It is interesting to emphasize that among the
analyzed TN/CK5 and EGFR- tumors that were also
negative for P-cadherin, CK14 and Vimentin,
approximately 50% of these cases presented low
histological grade (Table 8). P-cadherin was expressed
alone in a higher number (15 cases) of TN/CK5 and
EGFR negative tumors, compared with CK14 (1 case)
and Vimentin (3 cases). When P-cadherin, CK14 and
Vimentin expression are considered along with CK5 and
EGFR for the BLBC identification, 34 cases are added to
the 37 already identified BLBC (CK5 and/or EGFR+)
and the percentage of basal-like tumors in the pool of
TN cases of our series rounds the 65% (71/109). This
rate is similar to the one identified by Bertucci (Bertucci
et al., 2008), where 70% of IHQ TN tumors presented a
basal phenotype by GEP. It is worth noticing that using
P-cadherin, CK14 and Vimentin to recruit BLBC from
the pool of tumors that could not be classified using only
CK5 and EGFR as basal makers, these newly identified
BLBC are clinically similar to basal-like tumors
identified by Nielsen’s criterion, since the majority of
the cases presented high histological grade and there are
no significant differences in what concerns overall
survival of the patients. 
Although CK5 and EGFR have been consistently
used to recognize BLBC, P-cadherin, CK14 and
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Vimentin could also be recruited for an
immunohistochemical recognition of BLBC (Paredes et
al., 2002, 2007a,b; Matos et al., 2005; Livasy et al.,
2006; Rodriguez-Pinilla et al., 2007). Our results showed
that these three markers can reliably identify the basal
phenotype, especially when associated to CK5, and can
be alternative options in this setting. We also
demonstrate that P-cadherin, due to its high sensitivity,
can recognize possible BLBC among the IHC TN
tumors, probably identifying patients with poor
prognosis that can benefit from this differential
recognition. Pathologists have faced continuous changes
in the diagnostic approach of breast cancer and,
regarding its classification, it is still controversial
whether or not the histological classification should be
replaced by the “molecular” taxonomy. Therefore, it is
essential to move towards a standardized methodology
to establish an IHC panel of biomarkers to the most
appropriate recognition of basal-like breast carcinomas.
Conflict of interest. The authors declare that they have
no conflict of interest.
Acknowledgements. This work was partially supported by research
grants from Bárbara Sousa (collaboration project at IPATIMUP); Joana
Paredes: Ciência 2007 – Portuguese Science and Technology
Foundation (FCT); Nair Lopes: FCT-SFRH/BD/39208/2007; Diana
Martins: FCT- SFRH/BD/66152/2009; André Albergaria: FCT-
SFRH/BD/15316/2005; Silvia Carvalho: FCT-SFRH/BD/21551/2005 and
José Costa: FCT-SFRH/BPD/20370/2004.
References
Abd El-Rehim D.M., Ball G., Pinder S.E., Rakha E., Paish C., Robertson
J.F., Macmillan D., Blamey R.W. and Ellis I.O. (2005). High-
throughput protein expression analysis using tissue microarray
technology of a large well-characterised series identifies biologically
distinct classes of breast cancer confirming recent cDNA expression
analyses. Int. J. Cancer 116, 340-350.
Abd El-Rehim D.M., Pinder S.E., Paish C.E., Bell J., Blamey R.W.,
Robertson J.F., Nicholson R.I. and Ellis I.O. (2004). Expression of
luminal and basal cytokeratins in human breast carcinoma. J.
Pathol. 203, 661-671.
Arnes J.B., Brunet J.S., Stefansson I., Begin L.R., Wong N., Chappuis
P.O., Akslen L.A. and Foulkes W.D. (2005). Placental cadherin and
the basal epithelial phenotype of BRCA1-related breast cancer. Clin.
Cancer Res. 11, 4003-4011.
Banerjee S., Reis-Filho J.S., Ashley S., Steele D., Ashworth A., Lakhani
S.R. and Smith I.E. (2006). Basal-like breast carcinomas: clinical
outcome and response to chemotherapy. J. Clin. Pathol. 59, 729-
735.
Bertucci F., Finetti P., Cervera N., Esterni B., Hermitte F., Viens P. and
Birnbaum D. (2008). How basal are triple-negative breast cancers?
Int. J. Cancer 123, 236-240.
Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K.,
Perou C.M. and Nielsen T.O. (2008). Basal-like breast cancer
defined by five biomarkers has superior prognostic value than triple-
negative phenotype. Clin. Cancer Res. 14, 1368-1376.
Collett K., Stefansson I.M., Eide J., Braaten A., Wang H., Eide G.E.,
Thoresen S.O., Foulkes W.D. and Akslen L.A. (2005). A basal
epithelial phenotype is more frequent in interval breast cancers
compared with screen detected tumors. Cancer Epidemiol.
Biomarkers Prev. 14, 1108-1112.
Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka
C.A., Lickley L.A., Rawlinson E., Sun P. and Narod S.A. (2007).
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin. Cancer Res. 13, 4429-4434.
Diaz L.K., Cryns V.L., Symmans W.F. and Sneige N. (2007). Triple
negative breast carcinoma and the basal phenotype: from
expression profiling to clinical practice. Adv. Anat. Pathol. 14, 419-
430.
Domagala W., Lasota J., Bartkowiak J., Weber K. and Osborn M.
(1990a). Vimentin is preferentially expressed in human breast
carcinomas with low estrogen receptor and high Ki-67 growth
fraction. Am. J. Pathol. 136, 219-227.
Domagala W., Lasota J., Dukowicz A., Markiewski M., Striker G., Weber
K. and Osborn M. (1990b). Vimentin expression appears to be
associated with poor prognosis in node-negative ductal NOS breast
carcinomas. Am. J. Pathol. 137, 1299-1304.
Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S., Nobel A.B., van't
Veer L.J. and Perou C.M. (2006). Concordance among gene-
expression-based predictors for breast cancer. N. Engl. J. Med. 355,
560-569.
Ferlay J., Autier P., Boniol M., Heanue M., Colombet M. and Boyle P.
(2007). Estimates of the cancer incidence and mortality in Europe in
2006. Ann. Oncol. 18, 581-592.
Foulkes W.D., Brunet J.S., Stefansson I.M., Straume O., Chappuis P.O.,
Begin L.R., Hamel N., Goffin J.R., Wong N., Trudel M., Kapusta L.,
Porter P. and Akslen L.A. (2004). The prognostic implication of the
basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-
proliferation+) phenotype of BRCA1-related breast cancer. Cancer
Res. 64, 830-835.
Fulford L.G., Easton D.F., Reis-Filho J.S., Sofronis A., Gillett C.E.,
Lakhani S.R. and Hanby A. (2006). Specific morphological features
predictive for the basal phenotype in grade 3 invasive ductal
carcinoma of breast. Histopathology 49, 22-34.
Fulford L.G., Reis-Filho J.S., Ryder K., Jones C., Gillett C.E., Hanby A.,
Easton D. and Lakhani S.R. (2007). Basal-like grade III invasive
ductal carcinoma of the breast: patterns of metastasis and long-term
survival. Breast Cancer Res. 9, R4.
Gamallo C., Moreno-Bueno G., Sarrio D., Calero F., Hardisson D. and
Palacios J. (2001). The prognostic significance of P-cadherin in
infiltrating ductal breast carcinoma. Mod. Pathol. 14, 650-654.
Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z.,
Krishnamurthy S., Lee J.S., Fridlyand J., Sahin A., Agarwal R., Joy
C., Liu W., Stivers D., Baggerly K., Carey M., Lluch A., Monteagudo
C., He X., Weigman V., Fan C., Palazzo J., Hortobagyi G.N., Nolden
L.K., Wang N.J., Valero V., Gray J.W., Perou C.M. and Mills G.B.
(2009). Characterization of a naturally occurring breast cancer
subset enriched in epithelial-to-mesenchymal transition and stem
cell characteristics. Cancer Res. 69, 4116-4124.
Herschkowitz J.I., Simin K., Weigman V.J., Mikaelian I., Usary J., Hu Z.,
Rasmussen K.E., Jones L.P., Assefnia S., Chandrasekharan S.,
Backlund M.G., Yin Y., Khramtsov A.I., Bastein R., Quackenbush J.,
Glazer R.I., Brown P.H., Green J.E., Kopelovich L., Furth P.A.,
Palazzo J.P., Olopade O.I., Bernard P.S., Churchill G.A., Van Dyke
T. and Perou C.M. (2007). Identification of conserved gene
971
P-cadherin, Vimentin and CK14 in basal-like-breast carcinomas
expression features between murine mammary carcinoma models
and human breast tumors. Genome Biol. 8, R76.
Honeth G., Bendahl P.O., Ringner M., Saal L.H., Gruvberger-Saal S.K.,
Lovgren K., Grabau D., Ferno M., Borg A. and Hegardt C. (2008).
The CD44+/CD24- phenotype is enriched in basal-like breast
tumors. Breast Cancer Res. 10, R53.
Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., Livasy C.,
Carey L.A., Reynolds E., Dressler L., Nobel A., Parker J., Ewend
M.G., Sawyer L.R., Wu J., Liu Y., Nanda R., Tretiakova M., Ruiz
Orrico A., Dreher D., Palazzo J.P., Perreard L., Nelson E., Mone M.,
Hansen H., Mullins M., Quackenbush J.F., Ellis M.J., Olopade O.I.,
Bernard P.S. and Perou C.M. (2006). The molecular portraits of
breast tumors are conserved across microarray platforms. BMC
Genomics 7, 96.
Jones C., Nonni A.V., Fulford L., Merrett S., Chaggar R., Eusebi V. and
Lakhani S.R. (2001). CGH analysis of ductal carcinoma of the breast
with basaloid/myoepithelial cell differentiation. Br. J. Cancer 85, 422-
427.
Jones C., Ford E., Gillett C., Ryder K., Merrett S., Reis-Filho J.S.,
Fulford L.G., Hanby A. and Lakhani S.R. (2004). Molecular
cytogenetic identification of subgroups of grade III invasive ductal
breast carcinomas with different clinical outcomes. Clin. Cancer Res.
10, 5988-5997.
Kim M.J., Ro J.Y., Ahn S.H., Kim H.H., Kim S.B. and Gong G. (2006).
Clinicopathologic significance of the basal-like subtype of breast
cancer: a comparison with hormone receptor and Her2/neu-
overexpressing phenotypes. Hum. Pathol. 37, 1217-26.
Korsching E., Packeisen J., Liedtke C., Hungermann D., Wulfing P., van
Diest P.J., Brandt B., Boecker W. and Buerger H. (2005). The origin
of vimentin expression in invasive breast cancer: epithelial-
mesenchymal transition, myoepithelial histogenesis or histogenesis
from progenitor cells with bilinear differentiation potential? J. Pathol.
206, 451-7.
Koutselini H., Markopoulos C., Lambropoulou S., Gogas H., Kandaraki
C. and Gogas J. (1995). Relationship of epidermal growth factor
receptor (EGFR), proliferating cell nuclear antigen (PCNA) and
vimentin expression and various prognostic factors in breast cancer
patients. Cytopathology 6, 14-21.
Kovacs A. and Walker R.A. (2003). P-cadherin as a marker in the
differential diagnosis of breast lesions. J. Clin. Pathol. 56, 139-
141.
Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H.,
Bartelink H. and van de Vijver M.J. (2007). Gene expression
profi l ing and histopathological characterization of tr iple-
negative/basal-like breast carcinomas. Breast Cancer Res. 9, R65.
Kusinska R., Potemski P., Jesionek-Kupnicka D. and Kordek R. (2005).
Immunohistochemical identification of basal-type cytokeratins in
invasive ductal breast carcinoma--relation with grade, stage,
estrogen receptor and HER2. Pol. J. Pathol. 56, 107-110.
Laakso M., Loman N., Borg A. and Isola J. (2005). Cytokeratin 5/14-
positive breast cancer: true basal phenotype confined to BRCA1
tumors. Mod. Pathol. 18, 1321-1328.
Laakso M., Tanner M., Nilsson J., Wiklund T., Erikstein B., Kellokumpu-
Lehtinen P., Malmstrom P., Wilking N., Bergh J. and Isola J. (2006).
Basoluminal carcinoma: a new biologically and prognostically
distinct entity between basal and luminal breast cancer. Clin. Cancer
Res. 12, 4185-4191.
Liu H., Fan Q., Zhang Z., Li X., Yu H. and Meng F. (2008). Basal-HER2
phenotype shows poorer survival than basal-like phenotype in
hormone receptor-negative invasive breast cancers. Hum. Pathol.
39, 167-74.
Livasy C.A., Karaca G., Nanda R., Tretiakova M.S., Olopade O.I.,
Moore D.T. and Perou C.M. (2006). Phenotypic evaluation of the
basal-like subtype of invasive breast carcinoma. Mod. Pathol. 19,
264-271.
Matos I., Dufloth R., Alvarenga M., Zeferino L.C. and Schmitt F. (2005).
p63, cytokeratin 5, and P-cadherin: three molecular markers to
distinguish basal phenotype in breast carcinomas. Virchows Arch.
447, 688-694.
Milanezi F., Carvalho S. and Schmitt F.C. (2008). EGFR/HER2 in breast
cancer: a biological approach for molecular diagnosis and therapy.
Expert Rev. Mol. Diagn. 8, 417-434.
Morris G.J., Naidu S., Topham A.K., Guiles F., Xu Y., McCue P.,
Schwartz G.F., Park P.K., Rosenberg A.L., Brill K. and Mitchell E.P.
(2007). Differences in breast carcinoma characteristics in newly
diagnosed African-American and Caucasian patients: a single-
institution compilation compared with the National Cancer Institute's
Surveillance, Epidemiology, and End Results database. Cancer 110,
876-884.
Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z.,
Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., Akslen
L.A., Ragaz J., Gown A.M., Gilks C.B., van de Rijn M. and Perou
C.M. (2004). Immunohistochemical and clinical characterization of
the basal-like subtype of invasive breast carcinoma. Clin. Cancer
Res. 10, 5367-5374.
Palacios J., Benito N., Pizarro A., Suarez A., Espada J., Cano A. and
Gamallo C. (1995). Anomalous expression of P-cadherin in breast
carcinoma. Correlation with E-cadherin expression and pathological
features. Am. J. Pathol. 146, 605-612.
Paredes J., Albergaria A., Oliveira J.T., Jeronimo C., Milanezi F. and
Schmitt F.C. (2005). P-cadherin overexpression is an indicator of
clinical outcome in invasive breast carcinomas and is associated
with CDH3 promoter hypomethylation. Clin. Cancer Res. 11, 5869-
5877.
Paredes J., Correia A.L., Ribeiro A.S., Albergaria A., Milanezi F. and
Schmitt F.C. (2007a). P-cadherin expression in breast cancer: a
review. Breast Cancer Res. 9, 214.
Paredes J., Lopes N., Milanezi F. and Schmitt F.C. (2007b). P-cadherin
and cytokeratin 5: useful adjunct markers to distinguish basal-like
ductal carcinomas in situ. Virchows Arch. 450, 73-80.
Paredes J., Milanezi F., Viegas L., Amendoeira I. and Schmitt F. (2002).
P-cadherin expression is associated with high-grade ductal
carcinoma in situ of the breast. Virchows Arch. 440, 16-21.
Peralta Soler A., Knudsen K.A., Salazar H., Han A.C. and Keshgegian
A.A. (1999). P-cadherin expression in breast carcinoma indicates
poor survival. Cancer 86, 1263-1272.
Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees
C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O.,
Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-
Dale A.L., Brown P.O. and Botstein D. (2000). Molecular portraits of
human breast tumours. Nature 406, 747-752.
Potemski P., Kusinska R., Watala C., Pluciennik E., Bednarek A.K. and
Kordek R. (2005). Prognostic relevance of basal cytokeratin
expression in operable breast cancer. Oncology 69, 478-485.
Rakha E.A. and Ellis I.O. (2009). Triple-negative/basal-like breast
cancer: review. Pathology 41, 40-47.
Rakha E.A., El-Rehim D.A., Paish C., Green A.R., Lee A.H., Robertson
J.F., Blamey R.W., Macmillan D. and Ellis I.O. (2006a). Basal
972
P-cadherin, Vimentin and CK14 in basal-like-breast carcinomas
phenotype identifies a poor prognostic subgroup of breast cancer of
clinical importance. Eur. J. Cancer 42, 3149-3156.
Rakha E.A., Putti T.C., Abd El-Rehim D.M., Paish C., Green A.R., Powe
D.G., Lee A.H., Robertson J.F. and Ellis I.O. (2006b). Morphological
and immunophenotypic analysis of breast carcinomas with basal
and myoepithelial differentiation. J. Pathol. 208, 495-506.
Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F. and
Ellis I.O. (2007a). Prognostic markers in triple-negative breast
cancer. Cancer 109, 25-32.
Rakha E.A., El-Sayed M.E., Green A.R., Paish E.C., Lee A.H. and Ellis
I.O. (2007b). Breast carcinoma with basal differentiation: a proposal
for pathology definition based on basal cytokeratin expression.
Histopathology 50, 434-438.
Rakha E.A., Tan D.S., Foulkes W.D., Ellis I.O., Tutt A., Nielsen T.O. and
Reis-Filho J.S. (2007c). Are triple-negative tumours and basal-like
breast cancer synonymous? Breast Cancer Res. 9, 404; author
reply 405.
Rakha E.A., Elsheikh S.E., Aleskandarany M.A., Habashi H.O., Green
A.R., Powe D.G., El-Sayed M.E., Benhasouna A., Brunet J.S.,
Akslen L.A., Evans A.J., Blamey R., Reis-Filho J.S., Foulkes W.D.
and Ellis I.O. (2009). Triple-negative breast cancer: distinguishing
between basal and nonbasal subtypes. Clin. Cancer Res. 15, 2302-
23,10.
Rakha E.A., Reis-Filho J.S. and Ellis I.O. (2008). Basal-like breast
cancer: a critical review. J. Clin. Oncol. 26, 2568-2581.
Raymond W.A. and Leong A.S. (1989). Vimentin--a new prognostic
parameter in breast carcinoma? J. Pathol. 158, 107-114.
Reis-Filho J.S. (2005). Re: Korsching et al. The origin of vimentin
expression in invasive breast cancer: epithelial-mesenchymal
transition, myoepithelial histogenesis or histogenesis from progenitor
cells with bilinear differentiation potential? J. Pathol. 2005; 206: 451-
457. J. Pathol. 207, 367-9; author reply 370-1.
Reis-Filho J.S. and Tutt A.N. (2008). Triple negative tumours: a critical
review. Histopathology 52, 108-118.
Reis-Filho J.S., Milanezi F., Paredes J., Silva P., Pereira E.M., Maeda
S.A., de Carvalho L.V. and Schmitt F.C. (2003). Novel and classic
myoepithelial/stem cell markers in metaplastic carcinomas of the
breast. Appl. Immunohistochem. Mol. Morphol. 11, 1-8.
Reis-Filho J.S., Milanezi F., Carvalho S., Simpson P.T., Steele D.,
Savage K., Lambros M.B., Pereira E.M., Nesland J.M., Lakhani S.R.
and Schmitt F.C. (2005). Metaplastic breast carcinomas exhibit
EGFR, but not HER2, gene amplification and overexpression:
immunohistochemical and chromogenic in situ hybridization
analysis. Breast Cancer Res. 7, R1028-1035.
Reis-Filho J.S., Milanezi F., Steele D., Savage K., Simpson P.T.,
Nesland J.M., Pereira E.M., Lakhani S.R. and Schmitt F.C. (2006).
Metaplastic breast carcinomas are basal-l ike tumours.
Histopathology 49, 10-21.
Ricardo S.A., Milanezi F., Carvalho S.T., Leitao D.R. and Schmitt F.C.
(2007). HER2 evaluation using the novel rabbit monoclonal antibody
SP3 and CISH in tissue microarrays of invasive breast carcinomas.
J. Clin. Pathol. 60, 1001-1005.
Rodriguez-Pinilla S.M., Sarrio D., Honrado E., Hardisson D., Calero F.,
Benitez J. and Palacios J. (2006). Prognostic significance of basal-
like phenotype and fascin expression in node-negative invasive
breast carcinomas. Clin. Cancer Res. 12, 1533-1539.
Rodriguez-Pinilla S.M., Sarrio D., Honrado E., Moreno-Bueno G.,
Hardisson D., Calero F., Benitez J. and Palacios J. (2007). Vimentin
and laminin expression is associated with basal-like phenotype in
both sporadic and BRCA1-associated breast carcinomas. J. Clin.
Pathol. 60, 1006-1012.
Santini D., Ceccarelli C., Taffurelli M., Pileri S. and Marrano D. (1996).
Differentiation pathways in primary invasive breast carcinoma as
suggested by intermediate filament and biopathological marker
expression. J. Pathol. 179, 386-391.
Siziopikou K.P. and Cobleigh M. (2007). The basal subtype of breast
carcinomas may represent the group of breast tumors that could
benefit from EGFR-targeted therapies. Breast 16, 104-107.
Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H.,
Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist
H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P. and
Borresen-Dale A.L. (2001). Gene expression patterns of breast
carcinomas distinguish tumor subclasses with clinical implications.
Proc. Natl. Acad. Sci. USA 98, 10869-10874.
Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A.,
Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M.,
Lonning P.E., Brown P.O., Borresen-Dale A.L. and Botstein D.
(2003). Repeated observation of breast tumor subtypes in
independent gene expression data sets. Proc. Natl. Acad. Sci. USA
100, 8418-8423.
Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A.,
Martiat P., Fox S.B., Harris A.L. and Liu E.T. (2003). Breast cancer
classification and prognosis based on gene expression profiles from
a population-based study. Proc. Natl. Acad. Sci. USA 100, 10393-
10398.
Spitale A., Mazzola P., Soldini D., Mazzucchelli L. and Bordoni A.
(2008). Breast cancer classification according to immunohisto-
chemical markers: clinicopathologic features and short-term survival
analysis in a population-based study from the South of Switzerland.
Ann. Oncol. 20, 628-635.
Tamimi R.M., Baer H.J., Marotti J., Galan M., Galaburda L., Fu Y., Deitz
A.C., Connolly J.L., Schnitt S.J., Colditz G.A. and Collins L.C.
(2008). Comparison of molecular phenotypes of ductal carcinoma in
situ and invasive breast cancer. Breast Cancer Res. 10, R67.
Tan D.S., Marchio C., Jones R.L., Savage K., Smith I.E., Dowsett M.
and Reis-Filho J.S. (2008). Triple negative breast cancer: molecular
profiling and prognostic impact in adjuvant anthracycline-treated
patients. Breast Cancer Res Treat. 111, 27-44.
Tang P., Wang J. and Bourne P. (2008). Molecular classifications of
breast carcinoma with similar terminology and different definitions:
are they the same? Hum. Pathol. 39, 506-513.
Thomas P.A., Kirschmann D.A., Cerhan J.R., Folberg R., Seftor E.A.,
Sellers T.A. and Hendrix M.J. (1999). Association between keratin
and vimentin expression, malignant phenotype, and survival in
postmenopausal breast cancer patients. Clin. Cancer Res. 5, 2698-
2703.
Tischkowitz M., Brunet J.S., Begin L.R., Huntsman D.G., Cheang M.C.,
Akslen L.A., Nielsen T.O. and Foulkes W.D. (2007). Use of
immunohistochemical markers can refine prognosis in triple negative
breast cancer. BMC Cancer 7, 134.
Tsuda H., Takarabe T., Hasegawa F., Fukutomi T. and Hirohashi S.
(2000). Large, central acellular zones indicating myoepithelial tumor
differentiation in high-grade invasive ductal carcinomas as markers
of predisposition to lung and brain metastases. Am. J. Surg. Pathol.
24, 197-202.
Turner N.C., Reis-Filho J.S., Russell A.M., Springall R.J., Ryder K.,
Steele D., Savage K., Gillett C.E., Schmitt F.C., Ashworth A. and
Tutt A.N. (2007). BRCA1 dysfunction in sporadic basal-like breast
973
P-cadherin, Vimentin and CK14 in basal-like-breast carcinomas
cancer. Oncogene 26, 2126-2132.
van de Rijn M., Perou C.M., Tibshirani R., Haas P., Kallioniemi O.,
Kononen J., Torhorst J., Sauter G., Zuber M., Kochli O.R., Mross F.,
Dieterich H., Seitz R., Ross D., Botstein D. and Brown P. (2002).
Expression of cytokeratins 17 and 5 identifies a group of breast
carcinomas with poor clinical outcome. Am. J. Pathol. 161, 1991-
1996.
van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M.,
Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T.,
Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards
R. and Friend S.H. (2002). Gene expression profiling predicts clinical
outcome of breast cancer. Nature 415, 530-536.
Accepted February 5, 2010
974
P-cadherin, Vimentin and CK14 in basal-like-breast carcinomas
!
  
 
 
 
 
 
 
 
 
 
PUBLICATIONS 
 Paper 6
 

Monocarboxylate transporter 1 is up-regulated in basal-like
breast carcinoma
Ce´line Pinheiro,1 Andre´ Albergaria,1,2 Joana Paredes,2 Ba´rbara Sousa,2 Rozany Dufloth,3
Daniella Vieira,3 Fernando Schmitt2,4 & Fa´tima Baltazar1
1Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of Gualtar,
Braga, 2IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal,
3Federal University of Santa Catarina – UFSC – Floriano´polis (SC), Brazil, and 4Medical Faculty of the University of
Porto, Porto, Portugal
Date of submission 10 March 2009
Accepted for publication 1 September 2009
Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F & Baltazar F
(2010) Histopathology 56, 860–867
Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma
Aims: Monocarboxylate transporters (MCTs) have been
considered promising targets for cancer therapy, since
they facilitate lactate efflux in glycolytic tumours.
However, their role in solid tumours is still poorly
understood. Thus, the present work aimed to contrib-
ute to understanding the involvement of MCT1 and
MCT4 in breast cancer progression as well as MCT
regulation by CD147.
Methods and results: The expression of the membrane
transporters MCT1 and MCT4 was analysed in a series
of breast carcinomas (249 cases) and their clinicopath-
ological significance investigated. Additionally, we
analysed the significance of CD147 co-expression, as
an important regulator of MCT expression and activity.
MCT1 was significantly increased in breast carcinomas
when compared with normal breast tissue and, impor-
tantly, both MCT1 and CD147 were associated with
poor prognostic variables such as basal-like subtype
and high grade tumours.
Conclusions: These results provide evidence for a prog-
nostic value of MCT1 in breast carcinoma and support
the exploitation of the complex MCT1 ⁄ CD147 as a
promising target for cancer therapy, especially in basal-
like breast carcinoma.
Keywords: breast carcinoma, CD147, immunohistochemistry, monocarboxylate transporter
Abbreviations: CK, cytokeratin; DAB, 3,3¢-diaminobenzidine; DCIS, ductal carcinoma in situ; EGFR, epidermal
growth factor receptor; ER, oestrogen receptor; MCTs, monocarboxylate transporters; PR, progesterone receptor;
TMA, tissue microarray
Introduction
Despite advances in cancer therapy, breast cancer is
still the leading cause of cancer-related death in women
worldwide.1 Breast cancer can be classified according
to gene expression profiles into four main groups:
basal-like, luminal (A and B), HER2+ and normal-like
breast carcinomas,2–7 which have important prognos-
tic implications: basal-like and HER2+ tumours have
more aggressive clinical behaviour when compared
with luminal and normal-like breast carcinomas.2–4,6,7
Basal-like breast carcinomas, in contrast to the other
groups, do not have a specific molecular therapy,
necessitating the search for new molecular targets in
this aggressive group of tumours.8,9
The extracellular pH of solid tumours is generally
low, whereas cytosolic pH is normal or higher than
that of normal tissues.10,11 In breast cancer cells, this
lower extracellular pH is explained by, inter alia,
two complementary mechanisms: increased lactate
production through glycolysis and proton-pump activ-
ity in the plasma membrane. The former, which is
quantitatively more important, is consistent with the
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known high glycolytic rates of cancer cells, especially
under anaerobic conditions, which results in produc-
tion of large amounts of lactate.12 Acidification of the
extracellular microenvironment has several implica-
tions in tumour progression, e.g. up-regulation of
various angiogenic molecules including vascular endo-
thelial growth factor,13,14 which support tumour
growth, invasion and metastasis, and up-regulation of
proteases implicated in cancer cell invasiveness,
through digestion of the extracellular matrix.14
One of the most important mechanisms involved in
intracellular pH regulation is the co-transport of lactate
and a proton, which is mediated by a family of
membrane proteins known as monocarboxylate trans-
porters (MCTs).15 These proteins are also responsible
for the transport of pyruvate and ketone bodies, being
critical for metabolic communication between cells.16
Taking into consideration the high glycolytic rates of
cancer cells, it is to be expected that MCTs would be
up-regulated, to allow maintenance of glycolysis rates
and prevent apoptosis by intracellular acidosis. Indeed,
there is evidence for the up-regulation of MCTs in
several tumours.17–24 However, only a few studies
have evaluated the clinicopathological significance of
MCT overexpression.23–25 We have recently described
MCT1 and MCT4 overexpression in colorectal car-
cinomas, as well as an association between plasma
membrane expression of MCT1 and vascular inva-
sion.24 Furthermore, we observed an increase in MCT1
and MCT4 during progression to invasive cervical
carcinoma and an association between both MCT1 and
MCT4 expression and high-risk human papillomavirus
infection.23 Moreover, we observed preferential expres-
sion of MCT4 in intestinal-type gastric carcinoma,
although with a decrease in MCT4 expression from
normal to malignant gastric mucosa.25
To the best of our knowledge, MCT analysis in breast
cancer samples has been performed in only one study,
where silencing of MCT1 by methylation of the 5¢
region of the gene was suggested, in four of 19 breast
cancer samples.26 However, this result is far from
clarifying the role of MCTs in breast cancer develop-
ment and ⁄ or progression.
It was recently demonstrated that CD147, a known
key regulator of oncogenesis,27–29 is an ancillary
protein required for cell surface expression and activity
of MCT1 and MCT4.30–32 On the other hand, silencing
studies have shown that maturation and cell sur-
face expression of CD147 depends on both MCT1 and
MCT4 expression.33,34 Recently, and supporting
this evidence, we described a close association
between both MCT1 and MCT4 and CD147 in cervical
cancer.35
In the present work, we sought to assess the
involvement of MCT1 and MCT4 in breast cancer
progression by analysing the expression of these
membrane transporters in a series of breast carcino-
mas, and to investigate its clinicopathological signifi-
cance. We also aimed to contribute to the
understanding of MCT regulation by CD147 in
tumours, by analysing the significance of MCT and
CD147 co-expression in breast carcinoma.
Materials and methods
case selection
Case selection was based on availability of follow-up
information and amount of material, ensuring adequate
numbers for statistical analysis. Thus, a series of 249
formalin-fixed paraffin-embedded primary breast carci-
nomas was retrieved from the files of the Department of
Pathology, Hospital do Divino Espı´rito Santo (Azores,
Portugal) and from the Federal University of Santa
Catarina (Floriano´polis-SC, Brazil). Samples were
obtained from patients aged 30–89 years. Haematoxy-
lin and eosin-stained sections of all cases were reviewed
by three pathologists (R.D., D.V. and F.S.) and the
diagnoses were confirmed as follows: 208 invasive
ductal carcinomas, seven invasive lobular carcinomas,
three mixed lobular-ductal carcinomas, three tubular,
eight medullary and 20 invasive breast carcinomas of
other special histological types. Representative areas of
tumour samples, as well as 53 samples of normal breast
tissue, mostly from the same breast with tumour, were
carefully selected and organized into tissue microarrays
(TMAs), with cores of 2 mm diameter. Each case was
represented in the TMA by at least two cores. In 45
cases, areas of ductal carcinoma in situ (DCIS) were
present and were also analysed. Relevant clinicopath-
ological data from these tumours included tumour size,
molecular classification, histological grade and lymph
node metastasis. The distribution of prognostic factors
with a high number of cases with lymph nodemetastasis
and oestrogen receptor (ER)-negative status, reflects a
large number of cancer patients with advanced disease.
The molecular classification was carried out based
on immunohistochemical results for ER, progesterone
receptor (PR), HER2, epidermal growth factor receptor,
cytokeratin (CK) 5, CK14, vimentin and Ki67.
Tumours positive for ER and ⁄ or PR were classified as
luminal. Cases positive for ER ⁄ PR and for HER2
and ⁄ or high Ki67 index were subclassified as luminal B.
Cases classified as HER2 overexpressing were char-
acterized by HER2 overexpression and negativity for
ER ⁄ PR, and cases defined as ‘basal-like’ were negative
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for ER ⁄ PR and HER2 and positive for at least one of the
‘basal markers’ tested.
Follow-up information was available for 218 cases,
ranging from a minimum of two to a maximum of
129 months (median 32 months). Disease-free survival
interval data were evaluated and defined as the time
from the date of surgery to the date of breast cancer-
derived relapse ⁄ metastasis. Due to the short follow-up
of the studied series and consequent limited number of
death events, overall survival was not analysed.
This study was conducted under the relevant
national law regulating the usage of biological speci-
mens from tumour banks, where the samples are
exclusively available for research purposes in the case
of retrospective studies.
immunohistochemistry
MCT detection
Immunohistochemistry was performed according to
the avidin–biotin–peroxidase complex principle [R.T.U.
VECTASTAIN Elite ABC Kit (Universal); Vector Labo-
ratories, Burlingame, CA, USA], with the primary
antibodies for MCT1 (AB3538P; Chemicon Interna-
tional, Temecula, CA, USA) and MCT4 (AB3316P;
Chemicon International), diluted 1:200 for MCT1 and
1:100 for MCT4, as previously described.23–25 Briefly,
deparaffinized and rehydrated tissue sections were
submitted to antigen retrieval by immersion in citrate
buffer (0.01 m, pH 6.0) and heated to 98!C for 20 min,
in a water bath. Tissues were then incubated with the
primary antibody overnight at room temperature and
immunoreactivity was visualized with 3,3¢-diamino-
benzidine (DAB+ Substrate System; Dako, Carpinteria,
CA, USA). Colonic carcinoma was used as positive
control for both MCT1 and MCT4.
CD147 detection
Immunohistochemistry was performed according to
the avidin–biotin–peroxidase complex principle (Ultra-
vision Detection System Anti-polyvalent, Horseradish
peroxidase; Lab Vision Corp., Fremont, CA, USA), using
a primary antibody raised against CD147 (18-7344;
Zymed Laboratories Inc., South San Francisco, CA,
USA) diluted 1:750, as previously described.35 Briefly,
deparaffinized and rehydrated tissue sections were
submitted to antigen retrieval by immersion in ethy-
lenediamine tetraaceticacid (pH 8.0) heated to 98!C for
15 min, in a water bath. Tissues were then incubated
with the primary antibody, 2 h at room temperature,
and immunoreactivity was visualized with DAB
(DAB+ Substrate System; Dako). Cervical squamous
carcinoma was used as positive control.
Immunohistochemical evaluation
Since plasma membrane location is essential for protein
activity, immunoreactions for MCTs and CD147 were
considered positive only when plasma membrane
reactivity was present. Sections were scored semiquan-
titatively in relation to the positive control as previ-
ously described:23–25,35 0, 0% of immunoreactive cells;
1, <5% of immunoreactive cells; 2, 5–50% of immu-
noreactive cells; and 3, >50% of immunoreactive cells.
Also, intensity of staining was scored as: 0, negative; 1,
weak; 2, intermediate; and 3, strong. Final immuno-
reactivity score was defined as the sum of both
parameters (extent and intensity), and grouped as
negative (score 0 and 2) and positive (3–6). Evaluation
was performed blindly by two independent observers
and discordant results were discussed at a double-head
microscope to reach the final score.
statistical analysis
Data were stored and analysed using Statview statis-
tical software (SAS Institute Inc., Cary, NC, USA). All
comparisons were examined for statistical significance
using Pearson’s chi-squared test or Fisher’s exact test,
as appropriate; the threshold for significance was set at
P < 0.05. Disease-free survival curves were estimated
by the method of Kaplan–Meier and data compared
using the log rank test. A cut-off of 60 months
(5 years) was considered, since in the first 5 years
following primary therapy recurrence rates are
expected to be highest, especially in series with high
numbers of ER–cases like ours, where the hazard of
recurrence is higher.36 Cases lacking one or more of the
clinicopathological variables were not included in the
specific statistical analysis.
Results
A total of 249 breast carcinoma samples for MCT1,
MCT4 and CD147 immunohistochemical expression
were analysed. Due to technical problems (mainly
tissue loss during immunohistochemistry), some cases
are missing in the expression analysis.
MCT1 expression was mainly found at the plasma
membrane whereas MCT4 was observed both in the
cytoplasm and plasma membrane (Figure 1A,B).
CD147 was mainly detected at the plasma membrane
(Figure 1C), with some cases also showing cytoplasmic
immunoreactivity. Table 1 summarizes the frequency
of MCT and CD147 expression in non-neoplastic
mammary epithelium and tumour samples. A signifi-
cant increase in MCT1 expression was observed in
tumours when compared with normal tissues
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(P = 0.0138), with 19.5% of tumours showing MCT1
expression, while no significant difference was observed
for MCT4 and CD147.
Analysis of CD147 and MCT plasma membrane
expression showed an association between CD147 and
both MCT1 and MCT4 (P < 0.0001 and P = 0.0083,
respectively, Table 2). DCIS, when present in tissue
sections, was also evaluated for MCT and CD147
expression. DCIS was found in 45 sections, and results
for MCT and CD147 expression were always concor-
dant with the corresponding invasive lesion.
Biological and clinical data available allowed the
assessment of correlations with MCT and CD147
expression (Table 3). Importantly, we found significant
correlations between prognostic parameters and both
MCT and CD147 membranous expression. Correlations
between MCT1 expression and basal-like subtype
(P < 0.0001), high histological grade (P = 0.0003),
absence of ER and PR expression (P < 0.0001 and
P = 0.0001, respectively), CK5 and CK14 expression
(P = 0.0362 and P = 0.0006, respectively), vimentin
expression (P < 0.0001) and Ki67 expression (P =
0.0297) were observed. No association was observed
between MCT4 expression and clinicopathological
Table 1. Frequency of monocarboxylate transporter (MCT)
1, MCT4 and CD147 expression in breast carcinoma tissues
compared with normal breast epithelium
n Positive (%) P
MCT1
Normal breast epithelium 53 3 (5.7) 0.0138
Breast carcinoma 221 43 (19.4)
MCT4
Normal breast epithelium 45 0 (0.0) 0.0823
Breast carcinoma 219 16 (7.3)
CD147
Normal breast epithelium 47 2 (4.2) 0.2570
Breast carcinoma 219 24 (11.0)
Significant values are shown in bold.
Table 2. Association between CD147 and monocarboxylate
transporter (MCT) expression in breast carcinoma samples
n
CD147
Positive (%) P
MCT1
Negative 172 5 (2.9) <0.0001
Positive 42 19 (45.2)
MCT4
Negative 200 19 (9.5) 0.0083
Positive 16 5 (31.2)
Significant values are shown in bold.
A
B
C
Figure 1. Immunohistochemical expression of monocarboxylate
transporter (MCT) 1, MCT4 and CD147 in breast carcinoma samples.
MCT1 expression is mainly found on the plasma membrane of
tumour cells (A), whereas MCT4 reactivity is found both in the
cytoplasm and plasma membrane (B). CD147 is mainly observed on
the plasma membrane of tumour cells (C).
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Table 3. Associations of monocarboxylate transporter (MCT) 1, MCT4 and CD147 expression with clinicopathological data
from breast cancer cases
Clinicopathological
data
MCT1 MCT4 CD147
n Positive (%) P n Positive (%) P n Positive (%) P
Tumour size, mm
<20 73 10 (13.7) 0.2544 72 6 (8.3) 0.3152 73 7 (9.6) 0.7334
20–50 105 21 (20.0) 104 9 (8.6) 104 13 (12.5)
>50 25 7 (28.0) 25 0 (0.0) 25 2 (8.0)
Subtype
Luminal 125 13 (10.4) <0.0001 122 10 (8.2) 0.9529 123 5 (4.1) <0.0001
Basal-like 42 21 (50.0) 42 3 (7.1) 42 14 (33.3)
HER2 overexpressing 32 5 (15.6) 33 3 (9.1) 32 4 (12.5)
Histological grade
I 45 5 (11.1) 0.0003 43 5 (11.6) 0.1637 44 0 (0.0) <0.0001
II 104 13 (12.5) 103 4 (3.9) 102 6 (5.9)
III 71 25 (35.2) 71 7 (9.8) 71 18 (25.4)
Oestrogen receptor
Negative 95 30 (31.6) <0.0001 95 6 (6.3) 0.5989 93 19 (20.4) 0.0002
Positive 125 13 (10.4) 122 10 (8.2) 123 5 (4.1)
Progesterone receptor
Negative 137 38 (27.7) 0.0001 139 11 (7.9) 0.6843 136 22 (16.2) 0.0014
Positive 80 5 (6.2) 78 5 (6.4) 80 2 (2.5)
HER2 overexpression
Negative 175 37 (21.1) 0.2135 172 11 (6.4) 0.4959 174 19 (10.9) >0.9999
Positive 40 5 (12.5) 41 4 (9.8) 39 4 (10.2)
EGFR
Negative 206 39 (18.9) 0.2343 204 14 (6.9) 0.1925 204 21 (10.3) 0.1108
Positive 11 4 (36.4) 11 2 (18.2) 11 3 (27.3)
CK5
Negative 174 29 (16.7) 0.0362 171 10 (5.8) 0.0974 170 14 (8.2) 0.0116
Positive 46 14 (30.4) 46 6 (13.0) 47 10 (21.3)
CK14
Negative 201 34 (16.9) 0.0006 199 15 (7.5) >0.9999 199 17 (8.5) <0.0001
Positive 15 8 (53.3) 15 1 (6.7) 15 7 (46.7)
Vimentin
Negative 175 26 (14.8) <0.0001 173 12 (6.9) 0.4869 172 9 (5.2) <0.0001
Positive 36 17 (47.2) 36 4 (11.1) 36 15 (41.7)
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factors. CD147 expression associations were very
similar to those of MCT1: CD147 correlated with
basal-like subtype (P < 0.0001), high histological
grade (P < 0.0001), absence of ER and PR expression
(P = 0.0002 and P = 0.0014, respectively), CK5 and
CK14 expression (P = 0.0116 and P < 0.0001, respec-
tively), vimentin expression (P < 0.0001) and Ki67
expression (P = 0.0179).
When analysing MCT1 ⁄ CD147 co-expression (data
not shown) as an indicator of transporter activity, we
observed the same associations as for MCT1 and
CD147 alone. The clinicopathological significance of
MCT4 ⁄ CD147 co-expression was not assessed since the
number of cases co-expressing these two molecules was
very low (n = 5).
Kaplan–Meier survival curves were estimated for
each marker (MCTs and CD147), but no significant
correlations were found (data not shown).
Discussion
Some evidence points to MCTs as potential targets for
cancer therapy.19,22,37 However, the role of these
proteins in solid tumour development and survival is
still unclear, especially in breast cancer, where there is
a very limited number of studies.
A previous report on breast cancer has suggested
a possible silencing of MCT1 expression.26 However,
in the present study we showed a significant gain in
MCT1 plasma membrane expression and no significant
alteration in MCT4 expression in tumours when
compared with non-neoplastic tissue. Considering the
metabolic alterations of cancer, where high glycolytic
rates lead to high levels of lactate, an increase in MCT1
expression would allow continuous glycolysis, avoiding
intracellular acidosis and subsequent apoptosis. Also,
and importantly, this would give a powerful growth
advantage to cancer cells, necessary for progression to
invasiveness.38 Notably, and besides the increased
expression in tumour cells, the presence of MCT1 in
the plasma membrane was associated with various
clinical and biological parameters. Importantly, MCT1
expression correlated with a basal-like phenotype, and,
as expected, was associated with most of the basal
markers studied, such as CK5, CK14 and vimentin, and
inversely associated with the expression of ER and PR.
These results are supported by data available in expres-
sion array datasets (ONCOMINE),39 where increased
expression in MCT1 can be seen in basal-like breast
carcinoma.40,41 Other correlations, such as the associ-
ation with Ki67 proliferative index and high histolog-
ical grade, suggest that MCT1 is present in more
aggressive tumours.
Taking into consideration the need to export lactate
in cancer cells and the fact that MCT4 is a low-
affinity transporter found in highly glycolytic tis-
sues,42 an increase in MCT4 expression would be
expected in breast tumours, similar to that observed
in both colorectal24 and cervical carcinomas.23 How-
ever, in the present work, although MCT4 was not
expressed in normal tissue and was detected in the
plasma membrane of some tumour samples, this
increase was not significant. Thus, our results point
to preferential expression of the MCT isoform 1, as
an adaptation to a malignant phenotype. Actually,
despite the similar physiological function of MCT1
and MCT4, they are regulated by different mecha-
nisms; for example, it has recently been described that
hypoxia-inducible factor 1a, a major regulator of
tumour cell adaptation to hypoxic stress, up-regulates
MCT4, but not MCT1.43
CD147, a protein that, among many other
functions,27–29 stimulates synthesis of matrix meta-
lloproteinases, is up-regulated in many human
Table 3. (Continued )
Clinicopathological
data
MCT1 MCT4 CD147
n Positive (%) P n Positive (%) P n Positive (%) P
Ki67
<20% 139 21 (15.1) 0.0297 138 9 (6.5) 0.5258 138 10 (7.2) 0.0179
>20% 81 22 (27.2) 79 7 (8.9) 79 14 (17.7)
Lymph node metastasis
Absent 95 21 (22.1) 0.2771 92 7 (7.6) 0.8866 95 15 (15.8) 0.1566
Present 100 16 (16.0) 99 7 (7.1) 99 9 (9.1)
EGFR, Epidermal growth factor receptor; CK, cytokeratin.
Significant values are shown in bold.
MCT1 in breast cancer 865
! 2010 Blackwell Publishing Ltd, Histopathology, 56, 860–867.
cancers,27,28,44,45 including breast carcinomas,44,45
where it is described as a prognostic factor.44 In the
present work, this documented increase in CD147 was
not observed, but the close association with both
MCT1 and MCT4 previously demonstrated25,30–35 was
confirmed in the breast tumour samples analysed here.
As observed for MCT1, CD147 expression was more
frequently found in basal-like, ER– and PR– and high
histological grade tumours as well as in tumours
expressing CK5, CK14, vimentin and Ki67, which is in
accordance with previous results on CD147 expression
in breast carcinoma.44 MCT1 ⁄ CD147 co-expression
showed similar associations with MCT1 and CD147
alone. A similar importance for MCT1 ⁄ CD147 co-
expression in gastric cancer has already been described
by our group in gastric cancer, where we observed an
association of MCT1 ⁄ CD147 co-expression with indi-
cators of worse prognosis, such as advanced gastric
cancer, higher TNM staging and presence of lymph
node metastasis.25 However, although these associa-
tions may be mostly attributed to CD147 and its many
functions in cancer,27–29 MCT1 alone also appears to
have an important role in tumours with worse prog-
nosis, as evidenced by the significant results obtained.
Importantly, it should be noted that less than half of
cases expressing MCT1 and MCT4 on the plasma
membrane co-express CD147. This suggests that MCT
trafficking to the plasma membrane might be depen-
dent on another ancillary protein, as pointed out by
recent in vitro evidence.46
In the present study, we have investigated the
expression of MCT isoforms 1 and 4, and their
chaperone CD147. Most importantly, we have evalu-
ated for the first time the correlation between MCT
expression in breast cancer and the clinicopathological
data. It is important to highlight that MCT1 is up-
regulated in a subset of aggressive breast carcinomas
(basal-like) and, since these tumours do not have a
specific molecular therapy,8 the development of ther-
apeutic approaches targeting MCT1 could be a prom-
ising strategy to treat such tumours. However, other
studies, including in vitro approaches are warranted to
confirm these observations.
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Alterations in Vitamin D signalling and metabolic
pathways in breast cancer progression: a study of
VDR, CYP27B1 and CYP24A1 expression in benign
and malignant breast lesions Vitamin D pathways
unbalanced in breast lesions
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Abstract
Background: Breast cancer is a heterogeneous disease associated with different patient prognosis and responses
to therapy. Vitamin D has been emerging as a potential treatment for cancer, as it has been demonstrated that it
modulates proliferation, apoptosis, invasion and metastasis, among others. It acts mostly through the Vitamin D
receptor (VDR) and the synthesis and degradation of this hormone are regulated by the enzymes CYP27B1 and
CYP24A1, respectively. We aimed to study the expression of these three proteins by immunohistochemistry in a
series of breast lesions.
Methods: We have used a cohort comprising normal breast, benign mammary lesions, carcinomas in situ and
invasive carcinomas and assessed the expression of the VDR, CYP27B1 and CYP24A1 by immunohistochemistry.
Results: The results that we have obtained show that all proteins are expressed in the various breast tissues,
although at different amounts. The VDR was frequently expressed in benign lesions (93.5%) and its levels of
expression were diminished in invasive tumours (56.2%). Additionally, the VDR was strongly associated with the
oestrogen receptor positivity in breast carcinomas. CYP27B1 expression is slightly lower in invasive carcinomas
(44.6%) than in benign lesions (55.8%). In contrast, CYP24A1 expression was augmented in carcinomas (56.0% in in
situ and 53.7% in invasive carcinomas) when compared with that in benign lesions (19.0%).
Conclusions: From this study, we conclude that there is a deregulation of the Vitamin D signalling and metabolic
pathways in breast cancer, favouring tumour progression. Thus, during mammary malignant transformation,
tumour cells lose their ability to synthesize the active form of Vitamin D and respond to VDR-mediated Vitamin D
effects, while increasing their ability to degrade this hormone.
Background
Breast cancer is one of the major causes of death by
cancer in women worldwide [1]. Nowadays, breast can-
cer is no longer considered to be a single disease, but is
rather comprised of distinct tumour subtypes displaying
different clinical outcomes [2]. Over the lifetime of the
individual, in order to a tumour to develop it needs a
combination of low-penetrance genetic factors and
environmental aspects. Ultimately, cancer results from
alterations in the control of the complex balance of pro-
liferation, differentiation and programmed cell death [3]
and these processes appear to be regulated by intrinsic
and extrinsic factors, like niche signals, hormonal and
dietary aspects, among others [4], [5].
Vitamin D is a lipid soluble substance that belongs to
the family of secosteroid hormones. Its physiological
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role has been classically associated with calcium regula-
tion and phosphate transport in bone metabolism. Apart
from this endocrine role, subsequent studies have
widened the range of functions for Vitamin D and this
has been particularly important in the field of cancer
research. Several authors have demonstrated, in various
models of cancer (including the breast), the ability of
Vitamin D to perform autocrine and paracrine func-
tions. Specifically, it has been demonstrated the capacity
to modulate cancer features, namely proliferation and
differentiation [6], apoptosis [7], angiogenesis [8], inva-
sion and metastasis [9].
Vitamin D exerts most of its biological activities by bind-
ing to a specific high-affinity receptor, the Vitamin D
Receptor (VDR), that was first identified in a breast cancer
cell line in 1979 [10]. The VDR belongs to the superfamily
of nuclear receptors for steroid hormones and regulates
gene expression by acting as a ligand-activated transcrip-
tion factor [11]. Several studies have demonstrated that
the VDR knockout mice display a higher incidence rate of
carcinogen-induced preneoplastic breast lesions when
compared with their littermates [12], [13]. These reports
highlight the importance of the VDR deficiency in sensitiz-
ing the mammary gland to transformation in response to a
carcinogenic agent. Immunohistochemical studies have
confirmed that the VDR is expressed in samples from nor-
mal breast tissues [14] and also in breast cancer biopsy
specimens [15]. Because the VDR is expressed in the
mammary gland and Vitamin D has been shown to display
anticarcinogenic properties, this hormone has emerged as
a promising targeted therapy. But in order to keep the
homeostasis of the organism the amount of circulating
Vitamin D has to be tightly regulated. This is a very com-
plex process, in which the main components are the
enzymes 1a-hydroxylase/CYP27B1 (encoded by the gene
CYP27B1) and 24-hydroxylase/CYP24A1 (encoded by the
gene CYP24A1). CYP27B1 is responsible for the synthesis
of the biologically active form of Vitamin D (1,25-dihy-
droxyvitamin D), whereas CYP24A1 mediates the catabo-
lism of Vitamin D [16]. Several studies have focused their
attention in the comparison of the levels of these enzymes
in normal and tumour tissue. It has been observed that
both CYP27B1 and CYP24A1 are up-regulated in breast
tumours when compared with normal tissue. However,
deregulated expression of CYP24A1 seems to abrogate the
effects of CYP27B1, resulting in the degradation of Vita-
min D to less active metabolites [17]. In contrast, a recent
paper has demonstrated that CYP27B1 mRNA in breast
tumours is decreased in comparison with normal mam-
mary tissue [18]. Despite these findings, no reports regard-
ing the expression by immunohistochemistry of the VDR,
CYP27B1 and CYP24A1 in the mammary gland have been
described. The main purpose of this work was to perform
an immunohistochemical study of the expression of the
VDR, CYP27B1 and CYP24A1 in a comprehensive series
of human breast tissues comprised of normal breast,
benign mammary lesions, carcinomas in situ and invasive
breast carcinomas.
Methods
Patient’s selection and Tissue Microarray construction
We have studied a cohort of 379 benign lesion samples
and 189 cases of carcinomas in situ, collected from the
archives of the Pathology Department of General Hospital
of UNIMED in Araçatuba, Brazil. Three hundred and fifty
cases of invasive breast carcinomas were retrieved from
the archives of the Pathology Department of the Federal
University of Santa Catarina, Florianópolis, Brazil (161
cases) and from the Pathology Department of General
Hospital of UNIMED in Araçatuba, Brazil (189 tumour
samples). This last series of 189 invasive carcinomas con-
tains, in the same block, the aforementioned carcinomas
in situ. Additionally, 29 cases of normal breast tissue were
included in the study. The normal breast tissue, carcino-
mas in situ and invasive tumour samples were collected
between 1994 and 2004. The series of benign lesions was
collected between 2002 and 2006.
Representative areas of the different lesions were care-
fully selected on the H&E-stained sections, by 2 pathol-
ogists (DV and LAV) and marked on individual paraffin
blocks. Two tissue cores (2 mm in diameter) were
obtained from each selected specimen and precisely
deposited into a recipient paraffin block using a TMA
(Tissue Microarray) workstation (TMA builder, LabVi-
sion Corporation, USA). Several TMA blocks were con-
structed (40 for the invasive breast carcinomas, 22 for
the carcinomas in situ and 17 for the benign lesions),
each containing 24 tissue cores, arranged in a 4×6 sec-
tor. In each TMA block, at least 3 nonneoplastic breast
tissue cores were also included as controls and 1 core of
a non-breast sample (we have used testicular and liver
tissues). To homogenize the paraffin of the receptor
block and the paraffin of the cores extracted from the
donor blocks, the TMAs were kept at 37°C for 3 hours.
After construction, 2-μm tissue sections were cut and
adhered to Superfrost Plus glass slides. An H&E-stained
section from each block was reviewed to confirm the
presence of morphological representative areas of the
original lesions.
The present study has been conducted under the
national regulative law for the usage of biological speci-
mens from tumour banks, where the samples are exclu-
sively available for research purposes in the case of
retrospective studies.
Immunohistochemistry
Immunohistochemical staining for Oestrogen Receptor
(ER), HER2 and CK5 (Cytokeratin 5) was performed
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using the streptavidin-biotin-peroxidase technique (Lab-
Vision Corporation) in each set of glass slides compris-
ing the TMAs, whereas P-cadherin (P-cad), EGFR
(Epidermal Growth Factor Receptor) and Progesterone
Receptor (PgR) used the HRP labelled polymer (Dako-
Cytomation, USA) as described elsewhere [19]. Antigen
unmasking for VDR was performed using a solution of
pepsin A (4 g/L; Sigma-Aldrich) for 30 minutes at 37°C.
Epitope retrieval for CYP27B1 and CYP24A1 was per-
formed using a dilution of 1:100 of citrate buffer, pH =
6.0 (Vector Laboratories, Burlingame, CA, USA) at 98°C
for 30 minutes. The antigen retrieval times, antibodies,
dilutions and suppliers are listed in Table 1. Primary
antibody incubation was performed overnight at 4°C for
VDR and CYP24A1 and for 1 h at room temperature
for CYP27B1. After washes, the slides were incubated
with secondary antibody associated with HRP labelled
polymer (ImmunoLogic, The Netherlands) for VDR or
incubated with biotinylated secondary antibody (Santa
Cruz, USA) followed by streptavidin-conjugated peroxi-
dase (Labvision) during 15 min for CYP24A1 and
CYP27B1, and immediately revealed with DAB (Dako-
Cytomation). Tissues were then counterstained with
Mayer’s haematoxylin, dehydrated and cover-slipped
using a permanent mounting solution (Zymed, USA).
Positive and negative controls were included in each run
in order to guarantee the reliability of the assays. Paraf-
fin sections of a basal cell carcinoma of the skin, normal
colon and normal liver were used as positive controls for
VDR, CYP27B1 and CYP24A1 expression, respectively.
Scoring and statistical analysis
The evaluation of the immunohistochemical results was
performed by three pathologists (FS, FM and LAV). VDR
nuclear expression was evaluated using the H-score
method: intensity ranked from 1 to 3 (1 - weak, 2 - mod-
erate, 3 - strong), and extension ranked from 1 to 10 (1 -
0-10% cells, 2 - 11-20% cells and so on, until a maximum
score of 10) [20]. The scores for intensity and extension
were multiplied and the following criterion was applied:
the cases were considered negative when ranging from 1
to 4; samples ranking from 5 to 30 were considered to be
positive. Considering the lack of previous reports for the
immunohistochemical evaluation of the CYP27B1 and
CYP24A1, we considered the cases to be positive only
when cytoplasmic staining was observed. The other
markers were scored as described in previous studies
from our group [19], [21].
The Statview 5.0 software package (SAS Institute,
USA) was used for all statistical analysis. Correlations
between discrete variables were performed using the
chi-square test and analysis of variance was employed to
search for associations between continuous and discrete
variables. In all analyses, a p value < 0.05 was considered
to be statistically significant.
Cell culture and Western blotting
MDA-MB-231 breast cancer cells were grown in com-
plete Dulbecco’s Modified Eagle Medium (DMEM) in
the presence of 10% foetal bovine serum (Invitrogen,
USA). Treatments with Vitamin D 100 nM (Cayman
Chemical, USA) and ethanol (vehicle) were performed
for 72 h, while the treatment with PTH (Parathyroid
Hormone) (Sigma-Aldrich, Germany) 100 nM and water
(vehicle) were performed for 4 h. Total cell lysates were
obtained and the samples were separated in an SDS-
polyacrylamide gel. After blotting into a nitrocellulose
membrane (GE Healthcare Life Sciences, UK), staining
for CYP27B1 and CYP24A1 was performed using the
antibodies (Santa Cruz, USA) presented on Table 1
overnight at a dilution of 1:200. After washes, the mem-
branes were incubated with a mouse anti-goat HRP sec-
ondary antibody (Santa Cruz) and were revealed with
ECL (GE Healthcare Life Sciences).
RNA extraction and Real-time PCR
RNA was extracted from formalin-fixed paraffin-
embedded breast lesions using the RecoverAll Total
Nucleic Acid Isolation Kit (Ambion, USA), according to
the manufacturer’s protocol. After extraction, RNA was
quantified using NanoDrop spectrophotometer (Thermo
Scientific, USA). cDNA was synthesized using the
Omniscript Reverse Transcription kit (Qiagen, Germany)
following the manufacturer’s instructions. Finally, real-
time PCR was performed using TaqMan Gene Expres-
sion Assays (Applied Biosystems, USA), using 2 mL of
cDNA and in accordance to the manufacturer’s protocol.
The TaqMan Gene Expression Assays used were
Hs00172113_m1 (VDR), Hs00168017_m1 (CYP27B1)
and Hs00167999_m1 (CYP24A1). Reactions were per-
formed using standard cycle parameters on an ABI
PRISM Sequence 7000 Detection System (Applied
Table 1 Sources and dilutions of primary antibodies related to the Vitamin D metabolism used in this study for
immunohistochemistry
Antibody Clone Manufacturer Time of incubation (min) Dilution Antigen retrieval (min)
VDR 9A7gE10.4 Calbiochem, Germany overnight 1:50 30
CYP27B1 C12 Santa Cruz, USA 60 1:200 30
CYP24A1 C18 Santa Cruz, USA overnight 1:75 30
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Biosystems). Relative transcript levels were determined
using Human GAPDH Endogenous Control (Applied
Biosystems) as an internal reference. Differences between
the breast tissue samples were determined using com-
parative delta CT method [22]. All reactions were done in
triplicate and expressed as mean of the values from three
separate experiments.
Results
VDR, CYP27B1 and CYP24A1 immunohistochemical
staining
The expression patterns of the VDR, CYP27B1 and
CYP24A1 have been evaluated by immunohistochemistry
in 947 breast tissue samples arranged in 79 TMAs. From
this set of cases, some samples could not be assessed due
to the fact that either the core had fallen out or it did not
have enough biological material to study. In all TMAs,
positive and negative cases were obtained for each protein.
The immunostainings for these markers had been pre-
viously validated in whole tissue sections with an overall
agreement of 90%. A panel with representative immunos-
tainings for each protein in different breast tissues is
shown in Figure 1. We have observed that the VDR
displays nuclear staining, as would be expected from a
nuclear receptor which acts as a transcription factor. Con-
sidering CYP27B1 and CYP24A1 expression, nothing has
ever been described on their expression status in the
mammary gland, as far as we know. This is the first report
showing the expression of these two enzymes in breast
lesions. These proteins present cytoplasmic and granular
staining, which could reflect their mitochondrial localisa-
tion. All proteins (VDR, CYP27B1 and CYP24A1) have
been found to be expressed in all lesions studied and also
in the normal breast tissue, although at different levels.
The differential expression of CYP27B1 and CYP24A1
was technically validated. MDA-MB-231 breast cancer
cells have been treated with PTH 100 nM and Vitamin
D 100 nM and total cell lysates have been extracted.
Western blotting analysis has confirmed the expression
of CYP27B1 and CYP24A1 upon treatment with the
aforementioned hormones (Additional file 1: Figure S1).
Additionally, using a group of randomly selected tissue
samples, RNA was isolated and used in real-time PCR
to confirm the immunohistochemical results (Additional
file 2: Table S1). Our results have shown that positive
cases in the TMAs displayed cDNA amplification in the
real-time PCR and the opposite situation was observed
for cases where no staining was present in the TMAs.
Expression of the VDR, CYP27B1 and CYP24A1 in
benign lesions of the mammary gland
In order to study the VDR, CYP27B1 and CYP24A1
expression in benign lesions of the mammary gland, we
have evaluated 379 cases arranged in 17 TMAs. The
series consisted of a variety of breast lesions, namely
usual and atypical ductal hyperplasias (UDH represent
20.1%, corresponding to 76 samples; while ADH repre-
sent 5.4%, corresponding to 21 samples), columnar cell
lesions (CCL - 25.6% of cases, corresponding to 97 sam-
ples), papillomatosis (16.9% of cases, corresponding to
64 samples) and adenosis (17.2% of cases, corresponding
to 65 samples). The percentage of immunoreactive cases
for the VDR was very high (93.5%, corresponding to 259
cases out of 277). Regarding the expression of CYP27B1,
we have observed 55.8% of positive cases, corresponding
to 173 lesions out of 310. Concerning CYP24A1 expres-
sion, we have detected 62 positive cases out of 327 sam-
ples (19.0%). Amongst all lesions, ADH cases were
overall less immunoreactive to the three proteins.
We have correlated the histological classification of
the benign lesions with the VDR, CYP27B1 and
CYP24A1 expression, but no significant associations
have been found (see Table 2 for further details).
Expression of the VDR, CYP27B1 and CYP24A1 in breast
carcinomas in situ
A fully characterized series of 189 breast carcinomas
in situ arranged in 22 TMAs was assessed for the
expression patterns of VDR, CYP27B1 and CYP24A1.
For the VDR, we have observed that 62 cases out of 131
cases (47.3%) displayed staining for this protein. Con-
cerning CYP27B1 expression, we have encountered posi-
tive staining in 66.4% of the cases (91 out of 137
samples); whereas CYP24A1 expression was observed in
56.0% of the tumours (70 out of 125 cases).
We have also assessed the expression of other breast
cancer biomarkers in our cohort (ER, HER2 and PgR and
basal markers as defined by our group [19] and others
[23]) and looked for the existence of correlations between
the expression of the Vitamin D partners and these mole-
cular markers (Table 3). ER expression has been observed
in 117 cases (61.9%), HER2 protein was present in 37
cases (15.6%) and PgR expression was detected in 90 cases
(47.6%). We have also tested our series for basal markers
and have obtained the following results: EGFR expression
is present in 10 cases (5.3%), CK5 is positive in 15 cases
(7.9%) and P-cadherin was observed in 36 samples
(19.0%). Expression of the VDR correlated positively with
ER status (p = 0.0227), with a higher percentage of VDR-
positive cases among the ER-positive tumours - 74.2% (46
out of 62 cases). Additionally, we have seen that there is
an inverse correlation between the expression of the VDR
and P-cadherin (p = 0.0078). CYP27B1 expression only
presented an inverse correlation (p = 0.0295) with EGFR
expression, but the number of cases positive for EGFR was
very low. No statistically significant associations have been
observed between CYP24A1 expression and the markers
studied.
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Figure 1 Immunohistochemical staining for the VDR, CYP27B1 and CYP24A1 in the different types of breast tissue
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Expression of the VDR, CYP27B1 and CYP24A1 in invasive
mammary carcinomas
We have evaluated 350 cases of invasive breast carcinomas
arranged in 40 TMAs. The cohort corresponds to 189
cases of the series for which there was an in situ compo-
nent in the adjacent area of the invasive tumour and an
additional series of 161 cases of invasive breast carcino-
mas. Positive staining for the VDR has been observed in
56.2% of the cases (172 out of 306 cases). Regarding
CYP27B1 expression, 44.6% of cases were positive
(123 out of 276 samples), whereas 53.7% of cases (151 out
of 281 tumours) presented positivity for CYP24A1.
Next, we searched for associations between the
expression of Vitamin D partners and the expression of
the molecular markers mentioned in the previous sec-
tion (Table 4). We have obtained 197 cases (56.3%)
positive for ER, 70 cases (20%) for HER2 and 143 cases
(40.9%) for PgR. As for basal markers, we have observed
that 13 cases (3.7%) were positive for EGFR expression,
48 cases (13.7%) presented positivity for CK5 and 93
cases (26.6%) stained for P-cadherin.
A statistically significant association was observed
between the VDR-positive cases and ER-positive cases
(p = 0.0002). Additionally, VDR-positive cases have also
been significantly correlated with HER2-negative cases
(p = 0.0238), but this is probably due to the low number
of positive cases for HER2 in our series of mammary
carcinomas. CYP27B1 expression presented no signifi-
cant associations with any of the markers analyzed. PgR
was the only marker that displayed an inverse correla-
tion with CYP24A1: specifically, cases positive for PgR
were mostly negative for CYP24A1 (p = 0.0485).
The series of 189 tumours with both components
(carcinomas in situ and the corresponding invasive
tumour) allowed the evaluation of the expression of the
VDR, CYP27B1 and CYP24A1 simultaneously in the
Table 2 VDR, CYP27B1 and CYP24A1 expression in the various types of benign breast lesions
VDR CYP27B1 CYP24A1
+ (%) - (%) + (%) - (%) + (%) - (%)
Usual ductal hyperplasia 84 (92.3) 7 (7.7) 57 (55.9) 45 (44.1) 23 (20.5) 89 (79.5)
Atypical ductal hyperplasia 9 (81.8) 2 (18.2) 4 (36.4) 7 (63.6) 1 (7.1) 13 (92.9)
Columnar cell lesions 63 (95.5) 3 (4.5) 43 (55.8) 34 (44.2) 13 (16.5) 66 (83.5)
Papillomatosis 45 (95.7) 2 (4.3) 30 (56.6) 23 (43.4) 9 (17.0) 44 (83.0)
Adenosis 49 (92.5) 4 (7.5) 32 (55.2) 26 (44.8) 13 (22.0) 46 (78)
p value 0.4847 0.7994 0.6842
Table 3 VDR, CYP27B1 and CYP24A1 and other breast cancer biomarkers expression in carcinomas in situ
VDR CYP27B1 CYP24A1
+ (%) - (%) + (%) - (%) + (%) - (%)
ER + (%) 46 (35.1) 38 (29.0) 58 (42.3) 29 (21.2) 41 (32.8) 36 (28.8)
- (%) 16 (12.2) 31 (23.7) 33 (24.1) 17 (12.4) 29 (23.2) 19 (15.2)
p value 0.0227 ns ns
HER2 + (%) 9 (6.9) 14 (10.7) 18 (13.1) 7 (5.1) 9 (7.2) 12 (9.6)
- (%) 53 (40.5) 55 (42.0) 73 (53.3) 39 (28.5) 61 (48.8) 43 (34.4)
p value ns ns ns
PgR + (%) 35 (26.7) 30 (22.9) 49 (35.8) 18 (13.1) 38 (30.4) 22 (17.6)
- (%) 27 (20.6) 39 (29.8) 42 (30.7) 28 (20.4) 32 (25.6) 33 (26.4)
p value ns ns ns
CK5 + (%) 3 (2.3) 8 (6.1) 7 (5.1) 4 (2.9) 8 (6.4) 4 (3.2)
- (%) 59 (45.0) 61 (46.6) 84 (61.3) 42 (30.7) 62 (49.6) 51 (40.8)
p value ns ns ns
EGFR + (%) 1 (0.8) 5 (3.8) 2 (1.5) 5 (3.7) 5 (4.0) 3 (2.4)
- (%) 61 (46.6) 64 (48.9) 89 (65.0) 41 (29.9) 65 (52.0) 52 (41.6)
p value ns 0.0295 ns
P-cad + (%) 4 (3.1) 16 (12.2) 14 (10.2) 12 (8.8) 16 (12.8) 7 (5.6)
- (%) 58 (44.3) 53 (40.5) 77 (56.2) 34 (24.8) 54 (43.2) 48 (38.4)
p value 0.0078 ns ns
ns: not significant.
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two types of tumours (Additional file 2: Table S2). The
results obtained show that the three proteins (VDR,
CYP27B1 and CYP24A1) display a statistically signifi-
cant correlation of expression between the two sections
(carcinomas in situ and the matching invasive tumour).
Thus, positive cases in the in situ component are also
positive in the invasive component and the same is
observed for the negative cases.
Expression of the VDR, CYP27B1 and CYP24A1 according
to the type of breast lesion
The frequencies of protein expression of the VDR,
CYP27B1 and CYP24A1 in the different mammary tis-
sues are shown in Figure 2. The normal mammary
gland (29 cases), as expected, is positive for the expres-
sion of the VDR in all the cases studied (100%). The
majority of the samples also displays immunostaining
for CYP27B1 (63.6%) and, in contrast, the levels of
expression of CYP24A1 are low (29.6%). The VDR is
also highly expressed in benign lesions (93.5%) with a
reduction in the percentage of positive cases in carcino-
mas in situ (47.3%) and in invasive carcinomas (56.2%).
CYP27B1 expression does not vary greatly between the
different breast lesions. However, between in situ and
invasive carcinomas, a statistically significant decrease in
the percentage of positive cases was observed (from
66.4% in carcinomas in situ to 44.6% in invasive carcino-
mas). In contrast, the expression of CYP24A1 is
increased in carcinomas (56.0% in carcinomas in situ
and 53.7% in invasive carcinomas) compared with the
benign lesions (19.0%), which are mostly negative.
Discussion
Vitamin D mediates anti-proliferative and pro-differen-
tiation signalling in various epithelial tissues, including
Table 4 VDR, CYP27B1 and CYP24A1 and other breast cancer biomarkers expression in invasive breast tumours
VDR CYP27B1 CYP24A1
+ (%) - (%) + (%) - (%) + (%) - (%)
ER + (%) 114 (37.3) 60 (19.6) 70 (25.4) 86 (31.2) 93 (33.1) 66 (23.5)
- (%) 58 (19.0) 74 (24.2) 53 (19.2) 67 (24.3) 58 (20.6) 64 (22.8)
p value 0.0002 ns ns
HER2 + (%) 26 (8.6) 34 (11.3) 31 (11.4) 25 (9.2) 29 (10.4) 30 (10.8)
- (%) 144 (47.7) 98 (32.5) 90 (33.1) 126 (46.3) 121 (43.5) 98 (35.3)
p value 0.0238 ns ns
PgR + (%) 71 (23.3) 59 (19.3) 52 (18.8) 64 (23.2) 71 (25.3) 46 (16.4)
- (%) 100 (32.8) 75 (24.6) 71 (25.7) 89 (32.2) 80 (28.5) 84 (29.9)
p value ns ns 0.0485
CK5 + (%) 27 (8.8) 19 (6.2) 15 (5.4) 24 (8.7) 27 (9.6) 16 (5.7)
- (%) 145 (47.4) 115 (37.6) 108 (39.1) 129 (46.7) 124 (44.1) 114 (40.6)
p value ns ns ns
EGFR + (%) 4 (1.3) 7 (2.3) 4 (1.5) 6 (2.2) 6 (2.1) 3 (1.1)
- (%) 166 (54.8) 126 (41.6) 118 (43.1) 146 (53.3) 145 (51.8) 126 (45.0)
p value ns ns ns
P-cad + (%) 42 (13.8) 40 (13.1) 30 (10.9) 42 (15.2) 40 (14.3) 37 (13.2)
- (%) 129 (42.3) 94 (30.8) 93 (33.7) 111 (40.2) 110 (39.3) 93 (33.2)
p value ns ns ns
ns: not significant.
Figure 2 Percentage of positive cases for VDR, CYP27B1 and
CYP24A1 in the various types of breast samples studied.
Statistical analysis shown use normal breast as reference. An
additional result is presented comparing the number of CYP27B1
positive cases between in situ and invasive carcinomas. (ns - not
significant; * p < 0.05).
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the mammary gland [6]. Therefore, it is reasonable to
assume that disruption of the Vitamin D signalling and
metabolic pathways may occur during tumour develop-
ment. To explore this hypothesis, we have evaluated a
cohort of 947 samples of human breast tissues for the
presence of VDR, CYP27B1 and CYP24A1. Specifically,
our series consisted of normal breast tissue (29 cases),
preneoplastic benign mammary lesions (379 cases),
carcinomas in situ (189 cases) and invasive breast carci-
nomas (350 cases). To the best of our knowledge, this is
the first time that the expression of the VDR, CYP27B1
and CYP24A1 has been evaluated in histological sec-
tions of mammary lesions.
The three proteins have been found to be expressed in
all breast tissues, although at different levels. VDR pre-
sented a nuclear localisation, as it would be expected for
a nuclear receptor, while CYP27B1 and CYP24A1
enzymes displayed cytoplasmic staining with a granular
pattern, which is consistent with their mitochondrial
localisation. The immunohistochemical results were
further validated and confirmed using quantitative real-
time PCR and Western blotting.
Some studies have demonstrated that the VDR protein
is expressed in samples from normal breast tissues and
also in breast cancer biopsy specimens [14,15,24,25].
Our results have shown that the VDR is expressed in
carcinomas. However, the percentage of positive cases
that we have obtained (47.3% in carcinomas in situ and
56.2% in invasive carcinomas) is lower than the 80% to
90% that had been previously described in the literature
[26,27]. This discrepancy can be explained by the devel-
opment of new detection techniques and the use of dif-
ferent scoring methods. In this study, we have used the
H-Score, the current method employed for other
nuclear receptors, like ER [20], whereas in previous stu-
dies the presence of any staining was marked as positive.
As far as we know, our study is the first to investigate
the immunohistochemical expression of the VDR in a
range of benign lesions and carcinomas in situ of the
mammary gland. The percentage of positive cases for
the VDR is higher in benign lesions than in invasive
tumours (93.5% and 56.2%, respectively), while the carci-
nomas in situ display the lowest value of all (47.3%).
There are some studies showing higher levels of VDR in
tumour tissues [18,28], but this discrepancy can be
attributed to the use of different evaluation techniques.
An interesting finding is the correlation between the
expression of the VDR and the ER in both in situ and
invasive carcinomas. In fact, the VDR is expressed in
most ER-positive cases (54.7% in in situ carcinomas and
65.5% in invasive tumours). It is thought that one of the
VDR functions is to counteract oestrogen-mediated pro-
liferation and maintain differentiation [12]. Indeed, data
support the concept that the anti-tumour effects of
Vitamin D and its analogues on ER-positive human
breast cancer cells are mediated through the down regu-
lation of the ER itself and the attenuation of oestrogen
responses, such as breast cancer cell growth [29,30].
Thus, being the VDR mostly expressed in ER-positive
carcinomas, Vitamin D or its analogues may become an
alternative therapy for these tumours in cases of resis-
tance to ER-targeted therapy.
The levels of protein expression of CYP27B1 and
CYP24A1 have not been previously studied in breast can-
cer. In colon cancer, a study using immunohistochemistry
has demonstrated that CYP27B1 is present at equally high
levels in normal colonic epithelium and colorectal cancer
[31]. For CYP24A1 it has been shown that increasing
amounts of this enzyme are present in normal colon tissue
and pre-malignant lesions. In cancer, the expression of
CYP24A1 decreases as a function of tumour cell dediffer-
entiation [32]. In breast tissues, McCarthy et al.[18] have
demonstrated that CYP27B1 mRNA expression was signif-
icantly down regulated in adjacent non-cancerous tissue
from women with breast cancer in comparison with indi-
viduals without cancer. Additionally, it has been shown
that the expression of mRNA for CYP27B1 and the VDR
was higher in carcinomas versus non-neoplastic tissue
[17]. Considering differences in expression in benign and
malignant breast tissues, we have observed an increased
expression of CYP24A1 and a decreased expression of
CYP27B1 with malignant progression. In fact, CYP27B1
was expressed in 55.8% of the preneoplastic lesions and
this percentage is decreased in invasive tumours (44.6%),
while carcinomas in situ display the highest value (66.4%)
and these differences are statistically significant. In con-
trast, CYP24A1 is augmented more than 2.5 fold in inva-
sive tumours (53.7%), compared with benign breast lesions
(19.0%) and this difference is also significant (p < 0.0001).
The in situ carcinomas exhibit the highest percentage of
positive cases (56.0%). These observations are consistent
with the results of Townsend and colleagues [17], which
have demonstrated that there was an up regulation of
CYP24A1 mRNA in breast tumour tissue, in comparison
with normal breast. It has also been described that the
CYP24A1 gene is amplified in breast cancer [33]. In con-
trast, another study has found no differences in the
expression of the VDR, CYP27B1 and CYP24A1 mRNA in
breast cancer and non-neoplastic mammary tissue [34].
These contradictory results may be explained by recent
reports where it is described that VDR and CYP24A1 are
under the post-transcriptional control of miRNAs [35,36].
Breast cancer is a process that evolves through the
accumulation of (epi)genetic events that drive uncon-
trolled proliferation and resistance to apoptosis. The
active form of Vitamin D is known for its capacity to
modulate proliferation and induce apoptosis [6]. Conse-
quently, malignant cells would need to develop
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mechanisms to deregulate Vitamin D metabolic and sig-
nalling pathways in order to allow tumour development
[37]. Furthermore, it has been suggested that the Vitamin
D produced in non-renal tissues is not released into the
blood stream, but instead acts locally [38]. Therefore, the
amount of Vitamin D available in the tissue depends on
the relative amounts of CYP27B1 (synthesis) and
CYP24A1 (catabolism). Accordingly, our results show a
deregulation of these two enzymes in the different stages
of breast carcinogenesis. The crucial step of transforma-
tion introduces a clear unbalance in the Vitamin D sig-
nalling and metabolic pathways. A reduction in the
expression of the VDR in carcinomas indicates lower sen-
sitivity of the tissue to Vitamin D control. Furthermore, a
strong increase in CYP24A1 positive cases points to an
enhanced ability of the cells to degrade this hormone. In
contrast, the stable levels of CYP27B1 throughout the
transformation process, with only a small decrease in
invasive carcinomas, may reflect a lower capacity to
metabolize Vitamin D into its active form.
Conclusions
In summary, this is the first study to report the expres-
sion of the VDR, CYP27B1 and CYP24A1 in a series of
normal breast, preneoplastic mammary lesions, breast
carcinomas in situ and invasive tumours. We have cor-
related the expression of these Vitamin D partners with
the expression of a panel of tumour biomarkers.
Furthermore, we have confirmed these results by real-
time RT-PCR. Overall, our results on the expression of
the VDR, CYP27B1 and CYP24A1 suggest that there is
a deregulation of the Vitamin D metabolic and signal-
ling pathways in breast cancer, in order to favour
tumour progression. Thus, during breast malignant
transformation, tumour cells lose their ability to synthe-
size the active form of Vitamin D and to respond to
Vitamin D effects, while increasing their ability to
degrade this hormone.
Additional material
Additional file 1: Figure S1: In MDA-MB-231 breast cancer cells
CYP27B1 expression is induced by the treatment with PTH 100 nM for 4
h and CYP24A1 expression is induced by the treatment with Vitamin D
(1,25(OH)2D3) 100 nM for 72 h. a-tubulin was used as a loading control
Additional file 2: Table S2: VDR, CYP27B1 and CYP24A1 expression in
tumours that display both the in situ and the invasive component in the
same histological section.
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Summary The current system of pathologic classification of human breast cancers does not take into
account the biologic determinants of prognosis, nor is there a consensus regarding the progression
from in situ to invasive carcinoma. The present study compared the molecular phenotypes of in situ
and invasive components of breast cancer in the same sample. We built a series of 189 in situ and
invasive carcinomas using tissue microarrays and classified them according to their immunoprofiles
regarding estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2,
epidermal growth factor receptor, cytokeratin 5, P-cadherin, and the antigen Ki-67 into luminal A and
B, human epidermal growth factor receptor 2 overexpressing, and basal-like carcinomas. We also
correlated the subgroups of carcinomas with some of the classical prognostic factors such as
histologic grade, tumor size, and lymph node metastasis, as well as with the age of the patient at
diagnosis. The overall concordance on the molecular phenotypes between in situ and invasive
components was 94%. For the in situ component, 63% of the cases were luminal A; 15%, luminal B;
12%, human epidermal growth factor receptor 2 overexpressing; and 7%, basal-like. Regarding the
invasive component, 61% of the cases were luminal A; 16%, luminal B; 12%, human epidermal
growth factor receptor 2 overexpressing; and 8%, basal-like. The present study allowed the
identification of different immunoprofiles of in situ and invasive breast carcinomas using a specific
panel of biomarkers and showed that in most cases, there is a concordance between in situ and
invasive component profiles, supporting the theory of parallel disease in breast tumorigenesis.
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1. Introduction
Breast cancer is the most common cancer in women, with
more than 1 million cases occurring worldwide annually [1].
Despite significant diagnostic and therapeutic innovations,
the effect on the mortality rate has been modest. One of the
factors contributing to this limited success is the relative lack
of understanding of the natural history of this disease [2]. For
example, the transition from in situ to invasive carcinoma is
still a poorly understood event [3].
Nowadays, it is widely stated that the natural history of
breast cancer involves progression through clinical and
pathologic stages [3,4] from premalignant hyperplastic
breast lesions, with or without atypia, to carcinoma in situ
and then invasive carcinoma [5-7]. On the basis of
molecular, epidemiologic, and pathologic studies, ductal
carcinoma in situ (DCIS) is thought to be a precursor of
invasive ductal carcinoma [4]. Although this model is
supported by clinical and molecular research [8-11], it is
only a starting point to understand breast tumorigenesis, as
the relation between preinvasive lesions and invasive
carcinoma remains unclear [12]. From the available data, 2
models have been proposed recently to explain the transition
from DCIS to invasive breast carcinoma (IBC). The first one,
the theory of linear progression [5,7,13], suggests that low-
grade DCIS progresses to high-grade DCIS and then to
invasive ductal breast carcinoma. This model implies that
tumor progression follows a linear pattern. However, there is
evidence that some in situ carcinomas never progress to
invasion and that some DCIS have more genetic alterations
than some invasive carcinomas [14], a finding which does
not fit in this multistep model. Consequently, a second model
of breast cancer tumorigenesis has been proposed: the theory
of the parallel disease, wherein low-grade DCIS tends to
progress to low-grade invasive ductal breast cancer, whereas
high-grade DCIS tends to progress to high-grade invasive
breast cancer [12]. In this model, a specific subtype of DCIS
matches a specific subtype of invasive breast cancer.
Gene expression profiling is known to be a powerful tool
for identifying tumor molecular profiles and for correlating
gene expression profiles with outcome in breast cancer [14].
In addition, it has been an important tool to explore the
transcriptional program that leads to invasion, comparing in
situ and invasive carcinomas. Recently, Dalgin et al [15]
studied 36 breast cancer patients with different pathologic
stages of disease and revealed a hierarchical portrait of breast
cancer progression, identifying genes and pathways for each
stage, grade, and molecular subtype. These authors
suggested that the heterogeneity of the disease across
molecular subtypes is higher than the heterogeneity of
disease progression within a subtype, suggesting that tumors
with different molecular profiles are in fact distinct diseases.
Several studies have concentrated on the identification of
specific biomarkers that could define the subtypes of in situ
and IBCs [16-18]. Our group and others demonstrated that it
is possible to translate the molecular classification, using
immunohistochemistry (IHC) and tissue microarrays
(TMAs) [18], where estrogen and progesterone receptors
(ER and PgR) and human epidermal growth factor receptor 2
(HER-2) expression identify luminal A and B and HER-2
overexpression subtypes, whereas tumor protein 63 (p63),
cytokeratin 5 (CK5), and P-cadherin (P-cad) allow the
identification of basal-like tumors [17]. Recently, Paredes et
al [18] also demonstrated the importance of P-cad and CK5
as useful adjunct markers to distinguish the basal-like
subtype among the in situ carcinomas.
However, it was never determined whether the in situ and
invasive carcinomas that develop in a particular breast cancer
patient belong to the same molecular subtype or are different
entities belonging to different molecular profiles.
In this study, our aim was to compare the molecular
phenotypes of in situ and invasive components of breast cancer
in the same sample, using IHC and TMAs and a specific panel
of biomarkers, previously described by our group [17,18].
2. Materials and methods
2.1. Tumor specimens
One hundred eighty-nine formalin-fixed, paraffin-
embedded samples harboring in situ and IBCs in the same
block were collected from the archives of the Pathology
Institute of Araçatuba, São Paulo, Brazil (1996-2006). All
cases were classified from hematoxylin and eosin (H&E)–
stained sections. The DCIS samples were subdivided into 3
groups: low, intermediate, and high grade, according to the
nuclear grade and the extent of necrosis, as previously
published by our group [19]. Briefly, tumors harboring nuclear
grade 3 were all considered high grade, whereas tumors with
nuclear grade 1 or 2 with necrosis were considered
intermediate grade, and those of nuclear grades 1 and 2
without necrosis were considered low grade. Invasive breast
cancers were classified as grade I, II, or III according to the
method described by Elston and Ellis [20]. Some relevant data
were available for analysis, including age and clinicopatho-
logic features such as tumor size and lymph node metastasis.
2.2. TMAs construction
Representative areas of the in situ and IBCs were selected
on H&E-stained sections and marked on the corresponding
paraffin blocks. Two 2-mm tissue cores were obtained from
each selected specimen (donor block) and deposited in a
paraffin (receptor) block using a TMA workstation (TMA
Builder ab1802; Abcam, Cambridge, UK). Twenty-two
TMA blocks were constructed, each containing 24 tissue
cores (4 × 6). In each TMA block, nonneoplastic breast and
liver tissue cores were included as a control and a TMA
guide, respectively. After the construction, 2-μm tissue
sections were cut and attached to Superfrost Plus glass slides.
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An H&E-stained section from each TMA block was
reviewed to confirm the presence of morphologically
representative areas of the original lesions.
2.3. Immunohistochemistry
The sections were immunostained with primary mono-
clonal antibodies against ER, PgR, HER-2, epidermal
growth factor receptor (EGFR), CK5, P-cad, and Ki-67.
Immunostaining for ER, HER-2, and CK5 was performed
using the streptavidin-biotin peroxidase technique (LabVi-
sion, Fremont, CA), whereas for PgR, EGFR, P-cad, and Ki-
67, a horseradish peroxidase–labeled polymer (DakoCyto-
mation, Carpinteria, CA) was used.
Antigen unmasking for ER, PgR, HER-2, and Ki-67 was
carried out using 1:100 commercial citrate buffer, pH 6.0
(Vector Laboratories, Burlingame, CA) at 98°C, whereas a
dilution of 1:10 from tris-ethylenediaminetetraacetic solution
at pH 9.0 (DakoCytomation) was used for CK5 and P-cad.
Epitope retrieval for EGFR was performed by proteolytic
digestion (pepsin A, 4 g/L; Sigma-Aldrich, St. Louis, MO,
USA) at 37°C.
The antigen retrieval time, antibodies, dilutions, and
suppliers are listed in Table 1. After the antigen retrieval
procedure, the slides were washed in phosphate-buffered
saline and submitted to blockage of endogenous peroxidase
activity by incubation of the slides in 3% hydrogen peroxide
(Panreac, Barcelona, Spain) inmethanol (Sigma-Aldrich). The
slides were further incubated with blocking serum (LabVision
Corporation kit) for 15 minutes and then incubated with the
primary antibodies. After washes, the slides were incubated
with biotinylated secondary antibody, followed by streptavi-
din-conjugated peroxidase (LabVision). Diaminobenzidine
was used as a chromogen (DakoCytomation).
For PgR, EGFR, P-cad, and Ki-67 staining, the secondary
antibodywas associated with horseradish peroxidase–labeled
polymer (DakoCytomation) and immediately revealed with
diaminobenzidine. Tissues were then counterstained with
Mayer hematoxylin, dehydrated, and covered using a
permanent mounting solution (Zymed, San Francisco, CA).
Positive controls were included in each run to guarantee
the reliability of the assays. Nonneoplastic breast tissues, as
well as normal breast surrounding the neoplastic cells, were
considered internal controls.
2.4. Quantification of immunostaining
The IHC results were evaluated by 2 pathologists (F.S., F.
M.). Both ER and PgR were examined for staining intensity,
ranked from 1 to 3 (1, weak; 2, moderate; 3, strong) and extent,
ranked from1 to 10 (1, 0-10% cells; 2, 11%-20%cells; 3, 21%-
30% cells; 4, 31%-40% cells; 5, 41%-50% cells; 6, 51%-60%
cells; 7, 61%-70% cells; 8, 71%-80% cells; 9, 81%–90% cells;
10, 91%-100% cells) using the H-score method, which is used
for other nuclear receptors as well [21,22]. The scores for
intensity and extension were multiplied, and the cases were
considered negative when the score was less than 4 and
positive from 5 to 30. Concerning Ki-67, tumors with
unequivocal nuclear staining in more than 14% of the cells
were classified as highly proliferative, whereas tumors with
less than 14% positive cells were considered to show low
proliferation [23]. We considered positive the cases with
membranous staining for P-cad and cytoplasmic staining for
CK5 in at least 10% of the neoplastic cells. Expression of
HER-2 was evaluated according to the DakoCytomation
Hercept Test scoring system [24]. Cases were considered
positive (overexpression) when immunostaining was classi-
fied as 3+. If a case is classified as 2+ by IHC, fluorescence in
situ hybridization analysis was performed to determine if the
tumor had HER2 amplification. If amplification was con-
firmed, the tumor was classified as positive. If the tumor did
not demonstrate amplification, it was considered negative.
Staining for EGFRwas also classified according to theHercept
Test scoring system. However, breast carcinomas were
considered positive whenever the immunostaining was 2+ or
3+. Cases that were ER+ or PgR+ and HER-2 negative were
classified as luminal A; cases ER+/PgR+ and HER-2+ or ER+
and with a high proliferative index (Ki-67+) were considered
luminal B; ER− and PgR− and HER-2+ cases were classified
as HER-2-overexpressing; cases that were negative for ER,
PgR, and HER-2 and positive for EGFR or CK5 or P-cad were
considered basal-like. Cases that lacked expression of all tested
markers were considered “unclassified.”
2.5. Statistical analysis
StatView 5.0 (SAS Institute Inc, Cary, NC) was used for
statistical analysis. Univariate associations between ER,
PgR, HER-2, EGFR, CK5, P-cad, KI67, tumor size,
Table 1 Sources and dilutions of primary antibodies used in
immunohistochemistry staining
Antibody Clone Manufacturer Time of
incubation
(min)
Dilution Antigen
retrieval
(min)
ER SP1 Neomarkers
(Fremont,
CA, USA)
60 1:100 30
PgR 1A6 Novocastra
(Newcastle,
UK)
60 1:40 30
HER-2 SP3 Neomarkers 30 1:80 30
P-cad 56 Transduction
Labs
(Franklin
Lakes,
NJ, USA)
60 1:50 30
CK5 XM26 Neomarkers 60 1:50 30
EGFR 31G7 Zymed 60 1:100 30
Ki67 SP6 Neomarkers 60 1:300 30
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histologic grade, and lymph node metastases in the presence
of DCIS and invasive breast cancer were assessed using
contingency tables and χ2 tests. In all statistical analyses, P
≤ .05 was considered significant.
3. Results
We performed IHC on each set of the 22 TMA slides for
ER, PgR, HER-2, P-cad, CK5, EGFR, and Ki-67. Tables 2
and 3 summarize the clustering of a total of 189
immunohistochemically interpretable cases to allow sample
characterization into 1 of the 5 previously described
molecular subtypes. The molecular classification was made
in an individual way for each of the tumor components (in
situ and invasive) in the same block.
3.1. Evaluation of the in situ component
Among the in situ components, we observed that 63% of
all tumors were considered luminal A, whereas the luminal B
and HER-2–overexpressing subtypes comprised 15% and
12% of the cases, respectively. Basal-like tumors represented
7%, and the ones with null phenotype/unclassified were 3%
(Table 2).
Because luminal cancer subtypes (A and B) were defined
as positive for hormone receptors (ER, PgR), the percentage
of cases positive for these 2 immunohistochemical markers
was extremely high, as expected, with a higher prevalence
for ER positivity (Table 3). For the luminal A subtype, 95%
and 66% of the cases were ER and PgR positive,
respectively, whereas for luminal B, 100% were positive
for ER and 61% were positive for PgR. As initially defined,
all luminal A tumors were negative for HER-2, and all
luminal B lesions were positive for this marker. In the
specimens negative for hormone receptors, all the cases
overexpressing HER-2 were included in the HER-2–over-
expressing cancer subtype, which are being the triple-
negative ones (negative for ER, PgR, and HER-2) divided
into basal-like or unclassified, according to the positivity for
P-cad, CK5, and EGFR. Among the basal-like tumors, P-cad
was the most prevalent marker, with 92% of the cases being
positive, whereas only 23% and 38% of the cases were
positive for EGFR and CK5, respectively.
Although basal markers are most commonly expressed in
basal-like tumors, these can also be present in other cancer
subtypes, if at a lower frequency. Concerning EGFR,
although there were almost no positive cases in the luminal
A and B subtypes, 10% of HER-2–overexpressing tumors
also expressed EGFR. Also, CK5 was expressed by 17% of
the HER-2–overexpressing in situ carcinomas, whereas only
3% and 7% of the tumors classified as luminal A or B,
respectively, showed CK5 expression. Expression of P-cad
also was common in HER-2–overexpressing tumors, which
is being positive in almost half the cases (48%). Concerning
the luminal cancer subtypes, P-cad expression was more
abundant in luminal B (14%) than in luminal A (8%) lesions.
Concerning cell proliferation indexes, addressed by Ki-67
staining, basal-like tumors were the ones showing higher
values (28%), followed by luminal B (19%). When we
studied the association between the in situ histologic grade
andmolecular cancer subtypes (Fig. 1), we found that luminal
A tumors were frequently classified as low grade (49%),
Table 2 Frequencies of immunohistochemically defined
subtypes of in situ and invasive breast cancers
Subtype Frequency in situ
component, n (%)
Frequency invasive
component, n (%)
Luminal A 120/189 (63) 116/189 (61)
Luminal B 28/189 (15) 31/189 (16)
HER-2
overexpressing
23/189 (12) 23/189 (12)
Basal-like 13/189 (7) 14/189 (8)
Unclassified 5/189 (3) 5/189 (3)
Table 3 Comparison of molecular subtypes and biomarkers for in situ and invasive components
Luminal A Luminal B HER-2 overexpressing Basal-like P
In situ Invasive In situ Invasive In situ Invasive In situ Invasive In situ Invasive
ER + 114 (95%) 108 (93%) 28 (100%) 31 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) P ≤ .0001 P ≤ .0001
− 6 (5%) 8 (7%) 0 (0%) 0 (0%) 23 (100%) 23 (100%) 13 (100%) 14 (100%)
PR + 79 (66%) 79 (68%) 17 (61%) 13(42%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) P = .0002 P = .0001
− 41 (34%) 37 (32%) 11 (39%) 18 (58%) 23 (100%) 23 (100%) 13 (100%) 14 (100%)
HER-2 + 0 (0%) 0 (0%) 15 (54%) 14 (45%) 23 (100%) 23 (100%) 0 (0%) 0 (0%) P ≤ .0001 P ≤ .0001
− 120 (100%) 116 (100%) 13 (46%) 17 (55%) 0 (0%) 0 (0%) 13 (100%) 14 (100%)
EGFR + 1 (1%) 1 (1%) 0 (0%) 0 (0%) 2 (10%) 2 (9%) 3 (23%) 3 (21%) P = .004 P = .001
− 119 (99%) 115 (99%) 28 (100%) 31 (100%) 21 (90%) 21 (91%) 10 (77%) 11 (79%)
CK5 + 4 (3%) 2 (2%) 2 (7%) 0 (0%) 4 (17%) 5 (22%) 5 (38%) 5 (36%) P = .001 P ≤ .0001
− 116 (97%) 114 (98%) 26 (93%) 31 (100%) 19 (83%) 18 (78%) 8 (62%) 9 (64%)
P-cad + 9 (7%) 9 (8%) 4 (14%) 4 (13%) 11 (48%) 11 (48%) 12 (92%) 13 (93%) P ≤ .0001 P ≤ .0001
− 111 (93%) 107 (92%) 24 (86%) 27 (87%) 12 (52%) 12 (52%) 1 (8%) 1 (7%)
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whereas most luminal B carcinomas were classified as
intermediate grade (53%); HER-2–overexpressing and basal-
like cases were more often of high grade (86% and 77%).
3.2. Evaluation of the invasive component
For the invasive component (Table 2), the luminal A
subtype represented 61% of all the tumors. Luminal B and
HER-2–overexpressing invasive tumors corresponded to
16% and 12%, respectively, whereas basal-like tumors
comprised 8% of the cases. Only 3% of the invasive
carcinomas were null phenotype/unclassified. For the
luminal A cancer subtype, 93% and 68% of the cases were
ER and PgR positive, respectively, whereas for luminal B,
100% were positive for ER and 42% were positive for PgR.
Again, all luminal A tumors were negative for HER-2, as
expected, and 45% of luminal B cases were positive for this
marker. The invasive carcinomas overexpressing HER-2 and
negative for hormone receptors were included in the HER-2–
overexpressing cancer subtype. In triple-negative basal-like
invasive tumors, as described for the in situ component, P-
cad expression was the most prevalent basal marker, with
93% positive cases, whereas only 21% and 36% of the cases
were positive for EGFR and CK5, respectively (Table 3).
When we studied the expression of basal markers in
cancer subtypes other than the basal-like, we found results
similar to the ones described for the in situ component of this
breast cancer series. Concerning EGFR, exactly the same
frequencies were found: 1% and 0 of the cases expressed this
receptor in luminal A and B subtypes, respectively, whereas
9% of HER-2–overexpressing tumors coexpressed these 2
tyrosine kinase receptors. CK5 was expressed by 22% of the
HER-2–overexpressing invasive carcinomas, whereas only
2% or none of the tumors classified as luminal A or B,
respectively, showed CK5 expression. Again, P-cad expres-
sion was highly expressed in HER-2–overexpressing tumors
(48%), but it was expressed by only 8% of luminal A and
13% of luminal B IBCs.
For Ki-67, the tumors included in the basal-like and
luminal B subtypes had the highest proliferative indexes
(29% and 25%, respectively). Regarding the histologic grade
(Fig. 1), we found that luminal A invasive tumors were often
grade I (55%), whereas luminal B lesions were from
intermediate (41%) to high grade (38%); once more, HER-
2–overexpressing and basal-like tumors were more regularly
classified as grade III (95% and 86%, respectively).
3.3. Combined evaluation of the in situ and
invasive counterparts in the same patient
Most cases (93%) maintained the molecular classification
when the in situ and invasive components were compared
(Fig. 2); there were just 13 cases (7%) in which the 2 areas
were classified differently (Table 4). One of the cases was
unclassified for the in situ component (negative for all
markers), but basal-like in the invasive counterpart in which
P-cad expression was seen. Both components were high
grade. Another case was classified as an in situ luminal A
carcinoma but was unclassified in the invasive component
because of the absence of expression of both hormone
receptors (Fig. 2D). Interestingly, although both components
were intermediate grade, the invasive counterpart had a
higher proliferative index. Four cases were classified as
luminal B for the in situ component but luminal A for
invasive counterpart because of the low proliferative index,
with the exception of one case that lacked HER-2 expression
also in the invasive area. Interestingly, in this case, the loss of
expression was accompanied by a difference in the histologic
grade: high grade in the in situ portion and grade II in the
invasive counterpart.
Finally, 7 cases that were classified as in situ luminal A
carcinomas were classified as luminal B in the invasive
portion because of a higher proliferative index. Other than
the increase in cell proliferation, no alterations were noticed
in histologic grade.
In general terms, we can conclude that there are no
important modifications of the breast cancer molecular
classification in most cases when the transition from an in
situ to an invasive carcinoma occurs. However, when we
compared the expression of the different biomarkers
individually (Table 3), we could find subtle differences
between components, which can add some biologic
information to the in situ/invasive transition. In the luminal
A cases, in addition to the higher proliferative rate in the
invasive component in 7 cases, just 3 cases showed P-cad
expression in the invasive component. No alterations in
hormone receptors were found between in situ and invasive
transition. In luminal B tumors, no alterations were found for
Fig. 1 Comparison of histologic grade among molecular
subtypes (luminal A, luminal B, HER-2, and basal) in situ and
invasive components. All correlations were statistically significant
(P ≤ .05).
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ER expression when the in situ and invasive components
were compared. However, there were 4 cases that lost PgR
expression in the invasive carcinoma, with the transition
from a high-grade in situ carcinoma to a grade II invasive
tumor in 2 cases; in the remaining 2, there were no alterations
in grade. The other differences were in basal markers, such as
CK5 and P-cad, with a loss of 7% and 3% of expression from
in situ to invasive tumors, respectively. Regarding the
HER-2–overexpression lesions, 7 did not show expression
of any basal marker, whereas 14 cases showed concomitant
Fig. 2 Expression of proteins studied by IHC staining on TMAs for in situ and invasive components. A and B, H&E staining of low-/I and
high-grade/III histologic grade, respectively. C, ER expression. D, Loss of ER expression in invasive component. E, HER-2 staining. F, P-cad
staining. Original magnifications: A-D ×200; E, F ×100.
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expression of EGFR, CK5, or P-cad together with HER-2. Of
these, P-cad was the most prevalent. There were 3 cases that
gained expression of basal markers in the transition from in
situ to invasive carcinoma, namely, 2 with CK5 and 1 with P-
cad. Only this last case changed histologic grade (from an
intermediate in situ grade to a grade III invasive tumor). In
the basal-like subtype, most cases were P-cad positive in
both components (11 cases). However, there was 1 case that
lost P-cad in the invasive fraction, but because it expressed
CK5 in the invasive component, its molecular classification
did not change.
Molecular subtypes of in situ and invasive breast cancers
did not differ with the histologic grade (P b .0001 and P =
.0002 for in situ and invasive counterparts, respectively).
High-grade lesions were associated with the HER-2–
overexpressing and basal-like phenotypes in both the in
situ and invasive components. Low-grade lesions were
frequently of the luminal A phenotype. In the luminal B
phenotype, the in situ component was more frequently high
grade (53%), whereas the invasive counterpart was
intermediate grade (41%).
As mentioned above, the only cases with alterations in
molecular classification were not accompanied by differences
in histologic grade. However, there were some alterations in
histologic grade in individual cases: 9 lesions with interme-
diate in situ components were grade III in the invasive
counterpart, whereas 5 classified as in situ low grade were
grade II lesions whenwe analyzed the invasive component. In
cases where there was a decrease in the histologic grade, 12
cases classified as high grade in the in situ component were
grade II in the invasive counterpart; 1 case was high grade in
the in situ component and grade I in the invasive one, and 10
cases classified as intermediate grade in the in situ component
were grade I in the invasive area.
4. Discussion
Two main branches of breast tumorigenesis have been
distinguished: one supports the multistep model and the
other the theory of parallel disease, where a specific subtype
of DCIS matches a specific subtype of invasive breast cancer
[12]. In 1997, Grupta et al [25], studying 300 patients with
IBC associated with DCIS, demonstrated that the degree of
differentiation of DCIS correlated with the grade of the
invasive carcinoma and the clinical outcome. They also
showed that patients with invasive breast cancer displayed
the same mutations as patients with preinvasive and invasive
lesions. In fact, recent data [26] demonstrate that the most
dramatic alterations in gene expression patterns occur during
the transition from normal breast tissue to DCIS [27,28], not
from in situ to invasive. In contrast, Tamimi et al [29],
studying 272 DCIS and 2249 invasive independent tumors,
showed that in situ and invasive phenotypes had different
prevalences. These authors found a higher prevalence of
luminal B and HER-2–overexpressing profiles among DCIS
tumors. However, analyzing independent series of in situ and
invasive tumors [17,18], no differences were found in
molecular subtype prevalence. So probably, the higher
percentage of the HER-2 phenotype in DCIS in the series
described by Tamimi et al [29] was attributable to the
examination of a mammographically screened population
and does not reflect a basis of progression to invasive tumors.
The great advantage of our series of 189 breast
carcinomas, which was characterized by several immuno-
histochemical markers, relies on the existence of in situ and
invasive components in the same sample. We classified the
in situ and invasive tumors into 4 main molecular subtypes
(luminal A, luminal B, HER-2–overexpressing, and basal-
like). When the components were compared, we verified that
there were no significant differences in the molecular
classification of in situ and invasive tumors, which led us
to conclude that different molecular subtypes have different
progression forms, low-grade in situ tumors evolving into
low-grade invasive tumors and high-grade in situ tumors into
high-grade invasive tumors [15].
Differences in molecular profiles between the in situ and
invasive carcinoma areas were observed in only 13 cases,
which seems more likely to be attributable to technical
immunohistochemical issues than a reflection of changes in
tumor biology. One case classified as luminal A in the in situ
component lost ER expression and became unclassified in
the invasive component. Another case, which did not express
any of the markers used for classification (unclassified) in the
in situ component, gained expression of P-cad in the invasive
component and could be characterized as having a basal-like
phenotype. In the remaining 11 cases, the changes were from
luminal A to B or vice versa, and these alterations can be
attributed to the fact that the criteria for classification of the
luminal B subtype are not well established. Although some
luminal B tumors can be identified by their expression of
HER-2, the chief biologic distinction between luminal A and
B is the proliferative signature, including genes such as
Ki-67. Chang and collaborators [23], using 14% as a cutoff,
supported Ki-67 as a well-established cell proliferation
marker in cancer and emphasized its role as a biomarker
candidate for identification of luminal B tumors. We also
used this cutoff, which allowed us to distinguish some
luminal B tumors that the standard biomarker panel (ER,
PgR, and HER-2) did not identify. Interestingly, and
although the percentages are close to that of the luminal B
subtype, the basal-like tumors had higher proliferative
Table 4 Discordant molecular classifications between in situ
and invasive components
No. In situ component Invasive component
7 Luminal A Luminal B
4 Luminal B Luminal A
1 Luminal A Unclassified
1 Unclassified “Basal-like”
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indices than the other subtypes in both the in situ and
invasive components (28% and 29%, respectively). Among
these fractions, the invasive one had a higher proliferative
rate, which can be associated with an increase in cell
proliferation when invasion occurs, and with the poor
prognosis associated with this molecular subtype.
An association between histologic grade and molecular
phenotype has been demonstrated, with low-grade inva-
sive tumors usually having the luminal A phenotype,
whereas high-grade tumors are more prevalent among
HER-2–overexpressing and basal-like subtypes [29,30].
Moreover, the HER-2–overexpressing and basal-like
subtypes are associated with a poor prognosis. In our
series, in in situ breast cancers, HER-2 and basal-like
subtypes were more frequently high grade than low or
intermediate grade (86% and 77%, respectively). These
results were consistent for invasive tumors, because 95%
of HER-2+ and 86% of basal-like tumors had high
histologic grades. It was interesting to note the percen-
tages of the luminal B type among DCIS and invasive
components, where intermediate/II and high grade prevail
in both, with 36% and 54% for the in situ component, as
well as 41% and 38% for the invasive counterpart,
respectively. This similarity between intermediate/grade II
and high grade probably is secondary to the cutoff used,
which enriched our series in luminal B cases.
We also looked for cases that showed alterations
simultaneously in biomarker expression and histologic
grade and found 8 cases. It is important to say that these
alterations were not accompanied by alterations in the
molecular classification. Two cases graded as having an
intermediate in situ component were grade III in the invasive
component, accompanied by gain of P-cad in one case and its
loss in the other. Other 2 cases, with the concordant loss of
PgR expression, classified as high grade in the in situ
component, were grade II in the invasive counterpart. One
case also lost PgR expression but changed from intermediate
in situ to grade I in the invasive counterpart. It is also
interesting that we had 2 cases that lost PgR expression and 1
basal marker, P-cad or CK5, simultaneously and were
classified as high-grade in situ and grade II in the invasive
component. Finally, the remaining case lost CK5 and
changed from intermediate to grade I.
We have shown that the prevalence of molecularly
defined phenotypes did not differ significantly between
DCIS and invasive breast cancers; probably, the molecular
alterations that drive invasion occur before the morphologic
modification of the lesion [31,32]. Dalgin et al [15] also
confirmed that the cancer phenotype develops early (in the
early hyperplasia or DCIS stage), and each subtype
progresses along its own specific pathway, as if each was a
distinct disease.
In conclusion, with this work, we showed that it is
possible to identify different immunohistochemical profiles
of in situ and invasive breast cancer using a small panel
of biomarkers (ER, PgR, HER-2, EGFR, CK5, P-cad, and
Ki-67) and that the technique of TMA is useful, efficient,
and reliable in the characterization and subclassification of
a large number of cases. Concerning the comparison of in
situ and invasive components, we found that in 176 (93%)
of the 189 cases, the molecular classification was identical
in the 2 components, which supports the theory of parallel
disease; that is, that in the progression of most breast
cancer cases, there is a commitment of the in situ subtype
carcinoma to a specific subtype of invasive carcinoma.
Otherwise, the finding supports the view that the
molecular phenotype is established at the DCIS stage.
Although there has been an improvement in understanding
the pathways of breast tumorigenesis, little is known about
the mechanisms associated with the transition from in situ
to invasive carcinomas. More than just genetic alterations
in the tumor cells, the codependency of epithelial cells and
stroma can regulate tumor progression. Recently, it was
demonstrated that myoepithelial cells can have a particular
role in tumor invasion. Studying normal myoepithelial
cells and the ones associated with DCIS, Schnitt [32,33]
demonstrated that the last ones differ substantially from
the normal, showing down-regulation of genes involved in
the normal function of cells and up-regulation of genes
associated with invasion. There is an immediate need to
characterize new molecules that not only uncover the
molecular biology of in situ carcinoma and its transition to
invasive breast cancer, but also the transcriptional program
that drives the invasive growth of each molecular subtype.
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Summary. The goal of the present work was to evaluate
the correlation of glucose transporter 1 (GLUT1) and
carbonic anhydrase IX (CAIX) with the
monocarboxylate transporters 1 (MCT1) and 4 (MCT4)
and their chaperone, CD147, in breast cancer. The
clinico-pathological value of GLUT1 and CAIX was
also evaluated. For that, we analysed the
immunohistochemical expression of GLUT1 and CAIX,
in a large series of invasive breast carcinoma samples
(n=124), previously characterized for MCT1, MCT4 and
CD147 expression. GLUT1 expression was found in
46% of the cases (57/124), while CAIX was found in
18% of the cases (22/122). Importantly, both MCT1 and
CD147, but not MCT4, were associated with GLUT1
and CAIX expression. Also, GLUT1 and CAIX
correlated with each other. Concerning the clinico-
pathological values, GLUT1 was associated with high
grade tumours, basal-like subtype, absence of
progesterone receptor, presence of vimentin and high
proliferative index as measured by Ki-67. Additionally,
CAIX was associated with large tumour size, high
histological grade, basal-like subtype, absence of
estrogen and progesterone receptors and presence of
basal cytokeratins and vimentin expression. Finally,
patients with CAIX positive tumours had a significantly
shorter disease-free survival. 
The association between MCT1 and both GLUT1
and CAIX may result from hypoxia-mediated metabolic
adaptations, which confer a glycolytic, acid-resistant and
more aggressive phenotype to cancer cells.
Key words: GLUT1, CAIX, Monocarboxylate
transporters (MCTs), CD147/EMMPRIN, Breast
carcinoma, Immunohistochemistry
Introduction
Early epithelial carcinogenesis occurs under hypoxic
conditions, since altered cells are separated from the
vascularised stroma, source of oxygen and nutrients. To
maintain the needed ATP levels, cancer cells increase
their rates of glycolysis, acquiring a significant
proliferative advantage. However, this phenotype leads
to an overload of lactic acid, which must be exported
from the cell, causing a decrease in the extracellular pH. 
Constitutive upregulation of glycolysis requires
additional adaptations, namely, resistance to apoptosis
and upregulation of membrane transporters to maintain
normal intracellular pH (Gatenby and Gilles, 2004). The
need to increase glucose uptake, to allow high glucose
consumption rates, is achieved by upregulation of
glucose transporters (GLUT) in the plasma membrane of
cancer cells, especially the hypoxia-responsive GLUT1
(Ganapathy et al., 2009). However, the role of GLUT1 in
breast cancer remains poorly elucidated (Younes et al.,
1995; Kang et al., 2002).
Besides being an adaptation to high glycolytic
phenotype, the acidic environment represents, per se, a
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significant advantage for tumour cells since it is
associated with increased migration, invasion and
metastases, among others (Gatenby and Gilles, 2004;
Gatenby et al., 2006). Although lactate produced by
glycolysis under hypoxic conditions is a significant
contributor to acidic extracellular pH, there is also a
substantial contribution from carbonic acid (Helmlinger
et al., 2002). In this context, the hypoxia-responsive
carbonic anhydrase isoforms, CAIX and CAXII, emerge
as important contributors to the regulation of cancer cell
intracellular pH (Swietach et al., 2007; Chiche et al.,
2009), with CAIX, in particular, being associated with
poor prognosis in breast cancer (Chia et al., 2001;
Trastour et al., 2007; Hussain et al., 2007; Tan et al.,
2009; Chen et al., 2010). 
Another important group of proteins involved in
intracellular pH regulation are monocarboxylate
transporters (MCTs), which are also responsible for
transmembrane transport of lactate (Izumi et al., 2003).
By performing these two inter-dependent activities
(lactate transport coupled with a proton), MCTs appear
as strong potential targets for cancer therapy. Indeed,
there is evidence for the up-regulation of MCTs in
tumours, such as high grade glial neoplasms (Mathupala
et al., 2004), colorectal (Koukourakis et al., 2006;
Pinheiro et al., 2008a), cervical (Pinheiro et al., 2008b),
and breast carcinomas (Pinheiro et al., 2010). Besides
analysing MCT expression in tumours, our group also
assessed for the first time the clinico-pathological value
of their overexpression (Pinheiro et al., 2008a,b, 2009a,
2010). MCT expression appears to be influenced by
altered physiological conditions; however, the
underlying molecular events involved in MCT regulation
are poorly understood. Recently, it was demonstrated
that proper expression and activity of MCT1 and MCT4
requires co-expression of CD147, also known as
EMMPRIN or Basigin (Kirk et al., 2000; Wilson et al.,
2005). Based on this, we described the association
between CD147 and both MCT1 and MCT4 in human
cervical (Pinheiro et al., 2009b), gastric (Pinheiro et al.,
2009a) and breast cancer (Pinheiro et al., 2010).
Furthermore, the hypoxia inducible-factor 1 alpha (HIF-
1α), which regulates many genes codifying proteins
involved in the glycolytic pathway (like GLUT1) and pH
regulation (like the Na+/H+ exchanger NHE1 and both
CAIX and CAXII) (Vaupel and Harrison, 2004), also
regulates MCT1 (Perez et al., 2010) and MCT4 (Ullah et
al., 2006; Perez et al., 2010). However, there is some
controversy around MCT1 regulation by hypoxia, with
some studies reporting MCT1 repression by hypoxia
(Ullah et al., 2006; Sonveaux et al., 2008).
One of the goals of the present study was to evaluate
the association between the HIF-1α downstream targets
GLUT1 and CAIX and both MCT1 and MCT4, as well
as their chaperone, CD147, in invasive breast
carcinomas. We also intended to strengthen the clinico-
pathological value of GLUT1 and CAIX in breast
cancer.
Materials and methods
Case selection
Case selection was based on availability of follow up
information and amount of material, ensuring adequate
numbers for statistical analysis. Thus, a series of 124
formalin-fixed paraffin embedded breast carcinoma
tissues was retrieved from the files of the Department of
Pathology, Hospital do Divino Espírito Santo, Azores,
Portugal, and from the Federal University of Santa
Catarina, Florianopolis-SC, Brazil. Haematoxylin/eosin
stained sections of all cases were reviewed by three
pathologists (R.D., D.V. and F.S.). Tumour samples were
organized into 14 tissue microarrays (TMAs), with 20
tumour cores (2 mm diameter) each, also including
several samples of normal breast tissue. Each case was
represented in the TMA by at least two cores. Relevant
clinico-pathological data included tumour size (TNM),
molecular subtype, histological grade, estrogen receptor
(ER) and progesterone receptor (PR), human epidermal
growth factor receptor 2 (HER2), epidermal growth
factor receptor 1 (EGFR), basal cytokeratins (CK5 and
CK14), vimentin and Ki67 expression status.
Information on lymph-node metastasis, disease-free
survival and overall survival was also available. These
tumour samples were previously analysed by our group
for MCT1, MCT4 and CD147 expressions (Pinheiro et
al., 2010).
The molecular classification was done by translating
the immunohistochemistry results for ER, PR, HER2,
EGFR, CK5, CK14, vimentin and Ki-67. Tumours
positive for ER and/or PR were classified as luminal.
Cases positive for ER/PR and for HER2 and/or high Ki-
67 index were subclassified as luminal B. Cases
classified as HER2 overexpressing were characterized
by HER2 overexpression and negativity for ER/PR, and
cases defined as “basal-like” were negative for ER/PR
and HER2 and positive for at least one of the “basal
markers” tested.
Immunohistochemistry
GLUT1 and CAIX detection
Immunohistochemistry was performed based on the
streptavidin–biotin–peroxidase complex principle
(Ultravision Detection System Anti-polyvalent, HRP,
Lab Vision Corporation, Fremont, CA), using rabbit
polyclonal primary antibodies raised against GLUT1
(ab15309, AbCam, Cambridge, UK, diluted 1:500) and
CAIX (ab15086, AbCam, Cambridge, UK, diluted
1:2000). Briefly, deparaffinized and rehydrated sections
were immersed in citrate buffer (0.01M, pH 6.0) heated
up to 98ºC, in a water bath, for 10 minutes (GLUT1) or
20 minutes (CAIX) and washed in PBS. Endogenous
peroxidase activity was blocked with 3% hydrogen
peroxide in methanol for 10 minutes, followed by
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washing with PBS. Tissue sections were incubated with
blocking solution for 10 minutes and incubated at room
temperature with the primary antibody for 2 hours.
Sections were then sequentially washed in PBS and
incubated with biotinylated goat anti-polyvalent
antibody for 10 minutes, streptavidin peroxidase for 10
minutes, and developed with 3,3’-diamino-benzidine
(DAB+ Substrate System, Dako, Carpinteria, CA) for 10
minutes. Negative controls were performed by using
adequate serum controls for the primary antibodies
(N1699, Dako, Carpinteria, CA) and skin and gastric
mucosa were used as positive controls for GLUT1 and
CAIX, respectively. Tissue sections were counterstained
with haematoxylin and permanently mounted.
Immunohistochemical evaluation
As described for MCTs and CD147 (Pinheiro et al.,
2010), GLUT1 and CAIX immunohistochemical
reactions were scored semi-quantitatively for plasma
membrane staining as follows: 0: 0% of immunoreactive
cells; 1: <5% of immunoreactive cells; 2: 5-50% of
immunoreactive cells; and 3: >50% of immunoreactive
cells. Also, intensity of staining was scored semi-
qualitatively as follows: 0: negative; 1: weak; 2:
intermediate; and 3: strong. The final score was defined
as the sum of both parameters (extension and intensity),
and grouped as negative (score 0 and 2) and positive
(score 3-6). Evaluation of GLUT1 and CAIX
immunohistochemical reactions were performed blindly
by two independent observers (F.S., J.P.). Discordant
results between observers were discussed in a double-
head microscope and a final score was agreed, while
discordant results between different cores of the same
tumour were handled by choosing the highest staining
intensity and finding the mean value for immunoreactive
cells. 
Statistical analysis
Data were stored and analysed using the Statview
statistical software (SAS Institute Inc., Cary, NC). All
comparisons were examined for statistical significance
using Pearson’s chi-square (χ2) test or Fisher’s exact
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Fig. 1. Immunohistochemcial expression of glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX) and monocarboxylate transporter 1 (MCT1),
in breast carcinoma samples. GLUT1 and CAIX expression was frequently observed in perinecrotic regions (A and B, respectively). CAIX expression
was usually focal and mainly restricted to tumour cells. Lower panel shows a breast ancer case simultaneously positive for MCT1 (C), GLUT1 (D) and
CAIX (E), with staining in the same tumour region.
test, as appropriate, the threshold for significance p
values being <0.05. Disease-free and overall survival
curves were plotted using the method of Kaplan-Meier
and data were compared using the log-rank test. The first
5 years following primary therapy was considered
because recurrence rates are expected to be highest in
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Table 1. Association of CAIX and GLUT1 with MCT1, MCT4 and CD147 expression in breast carcinoma samples.
n MCT1 Positive (%) p MCT4 Positive (%) p CD147 Positive (%) p
GLUT1 106 <0.0001 0.3473 0.0032
Negative 55 1 (1.8) 4 (7.3) 2 (3.6)
Positive 51 15 (29.4) 7 (13.7) 12 (23.5)
CAIX 105 <0.0001 0.6897 0.0005
Negative 84 6 (7.1) 8 (9.5) 7 (8.3)
Positive 21 10 (47.6) 3 (14.3) 8 (38.0)
Table 2. Associations of CAIX and GLUT1 expression with clinico-pathological data from breast cancer cases.
Clinico-pathological data GLUT1 CAIX
n Positive (%) p n Positive (%) p
T size (TNM) 121 0.5218 119 0.0034
T1 46 23 (50.0) 45 6 (13.3)
T2 63 25 (39.7) 63 9 (14.3)
T3 12 6 (50.0) 11 6 (54.5)
Histological grade 124 0.0014 122 0.0263
I 23 5 (21.7) 24 2 (8.3)
II 55 22 (40.0) 51 6 (11.8)
III 46 30 (65.2) 47 14 (29.8)
Subtype 114 0.0008 113 0.0050
Luminal 78 31 (39.7) 79 8 (10.1)
Basal-like 25 20 (80.0) 24 9 (37.5)
HER2 overexpressing 11 3 (27.3) 10 3 (30.0)
Estrogen receptor 124 0.1059 122 0.0014
Negative 45 25 (55.6) 42 14 (33.3)
Positive 79 32 (40.5) 80 8 (10.0)
Progesterone receptor 124 0.0162 122 0.0292
Negative 75 41 (54.7) 73 18 (24.6)
Positive 49 16 (32.6) 49 4 (8.2)
HER2 overexpression 123 0.5885 121 0.4556
Negative 110 51 (46.4) 109 19 (17.4)
Positive 13 5 (38.5) 12 3 (25.0)
EGFR 124 >0.9999 122 0.6643
Negative 115 53 (46.1) 113 20 (17.7)
Positive 9 4 (44.4) 9 2 (22.2)
CK5 124 0.1188 122 0.0002
Negative 98 42 (42.8) 97 11 (11.3)
Positive 26 15 (57.7) 25 11 (44.0)
CK14 121 0.0508 121 0.0102
Negative 114 51 (44.7) 115 18 (15.6)
Positive 7 6 (85.7) 6 4 (66.7)
Vimentin 106 0.0033 106 0.0004
Negative 89 38 (42.7) 88 12 (13.6)
Positive 17 14 (82.4) 18 9 (50.0)
Ki67 124 0.0339 122 0.5214
< 20% 65 24 (36.9) 63 10 (15.9)
> 20% 59 33 (55.9) 59 12 (20.3)
Lymph-node metastasis 117 0.6326 115 0.5840
Absent 58 24 (41.4) 55 8 (14.5)
Present 59 27 (45.8) 60 11 (18.3)
this period of time, especially in series with high number
of ER negative cases like the one herein studied (Emens
and Davidson, 2003). Cases lacking one or more of the
clinico-pathological variables were not included in the
specific statistical analysis.
Results
A total of 124 breast carcinoma samples, organised
into TMAs (Tissue Microarrays), were assessed for
GLUT1 and CAIX immunohistochemical expressions. 
In general, positive GLUT1 expression was
observed in both plasma membrane and cytoplasm (Fig.
1A), while CAIX expression was mainly observed in the
plasma membrane, with some cases also presenting
cytoplasm staining (Fig. 1B). GLUT1 expression was
observed only in the epithelial cells of 1 out of 20
normal samples evaluated (5%), with a significantly
higher frequency (46%) in tumour samples (57/124,
p=0.0005), while CAIX expression was absent in normal
tissue but was found in 18% (22/122) of breast cancer
cases (p=0.0388). Importantly, the expression of both
molecules was frequently observed in perinecrotic
regions, as can be observed in Figure 1A,B, especially
CAIX, which was usually focal and mainly restricted to
tumour cells adjacent to areas of necrosis.
Importantly, when comparing the expression of the
previously analysed MCT1, MCT4 and CD147 (Pinheiro
et al., 2010) with GLUT1 and CAIX, we found that both
MCT1 and CD147, but not MCT4, were more frequently
expressed in GLUT1 and CAIX positive tumour samples
(Table 1). Also, as expected, GLUT1 and CAIX were
significantly co-expressed, with 81.8% (18/22) of CAIX
positive cases also positive for GLUT1, versus 37.5%
(36/96) GLUT1 positive in the CAIX negative group,
p=0.0002. Figure 1C-E shows a breast cancer case
simultaneously positive for MCT1, GLUT1 and CAIX,
in the same tumour area.
Assessment of the clinico-pathological value of
GLUT1 and CAIX also retrieved important results
(Table 2). We found significant associations between
GLUT1 expression and high grade tumours (p=0.0014),
basal-like subtype (p=0.0008), absence of PR
(p=0.0162), presence of vimentin (p=0.0033) and high
proliferative index as measured by Ki67 expression
(p=0.0339). Additionally, CAIX was associated with the
majority of the clinico-pathological parameters analysed,
including tumour size (p=0.0034), histological grade
(p=0.0263), molecular subtype (p=0.0050), ER and PR
negativity (p=0.0014 and p=0.0292, respectively),
expression of CK5 (p=0.0002), CK14 (p=0.0102) and
vimentin (p=0.0004). 
Analysis of GLUT1 expression and patients’
survival (disease-free survival and overall survival)
showed no significant differences between negative and
positive groups (data not shown), but, importantly,
patients with CAIX positive tumours had a lower
disease-free survival than patients with CAIX negative
tumours (43.2 versus 52.4 months, respectively,
p=0.045) (Fig. 2). No significant differences in overall
survival were observed between the CAIX negative
group and the CAIX positive group.
Discussion
Upregulation of glucose conversion into lactate,
even in the presence of oxygen (Warburg effect), has
been described as a possible adaptive mechanism to
overcome intermittent hypoxia in pre-malignant lesions.
This metabolic switch leads to an increase in acid
production by cancer cells and, therefore, the need for
further adaptation by means of intracellular pH
regulation and resistance to extracellular acidity
(Gatenby and Gilles, 2004). In this perspective, MCTs
emerge as important contributors to cancer cell
adaptation due to their function, on one hand, of lactate
export, allowing continuous glycolysis, and, on the other
hand, of tumour intracellular pH regulation and
induction of extracellular acidosis, by co-transporting
lactate and a proton. Although the contribution of MCTs
to the glycolytic and acidic phenotype of tumours is
suggested (Mathupala et al., 2007), the significance of
tumour MCT expression in this context is still not clear.
Thus, the main aim of the present work was to determine
whether glycolytic and acid-resistant tumours, with
upregulation of GLUT1 and CAIX, present a higher
expression of MCTs, supporting the involvement of
these transporters in the metabolic adaptations of cancer
cells.
GLUT1, involved in glucose uptake, is upregulated
in a variety of tumours (for a review see Macheda et al.,
2005), being the hypoxia transcription factor HIF-1α the
major regulator of its expression in cancer cells
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Fig. 2. Disease-free survival (DFS) curve regarding CAIX
immunoreaction in breast cancer patients. Patients with positive
tumours for CAIX expression show shorter disease-free survival
(interrupted line) than patients with CAIX negative tumours (continuous
line) (p=0.045).
(Baumann et al., 2007). HIF-1α , the master
transcriptional regulator of tumour cell adaptation to
hypoxic stress, activates a number of genes, many of
which code for proteins involved in O2 delivery,
angiogenesis, energy preservation (including glucose
transporters and glycolytic enzymes), and other
processes essential to tumour cell survival, proliferation,
and spread (Vaupel and Harrison, 2004). Moreover,
CAIX and MCT4 are also downstream targets of HIF-1α
(Wykoff et al., 2000; Ullah et al., 2006; Perez et al.,
2010) and both GLUT1 and CAIX are recognised as
tumour hypoxia markers (Vordermark and Brown,
2003). However, in our study, MCT4 expression was not
increased in GLUT1 or CAIX positive tumours. In
contrast, MCT1 was more frequently expressed in both
GLUT1 and CAIX positive tumours, pointing to a
hypoxia dependent upregulation of this MCT isoform,
which is accompanied by co-expression of its chaperone
CD147, essential for plasma membrane localization and
transporter activity (Kirk et al., 2000; Wilson et al.,
2005). This finding is of major importance since it
supports the induction of MCT1 expression by hypoxia
(Perez et al., 2010), which is contested by some groups
(Ullah et al., 2006; Sonveaux et al., 2008). With these
associations, one can support the role of functional
MCT1 as the lactate transporter responsible for lactate
efflux in highly glycolytic breast cancer cells, especially
in basal-like tumours. The transport activity of MCT1 is
considered one of the most important mechanisms of
intracellular pH regulation (Izumi et al., 2003). Besides
MCTs, carbonic anhydrases, especially CAIX, play a
major role in maintenance of intracellular (and
extracellular) pH levels, by contributing to the extrusion
of the protons generated by the high metabolic rates of
glycolytic cancer cells. At the tumour cell surface, CAIX
catalyses the extracellular trapping of acid, by hydrating
the cell-generated CO2 into HCO3- and H+ (Swietach et
al., 2007). Thus, it is not surprising to see an association
between MCT1 and both GLUT1 and CAIX, which is
likely a result of the overall HIF-1α-mediated metabolic
adaptations, conferring a glycolytic, acid-resistant
phenotype to cancer cells. 
As described previously (Chia et al., 2001; Vleugel
et al., 2005), GLUT1 and CAIX were mainly observed
in the vicinity of necrotic areas (a consequence of
tumour hypoxia) in our tumour series, which supports
the hypoxia-mediated regulation of the expression of
these proteins. Both hypoxia markers were absent in
normal breast tissue, but upregulated in breast tumour
tissues, with expression frequencies concordant with
previous reports (Kang et al., 2002; Younes et al., 1995;
Hussain et al., 2007; Trastour et al., 2007; Tan et al.,
2009; Chen et al., 2010). Although the clinico-
pathological value of GLUT1 and CAIX in breast cancer
has already been studied by others (Chia et al., 2001;
Younes et al., 1995; Hussain et al., 2007; Trastour et al.,
2007; Tan et al., 2009), our data strengthens the
importance of these proteins as prognostic markers,
especially GLUT1, which has been little explored in
breast cancer (Kang et al., 2002; Younes et al., 1995;
Chen et al., 2010). So far, GLUT1 has been associated
with lower disease-free survival, loss of ER and PR
(Kang et al., 2002) and both higher grade (Younes et al.,
1995; Kang et al., 2002; Chen et al., 2010) and
proliferative activity (through Ki67 expression) (Younes
et al., 1995). In the present work, although we did not
find associations of GLUT1 with disease-free or overall
survival, GLUT1 was more frequently expressed in high
grade tumours, negative for PR and with high
proliferative index (Ki67). Importantly, we found
GLUT1 to be more frequently expressed in basal-like
tumours, as well as in vimentin positive tumours. With
respect to CAIX, more data has been published in breast
carcinomas, which identifies CAIX as a marker of
aggressive tumour behaviour. This protein was
positively correlated with larger tumour size, basal-like
(Tan et al., 2009) and high grade tumours (Chia et al.,
2001; Span et al., 2003; Trastour et al., 2007; Tan et al.,
2009, Chen et al., 2010), loss of ER (Chia et al., 2001;
Span et al., 2003; Trastour et al., 2007; Tan et al., 2009)
and PR (Span et al., 2003) as well as with shorter
disease-free survival (Chia et al., 2001; Hussain et al.,
2007; Tan et al., 2009). Here, we support all the previous
findings described by other groups, by associating CAIX
expression with high histological grade, loss of ER and
PR and, importantly, basal-like subtype and disease-free
survival. These results suggest that the basal-like
subtype tumours may be more representative of the
glycolytic, acid-resistant phenotype proposed for cancer
cells and this hypoxia mediated phenotype may explain,
at least partly, the more aggressive phenotype of this
breast carcinoma subtype.
In the present study, we investigated the expression
of the key hypoxia regulated proteins GLUT1 and
CAIX. Importantly, they were positively associated with
the major lactate transporter, MCT1, especially in a
subset of aggressive breast carcinomas (basal-like),
where these proteins are more frequently expressed.
Since this subtype of tumours does not have a specific
molecular therapy (Matos et al., 2005), the development
of therapeutic approaches targeting these particular
metabolic features could be a promising strategy to be
explored in the treatment of basal-like breast tumours. 
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Abstract. Background: The triple-negative subgroup of breast
cancer includes a cluster of tumors exhibiting low E-cadherin
expression (metaplastic carcinomas). In several cancer models,
1alpha,25-dihydroxyvitamin D3 (1α,25(OH)2D3) induces
differentiation by increasing E-cadherin expression. The
Vitamin D receptor (VDR) was evaluated as a possible
therapeutic target for metaplastic carcinomas and
1α,25(OH)2D3 effects as a differentiating agent in triple-
negative breast cancer cells were assessed. Materials and
Methods: Metaplastic carcinomas were assessed for VDR
expression by immunohistochemistry; differences in E-cadherin
expression in triple-negative breast cancer cells were evaluated
by real-time PCR, western blotting and Cadherin 1 (CDH1)
methylation status. Results: Most of the metaplastic carcinomas
were positive for VDR expression. Furthermore, 1α,25(OH)2D3
promoted differentiation of MDA-MB-231 cells by inducing de
novo E-cadherin expression, an effect that was time- and dose-
dependent. Also, E-cadherin expression was due to promoter
demethylation. Conclusion: Metaplastic carcinomas may
respond to 1α,25(OH)2D3, since they express VDR and
1α,25(OH)2D3 induces de novo E-cadherin expression in
breast cancer cells by promoter demethylation.
Breast cancer is a heterogeneous disease, comprised of
diverse molecular subtypes associated with different
biological behaviours and clinical outcomes (1, 2). Among
all breast cancer subgroups, the triple-negative basal-like
type is the most aggressive, presents poor patient outcome
(2) and comprises a rare cluster of carcinomas entitled
metaplastic tumors (3-5). Our group and others have
demonstrated that metaplastic carcinomas are distinguished
by high levels of expression of classical basal-like markers,
such as cytokeratin (CK) 5/6, CK14, epidermal growth factor
receptor (EGFR), vimentin and P-cadherin, as well as E-
cadherin down-regulation (5-7). Furthermore, patients
harbouring metaplastic tumors display a worse prognosis,
exhibiting lower rates of disease-free survival than those with
invasive ductal carcinomas (8, 9). Due to their triple-negative
phenotype, metaplastic carcinomas do not have a directed
therapy. Since radiation and chemotherapy remain the only
options to treat these carcinomas, intensive research on
alternative therapeutic strategies is mandatory.
1Alpha,25-dihydroxyvitamin D3 (1α,25(OH)2D3), the
biologically active form of vitamin D, is a steroid hormone that
exerts most of its biological activities by binding to a specific
high-affinity receptor, the vitamin D receptor (VDR) (10). We
previously reported that 56% of invasive breast carcinomas
express the VDR and, among these, 56% of the cases classified
as triple-negative basal-like tumors are positive for VDR
expression (11), suggesting that they may be responsive to the
anti-carcinogenic properties of 1α,25(OH)2D3. In several
cancer models, 1α,25(OH)2D3 participates in cell growth
regulation and cell differentiation (12). In breast cancer cells, it
was demonstrated that 1α,25(OH)2D3 is able to induce cells to
be more adhesive to each other, as well as to some substrates,
through an increase in the expression of endogenous E-
cadherin and other adhesion molecules (13). Additionally,
1α,25(OH)2D3 promotes the differentiation of colon cancer
cells by inducing the expression of E-cadherin in VDR-
expressing cells (14) and a similar result was obtained in
prostate cancer with a 1α,25(OH)2D3 analogue (15).
These data provide good evidence for the ability of
1α,25(OH)2D3 to act as an epithelial differentiation-inducing
agent. Therefore, the purpose of the current work was to
study if the VDR could be a potential therapeutic target for
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metaplastic triple-negative breast carcinomas. Additionally,
the in vitro effects of 1α,25(OH)2D3 as a differentiating
agent in triple-negative breast cancer cell lines were
evaluated.
Materials and Methods
Immunohistochemistry. A series of 12 formalin-fixed paraffin-
embedded metaplastic breast carcinomas were retrieved from the
archives of the Federal University of São Paulo, Brazil and from the
Federal University of Santa Catarina, Brazil. The cases were
collected between 1994 and 2009. Immunohistochemical staining
for the VDR was performed as described elsewhere (11).
Cell culture and treatments. All the breast cancer cells (MDA-MB-
231, Hs578T and BT-549, commercially available from ATCC),
representative of mesenchymal triple-negative breast cancer (16, 17)
were grown in complete GIBCO, Dulbecco’s Modified Eagle’s
Medium (DMEM, Invitrogen, Carlsbad, CA, USA) in the presence of
10% foetal bovine serum (Invitrogen) and 1% penicillin/streptomycin
(Invitrogen). Treatments with 1α,25(OH)2D3 100 nM (Cayman
Chemical, Denver, CO, USA), 5-aza-2-deoxycytidine 5 μM (5-aza-
dC, Sigma, Munich, Germany), DMSO (dimethyl sulfoxide, vehicle
for 5-aza-dC and Trichostatin A [TSA]) and ethanol (vehicle for
1α,25(OH)2D3) were performed for 72 hours, while the treatment
with TSA 100 nM (Sigma) was performed only for 16 hours. Every
24 hours, the culture medium was changed and a fresh new treatment
agent was added. 
Western blotting. Total protein lysates were prepared from the
cultured cells and the protein concentration was determined using
the Bradford assay (Bio-Rad protein quantification system,
Berkeley, CA, USA). Equal protein samples were separated in an
8% SDS-PAGE and the proteins were transferred onto nitrocellulose
membranes (GE Healthcare Life Sciences, Chalfont St Giles, UK).
For immunostaining, the membranes were blocked for non-specific
binding with 5% (w/v) non-fat dry milk, in PBS containing 0.5%
(v/v) Tween-20. The membranes were incubated with the primary
antibodies (α-tubulin, clone DM1A, Sigma, 1:10000 for 1 hour; β-
actin, clone I19, Santa Cruz [Santa Cruz, CA, USA], 1:1000 for 1
hour; E-cadherin, clone 24E10, Cell Signaling [Beverly, MA, USA],
1:1000 for 1 hour; and VDR, clone 9A7γE10.4, Calbiochem
[Darmstadt, Germany], 1:400 overnight), followed by four 5 min
washes in PBS/Tween-20; then they were incubated with
horseradish peroxidase-conjugated secondary antibodies (all 1:1000,
Santa Cruz) for 60 min. The membranes were then washed six times
more for 5 min and the proteins detected using the ECL detection
system (GE Healthcare Life Sciences).
RNA extraction, cDNA synthesis and quantitative real-time PCR.
The RNA was extracted from the breast cancer cells using TRIzol®
reagent (Invitrogen) and cDNA was synthesised from 1 μg of RNA,
using an Omniscript Reverse Transcription kit (Qiagen, Düsseldorf,
Germany), following the manufacturer’s instructions. Real-time
PCR was performed using TaqMan Gene Expression Assays
(Applied Biosystems, Carlsbad, CA, USA), using 1 μL of cDNA
and in accordance with the manufacturer’s protocol. The TaqMan
Gene Expression Assays used were Hs01023895_m1 (for CDH1
[Cadherin 1], Applied Biosystems) and TaqMan PreDeveloped
Assay Reagents Human GAPDH (for GAPDH [Glyceraldehyde 3-
phosphate dehydrogenase], Applied Biosystems). The reactions
were performed using standard cycle parameters and relative
transcript levels were determined using human GAPDH as an
internal reference. Differences between samples were determined
using the Quantitation–Relative Standard Curve method.
DNA extraction and CDH1 promoter methylation analysis. The
DNA was extracted from the breast cancer cell lines using an
ULTRAPrep Genomic DNA Blood and Cell Culture Kit (AHN
Biotechnologie, Nordhausen, Germany), according to the
manufacturer’s instructions. Bisulfite treatment was performed on
300 ng of DNA, using an EpiTect Bisulfite kit (Qiagen) following
the manufacturer’s guidelines. Unmethylated cytosines were
converted to uracil, whereas methylated ones remained unmodified.
The 12 CpG sites (cytosine-phosphate-guanine) within the 90 base
pairs upstream of the CDH1 translation start site (ATG) were
analysed, as described elsewhere (18).
Immunofluorescence. The cells were seeded on coverslips and fixed
with formaldehyde 4% (v/v) for 30 min The coverslips were washed
three times with PBS for 5 min, followed by incubation with 50 mM
NH4Cl in PBS for 10 min. Following another set of three 5 minute
washes with PBS, the coverslips were incubated with Triton X-100
0.2% (v/v) for 5 min and washed with PBS three times for 5 min.
Subsequently, they were blocked for non-specific binding with BSA
5% in PBS, containing 0.5% (v/v) Tween-20, for 30 min and
incubated with the primary antibody for E-cadherin (Zymed, San
Francisco, CA, USA, clone HECD1, 1:100) for 1 hour. After three 5
minute washes with PBS, the coverslips were incubated with a goat
anti-mouse secondary antibody (Alexa Fluor 594, 1:500, Invitrogen),
washed with PBS for 3 times 5 min and mounted using Vectashield
with DAPI (Vector Laboratories, Burlingame, CA, USA).
Transfection with siRNA for VDR. MDA-MB-231 cells (2.5×105 cells)
were cultured in 6-well plates for 24 hours. For each well, 150 nmol of
siRNA against VDR (Hs_VDR_8 FlexiTube siRNA, Qiagen) or
control siRNA (Qiagen) was used according to the manufacturer’s
instructions. After 5 hours of incubation, the cell medium was replaced
and the cells were treated with 1α,25(OH)2D3 100 nM and ethanol.
The evaluation of siRNA efficiency occurred 48 hours after
transfection.
Statistical analysis. Differences between groups were assessed using
Student’s t-test. Differences with p-values <0.05 were considered
statistically significant. All the presented results are representative of
at least three independent experiments, unless stated otherwise.
Results
VDR expression in metaplastic breast carcinomas. Out of the
12 metaplastic breast carcinomas, 8 cases (66.7%) were
positive for the expression of VDR (Figure 1). 
VDR expression in triple-negative breast cancer cell lines.
By western blotting, it was shown that all the cell lines
studied were positive for VDR expression. The MDA-MB-
231 and BT-549 cells seem to be more sensitive to
1α,25(OH)2D3, as in these cells there was a clear increase in
VDR expression upon hormonal treatment (Figure 2).
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Effect of 1α,25(OH)2D3 on the expression of E-cadherin. A
de novo expression of E-cadherin, by western blotting, was
observed upon 1α,25(OH)2D3 treatment in the MDA-MB-
231 cells (Figure 3A). As presented in Figure 3B, the
expression of E-cadherin was dependent on the duration of
treatment. The protein expression was first detected at 24
hours and increased with time. With 72 hours of treatment
the E-cadherin expression level was dependent on the dose
of 1α,25(OH)2D3 and was identified even with the very low
dose of 1 nM (Figure 3C). 
In the MDA-MB-231 cells, 1α,25(OH)2D3 was a potent
inducer of CDH1 mRNA expression, displaying more than
10-fold induction, compared with the control (p<0.01)
(Figure 4A). Furthermore, the level of expression induced
by 1α,25(OH)2D3 was 2-fold higher than that produced by
the demethylating agent 5-aza-dC alone and 3-fold higher
than that induced by the histone deacetylation (HDAC)
inhibitor agent TSA alone. However, both agents displayed
an additive effect to 1α,25(OH)2D3, the highest levels of
expression being induced when the three drugs were
combined. These results were also confirmed by the protein
expression (Figure 4A). In the BT-549 cells, 1α,25(OH)2D3
was unable to induce E-cadherin expression on its own.
However, in the Hs578T cells CDH1 expression was
significantly induced upon 1α,25(OH)2D3 treatment (Figure
4B). Furthermore, in both cell lines CDH1 mRNA
expression was induced upon treatment with 5-aza-dC.
Interestingly, 1α,25(OH)2D3 seemed to display an additive
effect when administered with both 5-aza-dC and TSA.
Again, the highest levels of CDH1 expression were achieved
whenever all the agents were added together and, in this
case, the BT-549 cells were more responsive than the
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Figure 1. H&E, magnification ×630 (A) and VDR, magnification ×400 (B) staining in a case of metaplastic breast carcinoma.
Figure 2. Western blot of VDR expression in MDA-MB-231, Hs578T and BT-549 breast cancer cell lines.
Figure 3. Effect of 1α,25(OH)2D3 on E-cadherin expression in MDA-
MB-231 breast cancer cells treated for 72 hours (A) or for various times
(B) or at various dose rates (C), and assessed by western blotting.
Hs578T cells, which corroborated the VDR expression
results. Furthermore, these results were confirmed by the
protein expression (Figure 4B and 4C).
As shown by immunofluorescence in Figure 5, upon
treatment with 1α,25(OH)2D3, the MDA-MB-231 cells
exhibited expression of E-cadherin at the plasma membrane.
In contrast, the expression of E-cadherin induced by 5-aza-
dC alone was granular and dispersed throughout the
cytoplasm. However, when these cells were treated with both
agents, the E-cadherin expression was located at the
membrane. 
Mediation of 1α,25(OH)2D3-induced expression of E-
cadherin. Since 1α,25(OH)2D3 alone induced E-cadherin
expression at the protein level only in the MDA-MB-231
cells, the experiments using VDR knockdown with siRNA
were only conducted in this cell line. Upon silencing of the
VDR in the MDA-MB-231 cells, the E-cadherin expression
after hormonal treatment was abrogated (Figure 6). 
Mechanism of E-cadherin expression. Upon 1α,25(OH)2D3
treatment, partial demethylation of the CDH1 promoter in the
MDA-MB-231 cells was observed (Figure 7). Demethylation
was detected in 7 out of the 12 CpG sites analysed. 
Discussion
The majority of the metaplastic breast carcinomas studied
were positive for VDR expression, suggesting that they might
be responsive to treatment with 1α,25(OH)2D3. In addition,
67% of the tumors had previously been characterised as
negative for E-cadherin expression and 83.3% exhibited
vimentin expression (unpublished results), showing that these
tumors were indeed undifferentiated and could benefit from
the differentiation-inducing properties of 1α,25(OH)2D3
treatment. In the in vitro model, 1α,25(OH)2D3 induced a de
novo E-cadherin (epithelial differentiation marker) expression
in the triple-negative MDA-MB-231 breast cancer cell line.
This is an important finding, given the major role of E-
ANTICANCER RESEARCH 32: 249-258 (2012)
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Figure 4. Continued
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Figure 4. Effect of 1α,25(OH)2D3, 5-aza-dC and TSA on CDH1 mRNA expression and E-cadherin expression in MDA-MB-231 (A), Hs578T (B) and
BT-549 (C) breast cancer cells (*p<0.05, **p<0.01).
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Figure 5. Immunofluorescence of E-cadherin expression in MDA-MB-231 breast cancer cells (magnification ×400).
Figure 6. Effect on E-cadherin expression induced by 1α,25(OH)2D3 of VDR knockdown by siRNA in MDA-MB-231 cells.
Figure 7. Methylation analysis of CDH1 promoter in MDA-MB-231 breast cancer cells. ! – methylation, – hemimethylation, ! – demethylation
(A); Example of DNA sequences treated with ethanol or 1α,25(OH)2D3 (B).
cadherin as a tumor suppressor protein in lobular breast
carcinomas and other cancer models (19, 20) and since down-
regulation of E-cadherin is required to initiate breast cancer
metastatic growth (21). Furthermore, this effect was
dependent on the duration of treatment and the quantity of
1α,25(OH)2D3 supplied to the cells. As far as we know, this
is the first study demonstrating the de novo induction of E-
cadherin expression in breast cancer cells by 1α,25(OH)2D3
due to CDH1 promoter demethylation, although it has been
reported that 1α,25(OH)2D3 can augment the expression of
endogenous E-cadherin in mammary tumor cells (13). In
addition, it has been demonstrated that a 1α,25(OH)2D3
analogue, increased the expression of E-cadherin in prostate
cancer cells (15). In colon carcinoma cells, 1α,25(OH)2D3 is
also known to promote differentiation by inducing E-cadherin
expression and other adhesion proteins, an effect only
observed in VDR positive cells (14). Likewise, in the MDA-
MB-231 cells, E-cadherin expression was dependent on the
presence of the VDR, suggesting it could mediate this effect. 
In MDA-MB-231 cells, CDH1 trancription is silenced due
to promoter methylation (22). Interestingly, the levels of
CDH1 expression upon 1α,25(OH)2D3 treatment in the
MDA-MB-231 cells were 2- and 3-fold higher than those
induced by the demethylating agent 5-aza-dC and by the
HDAC inhibitor TSA, respectively, while the combination of
1α,25(OH)2D3 with either of these molecules promoted an
additive effect, which was further confirmed by the protein
expression. In gastric cancer cells, 1α,25(OH)2D3 has been
shown to work in synergy with 5-aza-dC and TSA (23), thus
supporting the effect obtained in the present study.
Additionally, in colon cancer cells with silenced HDAC3, E-
cadherin expression increased upon treatment with
1α,25(OH)2D3 (24), a result that mimics that observed in the
MDA-MB-231 cells upon treatment with TSA and
1α,25(OH)2D3. In the other cells tested (Hs578T and BT-
549) the results were not so encouraging when
1α,25(OH)2D3 was used alone; however, CDH1/E-cadherin
expression was detectable when the cells were treated with
1α,25(OH)2D3 together with 5-aza-dC or TSA.
Also remarkably, the 1α,25(OH)2D3 treatment promoted
the correct localisation of E-cadherin at the cell membrane
in the MDA-MB-231 cells, suggesting a functional adhesion
molecule, unlike the granular and dispersed pattern of
expression induced by treatment with 5-aza-dC, which is
suggestive of a non-functional protein. Similarly, in colon
carcinoma, upon 1α,25(OH)2D3 treatment, E-cadherin
expression was observed at the cell membrane (14).
However, this 1α,25(OH)2D3 effect on E-cadherin induction
is not exclusive of disease settings, as in normal
keratinocytes, the treatment with 1α,25(OH)2D3 stimulates
the assembly of adherens junctions, assessed by translocation
of E-cadherin to the cell membrane (25). Surprisingly, when
the MDA-MB-231 cells were treated with both
1α,25(OH)2D3 and 5-aza-dC, the effect induced by
1α,25(OH)2D3 prevailed over the 5-aza-dC-induced effect
and there was a rescue of E-cadherin expression back to the
membrane, hinting that 1,25(OH)2D3 is indeed inducing not
only the expression of E-cadherin, but, apparently, it is also
important for the correct membrane localisation of the
protein as a cell-cell adhesion molecule. Unlike the current
results, 5-aza-dC was found to be necessary to sensitise
leukaemia cells to differentiate in response to 1α,25(OH)2D3
treatment (26). 
For the first time, 1α,25(OH)2D3 was found to promote
partial CDH1 promoter demethylation, suggesting that
1α,25(OH)2D3 can work as a demethylating agent in MDA-
MB-231 breast cancer cells. To the best of our knowledge,
only one study has correlated 1α,25(OH)2D3 with
methylation and reported that it induced methylation of
CYP27B1 (the enzyme responsible for its synthesis) and, thus,
silenced its expression (27). In colon cancer cells, where
1α,25(OH)2D3 induces E-cadherin expression, a new
mechanism involving phosphoinositide signalling was
recently proposed (28). Also in colonic cancer cells, a novel
mechanism involving 1α,25(OH)2D3 in epigenetic events was
reported, where the knockdown of KDM6B/JMJD3, a histone
demethylase induced by 1α,25(OH)2D3, down-regulated E-
cadherin expression (29). Studies addressing the importance
of these mediators in breast cancer are still lacking. 
In summary, the majority of metaplastic carcinomas
examined were positive for VDR expression, hinting that this
rare type of aggressive cancer may be responsive to the
antitumor effects of 1α,25(OH)2D3. Furthermore,
1α,25(OH)2D3 induced the de novo expression of the
epithelial differentiation marker E-cadherin in the highly
metastatic, triple-negative MDA-MB-231 breast cancer cell
line. To the best of our knowledge, this is the first report of
the de novo induction of E-cadherin in breast cancer cells by
1α,25(OH)2D3 due to CDH1 promoter demethylation,
therefore, revealing a novel mechanism for the action of
1α,25(OH)2D3 in breast cancer cells. The induction of
differentiation promoted by 1α,25(OH)2D3 in triple-negative
metaplastic breast cancer may decrease the aggressiveness of
this subtype of mammary carcinomas and improve patient
outcome, but further studies are necessary to confirm this
hypothesis. 
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Loss of WNK2 expression by promoter gene
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The gene encoding protein kinaseWNK2 was recently identified to be silenced by promoter hypermethylation
in gliomas and meningiomas, suggesting a tumour-suppressor role in these brain tumours. Following experi-
mental depletion in cell lines, WNK2 was further found to control GTP-loading of Rac1, a signalling guanosine
triphosphatase involved in cell migration and motility. Here we show that WNK2 promoter methylation also
occurs in 17.5% (29 out of 166) of adult gliomas, whereas it is infrequent in its paediatric forms (1.6%; 1
out of 66). Re-expression of WNK2 in glioblastoma cells presenting WNK2 gene silencing reduced cell pro-
liferation in vitro, tumour growth in vivo and also cell migration and invasion, an effect correlated with
reduced activation of Rac1. In contrast, when endogenous WNK2 was depleted from glioblastoma cells
with unmethylated WNK2 promoter, changes in cell morphology, an increase in invasion and activation of
Rac1 were observed. Together, these results validate the WNK2 gene as a recurrent target for epigenetic si-
lencing in glia-derived brain tumours and provide first mechanistic evidence for a tumour-suppressing role of
WNK2 that is related to Rac1 signalling and tumour cell invasion and proliferation.
INTRODUCTION
Gliomas are the most common primary adult and paediatric
brain tumours, and are composed by distinct histological sub-
types and World Health Organization (WHO) malignancy
grades (1,2). Astrocytic tumours are the most frequent
histological subtype and can be divided into pilocytic astrocyto-
mas (WHO grade I), diffuse astrocytomas (WHO grade II),
anaplastic astrocytomas (WHO grade III) and glioblastomas
(WHO grade IV) (1). Oligodendrogliomas are the second
most frequent subtype, and can be subdivided into low-grade
oligodendrogliomas (WHO grade II) and anaplastic
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oligodendrogliomas (WHO grade III). In adults, glioblastoma
(WHO grade IV) is not only the most aggressive type, with a
mean survival of!16months, but also themost frequent, account-
ing for !50% of all gliomas and !15% of all primary brain
tumours (1). In contrast to adults, in children, the most common
form is pilocytic astrocytomas. Despite the rarity of malignant
gliomas in the paediatric context, they are one of the leading
causesof cancer-relateddeaths in children.Agrowingbodyof evi-
dence demonstrates that paediatric malignant gliomas not only
exhibit distinct clinicopathological features but also harbour a dif-
ferent genetic profile (3). One of themajor causes of the highmor-
tality of glioblastoma is their infiltrative and invasive property that
hampers complete surgical excision, with consequent tumour re-
growth and recurrence (2,4).
Cell invasion is known to be regulated by Rho family
guanosine triphosphatases (GTPases), which control the dy-
namics of the actin cytoskeleton (5). Meanwhile, two different
types of tumour cell motility have been identified in 3D matri-
ces (6,7). A RhoA-dependent bleb-associated motility (amoeb-
oid migration mode) exists that does not require pericellular
proteolysis and generates hydrostatic pressure, which squeezes
tumour cells through pre-existing gaps in the matrix. In con-
trast, an elongated mechanism of cell motility (mesenchymal
migration mode) is associated with Rac1-dependent polymer-
ization of actin filaments and induces branching of existing
actin filaments that results in cell-surface structures, known
as lamellipodia or membrane ruffles.
WNK2 is a member of theWNK (with-no-lysine [K]) subfam-
ily of protein kinases (8,9), which is predominantly expressed in
the brain, heartmuscle, small intestine and colon (10). Functional
analysis has revealed that reducing WNK2 expression by RNA
interference in epithelial cell lines resulted in increased
GTP-loading of Rac1 and concomitant stimulation of the
Rac1-effector kinase PAK1 (p21-activated kinase). This effect
activates a signalling cross-talk, in which PAK1 phosphorylates
MAPK/extracellular signal-regulated kinase (ERK) 1 (MEK1)
at serine 298, thereby increasing the efficiency with which
MEK1 activates ERK1/2 upon growth factor stimulation (11).
Recently, WNK2 has been proposed to act as a specific
tumour-suppressor gene for brain tumours. First, an unbiased
genome-wide approach to mapping non-random and tumour
type-specific epigenetic gene silencing identified the WNK2
gene in 29 of 31 infiltrative gliomas (12), the underlying
mechanism being promoter methylation. Second, WNK2 was
reported to be aberrantly methylated in 83 and 71% of grade
II and III meningiomas, respectively, but rarely in a total of
209 tumours from 13 other tumour types (13).
In this study, we detected WNK2 silencing in !17.5% of
adult gliomas and describe that experimental manipulation
of WNK2 expression levels affected tumorigenic growth prop-
erties of glioblastoma cell lines and conferred increased inva-
siveness in a Rac1-dependent manner.
RESULTS
Methylation of the human WNK2 gene promoter in
glioblastoma
Based on previous reports showing that the WNK2 gene is a
recurrent target for epigenetic silencing in oligodendrogliomas
and meningiomas (12,13), we developed a methylation-
specific polymerase chain reaction (PCR) (MSP) to test for
the prevalence of WNK2 promoter methylation in adult
and paediatric malignant glioma cases. Among 61 childhood
high-grade gliomas, only one case (1.6%) was identified
with WNK2 promoter methylation, corresponding to an
18-year-old patient. In contrast, we found that 29 out of 166
adult glioma samples (17.5%) showed WNK2 methylation
(Fig. 1A). The majority of samples were glioblastoma (n ¼
115; 18.3% methylated). In order to further confirm the
MSP results in six adult glioblastoma cases (three methylated
and three unmethylated), we performed bisulphite sequencing
Figure 1. Methylation of the human WNK2 gene promoter in gliomas. (A)
Graphic representation of the analysis of 166 adult and 61 paediatric
gliomas by MSP at the WNK2 promoter. (B) Bisulphite sequencing of the
WNK2 CpG island in three MSP-positive, three MSP-negative adult glioblast-
oma samples and normal brain (NB). Shown are a graphical representation of
the CpG island with 74 CG dinucleotides (top) and a grey-scale-coded fre-
quency chart of methylated positions in the seven samples. (C) MSP analysis
of the WNK2 gene promoter in the eight indicated glioblastoma cell lines
and NHA. The cell lines found to be promoter-methylated are marked by an
asterisk.
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of their WNK2 promoter region and were able to fully validate
the observed methylation status at nucleotide-level resolution
(Fig. 1B and Supplementary Material, Fig. S1).
No significant association was observed between WNK2 pro-
moter methylation and clinicopathological data such as age,
gender, cellular lineage, histological subtype, malignancy
grade or patient survival (Supplementary Material, Table S1).
Additionally, we made use of a glioblastoma data set from
The Cancer Genome Atlas (TCGA) containing data for both
methylation and mRNA expression ofWNK2. A significant cor-
relation between the downregulation of WNK2 expression and
the presence of promoter methylation was found; however,
similar to our data, there was no correlation between WNK2
methylation and clinicopathological data (Supplementary Ma-
terial, Table S2). Interestingly, when only mRNA expression
was considered, a significant correlation was found between
WNK2 downregulation and higher age or lower survival time
(Supplementary Material, Table S2 and Fig. S2).
These results suggested that other mechanisms may exist
besides the described promoter methylation, which lead to
the downregulation of WNK2 expression. In fact, a genome-
wide sequencing of 22 glioblastoma identified one case with
the missense mutation A1267T (14). In order to test the hy-
pothesis that this mutation could be an alternative genetic
event, we determined the frequency of this mutation in 48
primary glioblastomas (12 methylated and 36 unmethylated).
None of the 48 glioblastomas exhibited the A1267T WNK2
mutation (data not shown).
In order to select appropriate models to assess the cellular
effects of WNK2 silencing, eight glioblastoma cell lines
(SNB-19, U87-MG, U251, U373, SW1783, SW1088, A172,
GAMG) and a cell line derived from normal human astrocytes
(NHA) were also characterized by MSP for their WNK2 pro-
moter methylation status. Promoter methylation was observed
in cell lines SNB19, U87-MG, U251, U373 and A172
(Fig. 1C), the latter presenting the strongest methylation
signal, confirming previously described data (12).
WNK2 expression in different glioblastoma cell lines
Next, we characterized the above-mentioned cell lines for their
expression levels of WNK2 transcript (Fig. 2A) and protein
(Fig. 2B). In general, we found that WNK2 expression was
absent or low in cell lines with promoter methylation, includ-
ing A172 cells in which we showed previously that WNK2 ex-
pression can be reactivated after treatment with demethylation
drugs (12). In contrast, WNK2 expression was clearly detect-
able in all non-methylated cell lines, among which SW1088
cells expressed the highest levels of WNK2 transcript and
protein. We thus selected two cell lines as models for the sub-
sequent experimental manipulation of WNK2 expression
levels: SW1088 cells that express endogenous WNK2 from
an unmethylated promoter and A172 cells that express no
WNK2 due to promoter methylation.
Depletion of endogenous WNK2 increases growth and
invasion of SW1088 cells
Expression of endogenous WNK2 in SW1088 cells was inhib-
ited by RNA interference. First, stable cell lines expressing
either a control short hairpin RNA (shRNA) or one of two dis-
tinct WNK2-specific shRNAs (shW2.2 and shW2.3) were
selected (Fig. 3A). Clones shW2.2 and shW2.3 were selected,
which revealed distinct degrees of WNK2 depletion. In add-
ition, transient transfection of parental SW1088 cells with
small interfering RNAs (siRNAs) allowed downregulation of
WNK2 expression in !50% of the cells (Fig. 3B).
The soft agar colony formation assay indicates anchorage-
independent growth and demonstrated a significant (P, 0.05)
increase in the number of the colonies formed by the stable
shW2-transfected cells (Fig. 4A).
During the selection of the shW2 clones, we also observed dif-
ferences in morphology and actin cytoskeleton organization
(Fig. 4B). Unlike parental SW1088 and shCtrl cells, shWNK2.2
cells and especially shWNK2.3 cells showed a more flat
spread-out appearance and displayed pronounced cytoplasmic
protrusions consistent with lamellipodia formation. Immuno-
fluorescence staining for actin and endogenous Rac1 showed
increased accumulation at the plasma membrane (Fig. 4C).
These observations prompted us to analyse cell migration
properties in wound-healing assays. First, parental SW1088
cells were transiently transfectedwith control or siWNK2 oligo-
nucleotides. Approximately 48 h after siRNA transfection,
scratch wounds were made across the cell monolayer and mon-
itored by time-lapse photography for 24 h (Fig. 5A).Under these
conditions, the depletion of WNK2 reached !50% (Fig. 3B),
and an increase in wound closure was observed.
Cell invasion and migration are known to be regulated by
Rho family GTPases, which control the dynamics of the
actin cytoskeleton (5), and our previous functional analysis
of WNK2 in epithelial cells has demonstrated that depletion
of WNK2 expression resulted in increased GTP-loading
Figure 2. Expression level of endogenous WNK2 in the indicated cell lines.
(A) Detection of WNK2 transcript by RT-PCR, including as positive control
the previously reported expression in colorectal HT29 cell line (11). (B) Detec-
tion of WNK2 protein by western blot, including as positive controls lysates
from HEK293 transfected with Myc-tagged WNK2 and HT29 cells. The cell
lines shown to be promoter-methylated are marked by an asterisk.
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of Rac1 and concomitant reduction in active RhoA (11).
We thus confirmed the occurrence of an increase in Rac1
activity and a concomitant reduction in RhoA active levels
in siWNK2-transfected SW1088 cells (Fig. 5B and C).
These data indicated increased cell migration capacity upon
the downregulation of WNK2 expression.
In order to study the motile and invasive cell properties in a
more homogenous cell population, the stable shW2 clones
were first investigated by in vivo time-lapse microscopy. Mi-
gration experiments confirmed that the shW2.2 and shW2.3
clones exhibited increased ability in closing scratch wounds
(Fig. 6A and Supplementary Material, Movies M1 and M2).
The in vivo live-cell observations further revealed that
shWNK2.2 and shWNK2.3 cells presented higher cell motility
and formed larger lamellipodia protrusions (Fig. 6B and Sup-
plementary Material, Movies M3 and M4).
Based on these findings, the clones were analysed inMatrigel
invasion assays. An increase in the number of cells that passed
the membrane was observed comparing control with shW2.2
and shW2.3 cells (Fig. 6C), and this increase was proportional
to the levels of active Rac1 measured in these cells (Fig. 6D).
Thus, clones expressing lower WNK2 levels showed higher
invasiveness compared with parental and shCtrl SW1088 cells.
Together, these data demonstrate that the downregulation of
WNK2 expression in glioblastoma cells increased their cell
migration and invasion capacity with a concomitant increase
in Rac1 activity.
Re-expression of ectopic WNK2 inhibits growth and
migration of A172 cells
Considering that our data have so far supported a role forWNK2
as a tumour-suppressor gene in gliomas, we wondered whether
restoration of WNK2 expression would inhibit the major cell
properties described above. Promoter-methylated A172 cells
that lost endogenous WNK2 expression were therefore trans-
fected with aWNK2 cDNA construct. Owing to the inefficiency
of transient plasmid transfection into A172 cells, we established
pools of stable transfected cells expressing either the WNK2
coding sequence (A172-HW2) or the corresponding empty
vector (A172-HEv), and documented the corresponding
WNK2 transcript and protein levels (Fig. 7A and 7B). These
pools were analysed for their growth and migration properties.
The soft agar colony formation assay demonstrated a sig-
nificant (P, 0.05) decrease in colony numbers formed by
A172HW2 cells, in comparison with A172HEv (Fig. 7C).
To examine the effect of WNK2 re-expression on tumour
growth in vivo, we performed the chick embryo chorioallantoic
membrane (CAM) assay (Fig. 7D). The stable A172 cell pools
were implanted into the embryo CAM in ovo (A172HEv cells,
n ¼ 10; A172HW2 cells, n ¼ 15), and 7 days later the chicken
embryos were sacrificed to evaluate tumour growth ex ovo, as
described (15). The mean perimeter values of the tumours
formed by the control A172HEv and the A172HW2 cells were
15405.82+ 3853.42 mm and 5502.97+ 2804.83 mm, respect-
ively, being the difference statistically significant (P , 0.05)
(Fig. 7E). The CAM assay further permits to evaluate angiogen-
esis modulation. When the number of vessels around the
tumours was counted, no statistically significant difference
was found between A172HEv and A172HW2 cells (73+ 10
and 66+ 17 vessels, respectively) (Fig. 7E).
Furthermore, control A172HEv cells were compared with the
stable A172-HW2 cells in wound closure assays. A clear delay
in wound closure was observed for A172-HW2 cells due to
re-expression of WNK2 (Fig. 8A). Because our previous data
found that the loss ofWNK2 expression promoted the activation
of the small GTPase Rac1, we compared these cells in CRIB
(Cdc42/Rac1 interactive binding)-domain pull-down assays.
We found lower Rac1 activity in A172HW2 cells than in
A172HEv or parental cells (Fig. 8B). In addition, treatment of
A172HEv cells with the Rac1 inhibitor NSC23766 also
delayed wound closure (data not shown). Together, these data
are consistent with a decreased cell growth and migration cap-
acity upon re-expression of WNK2 in promoter-methylated
glioblastoma cells, indicating it as a therapeutic target.
DISCUSSION
The main novel findings described in this article are that the
loss of WNK2 expression (i) occurs in a subset of 17.5% of
adult but not paediatric malignant gliomas, and (ii) leads to
increased Rac1 activity and invasion of glioblastoma cells.
Initially, we started by confirming whether epigenetic silen-
cing of the WNK2 gene through promoter methylation was a
Figure 3. Efficiency of WNK2 depletion in SW1088 cells by RNA interfer-
ence. (A) Cells were transfected with control or one of two different
WNK2-specific shRNA vectors, and individual cell clones selected in the pres-
ence of puromycin. The resulting WNK2 expression levels were determined
and graphically displayed (n ¼ 4). (B) SW1088 cells were transiently trans-
fected (n ¼ 7) with control (siCtrl) or WNK2-specific (siWNK2) siRNAs oli-
gonucleotides and remaining WNK2 transcript levels analysed by RT-PCR
after 48 h. Statistically significant differences are indicated as ∗P , 0.05.
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specific target inmalignant gliomas. First, our results showed that
methylation occurred less frequently in adult gliomas (17.5%;
n ¼ 166) than in previously described limited series of mainly
oligodendrogliomas (94%; n ¼ 31) (12) or in meningiomas
(83% in grade II, n ¼ 6; 71% in grade III, n ¼ 7) (13). These dif-
ferences may in part be overestimated due to the varying sample
sizes analysed in the three studies. Nevertheless, our results
clearly confirm that WNK2 gene silencing occurs in gliomas
and support the hypothesis of a brain-specific tumour-suppressor
gene function (13,16); however, it can formally not be excluded
that these WNK2-silenced tumours arose from a glia stem cell
type in which theWNK2 gene is normally methylated.
Second, we found that paediatric malignant gliomas did not
share WNK2 promoter methylation as a common epigenetic
event. This underlines our and other authors’ reports demon-
strating that adult and paediatric gliomas are genetically dis-
tinct entities (17–19).
Third, we analysed a presumably alternative WNK2-com-
promising mutation, the p.A1267T point mutation previously
identified by whole-genome sequencing in one glioblastoma
sample (14). In 48 of the glioblastoma samples, this mutation
could not be detected, indicating that it does not significantly
contribute to WNK2 dysfunction, similar to what has been
reported in oligodendroglioma samples (12).
Subsequently, we tested the effect of experimental reduc-
tion of WNK2 expression by siRNAs in SW1088 cells,
which have no promoter methylation and thus express en-
dogenous WNK2. We found that anchorage-independent cell
growth increased under conditions of reduced WNK2 expres-
sion and that changes in cell morphology occurred, including
increased cell spreading and formation of lamellipodia. Con-
sistently, an increase in Rac1 activation was detected in
WNK2-depleted cells, in agreement with the changes in activ-
ity that we previously described to occur in HeLa cells (11).
Several recent studies have suggested a predominant role
for Rac1 in glioma cell motility and invasiveness, based on
the identification of changes in expression or activity of
either Rac1 (20–29), or individual Rac-specific guanine nu-
cleotide exchange factors (GEFs) (30–33), or Rac effector
proteins (34,35). It is well known that Rac1 drives a mesen-
chymal type of cell migration, suggesting that this type
allows the infiltration of glia-derived tumour cells within the
neuronal matrix of the brain (29). Consistent with this role
of Rac1, experimental WNK2 suppression in SW1088 cells
Figure 4. Effect of stable WNK2 depletion in SW1088 cells. (A) The tumorigenic growth properties of stable SW1088 clones expressing either shCtrl or shW2.2
or shW2.3 (Fig. 3) were compared in soft agar colony formation assays and the obtained colony numbers graphically displayed. All the experiments were done in
triplicate at least three times. Data are represented as the mean+SD, and differences with a ∗P , 0.05 in the Student’s t-test were considered statistically sig-
nificant. (B) Changes in cell morphology and actin cytoskeleton in WNK2-depleted SW1088 cells. Bright-field microscopic images showing the morphology of
the indicated cell lines. (C) Immunofluorescence staining for actin (red) and endogenous Rac1 (green) in the indicated cell lines. Note that cell clones shW2.2 and
shW2.3 show increased cell spreading with membrane protrusions which are also detected as Rac1 and actin-containing structures by immunofluorescence.
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led to increased cell migration in wound-healing assays and
increased invasion in Matrigel assays. Our findings indicate
that distinct mechanisms can contribute to the activation of
Rac1 during glioma progression, including the loss of
WNK2 expression described in this article. Our previous ana-
lysis of WNK2 indicated that its direct target could be a
Rho-GEF so that the loss of WNK2 leads to a decrease in
RhoA and a reciprocal increase in Rac1 activity (11).
Finally, the tumour-suppressing role of WNK2 in gliomas
implies that its re-expression should be able to revert the ag-
gressive phenotype of tumour cells. We clearly found that res-
toration of WNK2 in the promoter-methylated cell line A172
inhibited colony formation in soft agar and the cell migration
capacity, including the endogenous levels of GTP-bound
active Rac1. Moreover, we found that tumour growth was
reduced using the in vivo CAM assay.
Together our data support an important role for WNK2 in
the control of glia-derived cell migration and tumorigenic
growth and provide mechanistic insights into the pathways
involved.
MATERIALS AND METHODS
Patient samples and cell lines
Representative formalin-fixed paraffin-embedded blocks from
227 glioma tissues (166 were from adult and 61 were from
paediatric patients) were retrospectively retrieved from path-
ology archives of the Department of Pathology at three hospi-
tals in northern Portugal—Hospital Sa˜o Joa˜o, Porto, Hospital
Santo Anto´nio, Porto, and Hospital Pedro Hispano, Matosin-
hos, and from the UK at the King’s College Hospital,
London, and St George’s Hospital, London (Supplementary
Material, Table S1). The cohort includes astrocytic and oligo-
dendroglial tumours, of diverse malignant grades including
115 adult glioblastoma, which were all classified according
to the WHO criteria (1). Follow-up data were available in
133 adult patients (range: 0–64 months, mean: 12.8+ 1.0
months) and only in 18 paediatric patients (range: 0–80
months, mean: 21.7+ 5.2 months). The procedures for this
study were approved by local and multicenter Ethical
Review Committees, and, in accordance with institutional
ethical standards, the biological samples were unlinked and
unidentified from their donors.
Eight glioblastoma cell lines were used in this study and
include SW1088, SW1783, U87-MG and A172 (obtained
from ATCC—American Type Culture Collection), SNB-19
and GAMG (obtained from DSMZ—German Collection of
Microorganisms and Cell Cultures) and U251 and U373
Figure 5. Effect of transient WNK2 depletion in SW1088 cells. (A) Cells were
transiently transfected with control (siCtrl) or WNK2-specific (siWNK2)
siRNAs under the conditions documented in Figure 3 and analysed. (A) Rep-
resentative images from wound-healing migration assays, in which scratch
wounds were made with a pipette tip across a confluent cell monolayer, and
distances between the wound edges measured after 8, 12 and 24 h. In the
graph below, the migration distances determined in seven independent
assays are expressed as fold differences compared with parental cells and
show the distances migrated in relation to time 0. (B) Activation levels of en-
dogenous Rac1 as determined under the same transfection conditions by
CRIB-domain pull-down assays and analysed by western blot comparing
total and GTP-loaded Rac1 fractions (n ¼ 7). (C) Control or WNK2-depleted
SW1088 cells were lysed and Rho A activation levels determined in a G-Lisa
assay (n ¼ 4). Note the increase in cell migration and Rac1 activation accom-
panied by a decrease in active RhoA following transient WNK2 depletion in
parental SW1088 cells. Statistically significant differences are indicated as
∗P , 0.05 or as ∗P , 0.005.
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(obtained from Costello Laboratory and described in ref. 36).
Their mutation profile of major cancer-associated genes is
shown in Supplementary Material, Table S3. Cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
medium as previously described (15) and regularly checked
for the absence of mycoplasm infection. Authentication of
cell lines was performed by IdentiCell Laboratories [Depart-
ment of Molecular Medicine (MOMA) at Aarhus University
Hospital Skejby in A˚rhus, Denmark] in August 2011. Geno-
typing confirmed the complete identity of all cell lines, with
the exception of U373, which was shown to be a subclone
of U251 cell line.
MSP, WNK2 promoter sequencing and mutation analysis
For the isolation of genomic DNA, selected areas from the
formalin-fixed paraffin-embedded blocks containing at least
85% of tumour tissue were macro-dissected into a microfuge
tube using a sterile needle (Neolus, 25G, 0.5 mm) and DNA
isolated using QIAampw DNA Micro Kit (Qiagen, Hilden,
Germany), as previously described (37). DNA from the cell
lines was isolated using TRIzolw Reagent (Invitrogen S.A.,
Barcelona, Spain) as recommended by the manufacturer.
For MSP, 500 ng of DNA were bisulphite-treated using EZ
DNA Methylation Golf Kit (Zymo Research Corporation,
Irvine, CA, USA), as previously described (37). Specific
primers to distinguish methylated (131 bp PCR product 1,
Fw: 5′-CGTTCGTTTTGTGAGTGTC; Rv: 5′-ACGACGACT-
CCACAAAAA) fromunmethylatedDNA (131 bpPCRproduct
2; Fw: 5′-GTTTGTTTGTTTTGTGAGTGTT and Rv:
5′-CCAACAACAACTCCACAAAAA) were designed using
theMethyl Primer Express Software v1.0. CpGenomeUniversal
Methylated DNA (Chemicon Millipore, Billerica, MA, USA)
was used as methylated control and blood DNA of a young
healthy individual was used as unmethylated control. Bisulphite
sequencing of theWNK2 promoter covered 73 contiguous CpGs
in the WNK2 CpG island and was analysed by sequencing 10
subclones of PCR products from bisulphite-treated DNA, as
previously described (12,13).
The prevalence of the WNK2-A1267T missense mutation
was determined following PCR amplification of exon 16
with primers WNK2-A1267T-F (5′-CGA GCA GAT GAA
GGA TGT CA) and WNK2-A1267T-R (5′-GAA TGA GGT
GGA GGG TCA GA) and direct sequencing of the obtained
product.
Cell culture, transfections and RNA interference
A172 and SW1088 cell lines were maintained in DMEM, sup-
plemented with 10% fetal bovine serum (Invitrogen) andFigure 6. Effect of stable WNK2 depletion in SW1088 cells. (A) Cells expres-
sing the indicated shRNA vectors were characterized for their migration cap-
acity in wound closure using in vivo time-lapse microscopy (see also
Supplementary Material, Movies M1 and M2). Shown is the quantification
(n ¼ 3) of the migrated distances by comparing the automatically acquired
images at the indicated time points. (B) Live cells seeded at low density
were analysed for their spontaneous motility properties. Shown is the quanti-
fication (n ¼ 3) of the mean speed (distances migrated during 12 h) of about
85 shCtrl and shW2.2 cells as well as representative still images picked
from the Supplementary Material, Movies M3 and M4. Note that
WNK2-depleted cells formed extensive lamellipodia (white arrows) and
were more motile. (C) The invasive properties of the indicated cell lines
were determined in Matrigel invasion assays. Shown are representative micro-
scopic images of the amount of cells able to cross the membrane barrier and a
graphical summary of six independent experiments. (D) Activation levels of
endogenous Rac1 determined in lysates from the three stable SW1088
clones by CRIB-domain pull-down assays (n ¼ 3). Shown is a representative
western blot comparing total and GTP-loaded Rac1 fractions and a graphical
quantification obtained from three independent experiments. Statistically sig-
nificant differences are indicated as ∗P , 0.05 or as ∗P , 0.005.
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regularly checked for the absence of mycoplasm infection.
Cells were transfected using a reverse transfection protocol
in which 1 × 106 cells were trypsinized and seeded together
with the premixed plasmid DNA/LipofectAMINE 2000 (Invi-
trogen) complex, according to the manufacturer’s instructions.
Cells were analysed after 22 h, and transfection efficiencies of
a GFP expression vector found to be "40%. Total amounts of
transfected plasmid DNA were kept constant at 4 mg per
60 mm dish or at 2 mg per 35 mm dish and adjusted with
empty vector if required. siRNAs were obtained from Eurofins
MWG-Biotech AG (Ebersberg, Germany) and reverse-
transfected using 5 × 105 trypsinized cells and siRNA/
LipofectAMINE 2000 complexes containing 300 pmol of
siRNA per 35 mm dish or 600 pmol per 60 mm dish. siRNA
sequences were siWNK2-a (5′-GCU CGA GGA UGC UGA
CAU ATT), siWNK2-b (5′-GGA CGC ACC CGA UGA
AAU UTT) and as control siGFP (5′-GGC UAC GUC CAG
GAG CGC ACC TT). Cells transfected with siRNAs were
analysed after 48 h, and transfection efficiencies found to be
"60% using an FITC-coupled siRNA (Qiagen). The achieved
reduction in target gene expression was determined in each ex-
periment by removing a 30 ml of aliquot from the cell lysate
for the extraction of total RNA, as described below.
For the selection of stable cell lines with reconstituted
WNK2 expression in A172 cells, the WNK2 cDNA was
subcloned as an EcoRI/EcoRV fragment into pcDNA3-Hygro
(Invitrogen). After cell transfection (see above), stable cell
pools were obtained following treatment with 200 mg/ml
of Hygromycin B (Sigma-Aldrich Quimica, Madrid, Spain).
A control stable cell pool transfected with the corresponding
empty vector was also selected. For the selection of stable
SW1088 cell lines with depleted endogenous WNK2
expression, shRNA encoding plasmids [part of the LKO.1
shRNA constructs obtained from the RNAi Consortium
(TRC) (Broad Institute, Cambridge, MA, USA)] containing
either a non-specific shRNA sequence (shCtrl) or two
previously validated shRNAs sequences targeting WNK2
were transfected. Cell clones were obtained following the
treatment of transfected cells with 2.5 mg/ml of puromycin
(Sigma-Aldrich).
Figure 7. Stable re-expression of WNK2 in A172 cells. (A) RT-PCR analysis of WNK2 transcript comparing parental (A172 par) and empty vector (A172 HEv)
control cells with WNK2-transfected A172 cells (A172 HW2). Colon HT29 and SW1088 cells were included as positive controls. Two serial dilutions of
HT29-input RNA were co-amplified to guarantee semi-quantitative PCR conditions. (B) Detection of WNK2 protein in the same cell lines after immunopreci-
pitation and western blot using a specific anti-WNK2 antibody. Note the re-expression of WNK2 in A172 HW2, but not in parental or empty vector-transfected
A172 HEv control cells. (C) In vitro tumorigenic growth properties of A172 HEv control and WNK2-transfected A172 cells (A172 HW2) were compared in soft
agar colony formation assays and the obtained colony numbers graphically displayed. (D) In vivo tumorigenic growth properties were analysed in CAM assays.
Representative pictures (16× magnification) of CAM assays after 7 days of tumour growth in ovo and ex ovo. We analysed 25 eggs (10 were injected with
A172HEv and 15 with A172HW2 cells) and observed statistically significant smaller perimeter (mm) in the tumours formed by A172HW2 cells (upper
panel). The counting of the blood vessels ex ovo revealed no differences in the number of vessels recruited to the tumours formed by both cell lines (lower
panel). (E) Graphical representation of the data quantitation obtained from all images, given as the mean+SD. Differences with a P, 0.05 in the Student’s
t-test are marked by an asterisk and were considered statistically significant.
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Soft agar colony formation assay
For soft agar colony formation, 1 ml underlayer (base agar
layers) consisting of 0.6% agar medium was prepared in
six-well plates by combining equal volumes of 1.2% Noble
agar with 2× DMEM medium containing 20% FBS. Cells
were trypsinized, centrifuged and resuspended in 0.35% agar
medium (top agar layer; equal volumes of 0.7% Noble agar
and 2× DMEM with 20% FBS) before 5 × 103 cells were
plated onto the previously prepared base agar layers. The
cells were incubated at 378C in a humidified 5% CO2 atmos-
phere for 3 weeks and the colonies formed stained with 0.05%
violet crystal for 15 min. Stained colonies were photographed
in a stereomicroscope (Olympus Z2× 16) using a digital
camera (Olympus DP71) (Olympus, Hamburg, Germany)
and counted with the Image J software. Results are expressed
as the mean number of colonies per field. The assay was done
in triplicate and repeated at least three times.
Cell lysis and immunoprecipitation, Rac1-CRIB pull-down
or Rho G-Lisa assays
Cells in 60 mm dishes were lysed on ice in 250 ml of lysis
buffer (20 mM Tris–HCl, pH 7.5, 1% NP-40, 130 mM NaCl,
10% glycerol, 10 mM MgCl2) containing 10 mM NaF, 0.1 mM
Na3VO4, 1 mM DTT and a protease inhibitor cocktail com-
posed of 1 mM PMSF, 1 mM 1,10-phenanthroline, 1 mM
EGTA, 10 mM E64 and 10 mg/ml of each aprotinin, leupeptin
and pepstatin A (all from Sigma-Aldrich). For RNA extrac-
tion, a 30 ml of aliquot was removed and processed as
described below. For protein analysis, a 40 ml of aliquot was
added to 10 ml of 5× Laemmli sample buffer, boiled for
10 min, centrifuged at 2500g for 30 s and analysed as given
below. To document WNK2 protein levels in A172HW2
cells, a confluent 100 mm dish was lysed and immunoprecipi-
tated with 15 mg of a rabbit polyclonal WNK2 antibody,
SPT81 (10). For comparison, an equivalent immunoprecipita-
tion was performed in SW1088 and in colorectal HT29 cell
lysates as a previously described positive control (11). The
Rac1 CRIB-domain pull-down assay and the activation
assays for RhoA were performed as described (11,38), the
latter using the G-Lisa RhoA luminescence-based Biochem
kit (Cytoskeleton, Denver, CO, USA).
Transcript expression analysis and semiquantitative PCR
Total RNA was extracted from cell lines or lysates with the
RNAeasy kit (Qiagen) and 1 mg reverse-transcribed using
random primers (Invitrogen) and Ready-to-Go You-Prime
beads (GE Healthcare, Buckinghamshire, UK). Primers and
reaction conditions for specific amplification of WNK2 and
for RNA polymerase II (Pol II) were as described (11).
These semi-quantitative amplification conditions were experi-
mentally controlled by co-amplification of serial dilutions of a
cDNA sample. Products were separated on 1.5% agarose gels
and band intensities quantified using the Image J software fol-
lowed by normalization to Pol II. No amplification was
obtained when RNA was mock-transcribed without adding
reverse transcriptase.
Antibodies and western blot procedures
Protein samples were separated in a 10% SDS–PAGE
Mini-Protean III gels (Bio-Rad, Hercules, CA, USA). Proteins
were transferred onto a PVDF membrane (Bio-Rad) using
Figure 8. Effect of WNK2 re-expression on A172 cell migration. (A) Repre-
sentative images from wound-healing migration assays (see legend to Fig. 5).
In the graph below, the migration distances determined in five independent
assays are expressed as fold differences compared with parental cells and
show the distances migrated in relation to time 0. (B) Activation levels of en-
dogenous Rac1 were determined in the same three cell lines by CRIB-domain
pull-down assays (n ¼ 5) as described in the legend to Figure 5. Note the de-
crease in cell migration and Rac1 activation following WNK2 re-expression
in A172 HW2 cells. Statistically significant differences are indicated as
∗P , 0.05.
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a Mini Trans-Blot cell (Bio-Rad) at 100 v for 60 min and
Coomassie-stained to check for equal transfer. Membranes
were blocked in TBS, 0.1% Triton X-100, 5% milk powder,
probed using the indicated antibodies, then incubated with a
secondary peroxidase-conjugated antibody (Bio-Rad) and spe-
cific binding detected in a chemiluminescence reaction. For
densitometric estimation of protein quantities, the lumines-
cence film exposures from at least three independent experi-
ments were digitalized and analysed using the ImageJ
software (NIH). The antibodies used were anti-a-tubulin
(clone B5-1-2) from Sigma-Aldrich, monoclonal anti-Rac1
(clone 23A8) from Upstate Millipore, Billerica, MA, USA,
and rabbit anti-WNK2 (10).
Immunofluorescence microscopy
Parental and selected shRNA-expressing SW1088 cells were
grown on cover slips and fixed with 3.7% paraformaldehyde
in PBS followed by permeabilization with 0.1% Triton
X-100 in PBS. Cells were washed 3 × 5 min in PBS/0.01%
Tween 20 (PBS-T), then labelled for 1 h with primary
anti-Rac1 antibody, washed 3 × 5 min in PBS-T and incu-
bated again for 1 h with a mixture of secondary anti-mouse
Alexa-488 antibody (Invitrogen-Molecular Probes) and
0.2 mg/ml phalloidin-TRITC (Sigma-Aldrich). Cover slips
were washed again 3 × 5 min in PBS-T, post-fixed for
15 min in 4% (v/v) formaldehyde and mounted on microscope
slides with Vectashield (Vector Laboratories, Burlingame,
CA, USA). Digital images were recorded on a Leica TCS
SPE (Leica Microsystems, Wetzlar, Germany) confocal
microscope and processed with the Adobe Photoshop soft-
ware.
Cell migration and invasion assays
For wound-healing assays, either transfected cells or stable
cell lines were allowed to grow to a confluent monolayer in
6-well or 12-well plates before a wound was carefully made
with a pipette tip so that the neighbouring cells were only min-
imally disturbed. The medium was replaced by fresh complete
medium and wound closure monitored by time-lapse photog-
raphy for 12 h, using a phase contrast microscope and a
10× magnification. Migration was measured on digital
images by determining the mean remaining distance between
the wound edges. In some experiments, cells were treated
with 200 mM of the inhibitor NSC23766 (Calbiochem) for
16 h prior to wounding.
Matrigel invasion assays were performed using 8 mm-pore
size BD BioCoatTM Matrigel Invasion Chambers (BD Bios-
ciences, San Jose, CA, USA). The upper compartment of the
chamber received 2.5 × 104 cells, whereas the lower compart-
ment contained only fresh medium supplemented with 10%
FBS. After 24 h incubation at 378C, the upper surface of the
filter was cleared from residual cells with a cotton swab, the
filter washed with PBS, then fixed with cold methanol and in-
vasive cells attached to the lower filter surface stained with
DAPI. Images were recorded on a Leica SPE confocal micro-
scope at 10× magnification and invasive cells counted.
Time-lapse microscopy for cell motility and wound-healing
For motility and migration assays of shRNA-transfected
clones, cells were either seeded in 6-well or 12-well dishes
and left to adhere for 24 h at 378C in a temperature- and 5%
CO2-controlled micro-chamber module, as described (39).
For each time-lapse experiment, bright-field images were
acquired in intervals of 5 min during 12 h using a 20× object-
ive of an Axiovert 200M microscope and the AxioVision soft-
ware (Carl Zeiss, Jena, Germany). For the wound-healing
assays, distance measurements were done between the
wound edges at several time points. For the cell motility
assay, the positions of 80–95 individual cells seeded at low
density were marked (based on the centre of their nuclei) for
each experimental condition and followed in the sequential
image series. The moved distances were determined manually
and expressed as cell speed (mm/h).
Chick CAM assay
To assess in vivo tumour proliferation and angiogenesis, we
used the CAM assay as previously described (15,40).
Briefly, fertilized chicken eggs were incubated at 378C and
70% humidity, and on day 4 of development, a window was
made into the shell, which was sealed with tape, and the
eggs were returned to the incubator. On day 9 of development,
small plastic rings were placed on the CAM, and on day 10 of
development, 3 × 106 cells, resuspended in 20 ml of DMEM
medium, were injected in the rings over the CAM. On day
17 of development, the tumour formed was photographed in
ovo using a stereomicroscope (Olympus S2 ×16). The
chicken embryos were sacrificed at 2808C for 10 min, and
the CAM and tumours were fixed with formaldehyde at 4%
and photographed ex ovo. The perimeter of the tumours was
measured using the Cell B software (Olympus), and blood
vessels were manually counted.
Statistical analysis
Correlations between WNK2 methylation, expression and clin-
ical data of the patients were performed using the chi-square
test. Cumulative survival probabilities were calculated using
the Kaplan–Meier method. Differences between survival
rates were tested using the log-rank test. The statistical ana-
lysis was performed using the SPSS software for Windows,
version 17.0. For in vitro assays, simple comparison between
two different conditions were analysed using Student’s t-test.
The level of significance in the statistical analyses is indicated
as ∗P , 0.05 or as ∗∗P , 0.005.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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Abstract
P-cadherin overexpression is associated with worse breast cancer survival, being a poor prognostic marker as
well as a putative therapeutic target for the aggressive triple-negative and basal-like carcinomas (TNBCs).
Previously, we have shown that P-cadherin promotes breast cancer invasion of cells where membrane E-cadherin
was maintained; however, it suppresses invasion in models without endogenous cadherins, like melanomas.
Here, we investigated if P-cadherin expression would interfere with the normal adhesion complex and which
were the cellular/molecular consequences, constituting, in this way, a new mechanism by which E-cadherin
invasive-suppressor function was disrupted. Using breast TNBC models, we demonstrated, for the first time, that
P-cadherin co-localizes with E-cadherin, promoting cell invasion due to the disruption caused in the interaction
between E-cadherin and cytoplasmic catenins. P-cadherin also induces cell migration and survival, modifying
the expression profile of cells expressing wild-type E-cadherin and contributing to alter their cellular behaviour.
Additionally, E- and P-cadherin co-expressing cells significantly enhanced in vivo tumour growth, compared with
cells expressing only E- or only P-cadherin. Finally, we still found that co-expression of both molecules was
significantly correlated with high-grade breast carcinomas, biologically aggressive, and with poor patient survival,
being a strong prognostic factor in this disease. Our results show a role for E- and P-cadherin co-expression in
breast cancer progression and highlight the potential benefit of targeting P-cadherin in the aggressive tumours
expressing high levels of this protein.
Copyright  2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
E-cadherin (epithelial cadherin, CDH1 ) is a transmem-
brane glycoprotein responsible for cell–cell adhesion
in epithelial tissues, being one of the most studied inva-
sion suppressor proteins in cancer [1,2]. E-cadherin
loss-of-function occurs during cancer progression [3]
and is associated with tumours with an infiltrative pat-
tern of growth, such as diffuse gastric and lobular
breast cancers [4–7]. Somatic CDH1 mutations, as
well as loss of heterozygosity, promoter hypermethy-
lation or overexpression of transcriptional repressors,
have been described as molecular mechanisms restrain-
ing E-cadherin normal function in invasive carcino-
mas [8–10]. Loss or delocalization of both catenins
(p120ctn and βctn) from the membrane adhesion com-
plex is usually related to an invasive cancer phenotype,
due to cadherin destabilization and disorganization of
the actin cytoskeleton [11,12].
However, some invasive epithelial tumours, namely
the local advanced inflammatory breast cancer, and
some highly metastatic breast cancer cells, such as the
4T1 cell model, maintain normal membrane E-cadherin
expression. Interestingly, these cells and tumours show
aberrant concomitant expression of another epithe-
lial cadherin, named P-cadherin (placental cadherin,
CDH3 ) [13].
P-cadherin is overexpressed in several solid tumours,
including breast cancer [14], being expressed in 30%
of all invasive carcinomas. It is associated with poor
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2013
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patient survival and is overexpressed in triple-negative
basal-like carcinomas (TNBCs), which still do not have
a targeted therapy [13,15–18]. We showed that one
of the mechanisms underlying the invasive capacity
of P-cadherin overexpression in breast cancer cells is
mediated by the secretion of MMPs, which cleave
its extracellular domain, producing a P-cadherin solu-
ble fragment with pro-invasive activity [19]. However,
while performing an extensive revision of the literature,
we noticed that the invasive phenotype mediated by
P-cadherin was seemingly dependent on the concomi-
tant expression of E-cadherin: in cell models where
P-cadherin showed an invasion promoter function,
E-cadherin was always also expressed [20–23]; con-
trarily, in models where P-cadherin was expressed
alone, it was described as an invasion suppressor
[24–26] (Supplementary Table 1).
Considering these observations, we evaluated if P-
and E-cadherin co-expression could induce an aggres-
sive biological cell behaviour compared to cells just
expressing one of each cadherin. Indeed, we found
that P-cadherin expression disrupts the normal inva-
sive suppressor function of E-cadherin by decreasing
the interaction between E-cadherin and intracellular
catenins. We showed that cells co-expressing P- and
E-cadherin have a specific molecular signature, as
well as an increased invasive and tumourigenic poten-
tial. The present work still reinforces the importance
of P-cadherin as a prognostic factor in breast can-
cer and suggests that its overexpression is an alterna-
tive mechanism for cancer progression and invasion
in E-cadherin-positive breast carcinomas. Therapeu-
tically, this knowledge supports the development of
anti-P-cadherin strategies to control highly aggressive
breast carcinomas co-expressing both cadherins.
Materials and methods
Cell culture and siRNA transfection
Human breast cancer cell lines were obtained as
described: BT20 (ATCC, Manassas, VA, USA) and
SUM149 (Dr Stephen Ethier, University of Michigan,
MI, USA). Cells were routinely maintained at 37◦C,
5% CO2, in the following media (Invitrogen Ltd,
Paisley, UK): DMEM (BT20) and DMEM/HamF12
(1 : 1) (SUM149), supplemented with 10% heat-
inactivated fetal bovine serum (Greiner bio-one,
Wemmel, Belgium), 100 IU/ml penicillin and, 100
µg/ml streptomycin (Invitrogen). SUM149 medium
was supplemented with 5 µg/ml insulin and 1 µg/ml
hydrocortisone (Sigma-Aldrich, St Louis, MO, USA).
Transient transfections with small interfering
RNAs (siRNAs), specific for P-cadherin and/or
E-cadherin silencing (50 nM Hs_CDH3_6 and 100 nM
Hs_CDH1_13, respectively; GW Validated siRNA;
Qiagen, Valencia, CA, USA), were performed with
LipofectamineTM 2000 (Invitrogen), according to the
manufacturer’s recommendations. A negative siRNA
control, with no homology to any gene, was also used
(Qiagen).
Antibodies and chemicals
The following primary antibodies were used:
P-cadherin (western blot: mouse, clone 56; BD Bio-
sciences, Lexington, KY, USA; immunofluorescence
and PLA: rabbit; Cell Signaling, Boston, MA, USA),
E-cadherin (western blot: mouse, clone HECD1;
Takara Bio Inc, Shiga, Japan; PLA: rabbit; Cell
Signaling), p120ctn and βctn (mouse, clone 98 and
clone 14; BD Biosciences), and β-actin (goat, clone
I19; Santa Cruz Biotechnologies, CA, USA).
The following chemicals were used: ZVAD.fmk
(pretreatment with 20 µM for 2 h; Peptide Institute,
Inc, Osaka, Japan).
Immunofluorescence and in situ proximity ligation
assay (PLA)
Immunofluorescence was performed as previously
described [19].
For the PLA, tumour sections were prepared and
treated with the same protocol used for immunohis-
tochemistry (IHC). Culture cell lines were deposited
on glass slides and fixed with methanol. PLA was
performed using the Duolink kit (Olink Bioscience,
Uppsala, Sweden) according to the manufacturer’s
recommendations. Slides were analysed with fluores-
cence microscopy (Zeiss Imager Z1 microscope) and
the Blobfinder V3.2 free software (Centre for Image
Analysis, Uppsala, Sweden) was used to quantify the
number of blobs (or dots). A detailed description may
be found in the Supplementary materials and methods.
Wound-healing assay and BrdU proliferation assay
Wound-healing migration and BrdU proliferation
assays were performed as previously described [19].
For the migration assay, 24 h after transfection,
cells were replated and left another 24 h to reach
confluence. A wound was made and cell migration
was evaluated for 24 h. For the proliferation assay, 48
h after transfection, cells were incubated for 6 h with
BrdU and fixed with 4% formaldehyde. A detailed
description may be found in the Supplementary
materials and methods.
Western blot and immunoprecipitation
For immunoprecipitation, 500 µg of protein was incu-
bated with 2 µg of the appropriate antibody. Western
blot was performed as previously described [27]. Rep-
resentative blots were selected to be shown.
Matrigel invasion assay, slow aggregation assay,
and TUNEL assay
The Matrigel invasion assay and slow aggregation
assay were performed as previously described [19,21].
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The TUNEL assay was carried out according to the
manufacturer’s recommendations (TUNEL kit, Roche).
A detailed description may be found in the Supplemen-
tary materials and methods.
cDNA microarrays
Total RNA from BT20 cell lines was extracted with
the RNeasy Extraction Kit (Qiagen) and quality was
assessed by BioAnalyser (Agilent Technologies, Santa
Clara, CA, USA). Samples were hybridized onto Agi-
lent 44K microarrays with probes for the Human
Genome (Agilent HPAG4112F), following the man-
ufacturer’s recommendations, using the Agilent One-
Color Microarray-Based Gene Expression Analysis
Protocol Version 5.7 (Quick Amp Labeling Kit).
Microarray images were obtained and fluorescence
intensity was measured using the Agilent Feature
Extraction Software (Version 10.5.1.1) and signal
processing was performed according to the Agilent
recommendations (GE1-v5_95_Feb07 Protocol). The
processed signal was annotated and filtered using
BRB Array Tools 3.8.0 (http://linus.nci.nih.gov/BRB-
ArrayTools.html). Differences in gene expression were
assessed using the Student’s t-test implemented in
BRB-tools, with a p-value cut-off of 0.01. Only genes
where expression was altered by at least 2-fold in rela-
tion to the control cell line (Ecad+Pcad+) were indi-
cated as differentially expressed.
A hierarchical clustering method was applied to
identify groups of differentially expressed genes
(DEGs) between samples, and the unsupervised
analysis was visualized using the TIGR MeV 4.4.1
program (http://www.tm4.org/mev/). DAVID software
was used to analyse gene ontology and pathway enrich-
ment (http://david.abcc.ncifcrf.gov/) [28]. A detailed
description may be found in the Supplementary
materials and methods.
The complete array data can be viewed in the
ArrayExpress microarray database (accession No
E-MEXP-3329).
Real-time quantitative RT-PCR (qRT-PCR)
Selected genes were analysed by qRT-PCR using gene-
specific TaqMan probes (Applied Biosystems, Foster
City, CA, USA). Analysis was performed with the ABI
PRISM 7700 Sequence Detection System Instrument
and software (Applied Biosystems), following the man-
ufacturer’s recommendations. A detailed description of
the probes may be found in the Supplementary mate-
rials and methods.
GTPase activity assays
GTP-bound RhoA and Rac1/2/3 were measured in
protein lysates with a commercially available acti-
vation kit (G-LISATM, Kit #BK124 and #BK125;
Cytoskeleton, Inc, Denver, CO, USA), according to
the manufacturer’s instructions. 30 µg of protein was
analysed and activation signals are expressed as fold
increase/decrease of control values.
Animal studies
Animal experiments were carried out in accordance
with the European Guidelines for the Care and Use
of Laboratory Animals, Directive 2010/63/UE. Female
N:NIH(s)II:nu/nu nude mice, aged 6–8 weeks, were
orthotopically inoculated with 106 viable cells in
the mammary fat pad using four different BT20
cell lines. Mice were weighed and tumour vol-
ume was estimated. Mice were euthanized 35 days
after tumour cell inoculation, and primary tumours
were extracted, fixed in 10% buffered formalin, and
then embedded in paraffin, sectioned, and stained
with haematoxylin and eosin. A detailed description
may be found in the Supplementary materials and
methods.
Tissue samples
A series of 467 primary invasive breast carcinomas,
diagnosed between 1978 and 1992, were retrieved from
the Pathology Department, Hospital Xeral-Cı´es, Vigo,
Spain. Patient follow-up information was available for
455 cases. The tumours have been characterized for
clinical and pathological features (data are summarized
in Supplementary Table 2). The study was conducted
under the national regulative law for the handling of
biological specimens from tumour banks, being the
samples exclusively available for research purposes in
retrospective studies.
Immunohistochemistry (IHC)
IHC was performed as previously described [17].
The assessment of immunohistochemical results was
based on a semi-quantitative evaluation, as previously
reported [15,29]. A detailed description may be found
in the Supplementary materials and methods.
Statistical analysis
Statistical analyses of the IHC results were performed
by SPSS 15.0 software package for Windows (SPSS,
Inc, USA). p values less than 0.05 were considered sta-
tistically significant. Concerning the functional in vitro
assays, data are expressed as mean values of at least
three independent experiments± SD. Student’s t-tests
were used to determine statistically significant differ-
ences (p< 0.05). A more detailed description may be
found in the Supplementary materials and methods.
Results
E- and P-cadherin co-expression in breast cancer:
effects on cell–cell adhesion, invasion capacity, and
stabilization of the cadherin/catenins complex.
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Figure 1. Establishment of a breast cancer cell model where the transcription of E-cadherin or P-cadherin or both cadherins was silenced.
(A) Scheme from the cell lines generated after transient siRNA KD for E- and P-cadherin in an initial cell line E- and P-cadherin positive
(Ecad+/Pcad+). (B) Analysis of E-cadherin and P-cadherin proteins by western blot in BT20 and SUM149 cells 48 h after specific E-
and P-cadherin siRNA transfection. Protein levels of α-tubulin were analysed and used as the loading control. (C) Immunofluorescence
for E- and P-cadherin in BT20 and SUM149 cells. (D, E) In situ PLA for E- and P-cadherin in BT20 and SUM149 cells and the respective
quantification of the number of blobs per cell from three independent experiments. Scale bar= 20 µm.
In order to study the functional effects of P- and
E-cadherin co-expression, we established cell mod-
els where the expression of both cadherins could
be manipulated. BT20 and SUM149 TNBC cell
lines were selected, due to high levels of E- and
P-cadherin expression. To knock-down (KD) selec-
tively the expression of E- and/or P-cadherin, we used
small-interfering RNAs (siRNAs), targeting each one
of the two cadherins (Figure 1A). An efficient and
specific KD for both cadherins was obtained for at
least 168 h after transfection (Figures 1B and 1C).
In situ proximity ligation assay (PLA) [30], to detect
E- and P-cadherin proximity, produced positive sig-
nals in both parental cell lines, showing a putative
interaction between proteins (Figure 1D). As expected,
decreased E- and P-cadherin proximity was detected in
all cell lines, where one or both cadherins were silenced
in comparison with the control cells (Figures 1D
and 1E).
To evaluate the functional effects on cell–cell adhe-
sion, a non-quantitative aggregation assay was per-
formed. The parental Ecad+/Pcad+ cells formed small
aggregates on the top of soft agar (Figure 2A and
Supplementary Figure 1A), as did the E-cadherin
(Ecad+/Pcad−) or P-cadherin (Ecad−/Pcad+) positive
cells, where cell aggregation was apparently main-
tained or even increased. Conversely, when both cad-
herins were silenced, the cells did not aggregate
(Figure 2A and Supplementary Figure 1A).
Concerning cancer cell invasion, Ecad+/Pcad+ co-
expressing cells or Ecad−/Pcad− cells were sig-
nificantly more invasive than the Ecad+/Pcad− or
Ecad−/Pcad+ cells (p< 0.01) (Figure 2B), showing
that invasion can be due to either lack of expression or
the co-expression of both cadherins.
In situ PLA was performed to measure the proxim-
ity between both cadherins and cytoplasmic catenins
(p120ctn and βctn), which are important for the sta-
bilization of the adhesion complex at the cell mem-
brane. The independent silencing of each cadherin
promoted a significant increase in interaction at the
cell membrane between the cadherin that remained
expressed and both catenins (Figure 2C and Sup-
plementary Figure 2A), compared with the interac-
tion detected in Ecad+/Pcad+ cells. As expected, in
Ecad−/Pcad− cells, the interaction with both catenins
was lost (Figures 2C and 2D). These results were fur-
ther confirmed by immunoprecipitation (Supplemen-
tary Figure 2B). Curiously, catenins maintained their
membrane expression in Ecad+/Pcad+ cells, as well as
in cells expressing only one cadherin (E- or P-cadherin)
(Supplementary Figure 2C).
E- and P-cadherin co-expression in breast cancer
cell migration and cell death
E-cadherin loss of expression/function also results in
increased cell migration and survival [31–33]. Taking
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Figure 2. Functional evaluation of E- and P-cadherin expression in breast cancer cells. AA) Cell–cell adhesion was evaluated by the slow
aggregation assay in the BT20 cell line. (B) Matrigel invasion assay for the BT20 and SUM149 cell lines after the knockdown of E- and
P-cadherin transcription. At least three independent experiments were performed. p values are relative to the control cell line and indicate
statistically significant results. (C, D) In situ PLA using E-cadherin, P-cadherin, p120ctn, and βctn specific antibodies in BT20 cells and the
respective quantification of the number of blobs per cell from three independent experiments. Scale bar= 20 µm.
this into consideration, we investigated if there were
alterations in these two in vitro cellular behaviours,
using the breast cancer models established in this
study.
The wound healing assay showed that Ecad+/Pcad+
cells are more motile than Ecad+/Pcad− cells
(p< 0.001) (Figures 3A and 3B and Supplementary
Figure 1B). Contrarily, Ecad−/Pcad+ cells showed
a significant increase in cell migration (p< 0.001);
importantly, this result was not due to an increase
in the cell proliferation rate of P-cadherin-expressing
cells (Supplementary Figure 3). Unexpectedly, KD of
both cadherins resulted in a decrease in cell migration
for BT20 cells (Figures 3A and 3B and Supplementary
Figure 1B). Although Ecad−/Pcad− cells migrated
faster than Ecad+/Pcad− cells, this difference was not
statistically significant.
The functional role of E- and P-cadherin in cell
survival was also analysed by the exposure of cells to
an apoptotic stimulus. Only Ecad+/Pcad− cells showed
a significant increase in the percentage of cell death
(p< 0.0001, Figure 3C and Supplementary Figure 1C).
This effect was minimized when cells were treated
with a pan-inhibitor of caspases (ZVAD); however,
the levels of cell death in Ecad+/Pcad− cells, even
after ZVAD treatment, were still significantly higher
compared with control cells (p< 0.05, Figure 3C).
Down-regulation of E-cadherin (Ecad−/Pcad+)
resulted in a significantly decreased level of cell death
for the SUM149 cell line (p= 0.0005, Supplementary
Figure 1C), although the effect in BT20 cells was
not as prominent (p= 0.07, Figure 3C). Therefore,
P-cadherin expression and/or loss of E-cadherin
expression induce a selective advantage to cancer cells
by promoting survival in apoptotic conditions.
Gene expression profile of E- and P-cadherin
co-expressing breast cancer cells
The above results prompted us to determine the influ-
ence of E- and P-cadherin expression in gene expres-
sion deregulation. After E- and P-cadherin KD, mRNA
profiles were determined for BT20 cells. The profiles
identified 382 genes, whose expression was deregu-
lated (DEGs) (p< 0.01; > 2-fold increase/decrease),
in at least one of the four groups in relation to the
control cells (Ecad+/Pcad+). The complete array data
can be viewed in the ArrayExpress microarray database
(accession No E-MEXP-3329).
As expected, CDH1 and CDH3 genes were signifi-
cantly altered after silencing (0.1- and 0.2-fold expres-
sion, respectively) compared with control cells. 32
DEGs were common to the three conditions tested,
when compared with cells expressing both cadherins,
and 15 DEGs were shared by cells with KD of one
of the cadherins. Interestingly 28 and 58 DEGs were
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Figure 3. Cell migration and survival in E- and P-cadherin co-expressing breast cancer cells. (A) Representative experiment from a
wound healing migration assay in BT20 cells. (B) Quantification of the wound healing migration assay for BT20 cells from three
independent experiments performed in duplicate. Significantly increased cell migration between Ecad−/Pcad+ cells compared with the
Ecad+/Pcad+ cell line was observed (represented as *; 2 h – p= 0.0002; 4 h – p= 0.001; 6, 8, and 24 h – p≤ 0.0001). Significantly
decreased cell migration between Ecad+/Pcad− cells compared with the Ecad+/Pcad+ cell line was observed (represented as ø; 2 h –
p= 0.0007; 4, 6, and 8 h – p≤ 0.0001; 24 h – p= 0.0006). (C) TUNEL assay for BT20 cells after pretreatment with DMSO or 20 µM ZVAD.
Statistically significant p values are indicated.
specific to P-cadherin or E-cadherin silencing, respec-
tively (Figure 4A).
The transcriptional gene expression profile showed
that distinct signalling pathways were differentially
modified by both cadherins (Figure 4B). Analysis
of gene ontology identified groups of genes signifi-
cantly enriched in each condition. Both cadherins were
involved in GTPase-mediated signal transduction and
actin cytoskeleton organization, which is consistent
with their role in cell adhesion, invasion, and migra-
tion. Moreover, apoptosis signalling was specifically
deregulated after P-cadherin silencing (Table 1).
qRT-PCR analysis was performed to validate some
of the DEGs found as differentially expressed by
microarrays in the different BT20 cells (Figure 4C),
namely ACTG1 , RAC1 , IFI6 , TAX1BP3 , and UNC
13B . To see how general the microarray results
were, these same genes were also tested in SUM149
cells. Despite the down-regulation of the CDH1 and
CDH3 mRNAs in silenced cells, the same differential
expression of the majority of the genes was also found
(Figure 4C and Supplementary Figure 4).
Since consistent results were found for ACTG1 and
RAC1 mRNA expression in both cell models, we
studied the activity of Rho/Rac GTPases, since they
play important roles in actin cytoskeleton organization,
cell adhesion, migration, and malignant transformation
[34]. Additionally, a link between cadherin unbounded
p120ctn and activation of Rac1 and inhibition of
RhoA GTPases has also already been shown [35]. In
fact, we found that Ecad+/Pcad+ cells are the ones
with increased Rac activity; however, no significant
differences were found concerning RhoA activation
(Supplementary Figure 5).
Effect of E- and P-cadherin co-expression on
tumour growth in nude mice
In order to investigate the effect of E- and P-
cadherin co-expression on in vivo tumour growth, we
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Figure 4. Gene transcriptional modulation for E- and P-cadherin
co-expression in BT20 breast cancer cells. (A) Venn diagram
depicting the genes with modified expression levels in the different
cell lines compared with the parental cell line. (B) Unsupervised
hierarchical clustering of the gene expression patterns induced
by E- or P-cadherin expression. Columns represent microarray
experiments and rows represent the expression of genes modified
at least 2-fold with respect to control cells. (C) Validation of
the microarray data of selected genes by qRT-PCR. Bars represent
mean gene expression± SEM (mRNA levels relative to control
GAPDH transcript) from three independent experiments.
injected 106 BT20 cells in the mammary fat pad
of nude mice. Visible and palpable nodules were
already observed 14 days after cell inoculation. After
35 days, tumours showed a characteristic pattern of
basal-like breast carcinomas, being solid, with push-
ing margins, high histological grade, and, as expected,
expressing membrane E- and P-cadherin (Figure 5A).
Subsequently, we inoculated control (Ecad+/Pcad+),
Ecad+/Pcad−, Ecad−/Pcad+ or Ecad−/Pcad− cells and
monitored tumour formation and growth for 35 days.
Ecad+/Pcad+ tumours showed a significant increase
in the tumour volume, compared with Ecad+/Pcad−
and Ecad−/Pcad+ tumours (Figures 5B and 5C) at
28 and 35 days (Figures 5D and 5E). Curiously,
Ecad−/Pcad− tumour cells showed similar tumour
growth to Ecad+/Pcad+ breast cancer cells.
Prognostic significance of E- and P-cadherin
co-expression in primary breast carcinomas
Since Ecad+/Pcad+ cells show increased invasive and
tumourigenic behaviour, but also considering that dis-
tinct cadherins can eventually interfere with each other
at the cell membrane [36,37], we decided to deter-
mine whether both cadherins co-localize in normal and
tumour cells.
In normal breast, E-cadherin is expressed in luminal
and myoepithelial cells, whereas P-cadherin expression
is restricted to the myoepithelium (Figure 6A). In the
case of breast carcinomas, the series included 24.4%
of the cases with membrane P-cadherin (114/452)
and 94.2% with membrane E-cadherin expression
(426/452, Supplementary Table 2). Considering the
combined expression of epithelial cadherins, 23.5%
of the tumours were Ecad+/Pcad+, 0.9% were
Ecad−/Pcad+, 70.7% were Ecad+/Pcad−, and 4.9%
were Ecad−/Pcad− (Supplementary Table 2). Although
in some cases the intensity of E-cadherin membrane
expression was reduced in cancer cells with P-cadherin
expression (as in normal myoepithelial cells), in the
majority of the cases E-cadherin expression was
maintained. Indeed, both cadherins co-localized at
the cell membrane and were positive for in situ PLA
signals; as expected, Ecad+/Pcad− tumours were
negative for in situ PLA signals (Figure 6A).
Ecad+/Pcad+ tumours showed a statistically sig-
nificant association with high histological grade
(p= 0.031); however, no significant association was
found with tumour size and nodal status (Table 2).
Ecad+/Pcad+ tumours were also significantly associ-
ated with negativity for hormonal receptor expression
[ERα and PR, respectively (p< 0.001 and p= 0.001)]
and positively associated with HER2 (p= 0.017)
and basal-like marker expression [CK14 (p< 0.001),
CK5 (p< 0.001), vimentin (p< 0.001), and EGFR
(p< 0.001)] (Table 2).
Disease-free (DFS) and overall survival (OS) also
differed significantly between tumours with distinct
patterns of E- and P-cadherin expression, which were
significantly lower for patients with Ecad+/Pcad+
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Table 1. List of the genes significantly altered after E- and P-cadherin silencing in BT20 breast cancer cells∗
Gene ontology E+/P+ E+/P− E−/P+ E−/P− p value
CDH1 1.0 0.9 0.1 0.1 3.2E-06
CDH3 1.0 0.2 1.1 0.2 9.0E-07
Small GTPase-mediated signal transduction
RABL4 1.0 2.3 2.6 2.3 4.4E-05
C1ORF89 1.0 2.0 1.3 1.6 1.6E-02
GRLF1 1.0 2.1 1.5 1.8 5.8E-03
RGS19 1.0 2.8 – – 1.1E-04
RHOB 1.0 1.8 – – 6.3E-03
MYO9B 1.0 2.0 – – 6.4E-03
TAX1BP3 1.0 2.1 1.1 1.6 5.2E-03
RAPGEF1 1.0 2.1 – – 8.5E-03
ARL4C 1.0 1.9 – – 4.6E-03
ARL5B 1.0 0.5 0.5 0.5 7.0E-03
Regulation of cell migration
PLD1 1.0 1.1 0.5 0.4 2.3E-06
KISS1R 1.0 – 0.4 – 9.9E-03
NISCH 1.0 2.2 2.1 2.0 4.1E-04
GAB1 1.0 0.8 0.5 0.4 1.2E-03
RAC1 1.0 1.9 2.2 1.8 3.1E-02
ARHGAP8 1.0 0.7 0.5 0.5 2.8E-02
Actin cytoskeleton organization
ACTG1 1.0 0.4 – – 1.3E-03
TRIOBP 1.0 0.5 0.7 0.6 1.1E-02
CDC42BPG 1.0 1.9 – – 4.0E-03
GNA11 1.0 0.5 0.6 0.5 7.0E-03
BIN3 1.0 0.6 0.6 0.5 7.0E-03
Apoptosis
AKT1 1.0 2.2 1.4 2.0 4.3E-02
CASP7 1.0 2.2 2.3 2.1 4.1E-04
CASP9 1.0 0.5 0.8 0.7 1.9E-03
IFI6 1.0 0.5 0.9 1.3 2.5E-02
FADD 1.0 2.2 1.0 1.5 2.4E-02
ARHGEF9 1.0 2.3 1.5 2 2.2E-03
MX1 1.0 0.4 0.7 0.7 1.9E-02
UNC13B 1.0 2.0 1.4 1.5 3.4E-03
TRAF3 1.0 2.0 1.7 1.9 1.6E-04
MAPK8 1.0 0.9 0.5 0.4 5.6E-03
MAL 1.0 1.1 2.5 2.2 2.3E-02
GCH1 1.0 0.8 0.6 0.5 6.5E-03
PLAGL2 1.0 0.6 0.4 0.4 2.7E-04
∗mRNA profiles were determined for the BT20 breast cancer cell model after E- and P-cadherin KD. The profiles identified 382 genes, whose expression was deregulated
(DEGs) (p< 0.01; > 2-fold increase/decrease), in at least one of the four groups in relation to the control cell line (Ecad+/Pcad+). The genes represented are the ones
that were differentially expressed in functional groups and in enriched signalling pathways, among the distinct BT20 cell lines. These genes are organized according
to gene ontology assignment, and the values represent the fold increase/decrease in gene expression when compared with control cells (Ecad+/Pcad+).
or Ecad−/Pcad− tumours [p= 0.043 (Figure 6B)
and p= 0.027 (Figure 6C), respectively]. Univariate
analysis showed that E- and P-cadherin co-expression
was a significant prognostic factor for DFS and OS,
since these cases carried an increased risk of recur-
rence (HR= 1.44, 95% CI= 1.04–1.99, p= 0.029) or
death (HR= 1.53, 95% CI= 1.09–2.15, p= 0.014),
compared with tumours expressing only E-cadherin
(Table 3). The same analysis performed for negative
tumours for both cadherins did not show a significant
association with patient prognosis. Indeed, single
E-cadherin expression was not found to be a signif-
icant prognostic marker for DFS or OS (p= 0.216
and p= 0.280, respectively), whereas P-cadherin
expression was a significant prognostic predictor for
OS (HR= 1.45, 95% CI= 1.04–2.02, p= 0.028), but
not for DFS (p= 0.059, Table 3). Additionally, the
multivariate analysis, with models including tumour
size, grade, and nodal status, demonstrated the inde-
pendent value of E- and P-cadherin co-expression as a
prognostic factor of patient outcome in breast cancer,
being significantly associated with worse breast cancer
OS (HR= 1.51, 95% CI= 1.03–2.22, p= 0.036,
Table 3).
Discussion
E-cadherin and P-cadherin mediate epithelial cell–cell
adhesion and harbour opposite roles in cancer.
Decreased E-cadherin expression is related to inva-
siveness [4,5,38–40], and the mechanisms underlying
its loss-of-function have already been studied [8,38].
However, in some cancer models, E-cadherin expres-
sion is maintained, being associated with increased
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Figure 5. Effect of E and P-cadherin co-expression on in vivo
tumour growth. Nude mice were injected in the mammary
fat pad with the different BT20 cell lines generated. (A) H&E
staining and immunohistochemistry for P- and E-cadherin of an
Ecad+/Pcad+ xenografted tumour. (B) Representative images of
the tumours formed 35 days after tumour cell inoculation. Scale
bar= 1cm. (C) Mean tumour volume in nude mice (n= 4 mice per
group). (D, E) Box plot for tumour volume 24 days (D) or 35 days
(E) after tumour cell inoculation. Error bars represent upper 95%
confidence intervals. p values were calculated using two-sided
Student t-tests; statistically significant p values are indicated.
cell survival and metastatic spread [41–45]. It was
shown that E-cadherin positive status is not always
predictive of good prognosis in breast cancer [46].
Moreover, local advanced inflammatory breast can-
cer [20,47] and some highly metastatic breast cancer
cells, such as the 4T1 cell model [48,49], maintain
normal membrane E-cadherin expression. Interestingly,
these tumours/cell models show the aberrant expres-
sion of P-cadherin (Supplementary Table 1). Actu-
ally, during breast cancer progression, P-cadherin is
overexpressed and is associated with worse patient
survival [14,15,20,50–52]; however, the cellular mech-
anism by which P-cadherin has an important role
in cancer remained elusive. We hypothesized that E-
and P-cadherin co-expression could be involved in a
more aggressive biological behaviour of breast can-
cer cells, due to interaction of both molecules at the
cellular membrane, interfering with the establishment
of a strong adhesion complex. Cadherins normally
form tight complexes with catenins, which function-
ally link them to the actin cytoskeleton. Changes in
the structure of the adhesion complex and alterations
in the interaction between molecules of the com-
plex with the actin cytoskeleton have been sug-
gested to play a role in cell–cell adhesion dereg-
ulation, as well as a mechanism to trigger specific
signalling pathways that induce cancer cell invasion
[22,25,42,53]. In fact, p120ctn is essential for the sta-
bility of cadherins [11,54] and its subcellular local-
ization plays an important role in motility-promoting
signals [55–57], since the JMD (which is the domain
where it binds) was found to be important to P-
cadherin pro-invasive activity [58–62]. We therefore
analysed the interaction between E- and P-cadherin
with catenins, demonstrating that Ecad+/Pcad+ cells
showed a deregulated cadherin/catenin complex at
the cellular membrane. In contrast, cells expressing
only one of the cadherins showed an increase in the
cadherin/catenin membrane interactions. Our results
indicate that E- and P-cadherin heterodimers are not
efficient in the stabilization of a strong cadherin/catenin
complex at the cellular membrane and, therefore, cells
show an aberrant cell behaviour.
This hypothesis was confirmed using functional
in vitro assays and microarrays. In fact, Ecad+/Pcad+
cells had a higher invasive capacity than cells
expressing only one of the cadherins. Indeed, P-
cadherin functions as an invasion suppressor when it
is the only cadherin expressed at the cell membrane
[24,25]; however, when co-expressed with E-cadherin,
it has a pro-invasive function, which explains the
poor prognosis of patients with tumours co-expressing
both molecules [19,21,23]. Microarrays confirmed
that the gene signature was also different, depending
on which cadherin was expressed, explaining in
part the results observed in in vitro assays. Sarrio´
et al have previously tried to tackle this issue; they
demonstrated that E- and P-cadherin independent
expression has similar functional consequences in
the suppression of the invasive behaviour of breast
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Figure 6. P-cadherin and E-cadherin expression in primary breast tumours. (A) Immunofluorescence and in situ proximity ligation assay
for E-cadherin and P-cadherin expression were analysed in normal breast and tumour samples. (B, C) Kaplan–Meier curves showing the
probability of disease-free survival (B) and overall survival (C) of patients harbouring invasive breast carcinomas with distinct E- and
P-cadherin expression patterns. Censored data correspond to patients that left the study before the end of the considered follow-up.
p values less than 0.05 were considered statistically significant. Since only four tumours showed positivity for P-cadherin without
E-cadherin expression, and to avoid a bias in the statistical method used, this group of patients was not considered in the survival analysis.
cancer cells, as well as being able to induce both
common gene expression programmes [25]. However,
we focused on E- and P-cadherin co-expression
and found that the simultaneous expression of the
cadherins promotes aggressive biological behaviour
and different gene expression profiles, compared with
the expression of each cadherin alone. We still proved
that Ecad+/Pcad+ cells have increased in vivo tumour
growth.
Interestingly, we observed a dominant effect of
P-cadherin in triggering cell migration. P-cadherin’s
role in cell migration has been previously described
[19,22] and gene expression profiles suggest that these
specific effects could be explained by alterations in
small GTPase-mediated signal transduction. Indeed,
increased Rac activity was observed in Ecad+/Pcad+
cells. Although the microarray results show that Rac1
mRNA expression increases after siRNA silencing, this
can mean that there is a gene transcription response, but
no activation of this protein by GEFs. Interestingly, the
microarrays also showed that the TRIOBP gene, which
encodes a protein that interacts with TRIO (a Rac-
GEF protein), is expressed in higher amounts in control
cells than in cells transfected with one or both siRNAs.
Based on these preliminary results, this pathway will
be further explored in the future as a possible molecular
mechanism activated in Ecad+/Pcad+ cells.
We have shown that P-cadherin is a regulator of cell
survival, since a significant increase in the cell death of
P-cadherin silenced cells was observed after an apop-
totic stimulus. This effect was partially counteracted
by adding a pan-caspase inhibitor, suggesting that cas-
pase activation has a crucial, but not unique, role in
this P-cadherin-induced mechanism of cell death. This
effect of P-cadherin as a potential survival factor was
strongly supported by microarray data, which showed
that genes involved in intrinsic and extrinsic apoptotic
signalling are enriched in Ecad+/Pcad−cells.
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Table 2. Correlation between E- and P-cadherin co-expression with clinico-pathological parameters and molecular markers∗
E- and P-cadherin expression
N Ecad−/Pcad− (%) Ecad+/Pcad− (%) Ecad−/Pcad+ (%) Ecad+/Pcad+ (%) p value
Tumour size T1: < 2 cm 100 1 (5.0) 80 (28.8) 1 (25.0) 18 (18.8) 0.15
T2: 2–5 cm 237 14 (70.0) 160 (57.5) 2 (50.0) 61 (63.5)
T3: > 5 cm 61 5 (25.0) 38 (13.7) 1 (25.0) 17 (17.7)
Missing 69
Nodal status Negative 154 4 (28.6) 114 (45.6) 2 (66.7) 34 (38.6) 0.359
Positive 201 10 (71.4) 136 (54.4) 1 (33.3) 54 (61.4)
Missing 112
Histological grade 1 78 4 (19.0) 62 (20.5) 2 (50.0) 10 (9.7) 0.031
2 130 8 (38.1) 95 (31.5) 1 (25.0) 26 (25.2)
3 222 9 (42.9) 145 (48.0) 1 (25.0) 67 (65.1)
Missing 37
ERα Negative 151 7 (31.8) 78 (24.5) 2 (50.0) 64 (61.0) < 0.001
Positive 298 15 (68.2) 240 (75.5) 2 (50.0) 41 (39.0)
Missing 18
PR Negative 230 13 (61.9) 144 (45.1) 2 (50.0) 71 (67.0) 0.001
Positive 220 8 (38.1) 175 (54.9) 2 (50.0) 35 (33.0)
Missing 17
HER2 Negative 381 21 (95.5) 276 (87.6) 3 (75.0) 81 (76.4) 0.017
Positive 66 1 (4.5) 39 (12.4) 1 (25.0) 25 (23.6)
Missing 20
EGFR Negative 429 21 (95.5) 316 (99.1) 3 (75.0) 89 (84.0) < 0.001
Positive 22 1 (4.5) 3 (0.9) 1 (25.0) 17 (16.0)
Missing 16
CK5 Negative 385 21 (95.5) 292 (91.5) 2 (50.0) 70 (66.0) < 0.001
Positive 66 1 (4.5) 27 (8.5) 2 (50.0) 36 (34.0)
Missing 16
CK14 Negative 427 21 (95.5) 312 (97.8) 3 (75.0) 91 (85.8) < 0.001
Positive 24 1 (4.5) 7 (2.2) 1 (25.0) 15 (14.2)
Missing 16
Vimentin Negative 370 15 (71.4) 281 (89.2) 3 (75.0) 71 (67.0) < 0.001
Positive 76 6 (28.6) 34 (10.8) 1 (25.0) 35 (33.0)
Missing 21
∗Contingency tables and the chi-square test were used to estimate the relationship between E- and P-cadherin staining patterns and the several parameters analysed.
The ANOVA test was used to evaluate the differences in tumour size, considering a confidence interval of 95%. Statistical analyses were performed by SPSS 15.0
software. p values less than 0.05 were considered statistically significant (indicated in italics in the table).
Table 3. Univariate and multivariate Cox proportional hazard analysis for classical prognostic factors, such as tumour size, lymph node
status, and tumour grade, as well as for E-cadherin, P-cadherin, and their co-expression∗
Univariate Cox proportional hazard analysis Multivariate Cox proportional hazard analysis
Disease-free survival Overall survival Disease-free survival Overall survival
Variable Evaluation HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Tumour size
T1 (≤ 2 mm) 1 1 1 1
T2 (2< T≤ 5 mm) 2.49 (1.59–3.91) < 0.001 2.73 (1.67–4.50) < 0.001 1.61 (0.96–2.71) 0.068 1.87 (1.06–3.32) 0.031
T3 (> 5 mm) 4.62 (2.76–7.73) < 0.001 5.25 (3.02–9.15) < 0.001 2.95 (1.65–5.29) < 0.001 3.54 (1.90–6.71) < 0.001
Lymph node status Negative 1 1 1 1
Positive 2.41 (1.70–3.41) < 0.001 2.64 (1.81–3.85) < 0.001 1.89 (1.30–2.77) 0.001 2.04 (1.35–3.08) 0.001
Tumour grade Grade I 1 1 1 1
Grade II 1.36 (0.84–2.19) 0.21 1.49 (0.90–2.46) 0.117 1.26 (0.64–2.45) 0.501 1.25 (0.62–2.50) 0.535
Grade III 1.91 (1.24–2.95) 0.003 1.94 (1.22–3.08) 0.005 1.9 (1.02–3.54) 0.043 1.66 (0.87–3.12) 0.122
E-cadherin
expression
Positive 1 1 1 1
Negative 1.45 (0.81–2.60) 0.216 1.41 (0.77–2.60) 0.269 1.066 (0.46–2.46) 0.88 0.8 (0.32–1.99) 0.627
P-cadherin
expression
Negative 1 1 1 1
Positive 1.36 (0.99–1.87) 0.059 1.45 (1.04–2.02) 0.028 1.35 (0.94–1.95) 0.109 1.51 (1.03–2.22) 0.036
E-/P-cadherin
expression
Positive/negative 1 1 1 1
Negative/negative 1.59 (0.88–2.88) 0.124 1.58 (0.85–2.93) 0.149 1.06 (0.46–2.46) 0.88 0.8 (0.32–1.99) 0.627
Positive/positive 1.44 (1.04–1.99) 0.029 1.53 (1.09–2.15) 0.014 1.35 (0.94–1.95) 0.109 1.51 (1.03–2.22) 0.036
∗This analysis allows the risk (hazard ratios and the corresponding 95% confidence interval, CI) to be predicted for disease-free and overall survival of breast cancer
patients. A significance level of 5% was considered.
We have demonstrated that P-cadherin is a putative
cancer stem cell marker in breast cancer [63],
since its expression, in E-cadherin wild-type cells,
promoted an increase in anoikis-resistant cells with
anchorage-independent growth. Curiously, induction of
anoikis resistance has also been observed after loss of
E-cadherin function [64] or by cytoplasmic localization
of p120ctn [12]. Ecad+/Pcad+ tumours
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Figure 7. Schematic representation of the different types of breast cancer in what concerns cadherin expression. Tumours that maintain
normal E-cadherin expression present a good prognosis. These cancer cells normally show intercellular adhesions, low ability to migrate,
low ability to invade, and are still sensitive to apoptosis. The tumours that only express P-cadherin are uncommon and the breast cancer
cells show intercellular adhesions, are resistant to apoptosis, and although they present high ability to migrate, they are not able to invade
the extracellular matrix. On the other hand, the tumours negative for both cadherins show a poor prognosis and the cancer cells do not
show intercellular adhesions, are resistant to apoptosis, and present a high ability to invade; however, these tumour cells are less motile.
Finally, in the breast cancer cells with co-expression of cadherins, intercellular adhesion is maintained, although the tumour cells present
an increase in the ability to migrate, to invade, and show resistance to apoptosis. Also, tumours co-expressing E- and P-cadherin present a
poorer prognosis compared with tumours that show exclusive E-cadherin expression.
show significantly decreased patient DFS and OS. The
evaluation of P-cadherin expression, in an E-cadherin+
background, has important value in the prognostic risk
assessment of patient recurrence and death [65–68].
Additionally, multivariate analysis showed that co-
expression of cadherins is an independent prognostic
marker for OS. With this study, P-cadherin can be
considered a robust independent biomarker of poor
prognosis in breast cancer.
In conclusion, tumour cells acquire features that give
them an advantage to survive in a hostile environment,
migrate, and invade [69]. Based on our data, we con-
clude that Ecad+/Pcad+ cells versus cells that express
only one of the cadherins show a more aggressive bio-
logical behaviour (Figure 7). Our results also show, for
the first time, that P-cadherin overexpression in an E-
cadherin wild-type context is an alternative mechanism
for cancer invasion, disrupting the interaction between
E-cadherin and intracellular catenins and leading to
alterations in biological behaviour and the gene expres-
sion profile of breast cancer cells. This work reinforces
the importance of P-cadherin expression as a prognos-
tic factor for breast cancer patients and supports the
development of new therapeutics to control aggressive
carcinomas co-expressing both cadherins.
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Abstract
P-cadherin is a cell-cell adhesion molecule codified by the CDH3 gene, which expression is highly associated with
undifferentiated cells in normal adult epithelial tissues, as well as with poorly differentiated carcinomas. In breast cancer, P-
cadherin is frequently overexpressed in high-grade tumours and is a well-established indicator of aggressive tumour
behaviour and poor patient prognosis. However, till now, the mechanisms controlling CDH3 gene activation have been
poorly explored. Since we recently described the existence of several CCAAT/Enhancer Binding Protein b (C/EBPb)
transcription factor binding sites at the CDH3 promoter, the aim of this study was to assess if the distinct C/EBPb isoforms
were directly involved in the transcriptional activation of the CDH3 gene in breast cancer cells. DNA-protein interactions,
mutation analysis and luciferase reporter assay studies have been performed. We demonstrated that C/EBPb is co-expressed
with P-cadherin in breast cancer cells and all the three isoforms function as transcriptional regulators of the CDH3 gene,
directly interacting with specific regions of its promoter. Interestingly, this transcriptional activation was only reflected at
the P-cadherin protein level concerning the LIP isoform. Taken together, our data show that CDH3 is a newly defined
transcriptional target gene of C/EBPb isoforms in breast cancer, and we also identified the binding sites that are relevant for
this activation.
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Introduction
The molecular changes that occur during breast cancer
progression, which include the amplification/overexpression of
transcription factors, can disrupt the delicate balance between cell
proliferation, differentiation and apoptosis. C/EBPb is one of
those transcription factors, which has been implicated in cell cycle
regulation, playing an important role in mammary gland
development and oncogene-induced breast tumorigenesis [1–4].
Encoded by an intronless gene, C/EBPb is expressed as distinct
protein isoforms, which can accomplish distinct biological and
regulatory functions, ultimately leading to gene transactivation [5].
The longer C/EBPb proteins (liver-enriched transcriptional
activating proteins, LAP1 and LAP2) regulate proliferation and
differentiation of many cell types [6]; the shorter protein product
(liver-enriched transcriptional inhibitory protein, LIP) lacks the
transactivation domain and acts mainly as a dominant-negative
[7]. AS LAP isoforms, LIP also binds to the consensus sequences
within genomic DNA, sometimes even with a higher affinity than
the other C/EBPb isoforms [6,7]. In fact, LIP inhibits the
transcriptional activity of LAPs by competing for the same
consensus binding sites or by forming inactive heterodimers with
them. However, some emerging evidence suggest that LIP can also
act as a transcriptional activator in some cellular contexts [5].
In breast, C/EBPb most likely contributes to tumorigenesis
through significant elevations in the LIP:LAP ratio, mostly
observed in ER-negative, highly proliferative and metastatic
mammary tumours, usually associated with a poor patient
prognosis [8]. Indeed, LIP isoform overexpression has been
associated to a lack of contact inhibition, resulting in proliferation
and foci formation in epithelial breast cancer cell lines [9]. It has
been hypothesized that aberrant expression of C/EBPb-LIP
isoform may contribute to an increased growth rate and result in
a more proliferative and aggressive breast carcinoma.
P-cadherin, a classical cadherin encoded by the CDH3 gene
[10], has been explored by our group for several years and has
been also extensively associated with breast tumour aggressiveness.
This protein was found to be aberrantly expressed in 20–40% of
invasive ductal carcinomas, being strongly associated with
proliferative lesions of high histological grade, decreased cell
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e55749
polarity and poor patient survival [11–16]. At the in vitro level, we
demonstrated that P-cadherin overexpression induces invasion
[14], motility and migration of wild-type E-cadherin expressing
breast cancer cells, through the secretion of pro-invasive factors,
such as matrix metalloproteinase (MMP)-1 and MMP-2 [17]. In
fact, P-cadherin-associated functions in breast cancer have been
widely studied, which reflects the growing importance of this
cadherin in human breast cancer biology and prognosis.
However, the mechanisms controlling its overexpression in
breast cancer have only recently started to be unrevealed [11,18].
In non-cancer models, CDH3 promoter was shown to be
genetically regulated through direct binding of transcription
factors, such as p63 [19] and b-catenin [20]. Gorski and
collaborators also demonstrated that BRCA1 and c-Myc form a
repressor complex on CDH3 promoter and on other promoters of
specific basal genes, representing a potential mechanism to explain
the overexpression of key basal markers in BRCA1-deficient breast
tumours [21]. Additionally, we established a direct link between P-
cadherin overexpression and the lack of oestrogen receptor (ER)-
signalling in breast cancer cells, categorizing CDH3 as a putative
ER-repressed gene [14]. In 2010, we described a regulatory
mechanism whereby a selective ER-downregulator is able to up-
regulate P-cadherin expression in MCF-7/AZ breast cancer cells
through chromatin remodelling at CDH3 promoter level [18]. This
epigenetic process was accomplished by the induction of high
levels of the active chromatin mark H3K4me2 and a consequent
de-repression of the CDH3 promoter, which exposed a high
number of putative C/EBPb transcription binding sites [18]. The
induction of CDH3 promoter activity by C/EBPb was also
confirmed by reporter assays, as well as its expression association
with worse prognosis of breast cancer patients [18].
However, since the mechanistic link and the consequent
transcriptional regulatory relevance of C/EBPb proteins on
CDH3 gene were not demonstrated, in the present study we
revealed that C/EBPb isoforms are indeed transcriptional
regulators of P-cadherin, directly interacting with conserved and
specific regions of the CDH3 promoter. Interestingly, we show that
this transcriptional activation is reflected in the P-cadherin protein
levels, especially for the LIP isoform. We conclude that CDH3 is a
newly defined transcriptional target gene of C/EBPb in breast
cancer.
Materials and Methods
Antibodies
The following primary anti-human antibodies were used for
Western Blot and/or Immunohistochemistry against: P-cadherin
(BD Transduction Biosciences, Lexington, KY), C/EBPb (Santa
Cruz Biotechnology, CA), b-actin (Santa Cruz Biotechnology) and
b-tubulin (Sigma-Aldrich, St. Louis, NO). Technical conditions
are described in Table S1 (Supporting Information). Anti-mouse
and anti-goat horseradish peroxidase-conjugated secondary anti-
bodies were used for WB [HRP-conjugated, dilutions: 1:2000]
(Santa Cruz Biotechnology). For chromatin immnunoprecipitation
(ChIP) assays, the following antibodies were used: anti-C/EBPb
(C-19, Santa Cruz Biotechnology), and two control IgGs (Active
Motif, CA and Santa Cruz Biotechnology).
Promoter Vectors and cDNA Constructs
The pLENTI-C/EBPb expression vectors (C/EBPb-LAP1, C/
EBPb-LAP2 and C/EBPb-LIP) were generated according to the
human CEBPB nucleotide sequence obtained from Ensembl and
Pubmed databases. Oligonucleotide primer sequences for LAP1,
LAP2, and LIP isoforms are listed in Table S2 (see Supporting
Information).
CEBPB cDNA was obtained from total RNA extracted from the
gastric cancer cell line AGS, and amplified for each CEBPB
isoform using HotStart Taq DNA Polymerase (Qiagen, Cam-
bridge, MA). Amplification was performed for 35 cycles as follows:
denaturation at 95uC for 1 minute, annealing at 60uC for LAP1
and LAP2 and 58uC for LIP for 1 minute, and extension at 68uC
for 2 minutes per cycle. PCR products for each isoform were
separated by electrophoresis in a 1.5% agarose gel and bands were
sequenced using the ABI Prism Dye Terminator Cycle Sequencing
Kit (Perkin-Elmer, Beaconsfield, UK). To validate the isoforms
nucleotide sequence, amplified products were purified through
Sepharose (GE Healthcare, Waukesha, WI) and sequenced on
both strands on an ABI Prism 3100 automated sequencer (Perkin-
Elmer). PCR products were inserted into the mammalian
expression vector pLENTI6/V5 Directional (Invitrogen, Ltd,
Paisley, UK), using manufacturer instructions, and incorporated
into chemically competent TOP10 E. coli (Invitrogen). Trans-
formed bacteria were grown overnight in ampicillin-supplemented
LB-Agar (Applichem, Germany). Plasmid DNA from transformed
E. coli cells was sequenced to check the orientation and nucleotide
sequence for each CEBPB isoform.
The human full-length CDH3-luciferase vector was generated
by our group, as previously described [18]. Normalization pRL-
CMV Renilla Luciferase Control Reporter Vector was purchased
to Promega (Promega Corporation, Madison, WI).
Immunohistochemistry
Double immunostaining for C/EBPb and P-cadherin was
performed in 3 mm sections of 23 formalin-fixed paraffin-
embedded (FFPE) invasive breast carcinomas that have previously
showed strong expression of both proteins, in order to illustrate
their consistent cellular co-localization. Standard immunohisto-
chemistry was performed as previously described [16]. For the
reaction, we used the Envision G2 Double-stain (DakoCytoma-
tion, Glostrup, Denmark), according to manufacturer instructions.
Specific conditions used for C/EBPb and P-cadherin are listed in
Table S1. FFPE sections from normal breast gland, skin or normal
gastric mucosa were used as positive controls for C/EBPb and P-
cadherin. Negative controls were performed by replacing the
primary antibody with PBS/non-immune serum.
The present study was conducted under the national regulative
law for the usage of biological specimens from tumour banks,
where the samples are exclusively available for research purposes
in the case of retrospective studies (National Regulative Law
number 12/2005 – I Serie-A, nu. 18–26th January, 2005).
Cell Culture
Human breast cancer cell line MCF-7/AZ was kindly provided
by Prof. Marc Mareel (Ghent University, Belgium) [22], while BT-
20 cells were purchased to American Type Culture Collection
(ATCC, Manassas, VA). Cell lines were routinely maintained at
37uC, 5% CO2, in the following media (Invitrogen): 50%
DMEM/50% HamF12 (MCF-7/AZ), or only DMEM (BT-20).
All media contained 10% of heat-inactivated foetal bovine serum
(Greiner Bio-one, Wemmel, Belgium), 100 IU/mL penicillin and
100 mg/mL streptomycin (Invitrogen).
Transient Transfection
For gene reporter assays, cells were grown in 96-well plates to
60–70% confluence and transfection was done using the liposome-
mediated FuGENE 6 transfection reagent (Roche Diagnostic
GmbH, Mannheim, Germany), prepared according to the
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manufacturer’s instructions. A ratio of FuGENE/DNA of 3:1 was
used. For protein expression assays, cells were grown in 6-well
plates to 60% confluence. Transient transfections of C/EBPb
expression vectors were done using Lipofectamine 2000 (Invitro-
gen), with a ratio of Lipofectamine/DNA of 3:1 and prepared
according to the manufacturer’s instructions.
For knock-down assays, cells were transiently transfected at 60%
confluence with specific siRNA for C/EBPb (100 nM, FlexiTube
siRNA – Hs_C/EBPb 5-Qiagen) using Lipofectamine 2000
(Invitrogen), according to the manufacturer’s procedure. Maxi-
mum C/EBPb knock-down was achieved after 48 h of incubation.
A siRNA with no homology to any gene was also used as a
negative control.
CDH3-luciferase Reporter Gene Analysis
Cells were co-transfected with pGL3-CDH3/luc promoter
vector (20 ng) and with pRL-CMV Renilla vector (5 ng). For
promoter analysis, 24 hours after transfection, cells were washed
twice in PBS-cold and lysed for firefly/Renilla luciferase assays,
using the Luclite Reporter Gene Assay System (Perkin Elmer),
according to the manufacturer. Luciferase bioluminescence from
Renilla was measured using native coelenterazine substrate
reagent (Lux Biotechnology, Edinburgh, UK). Individual trans-
fection experiments were repeated at least three times and in
quadruplicate per transfection condition. Empty pGL3-basic
vector and pGL3/luc-Control (pLUC) vector (Promega) were
included as controls in all CDH3-reporter assays. Luminescence
was read using the Wallac/Perkin Elmer-1450-028 Trilux
Microbeta (Perkin Elmer) plate reader, and the results are shown
as a mean of relative light units (RLU), which was calculated by
the ratio between the luminescence signal emitted from luciferase
and the luminescence signal obtained by the Renilla (normaliza-
tion).
Western Blot
Cells were lysed and the concentration of total protein was
determined by Bradford quantification. Western Blot was
performed as earlier described [17,18]. For MCF-7/AZ cell line,
due to its lower expression of P-cadherin, 50 mg of total protein
lysate has been loaded; for BT-20, due to its P-cadherin
overexpression, the gel loading was done only with 20 mg of
protein lysate. Membranes were incubated with primary antibod-
ies according to the conditions described in Table S1.
Site-Directed Mutagenesis
All the C/EBPb binding sites mutations in CDH3 promoter
were performed in order to impair the binding of any predicted
transcription factor: bioinformatic prediction tools were used to
blast all point mutated sequences. To introduce point mutations in
the CDH3 promoter region, the QuickChange Site-directed
Mutagenesis Protocol (Stratagene, Cedar Creek, USA) was
followed, and the oligos used are listed in Table S2. The PCR
cycles were set as follows: 95uC for 30 seconds; 16 cycles of 95uC
for 30 seconds, 55uC for 1 minute, and 68uC for 5 minutes.
Following PCR reaction, products were incubated with DpnI
(1 hour at 37uC) and transformed into E-coli competent cells
(Stratagene). All mutated plasmids were checked by sequencing
and primer sequences are also listed in Table S2.
Chromatin Immunoprecipitation (ChIP) Assay
For chromatin immunoprecipitation of the endogenous CDH3
promoter regions in MCF-7/AZ cells, the ChIP-ITTM kit (Active
Motif) was used and the assay was performed according with the
manufacturer’s procedures. Briefly, cells (4.56107) were fixed with
1% formaldehyde in culture medium for 10 minutes. Fixation was
stopped by incubating the cells for 5 minutes with a 16Glycine
Stop-Fix Solution, homogenized and centrifuged. The cell-pellets
were resuspended in a shearing buffer and sonicated into
chromatin fragments of 200–1500 bp in length. To reduce non-
specific background, sonication-sheared lysates were pre-cleared
with Protein G beads. The sheared chromatin lysates were
incubated with 5 mg of C/EBPb antibody or with a control rabbit
IgG, overnight at 4uC, and immunoprecipitated with Protein G
beads (2 hours at 4uC). The precipitated DNA-protein complex
was washed 7 times, eluted, incubated for 8 hours at 65uC in a
reverse cross-link buffer, and digested with proteinase K for
2 hours at 42uC. The resultant DNA was purified, resuspended in
DEPC H2O and quantified by real-time qPCR amplification. The
PCR primers sequences used in this amplification are listed in
Table S2.
For chromatin Immunoprecipitation in BT-20 cells and in an
invasive breast carcinoma highly positive for P-cadherin and C/
EBPb, the Magna ChIP G Kit (Millipore) was used, according to
manufacturer’s protocol. Basically, the essential steps applied for
BT-20 cells were the same as the ones used for MCF-7/AZ cells,
differing only in the use of protein G magnetic beads instead of
non-magnetic beads for simplicity of use. However, for the tumour
sample, some alterations in the basic protocol were employed.
Briefly, the tumour sample, that was frozen at 280uC since
surgical extraction, was thawed and immediately fixed in 1%
formaldehyde for 25 minutes, followed by the addition of 16
glycine solution for 5 minutes, washed in 16PBS twice, frozen in
liquid nitrogen, and finally pulverized mechanically. The following
steps were the same used for breast cancer cell lines.
Statistical Analysis
Data are expressed as mean values of at least three independent
experiments 6 s.d. Student’s t-tests were used to determine
statistically significant differences (*P,0.05).
Results
P-cadherin is co-expressed with C/EBPb and is regulated
by this transcription factor in breast cancer cells
Using a large cohort of invasive breast carcinomas, the
expression of C/EBPb was previously demonstrated to be
significantly associated with P-cadherin expression in about 60%
of the cases [18]; however, the cellular co-expression of these two
proteins was not verified. Thus, based on the hypothesis that C/
EBPb directly activates the CDH3 gene promoter, a double
immunostaining was performed in all invasive breast carcinomas
that previously showed strong positivity for both proteins. As
represented in Figure 1A, C/EBPb expression was found in the
nuclei of the same cells that were expressing P-cadherin at the cell
membrane, pointing for a putative functional relationship between
both proteins.
Based on these results, two different breast cancer cell models
were used to demonstrate if P-cadherin expression could be
affected by C/EBPb: 1) MCF-7/AZ, which is an ER+/luminal
type breast cancer cell line expressing moderate levels of P-
cadherin, and 2) BT-20, an ER-negative/basal-like breast cancer
cell line, highly positive for P-cadherin [17]. The siRNA mediated-
knock-down of C/EBPb induced a significant downregulation of
all C/EBPb isoforms (LAP1, LAP2 and LIP) in both cell lines.
Interestingly, P-cadherin expression was also affected by the
reduction of C/EBPb isoforms, being this effect more pronounced
in MCF-7/AZ cells (Figure 1B). According with these results, and
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in order to decipher which C/EBPb isoform was more relevant for
P-cadherin activation, the expression of LAP1, LAP2 and LIP was
induced in both breast cancer cell lines. As shown in Figure 1C,
only C/EBPb-LIP isoform was able to induce P-cadherin
expression in more than 1.5-fold increase in MCF-7/AZ cells,
while the remaining isoforms did not produce valuable effects on
P-cadherin expression. This result was not found for BT-20 cells,
probably due to their high basal levels of P-cadherin expression
(data not shown).
Interestingly, in a previous study performed by our group, we
found that the CDH3/P-cadherin promoter activation induced by
the LIP isoform was significantly greater compared with the
activation induced by LAP1 and LAP2 [18]. However, in the
present study, this same experiment has been performed and,
although the same significant result was observed at the promoter
level for LIP (p = 0.00079), the CDH3 promoter was also strongly
and significantly activated by LAP1 (p = 0.00002) and less
prominently, but also in a significant way, by LAP2
(p = 0.00032) (Figure 1D). Nevertheless, since it has been described
that LIP can function as a dominant negative inhibitor of both
LAP’s activity [5], we decided to co-transfect both LIP and each
LAP1 or LAP2 , in order to study their combined effect on CDH3
promoter activity. The results showed that there is a significant
increased activation of the promoter with any of the combinations
compared with LAP1 or LAP2 alone, demonstrating that there is
an additive effect of both isoforms (p = 0.00164 and p = 0.00024,
respectively) on CDH3 promoter activation, when added to LIP.
C/EBPb physically interacts with endogenous CDH3 gene
promoter in breast cancer cells
Since the three C/EBPb isoforms were able to transactivate the
1.8 Kb CDH3 promoter gene construct (Figure 1D), we decided to
evaluate in detail the sequence of this putative regulatory region
using distinct bioinformatic tools, which can predict for the
binding of specific transcription factors. Four concordant C/
EBPb-putative binding sites were identified within the first 1400
nucleotides. Interestingly, we found that there is a high degree of
conservation of these predicted C/EBPb binding sites between
humans and other primates within the CDH3 promoter
(Figure 2A), and the left panel of Figure 2B shows their relative
localization.
In fact, in order to demonstrate if there was a physical
interaction between C/EBPb proteins and CDH3 promoter in
these specific binding sites, ChIP has been performed in MCF-7/
AZ breast cancer cells. Indeed, The results showed that there was
an enrichment (relative to input) of the CDH3 DNA-amplified
fragments precipitated with the C/EBPb antibody in all binding
sites (Figure 2B, right panel), demonstrating that C/EBPb
transcription factors directly bind to the selected regions within
the CDH3 promoter.
This same experiment has been performed in BT-20 breast
cancer cells, as well as in a frozen primary basal-like breast
carcinoma, which was selected for being highly positive for P-
cadherin and C/EBPb expression. Interestingly, we could confirm
the results, since there was precipitation with the C/EBPb
antibody in all the binding sites studied, in both cells and primary
tumour (Figure 2C). Moreover, in BT-20 cells, which overexpress
P-cadherin, the binding in all sites was very strong compared with
the one found in MCF-7/AZ breast cancer cells.
C/EBPb binding sites are important for CDH3 gene
activity and are selectively activated by the different C/
EBPb isoforms
In order to evaluate the importance of the aforementioned
binding sites to the CDH3 gene activation, as well as the specificity
of the different C/EBPb isoforms to the CDH3 promoter, point
mutations were introduced in the specific C/EBPb binding
sequences. Figure 3A illustrates the CDH3 point mutations and
their position within the C/EBPb binding sites in relation to the
wild-type CDH3 promoter.
Interestingly, when MCF-7/AZ cells were transfected with the
CDH3 promoter containing point mutations at the binding sites 1
and 4 (CDH3-BS1 and BS4), there was a statistically significant
alteration in CDH3 promoter activity related to the wild-type
promoter sequence (Figure 3B). In contrast, the activity of the
CDH3 promoter was not affected by the mutation introduced at
the BS3 site, and only slightly affected by the introduced mutation
at the binding site 2 (BS2). These results were mostly confirmed in
BT-20 cells, especially for the BS4 mutation, located at the
transcription start site region of the CDH3 promoter, which also
significantly induced its activity (Figure 3B). Although not
significant, the reduction on CDH3 promoter activity observed
with the BS1 mutant was also found in BT-20 cells, suggesting that
this distal C/EBPb binding site is also important to CDH3 gene
transcriptional activation. In addition, the BS2 mutant signifi-
cantly reduced CDH3 promoter activity in BT-20 cells, showing
that this is also a crucial site for the activation of P-cadherin
transcription in this model. Finally, we could not find any effect of
BS3 mutation in CDH3 promoter activity also in BT-20 cells,
proving that this site is not relevant for its regulation.
Since the distinct C/EBPb isoforms have been documented has
having different functions in cancer gene activation and in a cell-
specific context, we co-transfected LAP1, LAP2 and LIP together
with the different mutants of CDH3 promoter in both breast
cancer cell lines. The results demonstrated that distal CDH3-BS1
and BS2 are significantly important for the induced promoter
activity mediated by all C/EBPb isoforms. In contrast, BS3 did
not play a significant role in C/EBPb-mediated CDH3 promoter
activity, since mutations in this specific region were not important
to impair the activation of CDH3 gene mediated by any of the
distinct isoforms. Similar results were observed concerning BS4,
which did not reveal to be important for CDH3 promoter activity
mediated by LAP1, LAP2 or LIP isoforms. Finally, although not
significant, the same trend was observed with BT-20 cells, proving
that BS1 and BS2 are most likely the binding sites where all C/
EBPb isoforms bind to induce P-cadherin transcription in breast
cancer.
Figure 1. Association and regulatory interplay between C/EBPb and CDH3/P-cadherin expression in breast cancer cells. A) Double
immunostaining for C/EBPb and P-cadherin of an invasive breast carcinoma specimen (basal-like carcinoma, histological grade III), where it can be
observed C/EBPb expression in the nuclei and P-cadherin at the cell membrane of tumour cells (magnification6200 and6400-inset); a haematoxylin-
eosin staining of this same case is shown to ascertain tissue integrity (magnification6100); B) Using C/EBPb-targeted siRNA, a consequent reduction
of P-cadherin protein levels was observed in both MCF-7/AZ and BT-20 breast cancer cell lines; C) MCF-7/AZ cells transiently transfected with the
different C/EBPb isoforms (LAP1, LAP2 and LIP) displayed upregulation of P-cadherin protein levels only after induction of the C/EBPb-LIP isoform; D)
Luciferase reporter assays performed in cells transfected with the different C/EBPb isoforms showed that the promoter activation induced by LIP and
LAP1 isoforms was significantly greater compared with the activation induced by LAP2. The co-transfection of both LIP and each LAP1 or LAP2
induced the activation of the CDH3 promoter in an additive manner.
doi:10.1371/journal.pone.0055749.g001
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Discussion
P-cadherin has been receiving a growing interest in the last
years, since its overexpression is significantly associated with high
histological grade breast tumours and with short-term patient
overall survival [11,23–25]. The important association between P-
cadherin expression and well-established markers correlated to
breast cancer poor prognosis, such as high levels of Ki-67,
epidermal growth factor receptor (EGFR), cytokeratin 5 (CK5),
vimentin, p53 and HER2, has been also largely documented [11].
Although P-cadherin has been detected as altered in distinct
tumour models, its effective role in the carcinogenesis process
remains discussible, since it behaves differently depending on the
studied cancer cell context [26]. If in some models P-cadherin has
been suggested to act as an invasion suppressor, such as in
colorectal cancer [27] or in melanoma [28], in several other
models, including breast cancer, P-cadherin behaves as an
Figure 2. C/EBPb physical interaction with the CDH3 gene promoter. A) Putative C/EBPb-binding sites within the CDH3 gene promoter,
where it can be observed their degree of conservation between human and other primates. Grey regions represent total sequence conservation in
comparison with human sequence; B) Proximal regulatory region of CDH3 promoter displaying the relative localization of the predicted C/EBPb
binding sites (left panel). The right panel illustrates the enrichment (relative to input) of the CDH3 promoter DNA-amplified fragments precipitated
from DNA-protein complexes obtained by ChIP in MCF-7/AZ breast cancer cells. C) ChIP experiment performed in BT-20 breast cancer cells and on a
frozen primary breast tumour, highly positive for P-cadherin and C/EBPb expression, also showed the same enrichment pattern for all the putative
binding sites.
doi:10.1371/journal.pone.0055749.g002
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Figure 3. Relevance of C/EBPb-isoforms and their putative binding sites in the activation of the CDH3 gene. A) Schematic
representation of the wild-type and mutated CDH3 promoter; B) CDH3-Luciferase Reporter Assays performed with each of the mutations introduced
at C/EBPb binding sites demonstrating that CDH3-BS1, BS2 and BS4 are the most important for the activity of CDH3 promoter in both MCF-7/AZ and
BT-20 breast cancer cells; *p-value,0.05; C) CDH3-Luciferase Reporter Assays upon co-transfection of LAP1, LAP2 and LIP C/EBPb isoforms, showing
the relevance of specific C/EBPb isoforms across CDH3 promoter binding sites in both MCF-7/AZ and BT-20 breast cancer cells. CDH3-BS1 and BS2, but
not BS3 and BS4, are responsive to all C/EBPb isoforms; *p-value,0.05.
doi:10.1371/journal.pone.0055749.g003
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oncogene, inducing increased tumour cell motility and invasive-
ness when aberrantly overexpressed [12–14,27,29–31].
However, data concerning CDH3 gene regulation in breast
cancer is still very limited. The induction of CDH3 promoter
activity in breast cancer cells was recently described by our group
to be putatively linked to the transcription factor C/EBPb, as well
as P-cadherin and C/EBPb expression have been reported to be
highly associated in human breast carcinomas and linked with a
worse prognosis of breast cancer patients [18]. In fact, the
expression of C/EBPb shares interesting biologic and functional
features with the ones attributed to P-cadherin expression.
Similarly to what has been described concerning C/EBPb biology,
P-cadherin is involved in homeostatic processes, such as cell
differentiation, development and embryogenesis [32]. We have
recently found that P-cadherin enriched cell populations show
enhanced mammosphere forming efficiency (MFE), as well as
increased expression of CD24, CD44 and CD49f, already
described as normal or cancer stem cell markers. These results
allowed to link P-cadherin expression to the luminal progenitor
phenotype of the normal breast hierarchy and established an
indirect effect of P-cadherin in stem cell biology [33]. Interestingly,
these findings come along with observations that C/EBPb
regulates stem cell activity and specifies luminal cell fate in the
mammary gland, categorizing C/EBPb as one of the several
critical transcription factors that specifies mammary stem cells fate
during mammary gland development [34]. In a breast cancer
biology setting, another interesting finding is related to the fact
that P-cadherin, like C/EBPb, is not mutated in breast tumours,
but its overexpression has been widely described in a subset of
aggressive breast cancers [5]. Importantly, at a clinicopathological
level, some C/EBPb isoforms, especially C/EBPb-LIP, correlates
with an ER-negative breast cancer phenotype, highly proliferative
and high grade lesions and poor patient outcome [8,35]. All these
characteristics overlap with the ones observed in highly malignant
breast tumours overexpressing P-cadherin.
The present work demonstrates for the first time that P-
cadherin and C/EBPb co-localize in the same breast cancer cells,
and that there is a physical interaction between this transcription
factor and CDH3 gene promoter. Herein, in addition to the
identification of the promoter binding sites that are relevant for the
transcriptional modulation of CDH3 gene activity by C/EBPb, we
still tested the relevance of the different C/EBPb isoforms along
the CDH3 promoter.
In fact, we show that C/EBPb-LIP is the only isoform capable
to significantly induce P-cadherin protein expression, confirming
in a way the results obtained in our previous study, where a
significant activation of the promoter was only revealed for LIP,
although LAP1 and LAP2 were also able to activate the promoter.
However, in this study, we found that CDH3 gene is also
significantly responsive to LAP1 and slightly to LAP2 isoform at
the promoter level. These significant results were probably due to
improved transfection efficiencies; however, although LAP1 and
LAP2 are activating the gene promoter, supporting the classical
knowledge described for these isoforms as transcriptional activa-
tors, this might not imply that these isoforms induce functional
activity through protein synthesis. In fact, it has been largely
discussed that the functionally transactivation potential of each C/
EBPb isoform can be highly modulated, since this ability strongly
depends not only on dimer composition formed by C/EBPs, but
specially on the partner proteins and responsive elements found in
target gene promoters [5]. The fact that LIP activates CDH3
promoter, leading to protein synthesis, reinforces the emerging
evidence that LIP acts as a transcriptional activator of gene
expression, challenging the long-standing concept that LIP
fashionably functions as a dominant-negative isoform [5]. We
also observed that LAP2 was the C/EBPb isoform that activated
CDH3 promoter in a less extent, which is apparently surprising in
light that LAP2 isoform is considered to be the most transcrip-
tionally active C/EBPb isoform [5]. However, it is also known
that, in transformed cancer cells, an increase in LIP expression
leads to a reduction in LAP2 activity and, therefore, impair its
mediated transcription potential [36].
A novel observation also obtained in this study was the existence
of interaction between C/EBPb proteins to the conserved regions
of the CDH3 gene promoter, identified as C/EBPb responsive
elements. The ChIP results, obtained from the DNA region
containing both BS2 and BS3 binding sites, revealed a cumulative
increased C/EBPb antibody-precipitated DNA when compared to
individual BS1 and BS4, reinforcing the existence of bounding
complexes. This was denoted for both MCF-7/AZ and BT-20
breast cancer cell lines and also for the basal-like tumour studied
by in vivo ChIP.
Concerning the impact of C/EBPb binding sites to the CDH3
promoter activity, we found that BS1, BS2 and BS4 were the most
relevant ones, while BS3 was not responsible for the modulation of
the CDH3 promoter. A detailed analysis of the CDH3 promoter
using the Ensemble ENCODE Project, revealed two DNAse
Hypersensitive (DHS) sites located around BS1 and BS4 specific
sequences, confirming an increased regulatory activity on these
specific regions.
Interestingly, one of the most curious effects was the one found
at BS4, which is located at the transcription start site region of
CDH3 promoter. In contrast with the distal sites, binding
impairment at BS4 significantly induced the activity of CDH3
promoter. In a first approach, we may hypothesize that specific C/
EBPb proteins are regulating negatively the activity of the
promoter through that specific binding site and, upon mutation,
this repression is released. However, since we did not find a
significant effect mediated by LAP1, LAP2 or LIP when BS4 was
mutated, we believe that other factors not C/EBPb-related are
responsible for the negative regulation in this binding site, or the
mutation introduced in BS4 generated a sequence which allowed
the binding of a transcription factor that is able to activate the
CDH3 gene promoter. Additionally, it is also interesting to note
that, although the BS2 mutation did not create a significant
decrease in CDH3 promoter activity in MCF-7/AZ cells, this
binding site is important to LAP2-mediated activation, indicating
that it may not be endogenously active in these breast cancer cells,
but probably highly active in BT-20 cells.
In conclusion, this study contributes to clarify the individual role
of C/EBPb proteins in breast cancer-related CDH3/P-cadherin
gene, as well as to expand the limited characterization of the
mechanisms and players that regulate this pro-invasive protein in
breast cancer.
Supporting Information
Table S1 Conditions of the primary antibodies.
(PDF)
Table S2 Primers sequences used in the different
assays.
(PDF)
Author Contributions
Conceived and designed the experiments: AA CR JP JCM RS FS.
Performed the experiments: AA CR BS ARN ASR. Analyzed the data: AA
JP FS. Contributed reagents/materials/analysis tools: AA CR JCM JP.
Wrote the paper: AA JP FS.
C/EBPb Targets CDH3 Gene in Breast Cancer Cells
PLOS ONE | www.plosone.org 8 February 2013 | Volume 8 | Issue 2 | e55749
References
1. Poli V (1998) The role of C/EBP isoforms in the control of inflammatory and
native immunity functions. J Biol Chem 273: 29279–29282.
2. Sebastian T, Johnson PF (2006) Stop and go: anti-proliferative and mitogenic
functions of the transcription factor C/EBPbeta. Cell Cycle 5: 953–957.
3. Zahnow CA (2002) CCAAT/enhancer binding proteins in normal mammary
development and breast cancer. Breast Cancer Res 4: 113–121.
4. Zahnow CA, Cardiff RD, Laucirica R, Medina D, Rosen JM (2001) A role for
CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in
mammary epithelial cell proliferation. Cancer Res 61: 261–269.
5. Zahnow CA (2009) CCAAT/enhancer-binding protein beta: its role in breast
cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med 11:
e12.
6. Lekstrom-Himes J, Xanthopoulos KG (1998) Biological role of the CCAAT/
enhancer-binding protein family of transcription factors. J Biol Chem 273:
28545–28548.
7. Xiong W, Hsieh CC, Kurtz AJ, Rabek JP, Papaconstantinou J (2001) Regulation
of CCAAT/enhancer-binding protein-beta isoform synthesis by alternative
translational initiation at multiple AUG start sites. Nucleic Acids Res 29: 3087–
3098.
8. Milde-Langosch K, Loning T, Bamberger AM (2003) Expression of the
CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBP-
delta in breast cancer: correlations with clinicopathologic parameters and cell-
cycle regulatory proteins. Breast Cancer Res Treat 79: 175–185.
9. Calkhoven CF, Muller C, Leutz A (2000) Translational control of C/EBPalpha
and C/EBPbeta isoform expression. Genes Dev 14: 1920–1932.
10. Takeichi M (1988) The cadherins: cell-cell adhesion molecules controlling
animal morphogenesis. Development 102: 639–655.
11. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, et al. (2005) P-
cadherin overexpression is an indicator of clinical outcome in invasive breast
carcinomas and is associated with CDH3 promoter hypomethylation. Clin
Cancer Res 11: 5869–5877.
12. Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, et al. (2007) P-
cadherin expression in breast cancer: a review. Breast Cancer Res 9: 214.
13. Paredes J, Lopes N, Milanezi F, Schmitt FC (2007) P-cadherin and cytokeratin
5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
Virchows Arch 450: 73–80.
14. Paredes J, Stove C, Stove V, Milanezi F, Van Marck V, et al. (2004) P-cadherin
is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of
human breast cancer cells. Cancer Res 64: 8309–8317.
15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000)
Molecular portraits of human breast tumours. Nature 406: 747–752.
16. Sousa B, Paredes J, Milanezi F, Lopes N, Martins D, et al. (2010) P-cadherin,
vimentin and CK14 for identification of basal-like phenotype in breast
carcinomas: an immunohistochemical study. Histol Histopathol 25: 963–974.
17. Ribeiro AS, Albergaria A, Sousa B, Correia AL, Bracke M, et al. (2010)
Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the
invasive behaviour of breast cancer cells. Oncogene 29: 392–402.
18. Albergaria A, Ribeiro AS, Pinho S, Milanezi F, Carneiro V, et al. (2010) ICI
182,780 induces P-cadherin overexpression in breast cancer cells through
chromatin remodelling at the promoter level: a role for C/EBP{beta} in CDH3
gene activation. Hum Mol Genet 19: 2554–2566.
19. Shimomura Y, Wajid M, Shapiro L, Christiano AM (2008) P-cadherin is a p63
target gene with a crucial role in the developing human limb bud and hair
follicle. Development 135: 743–753.
20. Faraldo MM, Teuliere J, Deugnier MA, Birchmeier W, Huelsken J, et al. (2007)
beta-Catenin regulates P-cadherin expression in mammary basal epithelial cells.
FEBS Lett 581: 831–836.
21. Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, et al. (2010) BRCA1
transcriptionally regulates genes associated with the basal-like phenotype in
breast cancer. Breast Cancer Res Treat 122: 721–731.
22. Bracke ME, Van Larebeke NA, Vyncke BM, Mareel MM (1991) Retinoic acid
modulates both invasion and plasma membrane ruffling of MCF-7 human
mammary carcinoma cells in vitro. Br J Cancer 63: 867–872.
23. Gamallo C, Moreno-Bueno G, Sarrio D, Calero F, Hardisson D, et al. (2001)
The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma.
Mod Pathol 14: 650–654.
24. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA (1999) P-
cadherin expression in breast carcinoma indicates poor survival. Cancer 86:
1263–1272.
25. Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, et al.
(2011) P-cadherin expression as a prognostic biomarker in a 3992 case tissue
microarray series of breast cancer. Mod Pathol 24: 64–81.
26. Albergaria A, Ribeiro AS, Vieira AF, Sousa B, Nobre AR, et al. (2011) P-
cadherin role in normal breast development and cancer. Int J Dev Biol 55: 811–
822.
27. Van Marck V, Stove C, Jacobs K, Van den Eynden G, Bracke M (2011) P-
cadherin in adhesion and invasion: opposite roles in colon and bladder
carcinoma. Int J Cancer 128: 1031–1044.
28. Van Marck V, Stove C, Van Den Bossche K, Stove V, Paredes J, et al. (2005) P-
cadherin promotes cell-cell adhesion and counteracts invasion in human
melanoma. Cancer Res 65: 8774–8783.
29. Cheung LW, Leung PC, Wong AS (2010) Cadherin switching and activation of
p120 catenin signaling are mediators of gonadotropin-releasing hormone to
promote tumor cell migration and invasion in ovarian cancer. Oncogene 29:
2427–2440.
30. Mandeville JA, Silva Neto B, Vanni AJ, Smith GL, Rieger-Christ KM, et al.
(2008) P-cadherin as a prognostic indicator and a modulator of migratory
behaviour in bladder carcinoma cells. BJU Int 102: 1707–1714.
31. Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, et al. (2005)
Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells
by interacting with p120ctn and activating rho-family GTPases. Cancer Res 65:
3092–3099.
32. Radice GL, Ferreira-Cornwell MC, Robinson SD, Rayburn H, Chodosh LA, et
al. (1997) Precocious mammary gland development in P-cadherin-deficient
mice. J Cell Biol 139: 1025–1032.
33. Vieira AF, Ricardo S, Ablett MP, Dionı´sio MR, Mendes N, et al. (2012) P-
cadherin is co-expressed with CD44 and CD49f and mediates stem cell
properties in basal-like breast cancer. Stem Cells.
34. LaMarca HL, Visbal AP, Creighton CJ, Liu H, Zhang Y, et al. (2010) CCAAT/
enhancer binding protein beta regulates stem cell activity and specifies luminal
cell fate in the mammary gland. Stem Cells 28: 535–544.
35. Zahnow CA, Younes P, Laucirica R, Rosen JM (1997) Overexpression of C/
EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in
human breast cancer. J Natl Cancer Inst 89: 1887–1891.
36. Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J (2006) C/EBPbeta
at the core of the TGFbeta cytostatic response and its evasion in metastatic
breast cancer cells. Cancer Cell 10: 203–214.
C/EBPb Targets CDH3 Gene in Breast Cancer Cells
PLOS ONE | www.plosone.org 9 February 2013 | Volume 8 | Issue 2 | e55749

!
  
 
 
 
 
 
 
 
 
 
PUBLICATIONS 
 Paper 14
 

©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
Cell Cycle 12:16, 2684–2690; August 15, 2013; © 2013 Landes Bioscience
 PAPER TYPE
2684 Cell Cycle Volume 12 Issue 16
*Correspondence to: Fernando Schmitt; Email: fschmitt@ipatimup.pt 
Submitted: 06/04/2013; Revised: 07/12/2013; Accepted: 07/17/2013 
http://dx.doi.org/10.4161/cc.25794
The progression from in situ to invasive breast carcinoma is still an event poorly understood. However, it has been 
suggested that interactions between the neoplastic cells and the tumor microenvironment may play an important role 
in this process. Thus, the determination of di!erential tumor-stromal metabolic interactions could be an important step 
in invasiveness.
The expression of stromal Caveolin-1 (Cav-1) has already been implicated in the progression from ductal carcinoma 
in situ (DCIS) to invasive ductal carcinoma (IDC). Additionally, stromal Cav-1 expression has been associated with the 
expression of stromal monocarboxylate transporter 4 (MCT4) in invasive breast cancer. However, the role of stromal MCT4 
in invasiveness has never been explored, neither the association between Cav-1 and MCT4 in the transition from breast 
DCIS to IDC.
Therefore, our aim was to investigate in a series of breast cancer samples including matched in situ and invasive 
components, if there was a relationship between stromal Cav-1 and MCT4 in the progression from in situ to invasive carci-
noma. We found loss of stromal Cav-1 in the progression to IDC in 75% of the cases. In contrast, MCT4 stromal expression 
was acquired in 87% of the IDCs. Interestingly, a concomitant loss of Cav-1 and gain of MCT4 was observed in the stroma 
of 75% of the cases, when matched in situ and invasive carcinomas were compared. These results suggest that alterations 
in Cav-1 and MCT4 may thus mark a critical point in the progression from in situ to invasive breast cancer.
Loss of caveolin-1 and gain of MCT4 
expression in the tumor stroma
Key events in the progression from an in 
situ to an invasive breast carcinoma
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Introduction
Breast cancer is a heterogeneous and complex disease, encom-
passing a variety of pathological entities with distinct clinical 
behaviors. The development of new technologies has offered the 
opportunity to explore the molecular complexity of human breast 
carcinomas.1 However, despite these advances, the mechanisms 
controlling the transition from an in situ to an invasive carcinoma 
still remain unclear. Therefore, there is a significant interest in 
identifying molecular events driving invasive progression, not only 
to determine at which point the lesion is most likely to progress to 
malignancy, but also to identify new molecular targets that could 
trigger the progression at early stages.1 Several studies have evalu-
ated the gene expression profiles of both ductal carcinomas in situ 
(DCIS) and invasive ductal carcinomas (IDC),2-8 but only few 
compared the in situ and invasive components within the same 
breast tumor.5-8 In fact, although some genes have been described 
as differentially expressed between in situ and invasive compo-
nents, the majority of the studies failed to demonstrate signifi-
cant differences between the expression of the codified proteins in 
the neoplastic epithelial cells of DCIS and IDC.5,9 Recently, our 
group, using patient-matched DCIS/IDC tumor samples, showed 
concordance between in situ and invasive molecular profiles in 
94% of the cases.10 These results suggested that the alterations in 
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the tumor microenvironment would have a more important role 
in the progression from an in situ to an invasive phenotype than 
the biology of the tumor cells per se, which showed a tendency to 
be maintained between these both components.
Actually, it is widely accepted that any cancer is a complex 
system composed not only by neoplastic cells but also by a fine-
tuned microenvironment. The first reference to the importance 
of the microenvironment in cancer comes from Paget, with his 
proposal of the “seed and soil” hypothesis. Unexpectedly, this 
concept was “forgotten” and only “recovered” several years later. 
In breast cancer, tumor microenvironment plays a key role in 
defining tumor behavior and patient outcome.11 Gene expression 
changes that occur in cancer-associated stroma are known to be 
implicated in prognosis, as well as in cancer progression.12-14 Ma 
and colleagues, using gene expression profiling, provided strong 
evidence that the stroma co-evolves with the epithelial compart-
ments during cancer progression.12 Analyzing 14 patients with 
matched normal epithelium, normal stroma, tumor epithelium, 
and tumor-associated stroma, the authors proposed that micro-
environment participates in tumorigenesis even before tumor 
cells invade the stroma, and it may play an important role in the 
transition from pre-invasive to invasive growth.12
Caveolin-1 (Cav-1), a scaffolding protein mainly involved in 
vesicular transport, cholesterol homeostasis, and signal transduc-
tion, has been associated to the progression from in situ to inva-
sive carcinoma.15,16 Lisanti and colleagues showed that Cav-1 loss 
in tumor stroma was associated with an increased risk for early 
recurrence, metastasis, and decreased overall survival in breast 
cancer, being also a strong prognostic factor for basal-like breast 
carcinomas.17,18 In DCIS, a loss of stromal Cav-1 was predictive 
of disease recurrence and progression to invasive cancer, since 
all the patients with loss of Cav-1 recurred, and 80% of them 
progressed to invasive disease.16 Moreover, loss of stromal Cav-1 
has been related with stromal MCT4 expression in triple-negative 
breast cancers, also predicting for poor clinical outcome.19 This 
protein is a major transporter directly responsible for L-lactate 
efflux from glycolytic cells and a functional marker of oxidative 
stress and hypoxia.20 In addition, it seems to have a role in stro-
mal breast cancer metabolism, since it has been demonstrated 
that breast cancer cells induce MCT4 overexpression in stromal 
fibroblasts.21
Since stromal expression of MCT4 and the association 
between Cav-1 and MCT4 had never been implicated in the pro-
gression from DCIS to IDC, the aim of this study was to bet-
ter understand the stromal interactions surrounding in situ and 
invasive components of breast carcinomas, evaluating the stromal 
expression of Cav-1 and MCT4 using patient-matched DCIS/
IDC tumor samples.
Results
IHC quantification for Cav-1 and MCT4 was performed on 
each set of the 22 TMA slides using patient-matched DCIS/IDC 
tumor samples. Data on ER, PgR, HER-2, P-cad, CK5, EGFR, 
Ki-67 status, histological grade, and lymph node metastases were 
already available and published for this series.10
Cav-1 and MCT4 expression in normal breast
In normal breast, it can be observed that Cav-1 expression was 
absent from the epithelium, whereas its expression was observed 
in the stromal component, as previously described.16-18 MCT4 
expression was absent in both epithelial and stromal components, 
as observed in Figure 1A.
Stromal Cav-1 expression in the progression from in situ to 
invasive carcinoma
In the DCIS component, only 19 cases (13%) showed no 
Cav-1 expression in the stroma, whereas 55 cases (39%) had 
moderate expression, and the majority had strong expression 
of stromal Cav-1 (67 cases, 48%). In the invasive component, 
the majority (n = 108, 76%) of the cases showed absent Cav-1 
expression in the stroma, with only 27 cases (19%) with moder-
ate expression and 7 cases (5%) with strong expression. Figure 2 
represents the expression levels of stromal Cav-1 in in situ and 
invasive components, where a significant decrease of Cav-1 from 
DCIS to IDC can be observed. An IHC example of Cav-1in in 
situ and invasive components is shown in Figure 3.
Regarding the progression from in situ to invasive carci-
noma, analyzing each case for both matched components, 106 
cases (75%) showed loss of stromal Cav-1 expression, whereas 
35 (25%) cases maintained protein expression. None of the cases 
showed gain of stromal Cav-1 expression.
Stromal MCT4 expression in the progression from in situ to 
invasive carcinoma
Considering the DCIS component, the majority of the cases 
were negative (n = 131, 93%) (Fig. 1B), 10 cases (7%) showed 
moderate expression, and 5 cases (3%) were classified as strong 
for stromal MCT4. In the invasive component, a strong expres-
sion of MCT4 in the stroma of the majority of the cases (n = 73, 
50%) was observed, whereas moderate expression was observed 
in 63 (43%) cases; in the remaining 11 cases (7%), no expression 
of stromal MCT4 was observed.
Figure 4 depicts the expression levels of stromal MCT4 in 
situ and invasive components, showing an increased expression 
of stromal MCT4 in the invasive component. Figure 5 repre-
sents by IHC the strong MCT4 stromal expression in invasive 
component.
Concerning the transition from in situ to invasive carcinoma 
in terms of gains and losses of MCT4 in the stroma, we found 
that 126 cases (87%) gained expression in the invasive compo-
nent, 19 cases (13%) maintained, and none lose the expression.
Combining stromal Cav-1/MCT4 in the progression from 
in situ to invasive carcinoma
Analyzing matched in situ and invasive components for stro-
mal expression of Cav-1 and MCT4 (Table 1), it was possible 
to observe a statistically significant association between the loss 
of stromal Cav-1 and the concomitant gain of MCT4 in the 
same case (P < 0.0001). Interestingly, 75% of the cases that lost 
Cav-1 stromal expression in the transition from in situ to inva-
sive cancer also gained MCT4 expression in the stroma. There 
were only 4 cases (3%) with loss of Cav-1 in the stroma that 
maintained MCT4 expression and 16 cases (12.5%) that gained 
MCT4 and maintained Cav-1 stromal expression. In 12 cases 
(10%), there was the maintenance of stromal expression for both 
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Figure 1. IHC expression of stromal MCT4 in normal and in situ compo-
nent. Absent stromal MCT4 expression can be observed in normal breast 
(A) and in in situ component (B), 200×.
Figure  2. Expression levels of stromal Cav-1 in in situ and invasive 
components of breast carcinomas. It is possible to notice a signi"cant 
decrease of Cav-1 stromal expression from DCIS to IDC.
markers. Figure 6 represents an IHC array with the expression 
levels of these proteins in the progression from in situ to invasive 
carcinoma.
Discussion
The mechanisms that mediate the progression from DCIS 
to IDC in the breast are still largely unknown. However, it is 
now widely acknowledged that accumulation of genetic anoma-
lies contributes to the acquisition of an increasingly aggressive, 
invasive, or therapy-resistant tumor phenotype.1 Nevertheless 
this knowledge did not improve the predictive power of standard 
pathological parameters for breast cancer, nor did it explain the 
mechanisms of invasiveness.
Cav-1 plays an important role in tumor stroma, and recent 
studies demonstrate that the loss of stromal Cav-1 is associated 
with advanced tumor and nodal stage, lymphovascular inva-
sion, metastasis, early recurrence, tamoxifen resistance, and 
reduced progression-free survival in invasive breast cancer.23-25 
Additionally, loss of stromal Cav-1 also has prognostic value in 
a particularly aggressive subgroup of breast cancers, namely the 
triple-negative and basal-like breast carcinomas, whereas high 
levels of this protein were correlated with reduced tumor size, 
low grade, reduced metastasis, and improved survival.18,25,26
Interestingly, loss of stromal Cav-1 also predicts for recurrence 
and early disease progression in DCIS patients. Witkiewicz et al. 
reported that 80% of the DCIS patients, which underwent surgi-
cal excision and recurred with invasive breast cancers, showed 
reduced or absent levels of stromal Cav-1 in these tumors.16 In 
our series, using patient-matched DCIS/IDC tumor samples, it 
was observed that the majority of the cases showed strong expres-
sion of Cav-1 expression in the stroma of DCIS, whereas 76% of 
the cases showed absent expression for this marker in the stroma 
of the invasive counterpart. Thus, regarding the progression to 
invasiveness, it seems that the loss of Cav-1 expression in the 
stroma is important for tumor invasion.
Actually, it has been already described that loss of Cav-1 in 
stromal cells may also increase angiogenesis and tumor growth.15 
Goetz et al. demonstrated that in vivo and in vitro expression 
of Cav-1 in cancer-associated fibroblasts facilitates tumor cells 
invasion and accelerates the in vitro proliferation and in vivo 
tumorigenesis.27,28
Recent data reveals that loss of Cav-1 induces a metabolic 
reprogramming of stromal cells to support the growth of adja-
cent epithelial tumor cells—the “reverse Warburg effect”, where 
cancer cells induce upregulation of multiple glycolytic enzymes 
in neighboring stromal fibroblasts.23,29,30 Cav-1 is degraded result-
ing in a loss of stromal Cav-1 expression.19 At the same time, 
the breast cancer cells induce MCT4 overexpression in stromal 
fibroblasts.19
MCT4 is a monocarboxylate transporter that functions as a 
shuttle to extrude L-lactate from cells using aerobic glycolysis for 
energy metabolism.20 Although the transporter role of MCT4 
has been widely accepted in cancer epithelium, the prognostic 
value of MCT4 expression is highly compartment-specific and 
restricted to the tumor stroma, high stromal MCT4 levels being 
associated to poor patient overall survival.21,31,32 In our series, 
analyzing DCIS and IDC separately, an increase of MCT4 
expression was observed, since in DCIS the majority of the 
cases were negative, whereas, in the invasive counterpart, 50% 
of the cases showed strong expression for MCT4. Considering 
the progression from in situ to invasive breast carcinoma, using 
matched DCIS/IDC tumor samples, 87% cases gained MCT4 
expression, whereas none showed loss of expression, suggest-
ing that the gain of stroma MCT4 provides evidence for the 
existence of a stromal–epithelial lactate shuttle which fuels the 
tumor growth.21
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Regarding the relation between MCT4 and Cav-1 expres-
sion, Witkiewicz et al.,19 using 164 invasive breast cancer sam-
ples, verified that stromal MCT4 and stromal Cav-1 levels were 
inversely related, high levels of stromal MCT4 being directly 
correlated with a loss of stromal Cav-1 immunostaining.19 Most 
notably, cases with absent stromal Cav-1 are most likely to pres-
ent strong stromal staining for MCT4, and, in contrast, cases 
with strong expression for Cav-1 are most likely to be stromal 
MCT4 absent.
Nevertheless, studies regarding the role of Cav-1 and MCT4 in 
the transition from in situ to invasive breast carcinoma were still 
lacking. In our series, using matched DCIS/IDC and analyzing 
the concomitant expression of stromal Cav-1 and MCT4, 75% of 
the cases showed loss of Cav-1 with simultaneous gain of MCT4 
in the stroma, suggesting that these events are important for 
tumor cells to progress and invade.
Our results are explained by the recent “two-compartment 
tumor metabolism” model and the “reverse Warburg effect”, sug-
gesting that the loss of Cav-1 causes the metabolic reprogram-
ming of stromal cells to support the growth of adjacent epithelial 
tumor cells.23 In Figure 7, a hypothetical model summarizing he 
alterations in Cav-1 and MCT4 in the stroma of matched in situ 
and invasive breast carcinoma is shown.
The oxidative stress promoted by the tumor cells induces 
autophagy in cancer-associated fibroblasts (CAFS) that degrade 
Cav-1 in the in situ stromal compartment and also secrete energy-
rich metabolites, such as L-lactate, ketone bodies, and pyruvate 
as a consequence of metabolic alterations. During the progression 
to invasive carcinoma, the loss of Cav-1 induces MCT4 expres-
sion due to the amount of energy metabolites, used to promote 
cancer cell glycolysis, aggressive tumor growth, and, ultimately, 
invasion of breast cancer cells.
Many of the cited studies quantify one or both markers in 
breast cancer stroma. However, one potential limitation of the 
quantification methodologies used is the lack of a clear and repro-
ducible definition of stroma, especially regarding DCIS cases. 
In our case, since all IHC scoring was performed by the same 
experienced pathologist, we consider this does not affect internal 
validity and therefore does not affect the results obtained and 
conclusions drawn.
In summary, it was shown that the loss of stromal Cav-1 and 
the concomitant gain of stromal MCT4 have a putative role in 
Figure 4. Expression levels of stromal MCT4 in in situ and invasive carci-
nomas. There is a signi!cant increased expression of stromal MCT4 in the 
invasive component of breast carcinomas, when compared with DCIS.\
Table 1. Association between stromal Cav-1 and MCT4 expression levels in the transition from in situ to invasive breast carcinoma
MCT4 (in situ to invasive)
Loss of expression N (%) Maintenance of expression N (%) Gain of expression N (%)
Cav-1 (in situ 
to invasive)
Loss of expression N (%) 0 (0%) 4 (3%) 94 (75%)
Maintenance of 
expression N (%) 0 (0%) 12 (10%) 16 (12.5%)
Gain of expression N (%) 0 (0%) 0 (0%) 0 (0%)
P value ≤ 0.001
Figure 3. IHC expression of stromal Cav-1 in in situ and invasive components. Note the strong expression of Cav-1 in DCIS, from low (A and B, 100× and 
200×, respectively) to higher magni!cation (C, 400×).
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the transition from in situ to invasive carcinoma of the breast. 
Therefore, we propose that Cav-1 and MCT4 may represent valu-
able biomarkers for breast cancer progression. Thus, determining 
the nature of the cooperation between tumor cells and the micro-
environment that leads to invasion could identify therapeutic 
strategies to prevent the transition from in situ to invasive breast 
carcinoma.
Material and Methods
Case selection and TMA (tissue microarray) construction
Formalin-fixed and paraffin-embedded samples from 189 
tumors, harboring in situ and invasive carcinoma areas in the 
same block, were consecutively retrieved from our archives. 
Available data included patient’s age and clinicopathological fea-
tures, such as tumor size and lymph nodes status. Representative 
areas of the in situ and invasive breast carcinomas were selected 
on H&E-stained sections and marked on the correspondent 
individual paraffin block. Two tissue cores (2 mm in diameter) 
were obtained from each specimen for TMA construction with 
each TMA block (donor block) and deposited into a paraffin 
block (receptor block) using a TMA workstation (TMA builder 
ab1802, Abcam). In each TMA block, non-neoplastic breast and 
liver tissue cores were also included as controls and TMA guide, 
respectively. An H&E-stained section from each TMA block was 
reviewed to confirm the presence of morphological representative 
areas of the original lesions.
All morphological and IHC assessments were conducted by 
a pathologist (FS). The study was conducted under the national 
regulative law for the handling of biological specimens from 
tumor banks, the samples being exclusively available for research 
purposes in retrospective studies.
Cav-1 and MCT4 immunohistochemistry
IHC was performed using the HRP labeled polymer 
(DakoCytomation) for Cav-1 and with the Ultravision Detection 
System Anti-polyvalent HRP (Lab Vision Corporation) for 
MCT4. Antigen unmasking was performed using a dilution 
of 1:100 from a commercially available solution of citrate buf-
fer, pH = 6.0 (Vector Laboratories) at 98 °C. After the antigen 
retrieval procedure, the slides were washed in a phosphate buf-
fer solution (PBS) and submitted to blockage of the endogenous 
peroxidase activity by incubation of the slides in a 3% hydrogen 
peroxide (Panreac) in methanol (Sigma-Aldrich). The slides were 
further incubated with the primary antibodies for Cav-1 (2297; 
BD Biosciences, diluted 1:50) and for MCT4 (H-90; Santa Cruz 
Biotechnology, diluted 1:500), as previously described.24 All 
Figure 5. IHC expression of stromal MCT4 in in situ and invasive components. Note the strong MCT4 stromal expression in invasive component, from 
low (A and B, 100× and 200×, respectively) to high magni"cation (C, 400×).
Figure 6. Immunohistochemistry array showing protein expression levels of stromal Cav-1 and MCT4 in the progression from in situ to invasive carci-
nomas. Cases are arranged along the x-axis and proteins are arranged along the y-axis. Within the heat map, red represents gain of expression, green 
represents loss of expression, and yellow represents maintained expression from in situ to invasive carcinoma within the same case.
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reactions were revealed with diaminobenzidine (DAB) chromo-
gen (DakoCytomation).
For both IHC assays, positive controls were included in each 
run, in order to guarantee the reliability of the assays. Non-
neoplastic breast tissues, as well as normal breast surrounding the 
neoplastic cells, were considered internal controls.
Cav-1 and MCT4 immunohistochemistry evaluation
Cav-1 and MCT4 expression in stroma were evaluated using 
the previously described methodology.16-19,21 In summary, Cav-1 
and MCT4 were semi-quantitatively scored as negative (0, no 
staining), weak (1, either diffuse weak or strong staining in less 
than 30% of stromal cells per core), or strong (2, defined as 
strong staining in 30% or more of the stromal cells).21
Statistical analysis
Statistical analyses were conducted using StatView 5.0 sof-
ware (SAS Institute Inc). The associations between categorical 
variables were tested for statistical significance using the chi-
square test. A two-tailed significance level of 5% was considered 
as statistically significant (P < 0.05).
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Figure 7. Alterations in Cav-1 and MCT4in the stroma of matched in situ and invasive breast carcinoma. (A) H&E-stained tissue section of human breast 
cancer, showing in situ and invasive components of breast carcinoma (100×). (B) Hypothetical model summarizing the importance of Cav-1 and MCT4 
in the progression from DCIS to IDC. During the progression to invasive carcinoma, Cav-1 is degraded by oxidative stress-induced autophagy in cancer-
associated "broblasts, resulting in a loss of Cav-1. At the same time, the loss of Cav-1 induces a metabolic reprogramming of stromal cells, where cancer 
cells induce upregulation of MCT4 by stromal "broblasts, in invasive counterpart.
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ABSTRACT:
P-cadherin is a classical cell-cell adhesion molecule that, in contrast to 
E-cadherin, has a positive role in breast cancer progression, being considered a poor 
prognostic factor in this disease. In previous reports, we have shown that this protein 
induces cancer stem cell and invasive properties to basal-like breast cancer cells. 
Here, we clarify the downstream signaling pathways that are triggered by P-cadherin 
to mediate these effects.
:HGHPRQVWUDWHG WKDW 3FDGKHULQ LQKLELWLRQ OHG WR D VLJQL¿FDQW GHFUHDVHG
adhesion of cancer cells to the basement membrane substrate laminin, as well 
DVWRDPDMRUUHGXFWLRQLQWKHH[SUHVVLRQRIWKHODPLQLQUHFHSWRUĮǃLQWHJULQ
5HPDUNDEO\WKHH[SUHVVLRQRIWKLVKHWHURGLPHUZDVUHTXLUHGIRUWKHLQYDVLYHFDSDFLW\
DQGLQFUHDVHGPDPPRVSKHUHIRUPLQJHI¿FLHQF\LQGXFHGE\3FDGKHULQH[SUHVVLRQ
0RUHRYHUZHVKRZHGWKDW3FDGKHULQWUDQVFULSWLRQDOO\XSUHJXODWHVWKHĮLQWHJULQ
VXEXQLWH[SUHVVLRQDQGGLUHFWO\LQWHUDFWVZLWKWKHǃLQWHJULQVXEXQLW:HVWLOOVKRZHG
that P-cadherin downstream signaling, in response to laminin, involves the activation 
of focal adhesion (FAK), Src and AKT kinases. The association between the expression 
RI3FDGKHULQĮǃKHWHURGLPHUDQGWKHDFWLYH)$.DQG6UFSKRVSKRU\ODWHGIRUPV
was validated in vivo.
Our data establish that there is a crosstalk between P-cadherin and the laminin 
UHFHSWRUĮǃLQWHJULQVLJQDOLQJSDWKZD\ZKLFKOLQNKDVQHYHUEHHQSUHYLRXVO\
described. The activation of this heterodimer explains the stem cell and invasive 
properties induced by P-cadherin to breast cancer cells, pointing to a new molecular 
mechanism that may be targeted to counteract the effects induced by this adhesion 
molecule.
INTRODUCTION
Cadherin molecules have a major role in tumor 
SURJUHVVLRQ $ VLJQL¿FDQW H[DPSOH LV (FDGKHULQ IRU
ZKLFKDWXPRUVXSSUHVVRUIXQFWLRQZDVDOUHDG\GHVFULEHG
LQ WKH PDMRULW\ RI KXPDQ FDQFHU PRGHOV ,Q IDFW RQH
RIWKH¿UVWVWHSVLQWKHPHWDVWDWLFFDVFDGHLVWKHORVVRU
GRZQUHJXODWLRQRI(FDGKHULQH[SUHVVLRQRUIXQFWLRQE\
FDQFHUFHOOVDQGLWLVNQRZQWKDWPXWDWLRQVRILWVFRGLI\LQJ
gene (CDH1LQFUHDVHVWKHULVNWRGHYHORSSDUWLFXODUW\SHV
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RIEUHDVWDQGJDVWULFFDQFHUV>@3FDGKHULQRQWKHRWKHU
KDQG KDV D SURPRWLQJ HIIHFW LQ VHYHUDO VROLG WXPRUV
LQFOXGLQJ WKH RQHV IURP SDQFUHDV SURVWDWH FRORQ DQG
EUHDVW >@ ,QGHHGZH KDYH SUHYLRXVO\ GHPRQVWUDWHG
WKDW 3FDGKHULQ LV D SRRU SURJQRVWLF IDFWRU IRU EUHDVW
FDQFHUSDWLHQWVEHLQJVLJQL¿FDQWO\DVVRFLDWHGZLWKODFNRI
FHOOGLIIHUHQWLDWLRQDQGKLJKJUDGHFDUFLQRPDV>@,WV
H[SUHVVLRQZDVIRXQGWREHXSUHJXODWHGLQWKHSDUWLFXODUO\
DJJUHVVLYHEDVDOOLNHPROHFXODUVXEW\SH>@DQGin 
vitroVWXGLHVIURPRXUJURXSKDYHVKRZQWKDW3FDGKHULQ
LQFUHDVHV FHOO LQYDVLRQ DQG PRWLOLW\ >@ DV ZHOO DV
LQGXFHVWKHVHFUHWLRQDQGDFWLYDWLRQRIPHWDOORSURWHLQDVHV
WR WKH H[WUDFHOOXODU PDWUL[ (&0 >@ 5HFHQWO\ ZH
IXUWKHUGHVFULEHGLWVFDSDFLW\WRLQGXFHVWHPFHOOSURSHUWLHV
LQEDVDOOLNHEUHDVWFDQFHUPRGHOV>@
7KH PDLQWHQDQFH RI VWHP FHOO DFWLYLW\ UHTXLUHV
VLJQDOLQJPHGLDWHGE\WKH(&0DQGE\(&0UHFHSWRUV
DOVR NQRZQ DV LQWHJULQV >@ ,QWHJULQV SOD\ D PDMRU
UROH LQ WKH LQWHJUDWLRQ RI VLJQDOV IRUP WKH H[WHUQDO
PLFURHQYLURQPHQWDQGIURPWKHFHOOLQWHUQDOPLOLHX,QWKH
QRUPDOEUHDVWWKHEDVDOP\RHSLWKHOLDOFHOOVDUHLQGLUHFW
FRQWDFWZLWKWKHEDVHPHQWPHPEUDQHZKLFKLVFRPSRVHG
RIDFRPSOH[PL[WXUHRI(&0PROHFXOHVWKDWFRQWULEXWH
WRWKHVXUYLYDODQGDGKHVLRQVLJQDOLQJRIHSLWKHOLDOFHOOV
DQGWRWKHPDLQWHQDQFHRIWKHVWHPFHOOQLFKHZLWKLQWKLV
WLVVXH,QWHUHVWLQJO\3FDGKHULQLVDOVRH[SUHVVHGE\WKLV
EDVDOFHOOOD\HUDQGZHKDYHSUHYLRXVO\GHPRQVWUDWHGWKDW
LWLVFRH[SUHVVHGZLWKĮLQWHJULQ(&0DGKHVLRQUHFHSWRU
RU&'ILQDSRSXODWLRQRIFHOOVWKDWVKRZVWHPOLNH
SURSHUWLHV>@
$OWHUDWLRQVLQWKH(&0RULQWKHLQWHJULQH[SUHVVLRQ
DUHLPSOLFDWHGLQWKHLQLWLDWLRQDQGSURJUHVVLRQRIEUHDVW
FDQFHU > @ )RU H[DPSOH (&0 UHPRGHOLQJ DQG
LQWHJULQDFWLYDWLRQDVVLVWLQWKHPDOLJQDQWWUDQVIRUPDWLRQ
RIFHOOV LQ WKHSULPDU\VLWHDVZHOODV LQ WKHDFWLYDWLRQ
RITXLHVFHQWFHOOVLQGLVWDQWPHWDVWDWLFVLWHVVXFKDVWKH
ERQHOLYHUOXQJDQGEUDLQ>@,QQRUPDOEUHDVWWKH
EDVHPHQWPHPEUDQHKDVDFUXFLDOUROHLQOLPLWLQJWXPRU
SURJUHVVLRQEHLQJFRPSRVHGPDLQO\E\FROODJHQ W\SH
,9 DQG VHYHUDO ODPLQLQV >@ EXW LQ FDQFHU HOHYDWHG
H[SUHVVLRQ RI ODPLQLQ LV FRQVLGHUHG D SRRU SURJQRVWLF
IDFWRU > @ ,Q IDFW DEQRUPDO RYHUH[SUHVVLRQ RI
ODPLQLQIRUPHUO\NQRZQDVODPLQLQLVSUHVHQWLQ
WKHPLJUDWLQJHGJHRIWKHWXPRUPDVVDQGWKHH[SUHVVLRQ
RIODPLQLQUHFHSWRUVDUHEHOLHYHGWRSURPRWHLQYDVLRQRI
EUHDVW FDQFHUFHOOV >@$OWKRXJKVHYHUDO LQWHJULQV
UHFRJQL]H ODPLQLQ VXEVWUDWHV WKH Į LQWHJULQV Įȕ
DQG Įȕ DUH WKH PDMRU UHFHSWRUV WKDW FRQWULEXWH WR
EUHDVW FDQFHU SURJUHVVLRQ > @ 7KXV WKH UROH RI
WKH KHWHURGLPHU Įȕ LQ WXPRU SURJUHVVLRQ KDV EHHQ
H[WHQVLYHO\LQYHVWLJDWHG$EHUUDQWDFWLYDWLRQRIWKHĮȕ
UHFHSWRU LV LPSOLFDWHG LQ FHOO VXUYLYDO PLJUDWLRQ DQG
LQYDVLYHSRWHQWLDO >@ ,QWHUHVWLQJO\ WKHH[SUHVVLRQ
RIWKHȕLQWHJULQVXEXQLWLVDVVRFLDWHGZLWKSRRUEUHDVW
FDQFHUSDWLHQWSURJQRVLV>@DQGVSHFL¿FDOO\ZLWKWKH
EDVDOOLNHPROHFXODUVXEW\SH>@$OWKRXJKPLFHLQZKLFK
ȕLQWHJULQZDVLQDFWLYDWHGLQWKHPDPPDU\JODQGKDYH
DQRUPDOEUHDVWGHYHORSPHQW>@ WKLVLQWHJULQVXEXQLW
ZDVIRXQGWREHFUXFLDOIRUEUHDVWFDQFHUSURJUHVVLRQ>@
)XUWKHUPRUHRYHUH[SUHVVLRQRI WKHĮ LQWHJULQ VXEXQLW
ZDVIRXQGLQLQYDVLYHEUHDVWFDUFLQRPDVFRUUHODWLQJZLWK
GHFUHDVHGRYHUDOOSDWLHQWVXUYLYDO>@EHLQJDQLPSRUWDQW
EUHDVWVWHPFHOOPDUNHULQERWKPLFHDQGKXPDQV>@
$PDMRUUROHKDVEHHQDOVRSURSRVHGIRUȕLQWHJULQVXEXQLW
LQWKHQRUPDOGHYHORSPHQWRIWKHPXULQHEUHDVWEHLQJDQ
LPSRUWDQWPDUNHURIQRUPDOPXULQHVWHPFHOOV>@DQG
UHJXODWLQJWKHDELOLW\RIWKHVWHPFHOOVWRVHOIUHQHZDQG
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RIDSRO\RPDYLUXVPLGGOH7DQWLJHQ3\07WUDQVJHQLF
PRXVHPRGHOFRPSOHWHO\EORFNHGWXPRUIRUPDWLRQ>@
7KXV WKH FURVVWDON EHWZHHQ FHOOFHOO DQG FHOO
(&0 DGKHVLRQ FRPSOH[HV UHÀHFWV D KLJKO\ LQWHJUDWHG
LQWUDFHOOXODU QHWZRUN ,QWHJULQ DQG FDGKHULQ DGKHVLRQ
PROHFXOHVRIWHQFRRSHUDWHDFWLYDWLQJWKHVDPHVLJQDOLQJ
SDWKZD\VDQGHOLFLWLQJVLPLODUFHOOXODUIXQFWLRQVWKDWDUH
SDUWRIDODUJHUDGKHVLYHVWUXFWXUH,QFDQFHUDQDVVRFLDWLRQ
RIFDGKHULQVDQGLQWHJULQVFDQRULJLQDWHFRPSOH[HVWKDW
PHGLDWH LPSRUWDQW RQFRJHQLF UHVSRQVHV RIWHQ WKURXJK
LQWHUDFWLRQ ZLWK RWKHU WUDQVPHPEUDQH SURWHLQV VXFK
DVJURZWKIDFWRUUHFHSWRUV6HYHUDOUHSRUWVIRFXVRQWKH
DVVRFLDWLRQ RI(FDGKHULQZLWK LQWHJULQPROHFXOHV >
@EXWQRLQWHUDFWLRQEHWZHHQ3FDGKHULQDQGLQWHJULQ
PROHFXOHV KDV HYHU EHHQ GHVFULEHG 3FDGKHULQ LVZHOO
GHVFULEHG DV KDYLQJ D UROH LQ FHOOFHOO LQWHUDFWLRQV
KRZHYHU LWV UROH LQ FHOO(&0 LQWHUDFWLRQ UHPDLQV
FRPSOHWHO\XQNQRZQ
7KH DLP RI WKLV VWXG\ ZDV WR ¿QG RXW LI WKH
3FDGKHULQLQGXFHGDJJUHVVLYHIHDWXUHVZHUHGHSHQGHQW
RQ PLFURHQYLURQPHQW VLJQDOV LQ SDUWLFXODU WKH (&0
FRPSRQHQWV DQG LQWHJULQ UHFHSWRUV +HUHZLWK ZH
GHPRQVWUDWHGWKDW3FDGKHULQLVQHHGHGIRUEUHDVWFDQFHU
FHOODGKHVLRQWRVSHFL¿F(&0FRPSRQHQWV7KHH[SUHVVLRQ
RI WKH ODPLQLQ UHFHSWRU Įȕ LQWHJULQ ZDV IRXQG WR
GHSHQGRQ3FDGKHULQH[SUHVVLRQ0RUHRYHUWKLVLQWHJULQ
KHWHURGLPHUZDVLQYROYHGLQWKHPDPPRVSKHUHIRUPDWLRQ
DELOLW\LQGXFHGE\3FDGKHULQH[SUHVVLRQLQEUHDVWFDQFHU
FHOOV$QHZVLJQDOLQJPHFKDQLVPWULJJHUHGE\3FDGKHULQ
LVGHVFULEHGWKDWLQYROYHVWKHDFWLYDWLRQRI)$.6UFDQG
$.7NLQDVHVLQUHVSRQVHWRODPLQLQ
RESULTS 
P-cadherin expression potentiates the adhesion of 
basal-like breast cancer cells to laminin 
7KH UROH RI 3FDGKHULQ DV D FHOOFHOO DGKHVLRQ
PROHFXOHLVZHOOGRFXPHQWHGKRZHYHULWVUROHLQFHOO
(&0DGKHVLRQLVFRPSOHWHO\XQNQRZQ7KXVWKHDGKHVLRQ
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RI FDQFHU FHOOV WR VHYHUDO (&0 FRPSRQHQWV W\SLFDOO\
implicated in tumour progression was assessed. 
7KH EDVDOOLNH HSLWKHOLDO EUHDVW FDQFHU FHOO OLQHV
0'$0'DQG%7ZHUHXVHGDVPRGHOV\VWHPV
ZKLFK DUH FKDUDFWHUL]HG E\ WKH SRVLWLYH H[SUHVVLRQ RI
(FDGKHULQ QHJDWLYLW\ IRU KRUPRQHUHFHSWRUV ODFN RI
+(5DPSOL¿FDWLRQDQGKLJK OHYHOVRIEDVDOPDUNHUV
LQFOXGLQJ KLJK H[SUHVVLRQ RI (*)5 DQG 3FDGKHULQ
7UDQVLHQW NQRFNGRZQ RI 3FDGKHULQ ZDV SHUIRUPHG
E\ VL51$  LQKLELWLRQ LQ0'$0% DQG 
LQKLELWLRQLQ%7DWWKHSURWHLQOHYHODQGDGKHVLRQWR
FROODJHQW\SH,FROODJHQW\SH,9ODPLQLQYLWURQHFWLQ
DQG ¿EURQHFWLQ ZDV PHDVXUHG E\ WKH FU\VWDOYLROHW
DGKHVLRQDVVD\)LJXUH
0'$0% DQG %7 FRQWURO FHOOV
SUHIHUHQWLDOO\DGKHUHGWRFROODJHQW\SH,DQGYLWURQHFWLQ
IROORZHG E\ D PRGHUDWH DGKHVLRQ WR FROODJHQ W\SH,9
ODPLQLQDQG¿EURQHFWLQ$GKHVLRQRIERWKFHOOOLQHV
WRSODVWLFZDVDSSUR[LPDWHO\IRU0'$0%FHOOV
DQGIRU%7FHOOV)LJXUH$:KHQ3FDGKHULQ
ZDV LQKLELWHG LQ 0'$0% FHOOV DGKHVLRQ WR
ODPLQLQYLWURQHFWLQDQG¿EURQHFWLQZDVVLJQL¿FDQWO\
UHGXFHGE\DERXWZKHUHDVDGKHVLRQWRWKHFROODJHQ
PROHFXOHVW\SH,DQG,9ZDVQRWDIIHFWHG)LJXUH$DQG
%)RUWKH%7FHOOOLQHDVLJQL¿FDQWGHFUHDVH
LQWKHDGKHVLRQWRWKHODPLQLQVXEVWUDWHZDVVSHFL¿FDOO\
REVHUYHGDIWHU3FDGKHULQNQRFNGRZQ)LJXUH$
P-cadherin regulates the expression of the laminin 
UHFHSWRUĮȕLQWHJULQLQEUHDVWFDQFHUFHOOV
6LQFH 3FDGKHULQ UHJXODWHV WKH DGKHVLRQ RI
FDQFHU FHOOV WR VSHFL¿F (&0 FRPSRQHQWV ZH VHW RXW
WR LQYHVWLJDWH ZKHWKHU WKLV HIIHFW ZDV PHGLDWHG E\
DQ\ DOWHUDWLRQ LQ WKH H[SUHVVLRQ RI LQWHJULQV WKHPDLQ
UHFHSWRUV LQYROYHG LQ (&0FHOO DGKHVLRQ ȕ LQWHJULQ
LV D PDMRU FRPSRQHQW RI PRVW LQWHJULQ KHWHURGLPHUV
UHFRJQL]LQJVHYHUDO(&0FRPSRQHQWVLQFOXGLQJODPLQLQ
YLWURQHFWLQDQG¿EURQHFWLQ9LWURQHFWLQDQG¿EURQHFWLQDUH
DOVRUHFRJQL]HGE\5*'LQWHJULQUHFHSWRUVVSHFL¿FDOO\
FRQWDLQLQJȕĮ9DQGĮLQWHJULQVXEXQLWV>@/DPLQLQ
LVPDLQO\UHFRJQL]HGE\LQWHJULQVWKDWFRQWDLQĮDQGȕ
VXEXQLWVZKLFKELQGH[FOXVLYHO\WRWKLV(&0VXEVWUDWH
DQGLWLVGHVFULEHGDVKDYLQJLPSRUWDQWWXPRUSURPRWLQJ
HIIHFWVLQEUHDVWFDQFHU>@%DVHGRQWKLVNQRZOHGJH
ZHDQDO\]HGWKHVXUIDFHH[SUHVVLRQRIȕȕȕĮĮ
DQGĮ9LQWHJULQVXEXQLWVE\ÀRZF\WRPHWU\LQWKH0'$
0% DQG %7 EDVDOOLNH EUHDVW FDQFHU PRGHOV
ZLWKRUZLWKRXWWKHVLOHQFLQJRI3FDGKHULQWUDQVFULSWVE\
VL51$
$VVKRZQLQ)LJXUHWKHLQKLELWLRQRI3FDGKHULQ
Figure 1: Adhesion of basal-like breast cancer cell lines to extracellular matrix (ECM) components is dependent 
on P-cadherin expression. $ ,QKLELWLRQ RI 3FDGKHULQ H[SUHVVLRQ LQ0'$0% FHOOV GHFUHDVHG DGKHVLRQ WR ODPLQLQ
YLWURQHFWLQDQG¿EURQHFWLQDGKHVLRQWLPH PLQ$VLJQL¿FDQWGHFUHDVHLQFHOODGKHVLRQZDVDOVRREVHUYHGIRU%7FHOOOLQHLQODPLQLQ
DGKHVLRQWLPH PLQ%%ULJKW¿HOGLPDJHVRI0'$0%FHOOVLQWKHWLVVXHFXOWXUHSODWHFRDWHGZLWK(&0VXEVWUDWHVDIWHUWKH
DGKHVLRQDVVD\&HOOVZHUH¿[HGDQGWKHQXFOHLVWDLQHGZLWKFU\VWDOYLROHW&ROO,±FROODJHQ,&ROO,9±FROODJHQ,9/DP±ODPLQLQ
9LW±YLWURQHFWLQ)LE±¿EURQHFWLQ%6$±ERYLQHVHUXPDOEXPLQQHJDWLYHFRQWURO
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H[SUHVVLRQKDGQRHIIHFW LQ WKHH[SUHVVLRQRIȕRUȕ
LQWHJULQVLQERWKFHOOOLQHVDQDO\]HG'HVSLWHKDYLQJIRXQG
DUHGXFWLRQLQWKHĮDQGĮ9LQWHJULQVXEXQLWVLQ0'$
0%FHOOVQRGLIIHUHQFHVZHUHIRXQGLQWKHFHOOVXUIDFH
H[SUHVVLRQ RI WKHVH LQWHJULQV LQ %7 1RWHZRUWK\
3FDGKHULQ NQRFNGRZQ FDXVHG D UHGXFWLRQ LQ WKH FHOO
VXUIDFH H[SUHVVLRQ RI WKH Į DQG ȕ LQWHJULQ VXEXQLWV
LQERWKFHOO OLQHV )LJXUH$ ,QWHUHVWLQJO\ĮDQGȕ
IRUP D KHWHURGLPHU DOVR NQRZQ DV KHPLGHVPRVRPH
in normal cells) that recognizes the major component 
RIWKHEDVHPHQWPHPEUDQH ODPLQLQIRUZKLFKZH
GHPRQVWUDWHGWKDWDGKHVLRQZDVLPSDLUHGXSRQ3FDGKHULQ
NQRFNGRZQLQERWKFHOOOLQHVDQDO\]HG)LJXUH$
)XUWKHUPRUHWKHH[SUHVVLRQRIĮDQGȕVXEXQLWV
ZDV DOVR HYDOXDWHG E\ LPPXQRÀXRUHVFHQFH DQG
LPPXQREORWWLQJFRQ¿UPLQJDGHFUHDVHLQWKHWRWDODPRXQW
RIWKHVHLQWHJULQVLQEUHDVWFDQFHUFHOOVDIWHU3FDGKHULQ
NQRFNGRZQ )LJXUH $ DQG6XSSOHPHQWDU\)LJXUH 
7KH GHFUHDVH LQ WKH Į LQWHJULQ SURWHLQ H[SUHVVLRQ LV
DFFRPSDQLHGE\DGHFUHDVHLQWKHP51$OHYHOVRIWKHĮ
LQWHJULQITGA6JHQHZKHUHDVWKHP51$OHYHOVRIWKHȕ
LQWHJULQITGB4JHQHDUHQRWDIIHFWHG)LJXUH%6LQFH
ODWHUDOLQWHJULQFDGKHULQDVVRFLDWLRQVDUHNQRZQWRRFFXU
>@ZHDOVR WHVWHG WKHH[LVWHQFHRIDSK\VLFDO
LQWHUDFWLRQ EHWZHHQ 3FDGKHULQ DQG Įȕ LQWHJULQ WKH
ȕ LQWHJULQ VXEXQLW DQG 3FDGKHULQ ZHUH DEOH WR FR
LPPXQRSUHFLSLWDWH)LJXUH&
3FDGKHULQDQGWKHĮLQWHJULQFRQIHUVWHPFHOO
properties and invasive features to breast cancer 
cells 
6LQFH 3FDGKHULQ H[SUHVVLRQ LPSDFWV FHOO
(&0 DGKHVLRQ DQG FOHDUO\ PRGL¿HV LQWHJULQ Įȕ
H[SUHVVLRQLQEUHDVWFDQFHUFHOOVZHVHWRXWWRVWXG\LI
this integrin heterodimer was also implicated in the 
DJJUHVVLYHSURSHUWLHVWKDWKDYHEHHQSUHYLRXVO\DVFULEHG
WR 3FDGKHULQ QDPHO\ WKH LQYDVLYH FDSDFLW\ DQG WKH
PDPPRVSKHUHIRUPLQJDELOLW\)XUWKHUPRUHWRFODULI\WKH
FURVVWDONEHWZHHQ3FDGKHULQDQGĮȕLQWHJULQWKHHIIHFW
RIERWKĮDQGȕLQWHJULQVXEXQLWVLQWKHH[SUHVVLRQOHYHOV
RI3FDGKHULQZHUHDOVRVWXGLHG
,QKLELWLRQRIĮȕLQEUHDVWFDQFHUFHOOVVLJQL¿FDQWO\
GHFUHDVHGWKHPDPPRVSKHUHIRUPLQJHI¿FLHQF\0)(
DVZHOO DV WKH LQYDVLRQ FDSDFLW\ SUHFLVHO\ LQ WKH VDPH
PDJQLWXGHDV WKHRQH LQGXFHGE\3FDGKHULQ LQKLELWLRQ
)LJXUH$DQG%,PSRUWDQWO\ĮLQWHJULQLQKLELWLRQ
DORQH VKRZHG WKH VDPH LPSDFW LQ 0)( DQG LQ WKH
LQYDVLRQSRWHQWLDODVWKHLQKLELWLRQRI3FDGKHULQRUWKH
)LJXUH3FDGKHULQNQRFNGRZQUHGXFHVLQWHJULQĮ
DQGȕH[SUHVVLRQLQ0'$0%DQGLQ%7FHOOV
&HOO VXUIDFH H[SUHVVLRQ RI 3FDGKHULQ DQG LQWHJULQ PROHFXOHV
ZDV DQDO\]HG E\ ÀRZ F\WRPHWU\ 7KH PHGLDQ LQWHQVLW\ RI
LQWHJULQVĮDQGȕVWDLQZDVGHFUHDVHGXSRQ3FDGKHULQNQRFN
GRZQ1RHIIHFWZDVREVHUYHGLQWKHH[SUHVVLRQRIWKHLQWHJULQ
VXEXQLWVȕRUȕ
)LJXUH3FDGKHULQFRQWUROV WKHH[SUHVVLRQRIĮȕ
integrin heterodimer in basal-like breast cancer cell 
lines. 7UDQVLHQW LQKLELWLRQ RI WKH 3FDGKHULQ&'+ JHQH LQ
0'$0% DQG %7 FHOOV OHDGV WR D GHFUHDVH LQ WKH
H[SUHVVLRQRIĮDQGȕLQWHJULQVXEXQLWVPHDVXUHGE\ZHVWHUQ
EORW $ WKHP51$ OHYHO RI Į LQWHJULQ,7*$ LV GHFUHDVHG
XSRQ3FDGKHULQVLOHQFLQJZKHUHDVȕLQWHJULQ,7*%P51$
OHYHO LV XQDIIHFWHG % &RLPPXQRSUHFLSLWDWLRQ H[SHULPHQWV
VKRZ WKDW 3FDGKHULQ GLUHFWO\ LQWHUDFWV ZLWK WKH ȕ LQWHJULQ
VXEXQLWEXWQRWZLWKWKHĮLQWHJULQVXEXQLWLQWKHVHFHOOVWKH
%7FHOOOLQHLVUHSUHVHQWHG
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UHSUHVVLRQRIWKHĮȕKHWHURGLPHU+RZHYHULQKLELWLRQ
RIWKHȕLQWHJULQVXEXQLWLQEUHDVWFDQFHUFHOOVGLGQRW
VKRZDVWDWLVWLFDOO\VLJQL¿FDQWLPSDFWLQWKHVHIXQFWLRQDO
SURSHUWLHV )LJXUH $ DQG % 7KHVH UHVXOWV LQGLFDWH
WKDW 3FDGKHULQ GRZQVWUHDP VLJQDOLQJ HIIHFWV FRXOG EH
SULPDULO\GHSHQGHQWRQWKHĮLQWHJULQVXEXQLWIXQFWLRQ
,WLVDOVRLQWHUHVWLQJWRQRWHWKDWZKLOH3FDGKHULQ
NQRFNGRZQ FDXVHG D UHGXFWLRQ LQ Į DQG ȕ LQWHJULQ
VXEXQLWV WKH RSSRVLWH ZDV QRW WUXH )LJXUH & 7KH
LQKLELWLRQRIĮDQGRUȕLQWHJULQVVKRZHGQRHIIHFWLQ
3FDGKHULQH[SUHVVLRQ1RQHWKHOHVVĮLQWHJULQNQRFN
GRZQOHGWRDGHFUHDVHLQWKHH[SUHVVLRQRILWVSDUWQHUWKH
ȕLQWHJULQVXEXQLWSRLQWLQJWKDW3FDGKHULQPD\LQIDFW
EHFRQWUROOLQJWKHĮVXEXQLWH[SUHVVLRQZKLFKLQWXUQ
FRQWUROVWKHȕVXEXQLWDVDOUHDG\VKRZQE\.OLQRZVND
DQGFROOHDJXHV>@,QVXPPDU\WKHIXQFWLRQDOSURSHUWLHV
DWWULEXWHG WR 3FDGKHULQ H[SUHVVLRQZHUH RQO\ DIIHFWHG
ZKHQ WKH Į LQWHJULQ VXEXQLW RU WKH Įȕ LQWHJULQ
KHWHURGLPHUZHUHLQKLELWHGWKHLQKLELWLRQRIȕLQWHJULQ
VXEXQLWKDGQRHIIHFWLQ0)(DQGLQYDVLRQ
P-cadherin overexpressing cells have increased 
adhesion to laminin as well as increased 
mammosphere forming ability and these 
SURSHUWLHV DUH GHSHQGHQW RQ Įȕ LQWHJULQ
expression
7KHSUHYLRXVUHVXOWVLQGLFDWHGWKDWWKHUHFRXOGEHD
FURVVWDONEHWZHHQWZRDGKHVLRQPROHFXOHV3FDGKHULQDQG
ĮLQWHJULQ7KXVWRIXUWKHUH[SORUHWKHUROHRIĮLQWHJULQ
DQGLWVSDUWQHUȕLQWHJULQ LQ WKHIXQFWLRQDOSURSHUWLHV
PHGLDWHG E\ 3FDGKHULQ ZH DQDO\]HG WKH FHOOODPLQLQ
DGKHVLRQFDSDFLW\DQGWKH0)(RIDEUHDVWFDQFHUFHOOOLQH
FRQVWLWXWLYHO\RYHUH[SUHVVLQJ3FDGKHULQ 0&)$=3
FDG DQG FRPSDUHG WKHVH SURSHUWLHVZLWK FRQWURO FHOOV
ZKLFKKDYHORZOHYHOVRI3FDGKHULQ0&)$=PRFN
3FDGKHULQH[SUHVVLRQZDVDFFRPSDQLHGE\DQLQFUHDVH
LQ WKH H[SUHVVLRQ RI ERWK WKH Į LQWHJULQ VXEXQLW DV
ZHOODVWKHȕLQWHJULQVXEXQLW)LJXUH$,PSRUWDQWO\
3FDGKHULQXSUHJXODWLRQOHGWRDQLQFUHDVHLQWKHDGKHVLRQ
RI 0&)$=3FDG FHOOV RQ WRS RI D ODPLQLQ FRDWHG
)LJXUH,QKLELWLRQRIĮȕLQWHJULQGHFUHDVHVWKHPDPPRVSKHUHIRUPLQJHI¿FLHQF\0)(LQEUHDVWFDQFHUFHOOVWR
the same extent as inhibition of P-cadherin (A). ,QWKHVDPHZD\WKHLQYDVLRQFDSDFLW\RIWKHVHFHOOVLQPDWULJHOZDVVHYHUHO\
FRPSURPLVHGZKHQ3FDGKHULQRUĮȕLQWHJULQZHUHNQRFNHGGRZQ%DOWKRXJKWKHH[SUHVVLRQRIWKHĮDQGȕVXEXQLWVLVGHFUHDVHG
XSRQ3FDGKHULQNQRFNGRZQWKHH[SUHVVLRQRI3FDGKHULQLVQRWDIIHFWHGDIWHUWKHLQKLELWLRQRIHLWKHUĮLQWHJULQRUȕLQWHJULQRUERWK
LQWHJULQVDWWKHVDPHWLPH&5HVXOWVIRUWKH%7FHOOOLQHDUHVKRZQLQWKH¿JXUH6LPLODUUHVXOWVZHUHREVHUYHGIRUWKHRWKHUEDVDOOLNH
FHOOOLQH0'$0%
Figure 5: P-cadherin overexpression induces increased adhesion to laminin-332 and increased mammosphere forming 
FDSDFLW\ LQ D Įȕ LQWHJULQ GHSHQGHQWPDQQHU 3FDGKHULQ RYHUH[SUHVVLRQ LQ0&)$= FHOOV 0&)$=3FDG LQGXFHV WKH
H[SUHVVLRQRIĮ DQGȕ LQWHJULQ VXEXQLWV 9V0&)$=PRFNFHOOVPHDVXUHGE\ZHVWHUQEORW $3FDGKHULQRYHUH[SUHVVLRQ DOVR
LQGXFHGLQFUHDVHGDGKHVLRQWRODPLQLQHYDOXDWHGE\WKHDGKHVLRQDVVD\DGKHVLRQWLPH PLQ%DQGLQFUHDVHGPDPPRVSKHUH
IRUPLQJHI¿FLHQF\0)(&,QKLELWLRQRIWKHĮȕLQWHJULQKHWHURGLPHULQWKH3FDGKHULQRYHUH[SUHVVLQJFHOOVUHVWRUHGWKHOHYHOVRI
DGKHVLRQWRWKHFRQWUROOHYHOVDQGVWURQJO\LQKLELWHGWKH0)(LQWKHVHFHOOV3FDGKHULQH[SUHVVLRQZDVXQDIIHFWHGE\ĮȕLQWHJULQNQRFN
down.
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VXUIDFH )LJXUH % DQG LQFUHDVHG WKH PDPPRVSKHUH
IRUPLQJDELOLW\RIWKHVHFHOOV)LJXUH&7KHVHHIIHFWV
ZHUH PHGLDWHG DW OHDVW SDUWLDOO\ E\ Įȕ LQWHJULQ
H[SUHVVLRQVLQFHWKHOHYHOVRIWKLVLQWHJULQKHWHURGLPHU
DUHLQFUHDVHGLQ3FDGKHULQRYHUH[SUHVVLQJFHOOV)LJXUH
$ZKHQ ERWK LQWHJULQ VXEXQLWVZHUH VLPXOWDQHRXVO\
NQRFNHGGRZQLQ0&)$=3FDGFHOOVWKHVHIXQFWLRQDO
SURSHUWLHVZHUH VLJQL¿FDQWO\ UHGXFHG )LJXUH  2QFH
PRUH3FDGKHULQOHYHOVZHUHQRWDIIHFWHGE\ĮȕLQWHJULQ
NQRFNGRZQLQGLFDWLQJWKDWWKHVHLQWHJULQPROHFXOHVDUH
PRVWOLNHO\DFWLQJGRZQVWUHDPRI3FDGKHULQDFWLYDWLRQ
)LJXUH$
Integrin signaling in response to laminin-332 is 
dependent on P-cadherin expression
7KHSUHYLRXVGDWDHVWDEOLVKHGDFURVVWDONEHWZHHQ
3FDGKHULQDQGĮȕLQWHJULQLQEDVDOOLNHEUHDVWFDQFHU
FHOO PRGHOV:H WKHUHIRUH VWXGLHG ZKHWKHU 3FDGKHULQ
FRXOG DIIHFW WKHPDLQ VLJQDOLQJPROHFXOHV GRZQVWUHDP
RIWKHĮȕLQWHJULQUHFHSWRULQFDQFHUFHOOVZKHQWKHVH
ZHUHJURZQRQWRSRIDODPLQLQVXEVWUDWH7KHDFWLYDWLRQ
RIWKHLQWHJULQUHODWHGNLQDVHV)$.DQG6UFZDVVWXGLHG
E\LPPXQREORWWLQJDIWHUFHOODGKHVLRQWRWKLVVXEVWUDWH
:HIRXQGWKDW3FDGKHULQLQKLELWLRQLQEUHDVWFDQFHUFHOOV
UHGXFHGS)$.7\UDQGS6UF7\UOHYHOV)LJXUH
$ 1RWDEO\ WKH S)$. 7\U UHGXFWLRQ ZDV DOVR
GHWHFWHGE\LPPXQRÀXRUHVFHQFHLQERWKFHOOOLQHVVWXGLHG
)LJXUH % )XUWKHUPRUH DFWLYDWLRQ RI$.7ZDV DOVR
DIIHFWHGVKRZQE\DUHGXFWLRQLQOHYHORIS$.76HU
)LJXUH$$OWRJHWKHUWKHVHUHVXOWVLQGLFDWHWKDW)$.
DQG6UFDFWLYDWLRQLQUHVSRQVHWRODPLQLQLVGHSHQGHQWRQ
3FDGKHULQH[SUHVVLRQLQEDVDOOLNHEUHDVWFDQFHUFHOOV
:HDOVR LQYHVWLJDWHG LI WKHFDQFHUFHOOSKHQRW\SH
ZDVDIIHFWHG LQFHOOVJURZQRQ WRSRI WKH VXEVWUDWH IRU
Įȕ LQWHJULQ 7KXV ZH DQDO\]HG WKH F\WRVNHOHWRQ
PLFUR¿ODPHQWV E\ SKDOORLGLQ VWDLQLQJ E\ ÀXRUHVFHQFH
PLFURVFRS\ LQ EUHDVW FDQFHU FHOOV DGKHUHG WR ODPLQLQ
FRDWHG FRYHUVOLSV )LJXUH % :H IRXQG WKDW FRQWURO
FHOOVVFUDPEOHGWUDQVIHFWHGKDGPRUHVWUHVV¿EUHVDQG
DSSHDUHGPRUHÀDWWHQHGWKDQFDQFHUFHOOVZLWK3FDGKHULQ
)LJXUH3FDGKHULQVLJQDOLQJLQUHVSRQVHWRODPLQLQ
involves FAK/Src activation. $QDO\VLV RI LQWHJULQ
GRZQVWUHDPVLJQDOLQJPROHFXOHVLQEUHDVWFDQFHUFHOOOLQHVZDV
SHUIRUPHG DIWHU DGKHVLRQ WR ODPLQLQ  PLQ IRU 0'$
0% DQG  PLQ IRU %7 $ 7KH QXPEHU RI VWUHVV
¿EHUV)DFWLQZDVVWDLQHGZLWKSKDOORLGLQUKRGDPLQHDQGIRFDO
DGKHVLRQVFRQWDFWV VWDLQHG ZLWK S)$. 7\U ±$OH[D 
LV UHGXFHGE\3FDGKHULQNQRFNGRZQLQ0'$%0%FHOOV
JURZQRQWRSRIODPLQLQ%7KHVDPHUHVXOWZDVIRXQGIRU%7
FHOOOLQH
)LJXUH7KHFURVVWDONEHWZHHQ3FDGKHULQDQGĮȕ
integrin in basal-like breast cancer. These signaling 
PROHFXOHV FRRSHUDWH OHDGLQJ WR WKH SKRVSKRU\ODWLRQ DQG
DFWLYDWLRQRI)$.6UFDQG$.7PHGLDWLQJWXPRUJURZWKDQG
important aggressive cancer properties in vitro, such as cell 
LQYDVLRQDGKHVLRQWRODPLQLQDQGPDPPRVSKHUHIRUPDWLRQ
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NQRFNGRZQ7KH VWUHVV ¿EUHV SURYLGH WKH F\WRVNHOHWDO
WHQVLRQZKLFK LV UHTXLUHG IRU IRFDO DGKHVLRQ IRUPDWLRQ
LQ ODPLQLQ LQGLFDWLQJ D VWURQJ DGKHVLRQ WR WKH (&0
VXEVWUDWH6WDLQLQJZLWKDQDQWLERG\IRUS)$.7\U
DOORZHG WKH LGHQWL¿FDWLRQ RI IRFDO DGKHVLRQV DQG VLWHV
RI FHOOWRFHOO FRQWDFWV %RWK IRFDO DGKHVLRQV DQG FHOO
FHOOFRQWDFWVZHUHGHFUHDVHGLQ3FDGKHULQGHSOHWHGFHOOV
)LJXUH%,QVXPPDU\3FDGKHULQKDVDUROHLQHOLFLWLQJ
FHOOVKDSHFKDQJHVDVVRFLDWHGZLWKDGKHVLRQWRWKH(&0
$VVHVVPHQWRI3FDGKHULQĮȕLQWHJULQ)$.6UF
cross-talk signaling  in in vivo tumor xenografts
6LQFHWKHGDWDFROOHFWHGin vitro pointed out to an 
DFWLYDWLRQRI)$.6UFVLJQDOLQJLQD3FDGKHULQGHSHQGHQW
PDQQHUZHGHFLGHGWRDQDO\]HLIWKLVVLJQDOLQJSDWKZD\
was also present in the in vivo VHWWLQJ,QRUGHUWRVWXG\
WXPRUV ZLWK GLIIHUHQW 3FDGKHULQ H[SUHVVLRQ OHYHOV
ZH KDYH XVHG WKH EDVDOOLNH DQG 3FDGKHULQ SRVLWLYH
0'$0% FHOO OLQH DQG )$&6 WR VHSDUDWH WKH WRS
 3FDGKHULQ H[SUHVVLQJ FHOOV IURP WKH ORZ 
3FDGKHULQH[SUHVVLQJFHOOVSXULW\RIVRUWHGSRSXODWLRQV
ZDV7KHVHVRUWHGFHOOVDVZHOODVWKHXQVRUWHG
SRSXODWLRQZHUHLQRFXODWHGLQWRWKHVXEFXWDQHRXVUHJLRQ
XQGHU WKH OHIW DEGRPLQDOPDPPDU\ IDWSDGRI LPPXQH
FRPSURPLVHG PLFH 7KH WXPRULJHQLF FDSDFLW\ ZDV
HYDOXDWHG DIWHU GD\V DQG WXPRUVZHUH FKDUDFWHUL]HG
E\LPPXQRKLVWRFKHPLVWU\IRU3FDGKHULQĮLQWHJULQȕ
LQWHJULQS)$.DQGS6UF
7KHSHUFHQWDJHRIWXPRUVIRUPHGZLWKWKHXQVRUWHG
SRSXODWLRQ ZDV   PLFH 7KH WRS 
3FDGKHULQJURXSRIDQLPDOVSUHVHQWHGDQLQFUHDVHGWXPRU
IRUPDWLRQ FDSDFLW\  PLFH FRPSDUHG WR WKH
3FDGKHULQ ORZ  JURXS  PLFH$OO WKH
WXPRUVIRUPHGZHUHKLVWRORJLFDOO\FODVVL¿HGDVVROLGZLWK
LQ¿OWUDWLYHJURZWKDQGH[WHQVLYHQHFURVLV6XSSOHPHQWDU\
)LJXUH$
&RQFHUQLQJ WKH LPPXQRKLVWRFKHPLFDO DQDO\VLV
  RI WKH WXPRUV VKRZHG KLJK H[SUHVVLRQ IRU
3FDGKHULQ   RI WKH WXPRUV IRUPHG ZHUH
FRQVLGHUHGSRVLWLYHIRUĮDQGȕLQWHJULQV
ZHUHSRVLWLYHIRUS)$.DQGZHUHSRVLWLYH
IRU S6UF 6XSSOHPHQWDU\ )LJXUH  DQG 6XSSOHPHQWDU\
7DEOH
2XU UHVXOWV VKRZHG WKDW WKHUH LV D VWDWLVWLFDOO\
VLJQL¿FDQW DVVRFLDWLRQ EHWZHHQ WKH WXPRUVZLWK D KLJK
H[SUHVVLRQRI3FDGKHULQ3FDGKLJKDQGWKHH[SUHVVLRQ
RIĮLQWHJULQS ȕLQWHJULQS S)$.
S DQGS6UFS 7DEOHYDOLGDWLQJWKH
VLJQDOLQJSDWKZD\SUHYLRXVO\IRXQGin vitro$GGLWLRQDOO\
ZH ZHUH DOVR DEOH WR ¿QG DQ DVVRFLDWLRQ EHWZHHQ Į
LQWHJULQ DQG ȕ LQWHJULQ S  GDWD QRW VKRZQ
DV ZHOO DV EHWZHHQ S)$. DQG ERWK LQWHJULQ VXEXQLWV
S GDWDQRWVKRZQ
Discussion
&DGKHULQV DUH FODVVLFDOO\ VHHQ DV PROHFXOHV WKDW
PDNH D PDMRU FRQWULEXWLRQ IRU FHOOWRFHOO DGKHVLRQ
6SHFL¿FDOO\LQEUHDVW3FDGKHULQH[SUHVVLRQLVIRXQGLQ
WKHP\RHSLWKHOLDOFHOOOD\HUVWURQJO\FRQWULEXWLQJWRWKH
VHOIRUJDQL]DWLRQRIWKHVHFHOOV>@1RWDEO\WKLVEDVDO
OD\HU RI WKH PDPPDU\ HSLWKHOLXP LV DOVR HQULFKHG LQ
PROHFXOHVLQYROYHGLQWKHDGKHVLRQRIHSLWKHOLDOFHOOVWR
WKH(&0QDPHO\LQLQWHJULQPROHFXOHVVXFKDVĮȕDQG
Įȕ,QQRUPDOFHOOVWKHODWHUKHWHURGLPHULVNQRZQDV
KHPLGHVPRVRPH DQG LW LV WKH UHFHSWRU IRU ODPLQLQ WKH
PDMRUFRPSRQHQWRIWKHEDVHPHQWPHPEUDQH
,Q EUHDVW FDQFHU 3FDGKHULQ PROHFXOH DSSHDUV
XSUHJXODWHG LQ  RI DOO GLDJQRVHG FDVHV EHLQJ
Table 1: In vivo DVVRFLDWLRQ RI 3FDGKHULQ H[SUHVVLRQ ZLWK WKH Įȕ
integrin heterodimer and the activation of FAK/Src pathway. Tumours 
ZHUH IRUPHG in vivo IURP WKH 0'$0% FHOO OLQH ZLWK GLIIHUHQW
OHYHOV RI 3FDGKHULQ H[SUHVVLRQ DQG WKH\ZHUH FKDUDFWHUL]HG E\ ,+& IRU
WKHH[SUHVVLRQRIĮ LQWHJULQȕ LQWHJULQS)$.DQGS6UF$VWDWLVWLFDOO\
VLJQL¿FDQWDVVRFLDWLRQZDVIRXQGEHWZHHQ3FDGKHULQDQGWKHH[SUHVVLRQRI
ĮLQWHJULQȕLQWHJULQS)$.DQGS6UF)LVKHU¶VH[DFWWHVW
3FDGKHULQ
+LJKQ  /RZQ  p value
ĮLQWHJULQ 3RVLWLYHQ    1HJDWLYHORZQ   
ȕLQWHJULQ SRVLWLYHQ   Q  1HJDWLYHORZQ   Q 
S)$. 3RVLWLYHQ    1HJDWLYHORZQ   Q 
S6UF 3RVLWLYHQ    1HJDWLYHORZQ   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VLJQL¿FDQWO\ DVVRFLDWHGZLWKSRRUSDWLHQW SURJQRVLV >
@,WLVNQRZQKRZHYHUWKDWEUHDVWFDQFHUSURJUHVVLRQ
LQYROYHVPRGL¿FDWLRQV RI WKH QRUPDO(&0 DVZHOO DV
RQFRJHQLFDFWLYDWLRQRILQWHJULQVLJQDOLQJLQERWKSULPDU\
WXPRUVDVZHOODVLQWKHPHWDVWDWLFVLWHV>@+HUHZH
HVWDEOLVKHGWKDW3FDGKHULQLVLQYROYHGLQWKHDWWDFKPHQW
RIFHOOVWR(&0VXEVWUDWHVVLQFHLWVVLOHQFLQJUHQGHUHG
FDQFHUFHOOVVLJQL¿FDQWO\OHVVDEOHWRDGKHUHWRYLWURQHFWLQ
¿EURQHFWLQDQGODPLQLQ:KHQLQWHJULQVH[SUHVVLRQZDV
LQYHVWLJDWHGZHIRXQGWKDW3FDGKHULQZDVQHFHVVDU\IRU
WKHDSSURSULDWHH[SUHVVLRQRIWKHLQWHJULQVXEXQLWVĮDQG
ȕ,PSRUWDQWO\WKHUHFRJQLWLRQRIODPLQLQE\FDQFHUFHOOV
KDV VLJQL¿FDQW WXPRU SURPRWLQJ HIIHFWV )RU H[DPSOH
ODPLQLQLQGXFHVPRWLOLW\LQWKH0&)EUHDVWFDQFHU
FHOOOLQH>@)XUWKHUPRUH,+&DQDO\VLVRIODPLQLQ
in human in situEUHDVWFDUFLQRPDVVKRZHGWKDWWKLV(&0
VXEVWUDWH LV ORFDWHG LQ WKH P\RHSLWKHOLXP DGMDFHQW WR
SUHLQYDVLYHFHOOV>@WKDWFRXOGSRWHQWLDOO\FRQWULEXWH
WRWKHHDUO\VWHSVRIVWURPDOLQYDVLRQ7KHLQWHUIDFH]RQH
EHWZHHQWKHWXPRXUFHOOVDQGWKHVWURPDLVHQULFKHGLQ
ODPLQLQDVZHOODVLQĮȕLQWHJULQ>@
:HKDYHSUHYLRXVO\VKRZQWKDW3FDGKHULQLQGXFHV
LQYDVLRQ DQGPLJUDWLRQ RI EUHDVW FDQFHU FHOOV >@ DQG
SOD\VDQLPSRUWDQWUROHLQEUHDVWWXPRXULJHQHVLVin vivo 
>@7KHVLJQDOLQJSDWKZD\VWKDWFRQWULEXWHWRWKLV
DJJUHVVLYHEHKDYLRUDUHSRRUO\XQGHUVWRRGLQYROYLQJWR
VRPHH[WHQWWKHDFWLYDWLRQRIPHWDOORSURWHLQDVHVDQGWKH
FRQVHTXHQWUHOHDVHRIDVROXEOHSURLQYDVLYH3FDGKHULQ
IUDJPHQW DQGRU WKH DFWLYDWLRQ RI VPDOO *73DVHV >
@5HFHQWO\ZHKDYHVKRZQWKDW3FDGKHULQKDVEHHQ
LPSOLFDWHG LQ WKH PDLQWHQDQFH RI VWHP DQG SURJHQLWRU
SURSHUWLHVLQEDVDOOLNHEUHDVWFDQFHUFHOOVLQFOXGLQJWKH
VHOIUHQHZDOFDSDFLW\DQGWKHWXPRULJHQLFDELOLW\LQQXGH
PLFH>@:HDOVRIRXQGWKDW3FDGKHULQLVFRH[SUHVVHG
ZLWKĮLQWHJULQLQEUHDVWFDQFHUFHOOV>@DPDUNHURI
WKHVWHPSURJHQLWRUSKHQRW\SHSUHVHQWLQWKHPRXVHDQG
KXPDQEUHDVW>@,QWKHSUHVHQWZRUNZHH[SORUHG
IXUWKHUWKLVDVVRFLDWLRQVKRZLQJWKDWWKHUHLVDFURVVWDON
EHWZHHQERWKDGKHVLRQPROHFXOHV3FDGKHULQ LV DFWLQJ
XSVWUHDPRIDPDMRUVLJQDOLQJSDWKZD\WKDWLQYROYHVWKH
DFWLYDWLRQRIĮLQWHJULQDQGLWVSDUWQHUWKHȕVXEXQLW
$V D FRQVHTXHQFH RI WKH DGKHVLRQ RI FDQFHU FHOOV WR
ODPLQLQVXUIDFHWKHDFWLYDWLRQRIWKHĮȕKHWHURGLPHU
ZRXOG OHDG WR 6UF DQG)$.DFWLYDWLRQ LQ D 3FDGKHULQ
GHSHQGHQW PDQQHU ,Q IDFW LQ WKH SUHVHQW VWXG\ ZH
VKRZHG WKDW 3FDGKHULQ NQRFNGRZQ UHGXFHV)$.DQG
6UFSKRVSKRU\ODWLRQin vitroDQGDQDVVRFLDWLRQZDVIRXQG
EHWZHHQ3FDGKHULQZLWKWKHĮȕKHWHURGLPHUDQG)$.
6UFDFWLYDWLRQin vivo,PSRUWDQWO\LWKDVEHHQUHSRUWHG
WKDW Įȕ LQWHJULQ SURPRWHV VXUYLYDO DQG LQYDVLRQ E\
DFWLYDWLQJWKH3,.$NWSDWKZD\>@DQGQRWDEO\LQ
RXUZRUNDUHGXFWLRQZDVDOVRIRXQGLQ$.7DFWLYDWLRQLQ
3FDGKHULQVLOHQFHGFHOOV
,WZDVSUHYLRXVO\IRXQGWKDWĮLQWHJULQDFWLYDWLRQ
LQGXFHV3FDGKHULQWUDQVFULSWLRQ>@IXUWKHUVXSSRUWLQJ
WKHLGHDWKDW3FDGKHULQFRXOGFRRSHUDWHZLWKĮLQWHJULQ
VLJQDOLQJ+RZHYHURXUZRUN UHYHDOHG WKDW3FDGKHULQ
DQGĮLQWHJULQGRQRWGLUHFWO\LQWHUDFW5DWKHU3FDGKHULQ
H[SUHVVLRQVHHPVWRFRQWUROWKHWUDQVFULSWLRQRIĮLQWHJULQ
VXEXQLWVLQFHVLOHQFLQJRI3FDGKHULQOHDGVWRDGHFUHDVH
LQWKHĮLQWHJULQP51$OHYHOV2QWKHRWKHUKDQGȕ
LQWHJULQ P51$ OHYHOV ZHUH XQDIIHFWHG E\ 3FDGKHULQ
LQKLELWLRQEXWWKHSK\VLFDOLQWHUDFWLRQEHWZHHQ3FDGKHULQ
DQGȕLQWHJULQVXEXQLWSRLQWVWRDSRVVLEOHUHJXODWLRQDW
D SRVWWUDQVFULSWLRQDO OHYHO ,Q IDFW WKH DEVHQFH RI ȕ
LQWHJULQ DIWHU 3FDGKHULQ VLOHQFLQJ PD\ EH GXH WR WKH
GRZQUHJXODWLRQ RI LWV XQLTXH SDUWQHU WKH Į LQWHJULQ
KHQFH EORFNLQJ WKH IRUPDWLRQ RI WKH KHWHURGLPHU DV
DOUHDG\VKRZQE\.OLQRZVNDDQGFROOHDJXHV>@
ȕLQWHJULQLVDOVRDSDUWQHURIĮLQWHJULQVXEXQLW
UHFRJQL]LQJODPLQLQEHLQJDOVRHVVHQWLDOIRUWKHFRUUHFW
GHYHORSPHQWRIWKHPDPPDU\HSLWKHOLXPDQGUHJXODWLQJ
WKHDELOLW\RIWKHPDPPDU\VWHPFHOOVWRVHOIUHQHZDQG
GLIIHUHQWLDWH SURSHUO\ >@ 'HVSLWH QRW KDYLQJ IRXQG
DQ\DOWHUDWLRQLQWKHȕLQWHJULQOHYHOVXSRQ3FDGKHULQ
LQKLELWLRQ ZH GR QRW H[FOXGH WKH SRVVLELOLW\ WKDW ȕ
LQWHJULQ VXEXQLW LV DOVR LPSOLFDWHG LQ WKHPDLQWHQDQFH
DFTXLVLWLRQRIFDQFHUVWHPFHOODQGLQYDVLYHSURSHUWLHVDV
WKLVLVWKHRWKHUPDMRUSDUWQHURIĮLQWHJULQFRQVWLWXWLQJ
an important laminin receptor. 
$GGLWLRQDOO\DOWKRXJKWKHFHOOPRUSKRORJ\ZDVQRW
VHYHUHO\ DIIHFWHG E\ 3FDGKHULQ NQRFNGRZQ DQG FHOOV
FOHDUO\ PDLQWDLQHG DQ HSLWKHOLDO SKHQRW\SH ZH IRXQG
WKDWWKHQXPEHURIFHOOWRFHOOFRQWDFWVDQGWKHQXPEHU
RIIRFDODGKHVLRQVWRODPLQLQZDVFOHDUO\UHGXFHGXSRQ
3FDGKHULQ LQKLELWLRQ ,W LV SRVVLEOH WKDW Įȕ LQWHJULQ
DQG WKH VXEVHTXHQW )$.6UF NLQDVH DFWLYLW\ PD\ DOVR
EHFRQWULEXWLQJWRWKHVWHPSURJHQLWRUFKDUDFWHULVWLFV,W
ZDV VKRZQ WKDW)$.GHOHWLRQ LQ WKHPXULQHPDPPDU\
JODQG VXSSUHVVHG WXPRULJHQHVLV E\ GHFUHDVLQJ WKH
QXPEHU RI FDQFHU VWHP FHOOV &'+&'+&'+ 
DQG $/'()/825+ SRSXODWLRQV >@ 1RWDEO\ )$.
DFWLYDWLRQDOORZVIRUWKHVXUYLYDORIFHOOVLQDQFKRUDJH
LQGHSHQGHQW FRQGLWLRQV >@ ZKLFK PD\ H[SODLQ ZK\
LQWHJULQNQRFNGRZQDVZHOODV3FDGKHULQNQRFNGRZQ
UHGXFHGVXUYLYDORIFHOOVJURZLQJDVVXVSHQVLRQFRORQLHV
LQZKLFKWKH(&0LVSUHVHQWZLWKLQWKHPDPPRVSKHUH
7KXVWKHSRRUSDWLHQWSURJQRVLVIRXQGLQ3FDGKHULQ
RYHUH[SUHVVLQJEUHDVWFDQFHUFDVHV>@PD\EHUHODWHGDW
OHDVWSDUWLDOO\WRWKHIDFWWKDWWKLVFDGKHULQHQDEOHVFHOOV
WRUHVSRQGWRLQWHJULQVLJQDOLQJSURPRWLQJDQRQFRJHQLF
UHVSRQVH ,PSRUWDQWO\ VWUDWHJLHV WR LQKLELW 3FDGKHULQ
could lead to a decrease in integrin activation and 
SRWHQWLDOO\RSSRVHWKHRQFRJHQLFVLJQDOLQJPHGLDWHGE\
ODPLQLQDQGLWVUHFHSWRU6LQFH3FDGKHULQXSUHJXODWLRQLV
DOVRIRXQGLQin situVWDJHVRIEUHDVWFDQFHUGHYHORSPHQW
>@LWLVSRVVLEOHWKDWLWPD\DOUHDG\EHFRQWULEXWLQJWRWKH
FKDQJHVLQLQWHJULQVLJQDOLQJLQWKHHDUO\VWDJHVRIEUHDVW
cancer development. 
,Q FRQFOXVLRQ RXU UHVXOWV VKRZ WKDW 3FDGKHULQ
FRQWUROV WKH FHOOWRODPLQLQ DGKHVLRQ E\ PRGXODWLQJ
WKH H[SUHVVLRQ DQG WKH DFWLYDWLRQ RI WKH Įȕ LQWHJULQ
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KHWHURGLPHU0RUHRYHU3FDGKHULQDQGĮȕLQWHJULQKDYH
RQFRJHQLFVLJQDOLQJSDWKZD\VWKDWFRRSHUDWHDQGFURVV
WDONLQRUGHUWRLQGXFHFDQFHUFHOOLQYDVLRQDQGVXUYLYDO
in anchorage independent conditions. These results are 
SDUWLFXODUO\ UHOHYDQW VLQFH WKH\SURYLGHDQHZ OLQN IRU
3FDGKHULQDQGWKHWXPRUPLFURHQYLURQPHQWDQGDQHZ
PROHFXODUPHFKDQLVPH[SODLQLQJ3FDGKHULQDJJUHVVLYH
EHKDYLRULQEUHDVWFDUFLQRPDV
METHODS
Ethics statement
,QYHVWLJDWLRQKDVEHHQFRQGXFWHGLQDFFRUGDQFHZLWK
WKHHWKLFDOVWDQGDUGVDQGDFFRUGLQJWRWKH'HFODUDWLRQRI
+HOVLQNL DQG DFFRUGLQJ WR QDWLRQDO DQG LQWHUQDWLRQDO
JXLGHOLQHV DQG KDV EHHQ DSSURYHG E\ WKH DXWKRUV¶
LQVWLWXWLRQDOUHYLHZERDUG
Cell culture
+XPDQEUHDVWFDQFHUFHOOOLQHV0'$0%DQG
%7ZHUHREWDLQHGIURP$7&&$PHULFDQ7\SH&XOWXUH
&ROOHFWLRQ0DQDVVDV9$7KHVHFHOOOLQHVZHUHJURZQLQ
'0(0VXSSOHPHQWHGZLWKIHWDOERYLQHVHUXP)%6
DQG  DQWLELRWLF VROXWLRQ SHQLFLOOLQ±VWUHSWRP\FLQ
,QYLWURJHQ&DUOVEDG&$7KHKXPDQEUHDVWFDQFHUFHOO
OLQH0&)$=ZDVREWDLQHGIURPDFROOHFWLRQGHYHORSHG
LQWKHODERUDWRU\RI3URI0DUF0DUHHO*KHQW8QLYHUVLW\
+RVSLWDO%HOJLXPZKLFKZDVJHQHWLFDOO\PDQLSXODWHG
WRVWDEO\RYHUH[SUHVV3FDGKHULQ0&)$=3FDG7KH
FRQWUROFHOOOLQH0&)$=PRFNVKRZVORZ3FDGKHULQ
OHYHOV LGHQWLFDO WR WKH SDUHQWDO FHOO OLQH >@ 7KHVH
FHOO OLQHV ZHUH FXOWXUHG LQ '0(0) VXSSOHPHQWHG
ZLWK  )%6 DQG  DQWLELRWLF VROXWLRQ SHQLFLOOLQ±
VWUHSWRP\FLQ ,QYLWURJHQ $OO FHOOV ZHUH URXWLQHO\
FXOWXUHGLQDKXPLGL¿HGDWPRVSKHUHZLWK&2 and at 
&DQGZHUHXVHGLQH[SHULPHQWVZKHQUHDFKHG±
FRQÀXHQFH
RNA knock-down of P-cadherin and integrin 
molecules
*HQHVLOHQFLQJZDVFRQGXFWHGE\VL51$VHTXHQFHV
WDUJHWLQJ VSHFL¿F JHQHV 3FDGKHULQ CDH3 gene) 
WDUJHW VHTXHQFH $$*&&7&77$&&7*&&*7$$$
,QWHJULQ   ITGA6 JHQH WDUJHW VHTXHQFH
&$***7$$7$$$&77$**7$$,QWHJULQ ITGB4 
JHQHWDUJHWVHTXHQFH*7**$7*$*77&&**$$7$$$
$OO VL51$ VHTXHQFHV ZHUH REWDLQHG IURP 4LDJHQ
+LOGHQ *HUPDQ\ &HOO WUDQVIHFWLRQ ZDV FDUULHG RXW
XVLQJ +L3HU)HFW WUDQVIHFWLRQ UHDJHQW 4LDJHQ LQ D
¿QDO FRQFHQWUDWLRQ RI  Q0 VL51$ DFFRUGLQJ WR WKH
PDQXIDFWXUHU¶VLQVWUXFWLRQV2SWLPDOVLOHQFLQJRIWKHWDUJHW
JHQHVZDVDFKLHYHGDWKDIWHUWUDQVIHFWLRQZKLFKZDV
FRQ¿UPHGE\LPPXQREORWDQDO\VLV$VL51$VFUDPEOHG
VHTXHQFHZDVLQFOXGHGDVDFRQWURO4LDJHQ
Adhesion assay to ECM substrates 
&HOODGKHVLRQDVVD\ZDVSHUIRUPHGE\WKHFU\VWDO
YLROHW DVVD\ LQ ZHOO PLFURWLWHU SODWHV FRDWHG ZLWK
ODPLQLQ6LJPD6W/RXLV02¿EURQHFWLQ6LJPD
YLWURQHFWLQ %' %LRVFLHQFHV 6DQ 'LHJR &$ W\SH,
RUW\SH,9FROODJHQ6LJPDJPORYHUQLJKWDW&
6XEVHTXHQWO\SODWHVZHUHZDVKHGWKUHHWLPHVLQ3%6DQG
QRQVSHFL¿FELQGLQJVLWHVZHUHEORFNHGE\DGGLQJ
%6$ ZY LQ 3%6 FRQWDLQLQJ 3HQ6WUHS ,QYLWURJHQ
IRUKDW&2QFHZDVKHGDJDLQZLWK3%6ORI
FHOOV  FHOOVPOZHUH VHHGHG LQ VHUXPIUHHPHGLXP
IRU  PLQXWHV IRU 0'$0% FHOO OLQH RU 
PLQXWHVIRU%7FHOOOLQH7KHUHDIWHUWKHSODWHVZHUH
ZDVKHGZLWK3%6WRUHPRYHQRQDGKHUHQWFHOOVDQGWKH
DWWDFKHG FHOOV ZHUH ¿[HG ZLWK DFHWRQHPHWKDQRO 
IRU  PLQXWHV DW & &HOO DGKHVLRQ ZDV GHWHUPLQHG
IROORZLQJ WKH FRORULPHWULF PHWKRG GHVFULEHG E\ %XVN
>@ 7KH DEVRUEDQFH ZDV PHDVXUHG DW QP ZLWK D
PLFURSODWHUHDGHU7KHDWWDFKPHQWRIFHOOVWRZHOOVFRDWHG
ZLWKPJPORISRO\//\V6LJPDDQG¿[HGZLWK
SDUDIRUPDOGHK\GHEHIRUHDVSLUDWLRQZDVGH¿QHGDV
RIDGKHVLRQ
Flow Cytometry analysis
&HOOVZHUHKDUYHVWHGZLWKYHUVHQHP0('7$
,QYLWURJHQ 'HWDFKHG FHOOV ZHUH ZDVKHG ZLWK 3%6
VXSSOHPHQWHGZLWK )%6 DQG UHVXVSHQGHG LQ WKH
VWDLQEXIIHUP0('7$ERYLQHDOEXPLQLQ3%6
$ VLQJOH FHOO VXVSHQVLRQ ZDV ODEHOHG E\ ÀXRUHVFHQFH
FRQMXJDWHGDQWLERGLHVDWDFRQFHQWUDWLRQRIWRLQVWDLQ
EXIIHU3(&\FRQMXJDWHG,QWHJULQȕ&'3(&\
FRQMXJDWHG,QWHJULQĮ&'IRU3(FRQMXJDWHG,QWHJULQ
ȕ &'7KHVH DQWLERGLHVZHUHREWDLQHG IURP%'
%LRVFLHQFHV 6DQ 'LHJR &$ 3FDGKHULQ PRQRFORQDO
DQWLERG\ $3&FRQMXJDWHG ZDV REWDLQHG IURP 5	'
0LQQHDSROLV01DQGXVHGDW WKHVDPHFRQFHQWUDWLRQ
DVDERYH$OLYHGHDGVWDLQ,QYLWURJHQDQGWKHSULPDU\
DQWLERGLHV RU WKH UHVSHFWLYH LVRW\SH FRQWUROV %'
%LRVFLHQFHVZHUHLQFXEDWHGDW&LQWKHGDUNIRU
PLQXWHV7KHODEHOHGFHOOVZHUHWKHQZDVKHGLQWKHVWDLQ
EXIIHUDQGDQDO\]HGRQD/65,,RU)$&6&DQWR,,%'
%LRVFLHQFHV
,PPXQRÀXRUHVFHQFHPLFURVFRS\
'LIIHUHQW FHOO OLQHV ZHUH VHHGHG RQ WRS RI JODVV
FRYHUVOLSVFRDWHGZLWKODPLQLQ6LJPD&HOOVZHUH
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¿[HG ZLWK  SDUDIRUPDOGHK\GH SHUPHDELOL]HG ZLWK
7ULWRQ ; DQG EORFNHG ZLWK  %6$ EHIRUH
VWDLQLQJ 7KH IROORZLQJ SULPDU\ DQWLERGLHV ZHUH XVHG
IRU LPPXQRÀXRUHVFHQFH ),7&FRQMXJDWHG Į LQWHJULQ
&'I  %' %LRVFLHQFHV 3(FRQMXJDWHG ȕ
LQWHJULQ  &' %' %LRVFLHQFHV DQG S)$.
W\U  GLOXWLRQ &HOO 6LJQDOLQJ 7R YLVXDOL]H
S)$.DQWLUDEELW$OH[D  ,QYLWURJHQZDV
LQFXEDWHGRQVOLGHVIRUPLQXWHV)DFWLQZDVGHWHFWHG
E\ VWDLQLQJ ZLWK SKDOORLGLQ FRQMXJDWHG WR UKRGDPLQH
,QYLWURJHQDWDGLOXWLRQRI&HOOVZHUHYLVXDOLVHG
XVLQJ D =HLVV ,PDJHU = PLFURVFRSH =HLVV:HOZ\Q
*DUGHQ&LW\8.DQGUHSUHVHQWDWLYHSKRWRVZHUHDFTXLUHG
XVLQJWKHDVVRFLDWHGVRIWZDUH3KRWRVKRSDQG,OOXVWUDWRU
ERWK&6$GREH
Immunoblotting analysis
$IWHUSHUIRUPLQJWKHDGKHVLRQDVVD\RYHUDODPLQLQ
FRDWHGVXUIDFHZHOOVSODWH%'%LRVFLHQFHVFHOOVZHUH
O\VHGZLWK3%6FRQWDLQLQJ1RQLGHW3136LJPD
$OGULFK 6W /RXLV02 DQG SKRVSKDWDVH 6LJPD DQG
SURWHDVHLQKLELWRUV5RFKH'LDJQRVWLFV*PEK0DQQKHLP
*HUPDQ\ 3URWHLQ FRQFHQWUDWLRQ ZDV GHWHUPLQHG E\
%LR5DG SURWHLQ DVVD\ %LR5DG 5LFKPRQG &$ DQG
JRIWRWDOSURWHLQZDVUHVROYHGRQDGHQDWXULQJ
SRO\DFU\ODPLGHJHODQGWUDQVIHUUHGRQWRDQLWURFHOOXORVH
PHPEUDQH $PHUVKDP3KDUPDFLD%LRWHFK 3LVFDWDZD\
1-$IWHUEORFNLQJQRQVSHFL¿FELQGLQJZLWKQRQIDW
GU\PLON IRU QRQSKRVSKRU\ODWHG SURWHLQ GHWHFWLRQ RU
%6$IRUSKRVSKRU\ODWHGSURWHLQGHWHFWLRQLQ3%6
FRQWDLQLQJ7ZHHQHDFKPHPEUDQHZDVLQFXEDWHG
IRUKRXUDWURRPWHPSHUDWXUHZLWKHDFKRIWKHIROORZLQJ
SULPDU\DQWLERGLHVDQWL3FDGKHULQFORQH%'
7UDQVGXFWLRQDQWLĮLQWHJULQ6LJPD$OGULFK
DQWLȕ LQWHJULQ  6DQWD &UX] %LRWHFKQRORJ\
DQWLS6UF 7\U   &HOO 6LJQDOOLQJ 'DQYHU
0$ DQWLWRWDO 6UF  &HOO 6LJQDOOLQJ DQWL
S)$.7\U&HOO6LJQDOOLQJDQWLWRWDO)$.
%'7UDQVGXFWLRQDQWLS$.76HU
&HOO 6LJQDOOLQJ DQG DQWL$.7  6DQWD &UX]
%LRWHFKQRORJ\$QWLĮWXEXOLQFORQH'0$
6LJPD$OGULFK ZDV XVHG LQ DOO WKH EORWV DV D ORDGLQJ
FRQWURO6HFRQGDU\DQWLERGLHVZHUHSHUR[LGDVHFRQMXJDWHG
IURP6DQWD&UX]%LRWHFKQRORJ\,PPXQRUHDFWLYHSURWHLQV
ZHUHGHWHFWHGE\HQKDQFHGFKHPLOXPLQHVFHQFHGHWHFWLRQ
NLW$PHUVKDP*(+HDOWKFDUH8SSVDOD6ZHHGHQDQG
H[SRVXUHWR+LSHU¿OP(&/$PHUVKDP
Mammosphere assay
0RQROD\HU FHOOV ZHUH HQ]\PDWLFDOO\ GHWDFKHG
ZLWK  WU\SVLQ('7$ 6LJPD$OGULFKPDQXDOO\
GLVDJJUHJDWHG ZLWK D JDXJH QHHGOH WR D VLQJOHFHOO
VXVSHQVLRQDQGVXVSHQGHGLQFROG3%6&HOOVZHUHSODWHG
DWFPLQQRQDGKHUHQWFXOWXUHFRQGLWLRQVLQÀDVNV
FRDWHG ZLWK  SRO\K\GUR[\HWK\OPHWKDFU\ODWH 
HWKDQRO6LJPD&HOOVZHUHJURZQIRUGD\VLQ
'0(0) FRQWDLQLQJ % VXSSOHPHQW  QJPO
K\GURFRUWLVRQH  QJPO LQVXOLQ  QJPO (*) DQG
PDLQWDLQHG LQ D KXPLGL¿HG LQFXEDWRU DW & DQG 
YY &2 0DPPRVSKHUH IRUPLQJ HI¿FLHQF\ 0)(
ZDV FDOFXODWHG DV WKH QXPEHU RIPDPPRVSKHUHV 
ȝPIRUPHGGLYLGHGE\WKHWRWDOQXPEHURIFHOOVLQLWLDOO\
SODWHGEHLQJH[SUHVVHGDVDSHUFHQWDJH
Invasion assay
0DWULJHOLQYDVLRQDVVD\ZDVSHUIRUPHGDFFRUGLQJ
WRPDQXIDFWXUHU¶VLQVWUXFWLRQV%'%LRVFLHQFHV%ULHÀ\
WUDQVZHOOFKDPEHUVZLWKSRO\FDUERQDWHPHPEUDQH¿OWHUV
PPGLDPHWHUȝPSRUHVL]HZHUHFRDWHGZLWKȝ/
RID0DWULJHOVROXWLRQ[4%7FHOOVRU0&)$=
FHOOVZHUHDGGHGWRWKHXSSHUFRPSDUWPHQWRIWKHFKDPEHU
7KHORZHUFRPSDUWPHQWZDV¿OOHGZLWK'0(0PHGLXP
VXSSOHPHQWHGZLWK)%6DQGDQWLELRWLFVROXWLRQ
SHQLFLOOLQ±VWUHSWRP\FLQ ,QYLWURJHQ $IWHU  RU 
KRXUVRILQFXEDWLRQ%7RU0&)$=UHVSHFWLYHO\DW
&&2WKHXSSHUVXUIDFHRIWKH¿OWHUZDVZDVKHG
ZLWKVHUXPIUHH'0(0DQGFOHDUHGIURPQRQPLJUDWRU\
FHOOVZLWKDFRWWRQVZDE7KHUHPDLQLQJLQYDVLYHFHOOV
DW WKH ORZHU VXUIDFH RI WKH ¿OWHU ZHUH ¿[HGZLWK FROG
PHWKDQRODQGVWDLQHGZLWKƍGLDPLGLQRSKHQ\OLQGROH
'$3,6LJPD$OGULFKPJP/,QYDVLYHFHOOVZHUH
VFRUHGE\FRXQWLQJWKHZKROH¿OWHUZLWKDÀXRUHVFHQFH
PLFURVFRSHDW[PDJQL¿FDWLRQ
Real-time RT-PCR
$IWHU WUDQVIHFWLRQ ZLWK VL51$V WKH 51$ ZDV
H[WUDFWHG XVLQJ 4LDJHQ 51HDV\ NLW 4LDJHQ 86$
&RQFHQWUDWLRQZDVGHWHUPLQHGLQD1'VSHFWURPHWHU
1DQRGURS DQG  ȝJ RI WRWDO 51$ ZDV FRQYHUWHG
WR F'1$ XVLQJ D UHYHUVHWUDQVFULSWDVH 57 HQ]\PH
,QYLWURJHQ 86$ 3FDGKHULQCDH3, Į ,QWHJULQ
ITGA6DQGȕ,QWHJULQITGB47DT0DQSUREHV$SSOLHG
%LRV\VWHPV86$ZHUHXVHGWRVSHFL¿FDOO\UHFRJQL]HWKH
FRUUHVSRQGLQJF'1$VHTXHQFHVZKLFKZHUHDPSOL¿HGIRU
F\FOHV$SSOLHG%LRV\VWHPV$7DT0DQSUREH
IRUGAPDHZDVDOVRXVHGDVDKRXVHNHHSLQJJHQHDQG
UHODWLYHJHQHH[SUHVVLRQZDVGHWHUPLQHGE\QRUPDOL]DWLRQ
Co-Immunoprecipitation
%7FHOOVJURZQLQPRQROD\HUZHUH O\VHGZLWK
3%6 FRQWDLQLQJ 13 6LJPD$OGULFK DQG P0
FDOFLXP FKORULGH 6LJPD$OGULFK ZLWK SKRVSKDWDVH
6LJPD$OGULFK DQG SURWHDVH LQKLELWRUV 5RFKH
'LDJQRVWLFV*PEKȝJRIFHOOO\VDWHZDVSUHFOHDUHG
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ZLWK3URWHLQ*PDJQHWLFEHDGV0LOOLSRUH7HPHFXOD&$
IRUPLQXWHVDWURRPWHPSHUDWXUHDQGWKHQLQFXEDWHG
RYHUQLJKWDW&ZLWKȝJRIPRXVHPRQRFORQDODQWL3
FDGKHULQ$EFDP&DPEULGJH8.RUUDEELWSRO\FORQDO
DQWLȕ LQWHJULQ 6DQWD &UX] %LRWHFKQRORJ\ RU LWV
FRUUHVSRQGLQJFRQWUROLVRW\SH,J*PRXVHRU,J*UDEELW
FRPSDQ\UHVSHFWLYHO\7KHVDPSOHVZHUHWKHQLQFXEDWHG
ZLWK WKH 3URWHLQ * PDJQHWLF EHDGV 0LOOLSRUH IRU 
PLQXWHV DW URRP WHPSHUDWXUH7KH EHDGVZHUHZDVKHG
WKUHHWLPHVZLWKZDVKLQJEXIIHUO\VLVEXIIHUGLOXWHG
FRQWDLQLQJSKRVSKDWDVHDQGSURWHDVHLQKLELWRUVDVVWDWHG
DERYHDQGERLOHGIRUPLQXWHVLQ/DHPPOLEXIIHUZLWK
ȕPHUFDSWRHWKDQRO %LR5DG +HUFXOHV &$ 6DPSOHV
ZHUH VXEMHFWHG WR 6'63$*( DQG LPPXQREORWWLQJ DV
SUHYLRXVO\GHVFULEHG
In vivo assay
7KH 3FDGKHULQ SRVLWLYH FHOO OLQH 0'$0%
was used to induce tumors in immunocompromised 
PLFH7KLV FHOO OLQHZDV VRUWHG LQ D%')$&6$ULD ,,
DFFRUGLQJWR3FDGKHULQH[SUHVVLRQ5	'DQWLERG\LQWR
WZRVXESRSXODWLRQV WRS3FDGKHULQDQG ORZ
3FDGKHULQ IUDFWLRQV7KHXQVRUWHG DQG WKH VRUWHG FHOOV
ZHUH[HQRWUDQVSODQWHGDW[4FHOOVLQȝO'0(0
FHOOVXVSHQVLRQLQWRWKHVXEFXWDQHRXVUHJLRQXQGHUWKH
OHIWDEGRPLQDOPDPPDU\IDWSDGRIZHHNVROGIHPDOH
11,+V,,QXQXQXGHPLFHXVLQJDJDXJHQHHGOH
0LFH ZHUH VDFUL¿FHG DIWHU WKUHH PRQWKV 0LFH ZHUH
PDLQWDLQHG DQG KRXVHG DW ,3$7,083 $QLPDO +RXVH
VLWHGDWWKH0HGLFDO)DFXOW\RIWKH8QLYHUVLW\RI3RUWRLQ
DSDWKRJHQIUHHHQYLURQPHQWXQGHUFRQWUROOHGFRQGLWLRQV
RIOLJKWDQGKXPLGLW\
Immunohistochemistry
$ WRWDO RI  WXPRUV IURP  [HQRJUDIWHG
PLFH ZHUH LVRODWHG DQG ¿[HG LQ  IRUPDOGHK\GH
,PPXQRKLVWRFKHPLVWU\ ,+& ZDV SHUIRUPHG ZLWK
DQWLERGLHVIRU3FDGKHULQ%'%LRVFLHQFHVKRXU
57ĮLQWHJULQ6LJPD$OGULFKKRXU57ȕ
LQWHJULQ6DQWD&UX]KRXU57S)$.7\U
&HOO6LJQDOOLQJ KRXU57 DQGS6UF7\U
&HOO6LJQDOOLQJ&RYHUQLJKW
+LJKWHPSHUDWXUH&DQWLJHQUHWULHYDOZLWK7ULV
('7$3FDGKHULQĮLQWHJULQS)$.RUFLWUDWHEXIIHU
ȕLQWHJULQS6UFZDVSHUIRUPHGEHIRUHSULPDU\DQWLERG\
LQFXEDWLRQ7KHSULPDU\DQWLERGLHVZHUHGHWHFWHGXVLQJD
VHFRQGDU\DQWLERG\ZLWKKRUVHUDGLVKSHUR[LGDVHSRO\PHU
&\WRPDWLRQ(QYLVLRQ6\VWHP+53'$.2&DUSLQWHULD
&$ XVLQJ GLDPLQREHQ]LGLQH '$% DV FKURPRJHQ
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
$OO WKH PDUNHUV ZHUH PDLQO\ GHWHFWHG DW WKH
PHPEUDQH RI WXPRU FHOOV &RQFHUQLQJ 3FDGKHULQ
H[SUHVVLRQ DOO WKH WXPRUV VKRZHG PRUH WKDQ  RI
SRVLWLYHFHOOV7KXVWKHWXPRUVZHUHHYDOXDWHGDFFRUGLQJ
ZLWKWKHVWDLQLQWHQVLW\EHLQJFODVVL¿HGLQWR3FDGKLJK
VWURQJVWDLQDQG3FDGORZZHDNDQGPRGHUDWHVWDLQ
$FFRUGLQJ ZLWK SUHYLRXV SXEOLVKHG UHSRUWV WKH
VFRULQJ IRU WKH UHPDLQLQJ PDUNHUV ZDV FRQVLGHUHG DV
IROORZVĮLQWHJULQVWDLQZDVFODVVL¿HGDFFRUGLQJWRWKH
VWDLQLQWHQVLW\LQWRVWURQJSRVLWLYHDQGPRGHUDWHZHDN
QHJDWLYHORZ>@ȕLQWHJULQZDVFODVVL¿HGDFFRUGLQJ
WRWKHVWDLQH[WHQVLRQLQWR! SRVLWLYHDQG
QHJDWLYHORZ>@S)$.ZDVFODVVL¿HGDFFRUGLQJWRWKH
VWDLQH[WHQVLRQLQWR! SRVLWLYHDQGQHJDWLYH
ORZ>@S6UFZDVFRQVLGHUHGSRVLWLYHZKHQPRUHWKDQ
RIWXPRUFHOOVVWDLQHGSRVLWLYHIRUWKLVPDUNHU>@
Statistical analysis
$GKHVLRQ0)( LQYDVLRQDQGFKDQJHV LQP51$
H[SUHVVLRQOHYHOVZHUHFRPSDUHGXVLQJWZRWDLOHGXQSDLUHG
WWHVW ,PPXQRKLVWRFKHPLFDO DVVRFLDWLRQV EHWZHHQ WKH
PROHFXODUPDUNHUVZHUHDVVHVVHGE\3HDUVRQ¶VFRUUHODWLRQ
DQG)LVKHU¶VH[DFWWHVW6WDWLVWLFDODQDO\VHVZHUHFDUULHG
RXWXVLQJ3ULVP*UDSK3DG/D-ROOD&$DQGDVLJQL¿FDQW
OHYHORIZDVFRQVLGHUHG)ORZ&\WRPHWU\GDWDZDV
DQDO\]HG ZLWK WKH )ORZ-R VRIWZDUH SDFNDJH 7UHHVWDU
$VKODQG2586$
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